{"title": "PDF", "author": "PDF", "url": "https://www.leitlinienprogramm-onkologie.de/fileadmin/user_upload/Downloads/Leitlinien/Melanom/S3-Melanom-OL-Evidenztabellen.pdf", "hostname": "PDF", "description": "PDF", "sitename": "PDF", "date": "PDF", "id": "PDF", "license": "PDF", "body": "PDF", "comments": "PDF", "commentsbody": "PDF", "raw_text": "PDF", "text": " \n \n \n \n \nEvidenz tabellen  \nder S3 Leitlinie \u201eDiagnostik, Ther apie \nund Nachsorge des Melanoms \u201c \n \nVersion 1.0 - Januar 2013  \nAWMF Registrierungsnummer: 032 -024OL  \n \n \n \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 2 von 732 Erg\u00e4nz ung zum Leitlinienreport  \nAutoren  \nDr. Annette Pflugfelder,  Universit\u00e4ts -Hautklinik T\u00fcbi ngen \nDr. Corinna Kochs, Klinik f\u00fcr Dermatologie,  \nUniversit\u00e4tskl inikum Essen  \nDr. Christina Czeschik, Klinik f\u00fcr Dermatologie, \nUnivers it\u00e4tsklinikum Essen  \nDr. Markus Follmann, MPH, MSc, Office des Leitlinienprogramms \nOnkologie \u2013 DKG e.V. \nProf. Dr. Claus Garbe, U niversit\u00e4ts -Hautklinik T\u00fcbingen  \nProf. Dr. Dirk Schadendorf, Klinik f\u00fcr Dermatologie, \nUniversit\u00e4tsklin ikum Essen  \nHerausgeber  \nLeitlinienprogramm Onkologie  \nder AWMF, Deutschen Krebsgesellschaft e.V.und Deutschen \nKrebshilfe e.V.  \nOffice:  c/o Deutsche Krebsgese llschaft e.V.  \nKuno \u2013 Fischer -Str. 8  14057  Berlin  \nleitlinienprogramm@krebsgesellschaft.de  \nwww.leitlinienprogramm -onkologie.de   \n \n \nFinanzier ung der Leitlinie  \nDie Entwicklung der  Leitlinie wurde von der Deutschen \nKrebshilfe im Rahmen des Onkologischen Lei tlinienprogramms \ngef\u00f6rdert.  \nFederf\u00fchrende Fachgesellschaft en \nDeutsche  Dermatologische  Gesellschaft (DDG)  \nArbeitsgemeinschaft Dermat ologische Onkologie (ADO)  \n \n \n \n \n \n \n \nKontakt  \nDr. med. Annette Pflugfelder  \nUniversit\u00e4ts -Hautklinik T\u00fcbingen , Sektion Dermatologische \nOnkologie  \nLiebermeisterstrasse 25  \nD-72076 T\u00fcbingen  \nTel.: 07071 29 84555    -   Fax: 07071 29 5265  \nannette.pflugfelder@med.uni -tuebingen.de  \n \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 3 von 732 Inhaltsverzeichnis   \n1. AG Diagnostik  ................................ ................................ ................................ ................................ ...........  10 \n1.1. Frage I.2. und I.3. Apparative Verfahren zur klinischen Diagnostik des malignen Melanoms - Adaptation  ................................ ..........................  10 \n1.1.1.  Synopse Quelleitl inien (kurz) ................................ ................................ ................................ ................................ ................................ ...... 10 \n1.1.2.  Empfehlung, Hintergrundstext und Literatur Australische Quell -Leitlinie  ................................ ................................ ................................ .... 11 \n1.2. Frage I.3. Konfokale Laser scan-Mikroskopie und optische Koh\u00e4renztomographie - De-novo -Recherche  ................................ ...........................  25 \n1.2.1.  PICO, Suchw\u00f6rter  ................................ ................................ ................................ ................................ ................................ .......................  25 \n1.2.2.  Datenbanken, Suchstra tegien, Trefferzahlen  ................................ ................................ ................................ ................................ ..............  26 \n1.2.3.  Auswahlkriterien  ................................ ................................ ................................ ................................ ................................ .......................  27 \n1.2.4.  Evidenztabelle  ................................ ................................ ................................ ................................ ................................ ...........................  27 \n1.2.5.  Literatur  ................................ ................................ ................................ ................................ ................................ ................................ .... 34 \n1.3. Frage I.6., I.7., I.8., VII.6. Ausbreitungsdiagnostik bei Patienten mit malignem Melanom \u2013 De-novo-Recherche  ................................ .................  35 \n1.3.1.  PICO, Suchw\u00f6rter  ................................ ................................ ................................ ................................ ................................ .......................  35 \n1.3.2.  Datenbanken, Suchstrategie, Trefferzahlen  ................................ ................................ ................................ ................................ ................  36 \n1.3.3.  Auswahlkriterien  ................................ ................................ ................................ ................................ ................................ .......................  40 \n1.3.4.  Evidenztabelle (zusammengefa\u00dft f\u00fcr I.6., I.7., I.8., VII.6.)  ................................ ................................ ................................ ...........................  40 \n1.3.5.  Literatur  ................................ ................................ ................................ ................................ ................................ ................................ .. 146 \n1.4. Frage I.9. Ausbreitungsdiagnostik beim metastasierten okkulten Melanom - Adaptation  ................................ ................................ .................  159 \n1.4.1.  Synopse Quellleitlinien (kurz)  ................................ ................................ ................................ ................................ ................................ ... 159 \n1.4.2.  Empfehlung, Hintergrundstext und Literatur Australische Quell -Leitlinie  ................................ ................................ ................................ .. 160 \n1.4.3.  Erg\u00e4nzende Recherche, Datenbanken, Suchstrategien, Trefferzahlen  ................................ ................................ ................................ ........  162 \n1.4.4.  Evidenztabelle  ................................ ................................ ................................ ................................ ................................ .........................  164 \n2. AG Sentinel Node Biopsie  ................................ ................................ ................................ .........................  166   \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 4 von 732 2.1. Frage II.1. Sentinel -Node -Biopsie \u2013 De-novo -Recherche  ................................ ................................ ................................ ................................ . 166 \n2.1.1.  PICO, Suchw\u00f6rter  ................................ ................................ ................................ ................................ ................................ .....................  166 \n2.1.2.  Datenbanken, Suchstrategien, Treff erzahlen  ................................ ................................ ................................ ................................ ............  167 \n2.1.3.  Auswahlkriterien  ................................ ................................ ................................ ................................ ................................ .....................  168 \n2.1.4.  Evidenztabelle  ................................ ................................ ................................ ................................ ................................ .........................  168 \n2.1.5.  Literatur  ................................ ................................ ................................ ................................ ................................ ................................ .. 214 \n2.2. Frage II.5. und III.4. Tumorlast am Sentinel -Node und komplettierende Lymphadenektomie \u2013 De-novo -Recherche ................................ ..........  216 \n2.2.1.  Datenbanken, Suchstrategien, Trefferzahlen  ................................ ................................ ................................ ................................ ............  216 \n2.2.2.  Auswahlkriterien  ................................ ................................ ................................ ................................ ................................ .....................  217 \n2.2.3.  Evidenztabelle  ................................ ................................ ................................ ................................ ................................ .........................  217 \n2.2.4.  Literatur  ................................ ................................ ................................ ................................ ................................ ................................ .. 244 \n3. AG Chirurgische Therapie  ................................ ................................ ................................ ........................  246  \n3.1. Frage III.1. S icherheitsabst\u00e4nde bei Prim\u00e4rexzision \u2013 De-novo -Recherche  ................................ ................................ ................................ ....... 246 \n3.1.1.  PICO, Suchw\u00f6rter  ................................ ................................ ................................ ................................ ................................ .....................  246 \n3.1.2.  Datenbanken, Suchstrategien, Tr efferzahlen  ................................ ................................ ................................ ................................ ............  246 \n3.1.3.  Auswahlkriterien  ................................ ................................ ................................ ................................ ................................ .....................  247 \n3.1.4.  Evidenztabelle  ................................ ................................ ................................ ................................ ................................ .........................  248 \n3.1.5.  Literatur  ................................ ................................ ................................ ................................ ................................ ................................ .. 258 \n3.2. Frage III.2. Prophylaktische Lymphadenektomie - Adaptation ................................ ................................ ................................ ..........................  259 \n3.2.1.  Synopse Quellleitlinien (k urz) ................................ ................................ ................................ ................................ ................................ ... 259 \n3.2.2.  Empfehlung,  Hintergrundstext und Literatur Australische  Quell Leitlinie  ................................ ................................ ................................ .. 259 \n3.3. Frage III.3. Therapeutische Ly mphadenektomie \u2013 De-novo-Recherche  ................................ ................................ ................................ ............  268 \n3.3.1.  PICO-Unterfragen  ................................ ................................ ................................ ................................ ................................ ....................  268 \n3.3.2.  Datenbanken, Suchstrategien, Trefferzahlen  ................................ ................................ ................................ ................................ ............  268 \n3.3.3.  Auswahlkriterien  ................................ ................................ ................................ ................................ ................................ .....................  270 \n3.3.4.  Evidenztabelle  ................................ ................................ ................................ ................................ ................................ .........................  270 \n3.3.5.  Literatur  ................................ ................................ ................................ ................................ ................................ ................................ .. 299  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 5 von 732 3.4. Frage III.7. Operative Therapie bei Fernmetastasen \u2013 De-novo -Recherche  ................................ ................................ ................................ ....... 301 \n3.4.1.  Datenbanken, Suchstrategien, Trefferz ahlen  ................................ ................................ ................................ ................................ ............  301 \n3.4.2.  Auswahlkriterien  ................................ ................................ ................................ ................................ ................................ .....................  302 \n3.4.3.  Evidenztabelle  ................................ ................................ ................................ ................................ ................................ .........................  302 \n3.4.4.  Literatur  ................................ ................................ ................................ ................................ ................................ ................................ .. 344 \n4. AG Adjuvante Therapie  ................................ ................................ ................................ ............................  346  \n4.1. Frage IV.1. Adjuvante Chemotherapie - Adaptation ................................ ................................ ................................ ................................ .........  346 \n4.1.1.  Synopse Quellleitlinien  ................................ ................................ ................................ ................................ ................................ ............  346 \n4.1.2.  Empfehlung und Hintergrundstext franz\u00f6sische Quell Leitlinie  ................................ ................................ ................................ .................  347 \n4.1.3.  Empfehlung und Hintergrundstext kanadische Quell Leitlinie  ................................ ................................ ................................ ...................  348 \n4.2. Frage IV.2. Adjuvante Vakzinierung \u2013 Adaptation  ................................ ................................ ................................ ................................ ............  350 \n4.2.1.  Synopse Quellleitlinien  ................................ ................................ ................................ ................................ ................................ ............  350 \n4.2.2.  Empfehlung und Hintergrundstext franz\u00f6sische Quell Leitlinie  ................................ ................................ ................................ .................  353 \n4.2.3.  Empfehlung und Hintergrundstext kanadische Quell Leitlinie  ................................ ................................ ................................ ...................  361 \n4.3. Frage IV.3. Adjuvante Extremit\u00e4tenperfusion - Adaptation  ................................ ................................ ................................ ..............................  363 \n4.3.1.  Synopse Quellleitlinien  ................................ ................................ ................................ ................................ ................................ ............  363 \n4.3.2.  Empfehlung und Hintergrundstext franz\u00f6sische Quell Leitlinie  ................................ ................................ ................................ .................  364 \n4.4. Frage I V.4. Adjuvante Immunstimulation - Adaptation  ................................ ................................ ................................ ................................ .... 367 \n4.4.1.  Synopse Quelleitlinien  ................................ ................................ ................................ ................................ ................................ .............  367 \n4.4.2.  Empfehlung und Hintergrundstext franz\u00f6 sische Quell Leitlinie  ................................ ................................ ................................ .................  369 \n4.4.3.  Empfehlung und Hintergrundstext kanadische Quell Leitlinie  ................................ ................................ ................................ ...................  370 \n4.5. Frage IV.5. und IV.6. Adju vante Interferon alpha Therapie \u2013 De novo Recherche  ................................ ................................ ..............................  373 \n4.5.1.  PICO, Suchw\u00f6rter  ................................ ................................ ................................ ................................ ................................ .....................  373 \n4.5.2.  Datenbanken, Suchstrategien, Trefferz ahlen  ................................ ................................ ................................ ................................ ............  374 \n4.5.3.  Auswahlkriterien  ................................ ................................ ................................ ................................ ................................ .....................  375 \n4.5.4.  Evidenztabelle - Kurzfassung  ................................ ................................ ................................ ................................ ................................ .. 376 \n4.5.5.  Hochdosis versus Niedrigdosis Interferon alpha  ................................ ................................ ................................ ................................ ....... 377  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 6 von 732 4.5.6.  Evidenztabellen \u2013 Langfassung  ................................ ................................ ................................ ................................ ................................  379 \n4.5.6.1.  Eviden ztabelle \u2013 Systematische Reviews and Metaanalysen  ................................ ................................ ................................ ..............  379 \n4.5.6.2.  Evidenztabelle \u2013 Niedrigdosis IFN alpha  ................................ ................................ ................................ ................................ ...........  387 \n4.5.6.3.  Evidenztabel le - Mittlere Dosis IFN alpha  ................................ ................................ ................................ ................................ ........  392 \n4.5.6.4.  Evidenztabelle - Hochdosis IFN alpha  ................................ ................................ ................................ ................................ ..............  393 \n4.5.6.5.  Evidenztabelle - Pegyliertes IFN al pha ................................ ................................ ................................ ................................ .............  398 \n4.5.7.  Subgruppenanalysen  ................................ ................................ ................................ ................................ ................................ ...............  399 \n4.5.8.  Toxizit\u00e4t  ................................ ................................ ................................ ................................ ................................ ................................ . 402 \n4.5.9 . Metaanalysen  ................................ ................................ ................................ ................................ ................................ ..........................  407 \n4.5.10.  Literatur  ................................ ................................ ................................ ................................ ................................ ................................ .. 411 \n5. AG Medikament\u00f6se Therapie bei Metastasierung  ................................ ................................ .......................  413  \n5.1. Frage V.1. Lokale medikament\u00f6se Therapie Intransitmetastasen \u2013 De novo Recherche  ................................ ................................ .....................  413 \n5.1.1.  PICO, Suchw\u00f6rter  ................................ ................................ ................................ ................................ ................................ .....................  413 \n5.1.2.  Datenbanken, Suchstrategien, Trefferzahlen  ................................ ................................ ................................ ................................ ............  414 \n5.1.3.  Auswahlkriterien  ................................ ................................ ................................ ................................ ................................ .....................  416 \n5.1.4.  Evidenztabelle  ................................ ................................ ................................ ................................ ................................ .........................  417 \n5.1.5.  Literatur  ................................ ................................ ................................ ................................ ................................ ................................ .. 434 \n5.2. Frage V.2. und V.3. Systemtherapie Einzelsubstanzen \u2013 De novo Recherche  ................................ ................................ ................................ .... 436 \n5.2.1.  PICO, Suchw\u00f6rter  ................................ ................................ ................................ ................................ ................................ .....................  436 \n5.2.2.  Datenbanken, Suchstrategien, Trefferzahlen  ................................ ................................ ................................ ................................ ............  437 \n5.2.3.  Auswahlkriterien  ................................ ................................ ................................ ................................ ................................ .....................  438 \n5.2.4.  Evidenztabelle  ................................ ................................ ................................ ................................ ................................ .........................  439 \n5.2.5.  Literatur  ................................ ................................ ................................ ................................ ................................ ................................ .. 463 \n5.3. Frage V.4. Biochemotherapie - Adaptation  ................................ ................................ ................................ ................................ ......................  466 \n5.3.1.  Synopse Quellleitlinien  ................................ ................................ ................................ ................................ ................................ ............  466 \n5.3.2.  Empfehlung,  Hintergrundstext und Literatur Kanadische Quell Leitlinie  ................................ ................................ ................................ ... 467 \n5.4. Frage V.5. Polychemotherapie \u2013 De novo Recherche  ................................ ................................ ................................ ................................ ........  470  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 7 von 732 5.4.1.  PICO, Suchw\u00f6rter  ................................ ................................ ................................ ................................ ................................ .....................  470 \n5.4.2.  Datenbanken, Suchstrategien, Trefferzahlen  ................................ ................................ ................................ ................................ ............  471 \n5.4.3.  Auswahlkriterien  ................................ ................................ ................................ ................................ ................................ .....................  471 \n5.4.4.  Evidenztabelle  ................................ ................................ ................................ ................................ ................................ .........................  472 \n5.4.5.  Literatur  ................................ ................................ ................................ ................................ ................................ ................................ .. 474 \n5.5. Frage V.7. Lebermetastasen \u2013 De novo Recherche  ................................ ................................ ................................ ................................ ...........  476 \n5.5.1.  PICO, Suchw\u00f6rter  ................................ ................................ ................................ ................................ ................................ .....................  476 \n5.5.2.  Datenbanken, Suchstrategien, Trefferzahlen  ................................ ................................ ................................ ................................ ............  477 \n5.5.3.  Auswahlkriterien  ................................ ................................ ................................ ................................ ................................ .....................  478 \n5.5.4.  Evidenztabelle  ................................ ................................ ................................ ................................ ................................ .........................  479 \n5.5.5.  Literatur  ................................ ................................ ................................ ................................ ................................ ................................ .. 494 \n5.6. Frage V.8. Lebensqualit\u00e4t \u2013 De novo Recherche ................................ ................................ ................................ ................................ ...............  496 \n5.6.1.  PICO, Suchw\u00f6rter  ................................ ................................ ................................ ................................ ................................ .....................  496 \n5.6.2.  Datenbanken, Such strategien, Trefferzahlen  ................................ ................................ ................................ ................................ ............  496 \n5.6.3.  Auswahlkriterien  ................................ ................................ ................................ ................................ ................................ .....................  497 \n5.6.4.  Evidenztabelle  ................................ ................................ ................................ ................................ ................................ .........................  498 \n5.6.5.  Literatur  ................................ ................................ ................................ ................................ ................................ ................................ .. 519 \n5.6.6.  \u00dcbersicht Frageb\u00f6gen zur Erhebung der Lebensqualit\u00e4t  ................................ ................................ ................................ ...........................  521 \n5.7. Frage V.9. Medikam ent\u00f6se Therapie Hirnmetastasen \u2013 De novo Recherche  ................................ ................................ ................................ ...... 524 \n5.7.1.  PICO, Suchw\u00f6rter  ................................ ................................ ................................ ................................ ................................ .....................  524 \n5.7.2.  Datenbanken, Suchstrategien, Trefferza hlen ................................ ................................ ................................ ................................ ............  524 \n5.7.3.  Auswahlkriterien  ................................ ................................ ................................ ................................ ................................ .....................  525 \n5.7.4.  Evidenztabelle  ................................ ................................ ................................ ................................ ................................ .........................  526 \n5.7.5.  Literatur  ................................ ................................ ................................ ................................ ................................ ................................ .. 532 \n6. AG Radiotherapie  ................................ ................................ ................................ ................................ ..... 533  \n6.1. Frage VI.1. Radiotherapie Prim\u00e4rtumor  ................................ ................................ ................................ ................................ ...........................  533 \n6.1.1.  PICO, Suchw\u00f6rter  ................................ ................................ ................................ ................................ ................................ .....................  533  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 8 von 732 6.1.2.  Datenbanken, Suchstrategien, Trefferzahlen  ................................ ................................ ................................ ................................ ............  534 \n6.1.3.  Auswahlkrite rien ................................ ................................ ................................ ................................ ................................ .....................  535 \n6.1.4.  Evidenztabelle  ................................ ................................ ................................ ................................ ................................ .........................  535 \n6.1.5.  Literatur  ................................ ................................ ................................ ................................ ................................ ................................ .. 547 \n6.2. Frage VI.2. und VI.3. Radiotherapie Intransit - und Fernmetastasen  ................................ ................................ ................................ .................  548 \n6.2.1.  PICO, Suchw\u00f6rter  ................................ ................................ ................................ ................................ ................................ .....................  548 \n6.2.2.  Datenbanken, Suchstrategie n, Trefferzahlen  ................................ ................................ ................................ ................................ ............  550 \n6.2.3.  Auswahlkriterien  ................................ ................................ ................................ ................................ ................................ .....................  552 \n6.2.4.  Evidenztabelle  ................................ ................................ ................................ ................................ ................................ .........................  553 \n6.2.5.  Literatur  ................................ ................................ ................................ ................................ ................................ ................................ .. 563 \n6.3. Frage VI.4. Radiotherapie und Chirurgie Hirnmetastasen  ................................ ................................ ................................ ................................ . 564 \n6.3.1.  PICO, Suchw\u00f6rter  ................................ ................................ ................................ ................................ ................................ .....................  564 \n6.3.2.  Datenbanken, Suchstrategien, Trefferzahlen  ................................ ................................ ................................ ................................ ............  565 \n6.3.3.  Auswahlkriterien  ................................ ................................ ................................ ................................ ................................ .....................  566 \n6.3.4.  Evidenztabelle  ................................ ................................ ................................ ................................ ................................ .........................  566 \n6.3.5.  Literatur  ................................ ................................ ................................ ................................ ................................ ................................ .. 597 \n6.4. Frage VI.5. Adjuvante Radiotherapie Regionale Lymphknotenstati on ................................ ................................ ................................ ...............  599 \n6.4.1.  PICO, Suchw\u00f6rter  ................................ ................................ ................................ ................................ ................................ .....................  599 \n6.4.2.  Datenbanken, Suchstrategien, Trefferzahlen  ................................ ................................ ................................ ................................ ............  599 \n6.4.3.  Auswahlkriterien  ................................ ................................ ................................ ................................ ................................ .....................  600 \n6.4.4.  Evidenztabelle  ................................ ................................ ................................ ................................ ................................ .........................  601 \n6.4.5.  Literatur  ................................ ................................ ................................ ................................ ................................ ................................ .. 610 \n6.5. Frage VI.6. Fraktionierung  ................................ ................................ ................................ ................................ ................................ ..............  611 \n6.5.1.  PICO, Suchw\u00f6rter  ................................ ................................ ................................ ................................ ................................ .....................  611 \n6.5.2.  Datenbanken, Suchstra tegien, Trefferzahlen  ................................ ................................ ................................ ................................ ............  612 \n6.5.3.  Auswahlkriterien  ................................ ................................ ................................ ................................ ................................ .....................  612 \n6.5.4.  Evidenztabelle  ................................ ................................ ................................ ................................ ................................ .........................  613 \n6.5.5.  Literatur  ................................ ................................ ................................ ................................ ................................ ................................ .. 614  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 9 von 732 7. AG Nachsorge  ................................ ................................ ................................ ................................ .........  615  \n7.1. Frage VII.3. Selbstuntersuchung im Rahmen der Nachsorge - Adaptati on ................................ ................................ ................................ ........  615 \n7.1.1.  Synopse (kurz)  ................................ ................................ ................................ ................................ ................................ .........................  615 \n7.1.2.  Empfehlung, Hintergrundstext und Literatur australischen und franz\u00f6sischen Quell -Leitlin ien ................................ ................................ .. 616 \n7.2. Frage VII.4., VII.5. und VII.6. Nachsorge -Dauer und -Intervalle \u2013 De-novo -Recherche  ................................ ................................ .....................  629 \n7.2.1.  PICO, Suchw\u00f6rter  ................................ ................................ ................................ ................................ ................................ .....................  629 \n7.2.2.  Datenbanken, Suchstrategien, Trefferzahlen  ................................ ................................ ................................ ................................ ............  629 \n7.2.3.  Auswahlkriterien  ................................ ................................ ................................ ................................ ................................ .....................  630 \n7.2.4.  Evidenztabelle  ................................ ................................ ................................ ................................ ................................ .........................  631 \n7.2.5.  Literatur  ................................ ................................ ................................ ................................ ................................ ................................ .. 707 \n8. AG Begleittherapie  ................................ ................................ ................................ ................................ ... 714  \n8.1. Frage VIII.1. Misteltherapie  ................................ ................................ ................................ ................................ ................................ .............  714 \n8.1.1.  PICO, Suchw\u00f6rter  ................................ ................................ ................................ ................................ ................................ .....................  714 \n8.1.2.  Datenbanken, Suchstrategien , Trefferzahlen  ................................ ................................ ................................ ................................ ............  714 \n8.1.3.  Auswahlkriterien  ................................ ................................ ................................ ................................ ................................ .....................  715 \n8.1.4.  Evidenztabelle  ................................ ................................ ................................ ................................ ................................ .........................  716 \n8.1.5.  Literatur  ................................ ................................ ................................ ................................ ................................ ................................ .. 721 \n9. AG Versorgungsqualit\u00e4t und Qualit\u00e4tsindikatoren  ................................ ................................ ......................  722  \n9.1. Frage IX.1. Klinische Studien - Adapt ation  ................................ ................................ ................................ ................................ ......................  722 \n9.1.1.  Synopse Quellleitlinien (kurz)  ................................ ................................ ................................ ................................ ................................ ... 722 \n9.1.2.  Empfehlung, Hintergrundstext und Literatur australischen und franz\u00f6si schen Quell -Leitlinien  ................................ ................................ .. 723 \n10.  Abk\u00fcrzungsverzeichnis  ................................ ................................ ................................ ............................  729  \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 10 von 732 1. AG Diagnostik  \n1.1. Frage I. 2. und I.3. Apparative Verfahren zur klinischen Diagnostik des malignen \nMelanoms  - Adaptation  \nFrage I.2. Welche diagnostischen Verfahren sind geeignet, die klinische Diagnose des MM zu verbessern?  \nFrage I .3. Welche Hilfsmittel oder apparativen Verfahren k\u00f6nnen die klinische Diagnostik des MM ggf. weiter verbessern ? \n \n1.1.1.  Synopse Quelleitli nien (kurz)  \n \n Thema/Fragestellung  LL Austr alien  \nNew Zealand Guidelines \nGroup 2008  LL GB  \nNICE 2006  LL Frankreich  \nFrench National Authority \nfor Health 2005 ) LL Kanada  \nCancer Care O ntario 2007  \n2. Welche diagnostischen \nVerfa hren/Hilfsmittel \nk\u00f6nnen helfen, d ie klinische \nDiagnose des MM zu \nsichern?  Klinische Unters uchung, \nAnamnese mit \nKonzentration auf \nVer\u00e4nd erungen von \nHautl\u00e4sionen;  \nDermatoskopie wird \nempfo hlen (A);  \nBeobachtungsper iode \nm\u00f6glich;  \nEinsatz von \u201eSequential Klinische Untersuchung, \nDermat oskopie  Klinische Untersuchung, \nDermat oskopie  (nur relevant f\u00fcr \nmedikament\u00f6se Therapie n)  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 11 von 732  Thema/Fragestellung  LL Austr alien  \nNew Zealand Guidelines \nGroup 2008  LL GB  \nNICE 2006  LL Frankreich  \nFrench National Authority \nfor Health 2005 ) LL Kanada  \nCancer Care O ntario 2007  \ndigital de rmoscopy imaging\u201c \nund/oder \u201eTot al body \nphotography\u201c kann in \nZweifelsf\u00e4llen in Erw\u00e4gung \ngezogen we rden (B)  \n3. Erh\u00f6ht der Einsatz der \nDermatoskopie (mit/ohne \nSchulung d er anwendenden \n\u00c4rzte) die diagnost ische \nGenauigkeit?  Training in Derm atoskopie \nwird em pfohlen f\u00fcr \u00c4rzte, \ndie regelm\u00e4\u00dfig pigmentierte \nHV unters uchen (A)  Empfohlen  Keine Erw\u00e4 hnung   \n \n1.1.2.  Empfehlung, Hintergr unds text und Literatur Australische Quell -Leitlinie  \n (mit Seitenangaben der Quellleitlinie)  \n LL Austr alien  \nNew Zealand Guidelines Group 2008  LL GB  \nNICE 2006  LL Frankreich  \nFrench National Authority for Health \n2005 ) \nSchl\u00fcsselempfe hlungen  S. 31  \n \n1. Training and utilisation of \ndermo scopy is recommended for \nclinicians routinely examining S. 84  \n \nA. Recommend ations  \n \nInvestigation and dia gnosis  Die franz\u00f6sische LL gibt keine \nEmpfehlungen zur klinischen \nErstdiagnose eines Melanoms; die \nDermatoskopie wird jedoch im \nAbschnitt \u00fcber Unte rsuchung und  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 12 von 732  LL Austr alien  \nNew Zealand Guidelines Group 2008  LL GB  \nNICE 2006  LL Frankreich  \nFrench National Authority for Health \n2005 ) \npigmented skin lesions  \nGrade of Recommendation: A  \n \n2. Consider the use of s equential \ndigital dermoscopy imaging to d etect \nmelanomas that lack dermoscopic \nfeatures of mel anoma  \nGrade of Recommendation: B  \n \n3. Consider the use of bas eline total \nbody photography as a tool for  \nthe early detection of mel anoma in \npatients who are at high risk for  \ndeveloping primary melan oma \nGrade of Recommendation: C   \nGPs should receive training as \nrecommended in the NICE Referral  \nguidelines for suspected ca ncer [44] on \nthe diagnosis of precanc erous and \ncancerous lesions, and should receive \nfeedback through audit on their \ndiagnostic accuracy.  \nGPs should refer certain groups of skin \nlesions as d escribed  in Box 1 and \nFigure 14 directly to an LSMDT without \nbiopsy. This practice should be subject \nto audit.  \n \nAll excised skin specimens should be \nsent for histopathological exam ination \nas recommended in the NICE Referral \nguidelines for su spected cancer . [45]  \n \nDermatoscopy should be ava ilable in all \nMDTs, but its use requires trai ning. \n \nThere should be equity of a ccess so \nthat all tissue samples are reviewed in \nhigh-quality histopathology se rvices. Nachsorge von R0 -resezierten \nPatienten (N0, M0) kur z bespr ochen \nsowie auf Gutachten der Haute Autorit\u00e9 \nde Sant\u00e9 (HAS) und der Agency for \nHealthcare Research and Quality \n(AHRQ) ve rwiesen:  \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 13 von 732  LL Austr alien  \nNew Zealand Guidelines Group 2008  LL GB  \nNICE 2006  LL Frankreich  \nFrench National Authority for Health \n2005 ) \nAccurate diagnosis in \nderma topathology depends on \nclinicopatholog ical correlation, \ninvolving input from both clinician and \npathologist. Although this can be \nachieved in difficult cases by \ninterspecialist discussion or seeing the \npatient re cords, in some instances \n(such as cutaneous ly mphoma) it may \nbe essential for the patient to be seen \njointly. Accordingly, for good clinical \ngovernance, it is recommended that \nthe histopathology r eporting of any \nspecimens likely to be consi dered by a \nskin cancer MDT should be unde rtaken \nin a laboratory having easy access to \nrelevant cli nicians, patient records and \nthe a ttending patient.  \nHintergrundtexte  S. 29 - 30 \n \n5.6 Evidence -based a ssessment of aids \nto the clinical diagnosis  \nof melanoma  \n \n5.6.1 Dermos copy S. 90  \n \nE. Evidence  \n \nDermatoscopy  \nOne RCT found that, following a brief \ntraining intervention for GPs in the use S. 44  \n \nEXAMEN CLINIQUE, DERM OSCOPIE  \nLes performances diagnostiques de \nl\u2019examen clinique et de la dermoscopie \ndans le diagnostic des t umeurs \ncutan\u00e9es font actuellement l\u2019objet  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 14 von 732  LL Austr alien  \nNew Zealand Guidelines Group 2008  LL GB  \nNICE 2006  LL Frankreich  \nFrench National Authority for Health \n2005 ) \nDermoscopy (surface m icroscopy, oil \nepiluminescence microscopy, \ndermatoscopy) is a technique that uses \na hand -held magnifying device \ncombined with either the application of \na liquid between the tran sparent plate \nof the device and the skin, or the use \nof cross -polarised light. This tec hnique \nallows the visualisation of diagnostic \nfeatures of pi gmented skin lesions that \nare not seen with the n aked eye. [15 \u2013\n18]  \nMeta-analyses performed on stu dies in \na variety of clinical and exper imental \nsettings have sho wn that using \ndermoscopy improves diagnostic \naccuracy for melan oma.[19,20]  \nFrom a meta -analysis of nine level II \ndiagnostic studies su bject to varying \ndegrees of verification bias  performed \nprospectively in a clinical setting [21 \u2013\n31] the diagnostic acc uracy for \nmelanoma, as expressed by the relative \ndiagnostic odds r atio, was 15.6 (95% CI \n2.9\u201383.7) times higher for dermoscopy of dermatoscopy, th ere was a  \nsignificant improvement in the \naccuracy of clinical diagnosis of \nmelan oma and in the diagnosis of \nmelan oma using dermatoscopy. The \nimprovement was si gnificantly greater \nfor the use of dermat oscopy than for \nclinical diagn osis.  \n \nThree systematic reviews an d one case \nseries provide ev idence that hand -held \ndermatoscopy i mproves diagnostic \naccuracy as compared with unaided \nexamination. There is evidence from \none systematic review that the \ndiagnostic accuracy of dermatoscopy \ndepends on the degree of experience \nof the exa miner. \n \nTeledermatology  \nOne RCT compared telede rmatology \nwith face -to-face consultation as a \nmethod of examining p atients with \nskin lesions at a dermatology \ndepartment. All patients r eceived a d\u2019une expe rtise par la Haute Autorit\u00e9 \nde Sant\u00e9 (HAS) et ne seront donc ici \nqu\u2019\u00e9voqu\u00e9es. Ces perfo rmances ont \nsurtout \u00e9t\u00e9 \u00e9tudi\u00e9es pour le diagnostic \ninitial du m\u00e9lan ome, et non dans la \nsituation sp\u00e9cif ique du patient ayant \nd\u00e9j\u00e0 eu un m\u00e9lanome. Pour ces \nderniers, la probabilit\u00e9 de surv enue \nd\u2019un autre m\u00e9lanome est beaucoup \nplus \u00e9lev\u00e9e que dans la population \ng\u00e9n\u00e9ral e. \nUne revue syst\u00e9matique publi\u00e9e par \nl\u2019Agency for healthcare research and \nquality (AHRQ) a r\u00e9cemment revu les \nperformances de l\u2019examen clinique \npour \u00e9tablir une \u00e9ventuelle strat\u00e9gie de \nd\u00e9pistage syst\u00e9matique des cancers de \nla peau et a montr\u00e9 que les \nperformances dia gnostiques (en termes \nde sensibilit\u00e9 et de sp\u00e9cificit\u00e9) des \nderm atologues \u00e9taient sup\u00e9rieures \u00e0 \ncelles des non -dermatologues [17]. \u00c0 \nnoter cepen dant que cette revue \nsyst\u00e9matique a \u00e9t\u00e9 faite avant que la \ndermoscopie, une technique  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 15 von 732  LL Austr alien  \nNew Zealand Guidelines Group 2008  LL GB  \nNICE 2006  LL Frankreich  \nFrench National Authority for Health \n2005 ) \ncompared with naked eye examination. \nImportantly the meta -analysis was \nrestricted to studies that directly \ncompared the two methods  within each \nstudy. Sensitivity of derm oscopy was \n18% (95% CI 9% \u201327%; P=0.002) higher \nthan for eye exam ination, but there \nwas no evidence of an effect on \nspecificity [31] (see A ppendix 4). \nSpecificity can also be exa mined by its \neffect on excision rates of  benign \nlesions, which was not a ddressed in the \nmeta -analysis. Two such stu dies \nsuggest reduced rates of excision of \nbenign lesions using derm oscopy \n(reduced benign to malignant ratio of \nexcised lesions and r eduction of \npatients referred to biopsy) and \nprovide indirect evidence for i mproved \nspecificity in a specialist se tting. \n[22,23]  \nWhile there are fewer studies on \ndermoscopy in general pra ctice, all \nthree that were unde rtaken in this \ncontext (one study with both general further, independent face -to-face skin \nexamination wi th a co nsultant \ndermatologist. For each randomised \ngroup, concordance between the two \nconsultations for each patient was \nmeasured, prima rily for management \nplan and secondarily for diagnosis. \nThere was significantly greater \nconcordance between consultation s for \nmanagement plan and for dia gnosis in \npatients randomised to face -to-face \nskin examination than in those \nrandomised to teledermato logy. No \ndifference was d etected between \nrandomised groups for patient \nsatisfaction.  \n \nOne RCT compared two types of \nteled ermatology (by live \nvideoco nference and by sending still \nphotographic images) with traditional \noutpatient consult ation, as methods for \nGPs to refer patients to dermatologists. \nThe de rmatologist requested a \nsubsequent hospital appointment for initialement m ise au point en Europe et \nen Australie, soit largement diff us\u00e9e \naux \u00c9tats -Unis.  \nDeux m\u00e9ta -analyses r\u00e9centes ont \nmontr\u00e9 que pour les dermatologues \nexp\u00e9riment\u00e9s, la dermoscopie \nam\u00e9liorait les performances \ndiagno stiques [160, 161]. Dans l\u2019\u00e9tude \nde Bafounta et al., le rapport de \nvraisemblance positif estim\u00e9 de la \ndermoscopie et de l\u2019examen clinique \nont \u00e9t\u00e9 respe ctivement de 9,0 [IC95 : \n5,9-19,0] et 3,7 [IC95 : 2,8 -5,3] [160]. \nLa m\u00e9ta -analyse de Kittler et al. a \nconfirm\u00e9 ces donn\u00e9es, montrant \nclairement que seu ls les op\u00e9rateurs \nexp\u00e9riment\u00e9s am\u00e9lioraient leurs \nperformances dia gnostiques [161].  \n \nKLINISCHE UNTERSUCHUNG, \nDERMATOSKOPIE  \nDie diagnostische Leistungsf\u00e4higkeit \nder klinischen Untersuchung und der \nDermatoskopie in der Diagnostik von \nHauttumoren ist zur Zeit  Gegenstand  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 16 von 732  LL Austr alien  \nNew Zealand Guidelines Group 2008  LL GB  \nNICE 2006  LL Frankreich  \nFrench National Authority for Health \n2005 ) \npractitioners and inexperienced \nspecialists or trainees) [32] show a \nconsistently improved sensiti vity for \nthe diagnosis of melanoma or the \nidentification of suspicious lesions \nrequi ring biopsy. [21,32,33] It should \nbe noted that all the stu dies cited were \nundertaken by clin icians with som e \ntraining in dermoscopy (restricted to \nlectures or reading material in some \nstudies). For this reason, and based on \nother ev idence [34], some formal \ntraining in dermoscopy is required to \nachieve improvement in diagnostic \naccuracy.  \n \n5.6.2 Sequential digita l ima ging \nSequential digital dermoscopy ima ging \n(SDDI) involves the capture and \nassessment of successive derm oscopic \nimages, separated by an i nterval of \ntime, of one or many mel anocytic \nlesions to detect suspicious change. \nThis is pe rformed in two settings : \nshort -term digital mon itoring (over a 69% of p atients examined by the still \nimage method, compared to 46% of \npatients examined by \nvideoconferencing and 45% of patients \nexamined in person.  \n \nOne RCT compared telede rmatology \nwith standard referral and found that \npatients in the telederm atology group \nreceived d efinitive treatment \nsignif icantly more quickly than patients \nin the standard referral group. \nTeledermatology patients were \nsignif icantly more likely to avoid the \nneed for a further clinic visit compared \nwith co ntrol patients.  \n \nOne RCT compared telede rmatol ogy \nconsultation using a videolink with \noutpatient consultation and found no \ndifference b etween the groups in the \nreported clinical dia gnoses.  \n \nOne RCT of teledermatology co mpared \nto traditional consultation found no eines Gutachtens der Haute Autorit\u00e9 de \nSant\u00e9 (HAS) und wird hier daher nur \nerw\u00e4hnt. Die Wirksamkeit dieser \nVerfahren ist vor allem f\u00fcr die \nPrim\u00e4rdiagnostik des Melanoms \nuntersucht worden, nicht f\u00fcr die \nspezielle Situation der Patienten, die \nbereits ein Melanom gehabt haben. F\u00fcr \nletztere ist die Wahrscheinlichkeit, ein \nweiteres Melanom zu \u00fcberleben, sehr \nviel h\u00f6her als in der \nAllgemeinbev\u00f6lk erung.  \nEin systematisches Review der Agency \nfor Healthcare Research and Quality \n(AHRQ) hat unl\u00e4ngst die Wir ksamkeit \nder klinischen Untersuchung \nuntersucht, um m\u00f6glicherweise eine \nStrategie zum systemat ischen \nScreening von Hauttumoren zu \netablieren und um zu zeigen, dass die \ndiagnostische Wirksamkeit der \nklinischen Untersuchung (Sensitivit\u00e4t \nund Spezifit\u00e4t) bei Dermatol ogen der \nvon Nicht -Dermatologen \u00fcberlegen ist. \n[17]  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 17 von 732  LL Austr alien  \nNew Zealand Guidelines Group 2008  LL GB  \nNICE 2006  LL Frankreich  \nFrench National Authority for Health \n2005 ) \nperiod of 1.5 \u20134.5 months) for \nsuspicious melanocytic lesions, and \nlong-term monitoring for surveillance \n(usually at inte rvals of 6 \u201312 months). \n[35] \nFour level II studies that were \nconducted in a specialist se tting sh ow \nconsistently that SDDI allows the \ndetection of melanoma that lack \ndermoscopic evidence of maligna ncy. \n[35\u201338]  \nIn one prospective study of melan omas \ndiagnosed by a variety of clin ical \nmeans, 34% were detected using the \nchanges detected by SDDI e xclusive ly \nand were without dermoscopic features \nof mel anoma. [36] Long -term digital \nmonitoring is generally used in the \nsurvei llance of high -risk patients, \nusually with multiple dysplastic naevi. \nIn contrast, short -term digital \nmonitoring of individual su spicious  \nnaevi can be used in any patient \nsetting. At this time diagnostic \naccuracy of the technique was not able significant difference b etween groups \nfor patient satisfaction  \nwith either their care or the \nmanagement of their skin pro blems, \nand \n85% of the telemedicine p atients \nreported that they would use the \nsystem again.  \n \nTwo systematic reviews suggest that \nthere is no conse nsus from primary \nstudies on whether telede rmatology is \nmore cost -effective than traditional \nmanagement of dermatology p atients.  \n \nAudit data from the UK ind icates that \nGPs report quicker referral of  \ndermatology patients through \nteledermatology.  \n \nS. 99  \n \nE. Resource impl ications  \n \nInvest igation and dia gnosis  Es ist allerdings zu bemerken, dass \ndieses systematische Review \ndurchgef\u00fchrt wurde, bevor die \nDermat oskopie, eine Technik, die \nzuerst in Europa und Australien \nentwickelt wurde, gr\u00f6\u00dfere Verbreitung  \nin den USA fand.  \nZwei aktuelle Meta -Analysen haben \ngezeigt, dass die Dermatoskopie bei \nerfahrenen Dermatologen die \ndiagnostische Leistung verbessert \n[160, 161]. In der Studie von Bafounta \net al. ist der gesch\u00e4tzte positive \npr\u00e4di ktive Wert der Dermatoskopi e und \nder klinischen Untersuchung 9,0 [IC95 : \n5,9-19,0] bzw. 3,7 [IC95 : 2,8 -5,3] \n[160]. Die Meta -Analyse von Kittler et \nal. hat diese Daten best\u00e4tigt und klar \ngezeigt, dass nur erfahrene Anwender \nder Dermatoskopie ihre diagnostische \nLeistung damit verbe ssern [161].  \n \n \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 18 von 732  LL Austr alien  \nNew Zealand Guidelines Group 2008  LL GB  \nNICE 2006  LL Frankreich  \nFrench National Authority for Health \n2005 ) \nto be a ssessed.  \n \n5.6.3 Automated instr uments for the \ndiagnosis of primary melan oma \nAn automated diagnostic i nstrument is \ndefined as one that requires  minimal or \nno input from the clinician to achieve a \ndiagnosis. Each automa ted instrument \noffers different tec hnology with \ndiffering diagnostic abi lity. Guidelines \nfor assessing such i nstruments have \nbeen published. [39] To date, only \nthree instruments hav e had their \ndiagnostic accuracy compared with a \nhuman d iagnosis in the clinical field \nwith a sample size that could allow \nsome assessment of their a pplication \nto the wider clinical arena. [25,40,41] \nThe instr uments  \nshowed a significantly inf erior [25,41] \nor equivalent [40] specificity for the \ndiagnosis of mel anoma compared with \nspecialists. In all stu dies sample sizes \nwere not large enough to be able to \ndetect pote ntial differences in the The main resource implication of the \nrecommendations co ncerning the \ninvestigation and diagnosis concerns \nthe additional role for \nhistopathologists. The increased \nworkload has been calculated taking \naccount of LSMDT and SSMDT working, \nimplementation of the minimum \ndataset, doubling the reporting of \nseverely atypical naevi, and MM and \nSSMDT mandatory review. \nApprox imately two -thirds of the \nadditional workload relates to SSMDT \nand tertiary review.  \n \nIt is estimated that approx imately 1.75 \nadditional consultant \nhistopathologists/dermatopathologists \nwould be required per network to \nsupport the guidance. In addition, \nthere would be an additional \nrequirement for laboratory staff, not \ncalculated here. The additional annual \nemployment costs of th e \nhistopathologists will be around  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 19 von 732  LL Austr alien  \nNew Zealand Guidelines Group 2008  LL GB  \nNICE 2006  LL Frankreich  \nFrench National Authority for Health \n2005 ) \nsensitivity for melanoma. Fu rther \nstudies are required to assess the \nimpact of automated instruments \nagainst human perfor mance in the \nclinical field.  \n \n5.7 Total body photogr aphy for early \nmelanoma dia gnosis  \nin high -risk subjects  \nTotal body photography (TBP) is widely \nused in the follow -up of high -risk \npatients [42], partic ularly those with \nlarge nu mbers of melanocytic naevi or \ndysplastic naevi. TBP has  \nbeen recommended for the detection \nof new or changing pigmented l esions. \nUse of TBP is advocated in the fo llow-\nup of high -risk patients by the authors \nof most stu dies. [43 \u201350] \nThe technique has been said to r educe \nthe need for unnecessary removal of \nbenign lesions to e xclude melanoma \n[45,46] and to increase the sensitivity \nand specificity of clinical e xamination \nfor the detection of melanoma. [46,47] \u00a3171,991 per network. (This cost has \nbeen included in the total cost for \nadditional staff required as a result of \nthe guidance, reported in the \n\u2018Organisation of skin cancer se rvices\u2019 \nchapter.)   \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 20 von 732  LL Austr alien  \nNew Zealand Guidelines Group 2008  LL GB  \nNICE 2006  LL Frankreich  \nFrench National Authority for Health \n2005 ) \nSeveral authors point out that TBP was \nthe key fa ctor in the detection of most \nmelanomas in their high -risk \npopulations. [44 \u201346,48] Two authors \nreferred to the role of TBP in enabling \nthe detection of clinically subtle or \nundia gnosable melanoma. [46,47]  \nNo appropriately controlled or \nrandomised study has been unde rtaken \nto confirm these observations in a \nhigh-risk population. Almost all \nmelanomas are new or changing \nlesions and baseline images are helpful \nin identifying a new or changing l esion. \n \nEvidence summary  \nFrom a meta -analys is of nine level II \nstudies prospectively performed in a \nclinical setting, the diagnostic accuracy \nfor melanoma, as e xpressed by the \nrelative diagnostic odds ratio, was 15.6 \ntimes higher for dermosc opy compared \nwith naked eye examination. Sensitivity \nof de rmoscopy was 18% (95% CI 9% \u2013\n27%; P=0.002) higher than for eye  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 21 von 732  LL Austr alien  \nNew Zealand Guidelines Group 2008  LL GB  \nNICE 2006  LL Frankreich  \nFrench National Authority for Health \n2005 ) \nexam ination, but there was no \nevidence of an effect on specifi city. \nLoE: I , References: 21, 22, 24 \u201331 \n \nDermoscopy has been shown to reduce \nthe b enign:malignant ratio of excised \nmelanocytic lesio ns and reduce the \nnumber of patients r eferred for biopsy \nin a specialist se tting  \nLoE: II, References: 22, 23  \n \nFour level II studies show consisten tly \nthat sequential digital derm oscopic \nimaging allows the detection of \nsuspicious dermoscopic change in \nmelanomas that lack dermoscopic \nevidence of melanoma at a partic ular \ntime \nLoE: II , References: 35 \u201338 \n \nTo date only three automated \ninstruments for the diagnosis of \nprimary melanoma have been a ssessed \nagainst clinicians with a reasonable \nsample size in the clin ical field. Here,  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 22 von 732  LL Austr alien  \nNew Zealand Guidelines Group 2008  LL GB  \nNICE 2006  LL Frankreich  \nFrench National Authority for Health \n2005 ) \ninstrument specificity was either \ninferior or equivalent to specialist \ndiagnosis, and sample sizes were \ninadequate to assess  \ndifferences in sensitivity  \nLoE: II, References: 25, 40, 41  \n \nEight level IV studies and one level III -3 \nstudy exa mined surveillance of high -\nrisk subjects with total body \nphotography but only one included a \ncompar ison arm (of lower -risk \nsubjects). All studies on high -risk \npatients showed early mel anoma \ndetection and/or high melanoma \nincidence.  \nAll studies were designed  to assess the \noutcomes of  \nsurveillance in high -risk groups r ather \nthan the value of TBP.  \nLoE: IV  \nReferences: 4 3\u201351 \nBemerkungen   Diese Leitlinie bezieht sich auf MM und \nauf NMSC.  \n Das Gutachten der HAS, der Artikel der \nAHRQ, auf den die Leitlinie sich \nbezieht, sowie dessen Aktualisierung  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 23 von 732  LL Austr alien  \nNew Zealand Guidelines Group 2008  LL GB  \nNICE 2006  LL Frankreich  \nFrench National Authority for Health \n2005 ) \nReferenzen und ausf\u00fchrliche \nEvidenztabellen dieser Leitlinie werden \nwegen ihres Umfangs als separates \nDokument zur Ve rf\u00fcgung gestellt:  \nGB NICE Guideline Evidence R eview, S. \n174 bis 211.  aus dem Jahr 2009 werden als \nZusatzmaterial zu dieser Tabelle zur \nVerf\u00fcgung gestellt.  \n \nLiteratur:  \n \nLL Austr alien New Zealand Guidelines G roup 2008  \n21. Agenziano G, Puig S, Zalaudek I, et al. Dermoscopy improves accuracy of primary care physicians to triage lesions suggestive of skin cancer. J Clin Oncol 2006;24:187 7-\n1882  \n20. Bafounta ML, Beauchet A, Aegerter P, et al. Is dermoscopy (epilumi nescence microscopy) useful for the diagnosis of melanoma? Results of a meta -analysis using techniques \nadapted to the evaluation of diagnostic tests. Arch Dermatol 2001;137:1343 -1350  \n51. Banky JP, Kelly JW, English DR, et al. Incidence of new and changed n evi and melanomas detected using baseline images and dermoscopy in patients at high risk for \nmelanoma. Arch Dermatol 2005;141:998 -1006  \n40. Bauer P, Cristofolini P, Boi S, et al. Digital epiluminescence microscopy: usefulness in the differential diagnosis o f cutaneous pigmentary lesions. A statistical comparison \nbetween visual and computer inspection. Melanoma Res 2000;10:345 -349 \n27. Benelli C, Roscetti E, Pozzo VD, et al. The dermoscopic versus the clinical diagnosis of melanoma. Eur J Dermatol 1999;9:470 -476 \n34. Binder M, Puespoeck -Schwarz M, Steiner A, et al. Epiluminescence microscopy of small pigmented skin lesions: short -term formal training improves the diagnostic \nperformance of dermatologists. J Am Acad Dermatol 1997;36:197 -202 \n25. Bono A, Bartoli C, Cascinelli N, et al. Melanoma detection. A prospective study comparing diagnosis with the naked eye, dermatoscopy and telespectrophotometry. \nDermatology 2002;205:362 -366 \n26. Bono A, Tolomio E, Trincone S, et al. Micro -melanoma detection: a clinical study o n 206 consecutive cases of pigmented skin lesions with a diameter < or = 3 mm. Br J \nDermatol 2006;155:570 -573 \n17. Bowling J, Argenziano G, Azenha A, et al. Dermoscopy key points: recommendations from the international dermoscopy society. Dermatology 2007;2 14:3-5 \n22 .Carli P, de Giorgi V, Chiarugi A, et al. Addition of dermoscopy to conventional naked -eye examination in melanoma screening: a randomized study. J Am Acad Dermatol \n2004;50:683 -689 \n23. Carli P, De Giorgi V, Crocetti E, et al. Improvement of malig nant/benign ratio in excised melanocytic lesions in the 'dermoscopy era': a retrospective study 1997 -2001. Br J \nDermatol 2004;150:687 -692 \n24. Carli P, Mannone F, De Giorgi V, et al. The problem of false -positive diagnosis in melanoma screening: the impact of dermoscopy. Melanoma Res 2003;13:179 -182 \n28. Cristofolini M, Zumiani G, Bauer P, et al. Dermatoscopy: usefulness in the differential diagnosis of cutaneous pigmentary les ions. Melanoma Res 1994;4:391 -394 \n32. Dolianitis C, Kelly J, Wolfe R, et al. Compar ative performance of 4 dermoscopic algorithms by nonexperts for the diagnosis of melanocytic lesions. Arch Dermatol \n2005;141:1008 -1014   \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 24 von 732 29. Dummer W, Doehnel KA, Remy W. Videomicroscopy in differential diagnosis of skin tumors and secondary prevention of ma lignant melanoma. Hautarzt 1993;44:772 -776 \n46. Feit NE, Dusza SW, Marghoob AA. Melanomas detected with the aid of total cutaneous photography. Br J Dermatol 2004;150:706 -714 \n36. Haenssle HA, Krueger U, Vente C, et al. Results from an observational trial: d igital epiluminescence microscopy follow -up of atypical nevi increases the sensitivity and the \nchance of success of conventional dermoscopy in detecting melanoma. J Invest Dermatol 2006;126:980 -985 \n41. Har-Shai Y, Glickman YA, Siller G, et al. Electrical i mpedance scanning for melanoma diagnosis: a validation study. Plast Reconstr Surg 2005;116:782 -790 \n45. Kelly JW, Yeatman JM, Regalia C, et al. A high incidence of melanoma found in patients with multiple dysplastic naevi by phot ographic surveillance. Med J  Aust \n1997;167:191 -194 \n35. Kittler H, Guitera P, Riedl E, et al. Identification of clinically featureless incipient melanoma using sequential dermoscopy imaging. Arch Dermatol 2006;142:1113 -1119  \n19. Kittler H, Pehamberger H, Wolff K, et al. Diagnostic accu racy of dermoscopy. Lancet Oncol 2002;3:159 -165 \n48. MacKie RM, McHenry P, Hole D. Accelerated detection with prospective surveillance for cutaneous malignant melanoma in high -risk groups. Lancet 1993;341:1618 -1620  \n18. Malvehy J, Puig S, Argenziano G, et al . Dermoscopy report: proposal for standardization. Results of a consensus meeting of the International Dermoscopy Society. J Am Acad \nDermatol 2007;57:84 -95 \n43. Marghoob AA, Kopf AW, Rigel DS, et al. Risk of cutaneous malignant melanoma in patients with 'cl assic' atypical -mole syndrome. A case -control study. Arch Dermatol \n1994;130:993 -998 \n47. Masri GD, Clark WH,Jr, Guerry D,4th, et al. Screening and surveillance of patients at high risk for malignant melanoma result  in detection of earlier disease. J Am Acad  \nDermatol 1990;22:1042 -1048  \n15. Menzies S, Crotty KA, Ingvar C, McCarthy WH. An Atlas of Surface Microscopy of Pi gmented  Skin Lesions: Dermoscopy. 2nd ed. Sydney: McGraw -Hill, 2003.  \n37. Menzies SW, Gutenev A, Avramidis M, et al. Short -term digital surface microscopic monitoring of atypical or changing melanocytic lesions. Arch Dermatol 2001;137:1583 -\n1589  \n16. Menzies SW, Zalaudek I. Why perform dermoscopy? The evidence for its role in the routine management of pigmented skin lesions . Arch Dermatol 2006;142:1 211-1212  \n44. Rivers JK, Kopf AW, Vinokur AF, et al. Clinical characteristics of malignant melanomas developing in persons with dysplastic nevi. Cancer 1990;65:1232 -1236  \n38. Robinson JK, Nickoloff BJ. Digital epiluminescence microscopy monitoring of high -risk patients. Arch Dermatol 2004;140:49 -56 \n39. Rosado B, Menzies S, Harbauer A, et al. Accuracy of computer diagnosis of melanoma: a quantitative meta -analysis. Arch Dermatol 2003;139:361 -7; discussion 366  \n42. Shriner DL, Wagner RF,Jr. Photographic utilizat ion in dermatology clinics in the United States: a survey of university -based dermatology residency programs. J Am Acad \nDermatol 1992;27:565 -567 \n30. Stanganelli I, Serafini M, Bucch L. A cancer -registry -assisted evaluation of the accuracy of digital epilum inescence microscopy associated with clinical examination of \npigmented skin lesions. Dermatology 2000;200:11 -16 \n50. Tiersten AD, Grin CM, Kopf AW, et al. Prospective follow -up for malignant melanoma in patients with atypical -mole (dysplastic -nevus) syndrom e. J Dermatol Surg Oncol \n1991;17:44 -48 \n31. Vestergaard ME, Macaskill P, Holt PE, et al. Dermoscopy compared with naked eye examination for the diagnosis of primary melanoma: a meta -analysis of studies \nperformed in a clinical setting. Br J Dermatol 2008;159 :669-676 \n49. Wang SQ, Kopf AW, Koenig K, et al. Detection of melanomas in patients followed up with total cutaneous examinations, total cutaneous photography, and dermoscopy . J Am \nAcad Dermatol 2004;50:15 -20 \n33. Westerhoff K, McCarthy WH, Menzies SW. Incre ase in the sensitivity for melanoma diagnosis by primary care physicians using skin surface microscopy. Br J De  \n \nLL Frankreich  French National Authority for Health 2005 ) \n17. AHRQ, Agency for Healthcare Research and Quality. Screening for Skin Cancer. File Inventory, Syste matic Evidence Review Number 2 [online]. AHRQ Publication 2001. \nAvailable: URL: http://www.ahrq.gov/clinic/prev/ skncainv.htm  \n160. Bafounta ML, Beauchet A, Aegerter P, et al. Is dermoscopy (epiluminescence microscopy) useful for the diagnosi s of melanoma? Results of a meta -analysis using \ntechniques adapted to the evaluation of diagnostic tests. Arch Dermatol 2001;137:1343 -1350  \n161. Kittler H, Pehamberger H, Wolff K, et al. Diagnostic accuracy of dermoscopy. Lancet Oncol 2002;3:159 -165  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 25 von 732 1.2. Frage I .3. Konfokale Laserscan -Mikroskopie und optische Koh\u00e4renztomographie - De-\nnovo-Recherche  \nFrage I.3.  Welche Hilfsmittel oder apparativen Verfahren k\u00f6nnen die klinische Diagnostik des MM ggf. weiter verbessern  \nBeantwortung durch Adaptation (s.o . I.2.)  \nErg\u00e4nz ende Recherche zu:   \n- Konfokale Laserscan -Mikroskopie (CLSM)  \n- Optische Koh\u00e4renztomographie (OCT)  \n \n1.2.1.  PICO, Suchw\u00f6rter  \n \nSuchw\u00f6rter  \nStichwort  melanoma  Confocal, laserscan microscopy  \nSynonyme  melanoma  Clsm  \nOber -/Unterbegriffe, MESH -Term  s. Suchstrategie  \n \n \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 26 von 732 1.2.2.  Datenbanken, Suchstrategien, Trefferzahlen  \nDatenbank  Suchstrategie  Datum  Treffer \n1. Suche     \nMedline  \"melanoma\"[tiab] AN D (\"confocal\"[tiab] OR \"laserscan microscopy\"[tiab] OR \n\u201cclsm\u201d[tiab]) NOT \"uveal\"[tiab] NOT \"models, animal\"[Mesh]  \n \n\"melanoma\"[tiab] AND (\" oct\"[tiab] OR \"optical coherence tomography\"[tiab] OR \n\u201coptical coherence tomographic\u201d[tiab] OR \u201cmultiphoton\"[tiab]) NOT \"uveal\"[tiab] \nNOT \"models, an imal\"[Mesh]  26.01.2012  275 \n \n \n92 \nCochrane Library  melanoma and (confocal or \"laserscan microscopy\" or clsm) .ti,ab.  \n \nmelanoma and (oct or \"optical coherence tomography\" or \u201coptical coherence \ntomographic\u201d or \u201cmultiphoton\").ti,ab.  26.01.2012  \n \n26.01.2012  1 \n \n4 \nBemerkungen: Datum der Erst -Recherche f\u00fcr Medline und Cochrane war der 21.09.2010. Eine letzte Update -Recherche erfolgte am 26.01.2012 f\u00fcr \nMedline bzw. am 19.01.2012 f\u00fcr Cochrane. In den Tabellen angegeben sind die Za hlen der letzten Update -Recherche.  \n \n31.08.2012: Aufgrund der eingegangenen Kommentare im Rahmen der Konsultationsphase in Bezug auf die  Literatu rauswahl zur konfokalen \nLaserscanmikroskopie wurde die Literatur, die bei der systematischen Recherche gefunden wurden, reevaluiert. Die Tabelle wurde daraufhin erg\u00e4nzt \nentsprechend der angegeben Ein - und Ausschlu\u00dfkriterien.  \n \nAbschlu\u00df Konsultationsphase, S tand 09/2012: Das Statement zur konfokalen Laserscanmikroskopie wurde aus der Leitlinie herausgenommen (Details: s. \n\u201eKommentare zur Konsulationsfassung\u201c). Eine \u00dcbera rbeitung der Evidenztabelle nach erneuter sytematischer Literaturrecherche ist f\u00fcr das Upda te der \nLeitlinie geplant.  \n \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 27 von 732 1.2.3.  Auswahlkriterien  \nAuswahl der Literatur  \nGesamttreffer  372 \nEinschlusskriterien  Thematische \u00dcbereinstimmung  \nSprachen: e,dt  \nAusschlusskriterien  Case Reports, narrative Reviews, Bench Research  \n \nCLSM: nur Artikel, bei Sensitivit\u00e4t  und Spezifit\u00e4t bestimmt wurden   \nAnzahl nach Abstractscreening  29 \nAnzahl ausgew\u00e4hlter Volltexte, vorges ehen f\u00fcr Bewertung  9 \n \n1.2.4.  Evidenztabelle  \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nSubtopic:  \nOptical coherence \ntomography (OCT), \nMultip hoton laser \ntomography (MLT)         \nDimitrow et al. \n(2009)  To examine the \nclinical applicability \nof mu ltiphoton laser \ntomography with \nregard to statistical \nevaluation of Diagnostic study  \n 83  patients  Sensitivity and \nspecificity in and ex \nvivo \n \nAccuracy  \n Overall sensitivity \n75% in vivo, 93% ex \nvivo \n \nSpecificity 80% in \nvivo, 74% ex vivo  Specificity and \nsensitivity for single \ncriteria: see full -text \nof publication  \n \n 2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 28 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \nsensitivity, \nspecificity, accuracy, \nand reli ability.  Interobserver \nreliability   \nDiagnostic accuracy \n85% in vivo, 97% ex \nvivo \n \nInterobserver \nagreement: kappa \nvalues for diffe rent \ncriteria ranging \nfrom 0.6 to 0.8  \nGambichler et al. \n(2007)  To visualize and \ncharacterize \nmelanocytic skin \nlesions (MSL) by \nusing OCT in vivo, \ncompare OCT \nfeatures of be nign \nnevi (BN) and MM, \nand histologically \nvalidate the OCT \nfindings. Diagnostic study  \n \n 75 patients with 92 \nMSL Frequency of seve ral \ncharacteristics of \nlesions  See full -text for \nfrequency of all \ninvestigated \ncharacteri stics of \nlesions.  The diagnostic \nperformance of OCT \nin the diagnosis of \nMSL could not be \nfully determined.  \nSensitivity and \nspecificity studies \nalso inclu ding other \nskin tumors have \nnot been pe rformed  \n 3b \nSubtopic:  \nConfocal laser scan \nmicroscopy (CLSM )        \nGerger et al. (2007)  To validate \ndiagno stic confocal A total of 3709 \nunselected CLSM 60 patients  Sensiti vity and \nspecificity  Sensitivity 97.5%  \n High risk of \nverific ation bias (no  3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 29 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \nexam ination of \nmelanocy tic skin \ntumours u sing \nunselected t umour \nimages.  tumour images \nobtained from 20 \nmalignant \nmelanomas and 50 \nbenign naevi   \nPositive and \nnegative predictive \nvalue (PPV, NPV)  \n \nDiagnostic accuracy  Specificity 99%  \n \nPPV 97.5%  \n \nNPV 99%  \n \nDiagnostic accuracy \n92.4% for benign \nnaevi and 97.6% for \nmelanoma i mages histol ogy if \ndiagnosed \u201con \nunequivocal clinical \nand conventional \nderm oscopic  \ncriteria as benign \nnevi\u201c)  \n \nComputerized \nimages were \nprovided, a loss in \nsensitivity or \nspecificity through \nacquisition of the \nimages by an \nunexperienced \nexaminer could \ntherefore not be \nobserved  \nGerger et al. (2005)   To systematically \nvalidate CLSM in \ndiagnosing \nmelan ocytic skin \ntumors in an \nobserver-blinded \nmanner, and to \nevaluate Diagnostic study  \n \n 88 patients with \n117 lesions (90 \nbenign nevi, 27 \nmelan omas) Sensitivity, \nspecific ity \n \nPositive and \nnegative predictive \nvalue (PPV, NPV)  5 independent \nobservers without \nprevious experience \nin CLSM  \n \n2 Residents:  \nsensiti vity 96.3%, \nspecificity 100% and High risk of \nverific ation bias \n(selective \nhistopathological \nconfirmation of \ndiagnosis)  \n 2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 30 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \nmorpholo gic \nfeatures dete rmined \nby CLSM for their \npresence or \nabsence, diagnostic \nperfor mance, an d \nreliability.  99%, PPV 100% and \n96.3%, NPV 99%  \n \nSenior physician \nwithout \ndermat opathologic \nqualific ation:  \nsensitivity 92.6% \nand specifi city 99%, \nPPV 96.2%, NPV 98%  \n \n2 \nDermat opathologist\ns: \nsensitivity 96.3% \nand 59.3%, \nspecificity 94% and \n96%, PPV 81.3% and \n80%, NPV 99% and \n89.7%  \n \nOverall sensitivity \n88.2%, specificity \n97.6%, PPV 90.7%, \nNPV 96.9%.  \nGerger et al. (2006)   To systematically \ninvestigate the  Diagnostic study  \n 119 patients with \n117 melanocytic Sensitivity, \nspecific ity Diagnostic \ndiffere ntiation of High risk of \nverific ation bias (see 2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 31 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \ndiagnostic i mpact \nand reliability of \nwell described \nmorph ologic \nfeatures in a large \nseries of \nmelanocytic and \nnonmelanocytic skin \ntumors.  and 45 non -\nmelanocytic skin \nlesions   \nPositive and \nnegative predictive \nvalue (PPV, NPV)  MM from BCC, BN, \nand SK reached \nsensiti vity and \nspecificity va lues of \n85.19% and 98.52% \n(Observer 1), \n92.59% and 98.52% \n(Observer  \n2), and 92.59% and \n99.26% (Observers 3 \nand 4), r espectiv ely \nwith the follo wing \noverall perfor mance: \nsensitivity, 90.74%; \nspecificity, 98.89%; \nPPV, 94.22%; and \nNPV, 98.17%.  above)  \n \nGerger et al. (2008)   To assess the \napplicability of \nimage analysis and \na machine le arning \nalgorithm on \ndiagnostic \ndiscrim ination of \nbenign and \nmalignant \nmelanocytic skin Diagnostic study  \n \n 60 patients (total of \n857 CLSM t umour \nimages inclu ding \n408 benign nevi and \n449 melanoma \nimages)  Sensitivity, \nspecific ity Correct \nclassific ation by \nCART anal ysis in \n97.55% and 96.32% \nof melan oma and \nnevi images, overall \nperfo rmance 96.97%  \n \nHuman observer:  \nsensitivity 85.52%, Use of pre -selected \nCLSM images (high \nrisk of s election \nbias) 3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 32 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \ntumours in in vivo \nconfocal laser -\nscanning \nmicrosc opy (CLSM).  specifi city 80.15%,  \noverall perfor mance \n82.84%, positive \npredictive value \n82.58%, negative \npredictive  \nvalue 83.42%  \nKoller et al. (2010)  To investigate the \napplicability of an \nautomated image \nanalysis system \nusing a m achine \nlearning algorithm \non diagnostic \ndiscrimination of \nbenign and \nmalignant \nmelanocytic skin \ntumours in \nreflectance confocal \nmicroscopy (RCM)  Diagnostic study  \n 178 patients with \n16269 RCM tumor \nimages  Diagnostic accuracy  Classification tree \nanalysis:  \ncorrect classific ation \nin 93.60% of \nmelanoma  and \n90.40% of nevi \nimages of the \nlearning set  \n \nWhen applied to the \nindependent test set \n46.71 \u00b1 19.97% \n(range 7.81 \u201383.87%) \nof the t umour \nimages in benign \nmelanocytic skin \nlesions were \nclassified as \n\u2018mali gnant\u2019, in \ncontrast to 55.68 \u00b1 Risk of verification \nbias (verification by \nhisto pathology \ndependent on \nclinical examination)  \n \nROC curve: see full -\ntext 3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 33 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \n14.58% (range \n30.65 \u201383.59%; t -\ntest: P < 0.036) in \nmalignant \nmelan ocytic skin \nlesions  \n \n78.95% of \nmelan ocytic skin \ntumours (62.50% of \nthe me lanoma and \n84.50% of the nevi) \ncorrectly classified \nby ind ependent \nclinical \ndermatol ogist \nLangley et al. (2007)  The aim of this study \nwas to eval uate the \ndiagnostic acc uracy of \nCSLM compared to \ndermoscopy in a \nprospective \nexamin ation of benign \nand malignant \nmelan ocytic l esions.  Diagnostic study  \n \n. 125 patients  Sensitivity, \nspecific ity \n \nPositive and \nnegative predictive \nvalue (PPV, NPV)  Dermoscopy:  \nsensitivity 89.2%, \nspecificity 84.1%, PPV \n70.2%, NPV 94.9%  \n \nCSLM:  \nsensitivity 97.3%, \nspecifi city 83.0%, PPV \n70.6%, NPV 98.6%  \n \nNo melan omas \nmisidentified when \nboth tec hniques were \nused  No verification bias \n(all diagnoses were \nconfirmed \nhistolog ically)  \n \nClinical, \ndermat oscopic and \nconfocal imaging \nwere pe rformed \nsequentially by a \nsingle obser ver; 2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 34 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \ntogether  result of clinical \nexamina tion and \ndermatoscopy may \nlead to bias in \nconfocal \nexamin ation \nLorber et al. (2009)  To examine the \ncorrelation between \nobjectively \nreproducible image -\nanalysis features \nund visual \nmorpho logy in \nmelan ocytic skin \ntumours using \nCLSM.  Diagnostic study  \n \n 60 patients with 70 \nmelanocytic skin \nlesions  Diagnostic accuracy  CART analysis of the \nwhole set of CLSM \ntumour ima ges \ncorrectly class ified \n97.55% of \nmelanoma images \nand 96.32% of nevi \nimages.  High risk of \nverific ation bias \n(selective \nhistopathological \nconfirm ation of \ndiagnosis).  \n 3b \n \nAnmerkung: Bei Studien, die f\u00fcr zwei oder mehrere Teilfragen relevant sind, ist nur der Ergebnisteil und LoE erneut angegeben, f\u00fcr die \n\u00fcbrigen Felder wird auf die erste Erw\u00e4hnung der Studie in der Evidenztabelle verwiesen.  \n1.2.5.  Litera tur \n \nDimitrow E, Ziemer M, Koehler MJ, et al. Sensitivity and specificity of multiphoton laser tomography for in vivo and ex vivo diagnosis of malignant melanoma. J Invest Dermatol \n2009;129:1752 -1758  \nGambichler T, Regeniter P, Bechara FG, et al. Characteri zation of benign and malignant melanocytic skin lesions using optical coherence tomography in vivo. J Am Acad \nDermatol 2007;57:629 -637 \nGerger A, Hofmann -Wellenhof R, Langsenlehner U, et al. In vivo confocal laser scanning microscopy of melanocytic skin tum ours: diagnostic applicability using unselected \ntumour images. Br J Dermatol 2008;158:329 -333  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 35 von 732 Gerger A, Koller S, Kern T, et al. Diagnostic applicability of in vivo confocal laser scanning microscopy in melanocytic skin tumors. J Invest Dermatol 2005;124:4 93-498 \nGerger A, Koller S, Weger W, et al. Sensitivity and specificity of confocal laser -scanning microscopy for in vivo diagnosis of malignant skin tumors. Cancer 2006;107:193 -200 \nGerger A, Wiltgen M, Langsenlehner U, et al. Diagnostic image analysis of m alignant melanoma in in vivo confocal laser -scanning microscopy: a preliminary study. Skin Res \nTechnol 2008;14:359 -363 \nKoller S, Wiltgen M, Ahlgrimm -Siess V, et al. In vivo reflectance confocal microscopy: automated diagnostic image analysis of melanocytic  skin tumours. J Eur Acad Dermatol \nVenereol 2010  \nLangley RG, Walsh N, Sutherland AE, et al. The diagnostic accuracy of in vivo confocal scanning laser microscopy compared to dermoscopy of benign and malignant melanocy tic \nlesions: a prospective study. Derma tology 2007;215:365 -372 \nLorber A, Wiltgen M, Hofmann -Wellenhof R, et al. Correlation of image analysis features and visual morphology in melanocytic skin tumours using in vivo confocal laser \nscanning microscopy. Skin Res Technol 2009;15:237 -241 \n \n1.3. Frage I.6. , I.7., I.8., VII.6.  Ausbreitungsdiagnostik bei Patienten mit malignem Melanom  \n\u2013 De-novo-Recherche  \nFrage I.6.  Welche Ausbreitungsdiagnostik ist bei asymptomatischen Patientien bei Diagnose des Prim\u00e4rtumors bis Stadium IIA/ab \nStadium IIB  indiziert?  \nFrage I. 7. Welche Ausbreitungsdiagnostik ist bei Patientien mit Verdacht auf bzw. Nachweis von lokoregionaler Metastasierung indiziert?  \nFrage I. 8. Welche Ausbreitungsdiagnostik ist bei Patientien mit Verdacht auf bzw. Nachweis von Fernmetastasen indiziert?  \nFrage V II.6. Welche Unersuchungen sind im Rahmen der Nachsorge bei asymptomatischen Patienten indiziert?  \n \n1.3.1.  PICO, Suchw\u00f6rter  \nVerfahren:  \n- LK-Sono  \n- R\u00f6ntgen -Thorax  \n- Abdomen -Sono  \n- MRT \n- CT \n- PET  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 36 von 732 - PET/CT  \n- Szintigraphie  \n- Labor  \n \nPICO-Unterf ragen:  \n- Wie ist die Sensitivit\u00e4t und Spezifi t\u00e4t des Verfahrens  zur Diagnose von Metastasen des MM bei Prim\u00e4rdiagnose?  \n- \u00c4ndert die Durchf\u00fchrung des Verfa hrens  bei Patienten mit Prim\u00e4rdiagnose des MM das Krankheitsstadium?  \n- \u00c4ndert die Durchf\u00fchrung des Verfahrens bei Patienten mit Prim\u00e4rdiagnose des MM die Therapie?  \n- \u00c4ndert die Durchf\u00fchrung des Verfahrens bei Patienten mit Prim\u00e4rdiagnose des MM das \u00dcberleben?  \n- Wie hoch sind die zus\u00e4tzlichen Kosten bei Durchf\u00fchrung des Verfahrens bei Patienten mit Prim\u00e4rdiagnose des MM?  \n \n1.3.2.  Datenbanken, Suchstrategie, Trefferz ahlen  \nDatenbank  Suchstrategie  Datum  Treffer \n1. Suche   Der letzten \nUpdate-\nRecherche:  \n Insgesamt (U pdate-\nRecherche)  \nMedline  \"melanoma\"[tiab] AND (\u201cstaging\u201d[all fields] OR \"diagnosis\"[all fields]) AND \n((\"ultrasono graphy\"[Mesh] OR \"ultrasonography\"[all field s] OR \n\"sonography\"[all fields]) OR (\"lymph nodes\"[all fields] OR (\"lymph\"[all fields] \nAND \"nodes\"[all fields]) OR \"lymph nodes\"[all fields] OR (\"lymph\"[ all fields] \nAND \"node\"[all fields]) OR \"lymph node\"[all fields]))  \n \n\"melanoma\"[tiab] AND (\u201cstaging\u201d[all fields] OR \"diagnosis\"[all fields]) AND \n(\"chest X -ray\"[all fields] OR \"chest radiography\"[all fields] OR \"Radiography, \nThoracic\"[Mesh])  26.01.2012  3153  \n \n \n \n \n \n83 \n \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 37 von 732 Datenbank  Suchstrategie  Datum  Treffer \n \n\"melanoma\"[tiab] AND (\u201cstaging\u201d[all fields] OR \"diagnosis\"[all fields]) AND \n((\"ultrasono graphy\"[Mesh] OR \"ultrasonograp hy\"[all fields] OR \n\"sonography\"[all fields]) OR \"abd omen\"[all fields] OR \u201cabdominal\"[all fields]) \nNOT (\"ophthalmology\"[Mesh] OR \"eye\"[Mesh] OR \"eye neoplasms\"[Mesh])  \n \n\"melanoma\"[tiab] AND (\u201cstaging\u201d[all fields] OR \"diagnosis\"[all fields]) AND \n(\"Magnetic Re sonance Imaging\"[Mesh] OR \u201cMagnetic Resonance Imaging\u201d[all \nfields] OR \u201cmri\u201d[all fields] OR \u201cmagnetic resonance\u201d[all fields]) NOT \n(\"ophthalmology\"[Mesh] OR \"eye\"[Mesh] OR \"eye neoplasms\"[Mesh])  \n \n\"melanoma\"[tiab] AND (\u201cstaging\u201d[all fields] OR \"diagnosis\"[all  fields]) AND \n(\u201cTomography, X -Ray Computed\"[Mesh] OR \u201ccomputer tomography\u201d[all \nfields] OR \u201cct\u201d[all fields] OR \"Tomography, Spiral Computed\"[Mesh] OR \n\"Tomography Scanners, X -Ray Compu ted\"[Mesh] OR \"Positron -Emission \nTomography\"[Mesh] OR \u201cpositron -emission t omogr aphy\u201d[all fields] OR \n\u201cpet\u201d[all fields] OR \"Tomography, Emission -Computed, Single -Photon\"[Mesh] \nOR \u201csingle -photon emission computed tomography\u201d[all fields] OR \u201cspect\u201d[all \nfields]) NOT (\"ophthalmology\"[Mesh] OR \"eye\"[Mesh] OR \"eye \nneoplasms\"[Mesh])  \n \n\"melanoma\"[tiab] AND (\u201cstaging\u201d[ tiab] OR \"diagnosis\"[ tiab]) AND \n(\"scintigraphy\u201d[ tiab] OR \u201cscinti*\u201d[tiab]) NOT (\"ophthalmology\"[Mesh] OR \n\"eye\"[Mesh] OR \"eye ne oplasms\"[Mesh])  \n \n\"melanoma\"[tiab] AND (\"LDH\"[all fields] OR \u201clactate dehydrogenase\u201d OR \n\"S100\"[all fields] OR \"MIA\"[tiab] OR \"melanoma -inhibiting activity\"[tiab]) AND  \n588 \n \n \n \n \n595 \n \n \n \n \n936 \n \n \n \n \n \n \n \n \n \n66 \n \n \n \n594 \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 38 von 732 Datenbank  Suchstrategie  Datum  Treffer \n(\u201cstaging\u201d[all fields] OR \"diagnosis\"[all fields]) NOT (\"ophthalmology\"[Mesh] \nOR \"eye\"[Mesh] OR \"eye ne oplasms\"[Mesh])  \n  \n \nCochrane Library  (melanoma and (staging or diagnosis) and (\"chest x -ray\" or \"chest \nradiography\")).ti,ab.  \n \n(melanoma and (staging or diagnosis) and (\"ultrasonography\" or \n\"sonography\" or \"ultr asound\" or sonogr*)).ti,ab.  \n \n(melanoma and (staging or diagnosis ) and (\"magnetic resonance\" or \nmri)).ti,ab.  \n \n(melanoma and (staging or diagnosis) and (\u201ccomputer tomography\u201d or ct or \n\u201cpositron emission tomography\u201d or pet or spect or \u201csingle -photon emission \ncomputed tomography\u201d or \u201cspect ct\u201d or \u201cpet ct\u201d)).ti,ab.  \n \n(melano ma and (staging or diagnosis) and (scintigraphy or scinti*)).ti,ab.  \n \n(melanoma and (staging or diagnosis) and (ldh or \"lactate dehydrogenase\" or \ns100* or mia or \"melanoma inhibiting activity\")).ti,ab.  \n \n 19.01.2012  7 \n \n \n7 \n \n \n5 \n \n \n9 \n \n \n \n4 \n \n10 \n \n \n \nEmbase  (melanom a and (staging or diagnosis) and (\"chest x -ray\" or \"chest \nradiography\")).ti,ab.  \n \n(melanoma and (staging or diagnosis) and (\"ultrasonography\" or 23.01.2012  79 \n \n \n546  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 39 von 732 Datenbank  Suchstrategie  Datum  Treffer \n\"sonography\" or \"ultr asound\" or sonogr*)).ti,ab.  \n \n(melanoma and (staging or diagnosis) and (\"magnetic resonance\"  or \nmri)).ti,ab.  \n \n(melanoma and (staging or diagnosis) and (\u201ccomputer tomography\u201d or ct or \n\u201cpositron emission tomography\u201d or pet or spect or \u201csingle -photon emission \ncomputed tomography\u201d or \u201cspect ct\u201d or \u201cpet ct\u201d)).ti,ab.  \n \n(melanoma and (staging or diagnosi s) and (scintigraphy or scinti*)).ti,ab.  \n \n(melanoma and (staging or diagnosis) and (ldh or \"lactate dehydrogenase\" or \ns100* or mia or \"melanoma inhibiting activity\")).ti,ab.   \n \n431 \n \n \n777 \n \n \n \n142 \n \n317 \nBemerkungen: Datum der Erst -Recherche  f\u00fcr Medline und Cochrane war der 17.08.2010. Die erste EMBASE -Recherche erfolgte am 11.05.2011. Eine letzte \nUpdate -Recherche (initiale Suche, Erg\u00e4nzungsrecherche) erfolgte am 23.01.2012 f\u00fcr EMBASE, am 26.01.2012 f\u00fcr Medline bzw. am 19.01.20 12 f\u00fcr Cochrane . In \nden Tabellen angegeben sind die Za hlen der letzten Update -Recherche.  \nBez\u00fcglich Tumor -Marker:  da eine Meta -Analyse (Mocellin et al. 2008) vorliegt, wurden lediglich Studien eingeschlossen, die nicht in der Meta -Analse enthalten \nwaren, die nach der Meta analyse erschienen sind oder die bestimmte Teilaspekte abdecken, die in der Meta -analyse nicht ber\u00fccksichtigt wurden.  \n \nBez\u00fcglich PET und PET/CT:  Die erste systematische Recherche zeigte zwei Meta -Analysen (Krug und Jimenez -Requena). Einzelne Studien wurde n nur mit \naufgenommen, s ofern sie noch nicht in diesen beiden Meta -analysen enthalten waren oder Aspekte beinhalteten, die aus den Meta -analysen nicht hervorgingen. \nDa die Meta -Analyse von Xing erst im Rahmen einer Update -Recherche identifiziert wurde, sin d einzelne Studien, die in der Meta -analyse enthalten sind, auch in \ndieser Tabelle aufgef\u00fchrt. Die Studien sind jedoch gekennzeichnet und haben einen dementsprechend schlechteren Ev idenzgrad.  \n \nBei gleicher Suchstrategie zu den Fragen I.6, I.7, I.8 und VII. 6 und teils \u00dcberschneidungen der Studien sind alle relevanten Recherche -Ergebnisse in dieser \nTabelle zusammengefasst. Eine \u00dcbersicht \u00fcber die Zuteilung der Studien zu den verschiedenen Fragestellungen befindet sich am Ende der Tabe lle. \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 40 von 732 1.3.3.  Auswahlkriterien  \nAuswahl der Literatur  \nGesamttre ffer 8349  \nEinschlusskriterien  Thematische \u00dcbereinstimmung  \nSprachen: e,dt  \nAusschlusskriterien  Case Reports, narrative Reviews, Bench Research  \nAnzahl nach Abstractscreening  296 \nAnzahl ausgew\u00e4hlter Volltexte, vorges ehen f\u00fcr Bewertung  114 \n1.3.4.  Evidenztabelle (zusammengefa\u00dft f\u00fcr I.6., I.7., I.8., VII.6.)  \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nSubtopic  \nLYMPH NODE \nULTRASOUND         \nXing et al. (2011)  To examine the \nutility of \nultrasonography, \ncomputed \ntomograph y (CT), \npositron emission \ntomography (PET), \nand a combination \nof both (PET -CT) for \nthe staging and \nsurveillance of Systematic review \nand meta -analysis  \n 10 528 patients \nwith cutaneous \nmelanoma at \nprimary diagnosis \nor under \nsurveillance \n(follow -up) Sensitivity, \nspecificity  \nDiagnostic odds\u2019 \nratio (OR)  Data for initial \nstaging of regional \nnodes:  \nSensitivity 60%  \nSpecificity 97%  \nDiagnostic OR 42  Very large patient \ncohort, but patients \nunder follow -up \nincluded  \n \n 1a  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 41 von 732 melanoma patients.  \nBafounta et al. \n(2004)  To in vestigate \nwhether lymph -\nnode \nultrasonography \nimproves detection \nof nodal invasion \nduring the initial \nstaging and follow -\nup of patients with \nmelanoma.  Systematic review \nand meta -analysis \nof 12 published \ndiagnostic studies \nuntil December \n2003   6642 patients  \nPredominantly \nstage I and II, six \nstudies also stage \nIII, very few (1.9% in \none study) stage IV  Sensitivity and \nspecificity  \nOdds\u2019 ratios  \nPositive and \nnegative likelihood \nratios  Odds ratio of \nsonography: 1755 \n(95% CI 726 \u20134238)  \nOdds\u2019 ratio of \npalpation 21 (4\u2013\n111) \nSonography:  \nPositive likelihood \nratio 41.9, negative \nlikelihood ratio \n0.024  \nPalpation:  \nPositive likelihood \nratio 4.55, negative \nlikelihood ratio \n0.22 Variations in the \ndefinition of false \nnegatives and \nverification bias in \nincluded studies  \n \n 1a \nVoit et al. (2010)  The aim of this \nstudy was to \nevaluate a number \nof specifically \ndefined morphology \nUS patterns and to \ncorrelate this with \ntumor involvement \nof the SN.  Prognostic and \ndiagnostic study  400 patients with \nCM before SLNE  Sensitivity, \nspecificity  \nPositive predictive \nvalue, negative \npredictive value  \nOverall and distant -\nmetastasis -free \nsurvival  \n Highest sensitivity \nand PPV in \nfollowing \ncombination: \npresence of \nperipheral \nperfusion, loss of \ncentral echoes, and \nballoon -shaped \nlymph nodes  \nSensitivity 82% Preliminary report \n(400 of 650 \npatients)  \n \n 1b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 42 von 732 Specificity 80%  \nPPV 52%  \nNPV 94%  \n5-year OS \naccording to \nperipheral \nperfusion 81% and \n92% for present and \nabsent  \n5-year OS for the \nloss of central \nechoes 49% vs. 92% \nwhen echoes still \npresent  \n5-year OS rates for \nthe presence and \nabsence of a \nballoon -shaped \nlymph node 48% \nand 92%  \nSibon et al. (2007)   To evaluate the \nability of high -\nresolution \nultrasonography \n(hrUS) to detect \nsentinel -node (SN) \nmelanoma \nmetastases Diagnostic study  \n 131 consecutive  \npatients with 132 \n\u22651-mm thick or \nulcerated CM  \n Sensitivity and \nspecificity  \nPositive and \nnegative predictive \nvalue  \nPositive and \nnegative likelihood \nratios  Targeted high -\nresolution \nsonography for the \ndetection of SLN:  \nStringent criteria:  \nSensitivity 8.8%  \nSpecificity 95.9%  \nPPV 42.9%  Patients with \nmucosal melanoma \nincluded  \n \n 1b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 43 von 732 preoperatively \nbefore sentinel -\nnode biopsy (SNB ), \nto define hrUS \nresolution, and to \nevaluate which US \ncriteria should be \nused.  NPV 75.2%  \nNon-stringent \ncriteria:  \nSensitivity 20.6%  \nSpecificity 89.8%  \nPPV 41.2%  \nNPV 76.5%  \nSaiag et al. (2005)   (1) to compare the \nrespective ability of \nultrasonography \nand palpation to \ndetect nodal \nmetastasis during \ninitial staging and \nfollow -up in \npatients having \nmelanomas  \n(2) to assess which \nultrasound criteria \nshould be used to \ndefine metastasis in \ncases of cutaneous \nor mucosal \nmelanoma  \n(3), because scar \ntissue can modify \nultrasonogr aphic Diagnostic study  160 consecutive \npatients with stage I \nto stage III CM  \n \n Sensitivity, \nSpecificity  Sonography:  \nSensitivity 76.9%  \nSpecificity 98.4%  \nPalpa tion: \nSensitivity 41.5%  \nSpecificity 95.7%  \n Patients with \nmucosal melanoma \nincluded  \n \n 1b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 44 von 732 images, to evaluate \nwhether \nultrasonography \nremains useful once \npatients have \nundergone radical \nLD \nStoffels et al. (2011 ) to clarify the \nreliability of \npreoperative \nultrasonography \n(US) in direct  \ncomparison to the \nresult of SLNE and \nseeks to identify \npotential \nadvan tages of \npreoperative \nultrasound if \nperformed in  \nconjunction with \nlymphoscintigraphy \nin detecting \nmalignant \nmelanoma \nmetastases in \nsentinel lymph \nnode (SLN).  Diagnostic study  221 patients with \nprimary malignant \nmelanoma with a \nBreslow  \nindex of >= 1.0 \nmm Sensitivity  \nSpecificity  \nPPV \nNPV US: \nSensitivity: 13.6%  \nSpecificity: 96.9%  \nPPV: 97.2%  \nNPV: 12,6%  \n \nSLNE alone:  \nSensitivity: 94%  \nSpecificity: 98.6%  \nPPV 100%  \nNPV 98,3%  \n \nPreoperative US in \nconjunction with \ndynamic \nlymphoscintigraphy\n, followed by SLNE:  \ndetectin g ratio: \n100% (n = 28) for \nmicrometastases,  \n98.6% (n = 42\u2044 43) Reference standard \nfor SLNE not \ndescribed  \n \n 2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 45 von 732 for \nmacrometastases  \nHinz et a. (2011)   To evaluate whether \nhigh-resolution \nultrasound \ncombined  \nwith power Doppler \nsonography (PDS) is \nan approp riate tool \nfor preoperative \nidentification and \ncharacterization of \nsentinel lymph \nnodes (SLNs) in \npatients with \ncutaneous \nmelanoma.  Diagnostic study   81 consecutive \npatients with CM in \nwhom dissection of \nSLNs was indicated \nunderwent \nultrasound \nexamination s \nbefore and after the \npreoperative \nlymphoscintigraphy\n. sensitivity, specifity,  \nPPV, NPV  \n \npositive likelihood \nratio \n \nnegative likelihood \nratio A total of 170 SLNs \n(mean 2.1 per \npatient) were \nremoved and \nexamined by \nhistopathology.  \n \nsensitivity, specifity,  \nPPV, NPV of \nultrasound: 22.2% \n(95% CI = 2.8 \u2013\n60.0), 100% (95% CI \n= 97.7 \u2013100.0), \n100.0% (95% CI =  \n15.8\u2013100.0), and \n95.8% (95% CI = \n91.6\u201398.3), \nrespectively.  \n \npositive likelihood \nratio: 0  \n \nnegative likelihood \nratio: 0.78.  patient cohort with \nonly 9 positive S LNs \nin total  \n \nNo information \nabout follow -up 2b \nChai et al. 2011  To assess feasibility \nand staging  Diagnostic study  325 patients with  \nmelanoma Sensitivity, \nspecificity, PPV, NPV  sensitivity of \nultrasound: 33.8%,  No information \nabout time interval 2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 46 von 732 results of clinically \ntargeted ultrasound \n(before \nlymphoscintigraphy\n) compared to SLNB.  underwent \nultrasound bef ore \nSLNB without \npalpable \nlymphadenopathy \nin regional  \nnodal basins   specificity: 85.7%, \nPPV: 36.5%, NPV:  \n84.2%  \n between US and \nSLNB  \n \nConfidence interva l \nnot given  \nSanki et al. (2009)  To reassess \ntraditional \nultrasound \ndescriptors of \nsentinel lymph \nnode (SLN) \nmetastases, to \ndetermine the \nminimum cross -\nsectional area (CSA) \nof an SLN \nmetastasis \ndetectable by \nultrasound (US), \nand to establish \nwhether tar geted, \nhigh-resolution US \nof SLNs identified \nby \nlymphoscintigraphy \nbefore initial Diagnostic study  716 CM patients  Sensitivity and \nspecificity  \nPositive and \nnegative predictive \nvalue  \nPositive and \nnegative likelihood \nratios  \nDiagnostic accuracy  Targeted high -\nresolution \nsonography for the \ndetection of SLN:  \nSensitivity 24.3%  \nSpecificity 96.8%  \nPPV 60.3%  \nNPV 86.2%  \nDiagnostic accuracy \n86.7%  Design \n(retrospective vs. \nprospective) not \ndescribed  2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 47 von 732 melanoma surgery \ncan be used as a \nsubstitute for \nexcisional SLN \nbiopsy.  \nTestori et al. (2005)  (1) To obtain, using \nUS, a pre -operative \nindication of the \npresence or \nabsence of \nmetastatic deposits \nin the sentinel node \n(SN); (2) to obtain, \nusing US, the \nprecise pre -\noperative location \nof superficial or \ndeep, or peculiarly \nsited, SNs; and (3) \nto evaluate the role \nof US in the early \ndiagnosis of \nfalsenegative SNs \n(i.e. recurrences in \nthe lymph node \nbasin)  \nduring follow -up. Diagnostic study  \n Of 300 melanoma \npatients who \nunderwent SNB, 88 \nreceived \nsonography of the \nlymph nodes \npreoperatively  Sensitivity, \nspecificity  \nPositive and \nnegative predictive \nvalue  Sensitivity 94.1%  \nSpecificity 89.8%  \nPPV 64%  \nNPV 98.7%  Inclusion criteria for \npatients who \nreceived pre -\noperative \nsonography unclear  \n \n 2b \nHocevar et al. (2004)  The aim of this Diagnostic study  57 patients with Sensitivity and Sensitivity 71%  Risk of verification 2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 48 von 732 study was to \nevaluate the ability \nof a \ncombination of US \nand US -FNAB to \nstage the regional  \nlymph node basins \nin patients with MM.   CM, in whom SLN \nbiopsy was planned  specificity  \nPositive and \nnegative predictive  \nvalue  Specificity 84%  \nPPV 59%  \nNPV 90%  bias \n \nDesign of study not \ndescribed \n(retrospective \nversus prospective)  \n \n \nHafner et al. (200 4) To evaluate the \nsensitivity and \nspecificity of \nbaseline staging in \nthe early det ection \nof \nregional lymph \nnode metastases or \ndistant metastases \nin patients with MM.  Diagnostic study  100 consecutive \npatients with CM > \n1.0 mm  \n Sensitivity, \nspecificity  \nPositive and \nnegative predictive \nvalue  Sensitivity 8%  \nSpecificity 88%  \nPPV 18%  \nNPV 73%  Risk of verification \nbias \n \n 2b \nKunte et al. (2009)  The aim of this \nstudy was to \nevaluate the ability \nof high resolution \nB-mode \nultrasonography \n(US) for pre -\noperative \nidentification and \ncharacterization of Prospective \ndiagnostic study  \n 25 consecutive \npatients before SLN \nfor CM  Sensitivity, \nspecificity  \nPositive and \nnegative predictive \nvalue  Sensitivity 33.3%  \nSpecificity 100.0%  \nPPV 100.0%  \nNPV 87.9%  Risk of verification \nbias \n \nSmall patient cohort  \n 3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 49 von 732 sentinel lymph \nnodes (SLN) in \npatients with \ncutaneo us \nmelanoma.  \nSchmid -Wendtner  \net al. (2004)  to evaluate whether \nsignal enhanced \ncolor Doppler \nsonography (CDS) is \nsuperior to native \nCDS in detection of \ncharacteristic \nvascularity patterns \nthat are important \nfor the \ndifferentiation \nbetween benign and \nmalignant \nlymphadenopathy \nin patients with \ncutaneous \nmelanomas.  Diagnostic study  \n \n \n \n \n 22 melanoma \npatients  Sensitivity  \nSecificity  signal -enhanced \nsonography : \nsensitivity = 92.3%, \nspecificity=100.0%. \nFor melanoma \nmetastases, a \nsensitivity of 90.0% \nand a specificity o f \n85.7% was \ncalculated. For both \nP-values <0.05  Prospective two -\ncenter study  \n \nlack of \nhistopathologic \ncorrelation in all \npresumptive  \nsonographic \ndiagnoses  \n \nsmall study group  \n \nsensitivity and \nspecifity of native \nCDS not given  \n \nstudy inclinded in \nXing et al.  2011  3b- \nUren (1999)  \n \n to determine if \nhigh-resolution \nultrasound could \nidentify metastases \nin newly palpable Diagno stic study  \n \n 52 patients  \n(61 individual node \nfields)  \n \n Ultrasound features \nin metastatic lymph \nnodes  \n \nSensitivity  specifity = 87%  \nsensitivity = 94%  \naccuracy = 89%  \n \nIf presence of 2 US -No information \nabout the time \ninterval between \nultrasound and \nFNAB/excision 3b-  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 50 von 732 lymph nodes found \nduring clinical \nfollow -up for \nmelanoma, and to \ndefine the \nultrasound features \nthat were \nassociated with this \ndiagnosis     \nspecifity  features (=node \nthicker greater than \ntwo-third of the \nlength and low -\nlevel internal echos) \nwere present: \nSensitivity = 94%, \nspecifity = 100%, \naccuray 98%  biopsy  \n \nSmall population  \n \nDifferent examined \nfields: axilla, groin, \nsupraclavicula ire, \nsubmental, cervical  \n \nstudy inclinded in \nXing et al. 2011  \nSubtopic  \nCHEST X -RAY        \nWang et al. (2004)  To examine the \nyield of a chest \nradiograph and \nserum lactate \ndehydrogenase \n(LDH) in the work -\nup for newly \ndiagnosed localized \nmelanoma, and to \ninvestigate how \noften the results of \nchest radiograph \nand LDH alter the \ninitial surgical \nmanagement.  Diagnostic study  \n 210 CM patients \nwithout clinical \nevidence of \nmetastasis  \n False positives  \nAlteration of \nsurgical \nmanagement  False positives \n15/210 (7%)  \nAlteration of \nsurgical \nmanagement in 0%   \n 2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 51 von 732 Hafner et al. (200 4) \n See above  Diagnostic study  100 consecutive \npatients with CM > \n1.0 mm  \n Sensitivity, \nspecificity  \nPositive and \nnegative predictive \nvalue  Sensitivity - \nSpecificity 96%  \nPPV 0%  \nNPV 100%  study i nclinded in \nXing et al. 2011  2b \n \nVermeerenet  et al. \n(2011 ) to evaluate \ntherapeutic \nconsequences of \npreoperative \nstaging with Chest \nX-ray (CXR) in \npatients with a \nprimary melanoma \nplanned for sentinel \nnode biopsy (SNB).  diagnostic study  248 medical \nrecords  of patients \ntreated for primary \nmelanoma  \n \nCXR in 227 patients  \n \nCXRs were made \nprior to SNB  False positives  Preoperative CXR \ndid not identify \npulmonary \nmetastasis and did \nnot change planned \ntreatment \nstrategies. In 5%, \nthe CXR was  \ninconclusive \uf0e0 false \npositives  Reference standard: \ncomplementary \nradiodiagnostic \nimaging and/or \nfollow -up. \n \n \n 3b \nPanagiotou et al.  \n(2001) To determine which \nimaging modalities \nshould be \nperformed during \nthe evaluation of \npatients with local -\nregional malignant \nmelanoma  Retrospe ctive study  158 asymptomatic \npatients submitted \nto at least a chest \nX-ray, an \nabdominal US and a \nCT of the chest, \nabdomen and pelvis  true-positive and \nfalse-positive rate  \n TP: 26.6%  \nFP: 7.6%  \nIn 12% CT was the \nonly imaging \nmodality depicting \nmetastases  \n \nhighest positive \nyield \n \nDuring the \nsurveillance period, \n118 asymptomatic  3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 52 von 732 patients relapsed.  \n \nDetection of \nrelapse:  \n.- in 33.1% by \nphysical \nexamination  \n- in 38.1% by chest \nX-ray \n- in 16,9% by \nabdominal CT  \nYancovitz et al. \n(2007)  To investigate \nwhether  initial \nimaging led to a \nchange in stage or \ntreatment plan  Diagnostic study  158 patients, 135 \nwith stage I/II \ndisease and 23 with \nstage III disease  \n True and false \npositives and \nnegatives  True positives 0/7 \n(0.0%),  \nFalse -positives 5/7 \n(71.4%)  \nTrue negat ives \n112/126 (88.9%)  \n2/126 lost to \nfollow -up study included in \nXing et al. 2011  3b \nTsao et al. (2004)  To determine if \nearlier detection of \npulmonary \nmetastasis by \nroutine chest \nradiography (CR) is \nassociated with a \nprolonged survival.  Case-control study  \n 994 CM patients in \nstages I \u2013 IV  Overall survival  28/1938 chest x -\nrays leading to first \ndiagnosis of CM \nstage IV (1.4%)  \nOverall survival \naccording to \nKaplan -Meier curve: \nno difference \nbetween patients Cohort consisting \nof stage I \u2013 IV \npatients  \n \n 3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 53 von 732 with known stage IV \nat the time of \ndiagnosis and initi al \ndiagnosis of stage \nIV by x -ray \nFalse positives (of \nall x-rays): 3.5%  \nHofmann et al. \n(2002 ) Assessment of the \nperformance, costs \nand survival \nbenefits of staging \nmethods (history \nand physical \nexamination; chest \nX-ray; \nultrasonography of \nthe abdomen; high \nresolution \nsonography of the \nperipheral lymph \nnodes) at initial \nstaging and during \nfollow -up of stage \nI/II+III disease.  Diagnostic study \nwith historical \ncohort; economical \nevaluation  \n 661 patients (stage \nI/II: 630 patients, \nstage III: 27 \npatients, stage IV: 4 \npatients)  True and false \npositives and \nnegatives  \nDetection rate  \nCost-efficiency of \nimaging procedures  \nSurvival  524 total chest x -\nrays \n1 true positive \n(0.2%)  \n23 false positives \n(4.4%)  \nDetection rate 3.2%  \nCost of chest x -ray \nat initial staging: \n11761 EUR  \n(1887 EUR due to \nfalse positive \nresults)  Diagnostic standard \nprocedures varied \nover time; no \ndefined gold \nstandard of \ndiagnosis  \n \n 3b \nTerhune et al. \n(1998 ) To evaluate the use \nof an initial staging \nchest x-ray film in \nasymptomatic Diagnostic study  \n 876 CM patients at \ninitial staging  \n \n True and false \npositives  \n. 130/876 (15%) \npatients with \nsuspicious findings  \nAdditional workup X-rays not obtained \nfrom all patients  \n\u201cInitial\u201d chest x -ray \nup to 6 months 3b \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 54 von 732 patients who \npresent with \nlocalized primary \ncutaneous \nmelanoma.  led to 1/876 true  \npositives (0.1%)  \n129/876 false \npositives (14.7%)  after diagnosis  \n \n \nIscoe et al. (1986)   The description of \npredictive value of \nclinical, laboratory \nand radiologic \ninvestigat ions in the \nstaging of patients \nwith clinical stage I \nmelanoma.  Diagnostic study  \n 393 consecutive CM \npatients  True and false \npositives  \nPositive and \nnegative predictive \nvalue  Number of chest x -\nrays: 345  \nTrue positives: 0  \nFalse positives: 8  \nPositive predic tive \nvalue: 0%  \nNegative predictive \nvalue: 97.6%  Index tests not \ncarried out on all \npatients  \n \n 3b \nKhansur et al. (1989 ) To evaluate the role \nof staging workup \nin primary and \nrecurrent malignant \nmelanoma.  Diagnostic study  \n 115 patients with \nprimary CM (72 in \nlocalized stage) and \n28 patients with \nrecurrent disease  True and false \npositives  0/72 true positives  \n2/72 false positives \n(3%) Criteria for \nselecting staging \nexaminations \nunclear  \n \n 3b- \nArdizzoni et al. \n(1987 ) To evaluate the \nyield, in terms of \ncost-benefit-ratio, \nof a multimodal \nstaging procedure \nconsisting of \nmultiple nuclear \nscans, chest X -ray Diagnostic study  116 patients; \nclinically 93 in \nstage I and 23 in \nstage II  True and false \npositives and \nnegatives  \n Positive results: 0 of \n116 chest x -rays \n0% true positives  \n0% false positives  \n2 patients with lung \nmetastases later in \nfollow -up => 2% \nfalse negatives, 98% Design (prospective \nvs. retrospective)  \nnot clear  \nFollow -up time not \ngiven  \n \n 3b-  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 55 von 732 and abdominal \nultrasonography to \ndetect silent \nmetastases in \nasymptomatic \nmelanoma patients  true negatives  \nMeyer and Stolbach \n(1978 ) To evaluate \nradiographic \nevaluation for the \nrecognition of \noccult sites of \nmetastatic disease \nbeyond the regional \nnodes in malignant \nmelanoma.  Diagnostic study  \n 53 CM patients \nwithout sy mptoms \nto suggest distant \nmetastasis  True and false \npositives  4/53 true positives \n(8%) \n0 false positives  \n Cohort probably \nincluded patients \nwith lymph node \nmetastases  \n \n 3b- \nZartman et al. \n(1987 ) To answer the \nquestion whether \nextensive \ndiagnostic staging \nprocedures are \njustified for \npatients with \nprimary diagnosis \nof melanoma  Cohort study  90 CM patients with \nlevel III and IV \nlesions  Positive results  No positive results \nfor chest x -ray Patients with \ncomplete staging \nincluded; \nindications for \ndifferent stag ing \nexaminations \nunclear  \n 4 \n \nGoerz et al. (1986)  To investigate \nwhich staging and \nfollow -up Diagnostic study  \n 378 patients with \nhistologically \nconfirmed CM True and false \npositives  0% positive results \nfor chest x -ray at \ninitial staging   3b-  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 56 von 732 examinations are \nnecessary for \npatients with \nmalignant \nmelanoma.  (stage not given)   \nDuring follow -up \nexaminations, \ndistant metastasis \nwas proven in \n34/378 patients, in \n32 of them by \nphysical \nexamination, in 2 \nby chest x -ray. \nKersey et al. (1985 ) To determine the \nvalue  of staging \nand serial follow -up \ninvestigations in \nnewly diagnosed \npatients with \ncompletely excised \nprimary cutaneous \nmalignant \nmelanoma  Diagnostic study  \n 393 patients at \nprimary diagnosis \nof CM  True and false \npositives  True positives 0  \nFalse positives \n8/345 (2%)  Extent of staging \nexaminations and \nextent/ length of \nfollow -up \ndepended on center \nand tumor site  \n \n 3b- \nCollins et al. (1993 ) \n to determine \nwhether the \ndetection of \nmetastatic disease \nwould be reduced if \nthe lateral \nprojection were not \nobtained.  Diagnostic study  follow -up of 227 \nconsecutive \npatients.  \n \n number of suspect \nlesions in PA and \nlateral radiographs  In 1 case  \nwas an abnormality \nevident on the \nlateral radiograph \nwhich was not \npreviously detected \non the PA films  \n Sensitivity and \nspecifity not given  \n \nNo reference test  \n \nPopulation not \ndescribed in detail  \n 4  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 57 von 732 Normal PA and \nlateral radiogra ph: \n60,8%. Abnormality \nequally visible on \nPA and lateral \nradiograph: 16,7%.  \nAbnormality more \neasily visualized on \nPA than on lateral \nradiograph: 11%.  \nAbnormality more \neasily visualized on \nlateral than on PA \nradiograph: 4,4%.  \nAbnormality on PA \nradiograph not \nvisualized on lateral \nprojection 6,6%. \nAbnormality on \nlateral radiograph \nnot visualized on \nPA projection: \n0,44%  No information \nabout the study \ndesign  \n \nNo inform ation \nabout selection \ncriteria  \n \nSensitivity or \nspecificity not given  \n \nWebb (1977)  to describe the \nfrequency of \nradiographic \npatterns of thoracic \nmetastasis in  diagnostic study  \n \n 65 patients with \nmalignant \nmelanoma \nmetastatic to the \nthorax  radiographic \npatterns of thoracic \nmetastasis  \n \nSurvival rates  Abnormalities in \nchest x -ray in \n42/62 patients  \n  \n 11 patie nts received \nx-ray and \ntomogram  \n \nTissue specimen in 4 \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 58 von 732 patients with \nmelanoma, and to \ncorrelate these \npatterns with the \nsymptoms, clinical \ncourse, a nd survival \nof the patients.   Survival: see full -\ntext \n only 31  \n \nSmall population, \nasymptomatic \npatients included  \n \n \nSubtopic  \nABDOMINAL \nULTRASOUND         \nHafner et al. (200 4)  See above  See above  100 consecutive \npatients with CM > \n1.0 mm  \n Sensitivity, \nspecificity  \nPositive and \nnegative predictive \nvalue  Sensitivity - \nSpecificity 97%  \nPPV 0%  \nNPV 100%   2b \nPanagiotou et al. \n(2001 ) See above  See above  See above  See above  See above  See above  3b \nHofmann et al. \n(2002)  See above  See above  661 patients (stage \nI/II: 630 patients, \nstage III: 27 \npatients, stage IV: 4 \npatients)  True and false \npositives and \nnegatives  \nDetection rate  \nCost-efficiency of \nimaging procedures  \nSurvival  487 total abdominal \nsonographies  \n2 true positive \n(0.4%)  \n25 false positives \n(5.1%)  \nDetection ra te 6.5%  \nCost of chest x -ray \nat initial staging: \n16618 EUR  Diagnostic standard \nprocedures varied \nover time; no \ndefined gold \nstandard of \ndiagnosis  \n \n 3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 59 von 732 (6421 EUR due to \nfalse positive \nresults)  \nPandalai et al. \n(2010 ) To evaluate the  \nclinical utility of \nstandardized \nradiographic \nstaging.  Diagnostic stuy  58 consecutive \nasymptomatic \npatients with stage \nIII AJCC melanoma  \n \n \n. True- positive (TP) \nrate \nfalse-positive (FP) \nrate Initial staging \nexaminations: 9% \nTP, 91% FP  \n \nAll examinations: \n3% TP; 23% FP.  \n \nAnalyzed per \npatient, in 37 (64%) \nof 58 patients, >=1 \nexamination was \ninitially reported as \npositiv e. 3 patients \n(5%) had a TP and \n34 (59%) had \u22651 FP \nreport. The positive \nreports of the \nstaging scans \ngenerated 45 \nadditional \nexaminations (0.78 \nper patient).  \n \nanalyzed by type of \nradiograph, the 5 Small sample size \n \nSensitivity and \nspecificity not given  \n \nSmall number of \nMRI/CT of the head, \nPET and bone scan  \n \nNo routine \nstandardized \nstaging procedure \nwas followed  3b-  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 60 von 732 TP findings were \nfound in 3 (13%) of \n23 suspicious chest \nCT scans, 1 (5%) of \n20 suspicious \nabdomen and pelvis \nCT scans, and in 1 \n(100%) of 1 PET \nscans. Of the 5 \nbrain MRIs, 2 head \nCT scans, and 1 \nbone scan that were \ninitially reported as \n\u2018\u2018suspicious,\u2019\u2019 none \nwas proven to be \nTP. \n \nratio of FP:TP: 34:3  \nKuan  et al. (1988 ) To emphasize the  \nsensitivity and \nspecificity of the \nexaminations both \nfor the  detection of \nspace -occupying \nlesions and for the  \nassessment of \nextent of metastatic \ndisease  Retrospective \ncohort study  88 patients with \npathologically \nproven cutaneous \nmelanoma in \nvarious clinical \nstages  \n Sensitivity  \n \nspecificity  In patients who had \nall 3 examinations \n(n=24): Sensitivity \nin detecting intra -\nabdominal \nmetastasis:CT: 94% \nvs. US: 62% (P< \n0.05)  \nCT vs. LS: 38% (P< \n0.01)  Poor information \nabout selection \ncriteria and \npopulation  \n \nPoor data about \npatients` follow -up \n \nSmall population  3b-  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 61 von 732  \nIn patients with \nonly US and LS \n(n=64):  \nSensitivity US: 88% \nvs. LS 54% (P< \n0.01).  \n \nCT detected \nmetastases \nsignificantly earl ier \nthan US  \n(P=0.03)  \nArdizzoni et al. \n(1987 ) See above  See above  116 patients; \nclinically 93 in \nstage I and 23 in \nstage II  True and false \npositives and \nnegatives  \n 0/66 positives for \nliver involvement  \n1/66 true positives \nfor iliac lymph node \ninvolvement (2%)  \n1/66 false positives \nfor iliac lymph node \ninvolvement (2%)  Design (prospective \nvs. retrospective) \nnot clear from \ndescription  \nFollow -up time not \ngiven  \n \n 3b- \nGoerz et al. (1986):  See above  See above  378 patients with \nhistologically \nconfirmed CM  True and false \npositives  0% positive results  Stage of patients \nnot given  \n \n 3b- \nHolloway et al. \n(1997)  To determine the \nfrequency of diagnostic study  \n 464 patients with \ncutaneaous Detection rate of \nmetatasis  Ultrasound \nappearances typical No further \ninformation about 4  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 62 von 732 gallbladder \npathology, other \nthan gallstones in \nthis group o \npatients.   melanoma except \none which arose on \nthe nasal mucosa.  of gallbladder \nmetastases in 4,1%  the population.  \nStutte (1989)  To describe \nultrasonographic \nfindings and to \nevaluate the \nsignificance of \nupper abdominal \nultrasonography in \nassessing the \nspread of \nmetastasizing \nmalignant \nmelanome during \nfollow up.  \n Prognosti c study  \n \nRetrospective study  42 patients with \ndistant metastases \nof CM  \n Mean overall \nsurvival  Mean survival time:  \n- for patients with \n\u2264 3 liver \nmetastases \u2264 3 cm \ndiameter: 8,4 \nmonths  \n- for patients with \nnumerous \nmetastases or \nmetastases > 3cm \ndiameter: 4,3 \nmonths  \n- for patients  with \nisoechoic \nmetastases: 2,6 \nmonths.  No information \nabout inclusion \ncriterias  \n \nSmall pa tient cohort  \n \n 4 \nZartman et al. \n(1987 ) See above  See above  90 CM patients with \nlevel III and IV \nlesions  Positive results  No positive results \nfor abdominal \nsonography  Patients with \ncomplete staging \nincluded; \nindications for \ndifferent staging \nexaminations \nunclear  4  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 63 von 732 Doiron et al. (1981)  To discusses which \nof these imaging \nmodalities yields \nthe most \ninformation in \npatients with \nintraabdominal \nmetastatic \nmelanoma  Diagnostic study  \n \n 163 patients with \nmalignant \nmelanoma in \nclinical stage III \nexamined by RN \nliver scan, US, and \nCT in various \ncombinations over a \n2-years -period.  \n \nPatients were \ndivided into 3 \ngroups according to \nthe examinations: \n(1) \nRN liver scan, US, \nand CT (38 \npatients)  \n(2) RN liver scans \nand CT (10 \npatients)  \n(3) US and RN liver \nscan.(115 patient s) False negatives (FN)  \n \nFalse positives (FP)  Group 1:  \nCT, US and RN \ndemonstrated 20, \n22 and 23 normal \nresults respectively \nand 18, 17 and 15 \nabnormal results \nrespectively  \n1 FN (CT)  \n1 FN (US)  \n8 FP and 1 FN (RN)  \n \nGroup 2:  \nCT, RN \ndemonstrated both \n7 normal results \nand both 3 negative \nresults.  \n2FP and 1 FN (RN)  \n \nGroup 3:  \nUS and RN \ndemonstated 52 \nand 75 normal \nresults respectively \nand \n43 and 40 \nabnormal results Sensitivity and \nspecificity not given  \n \nNo information \nabout follow -up 4  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 64 von 732 respectively  \n2 FP (US)  \n10 FP (RN)  \nSubtopic  \nMRI        \nHausmann et al. \n(2011 ) to compare the \ndiagnostic accuracy  \nof whole -body MRI \nwith the standard \ndiagnostic \nalgorithm (whole -\nbody CT  \nand brain MRI) in \npatients with stage \nIII/IV MM.  diagnostic study  33 consecutively \nadmitted patien ts \nwith histologically \nconfirmed  \ndiagnosis of stage \nIII or IV MM  Sensitivity  \n \nspecificity  The sensitivity of \nwhole -body MRI \nwas \nobserverdependent.  \n \nSensitivity:  \nMRI vs. CT: 73.4 % \nvs. 78.2 %, p = \n0.0744.  \n \nSensitivity in the \ndetection of small \n(1\u20135 mm) \npulm onary nodules: \nMRI vs. CT: 2.9 % \nvs. 66.9 %, p < \n0.0001  \n \nOverall specificity:  \nMRI vs. CT: 83.4 % \nvs. 50.4 %, p < \n0.0001  Data interpretation  \nby two blinded \nexaminers  \n  2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 65 von 732 Pfannenberg et al. \n(2007)  \n to compare the \noverall and site -\nbased accuracy and \nimpact  on patient \nmanagement of \npositron emission \ntomography/compu\nted tomography \n(PET/CT)  \nand whole -body \n(wb) magnetic \nresonance imaging \n(MRI) in staging of \nadvanced \nmelanoma.  \n \n Diagnostic study  \n 64 patients:  \n25 patients stage \nIII, 39 patients \nstage IV  \n \n Sensit ivity  \n \nSpecificity  \n \npositive predictive \nvalue (PPV)  \n \nnegative predictive  \nvalue (NPV)  \n \naccuracy  The overall \naccuracy:  \nPET/CT: 86.7%  \nwbMRI: 78.8%  \nCT: 75.0%  \nPET: 74.3%  \n \nPET vs. wbMRI: P = \n0.0007  \n \nPET vs. PET/CT:  \nP < 0.0001  \n. \nSensitivity, \nspecifity, TN, FN, \nTP, FP: see full \ntext/table 2  \n \n Cerebral lesions in \nwbMRI were \nrecorded, but \nexcluded from the \nanalysis because of \nthe lack of \ncomparable PET \ndata.  \n \nThe selection of \ninclusion criteria \nled to \nunderestimated \ncalculated \nspecificity, because \nonly the lesi ons \nsuspicious of \nmalignancy in one \nof the different \nmethods were \nincluded in the \nstudy and \ncompared by \ndifferent methods.  \n \nStudy included in \nXing et al. 2011 and \nKrug et al. 2008  2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 66 von 732 Dellestable et al. \n(2011 )  \n to assess the Se and \nspecificity (Sp) of \nwb-MRI with a \ndiffusion sequence \nfor detecting \nmelanoma \nmetastasis \ncompared to \nPET/CT.  Diagnostic study  40 patients were \nincluded and a total \nof 72 metastases \nwere noted  Sensitivity  \n \nspecificity  CT: \nsensitivity: 80%, \nspecificity: 95%  \n \nPET/CT  \nsensitivity: 74%  \nspecificity: 89%  \n \nWb-MRI  \nsensitivity: 83%  \nspecificity: 96%  \n \nThe sensitivity of \nMRI was distinctly \nsuperior to PET/CT \nfor both hepatic \nand pulmonary \nlesions.  \n \n no detailed \ninformation about \npatient cohort  \n \nsmall patient cohort  2b- \nLaurent et al. (2011)  to compare whole -\nbody MRI with a \nmulti -contrast \nprotocol including a \nDW (Diffusion \nWeighted) sequence \nto PET -CT using \n(18)FDG for staging Diagnostic study  35 patients  Sensitivity  \n \nspecificity  sensitivity and \nspecificity for \nwhole -body M RI: \n82% and 97%  \n \nPET-CT: 72.8% and \n92.7%.  \n prospective blinded \nstudy  \n \nsmall patient cohort  2b-  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 67 von 732 advanced \nmelanoma.  DW sequence \nallowed the \ndetection of 14 \nsupplementary \nmalignant lesions \n(20%) in comparison \nwith standard MRI \nprotocol. DW \nsequence has been \nshown to be the \nmost accurate for \ndetecting \nmetastases in the \nliver, bo ne, \nsubcutaneous and \nintra-peritoneal \nsites.  \nMueller -Horvat \n(2005 ) \n \n to compare \ncontrast -enhanced \nwhole -body \nmagnetic resonance \nimaging (wbMRI) \nand whole -body \ncomputed  \ntomography (wbCT) \nto detect distan t \nmetastases for \nstaging.  Diagnostic study  \n \n 43 patients  \nAJJC stage III \u2013IV \nmalignant \nmelanoma  Metastasis \ndetection rate  \n \n wbCT vs. wbMRI: \ndetection of 522 vs. \n730 metastases  \n \nwbCT vs. wbMRI:  \n-pulmonary \nmetastases: 188 vs. \n143 \n- metastases in \nkidneys, adr enal \nglands and lymph 4 patients had \nchoroid malignant \nmelanoma  \n \nspecifity and \nsensitivity not given  \n \nno follow -up \n \nsmall population  \n 3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 68 von 732 nodes: same \nnumber of detected  \nlesions  \n- liver: 122 vs. 199.  \n- spleen 26 vs. 54  \n- subcutaneous \ntissue 39 vs. 61  \n- muscle 4 vs. 11  \n- bone marrow 23 \nvs. 132  \nBrain 15 vs. 25  \n \nTherapy was \nmodified as a \nconsequence of \nwbMRI findings in \n10/41 (24%) \npatients.  uninterpretable \nresults not \ndescribed  \nSchlamann et al. \n(2008 ) To investigate the \nincidence of \ncerebral metastasis \nin asymptomatic \nmelanoma patients \nin relation to the \nstage of disease to \nestimate the \nreasonability of this \nexamination.  Diagnostic study  120 CM patients \nwithout other \nmalignancy or \nneurological \ndisease  Incidence of \ncerebral metastasis  Stage I:  \n0/27 positive \nresults \nStage II:  \n1/29 positive \nresults (3%); patient \nin stage IIC  \nStage III/IV:  \n14/64 positive \nresults (22%)  Criteria for patient \nselection unclear  \n \n 3b-  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 69 von 732 Fogarty et al. (2006)  To retrospectively \nevaluate the use of \nbrain magnetic \nresonance imaging \n(MRI) i n the initial \nstaging of patients \nwith cutaneous \nmelanoma  Diagnostic study  100 of 193 \nconsecutive CM \npatients without \nneurological \nsymptoms  Detection rate  \nUpstaging by MRI  Patients in stages I \n\u2013 III: 0% positive \nresults  \nNo patients \nupstaged by \nstaging MRI  Patients in stages I \n\u2013 IV included  \n \n 3b- \nSubtopic  \nPET        \nXing et al. (2011)   \n To examine the \nutility of \nultrasonography, \ncomputed \ntomography (CT), \npositron emission \ntomography (PET), \nand a combination \nof both (PET -CT) for \nthe staging and \nsurveillanc e of \nmelanoma patients.  Systematic review \nand meta -analysis  \n 10 528 patients \nwith cutaneous \nmelanoma at \nprimary diagnosis \nor under \nsurveillance \n(follow -up) Sensitivity, \nspecificity  \nDiagnostic odds\u2019 \nratio (OR)  Data for initial \nstaging of regional \nnodes:  \nSensitivity 30%  \nSpecificity 96%  \nDiagnostic OR 9.45  Very large patient \ncohort, but patients \nunder follow -up \nincluded  \n \n 1a \nKrug et al. (2008)  To calculate \nsummary estimates \nof the diagnostic \nperformance of \nfluorine 18 Systematic review \nwith meta -analysis  \n 2905 CM patients in \n28 studies of which \n2096 underwent \nPET alone and 809 \nunderwent PET/CT  Pooled sensitivity \nand specificity  \nPositive and \nnegative likelihood \nratio (LR+, LR -) Pooled sensitivity: \n83%  \nPooled specificity: \n85%  \nLR+: 4.56  In 17 studies, \npatients enrolled \nexclusively for \ninitial staging; in 11 \nstudies, proportion 1a  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 70 von 732 fluorodeoxyglucose \n(FDG) positron  \nemissio n \ntomographic (PET) \nimaging in the \ninitial staging of \ncutaneous \nmalignant \nmelanoma (CMM)  Diagnostic odds\u2019 \nratio (OR)  \nChanges in disease \nmanagement  LR-: 0.27  \nOverall diagnostic \nOR: 19.8  \nEarly-stage \nsubgroup (10 \nstudies, 755 \npatients):  \nPooled diagnostic \nOR 4.3 (95% CI: 1, \n18) \nMean sensitivity \n60%  \n8 studies suggested \nthat FDG PET was \nassociated with 33% \n(range, 15% \u201364%) \ndisease \nmanagement \nchanges  of initial staging \npatients 18 \u2013 97% \nOverall, many low -\nquality studies resp. \nsmall patients \ncohorts  \n \n \nJimenez -Requena et \nal. (2010 ) The aim of this \nstudy was to \nperform a \nsystematic review of \nthe literature to \nevaluate the \naccuracy of FDG -\nPET in staging  and \nrestaging of Systematic review \nwith meta -analysis  \n 444 CM patients \n(group I = regional \nstaging), stages I \u2013 \nIII, in 7 studies  Pooled specificity \nand sensitivity  \nPositive and \nnegative likelihood \nratio (LR+, LR -) \nSummary receiver -\noperating curve \n(ROC)  Group I (regional \nstaging):  \nPooled specificity: \n0.99 \nNo global \nhomogeneity for \nsensitivity, LR+ or \nLR- \nROC curves Overall, many low -\nquality studies resp. \nsmall patients \ncohor ts \n \n 2a  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 71 von 732 cutaneous \nmelanoma.  grouped in the left \nmargin, indicating \nglobal high \nspecificity  \nSchwimmer et al. \n(2000 )      Data included in \nJimenez -Requena et \nal. (2010): Meta -\nanalysis of the \nperformance of \n(18)F -FDG PET in \ncutaneous \nmelanoma   \nBastiaannet et al. \n(2009)  \n to perform a head -\nto-head-\ncomparison of \nFDG-PET and CT in \nstaging of patients \nwith melanoma with \npalpable lymph \nnode metastases \n(AJCC stage III) in \nterms of diagnostic \naccuracy and \nimpact on \ntreatment.  Prospective \nmulticenter study  \n \n In total 251 Patients \nwith palpable and \nhistologically or \ncytologically proven \nlymph node \nmetastases (after \nnegative sentinel \nlymph node)  \n \n \n \n False negatives (FN)  \n \ntrue positives (TP)  \n \nfalse positives (FP)  \n \ntrue negatives (TN)  \n \nsensitivity  \n FDG-PET detected \nmore metastatic \nsites (133 v 112, P \n= .03), detecting \nsignificantly more \nbone and \nsubcut aneous \nmetastases.  \n \nCT had more FN \nresults (n=17) than \nPET (n=11).  \n \nNumbers of FN, TP, \nFP and TN: see full  \n study included in \nXing et al. 2011 and \nJimenez -Requena \n2008  2b \n \n \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 72 von 732 Sensitivity to detect \ndistant metastases  \nCT scan 78%  \nPET scan 86%  \nPfannenberg  et al. \n(2007)  See above  See above  See above  See above  See above  See above  2b \nLaurent et al. (2011 ) See above  See above  See above  See above  See above  See above  2b- \nKoskivuo et al. \n(2007 ) to determine the \nclinical impact of \nwhole body \npositron emission \ntomography (FDG \nPET) to  \ndetect clinically \nsilent metastases in \nthe follow -up of \npatients with high \nrisk melanoma.  Prospective study  30 asymptomatic \nmelanoma patients \n(AJCC stage IIB -IIIC) \n7-24 months after \nthe primary surgery \nand sentinel node \nbiopsy.  Sensi tivity \n \nSpecificity  \n \nPPV \n \nNPV \n \nClinical impact  sensitivity and \nspecificity for \nmelanoma \nrecurrence: 86% and \n96%, respectively.  \n \nPPV: 86%  \nNPV: 96%  \n \npositive PET finding \nhad an impact on \ntreatment decisions \nin every case: 3 \npatients underwent \nsurgical resect ion, \n4patients received \nchemotherapy or \ninterferon.  Small patient cohort  \n \nStudy included in \nXing et al. 2011  \n 2b- \nMaubec et al. (2007 ) To determine the \nvalue of F -18 Diagnostic study  \n 25 CM patients with \nlesions > 4 mm  Sensitivity, \nspecificity  Initial tumor site:  \n14/19 true Prospective design  \n 2b-  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 73 von 732 fluorodeoxy -D-\nglucose positron \nemission \ntomography \nscanning in the \ndetection of \nregional and/or \ndistant metastasis  negatives (74%)  \n5/19 false positives \n(26%)  \nSensitivity 17%, \nspecificity 74%  \nMicroscopic lymph \nnode disease:  \n12/19 true \nnegatives (63%)  \n7/19 false \nnegatives (37%)  \nSensitivity 0%  small number of \npatients  \n \nStudy included in \nXing et al. 2011  \n \nEl-Maraghi and \nKielar (2008 ) To evaluate PET and \nPET/computed \ntomography  \n(CT) compared with \nSLNB for staging \nlocal lymph nodes \nin patients with \nintermediate -risk \nmelanoma.  Systematic review \nwithout meta -\nanalysis  \n 20 studies; number \nof patients unclear \nbecause some \nincluded studies did \nnot report cohort \nsize True and false \nnegatives and \npositives  \nSensitivity and \nspecificity  \nPositive and \nnegative predictive \nvalue  Ranges (no meta -\nanalysis):  \nTP 0 \u2013 10% \nFP 0 \u2013 18% \nTN 60 \u2013 74%  \nFN 3 \u2013 40% \nSensitivity 0 \u2013 92% \nSpecificity 7 \u2013 100%  \nPPV 0 \u2013 100%  \nNPV 20 \u2013 85% \n \n Levels of evidence \naccording to \nauthors: 7 studies \n2b, 1 review 3 a, 3 \nreview 3b, 3 studies \n3b, 3 studies 4, 2 \nletters/opinion \narticles 5  \nOverall, many low -\nquality studies resp. \nsmall patients \ncohorts  \n \n 3a \nPleiss et al. (2007)   to assess the \npotential of fluor -Prognostic and \ndiagnostic study  95 Patients with \nmaligant melanoma overall 5 -year \nsurvival  Sensitivity, \nspecificity, and No information \nabout the final 3b \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 74 von 732 18-FDGPET  \nin order to evaluate \nthe survival \nprognosis in \nmelanoma   \n \n who had received a \nPET   \nsensitivity  \n \nspecifity  accuracy of FDG -\nPET were 91%, 86%, \nand 89%, \nrespectively, and of \nCT 58%, 91%, and \n73%, respectively.  \n \nsurvival in patients \nwith \n-  both studies (CT \nand PET) being \nnegative: 5 -year \nsurvival, 83%  \n- both studies (CT \nand PET) being  \npositive: 5 -year \nsurvival, 61%; p < \n0.02 \n- PET being positive \nbut CT still \nnegative: 5 -year \nsurvival, 73%  assessment of \nfindings (e.g. \nhistology and/or \nclinical follow -up)  \n \nNumber of TP and \nFP etc. missing. \nData for the \ncalculation of \nsensitivity/specificit\ny not given  \n \nNo information \nabout the time -\nperiod between PET \nand CT  \n \n \nClark et al. (2006)  To investigate the \nutility of whole -\nbody PET imaging \nin 64 patients with \nT2 to T4 \nmelanomas prior to diagnostic study  64 CM patients \nwithout clinical \nevidence o f \nmetastasis  True and false \npositives and \nnegatives  \nChange in \nmanagement  PET scans normal in \n60 of 64 patients \n(94%)  \n2/64 (3%) false \npositives  \n2/64 true positives  22/64 patients with \nT4 lesions  \n \nStudy included in \nXing et al. 2011  3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 75 von 732 sentinel lymph \nnode dissection \nwithout clinically \nsuspected \nmetastases  19/64 false \nnegatives \n(regarding  sentinel \nnode status)  \nNo change in \nmanagement by PET \nresults  \nVereecken et al. \n(2005) The purpose of this \nstudy was to \nevaluate the impact \nof extensive initial \nstaging on the \nmanagement of \nmelanoma patients.  Diagnostic study  43 patients with  \nintermediate/high \nrisk melanoma \n(Breslow thickness \n\u2265 1 mm or \nregression/ \nulceration)  Evidence of \nmetastasis  Paraclinical \ninvestigation (CT \nscan of the chest, \nCT of the abdomen, \nCT or NMR of the \nbrain and whole \nbody FDG PET scan) \nfailed to reveal any \nsign of evidence of \ndisseminated \ndisease in the series \nof 43 patients.  \n \nPositivity:67%  \nSensitivity: 40%  \nPPV: 9,3%  Results concerning \nPET already \nconsidered in \nJimenez -Requena et \nal. 2010, in Krug et \nal. 2008 and in Xing \net al. 2011  \n \nNo distinction \nbetween resu lts for \nMRI and CT of the \nbrain.  \n \nImaging results \nvalidated by 6 \nmonths follow -up.  3b \nStas et al. (2002)  \n \n to evaluate (1) the \nsensitivity and \nspecificity of PET \nscan at a single \nlesion level Retrospective \ndiagnostic study  \n \n \nCSP= chest X -ray, 100 PET scans on \n84 melanoma \npatients with \nregional or distant \nrecurrences Sensitivity  \n \nSpecifity  \n \nAccuracy  At the single lesion \nlevel:  \nSensitivity:  \nPET: 85%  \nCSP: 81%  Comparison of PET \nscan and CSP \nresults at a lesion -\nbased level \uf0e0 see \nfull-text 3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 76 von 732 compared with \nconventional \nscreening \nprocedures (CSP) \u2013 \nboth of these \naccompanied by  \nclinical \nexamination; and \n(2) the additional \nvalue of the PET \nscan at the level of \nthe individual \npatient and its \ntherapeutic impact \nfor different types \nof melanoma \nrecurrence.  blood analysis, \nultrasonography, \n(US), computed \ntomography (CT), \nmagnetic resonance \nimaging (MRI) and \nnuclear bone scans  \n according to CSP  \n  \nTherapeut ic impact  \n Specificity:  \nPET: 90%  \nCSP: 87%  \nAccuracy:  \nPET 88%  \nCSP: 84%  \n \nThe overall \ntherapeutic impact \n(PET): 26%  \n \n  \nTherapeutic impact \nof PET scan results \n\uf0e0 see full text  \n \nStudy included in \nJimenez -Requena et \nal. 2010 and Xing et \nal. 2011  \nWagner et al. (2011 ) To assess the rate \nof distant \nmetastases in \npatients with a \npositive SLN  \nbiopsy (SLNB).  Diagnostic study  46 con secutive \npatients with a \npositive SLNB \nunderwent PET or \nPET\u2013computed \ntomography within \n6 weeks of the SLNB \nprocedure and \nwithout  \nany clinical sign of \nnodal involvement FN Positive PET -scan: \n0% \nNonconclusive PET \nscan 13%  \nNegative  PET in \n87%,  \namong them 12% \npresented with \ndistant metastasis \nwithin 12 months.  46 PET procedures \nwere performed:  \nIn 22 patients: \nstand -alone PET \nand aCT scan with a \ncontrast medium. In \n24 patients: PET \u2013CT \nscan without \ninjection of contrast \nmedium.  \n 3b-  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 77 von 732 or of distant \nmetastasis.  \n Resul ts: no \ndifferentiation \nbetween PET and \nPET/CT  \n \nImages were \ninterpreted by a \nspecialist aware of \nall the clinical \nfindings \uf0e0 not \nblinded  \nConstantinidou et al. \n(2008)  to evaluate the role \nof PET or PET/  \ncomputed \ntomography (CT) as \na routine procedure \nin \npatients with \npositive sentinel \nnode biopsy (SNB).  \n Diagnostic study  \n  \n \n 30 patients with \nBreslow thickness \nof at least 1mm and \nwho had a positive \nsentinel node \nbiopsy.  Positive rate  Positive PET in 2 \npatients (6%)  \n \nLN dissection \npositive in 5 cases \n(16%) \n \nWith a median \nfollow -up of 24 \nmonths, 21 patients \nremained disease \nfree.alteration of \nmelanoma \nmanagement in \nnone of the 30  Follow -up methods \nnot described in \ndetail  \n \nSmall patient \nnumber  3b- \n \n \nHorn et al. (2005)  \n To investigate the \nclinical value of Diagnostic study  \n 33 patients with \ncutaneous sensitivity  \nspecificity  Sensitivity and a \nspecificity for Small patient cohort  \n 3b-  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 78 von 732 implementing \nwhole -body FDG -\nPET as a routine \ninvestigation in \nstage III melanoma \npatients with sub -\nclinical regional \nlymph node \nmetastases \ndiagnosed by SNB.  \n  malignant \nmelanoma and \nsubclinical lymph \nnode metast ases \ndiagnosed by \nsentinel node \nbiopsy (SNB)  \n \n \n \n \n NPV melanoma \nmetastases: 80% \nand 88%, \nrespectively.  \n \nNPV: 96%.  \n \n Only cases with \npositive PET \nfindings received \nverificati on via CT \nscan, MRI, \nultrasonography or \nbiopsy  \n \nSmall population  \n \nStudy included in \nKrug et al. 2008 \nand in Xing et al. \n2011  \nLoffler et al. (2003)  \n To disclose the \ndiagnostic benefit \nof scanning the legs \nand to evaluate the \ntherapeutic benefit \nresult ing. Diagnostic study  \n 213 consecutive \nPET studies in 153 \npatients with \nsuspected or recent \nmelanoma  Detection rate  Suspicious findings \nat the legs in 53 \npatients on 76 \noccasions.  \n \n38/53 showed \npathologic uptake \nin the torso as well. \nIn 15/53 patients it \nwas restricted to \nthe legs. 11 of \nthose 15 patients \nhad a previous \nhistory in that Sensitivity and \nspecificity not given  3b-  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 79 von 732 location. In 1 \npatient the finding \nwas a new and \nclinically relevant \nmetastasis, in 3 \nother patients the \nleg manifestations \nwere already \nknown.  \n \nIn 6 other patients a \nvalida tion of the \npositive PET \nfindings was not \npossible  \nKrug et al. (2000)  \n To assess the \ndiagnostic value of \nfluor-18-\nFluorodeoxy -\nglucose positron \nemission \ntomography (FDG -\nPET) in screening \nfor melanoma \nmetastases  Diagnostic study  \n \n 94 melanoma \npatients who had \nbeen examined by \nwhole -body FDG -\nPET. 40 patients \nshowed evidence of \nlymphogenous, 42 \nof hematogenous \nmetastasis.  \n Metastases -\ndetection rate  \n In no case did PET \nchange the staging. \nIn 13 patients, PET \nagreed wit h \nmorphological \ndiagnosis in the \nnumber of \nmetastatically \ninvaded organs. \nThis included 3 \npatients without \nmetastases. The \nestimated number Different reference \ntests \n \nSensitivity and \nspecifity not given  \n \n 3b-  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 80 von 732 of organs invaded \nby metastases was \nhigher with PET in 5 \npatients and higher \nwith morphological \nimaging techniques \nin 6 patients. \nAmong the PET \nfindings with higher \nor equivocal counts \nof organs with \nmetastases there \nwere 2 confirmed \nfalse-positive \nfindings.  \n \n(Results for the \ndifferent organs \n(lungs, liver\u2026): see \nfull text)  \nDietlein et al. (199 9) \n To examine if  \n- FDG-PET can \nimprove staging of \npatients with \nmelanoma when \ncompared with \ncombinations of \nstandard Diagnostic study  91 FDG -PET \nexaminations \nperfomed on 68 \npatients with \nadvanced \nmelanoma.  True positives  \n \nFalse positives  FDG-PET detected \nmore lymph node \nand bone \nmetastases  \n \nHigh proportion of \nnon-verifiable PET \nfindings  FDG-PET images \nfrom various \ninstitutes  \n \nDifferent staging \nexaminations  \n \nSensitivity 3b-  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 81 von 732 radiological \nexaminations \ncurrently used in \nroutine practice?  \n- if the setting of \nindications  for PET \ncan be opimized?  \n  \nCompar ision of \nultrasonographic \nand radiological \nmethods with FDG -\nPET for examining \nthe lungs, \nabdominal organs, \nLN and skeleton: \nsee full -text. /specificity not \ngiven  \n \nNo data  concerning \nfollow -up \n \nStudy included in \nJimenez -Requena et \nal. 2010  \nSubtopic  \nCT        \nXing et al. (2011)  See above  Systematic review \nand meta -analysis  \n 10 528 patients \nwith cutaneous \nmelanoma at \nprimary diagnosis \nor under \nsurveillance \n(follow -up) Sensitivity, \nspecificity  \nDiagnostic odds\u2019 \nratio (OR)  Data for initial \nstaging of regional \nlymph nodes:  \nSensitivity 9%  \nSpecificity 92%  \nDiagnostic OR 1.13  Very large patient \ncohort, but patients \nunder follow -up \nincluded  \n \n 1a \nBastiaannet et al. \n(2009 ) \n See above  See above  See above  See above  See above  study included in \nXing et al. 2011 and \nJimenez -Requena \n2008  2b \n \nPfannenberg et al. \n(2007)  See above  See above  See above  See above  See above  See above  2b \nDellestable et al. See above  See above  See abov e See above  See above  See above  2b-  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 82 von 732 (2011 ) \nHausmann et al. \n(2011 ) See above  See above  See above  See above  See above  See above   \n  2b \nPanagiotou et al. \n(2001 ) See above  See above  See above  See above  See above  See above  3b \nSawyer et al. (200 9) \n \n \n \n \n \n \n \n \n \n \n \n \n \n The a im of this \nstudy was to \ndetermine whether \nCT changes \nmanagement in \nAJCC IIB disease or \nworse with regard \nto initial staging \nscans and \nsubsequent follow \nup scans. A second \nobjective was to \ndetermine whether \nCT of the head and \nneck should be \nperformed.  Diagn ostic study  \n 132 CM patients in \nstages IIB/C (42 IIB, \n90 IIC)  True and false \npositives  \nChange in clinical \nmanagement  Region \u2013 number of \nscans with \nmetastases \u2013 \nchange in \nmanagement in %  \nChest \u2013 3 \u2013 0% \nAbdomen \u2013 2 \u2013 0% \nPelvis \u2013 0 \u2013 0% \nHead \u2013 3 \u2013 0.7% \nNeck \u2013 0 \u2013 0% \nTrue and false \npositives of regional \nCT scans:  \nChest  \nTrue positives: 9 \n(81%)  \nFalse positives: 2 \n(19.0%)  \nAbdomen  \nTrue positives: 7 \n(53%)  \nFalse positive: 6 No homogenous \nreference standard  \nValues for true and \nfalse positive based \non initial and \nfollow -up scans; \nprobably lower if \nonly initial scans \nwere considered  \n \n 3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 83 von 732 (47%)  \nPelvis  \nTrue positives: 3 \n(38%)  \nFalse positives: 5 \n(62%)  \nHead  \nTrue positives: 6 \n(100%)  \nFalse positives: 0  \nYancovitz et al. \n(2007 ) See above  Diagnostic study  158 patients,  135 \nwith stage I/II \ndisease and 23 with \nstage III disease  \n True and false \npositives and \nnegatives  Number of CT \nstudies: 57 chest, \n57 abdomen/ \npelvis, 57 head  \nPositives:  \nChest CT 24 of 57  \nAbdomen/ pelvis \n11 \nCranial CT 2  \nTrue positives:  \nChest CT 0 of 57 \n(0.0%) \nAbdomen/ pelvis \nCT 0 of 57 (0.0%)  \nCranial CT 0 of 57 \n(0.0%)  \nFalse positives:  \nChest CT 21 of 57 study included in \nXing et al. 2011  3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 84 von 732 (37%)  \nAbdomen/ pelvis \nCT 10 of 11 (18%)  \nCranial CT 2 of 57 \n(4.0%)  \nTrue negatives:  \nChest CT 50 of 57 \n(88%)  \nAbdomen/ pelvis \nCT 46 of 57 (81%)  \nCranial CT 53 of  57 \n(93%)  \n(Rest lost to follow -\nup) \nNo false negatives  \nVan den Brekel et al. \n(1998 ) To assess the value \nof CT scanning in \ndetecting lymph \nnode metastases in \nthe neck from \nmalignant \nmelanoma and to \nlook at possible CT \ncharacteristics of \nsuch metastases.  Diagnostic study  \n 26 CM patients with \nneck CT before \nneck dissection, 8 \nof them negative \nfor palpation  \n Sensitivity and \nspecificity  \nTrue and false \npositives and \nnegatives  CT scans of the \nneck:  \n2/26 (8%) false \nnegatives (s lices of \n8 mm instead of 5 \nmm) \nSensitivity of both \npalpation and CT \nscanning 86%, \nspecificity 100%  Different reference \nstandards \n(comprehensive and \nselective neck \ndissection)  \nInclusion criteria \nunclear  \nOnly 8 \nasymptomatic \npatients  \n \n 3b \nIscoe et al. (1986 ):  See above  Diagnostic study  393 consecutive CM True and false Chest CT:  Index tests not 3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 85 von 732  patients  positives  \nPositive and \nnegative predictive \nvalue (PPV, NPV)  Number of exams: \n59 \nTrue positives: 0  \nFalse positives: 9  \nPPV: 0%  \nNPV: 98.0%  \nCranial CT:  \nNumber of exams: \n52 \nTrue positives: 0  \nFalse positives: 9  \nPPV: /  \nNPV: 98.1%  done on all patients  \n \n \nHeaston et al. (1983)  First, to determine \nprospectively the \nsensitivity and \nspecificity of \nconventional chest \nradiography, \ntomography, and \ncomputed \ntomography i n a \nselected group of \npatients with high \npropensity for \npulmonary \nmelanoma \nmetastases; second, Diagnostic study  42 CM patients in \nstages I \u2013 III (11 in \nstages  I \u2013 II) Sensitivity, \nspecificity  \nFalse -positive and \nfalse-negative rate  \nOverall accuracy  Chest CT:  \nSensitivity 100%  \nSpecificity 95%  \nFalse positives 2%  \nFalse negatives 0%  \nOverall accuracy \n98% Sensitivity and \nspecificity \ncalculated for a \ncohort including \nstage III melanoma \npatients; not \nenough data given \nto calculate for \nstage I and II alone  \n \n 3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 86 von 732 to evaluate the \nimpact of the \ndiscovery of \npulmonary nodules \non the clinical \ntherapy of \nmelanoma.  \nAloia et al. (2006)  To analyse the \nefficacy of routine \nradiologic staging \nin asymptomatic \npatients with \nmicroscopic nodal \ninvolvement before \ncompletion of \nlymphade nectomy.  \n Diagnostic \nretrospective cohort \nstudy  \n 270 staged patients \nwith positive SLNB \nmelanoma  \n \n \n True positive and \nFalse negative rate  TP detection rate of \noccult distant \nmetastases: 1,9%  \nFP: 12%.  \n Calculation of \nsensitivity and \nspecificity not \npossible  \n \nFalse and true \nnegatives not given  3b- \nMiranda et al. (2004 ) \n To determine the \nrate of detectable \nsystemic metastasis \nat the time of SSL in  \nasymptomatic \npatients with \nmelanoma in North \nAmerica  \n \n Diagnostic study  \n \n 185 patients with \npathologic evid ence \nof metastasis to at \nleast 1 SLN  \n Diagnostic yield of \nimaging studies:  \n 142 patients \nunderwent chest \nCT: \n- 1 positive finding  \n- 114 negative  \n-  27 indeterminate  \n \n146 patients \nunderwent CT of \nthe abdomen and \npelvis:  Not in eve ry case of \nindeterminate \nfindings additional \ndiagnostic was \nperformed  \n \nSensitivity/specificit\ny not given  3b-  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 87 von 732 - 1 positive finding, \n- - 123 negativ e \n- 22 indeterminate.  \n \n96 underwent MRI \nimaging (brain), 16 \nunderwent CT \n(brain):  \n- no positive \nfindings  \n- 105 negative  \n-  7 were \nindeterminate.  \n \nCT of the chest and \nabdomen/pelvis/br\nain: indeterminate \nrates were 19%, 15% \nand 6,3% \nrespectively.  \nJohnson (1997)  \n To evaluate the \nyield and clinical \nimpact of computed \ntomography (CT) \nimaging in \notherwise \nasymptomatic \npatients with stage Diagnostic study  \n \n \n 127 asymptomatic \npatients stage III  \n(28 patients: \nmicroscopic disease \nat ELND. 99 \npatients with \npalpable disease \ndiagnosed by fine True (TP) and false \npositives (FP)  \n \n 20 patients: TP CT \nscan revealing \nunsuspected \nmetastases.  \n \n15 patients: \nabnormal CT scans \nsubsequently TP and FP rates: see \nfull text \n \nFP and FN not given  3b-  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 88 von 732 III me lanoma \nmetastatic to the \nregional nodes  \n needle aspirate, \nopen biopsy, or \nTLND)  \n shown to be a \nbenign process or \nsecond malignancy.  \n \nNo difference in the \nincidence of TP CT \nbetween the groups \nof patients with \nclinically  apparent \nvs. occult nodal \ndisease.  \n \nsignificantly higher \nincidence of \nabdominal and \npelvic metastatic \nsites identified by \nCT scan in patients \nwith inguinal nodal \ndisease vs. patients \nwith axillary or \nhead and neck \nnodal disease.  \nBuzaid et al. (1995 ) \n To determine the \nvalue of CT scans in \nthe staging of \nasymptomatic \nmelanoma patients Diagnostic study  \n \n 89 patients who \neither presented \nwith or developed \nlocalregional \ndisease as the first TP-rate \n \nTN-rate Findings on CT scan \nwere TP for six \npatients  \n(7%), FP for 2 0 \n(22%), and TN for No detailed data \nabout the follow -up \nregime/time of \nfollow up  \n 3b-  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 89 von 732 who presented with \nor developed \nlocalregional \ndisease as the first \nsite of recurrence \nand had both a \nnormal chest \nradiograph and \nserum lactate \ndehydrogenase \n(LDH) level.  site of recurrence  \n \n \n 63 (71%).  \n \n Sensitivity and \nspecificity not given  \n \nStudy included in \nXing et al. 2011  \nKhansur et al. (1989 ) See above  Diagnostic study  \n 115 patients with \nprimary CM (7 2 in \nlocalized stage) and \n28 patients with \nrecurrent disease  True and false \npositives  Cranial CT:  \n0 true positives and \n0 false positives in \npatients with \nlocalized disease  Criteria for \nselecting staging \nexaminations \nunclear  \n \n 3b- \nKuan et al. (1988)  See a bove See above  See above  See above  See above  See above  3b- \n \n \nGoerz et al. (1986):  See above  Diagnostic study  \n 378 patients with \nhistologically \nconfirmed CM  True and false \npositives  Whole -body CT:  \n2/378 true \npositives (distant \nmetastasis)  Stages not giv en \n \n 3b- \nKersey et al. (1985 ) See above  Diagnostic study  \n 393 patients at \nprimary diagnosis \nof CM  True and false \npositives  CT chest:  \n0/59 true positives  \n9/59 false positives Extent of staging \nexam inations and \nextent/ length of 3b-  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 90 von 732 (15%)  \nCranial CT:  \n0/51 true positives  \n0/51 false positives  follow -up \ndepended on center \nand tumor site  \n \n \nPatten et al. (1990)  To determine \nwhether the \nfrequency of CT \ndetection of axial \nskeletal metastases \nwas greater than \nthat reported for \nplain film radiology \nand to determine if \nthe thickness and \ndepth of \npenetration of the \nprimary melanoma \n(according to the \nBreslow and Clark \nclassifications) can \nbe used to predict \nthe occurrence of \nskeletal metastases.  Cross -sectional \nstudy  \n 125 CM patients  Prevalence of bone \nmetastasis  Examin ations: CT \nabdomen (41%), \nchest (27%), pelvis \n(25%), and neck \n(7%) \n98/125 patients \n(78%) with CT \nevidence of \nmetastatic \nmelanoma  \n17/98 (17%) \nskeletal metastases  \n2/17 only evidence \nof metastatic \ndisease  Not enough data \ngiven to \ndifferentiate \nbetween preval ence \nof bone metastasis \nin early stage and \nadvanced stage \nmelanoma  \n \n 4 \nZartman et al. \n(1987 ) See above  Cohort study  90 CM patients with \nlevel III and IV \nlesions  Positive results  No positive results \nin cranial CT  Patients with \ncomplete staging \nincluded; \nindications for 4  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 91 von 732 different staging \nexaminations \nunclear  \nSilverman et al. \n(1984 ) To assess the value \nof computed \ntomography in the \ndetection of \nabdominal spread \nof malignant \nmelanoma.  Cross -sectional \nstudy  \n \n 70 CM patients  \n Prevalence of \nabdominal \nmetasta ses 52 scans of \nabdomen and \npelvis, 5 of \nabdomen, 2 of \npelvis, 11 limited to \nthe liver  \nNodal enlargement \nin abdomen or \npelvis in 30%  \nLiver metastases in \n17%  \nAdrenal metastases \nin 11%  \nNodular masses in \nthe subcutaneous \nfat in 8,6%  \nSplenic metastases \nin 2% \nMesenteric \nmetastases in 4%  Most patients \nsymptomatic at \ntime of CT scan \n(abdominal pain, \nabnormal liver \nfunction tests or \nliver imaging)  \n \n 4 \nGinaldi et al. (1981 ) To investigate the \nvalue of CT as a \nstaging procedure \nin neurologically \nasymptomatic Diagnostic study  \n 179 CM patients; \n74 of them with no \nneurological \nfindings  Detection rate  Cranial CT:  \nPositive results in \n9/74 patients (11%)   \n2/9 had known \nsingle metastases No clear distinction \nbetween patients of \ndifferent stages  \n \n 4  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 92 von 732 melanoma patients, \nand to describe the \nneurological \nfeatures of \nmetastases and \ntheir incidence in \nmelanoma patients.  in the liver and \nlung, 2/9 others \nrecurrent local \ndisease, 5/9 other \nsystemic \nmetastases  \nDoiron et al. (1981)  See above  See above  See above  See above  See abov e See above  4 \nSubtopic  \nPET/CT         \nXing e t al. (2011)  \n See above  Systematic review \nand meta -analysis  \n 10 528 patients \nwith cutaneous \nmelanoma at \nprimary diagnosis \nor under \nsurveillance \n(follow -up) Sensitivity, \nspecificity  \nDiagnostic odds\u2019 \nratio (OR)  Data for initial \nstaging of regional \nnodes:  \nSensitivity 11%  \nSpecificity 97%  \nDiagnostic OR 4.39  Very large patient \ncohort, but patients \nunder follow -up \nincluded  \n \n 1a \nKrug et al. (2008)  See above  Systematic review \nwith meta -analysis  \n 2905 CM patients in \n28 studies of which \n2096 underwent \nPET alone and 809 \nunderwent PET/CT \n(4 studies)  Positive and \nnegative likelihood \nratio (LR+, LR -) \nDiagnostic odds\u2019 \nratio (OR)  LR+ 9.68  \nLR- 0.10 \nDiagnostic OR 37.6  \n 4 eligible studies \nabout PET/CT  \n \n 1a \nEssler et al. (2011 ) To assess the \nprognostic value of \nFDG PET/CT diagnostic and \nprognostic study   125 consecutive \npatients  \n specificities  \nsensitivities  \nNPV Overall specificity \nfor FDG PET/CT:  \n96.8% (95% CI,  2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 93 von 732 compared to the \ntumor markers \nS100B and \nmelanoma \ninhibitory  \nactivity (MIA) in \npatients with high \nrisk melanoma.  Patients who had a \nBreslow tumor \nthickness  .2.0 mm,  \nelevated S100B or \nMIA level  PPV \n 89.1% to 99.1%)  \ncorresponding \nsensitivity: 96.8% \n(89.0% to 99.1%)  \n \nNPV for PET/CT  \n96.8% (89.1% to \n99.1%), PPV: 96.7% \n(89.0% to 99. 1%), \n \nPatients with \nelevated S100B - or \nMIA values or \nPET/CT positive \nfindings showed a \nsignificantly \n(p,0.001 each, \nunivariate Cox \nregression models)  \nhigher risk of \nmelanoma \nassociated death \nwhich was \nincreased 4.2 -, \n6.5- or 17.2 -fold, \nrespectively.  \nEtchebehere et al. \n(2010 ) To assess the \nimpact of [F -18] Diagnostic study  78 patients  \n Impact on patient \nmanagement  In 27% of the \npatients the AJCC 2001 staging  \nSystem was used  2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 94 von 732 FDG-PET/CT on the \nrestaging and \nchanging \nmanagement of \npatients with  \nmalignant \nmelanoma.  (Initial \nrestaging/before \nPET/CT): local \nrecurrence in 11 \npatients, \nlocoregional \nrecurrence in 23 \npatients and distant \nrecurrence in 44 of \n78 patients.  \n  \nSensitivity  \n \nSpecificity  \n \n management was \nchanged after the \n[F-18] FDG -PET/CT \nstudies. Upstaging  \nin 5 of 23 (22%) \npatients.  \n \nsensitivity, \nspecificity, PPV, NPV \nfor \nlesion detection: \n95% \n \naccuracy: 94.9%.  \n \n2FP, 2 FP  \nKlode et al. (2010)  Comparison of SLNE \nand PET -CT in \npatients with early -\nstage malignant \nmelanoma  Diagnostic study  \n 61 CM patien ts in \nstages I and II \nbefore sentinel \nbiopsy  Sensitivity and \nspecificity  \nPositive and \nnegative predictive \nvalue (PPV, NPV)  Sensitivity 5.9%  \nSpecificity 100%  \nPPV 100%  \nNPV 78%  50% of eligible \npatients declined \nPET-CT  \n \n 2b \nVeit-Haibach et al. \n(2009 ) To eval uate the \ndiagnostic accuracy \nof \ncontrastenhanced \nFDG-PET/CT (ce -\nPET/CT), PET -only, \nand CT -only in Diagnostic study  \n 56 CM patients \nafter surgical \nresection who \nunderwent \ncombined PET/ CT \nimaging and had \nsufficient follow -Sensitivity and \nspecificity  \nPositive and \nnegative predictive \nvalue (PPV, NPV)  Sensitivity and \nspecificity \nregarding N -stage:  \n38.5% and 100%  \nPPV and NPV \nregarding N -stage:  \nPET-CT 100% an d Insufficient data for \n24% of patients  \n \nStudy included in \nXing et al. 2011  \n 2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 95 von 732 patients with newly \ndiagnosed and \nresected cutaneous \nmalignant \nmelanoma.  up; 18 of them in \nstage III or IV  84.3%  \nSensitivity and \nspecificity \nregarding M -stage:  \nPET-CT 38.5% and \n100%  \nPPV and NPV \nregarding M -stage:  \nPET-CT 41.7% and \n93.2%  \nSingh et al. (2008)  To evaluate the role \nof preoperative \n18F-\nfluorodeoxyglucose\n-positron emission \ntomography/ \ncomputed \ntomography \nscanning, \npreoperative \nlymphoscintigraphy \n(LS), and sentinel \nlymph node biopsy \nin patients with \nmalignant \nmelanoma.  Diagnostic study  \n 52 CM patients \ninitially classified as  \nstage I or II, before \nsentinel biopsy  Sensitivity and \nspecificity  \nPositive and \nnegative predictive \nvalue (PPV, NPV)  \nOverall diagnostic \naccuracy  18F-FDG PET \nimaging for the \ndetection of \nregional lymph \nnode metastases:  \nSensitivity 14.3%  \nSpecificity 94.7%  \nPPV 50%  \nNPV75%  \nDiagnostic accuracy \n73% Study included in \nXing et al. 2011  2b \nLagaru et al. (2007)  To analyse \nsensitivity and Diagnostic study  \n 106 CM patients \nwho had whole -Sensitivity and \nspecificity  Per patient:  \nSensitivity 89.3%  Studies were done \nfor disease re -2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 96 von 732 specificity of \nPET/CT for the \ndetection of \nmetastases of \nmalignant \nmelanoma.  body FD G-PET/CT, \n30 of them with \nstages IIIC and IV  Specificity 88.0%  \nTrue positives 50  \nFalse positives 6  \nFalse negatives 6  \nTrue negatives 44  \nPer lesion:  \nSensitivity 89.6%  \nSpecificity 84.6%  \nTrue posi tives 78  \nFalse positives 8  \nFalse negatives 9  \nTrue negatives 44  staging in all \npatients; time \ninterval from initial \ndiagnosis not given  \n \nStudie included in \nXing et al. 2011  \n \nPfannenberg et al. \n(2007)  See above  See above  See above  See above  See above  See above  2b \nStrobel et al. (2007)  To prospectively \ndetermine the \naccuracy of \npositron emission \ntomography \n(PET)/computed \ntomography (CT) \nwith added CT \nmorphologic \ninformation for \ndepiction of \nmetastases in \npatients with hig h-\nrisk melanoma and Diagnostic study  124 CM patients \nwith tumor \nthickness > 4 mm; \nClark level, III or IV; \nor known \nmetastases  True and false \npositives and \nnegatives  \nSensitivity and \nspecificity  \nDiagnostic accuracy  Without dedicated \nCT readout:  \n45/124 true \npositives (36%)  \n3/124 false \npositives (2%)  \n68/124 true \nnegatives (55%)  \n8/124 false \nnegatives (6%)  \nSensitivity 85%  \nSpecificity 96%  \nDiagnostic accuracy \n91% Cohort includes \npatients with \nalready known \nmetastasis  \n \nStudy included in \nXing et al. 2011  2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 97 von 732 negative findings \nfor metastases at \nPET, by using \nhistologic findings \nor additional \nimaging and/or \nfollow -up findings \nas reference \nstandard.  With dedicated CT \nreadout:  \n52/124 true \npositives (34%)  \n4/124 false \npositives (3%)  \n67/124 true \nnegatives (54%)  \n1/124 false \nnegatives (1%)  \nSensitivity 98%  \nSpecificity 94%  \nDiagnostic accuracy \n96% \nDellestable et al. \n(2011 ) See above  Diagnostic study  See above  See above  See above  See above  2b- \nWagner et al. (2011 ) To assess the role \nof routine staging \nwith FDG PET -CT in \nmelanoma p atients \nwith localized high \nrisk melanoma.  Diagnostic study  48 consecutive \npatients with 1 < BT \n< 4 mm with \nulceration and with \nBT >= 4 mm were \nstaged  \nwith PET -CT (initial \nstaging) prior to  \nSLNB.  sensitivity, \nspecificity, PPV, NPV  For regional nodal \nasses sment:  \nsensitivity, \nspecificity, PPV, NPV \nof PET: 43%, 100%, \n100% and 78%, \nrespectively.  \n \nFor distant \nmetastases: positive \nPET in 0%, negative \nPET in 13% and Images were \ninterpreted by a \nspecialist, aware of \nall clinica l \nfindings/not \nblinded  \n \nSmall patient \ncohort, not \ndescribed in detail  \n \n 2b-  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 98 von 732 indeterminate PET \nin 13% of patients  \nMansour et al. \n(2010)  (1) to determine the \nanatomic scatter \nplot of false -\npositive and true -\npositive FDG -avid \nsites; (2) to \ndescribe and \ndetermine the \ncharacteristics of \nfalse-positive FDG -\navid sites; and (3) \nto identify patterns \nthat are useful in \npredicting false -\npositive findings for \npatient \nmanagement and \ncounseling.  Diagnostic study  342 CM patients \nwith PET/CT  \n True and false \npositives  True positives:  \nBreslow 0 \u2013 2 mm: \n46.9%  \nBreslow 2.01 \u2013 4 \nmm: 18.8%  \nBreslow > 4 mm: \n34.4%  \nStage II: 3.2%  \nStage III: 33%  \nStage IV: 63.8%  \nFalse positives:  \nBreslow 0 \u2013 2 mm: \n30% \nBreslow 2.01 \u2013 4 \nmm: 30%  \nBreslow > 4 mm: \n40% \nStage II: 27.3%  \nStage III: 45.4%  \nStage IV: 27.3%  Limited purpose of \nthe study  (musculo -\nskeletal findings in \nPET/CT)  \nNo fixed indications \nfor PET/CT  \n 3b \nRevel et al. (2010)  To assess the utility \nof PET -CT 18FDG in \na group of N \npatients with \ncutaneous head and \nneck melanoma, Diagnostic study  \n 22 patients with N0  \ncutaneous head and \nneck melanoma \nwith PET/CT before \nsentinel biopsy  Sensitivity and \nspecificity  Sensitivity 18%  \nSpecificity 84%   3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 99 von 732 combined with \nSLNB.  \nYancovitz et al. \n(2007)  See above  Diagnostic study  158 patients, 135 \nwith stage I/II \ndisease and 23 with \nstage III diseas e \n True and false \npositives and \nnegatives  Number of PET/CT \nstudies:  \n42 \nPositives:  \n5/42 (12%)  \nTrue positives  \n1/42 (2%)  \nFalse positives:  \n3/42 (7%)  \nTrue negatives:  \n37/42 (88%)  \nFalse negatives:  \n0 \nLost to follow -up: \n1/42  study included in \nXing et al. 2011  3b \nWagner et al. (2011 ) See above  See above  See above  See above  See above  See above  3b- \nAbbott et al. (2011)   to evaluate the role \nof [18F] \nfluorodeoxyglucose \nPET/CT as a \nsurveillance tool in \nasymptomatic \npatients with \nprimary cutaneous \nmelanoma  Diagnostic s tudy 34 patients with \nprimary cutaneous  \nmalignant \nmelanoma with \nAJCC stage III  Metastases \ndetection  In 20 patients with \nmicroscopic stage 3  \ndisease at \ndiagnosis: PET/CT \ndetected 2 of 3 \nrecurrences and 1 \nincidental breast \ncarcinoma.  \n  \nNo reference \nstandard  4  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 100 von 732  In 14 patients with \nmacroscopic stage \n3 \ndisease at, or \nsubsequent to, their \ninitial diagnosis: \nPET/CT detected 4 \nof 4 recurrences, \nmetastases in 1 \npatient who \nremains \nasymptomatic and  \n1 incidental thyroid \ncarcinoma.  \nSubtopic  \nSPECT/CT         \nVan der Pl oeg (2009)  To explore whether \nhybrid SPECT/CT  \nleads to better \nanatomical \nlocalization of \nsentinel nodes or to \nthe depiction of \nextra sentinel \nnodes in patients \nwith melanoma \nwhen conventional \nimaging is Cohort study  \n 85 CM patients who \nunderwent both \nconventional \nlymphoscintigraphy \nand subsequent \nSPECT/CT  Additional \ndiagnostic value of \nSPECT/CT (change \nof surgical \napproach)  Additional \ndiagnostic value of \nSPECT/CT in 35% \n(30 patients)  \n Only pa tients with \nquestionable results \nin lympho -\nscintigraphy or \nunusual drainage \npattern included  \n \n 2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 101 von 732 inconclusive, and \nwhether this \ninfluences the \nsurgic al approach.  \nSubtopic BONE \nSCINTIGRAPHY         \nAu et al. (1984)  To evaluate the \nyield and accuracy \nof preoperative \nradionuclide scans \nin patients with \nprimary melanoma \nfor the detection of \noccult metastasis to \nbrain, liver and \nbone.  Diagnostic study  \n 192 CM patients; \n171 in stage I \n(localized) and 21 \nin stage II (lymph \nnode metastasis \naccording to old \nAJCC staging)  True and false \npositives, false \nnegatives  107/112 (96%) t rue \nnegatives  \n5/112 (4%) false \npositives  \n0 true positinves  No information \nabout false \nnegatives (follow -\nup of patients with \nnegative results \nunclear)  \n \n 3b \nHofmann et al. \n(2002)  See above  Diagnostic study \nwith historical \ncohort; economical \nevaluation  \n 661 patients (stage \nI/II: 630 patients, \nstage III: 27 \npatients, stage IV: 4 \npatients)  True and false \npositives and \nnegatives  \nCost-efficiency of \nimaging procedures  \n 325 total bone \nscintigraphies  \n0 true positives  \n62 false positives \n(19%)  \nDetection rate /  \nCost o f bone \nscintigraphy at \ninitial staging: \n80654 EUR  \n(4099 EUR due to Diagnostic standard \nprocedures varied \nover time; no \ndefined gold \nstandard of \ndiagnosis  \n \n 3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 102 von 732 false positive \nresults)  \nKhansur et al. (1989)  See above  Diagnostic study  \n 115 patients with \nprimary CM (72 in \nlocalized stage) and \n28 patients with \nrecurrent disease  True and false \npositives  0/141 true \npositives  \n3/141 false \npositives (2%)  Criteria for \nselecting staging \nexaminations \nunclear  \n 3b- \nArdizzoni et al. \n(1987)  See above  Diagnostic study  116 patients; \nclinically 93 in \nstage I and 23 in \nstage II  True and false \npositives and \nnegatives  \n 68/73 (93%) true \nnegatives  \n5/73 (7%) false \npositives  \n0 true positives  Design (prospective \nvs. retrospective) \nnot clear  \nFollow -up time not \ngiven  3b- \nKersey et al. (1985)  See above  Diagnostic study  \n 393 patients at \nprimary diagnosis \nof CM  True and false \npositives  True positives 0  \nFalse positives \n7/116 (6%)  Extent of staging \nexaminations and \nextent/ length of \nfollow -up \ndepended on center \nand tumor site  \n 3b- \nZartm an et al. \n(1987)  See above  Cohort study  90 CM patients with \nlevel III and IV \nlesions  Positive results  No positive results \nfor bone \nscintigraphy  Patients with \ncomplete staging \nincluded; \nindications for \ndifferent staging \nexaminations \nunclear  \n 4  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 103 von 732 Subtopic  \nTUMOR MARKERS         \nMocellin et  al. \n(2008)  Analysis of the \nprognostic value of \nS100B serum levels \nin patients with \nmelanoma, with \nspecial regard to \nstages I \u2013 III (AJCC)  Meta-analysis of 20 \nprognostic studies \ncontaining 22 series \nof 3393 patients  \n5 series  considered \npatients in stages I \n\u2013 IV \n8 series considered \npatients in stage IV \nonly \n6 series considered \npatients in stages I \n\u2013 III only  \nOther combinations \nin the remaining 3 \nseries  \n 3393 patients with \nmelanoma, stages I \n\u2013 IV  \n \n Summary hazard \nratio for sur vival \n \n Summary hazard \nratio for survival  \n2.23 (95% CI 1.92 \u2013 \n2.58)  \nSummary hazard \nratio considering \nonly patients in \nstages I \u2013 III: \n2.28 (95% CI 1.8 \u2013\n2.89)  High degree of \nheterogeneity, \nwhich is not present \nwhen only studies \nof stages I \u2013 III are \ninclude d \nPublication bias \npresent (shown with \na funnel plot), but \nafter correction, \nHazard Ratio still \nsignificantly higher \nfor patients with \nelevated S100B  \nPublication bias not \npresent when only \nstudies of stages I \u2013 \nIII included  1a \nBalch et al. (2009)  To revi se the \nstaging system for \ncutaneous \nmelanoma on the \nbasis of data from \nan expanded \nAmerican Joint \nCommittee on Prognostic study  30,946 patients \nwith stages I, II, and \nIII melanoma and \n7,972 patients with \nstage IV me lanoma  Survival rate  Elevated serum \nLDH: \nThe updated AJCC \nMelanoma Staging \nDatabase \ndemonstrated that \nan elevated serum \nLDH is an Study included just \nfor reference here; \nno data abou t LDH \nin earlier stages \nthan IV  \n \n 1b   \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 104 von 732 Cancer (AJCC) \nMelanoma Staging \nDatabase.  independent and \nhighly significant \npredictor of survival \noutcome among \npatients with stage \nIV disease. Thus 1 - \nand 2 -year over all \nsurvival rates for \nthose stage IV \npatients in the 2008 \nAJCC Melanoma \nStaging Database \nwith a normal \nserum LDH were \n65% and 40%, \nrespectively, \ncompared with 32% \nand 18%, \nrespectively, when \nthe serum LDH was \nelevated at the time \nof staging (P < \n.0001). T herefore, \nserum LDH should \nbe measured at the \ntime stage IV \ndisease is \ndocumented, and if  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 105 von 732 the LDH level is \nelevated, those \npatients are \nassigned to M1c \nregardless of the \nsite of their distant \nmetastases.  \nNowecki et al. \n(2008 ) to assess the \nprognostic value of \nmultimarker reverse \ntranscriptase - \npolymerase chain \nreaction (RT -PCR) \nassay in lymphatic \ndrainage (LY) after \nlymph node \ndissection (LND) \nand of preoperative \nserum lactate \ndehydrogenase \n(LDH) levels in AJCC \nstage III melanoma \npatients.  Prognostic study  \n \n 255 consecutive \npatients with \nhistological \ndiagnosis of CM \nand regional \n(inguinal or axillary) \nLN involvement who \nunderwent radical \nLND \n \n Overall survival  \n \nDisease -free \nsurvival  \n \nRecurrence rate  estimated 3 -year \nOS rate for patients \nwith increased \npreoperative serum \nLDH level: 41.3% \n(95% CI: 28.4 \u2013\n54.6%), vs. 55.3% \n(95% CI: 45.8 \u2013\n64.9%) for patients \nwith a normal \nbaseline serum LDH \nlevel (P = 0.007).  \n \ndisease recurren ce \nin 70% of patients \nwith an increased \npreoperative serum \nLDH level compared \nwith 53% patients \nwith a normal \nserum LDH level (P  \nResults for RT -PCR: \nsee full -text 1b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 106 von 732 = 0.01).  \n \nNegative impact of \nincreased pre -\nlymphadenectomy \nserum LDH level on \nOS of melanoma \npatients with \nmacrometastases \nafter TLND. Serum \nLDH level does not \ndifferentiate the \nprognostic groups \nin patients with \nmicrometastases  \nVereecken et al. \n(2009 ) To investigate the \nprognostic \nsignificance of \ngalectin -3 in \ncomparison to \nS100B, LDH and \nCRP Prognostic study  \n \n  83 patients in stage \nIII and IV  Overall survival  3 groups of \npatients were \ndefined according \nto Gal -3 levels: <8 \nng/ml (group 1), 8 \u2013\n10 ng/ml (group 2), \n>10 ng/ml (group \n3).  \n \nGroup 1 and 2: \nsimilar overall \nsurvival, group 3: \nworst ou tcome. LDH was omitted \nfrom the analysis \nbecause only 8 \npatients showed \nelevated LDH serum \nlevels  \n \n 1b- \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 107 von 732 median  \nsurvival was 4.1 \nmonths.  \n \nmultivariate Cox \nproportional \nhazards model: \nAJCC stage and CRP \nserum levels =most \nimportant \nindependent \nprognostic factors \n[HR =9.60, \nP=0.0002 and \nHR=2.75, P=0.002,  \nrespectively].  \n \nAt a cut -off value of  \n10 ng/ml for  Gal-3, \n(on quatrivariate \nanalysis) serum \nGal-3: strong \nindependent \nprognostic value, \nsuperior to the \nother markers \n(HR=4.64, \nP=0.0001).   \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 108 von 732 Essler et al. (2011 ) To assess the \nprognostic value of \nFDG PET/CT \ncompared to the \ntumor markers \nS100B and \nmelanoma \ninhibitory  \nactivity (MIA) in \npatients with high \nrisk melanoma.  Retrospective \ndiagnostic and \nprognostic study   125 consecutive \npatients  \n \nPatients who had a \nBreslow tumor \nthickness .2.0 mm,  \nelevated S100B or \nMIA level  specificities  \nsensitivities  \nNPV \nPPV \n S100B: Overall \nspecificity 85.7% \n(75.0% to 92.3%)  \ncorresponding \nsensitivity:45.2% \n(33.4% to 55.5%),  \nNPV 61.4% (50.9% \nto 70.9%). PPV: \n75.7% (59.9% to \n86.6%)  \n \nMIA: O verall \nspecificity 95.2% \n(86.9% to 98.4%). \ncorresponding \nsensitivity 36.1% \n(25.2% to 48.6%), \nrespectively. NPV:  \n60.6% (50.8% to \n69.7%), PPV: 88.0% \n(70.0% to 95.8%).  \n \nPatients with \nelevated S100B - or \nMIA values or \nPET/CT positive \nfindings showed a \nsignific antly  2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 109 von 732 (p<0.001 each, \nunivariate Cox \nregression models) \nhigher risk of \nmelanoma \nassociated death \nwhich was \nincreased 4.2 -, \n6.5- or 17.2 -fold, \nrespectively.  \nKruijff et al. (2011)  Aim was to assess \nthe correlation and \nthe prognostic \nvalue of S -100B and \nStandardized \nUptake Values (SUV) \nof \nFluorodeoxyglucose \n(FDG)  Retrospective \ncohort study  62 patients with \npalpable nodal \nmetastases, without \ndistant metastases  DFS and DSS  No relation was \nfound between S -\n100B and SUV.  \n \nDFS for patients \nwith an elevated vs. \nnormal S -100B: \n31% vs. 44,6% (HR \n= 3.1; p = 0.02)  \n \nDFS for patients \nwith normal vs. \nelevated SUV: 42% \nvs. 29% (HR = 1.1; \np = 0.8).  \n \nDSS for patients \nwith normal vs.  2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 110 von 732 elevated S100B: \n60.7% va. 44.7% (HR \n= 2.2; p = 0.07).  \n \nDSS for patients \nwith normal vs. \nelevated SUV: 59.1% \nvs. 43.5% (HR = \n1.1; p = 0.8).  \n \nS-100B is \nassociated with \ntumor load and a \nstrong predictor for \nDFS in stage III \nmelanoma  \nNeuss et al. (2011 ) To evaluate the \ncorrelation to \nclinical and \npathological data.of \nthe following \npreoperat ive serum \ntumour markers: \nS100, NSE, \nAlbumin, LDH and \nCRP  Prognostic study  \n patients in tumour \nstage III before \nradical lymph node \ndissection  Serum levels  The serum level of \nCRP correlated with \nincreasing number \nof LN node \nmetastases.  \n \nSignificant elevat ed \nserum levels of \nS100 in patients \nwith more than one \npositive SLN   2b \nBouwhuis et al. To determine the Prognostic study  918 se rum samples distant metastasis - Multivariate  2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 111 von 732 (2011 ) prognostic value of \nS100B based on \nupdated \ninformation  \nusing serial \ndeterminations in \nstage IIb/III \nmelanoma patients.  of 211 Patients who \nparticipated in the \nEORTC 18952 trial, \nevaluating efficacy \nof adjuvant  \nintermediate doses \nof interferon a2b \n(IFN) versus \nobservation  \n \nSerum S100B levels \nwere measured \nduring treatment \nand follow -up free i nterval (DMFI)  \n \ndistant metastasis - \nfree survival (DMFS)  \n \nOS \n \nHR analyses:  \nDMFS:  \nHR of S100B >= 0.2 \nversus S100B < 0.2 \nwas 5.57 (95% CI \n3.81\u20138.16), P < \n0.0001, after \nadjustment for \nstage, number of \nlymph nodes and \nsex.  \nIn stage IIb \npatients:  HR \nadjusted for \nsex=2.14 (95% CI \n0.71, 6.42)  \nIn stage III patients: \nthe HR adjusted for \nstage, number of \nLN and sex=6.76  \n(95% CI 4.50 \u2013\n10.16).  \n \nOS: \nHR: 4.73 (95% CI \n3.14\u20137.12), P < \n0.0001.  \nIn stage IIb  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 112 von 732 patients: HR 2.73 \n(95% CI 0.79 \u20139.44; \nP = 0.11).  \nIn stage III patients:  \n5.46 (95% CI 3.52 \u2013\n8.45; P < 0.0001).  \n \nSerial determination \nof S100B in stage \nIIb\u2013III melanoma is \na strong \nindependent \nprognostic  \nMarker, the \nprognostic impact \nof S100B >= 0.2 \nlg/l is more \npronounced in \nstage III disease \nthan in stage IIb . \nPaschen et al. (2009)  To investigate the \ncorrelation between \nsULBP2, sMICA and \nS100B levels and \nthe prognostic \nvalue of sULBP2 \nlevels  Prognostic study  \n 208 patients (25 in \nstage I/II, 54 in \nstage III, 129 stage \nIV)  \n50 healthy controls  \n Clinical sta ge \nTumor load  \nOverall survival  \n \n S100B serum \nconcentrations \nsignificantly \ncorrelated with \nstage of disease  \nPatients with \nmeasurable tumor \nsignificantly higher  2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 113 von 732 serum \nconcentrations of \nS100 than patients \nwith clinically non -\napparent tumor  \nAndr\u00e9s et al . (2008 )  To compare the \nvalue of tyrosinase \nmRNA by reverse  \ntranscription \npolymerase chain \nreaction (RT -PCR) in \nperipheral blood \nand of serum S -100 \nprotein in patients \nwith melanoma at  \ndifferent stages of \ndisease.  Prospective \ndiagnostic and \nprognostic stu dy 90 CM patients in \nstages I \u2013 IV  Sensitivity  \nProgression -free \nsurvival  \nOverall survival  Sensitivity of S100:  \n22.2% for stage I  \n10.5% for stage II  \n7.4% for stage III  \n94.1% for stage IV  \nMedian follow -up: \n312 days or to \ndeath  \nMedian \nprogression -free \nsurviv al 213 days \nfor elevated serum \nS100; not reached \nfor patients with \nnormal S100  \nMedian overall \nsurvival 282 days \nfor elevated serum \nS100; not reached \nfor patients with \nnormal S100 level  Very small control \ngroup for S100 (2 \nhealthy subjects, 3 \npatients with breast \ncancer, Hodgkin \nlymphoma and \nEwing\u2019s sarcoma, \nrespectively)  \nAlso contains data \non tyrosinase  \nPatients in stage I \u2013 \nIV \n \n 2b \nKruijff et al. (200 9) \n To investigate \nwhether the Prognostic study  \n 56 patients with \nclinically and Disease -free \nsurvival  2-year DFS in \npatients with  Follow -up \ndiagnostic 2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 114 von 732 perioperative \nmeasurement of the \ntumor markers S -\n100B has \nprognostic value  in \nFDG-PET and spiral \nCT staged patients  \nwith stage III \nmelanoma who are \nselected for \ntherapeutic lymph \nnode dissection   \n cytologically proven \nregional nodal \nmetastases of \nmelanoma  \n  \nPrognostic factors  - elevated vs. non -\nelevated \npreoperative S -\n100B \nconcentrations: 34% \nvs. 61% (HR:2.6, \nP=0.03)  \n- elevated vs. non -\nelevated \npostoperative S -\n100B  \nconcentrations: 30% \nvs. 51% (HR:2.0, P \n=0.1).  \n \nIn multivariate \nanalysis: extranodal \ngrowth (HR 0.4, P = \n.05), and elevated \npreoperative S -\n100B \nconcentrations (HR \n2.6, P = .03) were \nsignificantly \nassociated with \ndecreased DFS.  procedures and \nfollow -up intervals \nnot stated in article  \n \nDesign not \ndescirbed \n(prospective/retros\npective)  \n \n \nWang et al. (2004)  See above  Diagnostic study  \n 210 CM patients \nwithout clinical True and false \npositives and LDH results \navailable in 96  2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 115 von 732 evidence of \nmetastasis  \n negatives  patients with \nmelanoma > 1 mm  \n82/96 (85%) wi thin \ninstitutional normal \nrange  \n14/96 patients with \nelevated LDH, but \nno detection of \nsystemic disease or \nalteration in \nsurgical \nmanagement (15% \nfalse positives)  \nNo true positives  \nKaskel et al. (1999)  \n To evaluate the \nclinical and \nprognostic value of \nS-100 in peripheral \nblood of patients \nwith melanoma as a \nmarker for \nmetastasis.  \n Diagnostic study  \n 1396 samples of \n570 patients with \nmelanoma and 53 \ncontrol subjects  \n \n(397: melanoma in \nsitu or stage I or II, \n104: stage III, 69: \nstage IV)  \n \n Sensitivity, \nspecifity, positive \npredictive value \n(PPV), negative \npredictive value \n(NPV), \ndetermination of \noptimal threshold \n(ROC).  \n For a cut -off of \n0.114 \u00b5/L  \n \nSensitivity: 94%  \nspecificity: 91%.  \n \nFor a cut -off of \n0,2\u00b5g/L:  \nsensitivity and \nspecifity both 92%  \n \nPPV value (cut-off \n0,114 \u00b5g/L) for \nnewly occurring Part of the data on \nS-100 levels \nobtained in Munich \nhave also be en \nevaluated in a \ndifferent study by \nBerking et al.  \nfollow -up \nperformed in 197 \npatients only  \n \nROC: see full text  \n 2b  \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 116 von 732 metastases: 65%, \nNPV (no \nmetastases): 99%. \nFN results included \npatients with \nunknown primary \nmelanoma and \nthose with \namelanotic \nmelanoma \nmetastases.  \n \nHofmann et al. \n(2009)  To determine the \nvalue of MIA testing \nin early -stage \nmelanoma  Diagnostic study  \n 1079 CM patients in \nstages I and  II \nReference group: \n313 dermatological \npatients without \nhistory of \nmelanoma or other \nmalignancy  Mean values  \nSensitivity  \nSpecificity  Mean MIA value did \nnot increase based \non stage  \nSensitivity of MIA \nfor metastasis:  \n67.6% in stage I and \n65.6% in stage II  \nSpecificity:  \n76.9% for stage I \nand 66.7% for stage \nII  \nMore frequent \nfalse-positive \nvalues in elderly \nwomen and in men \nwith an increased Different reference \nstandard for \npatients with \nabnormal \nlaboratory values  \n \n 2b-  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 117 von 732 Breslow thickness  \nGarbe  et al. (2003)  To evaluate the \ndiagnostic accuracy \nof protein S -100B, \nmelanoma -\ninhibitory activity \n(MIA), LDH, AP, and \ntyrosinase/MART -1 \nreverse \ntranscription -\npolymerase chain \nreaction (RT -PCR).  Diagnostic and \nprognostic study  \n \n 296 consecutive  \nAJCC Stage II or III \nclinically disease -\nfree melanoma \npatients  \n \n120 healthy \ncontrols without \nmelanoma or other \nknown \nmalignancies.  Sensitivity  \n \nSpecificity  \n \nDiagnostic accuracy  Cutoff levels:  \nS100: 0.12 \u00b5g/L  \nMIA: 10.49 ng/mL  \n \nSensitivity: S - 100: \n29%, PCR: 24%, MIA: \n22%, AP: 17% , LDH: \n2% \n \nSpecificity: S -100: \n93%, PCR : 80%  \nMIA: 97%, AP: 89%  \nLDH: 90%  \n \nDiagnostic \naccuracy: MIA: 86%, \nS100: 84%, AP: 79%, \nLDH: 77%  \nRT-PCR: 72%  \n \nROC analysis: \ndiagnostic accuracy:  \nS-100: 66%, MIA: \n62%, LDH: 53%, AP: \n51% \n \nSignificant P values Different reference \nstandard (CT) for \npatients with \nabnormal \nlaboratory values \n(may lead to a \nhigher sensitivity of \nthe tumor markers \nthan in reality)  \n \nDetai led description \nof follow up; no \ndrop-outs \n \n 2b-  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 118 von 732 for S-100 (0 .001) \nand MIA (0.011), \nbut not for LDH \n(0.571), AP (0.807), \nand PCR (0.519).  \n \nSomer\u2019s Dxy : S -\n100 had the highest \npredictive value  \n \nKaplan \u2013Meier \nsurvival curves: \nhighly significant \ndifference in \nrecurrence -free \nsurvival time in the \ntime period after \nthe follow -up \nexaminations \nbetween patients \nwith normal and \npathologic values \nfor both MIA and S -\n100.  \nAgarwala et al. \n(2009 )  To assess each of \nthe three \nstratification factors \nin this study Prognostic study  \n \n 760 p atients (in \nstudy 301) and 760 \n(in study 18951)  \n Overall survival  LDH was within the \nupper range of \nnormal for a large \nnumber of patients.  Post-hoc analysis o f \ntwo randomised \ntrials (Oblimersen \nGM301 and EORTC 2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 119 von 732 (performance \nstatus, metastatic \nsite and LDH) for an \ninteraction with \ntreatment on \nsurvival.   \nhighly ordered and \nmonotonic \nrelationship \nbetween LDH and \nsurvival: survival \nworsened as LDH \nbecame more \nelevated, even when \nLDH remained \nwithin normal \nrange.  \n \n \nLDH and tumour \nsize poorly \ncorrelated; elevated \nLDH was not \nassociated with any \none disease site. \nLDH was highly \npredictive of \noblimersen effect.  \n \nKaplan \u2013Meier \nsurvival curves: see \nfull-text 18951)  \n \n \nDeichmann et al. LDH was compared Diagnostic study  91 patients with Sensitivity  LDH not Sensitivity an d 2b-   \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 120 von 732 (2004)  to CRP to evaluate, \nif LDH is of value in \ndiscriminating \nmelanoma patients \nentering AJCC stage \nIV from patients \nstaying in AJCC \nstages I, II or III.  \n  \n histologically \nproven melanoma \nprogressing into \nstage IV, 125 \npatients stage I, II \nor III in follow -up \nexaminations   \nspecificity  significantly \nelevated in patients \nentering stage IV \nmelanoma \n(P=0.785) , whereas \nCRP was (P<0.001).  \n \nLDH did not \ndiscriminate \nbetween the \ndefined groups of \npatients \n(AUC=0.491; 95% \nCI, 0.410, 0.581), \nwhereas CRP did \n(AUC=0.933; 95% \nCI, 0.900, 0.966; \nP<0.001).  \n \nCRP in diagnosing \nAJCC stage IV entry: \ncutoff =2,1 or \n2,2mg/dl: \nspecificity=80%, \nsensitivitie=83,5%.  \n \ncutoff 2,4 or \n2,5mg/dl: specificity for LDH \nnot given  \n \nSmall population  \n \nNo information on \nblinding   \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 121 von 732 specificity = 83,2% \nand 85,66, \nrespectively. \nsensitivity of 81,3%.  \n \nCutoff=2.9mg/dl:  \nSpecificity=89,6%  \nsensitivity=79,1  \n \ncutoff \npoint=3.0mg/dl:  \nspecificity=90,4  \nsensitivity=76,9  \nDeichmann (2001)       Same data as in:  \nDeichmann et al. \n(1999): S100 -Beta, \nmelanoma \ninhibiting activity, \nand lactate \ndehydrogenase \ndiscriminate \nprogressive from \nnon-progre ssive \namercan joint \ncommittee on \ncancer stage IV \nmelanoma   \nStoitchkov et al. To define the Diagnostic study  60 melanoma Overall survival  In stage III  Small patient 2b-  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 122 von 732 (2003)  potential use of this \nnew marker for the \nfollow -up of \nmelanoma patients \nby means of serial \nmeasurement \n(before and after \ntreatments, and \nduring follow -up) patients  \n(24: stage I \u2013II, 18 \nstage III, 18 stage \nIV)  \nChange in serum \nconcentrations by \ntherapeutic \ninterventions  patients with \nelevated marker \nconcentration, LN \ndissection \ndecreased the \nS100B level  (from \n0.27 to  \n< 0.13 g/l, P= \n0.008), but not the \nL-dopa/L -tyrosine \nratio.  \n \nChemotherapy \ndecreased the ratio \nby \n38% (P 0.04) and \nthe S100B level by \n45% (P 0.02) in \nstage IV \nresponders.  \n \nincrease in one or \nboth markers \nduring follow -up in \npatients with \nprogressive \ndisease:  \n numbers divided \ninto many \nsubgroups  \n \nStudy included here \nin addition to S100 \nmeta -analysis \nbecause of results \nabout L -dopa/L -\ntyrosine ratio  \n \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 123 von 732 shorter survival in \nstage IV patients \nwith high vs. \nnormal L -Dopa/L -\nTyrosine ratio at \ninclusion (3 vs. 15 \nmonths).Levels of \nS100B had no \nimpact on survival, \nin stage IV patients.  \n \nNo correlation \nbetween L -dopa/L -\ntyrosine ratio and \nS100 B.  \nStoitchkov et al. \n(2002)  Prospective \nevaluation of the \npotential of the \nserum L -dopa/L -\ntyrosine ratio in the \nmanagement of \nmelanoma, with an \nemphasis on \nstaging, tumour \nburden and \nprognosis (the \npredictive value for \ndisease progression Diagnostic study  \n \n 89 melanoma \npatients with \nhistologically \nproven primar y \nand/or metastatic \nmelanoma or \nmeasurable \nmetastatic disease \n(by imaging).  \n \n \n(9 stage I, 33 stage \nII, 19 stage III, 28 Sensitivity and \nspecificity  overall sensitivity \nfor melanoma: 51% \nfor the ratio and \n66% for S100B.  \n(range: 33% (stage I) \nto 71% (stage IV) for \nthe ratio, 56 \u201389% \nfor S100B)  \n \nno statistical \ndifference between \nstages I, II and III \npatients for both Precursor  study to \nStoitchkov et al., \n2003  \n \nPatients lost to \nfollow -up are not \nincluded in analysis \n(risk of bias)    \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 124 von 732 in metastatic \npatients and \nsurvival).  stage IV).  markers. Significant \nhigher median ratio \nin stage IV.  \n \nIn stage III \u2013IV \npatients, both \nmarkers were \nsignificantly higher \nin evolutive p atients \nthan in stable ones.  \n \nThe ability \n(sensitivity/specifici\nty) of markers to \npredict disease \nprogression in \nmetastatic patients: \n78%/67% for the \nratio, 74%/83% for \nS100B (select cut -\noff) and 87%/33% \nusing the \nmanufacturer\u2019s \nreference values.  \nKrahn et al. (2001)  To evaluate tumor \nmarkers S100, MIA, \nLDH and albumin in \nperipheral blood of Diagnostic study  \n 373 melanoma \npatients (284 with \nmelanoma in situ or \nstage I/II and 89 Sensitivity  \nSpecificity  Presence of lymph \nnode, visceral and \nbrain metastases:  \nSensitivity ( for No follow -up as \nreference standard \n(cross -sectional \ndesign)  2b-  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 125 von 732 melanoma patients  with melanoma \nstage III/IV; 54 of \nthese tumor free \nand 29 with newly \noccurred \nmetastases)  \n10 control subjects  newly occurred \nmetastases) for LDH \n48%, for MIA 80%, \nfor S100 86%  \nSpecificity for LDH \n98%, for S100 91%, \nfor MIA 62%  \nNo false positive \nresults in the \ncontrol group   \n \nDeichmann et al. \n(1999)  serum levels of \nS100 -beta (S100b) \nand melanoma -\ninhibiting activity \n(MIA) were assessed \nfor the ability to \ndiscriminate \nprogressive from \nnonprogressive  \ndisease.  Diagnostic study  \n \n \n 71 consecutive \npatients with stage \nIV melanoma  \n \nControl group: 38 \nhealthy adult  \n \n Sensitivities  \nand specificities  \n \ndiscrimination \nability  Cut-offs:  \nS100b 0.12 \u03bcg/L, \nMIA 6.50 ng/mL All \ntested serum \nparameters were \nsignificantly \nelevated in patients \nwith progressive \ndisease.  \n \nSensitivity:  \nS100b=91%  \nMIA=88%  \nLDH=79%  \n \nSpecificity:  \nS100b=76%  \nMIA=73  Patients received \ndifferent therapies  \n \nSmall population  \n \nNo information \nabout follow -up \n \n 2b-  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 126 von 732 LDH=92%  \n \nIn calculating \nSomers\u2019 Dxy and \nROC-AUC values, \nS100b, MIA,  and \nLDH showed high \ndiscrimination  \nability. Multiple \nlogistic regression: \nLDH was the only \nstatistically \nsignificant marker \nfor progressive \ndisease.  \nHofmann et  al. \n(2011)  to assess the utility \nof melanoma \ninhibitory activity \n(MIA) serum marker \nin the follow up and \nprimary diagnosis \nof stage III \nmelanoma patients  Diagnostic study  138 melanoma \npatients in stage III \nat time of primary \ndiagnosis and \nduring periodica l \nroutine follow up  Sensitivity  \n \nSpecificity  \n \n5-year survival rate  MIA cut -off value of \n12 ng\u2044mL: \nsensitivity: 69.2%, \nspecificity: 69.9%. \nPPV for relapsing \ndisease: 67.2%, \nNPV: 72.0%  \n \n5-year survival rate: \n78.1% (MIA <12 \nng\u2044mL) vs. 72.7% \n(MIA >=12 ng\u2044mL).   \n(P = 0.230).  No information \nabout time interval \nbetween blood \nsample and \nstaging/restaging \nexaminations  \n \n\u201crelapse\u201d not \ndescribed in detail, \nstaging results not \ngiven.  \n 3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 127 von 732 Garnier et al. (2007)  L-DOPA/tyrosine \nratio (an index of \ntyrosinase activity), \nmelanoma antigens \nS100B and MIA, \nlactate \ndeshydrogenase \n(LDH) and their \ncombinations were \nevaluated for \nclinical value as \ntumour markers in \nmelanoma.  Diagnostic study  \n 170 CM patients \n(stage I \u2013II: 57, III: \n54, IV: 59)  Sensitivity  \nSpecificity  \nIncrease with \ndisease progression  \nOverall survival  At inclusion:  \nSensitivity/ \nspecificity of L -\nDOPA/tyrosine ratio \nwith S100:  \n73%/70%  \nL-DOPA/ tyrosine \nratio with LDH:  \n69%/69%  \nL-DOPA/ tyrosine \nratio with MIA:  \nL-DOPA/ tyrosine \nratio with MIA and \nLDH:  \n74%/68%  \nDuring fol low-up: \nDisease progression \n(11 stage I \u2013II, 7 \nstage III patients) \nincreased the L -\nDOPA/ tyrosine \nratio by +35.7%, \nbut not other \nmarker levels (MIA: \n+18%, S100B: -20%, \nLDH: -9.7%)  \nCox regression \nmodel: survival  3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 128 von 732 predictors were \nS100B and MIA  \nTas et al.  (2004)  To investigate the \nclinical value of \nS100 and MIA as \ntumor markers for \nmalignant \nmelanoma.  \n \n Diagnostic and \nprognostic study  \n 48 CM (5 in stage I \nand II, 22 stage III, \n21 in stage IV)  \nControl group: 15 \nhealthy subjects  Sensitivity, \nspecificity  \nOverall survival  Only 5 patients in \nstages I and II \nincluded; none of \nthem had increased \nMIA, 2 had \nincreased S100  \n \nOnly sensitivity of \nserum MIA \nstatistically \nsignificantly \ncorrelated  \n \nin Cox analysis, the \nprognostic \nsignificance of MIA \nlevel \nwas lost  Small patient \nsample in stage I  \n \nSmall patient \nsample, especially \nin stage I  \n \nSmall control group \nof healthy people, \nno details given  \n \nDetails of staging \nand follow -up (e.g. \ntime intervals, \nexaminations at \nfollow -up) not \nreported  3b \nBanfalvi et al. (2002)  to compare the \nprognostic values of  \nserum 5 -S-\nCysteinyldopa, S -\n100B and LDH \nconcentrations  \nin Stage III -IV \nmelanoma patients  Retrospective \ndiagnostic and \nprognostic study  \n \n \n Data from 179 \npatients Stage III -IV \nmelanoma patients \nat diagnosis:  \n(37 in Stage III, 142 \nin Stage IV).  \n \nThe age of patients Specificity  \nSensitivity  \nPPV \n \nOverall Survival  Stage III: 5 -S-CD \nwas 60 % \nsensitivity, 91.6 % \nspecificity, 93.8 % \nPPV \n \nStage IV:  \nLDH: In stage III  data for \nsensitivity and \nspecificity for \nS100B and LDH not \ngiven  \n \nNo further \ninformation about 3b \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 129 von 732 ranged from 22 to \n88 years (mean \n59.8). Median \nfollow up time was \n15 months.  \n \n63 patients (with  \nother skin diseases) \nwere enrolled as \ncontrol group.  Sensitivity=48.5 %, \nSpecificity =83.3, \nPPV= 98.5.  \nS 100B: \nSensitivity=70.5, \nSpecificity = 100, \nPPV= 100.  \n5-S-CD \nSensitivity=69.1 \nSpecificity =50, \nPPV= 96,9  \n \ncalculated median \nsurvival: 4.6 \nmonths. Kaplan -\nMeyer analysis of \nthe survival of \npatients with \nelevated vs. normal \nmarker levels \nindicated significant \ndifferences in case \nof all the 3 markers, \nwith the shortest \nsurvival of patients \nwith elevated S \n100B or LDH levels \n(p<0.05).  staging (reference \nstandard)   \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 130 von 732 Meral et al. (2001)  To investigate the \nhypothesis that the \ndecline in serum \nmelanoma -\ninhibiting acitivity \n(MIA) levels \nfollowi ng initiation \nof treatment might \nhave prognostic \nvalue  Prognostic study  \n \n 35 patients with \nadvanced stage \nmelanoma (11 \nstage III, 24 stage \nIV) \n \nmean age 52.2 \nyears  \n \nControl group \nconsisting of 20 \nadults without \ndegenerative \ndiseases of \ncartilage or joint \npain Overall survival  The mean serum \nLDH, S100 and MIA \nlevels of the \npatients with MM \nbefore treatment \nwere significantly \nhigher than in the \ncontrol group.  \n \nPatients with \nvisceral \ndissemination vs. \npatients with nodal \nspread: MIA -levels \n30.1 ng/ml vs.14.5 \nng/ml. mean serum \nMIA level in the \ncontrol group: 12.4 \n\u00b1 3.2 ng/ml. (cut -\noff level: 8.7 ng/ml \n(mean + 2SD).  \n \n1-year OS rates: no \nchange according \nto the site of the \nprimary tumour, the \ntype of surgical or \nradiation treatment See original article \nfor overall survival \ncurves (Kaplan -\nMeier)  \n \nSurvival analysis \nwere not perfomed  \nwith serum S100 \nlevels  \n \nAnalysis of LDH \nkinetics revealed no \nuseful \ninformation.`  3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 131 von 732 or the \nchemotherapy \nregimen.  \n \nAdvanced stage MM  \npatients in whom \nserum MIA levels \ndid not decrease \nduring systemic \ntreatment had a \nless favourable \nprognosis.  \nBrouard et al. (2000)  To determine if \nserial PS100B is a \nmarker for \nmetastatic evolution \nby observation of \nits \nlevel/variation/eval\nuation in patients in \ncomplete remission \nand patients \nreceiving  \nchemotherapy   Diagnostic study  \n \n. \n \n 239 blood samples \nwere taken in 122 \npatients with \ncutaneous \nmelanoma (56 \npatients in \ncomplete remission, \n56 patients with \nmelanoma in \nprogression  \n Sensitivity and \nspecifictiy  The threshold to \nseparate patients \nwith met astases \nfrom those in \ncomplete remission \nwas 0,09\u00b5g/L \n(Specificity 92%, \nsensitivity 70%).  \n \nPPV (Stage III/IV): \n77%, NPV 89%  Only results of 90 \npatients are \npresented. Drop \nouts are not \ncommented.  \n \n \n \n \n \n 3b \nSchmitz et al. (2000)  To analyse the \nserum levels of \nS100B and MIA in \nnon-melanoma Diagnostic study  \n 87 CM patients  Specificity  \nPositive results  Specificity for S100 \nregarding the \ndiagnosis of \nmelano ma: No follow -up \n(cross -sectional \ndesign)  \n 3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 132 von 732 control patients and \nmelanoma patients \nto report on the \nsensitivity and \nspecificity of both \ntumor markers  85.8% with a cut -\noff value of 0.12 \n\u00b5g/l  \n94.6% with a cut -\noff value of 0.20 \n\u00b5g/l \nSpecificity for MIA:  \n89.9% with a cut -\noff of 6.5 \u00b5g/l  \n97.4% with a cut -\noff of 8.5 \u00b5g/l  \nValues > 6.5 \u00b5g/l \nfor MIA prior to \ntreatment:  \n0% for stage I/ II  \n53.8% for stage II I  \n68.3% for stage IV  \nValues > 6.5 \u00b5g/l \nfor MIA post \ntreatment:  \n11.7% for stage I/II  \n9.7% for stage III  \n6.9% for stage IV  \nValues > 0.12 \u00b5g/l \nfor S100 prior to \ntreatment:  \n50% for stage III  \n80% for stage IV    \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 133 von 732 Values > 0.12 \u00b5g/l \nfor S100 post \ntreatment:  \n16.1% for stage I/II  \n18% for stage III  \n14.3% for stage IV  \nStahlecker et al. \n(2000)  To evaluate whether \nMIA is a reliable \ntumor marker in \nterms of course of \ndisease, therapy -\nmonitoring and \nprognostic value  Diagnostic s tudy \n  326 melanoma \npatients: 250 stage \nI, 52 stage II, 5 \nstage III and 19 \nstage IV  \nControl group of \n100 healthy blood \ndonors  Positive results  \nSensitivity  \nSpecificity  \n Increased MIA \nlevels:  \n4.4% in stage I (n = \n250)  \n11.5% in stage II (n \n= 52)  \n60.0% in st age III (n \n= 5)  \n89.5% in stage IV (n \n= 19).  \nElevated MIA 22 \npatients with no \nclinical evidence of \ndisease (stage I, II \nor stage III, IV after \nmetastatic surgery)  \n8 of them had \ndetection of \nmetastases at the \nsame time, 5 of \nthem 2 \u2013 6 months \nlater  3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 134 von 732 9 stayed  free of \nclinically detectable \ndisease (false \npositives = 3%)  \nBosserhoff et al. \n(1997 ) To investigate \nwhether MIA \nprovides a clinically \nuseful parameter in \npatients with \nmalignant \nmelanomas, and to \ncompare this with \nthe diagnostic value \nof S100.  Diagn ostic study  \n 112 CM patients \n(38 stage I, 13 \nstage II, 6 stage Ill, \nand 44 stage IV)  \n350 clinically \ntumor -free patients \nduring a follow -up \nperiod after \nremoval of a \nprimary stage I or II \nmelanoma  \n \nControls: 72 \nhealthy blood \ndonors  \nAdditional controls: \n50 patients with \nsepsis, 23 patients \nwith brain tumors, \n243 patients with \nadvanced epithelial \nand mesenchymal \ntumors  Positive rates  \nTP \nFN \n Positivity of MIA:  \n- 100% of sera from \n50 patients with \nstage III and IV  \n- 13% of sera from \nstage I  \n- 23% of sera fro m \nstage II patients  \n- 9% of clinically \ntumor -free \npatients; 15 (4%) of \nthese patients \ndeveloped \nmetastases  \n \nMIA-levels in \npatients with other \nmalignancies: see \nfull-text \n \nS100 -positivity, \ncut-off: 0.15 ng/ml  \n- 30/49 (61%) sera \nfrom stage III and IV Sample of stage II \nand III patients \nsmall  \n \n \n5 patients during \nchemothera py of \nstage IV melanoma  \n \nSensitivity/specificit\ny not given  \n 3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 135 von 732 patients  \n- 0% of stage I and \nII sera  \n- 4% of sera from \nhealthy donors  \n- 20% from septic \npatients, 16% from \npatients with \ngliomas, and 5% \nfrom patients with \nadvanced \ncarcinomas positive  \nBosserhoff et al. \n(1999 )      Same patient cohort \nas Bosserhoff et al. \n(1997), less data  \n \n  \nHenze et al. (1997)  To examine serum \nS100 \nconcentrations of \npatients with \ndifferent stages of \nmalig nant \nmelanoma and to \ndetermine the value \nof serum S100 in \nthe follow -up of \nmelanoma patients Diagnostic study  \n \n Blood samples from \n73 patients with \nmalignant \nmelanoma (25 \npatients: stage I/II, \n14: stage III, 34: \nstage IV)  \n \nControl group: 1 30 \nhealthy patients.  sensitivity  1/25 stage I/II \npatients, 3/14 \nstage III patients \n(sensitivity 21,4%) \nand 27/34 stage IV \npatients (sensitivity \n79,4%) showed \ndetectable S100 \nlevels.  \nFor metastastic \nmelanoma (stage Small population  \n \nChoroid melanoma \nincluded (n=1)  \n \nNo information \nabout staging given  3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 136 von 732 during treatment  III/IV): sensitivity \n62,5%.  \n \nCorrelation b etween \nserum S100 and \nclinical stage \n(p=0,0899 stage \nI/II versus \np<0,0001 stage \nIII/IV)  \nDumitrascu et al. \n(2009)  To investigate S -\n100B and MIA in \nrelation to disease \ndevelopment  Diagnostic study  \n  51 patients with \nskin melanoma \n(34% stage I, 40% \nstage II, 15% stage \nIII and 11% stage IV) \nand 72 healthy \nvolunteers  \n True  and false \npositives  Mean serum level of \nS100 in healthy \nvolunteers:  \n0.172 \u00b5g/l  \n5.55% FP  \nMean serum l evel of \nMIA in healthy \nvolunteers:  \n7.28 \u00b5g/l  \nNo false positives  \nS-100B significantly \nelevated only in \nstage IV patients (p \n= 0.02)  \nMIA significantly \nelevated both stage \nII, III and IV  \nMIA levels Low patient \nnumbers for each \nstage  \nSelection critera for \npatients and \nhealthy volunteers \nnot given  \n \n 3b-  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 137 von 732 decreased after \nsurgical removal of \ntumors and/or after \ngood  response to \nspecific therapy; \nincrease followed \ntumor progression \nand poor clinical \nresponse to \ntreatment  \nVucetic et al. (2008)  To investigate \nwhethe r MIA serum \nlevel will be \nelevated in patients \nwith \nmetastases or local \nspreading of the \ndisease before any  \nsymptom of such \nprogression is \nclinically apparent  Diagnostic study  \n 140 patients:  \n(50 with positive \nSN,  \n50 with negative \nSN,  \n20 controls with \ndysplastic nevi  \n20 controls with \nbasal cell carcinoma  \nExclusion criterion: \npalpable lymph \nnodes  Mean values  \nSensitivity  \nSpecificity  Mean MIA value in \npatients with \npositive sentinel \nnodes:  \n14.53 ng/ml  \nMean MIA value in \npatients with \nnegative sentinel \nnodes:  \n7.32 ng/ml  \nAt a cutoff value of \n8.5 ng/ml, 82% \nsensitivity and 82% \nspecificity of MIA  No follow -up as \nreference standard \n(cross -sectional \ndesign)  \n \n 3b- \nArenberger (2007)  quantification of \nthe following five \nmelanoma markers \nby establishing a Prospective study  \n \n 65 patients with  \nresected cutaneous \nmelanoma stage \nIIB\u2013III  Detection rate  Tumour marker \nmean levels in \npatients with \nprogression: MIA, Small population  \n \nElevation of tumour \nmarkers varies 3b-  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 138 von 732 quantitativ e \nmultimarker real -\ntime RT -PCR assay: \nmelanoma antigen \nrecognized by T \ncells (Melan -\nA/MART -1), \nmelanosomal \nmatrix protein \n(gp100), melanoma \nantigen -A3 family \n(MAGE -3), \nmelanoma \ninhibitory protein \n(MIA),  \nand tyrosinase.  \nAdditionally human  \ntelomerase reverse  \ntranscriptase \n(hTERT) was \nfocused on  \n \nThe final aim is the \nroutine usage of \nthis method for \nrapid  \nscreening of early \nmetastasis and 33.9% stage IIA, \n24.6% stage IIB, \n12.3% stage IIC, \n15.4% IIIA,  \n9.2% stage IIIB and \n4.6% stage IIIC.  \n \nControl group: 23 \nhealthy donors  \n \n 4.272\u00b12.183 \n(statistically \nsignifi cant \ndifference \ncompared with cut -\noff value, P<0.01); \nMelan -A, \n0.026\u00b10.016 \n(P>0.05); MAGE  \n3332.927\u00b1196.239 \n(P<0.01); gp100, \n0.953 \u00b10.827 \n(P<0.05). MAGE -3 \nwas the most \nfrequent positive \nmarker (17x), than \ngp100 (10x), MIA \n(9x) and tyrosinase \n(1x). Melan -A did \nnot show any \nsignificant elevation \ncompared with cut -\noff. \n \nIn patients with  \nprogression, in 39% \nthree markers were \nconcomitantly strongly (e.g. \npatient 35: MAGE -\n3= 36.4, in patient \n2: MAGE -3=40 \n580).  \n \npoor information \nabout the patients` \nfollow -up after the \nstudy.   \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 139 von 732 treatment response \nin high -risk \nmelanoma patients.  \n positive, in 28% two \nmarkers and in 33% \none marker were \npositive.  \nArenberger (2007)  See above  See above  See above  See above  See above  Same \npopulation/same \nresults as in the \npreviously \ndescribed study \n(Arenberger P \n(2007): Multimarker \nreal-time reverse \ntranscription -PCR \nfor quantitative  \ndetection of \nmelanoma -\nassociated \nantigens: a novel \npossible staging \nmethod)   \nSmit et al. (2008)  to evaluate S -100B \nfor monitoring \nresponse to \nchemoimmuno thera\npy followed by \nsurgery and its \npredictive value for \nrelapse and overall Prognostic study.  \n \n 44 patients with \nlocoregional -lymph  \nnode or intransit \nmetastases \n(cytologically \nproven, clinically \ndetectable regional \nmetastases of Overall survival  \n \nRenissionrate  \n Correlations \nbetween the pattern  \nand intensity of S -\n100B expression in \nthe tumor specimen  \nand the value of \nserum the S -100B \ndid not reach Small population  \n \n 3b-  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 140 von 732 survival in patients \nwith clinically \ndetectable localized \ndisease.  \n \nAnother aim was to \nanalyze the \nexpression of S -\n100B in the lymph \nnodes and in -\ntransit metastases \nof the includ ed \npatients and to \ncompare these \nfindings with the \nvalues of S -100B in \nthe serum.  \n melanoma without \nevidence of distant \nmetastases.  statistical \nsignificance  \nLugovi c et al. (2007)  To determine and \ncompare levels of \nS100, MIA, LDH and \ntyrosinase in the \nserum of patients \nwith MM in different \ndisease stages, and \nto conclude \nwhether these \nmight be useful Diagnostic study  \n 50 melanoma \npatients (30% in \nstage I, 52% in \nstage II, 16% in \nstage III and 8% in \nstage IV)  Positive results  Increased MIA in \n26% of stage I \npatients, 26% of \nstage II patients, 0% \nof stage III patients \nand 50% of stage IV \npatients  \nIncreased S100 in \nof stage I patients,  \n9% of stage II No follow -up as \nreference standard  \n \n 3b-  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 141 von 732 prognostic tools for \nMM progression  patients, 0% of \nstage III patients \nand 50% of stage IV \npatients  \nIncreased LDH in \n26% of stage I \npatients, 4% of \nstage II patients, \n13% of stage III \npatients and 25% of \nstage IV patients  \nAuge et al.  (2005)  To compare the \nsensitivity and \nspecificity of S -100 \nand MIA and their \ncombination in \nadvanced \nmelanoma, and the \nrelationship with \nprognostic factors \nsuch as growth \npatterns and site of \nmetastases.  Diagnostic study  \n 182 CM patients: \n96 patients with  no \nevidence of disease \n(NED, stages I and \nII) and 86 patients \nwith stages III, IV  Sensitivity  Sensitivity of S100 \n(cutoff > 0.2 \u00b5g/l):  \n53.8% for SSM, 40% \nfor ALM,  75% for \nNM \nSensitivity of MIA \n(cutoff > 14 ng/l):  \n61.5% for SSM, 40% \nfor ALM, 65% for \nNM \nSlightly elevated \nlevels of S100 (< \n0.24 \u00b5g/l) and MIA \n(< 16.4 ng/ml) in \n1.2% and 3.2% of \nNED patients, \nrespectively  No data given for \nspecificity  \nReference test not \ndescrib ed in detail  3b-  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 142 von 732 Sensitivity of S100 \nfor LN metastasis \n58.3%, for multiple \nmetastases 58.3%, \nfor multiple with \nliver metastasis \n70%, for brain \nmetastasis 77%  and \nfor lung metastasis \n30% \nSensitivity of MIA \nfor LN metastasis \n54.1%, for multiple \nmetastases 62.5%, \nfor multiple with \nliver metastasis \n70%, for brain \nmetastasis 66.6% \nand for lung \nmetastasis 23%  \nGuba et al.  (2002)  To evaluate the \nassociation between \npre- and \nposttreatment \nlevels of MIA and \nsurvival in 70 \npatients with \nadvanced Diagnostic and \nprognostic study  \n \n 70 patients with \nhistologically \nconfirmed \nmetastastic \nmelano ma. (50 \nstage III, 17 stage \nIV) Overall -survival  \nSpecificity  \n Mia positivity \nconcentrations:  \n>8,8ng/l.:  \n- stage III: 46%  \n- stage IV: 65%  \n \nMedian OS in MIA \npositive patients No data for \nsensitivity given  \n \nSmall population  \n \n 3b-  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 143 von 732 melanoma.  (stage III/IV): 13 vs. \n28 months in \npatients with \nnegative pre -\ntreatment MIA \nlevels. \n \nstaging -related \nanalysis:  \nstage III: median \nOS: 14 months in \nMIA positive \npatients vs. 28 \nmonths in negative \npatients.  \nstage IV: 12 vs. 19 \nmonths \nrespectively.  \n \nSpecifitiy (cut -\noff>8,8ng/l) = 95%  \nKlimek et al. (2002)  To evaluate the \nsensitivity of serum \nMIA levels in \npredicting the risk \nof relapse in \npatients with AJCC \nstage II, III and IV Diagnostic study  \n  39 patients with \nstage II, III and IV \nmelanoma  \n14 patients with \nclinically adva nced \nmelanoma (IV or \nunresectable III) as Sensitivity  \nFalse positives  MIA: \n17% sensitivity for \nrecurrence  \n6% false positives  \nNo signi ficant \ndifference in the \nproportion of MIA values taken at \ndifferent intervals \nafter diagnosis and \ntreatment of \nmelanoma  \n \n 3b-  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 144 von 732 melanoma  positive controls  \nSerum from 20 \npatients with \nprostate or small \ncell lung cancer to \nestablish a \nbackground \nreference range  patients with \nelevated MIA levels \nbetween the group \nof patients who \nrelapsed (17%) and \nthose who did not \nrelapse (6%)  \nMatsushita  et al. \n(2002)  To compare the \nusefulness of the \nserum markers 5 -\nS-cysteinyldopa (5 -\nS-CD) and \nmelanoma \ninhibitory activity \n(MIA) in the \nmonitoring of \npostsurgical \nmelanoma patients  Diagnostic study  \n 45 CM patients (7 in \nstage I, 20 in stage \nII, 18 in stage III)  \n30 age -matched \nhealthy volunteers  Sensitivity  \nFalse positives  Sensitivity for \ndetection of \nrelapse:  \n64% for MIA  \nFalse positives \n(non-progressive \npatients) for MIA \n8.3% (6/72)  \n No selection criteria \nfor the included \npatients given  \n \nEvaluation per \nsample, not per \npatient  \nNo description of \nfollow -up  \n \n 3b- \nDreau et al. (1999)  To measure plasma \nMIA concentration \nin patients with \nmetastatic \nmelanoma or \npatients at high risk \nfor recurrence \ntreated with various \nimmunotherapy Diagnostic study  \n 84 CM patients (16 \nin stage II, 29 in \nstage III and 39 in \nstage IV) under \ntreatment  \nMost of stage II and \nIII patients (36/45) \nwere treated with \npolyvalent Sensitivity and \nspecificity  At a threshold of \n4.5 ng/ml values \nfor discrimination \nbetween \nprogression and no \nprogression were: \nSensitivity of 82% \nand specificity of \n71% before Low patient \nnumbers for each  \ntreatment modality  \nMethod of \nassigning patients \nto treatment \nregimens not \ndescribed  \n 3b-  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 145 von 732 regimens  melanoma vaccine \nafter surgical \nresection; all \npatients treated \nwith IL -2 were \nstage IV  treatment  \nSensitivity of 67% \nand specificity of \n79% after treatment   \nTofani et al. (1997)  To assess the \nreliability of NSE \nand S100 as \nindexes of disease \nactivity.  Diagnostic and \ncross -sectional \nstudy  \n \n 53 consecutive \npatients with \nmelanoma  \n \n24 patients \npresented with local \ndisease (stage I or \n11), 29 had \nmetastases (stage \nIII or IV).  \n \nTwenty healthy \nvolunteers were \nused as a control \ngroup.  Prevalence of \nincreased NSE and \nS100 levels  \n \nSensitivity and \nspecificity  In the whole group, \nelevation of  \nS-100 in 30% of \npatients. No \nelevated levels in \nthe subgroup of 24 \npatients stage I and \nII. Inceased levels in \n55% of patients \nstage III and IV  \n \nSerum NSE: \nelevated in 26%. \n4/24 patients (16%) \nwith melanoma in \nstages I and II had \nincreased NS E \nvalues. Inceased \nlevels in 34% of \npatients stage III \nand IV.  \n Small patient \nsamples  \n \nStudy included in \naddition to S100 \nmeta -analysis \nbecause of results \nabout NSE  \n \nNo details about \nreference standard \nfor the calculation \nof sensitivity and \nspecificity  3b-  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 146 von 732 1.3.5.  Literatur  \nLiteratur :  Zuteilung zu Fragestellung:  \nI.6 I.7 I.8 VII.6 \nAbbott et al. (2011 ) x x  x  \nFor the whole \ngroup: sensitivity of \nS100 and NSE: 30 \nand 26%, \nrespectively  \n \nFor patients I and II:  \nPoor sensitivity for \nNSE, S -100 values \nwere normal in all \npatients.  \n \nFor patients stage \nIII and IV: sensitivity \nfor  S -100 and NSE: \n55% and 34% \nrespectively  \n(p < 0.5).   \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 147 von 732 Agarwala et al. (2009 )    x  \nAloia et al. (2006)   x   \nAndr\u00e9s et al. (2008)  x x x  \nArdizzoni et al. (1987)  x    \nArenberger (2007)  x x   \nAu et al. (1984)  x    \nAuge et al. (2005)  x x x  \nBafounta et al. (2004)   x x x x \nBalch et al. (2009)  (x) (x) (x) x \nBastiaannet et al. (2009)   x  x \nBosserhoff et al. (1997)  x x x x \nBouwhuis et al. (2011)  x x  x \nBrouard et al. (2000)  x x x x \nBuzaid  et al. (1995)   x   \nChai et al. (2011 ) x     \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 148 von 732 Clark et al. (2006)  x    \nCollins et al. (1993)     x \nConstantinidou et al. (2008)   x   \nDeichmann et al. (2004)  x x x x \nDellestable et al. (2011 )   x  \nDietlein  et al. (199 9)  x x x \nDoiron et al. (1981)    x  \nDreau et al. (1999)  x x x  \nDumitrascu et al. (2009 ) x x x  \nEtchebehere et al. (2010 )  x x  \nEl-Maraghi and Kielar (2008)  x    \nEssler et al. (2011 ) x x x x \nFogarty et al. (2006)  x x x x \nGarbe et al. (2003 )    x \nGarnier et al. (2007 ) x x x   \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 149 von 732 Ginaldi  et al. (1981)  x  x x \nGoerz et al. (1986)  x x x x \nGuba et al. (2002 )  x x  \nHafner et al. (200 4) x    \nHausmann et al. (2011 )  x x x \nHeaston et al. (1983 ) x x   \nHenze et al. (1997 )    x \nHinz et al. (2011 ) x    \nHocevar et al. (2004 ) x    \nHofmann et a l. (2002 )  x   x \nHofmann et al. (2009 )    x \nHofmann et al. (2011 )  x  x \nHolloway et al. (1997)   x x x \nHorn et al. (2005 )  x   \nLagaru et al. (2007 )m x x x x  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 150 von 732 Iscoe et al. (1986 ) x    \nJohnson (1997 )  x   \nKaskel et al. (1999 )  x x x x \nKersey et al. (1 985) x   x \nKhansur et al. (1989 ) x x x x \nKlode et al. (2010 ) x    \nKoskivuo et al. (2007)  x x  x \nKrahn et al. (2001 ) x x x x \nKrug et al. (2000)   x x x \nKrug et al. (2008 ) x x x x \nKruijff et al. (2009 )  x   \nKruijff et al. (2011)   x   \nKuan et al. (19 88) x x x  \nKunte et al. (2009 ) x    \nLaurent et al. (2011)    x   \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 151 von 732 L\u00f6ffler et al. (2003)   x x x \nLugovic et al. (2007)  x x x  \nMansour et al. (2010)  x x x x \nMatsushita et al. (2002 ) x x x  \nMaubec et al. (2007 ) x    \nMeyer and Stolbach (1978)  x    \nMiranda  et al. (2004 )  x   \nMocellin et al. (2008)  x x x x \nMueller -Horvat (2005)   x x x \nNeuss et al.  (2011 )  x   \nPanagiotou et al. (2001 ) x   x \nPandalai et al. (2010 )  x   \nPaschen et al. (2009 ) x x x x \nPatten et al. (1990 ) x x x x \nPfannenberg et al. (2007)    x x x  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 152 von 732 Pleiss et al.(2007)  x x x x \nRevel et al. (2010 ) x    \nSaiag et al. (2005 ) x x  x \nSanki et al. (2009)  x    \nSawyer et al. (200 9) x   x \nSchlamann et al. (2008 ) x x x x \nSchmid -Wendtner et al. (2004)  x x   \nSchmitz et al. (2000)  x x x  \nSibon et  al. (2007)  x    \nSilverman et al. (1984)  x  x x \nSingh et al. (2008)  x    \nSmit et al. (2008)   x  x \nStahlecker et al. (2000)  x x x x \nStas M et al. (2002)   x x  \nStoffels et al. (2011 ) x x    \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 153 von 732 Stoitchkov et al. (2003)  x x x  \nStrobel et al. (2007)  x x x x \nStucky et al. (2010 ) x x   \nStutte (1989)   x x x \nTas et al. (2004 ) x x x x \nTerhune et al. (1998)  x    \nTestori et al. (2005 ) x   x \nTofani et al. (1997 ) x x x x \nTsao et al. (2004 ) x   x \nUren (1999)   x   \nVan den Brekel et al. (1998 ) x x  x \nVan de r Ploeg (2009 ) x    \nVeit-Haibach et al. (2009 ) x x x  \nVereecken et al. (200 5) x    \nVereecken et al. (2009)   x x   \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 154 von 732 Vermeerenet al. (2011 ) x    \nVucetic et al. (2008)  x    \nWagner et al. (2011 )  x   \nWang et al. (2004)  x    \nWebb (1977 ) x x x x \nXing et a l. (2011 ) x x x x \nYancovitz et al. (2007 ) x x   \nZartman et al. (1987)  x    \n \n \nAbbott RA, Acland KM, Harries M, et al. The role of positron emission tomography with computed tomography in the follow -up of asymptomatic cutaneous malignant \nmelanoma patients  with a high risk of disease recurrence. Melanoma Res 2011;21:446 -449 \nAgarwala SS, Keilholz U, Gilles E, et al. LDH correlation with survival in advanced melanoma from two large, randomised trials (Oblimersen GM301 and EORTC 18951). Eur J \nCancer 2009;45:18 07-1814  \nAloia TA, Gershenwald JE, Andtbacka RH, et al. Utility of computed tomography and magnetic resonance imaging staging before completion lymphadenectomy in patients with \nsentinel lymph node -positive melanoma. J Clin Oncol 2006;24:2858 -2865  \nAndres R, Mayordomo JI, Visus C, et al. Prognostic significance and diagnostic value of protein S -100 and tyrosinase in patients with malignant melanoma. Am J Clin Oncol \n2008;31:335 -339 \nArdizzoni A, Grimaldi A, Repetto L, et al. Stage I -II melanoma: the value of met astatic work -up. Oncology 1987;44:87 -89 \nArenberger P, Arenbergerova M, Gkalpakiotis S, et al. Multimarker real -time reverse transcription -PCR for quantitative detection of melanoma -associated antigens: a novel \npossible staging method. J Eur Acad Dermatol V enereol 2008;22:56 -64 \nArenberger P, Arenbergerova M, Vohradnikova O, et al. Early detection of melanoma progression by quantitative real -time RT -PCR analysis for multiple melanoma markers. \nKeio J Med 2008;57:57 -64 \nAu FC, Maier WP, Malmud LS, et al. Preoper ative nuclear scans in patients with melanoma. Cancer 1984;53:2095 -2097  \nAuge JM, Molina R, Filella X, et al. S-100beta and MIA in advanced melanoma in relation to prognostic factors. Anticancer Res 2005;25:1779 -1782  \nBafounta ML, Beauchet A, Chagnon S, et a l. Ultrasonography or palpation for detection of melanoma nodal invasion: a meta -analysis. Lancet Oncol 2004;5:673 -680 \nBalch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009;27:6199 -6206  \nBanfalvi T, Boldizsar M, Gergye M, et al. Comparison of prognostic significance of serum 5 -S-Cysteinyldopa, LDH and S -100B protein in Stage III -IV malignant melanoma. \nPathol Oncol Res 2002;8:183 -187  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 155 von 732 Bastiaannet E, Wobbes T, Hoekstra OS, et al. Prospective  comparison of [18F]fluorodeoxyglucose positron emission tomography and computed tomography in patients with \nmelanoma with palpable lymph node metastases: diagnostic accuracy and impact on treatment. J Clin Oncol 2009;27:4774 -4780  \nBosserhoff AK, Kaufmann M , Kaluza B, et al. Melanoma -inhibiting activity, a novel serum marker for progression of malignant melanoma. Cancer Res 1997;57:3149 -3153  \nBosserhoff AK, Lederer M, Kaufmann M, et al. MIA, a novel serum marker for progression of malignant melanoma. Anticanc er Res 1999;19:2691 -2693  \nBouwhuis MG, Suciu S, Kruit W, et al. Prognostic value of serial blood S100B determinations in stage IIB -III melanoma patients: a corollary study to EORTC trial 18952. European \njournal of cancer (Oxford, England : 1990) 2011;47:361 -368 \nBrouard M, Quillien V, Ollivier I, et al. Serum S100B protein and stage of cutaneous melanoma: a prospective study. Ann Dermatol Venereol 2000;127:56 -59 \nBuzaid AC, Tinoco L, Ross MI, et al. Role of computed tomography in the staging of patients with l ocal-regional metastases of melanoma. J Clin Oncol 1995;13:2104 -2108  \nChai CY, Zager JS, Szabunio MM, et al. Preoperative Ultrasound is Not Useful for Identifying Nodal Metastasis in Melanoma Patients Undergoing Sentinel Node Biopsy: \nPreoperative Ultrasound  in Clinically Node -Negative Melanoma. Ann Surg Oncol 2011  \nClark PB, Soo V, Kraas J, et al. Futility of fluorodeoxyglucose F 18 positron emission tomography in initial evaluation of patients with T2 to T4 melanoma. Ar ch Surg \n2006;141:284 -288 \nCollins CD, Pa dley SP, Greenwell F, et al. The efficacy of a single posteroanterior radiograph in the assessment of metastatic pulmonary me lanoma. Br J Radiol 1993;66:117 -119 \nConstantinidou A, Hofman M, O'Doherty M, et al. Routine positron emission tomography and positr on emission tomography/computed tomography in melanoma staging with \npositive sentinel node biopsy is of limited benefit. Melanoma Res 2008;18:56 -60 \nDeichmann M, Benner A, Bock M, et al. S100 -Beta, melanoma -inhibiting activity, and lactate dehydrogenase dis criminate progressive from nonprogressive American Joint \nCommittee on Cancer stage IV melanoma. J Clin Oncol 1999;17:1891 -1896  \nDeichmann M, Benner A, Kuner N, et al. Are responses to therapy of metastasized malignant melanoma reflected by decreasing serum values of S100beta or melanoma \ninhibitory activity (MIA)? Melanoma Res 2001;11:291 -296 \nDeichmann M, Kahle B, Moser K, et al. Diagnosing melanoma patients entering American Joint Committee on Cancer stage IV, C -reactive protein in serum is superior to lacta te \ndehydrogenase. Br J Cancer 2004;91:699 -702 \nDellestable P, Granel -Brocard F, Rat AC, et al. Impact of whole body magnetic resonance imaging (MRI) in the management of melanoma patients, in comparison with positron \nemission tomography/computed tomography (TEP/CT) and CT. Annales de dermatologie et de v\u00e9n\u00e9r\u00e9ologie 2011;138:377 -383 \nDietlein M, Krug B, Groth W, et al. Positron emission tomography using 18F -fluorodeoxyglucose in advanced stages of malignant melanoma: a comparison of ultrasonographic \nand radiol ogical methods of diagnosis. Nucl Med Commun 1999;20:255 -261 \nDoiron MJ, Bernardino ME. A comparison of noninvasive imaging modalities in the melanoma patient. Cancer 1981;47:2581 -2584  \nDreau D, Bosserhoff AK, White RL, et al. Melanoma -inhibitory activity pr otein concentrations in blood of melanoma patients treated with immunotherapy. Oncol Res \n1999;11:55 -61 \nDumitrascu G, Constantin C, Manda G, et al. Serum markers in skin melanoma --preliminary study. Roum Arch Microbiol Immunol 2009;68:125 -135 \nEl-Maraghi RH,  Kielar AZ. PET vs sentinel lymph node biopsy for staging melanoma: a patient intervention, comparison, outcome analysis. J Am Coll Radio l 2008;5:924 -931 \nEssler M, Link A, Belloni B, et al. Prognostic value of [18F] -fluoro -deoxy -glucose PET/CT, S100 or MIA  for assessment of cancer -associated mortality in patients with high risk \nmelanoma. PLoS One 2011;6:e24632  \nEtchebehere EC, Romanato JS, Santos AO, et al. Impact of [F -18] FDG -PET/CT in the restaging and management of patients with malignant melanoma. Nucl Med Commun \n2010;31:925 -930 \nFogarty GB, Tartaguia C. The utility of magnetic resonance imaging in the detection of brain metastases in the staging of cut aneous melanoma. Clin Oncol (R Coll Radiol) \n2006;18:360 -362 \nGarbe C, Leiter U, Ellwanger U, et al. Diagn ostic value and prognostic significance of protein S -100beta, melanoma -inhibitory activity, and tyrosinase/MART -1 reverse \ntranscription -polymerase chain reaction in the follow -up of high -risk melanoma patients. Cancer 2003;97:1737 -1745  \nGarnier JP, Letellie r S, Cassinat B, et al. Clinical value of combined determination of plasma L -DOPA/tyrosine ratio, S100B, MIA and LDH in melanoma. Eur J Cancer \n2007;43:816 -821 \nGinaldi S, Wallace S, Shalen P, et al. Cranial computed tomography of malignant melanoma. AJR Am J Roentgenol 1981;136:145 -149 \nGoerz G, Schulte -Beerbuhl R, Roder K, et al. Malignant melanoma: which examinations are useful in staging and follow -up? Dtsch Med Wochenschr 1986;111:1230 -1233  \nGuba M, Steinbauer M, Ruhland V, et al. Elevated MIA serum levels  are predictors of poor prognosis after surgical resection of metastatic malignant melanoma. Oncol Rep \n2002;9:981 -984 \nHafner J, Schmid MH, Kempf W, et al. Baseline staging in cutaneous malignant melanoma. Br J Dermatol 2004;150:677 -686  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 156 von 732 Hausmann D, Jochum S , Utikal J, et al. Comparison of the diagnostic accuracy of whole -body MRI and whole -body CT in stage III/IV malignant melanoma. JDDG - Journal of the \nGerman Society of Dermatology 2011;9:212 -222 \nHeaston DK, Putman CE, Rodan BA, et al. Solitary pulmonary m etastases in high -risk melanoma patients: a prospective comparison of conventional and computed tomography. \nAJR Am J Roentgenol 1983;141:169 -174 \nHenze G, Dummer R, Joller -Jemelka HI, et al. Serum S100 --a marker for disease monitoring in metastatic melanoma . Dermatology 1997;194:208 -212 \nHinz T, Wilsmann -Theis D, Buchner A, et al. High-resolution ultrasound combined with power Doppler sonography can reduce the number of sentinel lymph node biopsies in \ncutaneous melanoma. Dermatology 2011;222:180 -188 \nHocevar M , Bracko M, Pogacnik A, et al. The role of preoperative ultrasonography in reducing the number of sentinel lymph node procedu res in melanoma. Melanoma Res \n2004;14:533 -536 \nHofmann MA, Gussmann F, Fritsche A, et al. Diagnostic value of melanoma inhibitory ac tivity serum marker in the follow -up of patients with stage I or II cutaneous melanoma. \nMelanoma Res 2009;19:17 -23 \nHofmann MA, Schicke B, Fritsch A, et al. Impact of lymph node metastases on serum level of melanoma inhibitory activity in stage III melanoma  patients. J Dermatol \n2011;38:880 -886 \nHofmann U, Szedlak M, Rittgen W, et al. Primary staging and follow -up in melanoma patients --monocenter evaluation of methods, costs and patient survival. Br J Cancer \n2002;87:151 -157 \nHolloway BJ, King DM. Ultrasound dia gnosis of metastatic melanoma of the gallbladder. Br J Radiol 1997;70:1122 -1125  \nHorn J, Lock -Andersen J, Sjostrand H, et al. Routine use of FDG -PET scans in melanoma patients with positive sentinel node biopsy. Eur J Nucl Med Mol Imaging 2006;33:887 -\n892 \nIagaru A, Quon A, Johnson D, et al. 2 -Deoxy -2-[F-18]fluoro -D-glucose positron emission tomography/computed tomography in the management of melanoma. Mol Imaging \nBiol 2007;9:50 -57 \nIscoe N, Kersey P, Gapski J, et al. Predictive value of staging investigations in patients with clinical stage I malignant melanoma. Plast Reconstr Surg 1987;80:233 -239 \nJimenez -Requena F, Delgado -Bolton RC, Fernandez -Perez C, et al. Meta-analysis of the performance of (18)F -FDG PET in cutaneous melanoma. Eur J Nucl Med Mol Imaging \n2010;37:284 -300 \nJohnson TM, Fader DJ, Chang AE, et al. Computed tomography in staging of patients with melanoma metastatic to the regional nodes. Ann Surg Oncol 1997;4:396 -402 \nKaskel P, Berking C, Sander S, et al. S-100 protein in peripheral blood: a marker for melanoma metastases: a prospective 2 -center study of 570 patients with melanoma. J Am \nAcad Dermatol 1999;41:962 -969 \nKersey PA, Iscoe NA, Gapski JA, et al. The value of staging and serial follow -up investigations in patients with completely resected, pr imary, cutaneous malignant melanoma. Br \nJ Surg 1985;72:614 -617 \nKhansur T, Sanders J, Das SK. Evaluation of staging workup in malignant melanoma. Arch Surg 1989;124:847 -849 \nKlimek VM, Williams L, Chapman PB. Serum levels of melanoma -inhibiting activity do n ot predict relapse in melanoma patients. Cytokines Cell Mol Ther 2002;7:71 -74 \nKlode J, Dissemond J, Grabbe S, et al. Sentinel lymph node excision and PET -CT in the initial stage of malignant melanoma: a retrospective analysis of 61 patients with \nmalignant melanoma in American Joint Committee on Cancer stages I and II. Dermatol Surg 2010;36:439 -445 \nKoskivuo IO, Seppanen MP, Suominen EA, et al. Whole body positron emission tomography in follow -up of high risk melanoma. Acta Oncol 2007;46:685 -690 \nKrahn G, Kask el P, Sander S, et al. S100 beta is a more reliable tumor marker in peripheral blood for patients with newly occurred melanoma metastases compared w ith MIA, \nalbumin and lactate -dehydrogenase. Anticancer Res 2001;21:1311 -1316  \nKrug B, Crott R, Lonneux M, et al. Role of PET in the initial staging of cutaneous malignant melanoma: systematic review. Radiology 2008;249:836 -844 \nKrug B, Dietlein M, Groth W, et al. Fluor -18-fluorodeoxyglucose positron emission tomography (FDG -PET) in malignant melanoma. Diagnostic c omparison with conventional \nimaging methods. Acta Radiol 2000;41:446 -452 \nKruijff S, Bastiaannet E, Kobold AC, et al. S-100B concentrations predict disease -free survival in stage III melanoma patients. Ann Surg Oncol 2009;16:3455 -3462  \nKruijff S, Bastiaannet  E, Speijers MJ, et al. The value of pre operative S -100B and SUV in clinically stage III melanoma patients undergoing therapeutic lymph node dissection. Eur \nJ Surg Oncol 2011;37:225 -232 \nKuan AK, Jackson FI, Hanson J. Multimodality detection of metastatic melanoma. J R Soc Med 1988;81:579 -582 \nKunte C, Schuh T, Eberle JY, et al. The use of high -resolution ultrasonography for preoperative detection of metastases in sentinel lymph nodes of patients with cutaneous \nmelanoma. Dermatol Surg 2009;35:1757 -1765   \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 157 von 732 Laure nt V, Trausch G, Bruot O, et al. Comparative study of two whole -body imaging techniques in the case of melanoma metastases: advantages of multi -contrast MRI \nexamination including a diffusion -weighted sequence in comparison with PET -CT. Eur J Radiol 2010;75 :376-383 \nLoffler M, Weckesser M, Franzius C, et al. Malignant melanoma and (18)F -FDG-PET: Should the whole body scan include the legs? Nuklearmedizin 2003;42:167 -172 \nLugovic L, Situm M, Buljan M, et al. Results of the determination of serum markers in pati ents with malignant melanoma. Coll Antropol 2007;31 Suppl 1:7 -11 \nMansour AA,3rd, Kelley MC, Hatmaker AR, et al. Verification of musculoskeletal FDG -PET-CT findings performed for melanoma staging. Ann Surg Oncol 2010;17:1144 -1151  \nMatsushita Y, Hatta N, Waka matsu K, et al. Melanoma inhibitory activity (MIA) as a serum marker for early detection of post -surgical relapse in melanoma patients: comparison \nwith 5 -S-cysteinyldopa. Melanoma Res 2002;12:319 -323 \nMaubec E, Lumbroso J, Masson F, et al. F-18 fluorodeoxy -D-glucose positron emission tomography scan in the initial evaluation of patients with a primary melanoma thicker \nthan 4 mm. Melanoma Res 2007;17:147 -154 \nMays MP, Martin RC, Burton A, et al. Should all patients with melanoma between 1 and 2 mm Breslow thic kness undergo sentinel lymph node biopsy? Cancer 2010;116:1535 -\n1544  \nMeral R, Duranyildiz D, Tas F, et al. Prognostic significance of melanoma inhibiting activity levels in malignant melanoma. M elanoma Res 2001;11:627 -632 \nMeyer JE, Stolbach L. Pretreatment radiographic evaluation of patients with malignant melanoma. Cancer 1978;42:125 -126 \nMiranda EP, Gertner M, Wall J, et al. Routine imaging of asymptomatic melanoma patients with metastasis to sentinel lymph nodes rarely identifies systemic disease.  Arch Sur g \n2004;139:831 -6; discussion 836 -7 \nMocellin S, Zavagno G, Nitti D. The prognostic value of serum S100B in patients with cutaneous melanoma: a meta -analysis. Int J Cancer 2008;123:2370 -2376  \nMorton DL, Thompson JF, Cochran AJ, et al. Sentinel -node biopsy or nodal observation in melanoma. N Engl J Med 2006;355:1307 -1317  \nMuller -Horvat C, Radny P, Eigentler TK, et al. Prospective comparison of the impact on treatment decisions of whole -body magnetic resonance imaging and computed \ntomography in patients with meta static malignant melanoma. Eur J Cancer 2006;42:342 -350 \nNeuss H, Koplin G, Raue W, et al. Analysing the serum levels of tumour markers and primary tumour data in stage III melanoma patients in correlation to the extent of lymph \nnode metastases --a prospecti ve study in 231 patients. Acta Chir Belg 2011;111:214 -218 \nNowecki ZI, Rutkowski P, Kulik J, et al. Molecular and biochemical testing in stage III melanoma: multimarker reverse transcr iptase -polymerase chain reaction assay of lymph \nfluid after lymph node di ssection and preoperative serum lactate dehydrogenase level. Br J Dermatol 2008;159:597 -605 \nPanagiotou IE, Brountzos EN, Bafaloukos D, et al. Evaluation of imaging studies at the initial staging and during follow -up of patients with local -regional malignan t melanoma. \nJournal of B.U.ON 2001;6:411 -414 \nPandalai PK, Dominguez FJ, Michaelson J, et al. Clinical Value of Radiographic Staging in Patients Diagnosed With AJCC Stage III Melanoma. Ann Surg Oncol 2010  \nPaschen A, Sucker A, Hill B, et al. Differential cli nical significance of individual NKG2D ligands in melanoma: soluble ULBP2 as an indicator of poor prognosis superior to S100B . \nClin Cancer Res 2009;15:5208 -5215  \nPatten RM, Shuman WP, Teefey S. Metastases from malignant melanoma to the axial skeleton: a CT study of frequency and appearance. AJR Am J Roentgenol 1990;155:109 -112 \nPfannenberg C, Aschoff P, Schanz S, et al. Prospective comparison of 18F -fluorodeoxyglucose positron emission tomography/computed tomography and whole -body magnetic \nresonance imaging i n staging of advanced malignant melanoma. Eur J Cancer 2007;43:557 -564 \nPleiss C, Risse JH, Biersack HJ, et al. Role of FDG -PET in the assessment of survival prognosis in melanoma. Cancer Biother Radiopharm 2007;22:740 -747 \nRevel A, Revel C, Dolivet G, et al . La TEP -TDM au 18FDG a -t-elle un int\u00e9r\u00eat dans la stadification ganglionnaire des m\u00e9lanomes malins cutan\u00e9s cervicofaciaux b\u00e9n\u00e9ficiant de la \ntechnique du ganglion sentinelle ? \u00c0 propos de 22 cas. M\u00e9decine Nucl\u00e9aire 2010;34:528 -539 \nSaiag P, Bernard M, Beauch et A, et al. Ultrasonography using simple diagnostic criteria vs palpation for the detection of regional lymph node metastases of melanoma . Arch \nDermatol 2005;141:183 -189 \nSanki A, Uren RF, Moncrieff M, et al. Targeted high -resolution ultrasound is not an e ffective substitute for sentinel lymph node biopsy in patients with primary cutaneous \nmelanoma. J Clin Oncol 2009;27:5614 -5619  \nSawyer A, McGoldrick RB, Mackey SP, et al. Does staging computered tomography change management in thick malignant melanoma? J Plast Reconstr Aesthet Surg \n2009;62:453 -456 \nSchlamann M, Loquai C, Goericke S, et al. Cerebral MRI in neurological asymptomatic patients with malignant melanoma. Rofo 2008;180:143 -147 \nSchmid -Wendtner MH, Dill -Muller D, Baumert J, et al. Lymph node metastases  in patients with cutaneous melanoma: improvements in diagnosis by signal -enhanced color \nDoppler sonography. Melanoma Res 2004;14:269 -276 \nSchmitz C, Brenner W, Henze E, et al. Comparative study on the clinical use of protein S -100B and MIA (melanoma inhibi tory activity) in melanoma patients. Anticancer Res \n2000;20:5059 -5063   \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 158 von 732 Schwimmer J, Essner R, Patel A, et al. A review of the literature for whole -body FDG PET in the management of patients with melanoma. Q J Nucl Med 2000;44:153 -167 \nSibon C, Chagnon S, Tch akerian A, et al. The contribution of high -resolution ultrasonography in preoperatively detecting sentinel -node metastases in melanoma patients. \nMelanoma Res 2007;17:233 -237 \nSilverman PM, Heaston DK, Korobkin M, et al. Computed tomography in the detection of abdominal metastases from malignant melanoma. Invest Radiol 1984;19:309 -312 \nSingh B, Ezziddin S, Palmedo H, et al. Preoperative 18F -FDG-PET/CT imaging and sentinel node biopsy in the detection of regional lymph node metastases in malignant \nmelanoma. Melanoma Res 2008;18:346 -352 \nSmit LH, Nieweg OE, Mooi WJ, et al. Value of serum S -100B for prediction of distant relapse and survival in stage III B/C melanoma. Anticancer Res 2008;28:2297 -2302  \nStahlecker J, Gauger A, Bosserhoff A, et al. MIA as a reliable tu mor marker in the serum of patients with malignant melanoma. Anticancer Res 2000;20:5041 -5044  \nStas M, Stroobants S, Dupont P, et al. 18 -FDG PET scan in the staging of recurrent melanoma: additional value and therapeutic impact. Melanoma Res 2002;12:479 -490 \nStoffels I, Dissemond J, Poeppel T, et al. Advantages of preoperative ultrasound in conjunction with lymphoscintigraphy in de tecting malignant melanoma metastases in sentinel \nlymph nodes: A retrospective analysis in 221 patients with malignant melanoma AJ CC Stages i and II. Journal of the European Academy of Dermatology and Venereology \n2012;26:79 -85 \nStoitchkov K, Letellier S, Garnier JP, et al. Evaluation of the serum L -dopa/L -tyrosine ratio as a melanoma marker. Melanoma Res 2003;13:587 -593 \nStoitchkov K, Letellier S, Garnier JP, et al. Melanoma progression and serum L -dopa/L -tyrosine ratio: a comparison with S100B. Melanoma Res 2002;12:255 -262 \nStrobel K, Dummer R, Husarik DB, et al. High-risk melanoma: accuracy of FDG PET/CT with added CT morphologic infor mation for detection of metastases. Radiology \n2007;244:566 -574 \nStutte H, Muller PH, d'Hoedt B, et al. Ultrasonographic diagnosis of melanoma metastases in liver, gallbladder, and spleen. J  Ultrasound Med 1989;8:541 -547 \nTas F, Yasasever V, Duranyildiz D, et  al. Clinical value of protein S100 and melanoma -inhibitory activity (MIA) in malignant melanoma. Am J Clin Oncol 2004;27:225 -228 \nTerhune MH, Swanson N, Johnson TM. Use of chest radiography in the initial evaluation of patients with localized melanoma. Ar ch Dermatol 1998;134:569 -572 \nTestori A, Lazzaro G, Baldini F, et al. The role of ultrasound of sentinel nodes in the pre - and post -operative evaluation of stage I melanoma patients. Melanoma Res \n2005;15:191 -198 \nTofani A, Cioffi RP, Sciuto R, et al. S-100 an d NSE as serum markers in melanoma. Acta Oncol 1997;36:761 -764 \nTsao H, Feldman M, Fullerton JE, et al. Early detection of asymptomatic pulmonary melanoma metastases by routine chest radiographs is not associated with improved su rvival. \nArch Dermatol 2004;1 40:67 -70 \nUren RF, Howman -Giles R, Thompson JF, et al. High -resolution ultrasound to diagnose melanoma metastases in patients with clinically palpable lymph nodes. Australas Radiol \n1999;43:148 -152 \nvan den Brekel MW, Pameijer FA, Koops W, et al. Computed tom ography for the detection of neck node metastases in melanoma patients. Eur J Surg Oncol 1998;24:51 -54 \nvan der Ploeg IM, Valdes Olmos RA, Kroon BB, et al. The yield of SPECT/CT for anatomical lymphatic mapping in patients with melanoma. Ann Surg Oncol 2009 ;16:1537 -1542  \nVeit-Haibach P, Vogt FM, Jablonka R, et al. Diagnostic accuracy of contrast -enhanced FDG -PET/CT in primary staging of cutaneous malignant melanoma. Eur J Nucl Med Mol \nImaging 2009;36:910 -918 \nVereecken P, Awada A, Suciu S, et al. Evaluation of  the prognostic significance of serum galectin -3 in American Joint Committee on Cancer stage III and stage IV melanoma \npatients. Melanoma Res 2009;19:316 -320 \nVereecken P, Laporte M, Petein M, et al. Evaluation of extensive initial staging procedure in inte rmediate/high -risk melanoma patients. J Eur Acad Dermatol Venereol \n2005;19:66 -73 \nVermeeren L, Van Der Ent FW, Hulsewe KW. Is there an indication for routine chest x -ray in initial staging of melanoma?. J Surg Res 2011;166:114 -119 \nVoit C, Van Akkooi AC, Sch afer-Hesterberg G, et al. Ultrasound morphology criteria predict metastatic disease of the sentinel nodes in patients with melanoma. J Clin Oncol \n2010;28:847 -852 \nVucetic B, Rogan SA, Hrabac P, et al. Biological value of melanoma inhibitory activity serum c oncentration in patients with primary skin melanoma. Melanoma Res 2008;18:201 -\n207 \nWagner T, Chevreau C, Meyer N, et al. Routine FDG PET -CT in patients with a high -risk localized melanoma has a high predictive positive value for nodal disease and high \nnegat ive predictive value for the presence of distant metastases. J Eur Acad Dermatol Venereol 2011  \nWagner T, Meyer N, Zerdoud S, et al. Fluorodeoxyglucose positron emission tomography fails to detect distant metastases at initial staging of melanoma patients w ith \nmetastatic involvement of sentinel lymph node. Br J Dermatol 2011;164:1235 -1240  \nWang TS, Johnson TM, Cascade PN, et al. Evaluation of staging chest radiographs and serum lactate dehydrogenase for localized melanoma. J Am Acad Dermatol 2004;51:39 9-\n405  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 159 von 732 Webb WR, Gamsu G. Thoracic metastasis in malignant melanoma. A radiographic survey of 65 patients. Chest 1977;71:176 -181 \nXing Y, Bronstein Y, Ross MI, et al. Contemporary diagnostic imaging modalities for the staging and surveillance of melanoma patients: a  meta -analysis. J Natl Cancer Inst \n2011;103:129 -142 \nYancovitz M, Finelt N, Warycha MA, et al. Role of radiologic imaging at the time of initial diagnosis of stage T1b -T3b melanoma. Cancer 2007;110:1107 -1114  \nZartman GM, Thomas MR, Robinson WA. Metastatic di sease in patients with newly diagnosed malignant melanoma. J Surg Oncol 1987;35:163 -164 \n \n \n \n1.4. Frage I.9. Ausbreitungsdiagnostik beim metastasierten okkulten Melanom  - Adaptation  \nFrage I.9.  Welche Untersuchungen sind beim metastasierten okkulten Melanom zur Pr im\u00e4rtumorsuche und Ausbreitungsdiagnostik \nindiziert?  \nDie Frage wurde letztendlich Konsens -basiert beantwortet . \n \n1.4.1.  Synopse Quellleitlinien (kurz)  \nThema/Fragestellung  LL Austr alien  \nNew Zealand Guidelines \nGroup 2008  LL GB  \nNICE 2006  LL Frankreich  \nFrench Nation al Authority \nfor Health 2005  LL Kanada  \nCancer Care O ntario \n2007  \n14. Welche Untersuchungen \nsind bei metastasiertem \nokkultem Melanom zur \nPrim\u00e4rtumorsuche und \nAusbreitungsdiagnostik \nindiziert?  Klinische Untersuchung: \nAugen, G eh\u00f6rgang, Kopfhaut, \nevtl. Kolosk opie (IV); PET zur \nweiteren \nAusbreitungsd iagnostik (IV)  Keine Angaben  Keine Angabe  nur relevant f\u00fcr \nmedikament\u00f6se Therapien   \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 160 von 732 1.4.2.  Empfehlung, Hintergrundstext und Literatur Australische Quell -Leitlinie  \n (mit Seitenangaben der Quellleitlinie)  \n LL Austr alien  \nNew Zealand Guidelines Group 2008  \nSchl\u00fcsselempfe hlungen  \n \n \n Recommendation  \nPatients with metastases and no obvious primary tumour be exa mined for primary melanomas in \nobscure sites. If none are found, a ssume that the  \nprimary melanoma has co mpletely regressed.   \nRecommendation grade:  \nD \n \nEvidenzgrundlage  Evidence summary  \nPatients with occult primary mel anoma usually present with lymph node disease, a soft tissue \nmetastasis, or widespread systemic disease, in the absence of a primary tumour and the diagnosis is \nmade by patholog ical examination of the  \nlymph node, or metastasis which shows the characteristics of mel anoma. Such patients should be \nexamined carefully to exclude the possibility of a hi dden primary by examination of the eyes, inner ears \nand scalp, and p ossibly colonoscopy. The presenting lymph nodes or metastases should be treated \nappropriately regardless of the inability to detect the primary t umour and a PET scan should be \nperformed  \nLevel IV , Referenz 1, 2  \n \nHintergrundtext  Melanoma is among a number of cancers in humans where the pr imary tumour cannot always be found. \nIn some p atients the primary may be in an obscure site such as the eye, ear or the intestine, but in the \nmajority it is likely that the primary tumour has been d estroyed by the host\u2019s im mune system via \nlymphocyte activation.1,2 It is likely that total r egression occurs in 10 \u201320% of melanomas, though only  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 161 von 732  LL Austr alien  \nNew Zealand Guidelines Group 2008  \nthose where there have been metastases are diagnosable (about 5% of melanomas). Partial regre ssion of \nprimary tumours is more  \ncommon and  is often reported on pathology reports (30 \u201350%). Two recent studies have shown that \nthose patients with metastases and an occult pr imary melanoma have a better prognosis than those \nwith metastases and a known primary mel anoma.3,4 This suggests  \nan intrinsi cally superior host tumour interaction in those with occult pr imary melanoma.  \nReferenzen  1. Tefany FJ, Barnetson RS, Halliday GM, McCarthy SW, McCarthy WH. Immunocytochemical analysis  \nof the cellular infiltrate in primary regressing and non -regressing m alignant melanoma. J Invest \nDermatol 1991; 97(2):197 \u2013202. \n \n2. Lowes MA, Bishop GA, Crotty K, Barnetson RS, Halliday GM. T helper 1 cytokine mRNA is increased  \nin spontaneously regressing primary melanomas. J Invest Dermatol 1997; 108(6):914 \u2013919. \n \n3. Vijuk G, Coates AS. Survival of patients with visceral metastatic me lanoma from an occult primary  \nlesion: a retrospective matched c ohort study. Ann Oncol 1998; 9(4):419 \u2013422. \n \n4. Lee CC, Faries MB, Wanek LA, Morton DL. Improved survival after lymphadenectomy for nod al \nmetastasis from an unknown primary melanoma. J Clin Oncol 2008; 26(4):535 \u2013541. \n \nLiteratur  : \n1. Lee CC, Faries MB, Wanek LA, et al. Improved survival after lymphadenectomy for nodal metastasis from an unknown primary melanoma. J Clin Oncol 2008;26:535 -541 \n2. Lowes MA, Bishop GA, Crotty K, et al. T helper 1 cytokine mRNA is increased in spontaneously regressing primary melanomas.  J Invest Dermatol 1997;108:914 -919 \n3. Tefany FJ, Barnetson RS, Halliday GM, et al. Immunocytochemical analysis of the cellular infiltrate in primary regressing and non -regressing malignant melanoma. J Invest \nDermatol 1991;97:197 -202 \n4. Vijuk G, Coates AS. Survival of patients with visceral metastatic melanoma from an occult primary lesion: a retrospective matched cohort study. Ann Oncol 1998;9:419 -422 \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 162 von 732 1.4.3.  Erg\u00e4nzende Recherche, Datenbanken, Suchstrategien, Trefferzahlen  \nDatenbank  Suchstrategie  Datum  Treffer \n1. Suche     \nMedline  (\"occult melanoma\"[tiab] or \u201cmelanoma\u201d AND \u201cunknown primary\u201d [tiab]) AND (\u201csta ging\u201d[all \nfields] OR \"diagnosi s\"[all fields]) AND ((\"ultrasonography\"[Mesh] OR \"ultrasono graphy\"[all \nfields] OR \"sonography\"[all fields]) OR (\"lymph nodes\"[all fields] OR (\"lymph\"[all fields] \nAND \"nodes\"[all fields]) OR \"lymph nodes\"[all fields] OR (\"lymph\"[ all fields] AND \n\"node\"[all fields]) OR \"lymph node\"[all fields]))  \n \n(\"occult melanoma\"[tiab] or \u201cmelanoma\u201d AND \u201cunknown primary\u201d [tiab]) AND (\u201csta ging\u201d[all \nfields] OR \"diagnosis\"[all fields]) AND ((\"ultrasonography\"[Mesh] OR \"ultrasono graphy\"[all \nfields] OR \"sonography\"[all fields]) OR (\"lymph nodes\"[all fields] OR (\"lymph\"[all fields] \nAND \"nodes\"[all fields]) OR \"lymph nodes\"[all fields] OR (\"lymph\"[ all fields] AND \n\"node\"[all fields]) OR \"lymph node\"[all fields]))  \n \n(\"occult melanoma\"[tiab] or \u201cmelanoma\u201d AND \u201cunknown primary\u201d [tiab])  AND (\u201csta ging\u201d[all \nfields] OR \"diagnosis\"[all fields]) AND (\"chest X -ray\"[all fields] OR \"chest radio graphy\"[all \nfields] OR \"Radiography, Thoracic\"[Mesh])  \n \n(\"occult melanoma\"[tiab] or \u201cmelanoma\u201d AND \u201cunknown primary\u201d [tiab]) AND (\u201csta ging\u201d[all \nfields] OR \"diagnosis\"[all fields]) AND ((\"ultrasonography\"[Mesh] OR \"ultrasono graphy\"[all \nfields] OR \"sonography\"[all fields]) OR \"abdomen\"[all fields] OR \u201cabdominal\"[all fields]) \nNOT (\"ophthalmology\"[Mesh] OR \"eye\"[Mesh] OR \"eye ne oplasms\"[Mesh])  \n \n(\"occult melanoma \"[tiab] or \u201cmelanoma\u201d AND \u201cunknown primary\u201d [tiab]) AND (\u201csta ging\u201d[all \nfields] OR \"diagnosis\"[all fields]) AND (\"Magnetic Resonance Imaging\"[Mesh] OR \u201cMagnetic \nResonance Imaging\u201d[all fields] OR \u201cmri\u201d[all fields] OR \u201cmagnetic resonance\u201d[all fields]) 26.01.2012  \n \n \n \n \n \n \n \n \n \n \n \n 9 \n \n \n \n \n \n9 \n \n \n \n \n \n0 \n \n \n \n0 \n \n \n \n \n \n \n3  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 163 von 732 Datenbank  Suchstrategie  Datum  Treffer \nNOT (\"o phthalmology\"[Mesh] OR \"eye\"[Mesh] OR \"eye neoplasms\"[Mesh])  \n \n(\"occult melanoma\"[tiab] or \u201cmelanoma\u201d AND \u201cunknown primary\u201d [tiab]) AND (\u201csta ging\u201d[all \nfields] OR \"diagnosis\"[all fields]) AND (\u201cTomography, X -Ray Computed\"[Mesh] OR \n\u201ccomputer tomography\u201d[all f ields] OR \u201cct\u201d[all fields] OR \"Tomography, Spiral \nComputed\"[Mesh] OR \"Tomography Scanners, X -Ray Computed\"[Mesh] OR \"Positron -\nEmission Tomography\"[Mesh] OR \u201cpositron -emission tomography\u201d[all fields] OR \u201cpet\u201d[all \nfields] OR \"Tomography, Emission -Computed, S ingle -Photon\"[Mesh] OR \u201csingle -photon \nemission computed tomography\u201d[all fields] OR \u201cspect\u201d[all fields]) NOT \n(\"ophthalmol ogy\"[Mesh] OR \"eye\"[Mesh] OR \"eye neoplasms\"[Mesh])  \n \n(\"occult melanoma\"[tiab] or \u201cmelanoma\u201d AND \u201cunknown primary\u201d [tiab]) AND (\u201cstaging\u201d [ \ntiab] OR \"diagnosis\"[ tiab]) AND (\"scintigraphy\u201d[ tiab] OR \u201cscinti*\u201d[tiab]) NOT \n(\"ophtha lmology\"[Mesh] OR \"eye\"[Mesh] OR \"eye neoplasms\"[Mesh])  \n \n(\"occult melanoma\"[tiab] or \u201cmelanoma\u201d AND \u201cunknown primary\u201d [tiab]) AND (\"LDH\"[all \nfields] OR \u201clactate dehyd rogenase\u201d OR \"S100\"[all fields] OR \"MIA\"[tiab] OR \"melanoma -\ninhibiting activity\"[tiab]) AND (\u201cstaging\u201d[all fields] OR \"diagnosis\"[all fields]) NOT \n(\"ophthalmology\"[Mesh] OR \"eye\"[Mesh] OR \"eye neoplasms\"[Mesh])   \n \n \n \n8 \n \n \n \n \n \n \n \n0 \n \n \n \n3 \n \nAuswahl der Literatur  \nGesamttre ffer 25 \nGesamttreffer nach Dublettenelimination   \nEinschlusskriterien  Thematische \u00dcbereinstimmung  \nSprachen: e,dt   \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 164 von 732 Ausschlusskriterien  Case Reports, narrative Reviews, Bench Research  \nAnzahl nach  Abstractscreening  1 \nAnzahl ausgew\u00e4hlter Volltexte, vorges ehen f\u00fcr Bewertung  1 \nBemerkungen: Eine Erg\u00e4nzungsrecherche f\u00fcr den Zeitraum nach 2008 wurde am 26.10.2011 auf Medline durchgef\u00fchrt, die Update -Recherche erfolgte am \n26.01.2012. Oben aufgef\u00fchrt sin d die Trefferzahlen der letzten Recherche. Hierbei wurde eine weitere relevante Studie identifiziert.  \n \n1.4.4.  Evidenztabelle  \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nTos T et al. (2011): \nExtensive Scree ning \nfor Primary Tumor \nis Redundant in \nMelanoma  \nof Unknown Primary  this article \nquestions whether \nextensive physical \nexamin ations \n(opthalmoscopy, \notoscopy, rhino -\npharygoscopy, \nlaryngoscopy, \nsigmoideoscopy, \nand in women, \ngynecological \nexamination) are \nnecessary.  retrospective study  \n \n \n 103 patient s \ndiagnosed with \nunknown primary \ntumor during the \nperiod 1986 \u20132006  \n \n Metastases \ndetection rate  39 (38%) presented \nprimarily with a \ncutaneous or a \nsubcutaneous \nMetastasis, 63 (61%) \nwith a lymph node \nmeta stasis. 1 \npatient pr esented \nwith a bone \nmetastasis (1% ). 87 \npatients (84%) were \nexamined by an \nophthalmologist. A \nchoroidal melanoma \nwas suspected as \nthe pr imary tumor \nin 1 patient. 84  4  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 165 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \npatients (82%) were \nexamined by an \noto-rhino -\nlaryngologist, \nwhereby no primary \ntumor was found. \n95 patients (92%) \nwere examin ed by \nsigmoide oscopy/  \nrectoscopy. No \nprimary tumor was \nfound. Of the 36 \nwomen, 32 had a \ngynecological \nexamination (89%), \nrevealing no \nprimary tumor.  \n \nLiteratur:  \nTos T, Klyver H, Drzewiecki KT. Extensive screening for primary tumor is redundant in mela noma of unknown primary. J Surg Oncol 2011;104:724 -727 \n \n \n \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 166 von 732 2. AG Sentinel Node Biopsie  \n \n2.1. Frage II.1. Sentinel -Node -Biopsie  \u2013 De-novo-Recherche  \nFrage II.1 . In welchen F\u00e4llen ist die Sentinel -Biopsie indiziert?  \n2.1.1.  PICO, Suchw\u00f6rter  \n \nPICO-Unterfragen:  \n- Senkt die Durch f\u00fchrung einer Sentinel -Biopsie die Rezidzivrate  \n- Senkt die Durchf\u00fchrung einer Sentinel -Biopsie die Mortalit\u00e4t  \n- Wie ist die Sensitivit\u00e4t und Spezifit\u00e4t einer Sentinel -Biopsie zum Nachweis einer lokoregion\u00e4ren Lymphknotenmetastasierung?  \n \nSuchw\u00f6rter : s. hierf\u00fcr  auch Suchstrategie  \nOber -/Unterbegriffe, Mesh Term  melanoma  survival, mortality, relapse, recurrence, \nsensitivity, specificity, accuracy, \noutcome, prognos*, predict*, assoc*  s. Suchstrategie  \n \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 167 von 732 2.1.2.  Datenbanken, Suchstrategien, Trefferzahlen  \nDatenbank  Suchstr ategie  Datum  Treffer \n1. Suche     \nMedline  \u201cmelanoma\u201c[tiab] AND (\u201csentinel\u201c[tiab] OR \u201cSentinel Lymph Node Biopsy\u201d[MeSH]) \nAND (\u201csurvival\u201d[tiab] OR \u201cmortality\u201d[tiab] OR \u201crelapse\u201d[tiab] OR \u201crecurrence\u201d[tiab] OR \n\u201csensitivity\u201d[tiab] OR \u201cspecificity\u201d[tiab] OR \u201ca ccuracy\u201d OR \u201coutcome\u201d[tiab] OR \n\u201cprognos*\u201d[tiab] OR \u201cpr edict*\u201d[tiab] OR \u201cassoc*\u201d[tiab])  26.01.2012  1039  \n \n \n \nCochrane Library  (melanoma and (sentinel or \"sentinel lymph node biopsy\" or snb or slne or sln) and \n(survival or mortality or relapse or recurrence o r sensitivity or specificity or accuracy \nor ou tcome or predict* or prognosis or assoc*)).ti,ab.  26.01.2012  43 \nEmbase  (melanoma and (sentinel or \"sentinel lymph node biopsy\" or snb or slne or sln) and \n(survival or mortality or relapse or recurrence or sens itivity or specificity or accuracy \nor ou tcome or predict* or prognosis or assoc*)).ti,ab.  23.01.2012  1751  \n2. Suche/Erg\u00e4nzungen     \nMedline  (sentinel[title] OR \"snb\"[title] OR \"slne\"[title] OR \"sln\"[title]) predict* melanoma[title]  26.01.2012  1176  \nBemerku ngen:  \nEine erste Literaturrecherche in Medline und und Cochrane erfolgte am 07.10.2010 bzw. f\u00fcr Embase am 11.05.2011. Die zweite Re cherche \n(Erg\u00e4nzungsrecherche) wurde am 18.04.2011 durchgef\u00fchrt. Die Update -Recherche wurde am 23.01.2012 f\u00fcr Embase bzw. am 26.01.2012 f\u00fcr Medline und am \n19.01.2012 f\u00fcr Cochrane durchgef\u00fchrt. In der Tabelle angegeben sind die Tre fferzahlen der letzten Recherche.  \n \nDie Beantwortung der Frage st\u00fctzt sich in erster Linie auf die Meta -Analysen. Weitere Studien wurden hinzugezogen, w enn sie Aspekte abd ecken, die in der \nMeta-Analyse nicht ber\u00fccksichtigt wurden bzw. die nach der letzten Meta -Analyse ver\u00f6ffentlicht wurden. Im Rahmen der Update -Recherche wurde, neben \neinzelnen Studien, weitere Sy stematische Reviews bzw. Meta -Analyse ident ifiziert. Einzelne relevante Studien wurden mit aufgenommen, da nur spezielle \nMelanompopulationen in der Metaanalyse bzw. im Review eingeschlossen wurden (Pat ienten mit Melanomen >4mm bzw. SNB im Kopf/Hals -Bereich)  \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 168 von 732 2.1.3.  Auswahlkriterien  \nAuswahl der Literatur  \nGesamttreffer  2970  \nEinschlusskriterien  Thematische \u00dcbereinstimmung  \nSprachen: e,dt  \nAusschlusskriterien  Case Reports, narrative Reviews  \nAnzahl nach Abstractscreening  77 \nAnzahl ausgew\u00e4hlter Volltexte, vorges ehen f\u00fcr Bewertung  48 \n \n2.1.4.  Evidenztabelle  \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE  \nValsecchi et al. \n(2011)  To perform a meta -\nanalysis of all \npublished studies of \nsentinel lymph node \n(SLN) biopsy for \nstaging patients \nwith melanoma.  Systematic review \nwith meta -analysis  \n \n Melanoma patien ts; \n53.4% male, median \nage 54 years  Proportion of \nsuccessfully \nmapped (PSM)  \n \nFalse -negative rate \n(FNR), post -test \nprobability negative \n(PTPN) and positive \npredictive value \n(PVP) in the same \nnodal basin \nrecurrence and for \ndistant/all Weighted PSM: \n98.1% (improved in \nmore recent studies \nand in articles with \nbetter quality \nscores)  \n \nDistribution of FNR \namong studies \nranged from 0.0% to \n34%, weighted \nsummary estimate \n12.5%  Very large number \nof patients (25240).  \n \nNo significant \ndifferences in \nresults were seen \nwhen data from \nthree large  clinical \ntrials or from \ncertain geographic \nregions were \nexcluded, or in \nother subgroup 1a  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 169 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE  \nrecurrences   \nPTPN for same \nnodal basin \nrecurrence ranged \nfrom 0.0% to 10.4%, \nsummary est imate \nacross studies 3.4%  \n \nWeighted summary \nestimate of PVP for \nnodal recurrence \n7.5% \n \nWeighted estimate \nfor FNR for distant \nrecurrence 17.4%, \nfor total recurrences \n29.9%  \n \nWeighted estimate \nfor PTPN for distant \nrecurrence 4.4%, for \ntotal recurrence \n10.5%  \n \nProbability of \nadditional nodal analyses.  \n \nNo statement \npossible about \nproportion of \npatients with \npositive SNB \nexperiencing \nsubsequent nodal \nrecurrence despite \nCLND.   \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 170 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE  \ninvolvement in \nCLND for patients \nwith positive SNB: \n20.1%  \n \nPVP for distant and \nany recurrence \n21.0% and 35.9%  \nWarycha et al. \n(2009)  To esti mate the \nrisk, potential \npredictors, and \noutcome of SLN \npositivity in patients \nwith thin \nmelanomas.  Systematic review \nwith meta -analysis  \n Patients with thin \n(\uf0a31 mm) primary \nmelanoma  \n \nTotal number of \npatients: 3651  SLN positivity rate  \n \nHeterogeneity  \n \nMelano ma-related \ndeaths  Pooled SLN \npositivity rate 5.6%  \n \nSignificant \nheterogeneity \namong studies; \nremained significant \nin subgroups of \nstudies with high \nvs. low quality \nscores, indicating \nother covariates or \npatient selection \ncriteria that are \nresponsible for \nheterogeneity  \n \nNo statistical \nevidence of Unclear source of \nheterogeneity in \nthis meta -analysis \n(may hint to \nunknown \nprognostic factors \nin patients with thin \nmelanoma which \nneed further \ninvestigation)  \n \nUlceration and Clark \nlevel > III have been \ncorrelated with a \nworse prognosis in \npatients with thin \nmelanoma, but \nmight not be \nassociated with 1a  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 171 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE  \npublication bias  \n \n4 melanoma -related \ndeaths were \nreported  positive SLN   \nKunte et al. (2010)  To assess which \nfactors predict the \noccurrence of \nmicrometastasis \nand ove rall \nprognosis and \nwhether SLNB \nshould also be \nperformed in \npatients with thin \nprimary tumors.  Prognostic study  \n \n 854 patients with \nmalignant \nmelanoma (56.8% \nmale, 43.2% \nfemale), mean age \n52.9 years  SLN status  \n \nDisease -free \nsurvival (DFS)  \n \nOverall surviva l (OS)  Rate of positive \nSLNs: 24.9%  \n \nProbability of \nfinding a positive \nSLN 5.7% in patients \nwith tumor \nthickness \uf0a3 0.75 \nmm, 57.3% in \npatients with tumor \nthickness > 4 mm  \n \nSLN positive in \n36.8% of patients \nwith nodular \nmelanoma (NM), \n27.1% of patients \nwith secondary \nnodular superficial \nspreading \nmelanoma, 26.1% in \nacral lentiginous Prospective design  \n \nFor detailed p \nvalues ac cording to \ntumor thickness etc. \nsee original file.  \n \nProspective design \nand large patient \nnumbers  \n \nPatients lost to \nfollow -up not \ndescribed for key \ncharacteristics \n(potential source of \nselection/attrition \nbias) 1b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 172 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE  \nmelanoma, 13.4% in \nsuperficial \nspreading \nmelanoma, 8.8% \nSpitzoid melanoma \nand 38.3% of \nulcerated \nmelanomas  \n \nIn multivariate \nanalysis, tumor \nthickness and \nhistological tumor \ntype s ignificantly \nassociated with SLN \nstatus  \n \nMelanoma with \ntumor > 4 mm \nrevealed 11.68 -fold \nrisk for a positive \nSLN in comparison \nwith tumors < 1 \nmm \n \n9.8% (63/641) of \nSLN negative  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 173 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE  \npatients had a \nrecurrence of the \ndisease, 8.4% \n(54/641) died of the \ndisease (5 -year \nsurvival rate: 90.1%, \nmean DFS 117.9 \nmonths, OS 119.8 \nmonths)  \n \nOf SLN positive \npatients, 39.4% had \na recurrence, 28.6% \ndied of the disease \n(mean DFS 80.75 \nmonths, OS 94.91 \nmonths, 5 -year \nsurvival rate: 58.1%  \nMays et al. (2010)  To evaluate \nprognostic factors \nin the subset of \npatients with a \nmelanoma Breslow \nthickness between 1 \nand 2 mm and to \ndetermine whether \nall such patients Prognostic study  \n \n 1110 patients with \ncutaneous \nmelanoma between \n1 mm and 2 mm in \nthickness  Rate of positi ve and \nnegative SLNs  \n \nOverall survival  \n \nDisease -free \nsurvival  Group A: melanoma \nfrom 1 mm to 1.59 \nmm in thickness  \n \nGroup B: melanoma \nfrom 1.60 mm to \n2.0 mm in thickness \n(n = 348)  \n Post-hoc analysis of \nthe multi -center, \nrandomized Sunbelt \nMelanoma Trial  \n \nSee full text (p. \n1539) for complete \npartition tree  1b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 174 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE  \nrequire SLN biopsy.  On multivariate \nanalysis, Breslow \nthickness, age and \nlymphovascular \ninvasio n were \npredictive of \npositive SLN  \n \nTestori et al. (2009)  To investigate the \nrelationship \nbetween primary \ntumor \ncharacteristics , SLN \nfindings, and the \nclinical outcome  Observational study  \n \n 1313 consecutive \npatients  Overall survival  \n \nPredictors of SLN \npositivity and \nsurvival  Overall SLN \nidentification rate \n99.3%  \n \nPatients were \ncategorized into \nfour different \nsubgroups: (1) \npatie nts with \nnegative SLN after \npathological \nexamination who \nnever developed \nregional lymph \nnode metastases \nduring follow -up; \n(2) patients with \npathological \ndiagnosis of Large patient cohort  \n \nLong median \nfollow -up 1b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 175 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE  \nmetastasis in the \nSLN without any \npositive NSLNs; (3) \npatients with \npositive SLNs and \nsecondary deposits \nin NSLNs at CLND; \nand (4) patients \nwith negative SLNs \nwho developed \nclinically detectable \nregional metastases \nin the SNB \nlymphatic basin \nduring follow -up. \n \n5-year OS rates \nwere 93%, 71.3%, \n50.4% and 49.8% for \ngroups A, B, C, and \nD, respectiv ely \nMorton et al. (2006)  Same study as \nMorton et al. (2005)  Same study as \nMorton et al. (2005)  Same study as \nMorton et al. (2005)  Relapse rate  \n \nDisease -free \nsurvival  \n \nMelanoma -specific Frequency of \nrelapse at any site: \n26.8% in the \nobservation group \nand 20.7% in the \nbiopsy group  Here, an intention -\nto-treat analysis \nwas performed \n(missing in Morton \net al., 2005)  1b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 176 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE  \nmortality and \nsurvival   \nDisease -free \nsurvival rate at 5 \nyears: in the biopsy \ngroup 78.3%; in the \nobservation group \n73.1%  \n \nMelanoma -specific \ndeath: 13.8% in the \nobservation group \nand 12 .5% in the \nbiopsy group  \n \nMelanoma -specific \nsurvival rate: 90.1% \nand 93.2%, \nrespectively, at 3 \nyears, and 86.6% \nand 87.1%, \nrespectively, at 5 \nyears  \n \nMelanoma -specific \nmortality rate in the \nbiopsy group: 9.7% \nwhen sentinel  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 177 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE  \ntumor -free and \n26.2% if sentinel \npositive  \n \nEstimated disease -\nfree survival rate at \n5 years: 53.4% for \npositive and 83.2% \nfor negative \nsentinel; \ncorresponding \nvalues for \nmelanoma -specific \nsurvival 72.3% and \n90.2%, respectively   \nMcMasters et al. \n(2001)  To identify \nprognostic factors \nthat are predictive \nof sentinel lymph \nnode (SLN) \nmetastasis in \nmelanoma.  Prognostic study  \n \n Total of 1058 \npatients evaluated; \n961 patients had \ncomplete data and \nwere included i n the \nstatistical analysis  Positive sentinel \nnode  \n \n SLN identification \nrate 99.7%  \n \nSLN positivity 22%  \n \nIndependent \npredictors of SLN \nmetastasis, in order \nof importance: \nBreslow thickness, \nClark level, \nulceration, and Prospective design  \n \nSubgrou p analysis \nof Melanoma \nSunbelt Trial (multi -\ncenter, randomized \ntrial); therefore \npatients partially \nidentical with \npatients in Mays et \nal. (2010)  1b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 178 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE  \npatient age  \nRondelli et al. \n(2011 ) to assess the \nprognostic role of \nSLN in thick \nmelanoma in  \nterms of disease -\nfree sur vival (DFS) \nand overall survival \n(OS). Systematic review \nwith meta -analysis  \n \n 9 studies included \nwith a total of 1261 \npatients  DFS \n \nOS \n \nIRR \n \nincidence rate ratios \n(IRD) \n \nincidence rate \ndifference (IRD)  Overall, DFS: 71% in \npatients with a \nnegative SLN, 39 % \nin patients with a \npositive SLN after a \nmedian follow -up \nof 33 months (IRR \n1.83, 95% CI = \n1.56\u20132.14).  \n \nOS: 71% in patients \nwith a negative SLN, \n49% in patients with \na positive SLN (IRR \n1.44, 95% CI = \n1.25\u20131.65).  Only retrospective \nstudies included in \nmeta-analysis  2a \nSmith et al. (2012 ) to compare \nmelanoma -specific \nsurvival among \npatients with head \nand neck \ndesmoplastic \nmelanoma based on \nSLN status  Prognostic study  244 patients with \ndesmoplastic \nmelanoma of the \nhead and neck who \nunderwent SLNB  5-year di sease -\nspecific survival \n(DSS)  \n \n On univariable and \nmultivariable \nanalysis, SLN \npositivity did not \nsignificantly affect \nDSS in head and \nneck desmoplastic \nmelanoma (P =.19 \nand P =.48,  2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 179 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE  \nrespectively).  \nBurton et al. (2011 ) to determine \nwhether regression \npredicts nodal \nmetastasis, \ndisease -free \nsurvival (DFS), or \noverall survival (OS).  Prognostic study  2220 patients who \nunderwent SLN \nbiopsy; those with \ntumor -positive SLN \nunderwent \ncompletion \nlymphadenectomy  \n \n(261 with \nregression; 1959 \nwithout regression)  \n \n DFS \n \nOS \n \nPrognostic factors  On multivariate \nanalysis, factors \nindependently \npredictive of DFS \nincluded Breslow \nthickness, \nulceration, and SLN \nstatus (P < 0.05 in \nall cases); the same \nfactors along with \nage, gender, and \nanatomic tumor \nlocation were \nsignif icantly \nassociated with OS \n(P < 0.05 in all \ncases). Regression \nwas not significantly \nassociated with DFS \n(risk ratio [RR], \n0.94; 95% \nconfidence interval \n[CI], 0.67 -1.27; P = \n0.68) or OS (RR, \n1.01; 95% CI, 0.76 -\n1.32; P = 0.93).  Post hoc analysis of \na multi center \nprospective \nrandomized trial  \n 2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 180 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE  \nDe Vries et al. \n(2011 ) To assess the long -\nterm outcome after \nsentinel lymph node \nbiopsy (SLNB) in \nmelanoma patients.  Prognostic study  450 melanoma \npatients who \nunderwent SLNB  \n(Survival and \nprognostic factors \nwere an alyzed for \n429 patients)  Relapse rate  \n \nFN-rate \n \nPrognostic factors  In 29% relapse \nduring follow -up; \n46% in the SLN -\npositive group who \nunderwent CLND \nand 22% in the SLN -\nnegative group (p < \n0.001).  \n \nFN- rate 11%.  \n \nOn multivariate \nanalysis strongest \nprognos tic factors \nfor DFS: primary \nmelanoma \nulceration and SLN \npositivity (HR: 2.2 \nand 2.3; p < 0.001). \nFor DSS the same \nwas found, HR of \n2.1 for ulceration \nand 2.0 for SLN \npositivity (p=0.001 \nand p=0.002 \nrespectively).  \n CLND was \nperformed in 119 \npatients and these \npatients were \nanalyzed for \nrecurrence and \nsurvival. \n 2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 181 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE  \n10-Year DFS was \n71% for SN -negative \npatients compared \nwith 48% for SLN -\npositive patients (p \n< 0.001). 10 -Year \nDSS was 77% for \nnode -negative \npatients compared \nto 60% for SLN -\npositive patients (p \n< 0.001).  \nMurali et al (2011 ) To investigate in \ndetail the influence \nof SN tumor \ncharacteristics and \nclinical and primary \ntumor  \nparameters on \nregional lymph \nnode recurrence, \ndistant metastasis,  \nand survival.  Prognostic study  409 patients with \nprimary cuta neous \nmelanoma who \nunderwent  \nSNB  DFS \n \nmelanoma -specific \nsurvival (MSS)  Primary tumor \nfeatures (presence \nof ulceration and \nsatellites) and \npresence of ENS in \nSNs were \nindependent \npredictors of DFS, \nDMFS, and MSS. In \naddition, poorer \nDFS was \nindependently \nassociated with \nprimary tumor site \n(head/neck and Same patient cohort \nas Murali et al. \n(2010): Non -\nSentinel Node Risk \nScore (N -SNORE): A \nScoring System for \nAccurately \nStratifying Risk of \nNon-Sentinel Node \nPositivity in Patients \nWith Cutaneous \nMelanoma With \nPositive Sentinel \nLymph Nodes  2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 182 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE  \nlimbs vs. trunk), SN  \ntumor features \n(MaxSize >2 mm, \npresence of PLI) and \npositive NSN in \nCLND; other factors \nindependently \npredictive of DMFS \nwere male sex, \nprimary tumor \nfeatures (absence of \nTILs), and SN t umor \nMaxSize >10 mm; \nand age \u226550 years \nwas an additional \nindependent \npredictor of MSS. \nCLND status was \nnot an independent \npredictor of DMFS \nor MSS.  \nG\u00f6ppner et al. \n(2011 ) To investigate the \nprognostic \nrelevance of SLNB \nand other risk \nfactors in the \nsubgroup of Prognostic study  87 patients  \nwith thick \nmelanomas 1 4.0 \nmm (T4).  Recurrence -Free \nSurvival  \n \nOverall survival  Multivariate \nanalysis: SLN and \nulceration, analyzed \nas separate risk \nfactors as well as \ntheir combination,  2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 183 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE  \nmelanomas >  4.0 \nmm and to \ncompared it to \npreviously \npublished results.  predicted a highly \nreduced life \nexpectancy in terms \nof recurrence -free \nsurvival (RFS).  \nSLN, but not \nulceration, also \npredicted overall \nsurvival (OS)  \nKoskivuo et al. \n(2011 ) to evaluate the \naccuracy and \nprognostic value of \nthe routin e use of \nSNB in elderly \npatients with \ncutaneous \nmelanoma.  Prognostic study  423 consecutive  \npatients >= 70 \nyears with CM AJCC \nstage I \u2013II \n FN-rate \n \nSensitivity  \n \nDiagnostic accuracy  \n \nRelapse -free \nsurvival rate  \n \nCancer specific \nsurvival rate  \n \nPrognostic factor s Recurrence in 18.9% \nof patients (median \nfollow -up: 2\u00b75 \nyears)  \n \nFN-rate: 8\u00b73%  \nSensitivity: 91.7%  \noverall diagnostic \naccuracy: 98\u00b70 %  \n \nat 5 years: relapse -\nfree survival rate: \n80\u00b70% in SN -\nnegative patients \nand 39% in SN -\npositive patients  \n \ncancer -specific  2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 184 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE  \nsurvival rates: \n88\u00b76% and 46% \nrespectively (P < \n0\u00b7001).  \n \nmultivariable \nanalysis: SN \nmetastasis (P < \n0\u00b7001), a Breslow \nthickness of >= \n2\u00b70 mm (P = \n0\u00b7007) and \npresence of \nulceration (P = \n0\u00b7012) were \nindependent \nprognostic factors \nfor cancer -specific \nsurvival.  \nTejera -Vaquerizo et \nal. (2012) To determine \nwhether growth rate \n(GR) of cutaneous \nmelanoma predicts \nthe histological \nsentinel lymph node \n(SLN) positivity  Prognostic study  698 patients with \ninvasive primary \ncutaneous \nmelanoma in whom \nthe SLN was \nidenti fied Growth rate  \n \nPrognostic factors  \n Multivariate logistic \nregression analysis:  \nGR, Breslow \nthickness, and the \npresence of \nmicroscopic \nsatellitosis \nindependently surrogate measure \nfor GR in primary \ninvasive melanoma \nwas calculated as \nthe ratio of Breslow \nthickness to time to \nmelanoma \ndevelopment.  2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 185 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE  \nassociated with SLN \npositivity.  \n \nprobability of SLN \npositivity: 8.2% for \nslow growth \nmelanom as (<0.10 \nmm/mo) compared \nwith 19.8% for \nintermediate -\ngrowth melanomas \n(0.10 -0.50 mm/mo) \nand 37.7% for fast -\ngrowth melanomas \n(>0.50 mm/mo).  \n \nSLN positivity was \nthe most important \nprognostic factor \nfor DFS (HR, 2.13; \n95% CI, 1.20 -3.76) \nand for OS (HR, \n3.99; 95% CI, 1.67 -\n9.53).  \nWhite et al. 2011  Prognostic study  undergoing sentinel \nlymph node (SLN) \nbiopsy for primary 3463 patients (561 \n(16.3%) had a \npositive SLN biopsy)  Predictive factors  multivariate \nanalysis: increasing \nBreslow thickness, retrospective and \nprospective data  \n 2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 186 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE  \nmelanoma  lymphovascular \ninvasion, ulceration, \nyounger age, the \nabsence of \nregression, and \ntumor location on \nthe trunk were \nstatistica lly \nsignificant \npredictors of a \npositive SLN  multivariate analysis \nperformed with data \nof 1526 patients \n(with complete \nrecords)  \n \n \nYonick et al. (2011)  To elucidate \npathologic factors \nthat are predictive \nof SLN posit ivity Prognostic study  \n \n 1199 patients  Correlation between \nhistopathological \nfeatures and SLN \npositivity  Thin melanomas in \n39%; of these, 31% \nunderwent SLNB  \n \nPositive SLNs found \nin 11%  \n \nMultiple logistic \nregression: \nulceration and \nthickness \nassociated wit h SLN \npositivity  \n \nFor scoring system, \nsee full article  Retrospective study  \n \nNo defined \ninclusion criteria for \nSNB 2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 187 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE  \nCadili and Dabbs \n(2010)  To identify the \npredictors of SLN \nmelanoma \nmetastasis.  Prognostic study  \n \n 348 patients with \nmalignant \nmelanoma  Relative risk  73% negative and \n27% positive SLN  \n \nBreslow thickness \nand nodular type \nsignificantly \ncorrelated with \npositive SLN; head \nand neck tumour \nlocation \nsignificantly \ncorrelated with \nnegative SLN  Retrospective \ndesign  \n \nCorrelation of head \nand neck tumou r \nand negative SLN \nresult may be \ncaused by \ninsufficient \nexperience in head \nand neck SLNEs in \nthis institution.  2b \nKretschmer et al. \n(2010)  To investigate the \nimpact of the \nconstitutional factor \nage on the clinical \ncourses of \nmelanoma patients \nwith sentine l lymph \nnode (SLN) biopsy.  Prognostic study  \n \n 2,268 consecutive \npatients  Correlation between \nhistological \nparameters/SNB \nstatus and age  \n \nMelanoma -specific \noverall survival  \n \nAdjusted relative \nrisk According to \nmultivariate \nanalysis, factors \npredictive for poor \noverall survival: age, \nmicrometastasis to \nSLN, Breslow \nthickness and \nepidermal \nulceration  \n \nIn multivariate \nlogistic regression \nanalysis, age of < Retrospective \ndesign  \n \nLarge  patient \nsample  2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 188 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE  \n40 years was \nsignificantly related \nto a 2 -fold \nprobability of SLN -\npositivity  \nRoach et al. (2010)  To investigate the \nsignificance of \nmitotic rate (MR) in \nmelanoma  Prognostic study  \n \n 551 patients had \nMR data reported  Overall survival  \n \nDisease -free \nsurvival  \n \nOdds\u2019 ratio (OR) for \nSLN positivity  High MR: thicker \ntumors, higher rate \nof ulceration, twice \nas many positive \nSLNs (31.3% vs. \n14.7%)  \n \nTumor thickness \nand ulceration \nsignificant survival \npredictors upon \nmultivariate analysis  \n \nFor SLN -negative \nand nonulcerated \npatients, MR groups \nwere not significant \nfor OS  Retrospective \ndesign  2b \nMandal a et al. \n(2009)  To investigate if the \ntumour infiltrating \nlymphocytes (TILs) Prognostic study  \n \n 1251 consecutive \npatients with CM  Overall survival  \n \nDisease -free TIL status of lesion \ncorrelated with the \nBreslow thickness, Retrospective \nanalysis (though of \nprospective 2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 189 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE  \nare able to predict \nthe sentinel lymph \nnode (SLN) \npositivity, the \ndisease -free \nsurvival (DFS) and \noverall survival (OS) \nin clinical stages I -II \nAJCC pri mary \ncutaneous \nmelanoma (PCM).  survival  \n \nCorrelation between \nTIL status and SLN \nstatus  Clark level and \nregressi on \n \nNo difference in \nother variables \nevaluated, including \nSLN status or the \npresence of \nulceration, among \npatients with brisk, \nnon-brisk and \nabsent TILs  \n \nSLN identified in \n394 patients \n(97.5%)  \n \n18.8% positive SLNs  \n \nIn multivariate \nanalysis, increasing \nBreslow thickness, \nanatomical site and \nabsence of TILs \nindependently \nassociated with \npositive SLN  database)   \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 190 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE  \n \n5-year DFS 75.9% in \nnegative SLNs, \n35.2% in positive \nSLNs \n5-year OS 88.7% \nversus 42.9%, \nrespectively  \nSocrier et al. (2009)  To determine if \nregression in \nmelanoma is \nassociated with an \nincreased risk of \nsentinel lymph node \n(SLN) metastasis.  Prognostic study  \n \n 397 consecutive \nmelanoma patients  Odds\u2019 ratio (OR)  SLN positive in 16% \nof melanomas with \nregressi on and 29% \nwithout regression  \n \nAdjusted OR for \nregressive \nmelanoma: 0.9  \n Retro - or \nprospective design \nunclear  2b \nGutzmer et al. \n(2008)  To investigate the \nvalue of the status \nof the sentinel \nlymph node (SLN) in \npatients with thick \nmelanomas (Breslow \nthick ness \u2265 4 mm)  Prognostic study  \n \n  152 patients  Recurrence -free \nsurvival  \n \nOverall survival  \n \nCorrelation between \nhistological \nproperties of \nprimary tumour and Probability of \nrecurrence -free 5 -\nyear-surviv al: 42.5 \n\u00b1 5% overall, 26.3 \u00b1 \n6.6 % for SLN+ and \n58.7 \u00b1 7.1 % for \nSLN- \n \nIn multivariate Retrospective \ndesign  2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 191 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE  \nSLN positivity  \n \nRelative risk (RR) for \nSLN positivity  analysis the \npathological status \nof the SLN had a \nhighly significant \nprognostic value (p \n= 0.000009); \nrelative risk (RR) 3.3  \n \nThe 5 -year overall \nsurvival 53.2 \u00b1 5.4 \n% (37.5 \u00b1 8.1 % with \npositive SLN and \n67.6 \u00b1 6.7 % with \nnegative SLN)  \nRoulin et al. (2008)  To confirm the \naccuracy of sentinel \nnode biopsy (SNB) \nand its morbidity, \nand to investigate \npredictive factors \nfor SN status, \ndisease -free \nsurvival (DFS) and \ndisease -specific \nsurvival (DSS).  Prospective \nprognostic study  \n \n 327 consecutive \npatients with \nprimary melanoma  Recurrence rate  \n \nSensitivity and \nfalse-negative rate \nof SNB  \n \n5-year disease -free \nsurvival (DFS)  \n \n5-year disease -\nspecific surviva l \n(DSS)  Success rate of SNB \n99.1%  \n \nOverall SNB + WE \nmorbidity 7.6%  \n \nSNB positivity rate \n22.6%  \n \nMean Breslow \nthickness of primary \nmelanoma 1.95 mm \nfor SN -negative Follow -up \npresumably too \nshort to discover all \nrecurrences (median \nfollow -up 33 \nmonths; median \ntime of recurrence \n30 months, mean \n34 months)  \n \nNo control group  2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 192 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE  \ncases and 3.22 mm \nfor SN -positive \ncases  \n \nBreslow thickness \nonly statistically \nsignificant pred ictor \nfor metastases  \n \n46% of positive and \n11% of negative SN \npatients recurred  \n \nFalse -negative rate \n8.6%, sensitivity \n91.4%.  \n \n5-year DFS 43% for \npatients with \npositive SN and \n83.5% for patients \nwith negative SN  \n \n5-year DSS 49.1% \nfor SN -positive \npatients an d 87.4% \nfor SN -negative  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 193 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE  \npatients  \nCecchi et al. (2007)  To report the \nexperience with \nlymphati c mapping \n(LM) and sentinel \nlymph node biopsy \n(SLNB) in a selected \ngroup of patients \nwith thin primary \ncutaneous \nmelanomas.  Prospective cohort \nstudy  \n \n 50 patients with \nthin melanomas  Prevalence of SLN -\npositivity in thin \nmelanomas  SLN positivity rate \n4% \n \n CLND only \nperformed on SLN -\npositive patients \n(risk of verification \nbias) 2b \nKaur et al. (2008 ) To understand the \nsignificance of \nregression in \nmelanoma and \nprovide further \ninformation on \nwhether patients \nshould be subjected \nto sentinel lymph \nnode biopsy ( SLNB) \non the basis of \nregression.  Prognostic study  \n \n 146 consecutive \nmelanoma patients  Correlation between \nhistopathologic \nparameters and SLN \npositivity  Statistically \nsignificant greater \nproportion of \nindividuals without \nregression showed \nsentinel lymph n ode \n(SLN) positivity \n(p=0.028) \ncompared with \npatients without \nregression  \n \nCorrelation of age, \nsex, site and \npresence of tumour Retrospective \ndesign, but 1  \u2013 6 \nyears prospective \nfollow -up in 79% of \nthe patients \n(recording survival \nand metastasis)  2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 194 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE  \ninfiltrating \nlymphocytes (TIL) \nwith regression and \nsentinel node status \nnot statistically \nsignificant  \nMorris et al. (200 8) To assess whether \nthe presence of RG \nwas associated with \na higher probability \nof a positive SLN or \nan increased risk of \nlocal or distant \nrecurrence.  Prognostic study  \n \n 1349 patients with \ncutaneous \nmelanoma  Correlation between \nregression and SLN \npositivity  \n \nOverall survival  \n \nDisease -free \nsurvival  10% of patients with \nRG and 18% of \npatients with NRG \nwho underwent SLN \nbiopsy had a \npositive SLN  \n \nWhen stratified by \nBreslow depth \ncategory, there was \nno evidence of an \nincreased risk of a \npositive SLN in \nthose with RG  \n \nOS not significantly \ndifferent between \nthe two groups  \n \nDFS significantly \nlonger for those Retrospective \ndesign  2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 195 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE  \nwith RG  \nPaek et al. (2007 ) To verify previous \nresults in which \nincreasing mitotic \nrate and decreasing \nage predicted \nsentinel lymph node \n(SLN) metastases in \npatients with \nmelanoma, and to \ncreate a prediction \nmodel for the better \nselection of which \npatients with \nmelanoma sho uld \nundergo SLN \nbiopsy.  Prognostic/ \ndiagnostic study  \n \n 910 patients with \ncutaneous \nmelanoma  Correlation between \nhistological features \nand SLN positivity  \n \nOR for SLN \npositivity  \u22651 positive SLNs \nidentified in 26.7% \nof patients  \n \nThe best \nmultivariate model \nincluded the \nfollowing single \nvariables: patient \nage, Breslow depth, \nthe presence of \nangiolymphatic \ninvasion, the \nnumber of mitoses, \nand body site \nlocation of the \nmelanoma  Retrospective \ndesign  2b \nTaylor et al. (200 7) To evaluate the \nprognostic \nimplication s of \ntumor -infiltrating \nlymphocytes (TILs)  Prognostic study  \n 887 patients who \nunderwent SLN \nmapping for \ncutaneous \nmelanoma  Correlation of \nhistopathologic \nfeatures with SLN \npositivity  \n \nOverall survival  \n \nDisease -free SLN identification \nrate 98.6%  \n \nSLN positivity rate \n17.6%  \n \nBy multivariate \nlogistic regression  2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 196 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE  \nsurvival  analysis, male sex, \nthickness, presence \nof ulceration, and \nabsence of TILs \nwere independently \nassociated with \npositive SLN  \n \nWhen brisk and \nnonbrisk TILs were \nanalyzed separately, \nboth levels we re \nsignificant \npredictors of a \nnegative SLN \ncompared with \nabsent TILs, by \nunivariate and \nmultivariate analysis  \n \nHistologic status of \nSLN was the most \nsignificant predictor \nof DFS and OS  \n \nNegative SLN: 5 -\nyear DFS 80.0%   \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 197 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE  \n \nPositive SLN: 5 -year \nDFS 32.8%  \n \nWhen  stratified by \nSLN status, no \nsurvival advantage \npresent with TILs  \nMorton et al. (2005)  The objective of this \nstudy was to \nevaluate, in an \ninternational \nmulticenter phase III \ntrial, the accuracy, \nuse, and morbidity \nof intraoperative \nlymphatic mapping \nand sentinel node \nbiopsy (LM/SNB) for \nstaging the regional \nnodal basin of \npatients with early -\nstage melanoma.  Randomized \ncontrolled clinical \nmulti -center trial  \n \n. 2001 patients with \ninvasive primary \ncutaneous \nmelanoma  Accuracy of sentinel \nnode identificat ion \n \nDissected -basin \nrecurrence in \npatients with \nnegative sentinel \nnode  \n \nSurgical morbidity  Overall rate of SN \nidentification: 95.3%  \n \n6.3% of patients \nwith tumor -\nnegative SNs \ndeveloped regional \nnodal recurrence at \na median followup \nof 54 months  \n \nIncidenc e of at least \none local wound \ncomplication: 13.9% \nin the WEO arm and \n13.8% in the \nLM/SNB arm  \n \nSurgical morbidity:  Method of \nrandomization \ndescribed in Morton \net al. (2006)  \n \nNo intention  to treat \nanalysis (ITT); \ninstead an as -\ntreated analysis was \nperformed  2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 198 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE  \n37.2% for LM/SNB \nwith immediate \nCLND vs 10.1% for \nLM/SNB without \nCLND  \nRoka et al. (2005)  To investigate the \naccuracy of SLNB \nand the clinical \noutcome of \npatients.  Prognostic study  \n \n 309 patients with \nmalignant \nmelanoma  Disease -free \nsurvival  \n \nOverall survival  SNB success rate: \n96.8%  \n \nSLN positivity rate: \n23% \n \nFalse -negative SLNB \nrate: 9.2%  \n \nAmong patients \nwith one or more \nmetastatic SLN, 21% \nhad further \nmetastases in non -\nSLNs in the \ndissected basin  \n \nMicrometastasis in \nSLN in 68%, \nmacrometastasis in \n32%  \n Prospective design  \n \nRelatively short \nmean follow -up \ntime \n \n 2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 199 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE  \n3-year DFSl for \nnegative and \npositive SLN \npatients: 82 and \n55%, respectively  \n \n3-year overall \nsurvival for negative \nand positive SLN: \npatients 93% and \n83%, respectively  \n \nBy multivariate \nanalysis, Breslow \nthickness the only \nstatistically \nsignificant \nprognostic factor \nwith respect to \noverall survival  \nCu\u00e9llar et al. (2004)   To describe \nindependent \nprognostic factors \nother than tumour \nthickness useful in \nSLN candidate \nselection.  Prognostic stud y \n \n 94 MM patients  Correlation between \npotential prognostic \nfactors and SLN \npositivity  SLN positivity rate \n20.2%  \n \nNo positive SLN in \nMM \uf0a3 1.0 mm and \nin patients with \nregression > 50%  Retrospective \ndesign  2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 200 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE  \n \nSmall cell and \nulceration were \nsignificant \nprognostic factors \nin multi variate \nanalysis  \n \nSLN positivity rate \nfor small cell: 56.9%  \n \nSLN positivity rate \nfor ulceration: \n35.5%  \n \nSLN positivity rate \nfor small cell and \nulceration: 86.3%  \nMacripo et al. \n(2004)  To analyse the \nparameters \nassociated with a \nhigher risk of occult \nnodal metastases, \nto evaluate the \nclinical outcome of \nmelanoma patients \nwho underwent SLN Prognostic study  \n \n 274 melanoma \npatients with \nmelanoma \u2265 1 mm \nor ulceration, \nregression or Clark \nlevel IV/V  Status of SLN \n(negative, \nmicrometastasis or \nmacrometastasis)  \n \nDisease -free \nsurvival  SLN positivity rate \n16.8%  \n \nSubsequent radical \nnode dissection \nrevealed further \nmelanoma \nmetastases in 33% \nof patients with Prospective des ign  \n \n 2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 201 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE  \nprocedure, and to \nidentify by means of \nmultivariate analysis \nthe prognostic \nparameters with \nindependent \npredictive value on \ndisease -free \nsurvival (D FS) in \nnode -positive and \nnegative patients.  macrometastases \nand 10% of patients \nwith \nmicrometastases  \n \nRelapse rate of SLN -\npositive patients: \n54.3%  \n \nRelapse rate of SLN -\nnegative patients: \n10.9%  \n \n5-year DFS and OS \n42% for SLN+ and \n69% for SLN - \n \nSLN status \n(micro metastases/ \nmacrometastases) \nand thickness were \nindependent \nprognostic factors \nin the SLN -positive \ngroup  \n \nLow-risk group:  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 202 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE  \nmicrometastases \nand Breslow \nthickness \u2264 2 mm; \n2-year DFS 100%  \n \nIntermediate -risk \ngroup: \nmacrometastases or \nBreslow thickness \n>2 mm; 2 -year DFS \n71% \n \nHigh-risk group: \nmacrometastases \nand Breslow \nthickness >2 mm; \n2-year DFS 28%  \nStitzenberg et al. \n(2004)  To investigate if \nlymphatic mapping \nand sentinel \nlymphadenectomy \n(LM/SL) with a \nfocused \nexamination of the \nsentinel node (SN) \nwill detect a \nsignificant number Prognostic study  \n \n 146 patients with a \nmelanoma tumor \nthickness of \uf0a3 1.0 \nmm Correlation of \nhistopathological \nfactors and SLN \npositivity  SLN positivity rate \n4% \n \nOn multivaria te \nanalysis, none of \nthe clinical or \nhistopathologic \nfactors examined \nsignificantly \nassociated with SN Retrospective \ndesign  2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 203 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE  \nof SN metastases in \npatients with thin \nmelanoma and \nwhich cl inical or \nhistopathologic \nfactors may serve as \npredictors of SN \ntumor involvement.  tumor involvement \nin patients with thin \nmelanoma  \n \nNone of the patients \nhad non -SN tumor \ninvolvement  \nMraz -Gernhard et \nal. (1998)  To develop a \nprognostic model, \nbased on clinical \nand pathological \ndata, to estimate \nthe probability of \nmicrometastasis in \nthe sentinel lymph \nnode in patients \nwith malignant \nmelanoma.  Prognostic study  \n \n 215 patients with \nAJCC stages I and II \ncutaneous \nmalig nant \nmelanoma  Incidence of SLN \npositivity depending \non histological \nfeatures  SLN positivity rate \n21.4%  \n \nOnly tumor \nthickness \nsignificantly \ncorrelated with SLN \npositivity  \n \nIncidence of \npositive SLN \naccording to \nnumber of high risk \nfeatures (HRFs):  \n14% with  no HRF  \n31% with 1 HRF  \n47% with 2 HRFs  \n75% with 3 or more \nHRFs  Retrospective \ndesign  \n \nSimilar rate of SLN \npositivity in \nmelanomas between \n1.0 and 2.9 and > 5 \nmm may be due to \nselection bias \n(exclusion of \npatients with \nevidence of regional \nlymph node \nmetasta sis) => may \nalso be true for \nother studies  2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 204 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE  \nSatzger et al. \n(2011)  To analyze the \npossible effect of \nSLND on the \nprognosis of \nmelanoma patients.  Prognostic study  \n \n 673 consecutive  \nmelanoma patients  Overall survival  \n \nRecurrence -free \nsurvival  Pre-SLN grou p: \n25.7% melanoma \nrelated deaths  \n \nSLN group: 17.6%  \n \n5-year melanoma -\nspecific survival \nrates: 80.3% in pre -\nSLN patients, 84.8% \nin SLN patients  \n \n5-year survival \nrates: 72.8% in SLN \npositive patients, \n89.9% in SLN \nnegative patients \n89.9%  \n \nRelapse rate 39.0% \nin pre -SLN patients, \n23.6% in SLN \npatients  Retrospective \ndesign  \n \nHistorical control \ngroup  2b- \nEllis et al. (2010)  To clarify \nindications, \npredictive factors, \nand outcomes of Prognostic and \ndiagnostic study  \n \n 397 patients with \nmelano mas  Correlation between \nhistological \nproperties and SLN \npositivity  Breslow thickness > \n2 mm, upper \nextremity primaries, \nand ulceration were Retrospective \ndesign  \n \nDifficult definition 2b-  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 205 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE  \nsentinel node \nbiopsy.   \nSensitivity and \nspecificity, NPV and \nPPV \n \n predictive for SLN+ \nstatus  \n \nSLN positivity rate \n12%; for lesions > 1 \nmm 16% \n \nFalse -negative rate \n4.0% \n \nSensitivity of SLNB \n75.4%, with a \nnegative predictive \nvalue of 95.4% and \naccuracy of 96.0%; \nspecificity and \npositive predictive \nvalue 100%  of \u201cfalse -positives\u201d \n(here declared as 0,  \nbut not defined)  \nKretschmer et al. \n(2008) To determine \nsurgical morbidity \nin melanoma \npatients with \nsentinel \nlymphnodectomy \nand complete \nregional lymph \nnode dissection  Cohort study  \n \n 315 melanoma \npatients  Complication rate  Mortality 0%  \n \nMorbidity ra te \nrelated to general \nanaesthesia 0%  \n \nComplication rates:  \n65.5% after CLND, \n13.8% after SLNE  Most data \nprospectively \nrecorded (325 vs. \n40 nodal basins)  \n \nSurgical morbidity \nnot recorded for all \npatients who \nunderwent SLNE or 2b-  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 206 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE  \n \n19.5% in inguinal \ndissection, 9.2% in \naxillary dissection  CLND (possible \nsource of bias)  \nde Rosa et al. \n(2011 ) to examine the test \nperformance of \nsentinel node \nbiopsy in head and \nneck melanoma, \nincluding the \nidentification rate \nand false -negative \nrate Systematic review \nwithout meta -\nanalysis  \n \n \n(32 studies eligible \nfor analysis)  3442 patients  predictive value \npositive (PPV) and  \nnegative (PVN) for \nnodal recurrence  \n \nposttest probability  \n \nFN-negative rate  \n \n Positive sentinel \nnode biopsy: in 15%  \nof patients.  \n \nSubsequent \ncompletion neck  \ndissection revealed \nadditional  \npositive nodes in \n13.67%.  \n \npredictive value \npositive for nodal \nrecurrence: 13.1%,  \n \nposttest probability \nnegative: 5%.  \nMedian FN -negative \nrate for nodal \nrecurrence was \n20.4%.  Distinct portions of \nthe included studies \nwere u sed to \ndetermine PVP, \nPTPN\u2026  \n \n32 studies clinically \nheterogeneous  3a \nDoeden et al. We directly Prognostic study  94 patients with Overall survival  SLN positi vity rate Small sample size 3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 207 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE  \n(2009)  compared the \nrelative contribution \nof lymphatic and \nhematogenous \npathways in a \ncohort of patients \nwith primary \ncutaneous \nmelanoma with 3 \nyears of clinical  \nfollow up.   \n primary cutaneous \nmelanoma, 57 of \nwhich had a known \nSLN status   \nDisease -free \nsurvival  \n \nCorrelation between \nlymphatic invasion \n(LI) resp. vascular \ninvasion (VI) and \nSLN positivity  75% in LI -positive \npatients, 39% in LI -\nnegative patients  \n \nPresence of LI was \nindependent of \ntumor thickness \nand not associated \nwith distant \nmetastasis  \n \nKaplan -Meier \nanalyses did not \ndetect a significant \ndifference in the \noverall or disease -\nfree survival in LI -\npositive or LI -\nnegative patients  \n \nBy multivariate \nanalysis, LI was not \na significant risk \nfactor for SLN \nmetastasis  (57 with known SLN \nstatus)  \n \nRetrospective \ndesign  \nLeiter  et al. (2010 ) To investigate the \npotential sur vival Prognostic study  \n 879 patients with \nprimary cutaneous Incidence of \nmetastasis  Rate of regional \nlymph node Retrospective \ndesign  3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 208 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE  \nbenefit of sentinel \nlymph node \ndissection (SLND).   melanoma   \nOverall survival  \n \nRecurrence -free \nsurvival  metastasis: 16.5% in \nnon-SLND \ncollecti ve, 7.3%  in \nSLND collective; no \ndifference in \nsatellite/in -transit \nmetastases and \ndistant metastases  \n \nDisease -free \nsurvival improved in \nthe SLND collective   \nHistorical control \ngroup without \nconsistent reporting \nof ulceration  \n \n \nMassi et al. (2006)  To evaluate whether \ntumour \nlymphangiogenesis \nand the expression \nof vascular \nendothelial growth \nfactor C (VEGF -C) is \nrelated to the risk of \nSLN metastasis and \nto clinical outcome \nin a case \u2013control \nseries of patients \nwith melanoma.  Case-control study  \n \n 15 patients affected \nby primary \ncutaneous \nmelanoma with \nmetastasis to SLN \nwere matched with \na group of 30 \npatients without \nSLN metastasis.  Correlation between \nLV and SLN \npositivity  \n \nOverall survival  Number and area of \nperitumorous and \nintratum orous \nlymphatics was \nsignificantly higher \nin melanomas \nassociated with SLN \nmetastasis than in \nnon-metastatic \nmelanomas  \n \nNo significant \ndifference in VEGF -\nC expression by \nneoplastic cells Retrospective \ndesign  \n \nSmall patient \nsample  3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 209 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE  \nbetween metastatic \nand non -metastatic \nmelanomas  \n \nIn multivariate \nanalysis, \nperitumorous LV \ndensity was an \nindependent \nvariable affecting \noverall survival  \nDadras et al. (2005)  To investigate \nwhether the extent \nof tumor \nlymphangiogenesis \ncan predict \nmelanoma \nmetastasis to \nsentine l lymph \nnodes.  Prognostic study  \n \n 45 consecutive \npatients with \nnonmetastatic (n = \n27) or metastatic (n \n= 18) primary \ncutaneous \nmelanoma to the \nSLN. Odds\u2019 ratio  Mean tumor \nthickness in SLN -\npositive patients \n3.01 \uf0b1 0.52mm, in \nSLN-negative \npatients 1.70 \uf0b1 \n0.31mm  \n \nAdditional \nprognostic \nparameters such as \ntumor ulceration, \nmitotic activity, \nregression and \nnumber of tumor \ninfiltrating Small patient \nsample  \n \nRetrospective \ndesign  3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 210 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE  \nlymphocytes did not \ndiffer between \ngroups  \n \nFrequency of \nintratumoral \nlymphatics in SLN -\npositive patients \n83.3 \uf0b1 0.09%, in \nSLN-negative \npatients 59.3 \uf0b1 \n0.09%  \nRoaten et al. (2005)  To investigate the \nassumption that \nSLNB has fewer \ncomplications than \nelective regional \nlymph node \ndissection (RLND).  Cohort study  \n \n 339 consecutive \npatients unde rgoing \nSLNB for melanoma  \n \n Complication rates  SLN positivity rate \n19.6%  \n \nComplication rate \n5.9% for SNB, 19.5% \nfor RLND  Retrospective \ndesign  \n \nNo clear inclusion \ncriteria and \ndifferent \ncharacteristics \n(thicker tumors, \nmore men, longer \nfollow -up) in \ncontrol group who \nreceived RLND  \n \nRole of closed \nsuction to be 3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 211 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE  \ninvestigated further  \nLeong et al. (2003)  To examine the role \nof sentinel lymph \nnode biopsy (SLNB) \nin patients with a \nprevious wide local \nexcision (WLE).  Prospective case -\ncontrol study  \n \n 168 patients  with \nclinically \nnodenegative \ntruncal or extremity \nmelanoma and \nBreslow thickness of \n\u2265 1 mm.  \nA total of 103 of the \n168 patients were \nreferred after their \nWLE. Number of positive \nSLNB  \n \nFalse -negatives  \n \nDisease -free \nsurvival  \n \nOverall survival  SLN positivit y rate \n32.3% both for \ncases and controls  \n \nNo significant \ndifference in \nrelapse -free \nsurvival: 72.3% for \ncases, 81.7% for \ncontrols at 2 years;  \n \nNo significant \ndifference in overall \nsurvival: 94.7% \nincases, 96.8% in \ncontrols at 2 years  Follow -up time \nspan to o short for \nreliable assessment \nof survival  \n \n 3b \nMcCready et al. \n(2001 ) To document \nexperience with \nsentinel lymph -\nnode biopsy in \npatients who have \nalready undergone a \nwide local excision \nfor melanoma \nbecause in many Prospective cohort \nstudy  \n \n 100 patients with \ncutaneous \nmelanoma  \n \n Accuracy of biopsy  \n \nFalse -negative rates  SLN positivity rate \n31%  \n \nAt completion \nlymphadenectomy, \n29% rate of other \npositive nodes in \nthe dissected basin  \n Only a historical \ncontrol group \navailable  \n \nSmall patient \nnumbers, especially \nin the false -\nnegative group  3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 212 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE  \ncentres previous \nwide excision has \nbeen a \ncontraindication for \nsentinel lymph node \nbiopsy.    \nNguyen et al. \n(2001)  To determine \nwhether primary \nmelanoma \nhistopathologic \nfeatures could be \napplied to predict \nsentinel node \nstatus.  Prognostic study  \n \n 112 consecutive \nmelanoma patients  Correlation between \nhistological features \nand SLN positivity  SLN positivity rate \n20% \n \nFalse -negative rate \n2.4% \n \nIn multivariate \nanalysis, the most \nsignificant cutoff for \nprediction of node \npositi vity was a \nthickness of 1.5 \nmm \n \nAdditional \nhistologic features \nsignificantly \npredictive of occult \nmicrometastases: \nulceration and \nlymphovascular Retrospective \ndesign  \n \nNo explicit \ninformation about \ninclusion criteria for \nSLNE 3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 213 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE  \ninvasion  \nPasquali et al. \n(2011) To test the \ndiscrimination, the \ncalibration and the \nNPV of MSKCC \nnomogram in 543 \npatients  Diagnostic study  543 patients   positive SN in 147 \npatients (27%).  \n \nMean predicted \nprobability: 17.8% \n(95%CI: 16.8 -\n18.8%). Nomogram \ndiscrimination was \nsignifica nt (area \nunder the curve = \n0.68; P < 0.0001) \n(R(2) = 0.99).  \n \nCut-off values \nbetween 4% and 9% \nled to a NPV, SNB \nreduction and \noverall error rates \nranging between \n100 and 91.2%, 2.2 \nand 27.2%, and 0 \nand 2.3%, \nrespectively.  \n \nincidence of SN \nmetastasis was  3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 214 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE  \nhigher than that \nobserved in the \nMSKCC series (27% \nvs 16%).  \n \n2.1.5.  Literatur  \nBurton AL, Gilbert J, Farmer RW, et al. Regression does not predict nodal metastasis or survival in patients with cutaneous melanoma. Am Surg 2011;77:1009 -1013  \nCadili A, Dabbs K. P redictors of sentinel lymph node metastasis in melanoma. Can J Surg 2010;53:32 -36 \nCecchi R, Buralli L, Innocenti S, et al. Sentinel lymph node biopsy in patients with thin melanomas. J Dermatol 2007;34:512 -515 \nCuellar FA, Vilalta A, Rull R, et al. Small ce ll melanoma and ulceration as predictors of positive sentinel lymph node in malignant melanoma patients. Melanoma Res \n2004;14:277 -282 \nDadras SS, Lange -Asschenfeldt B, Velasco P, et al. Tumor lymphangiogenesis predicts melanoma metastasis to sentinel lymph nodes. Mod Pathol 2005;18:1232 -1242  \nde Rosa N, Lyman GH, Silbermins D, et al. Sentinel node biopsy for head and neck melanoma: a systematic review. Otolaryngol Head Neck Surg 2011;145:375 -382 \nde Vries M, Speijers MJ, Bastiaannet E, et al. Long -term follow -up reveals that ulceration and sentinel lymph node status are the strongest predictors for survival in patients with \nprimary cutaneous melanoma. Eur J Surg Oncol 2011;37:681 -687 \nDoeden K, Ma Z, Narasimhan B, et al. Lymphatic invasion in cutaneous melanoma is associated with sentinel lymph node metastasis. J Cutan Pathol 2009;36:772 -780 \nEllis MC, Weerasinghe R, Corless CL, et al. Sentinel lymph node staging of cutaneous melanoma: predictors and outcomes. Am J Surg 2010;199:663 -668 \nGoppner D, Ulrich J, Pokryw ka A, et al. Sentinel lymph node biopsy status is a key parameter to stratify the prognostic heterogeneity of malignant melanoma in high -risk \ntumors >4.0 mm. Dermatology 2011;222:59 -66 \nGutzmer R, Satzger I, Thoms KM, et al. Sentinel lymph node status is th e most important prognostic factor for thick (> or = 4 mm) melanomas. J Dtsch Dermatol Ges \n2008;6:198 -203 \nKaur C, Thomas RJ, Desai N, et al. The correlation of regression in primary melanoma with sentinel lymph node status. J Clin Pathol 2008;61:297 -300 \nKoskivuo I, Hernberg M, Vihinen P, et al. Sentinel lymph node biopsy and survival in elderly patients with cutaneous melanoma. Br J Surg 2011;98:1400 -1407  \nKretschmer L, Starz H, Thoms KM, et al. Age as a key factor influencing metastasizing patterns and dise ase-specific survival after sentinel lymph node biopsy for cutaneous \nmelanoma. Int J Cancer 2010  \nKretschmer L, Thoms KM, Peeters S, et al. Postoperative morbidity of lymph node excision for cutaneous melanoma -sentinel lymphonodectomy versus complete region al lymph \nnode dissection. Melanoma Res 2008;18:16 -21 \nKunte C, Geimer T, Baumert J, et al. Prognostic factors associated with sentinel lymph node positivity and effect of sentinel status on survival: an analysis of 1 049 patients with \ncutaneous melanoma. Melanoma Res 2010;20:330 -337 \nLeiter U, Buettner PG, Bohnenberger K, et al. Sentinel lymph node dissection in primary melanoma reduces subsequent regional lymph node metastasis as well as distant \nmetastasis after nodal involvement. Ann Surg Oncol 2010;17:129 -137 \nLeong WL, Ghazarian DM, McCready DR. Previous wide local excision of primary melanoma is not a contraindication for sentinel lymph node biopsy of the trunk and extremity. J \nSurg Oncol 2003;82:143 -146 \nMacripo G, Quaglino P, Caliendo V, et al. Sentinel ly mph node dissection in stage I/II melanoma patients: surgical management and clinical follow -up study. Melanoma Res \n2004;14:S9 -12 \nMandala M, Imberti GL, Piazzalunga D, et al. Clinical and histopathological risk factors to predict sentinel lymph node positi vity, disease -free and overall survival in clinical \nstages I -II AJCC skin melanoma: outcome analysis from a single -institution prospectively collected database. Eur J Cancer 2009;45:2537 -2545   \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 215 von 732 Massi D, Puig S, Franchi A, et al. Tumour lymphangiogenesis is a  possible predictor of sentinel lymph node status in cutaneous melanoma: a case -control study. J Clin Pathol \n2006;59:166 -173 \nMays MP, Martin RC, Burton A, et al. Should all patients with melanoma between 1 and 2 mm Breslow thickness undergo sentinel lymph node biopsy? Cancer 2010;116:1535 -\n1544  \nMcCready DR, Ghazarian DM, Hershkop MS, et al. Sentinel lymph -node biopsy after previous wide local excision for melanoma. Can J Surg 2001;44:432 -434 \nMcMasters KM, Wong SL, Edwards MJ, et al. Factors that predict the presence of sentinel lymph node metastasis in patients with melanoma. Surgery 2001;130:151 -156 \nMorris KT, Busam KJ, Bero S, et al. Primary cutaneous melanoma with regression does not require a lower threshold for sentinel lymph node biopsy. Ann Surg Oncol \n2008;15:316 -322 \nMorton DL, Cochran AJ, Thompson JF, et al. Sentinel node biopsy for early -stage melanoma: accuracy and morbidity in MSLT -I, an international multicenter trial. Ann Surg \n2005;242:302 -11; discussion 311 -3 \nMorton DL, Thompson JF, Cochran AJ, e t al. Sentinel -node biopsy or nodal observation in melanoma. N Engl J Med 2006;355:1307 -1317  \nMraz -Gernhard S, Sagebiel RW, Kashani -Sabet M, et al. Prediction of sentinel lymph node micrometastasis by histological features in primary cutaneous malignant mel anoma. \nArch Dermatol 1998;134:983 -987 \nMurali R, Desilva C, Thompson JF, et al. Factors predicting recurrence and survival in sentinel lymph node -positive melanoma patients. Ann Surg 2011;253:1155 -1164  \nNguyen CL, McClay EF, Cole DJ, et al. Melanoma thicknes s and histology predict sentinel lymph node status. Am J Surg 2001;181:8 -11 \nPaek SC, Griffith KA, Johnson TM, et al. The impact of factors beyond Breslow depth on predicting sentinel lymph node positiv ity in melanoma. Cancer 2007;109:100 -108 \nPasquali S, Mo cellin S, Campana LG, et al. Maximizing the clinical usefulness of a nomogram to select patients candidate to sentinel node b iopsy for cutaneous melanoma. Eur J \nSurg Oncol 2011;37:675 -680 \nRoach BA, Burton AL, Mays MP, et al. Does mitotic rate predict senti nel lymph node metastasis or survival in patients with intermediate and thick melanoma? Am J Surg \n2010;200:759 -63; discussion 763 -4 \nRoaten JB, Pearlman N, Gonzalez R, et al. Identifying risk factors for complications following sentinel lymph node biopsy fo r melanoma. Arch Surg 2005;140:85 -89 \nRoka F, Kittler H, Cauzig P, et al. Sentinel node status in melanoma patients is not predictive for overall survival upon multivariate analysis. Br J Cancer 2005;92:662 -667 \nRondelli F, Vedovati M, Becattini C, et al. Prognostic role of sentinel node biopsy in patients with thick melanoma: a meta -analysis. J Eur Acad Dermatol Venereol 2011  \nRoulin D, Matter M, Bady P, et al. Prognostic value of sentinel node biopsy in 327 prospective melanoma patients from a singl e institu tion. Eur J Surg Oncol 2008;34:673 -679 \nSatzger I, Meier A, Hoy L, et al. Sentinel node dissection delays recurrence and prolongs melanoma -related survival: an analysis of 673 patients from a single center with long -\nterm follow -up. Ann Surg Oncol 2011;18:51 4-520 \nSmith VA, Lentsch EJ. Sentinel node biopsy in head and neck desmoplastic melanoma: An analysis of 244 cases. Laryngoscope 2012;122:116 -120 \nSocrier Y, Lauwers -Cances V, Lamant L, et al. Histological regression in primary melanoma: not a predictor of s entinel lymph node metastasis in a cohort of 397 patients. Br J \nDermatol 2010;162:830 -834 \nStitzenberg KB, Groben PA, Stern SL, et al. Indications for lymphatic mapping and sentinel lymphadenectomy in patients with thin melanoma (Breslow thickness < or =1.0  mm). \nAnn Surg Oncol 2004;11:900 -906 \nTaylor RC, Patel A, Panageas KS, et al. Tumor -infiltrating lymphocytes predict sentinel lymph node positivity in patients with cutaneous melanoma. J Clin Oncol 2007;25:869 -\n875 \nTejera -Vaquerizo A, Nagore E, Herrera -Acost a E, et al. Prediction of Sentinel Lymph Node Positivity by Growth Rate of Cutaneous Melanoma. Arch Dermatol 2012  \nTestori A, De Salvo GL, Montesco MC, et al. Clinical considerations on sentinel node biopsy in melanoma from an Italian multicentric study on 1,313 patients (SOLISM -IMI). Ann \nSurg Oncol 2009;16:2018 -2027  \nValsecchi ME, Silbermins D, de Rosa N, et al. Lymphatic Mapping and Sentinel Lymph Node Biopsy in Patients With Melanoma: A Meta -Analysis. J Clin Oncol 2011  \nWarycha MA, Zakrzewski J, Ni Q, et al . Meta-analysis of sentinel lymph node positivity in thin melanoma (<or=1 mm). Cancer 2009;115:869 -879 \nWhite J, R.L.R, Ayers GD, et al. Factors predictive of the status of sentinel lymph nodes in melanoma patients from a large multicenter database. Annals of Surgical Oncology \n2011;18:3593 -3600  \nYonick DV, Ballo RM, Kahn E, et al. Predictors of positive sentinel lymph node in thin melanoma. Am J Surg 2011;201:324 -7; discussion 327 -8  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 216 von 732 2.2. Frage II.5. und III.4. Tumorlast am Sentinel -Node und komplettierende \nLymphad enektomie \u2013 De-novo-Recherche  \nFrage II.5 . Hat die Tumorlast am Sentinel -Node eine prognostische Bedeutung?  \nFrage III .4. Ist eine komplettierende LAD bei Mikrometastasen am SLN indiziert?  \n \n2.2.1.  Datenbanken, Suchstrategien, Trefferzahlen  \nDatenbank  Suchstrategie  Datum  Treffer \nMedline  melanoma[title] AND ((\"sentinel\"[tiab] OR \"sentinel lymph node\"[tiab] OR sln[tiab] OR \nslne[tiab]) AND ((\"tumor load\"[tiab] OR \"tumor burden\"[tiab]) OR (prognosis[tiab] OR \nsurvival[tiab])) OR starz OR dewar OR rotterdam OR s -classifica tion) 26.01.2012  747 \nCochrane Library  (melanoma and (sentinel or \"sentinel lymph node\" or sln or slne) and (\"tumor load\" or \n\"tumor burden\" or prognosis or survival or starz or dewar or rotterdam or \"s \nclassific ation\")).ti,ab.  19.01.2012  27 \nEmbase  (melano ma and (sentinel or \"sentinel lymph node\" or sln or slne) and (\"tumor load\" or \n\"tumor burden\" or prognosis or survival or starz or dewar or rotterdam or \"s \nclassific ation\")).ti,ab.  23.01.2012  872 \nBemerkungen: Eine erste Literaturrecherche in Medline und u nd Cochrane erfolgte am 01.02.2011 bzw. f\u00fcr Embase am 11.05.2011. Die Update -Recherche \nwurde am 23.01.2012 (Embase) bzw. am 26.01.2012 (Medline) und am 19.01.2012 (Cochrane) durchgef\u00fchrt. In der Tabelle angegeben  sind die Trefferzahlen \nder letzten Reche rche.  \n \nDa die Literaturbasis f\u00fcr die Fragen II.5 und III.4 die gleiche ist (bei gleicher Suchstrategie), diente die Tabelle sowohl der AG chirurgische Ther apie als auch der \nAG Sentinel als Grundlage zur Beantwor tung der Fragen III.4 bzw. II.5.  \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 217 von 732 2.2.2.  Auswahlkrite rien \nAuswahl der Literatur  \nGesamttreffer (inkl. Dupletten)  1646  \nEinschlusskriterien  Thematische \u00dcbereinstimmung  \nSprachen: e,dt  \nAusschlu sskriterien  Case Re ports, narrative Reviews  \nAnzahl nach Abstractscreening  79 \nAnzahl ausgew\u00e4hlter Volltexte, vorges ehen f\u00fcr Bewertung  25 \n \n2.2.3.  Evidenztabelle  \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE  \nMocellin et al. \n(2007)  To investigate the \nprognostic value of \nPCR status of SLN.  Systematic review \nand meta -analysis  \n \n 4019 patients who \nunderwent SLN \nbiopsy  for clinical \nstage I to II \ncutaneous \nmelanoma  Recurrence rate  \n \nOverall survival  \n \nSensitivity, \nspecificity, positive \nand negative \npredictive value \n(PPV, NPV)  Pooled positivity \nrate: 20.3% \npathology -based  \n \nIn patients with \npathology -negative \nSLN: PCR positi ve in \n42.3%  \n \nIn patients with \npathology -positive \nSLN: PCR negative \n(false negative) in Funnel plot did not \nshow publication \nbias 1a  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 218 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE  \n49% \n \nPCR positivity in \npatients with \npathology -positive \nSLN: 95.1%  \nIn patients with \npathology -negative \nSLN: 46.6%  \n \nDisease recurrence \nrate: 16.8% among \nPCR-positive \npatients; 8.7% in \nPCR negative \npatients  \n \nPCR sensitivity \n57.4%, specificity \n61.1%, accuracy \n60.6%, PPV 16.8%, \nNPV 91.3%  \nElsaesser et al. \n(2012 ) investigated survival \nprobabilities and \nprognostic factors \nin sentine l lymph \nnode biopsy (SLNB) Cohort study  \n 1909 SLNB staged \npatients  with \nprimary CM  5-year-OS \n \nPrognostic factors  5-year OS in SLNB \nnegative patients: \n90.3% (IB 96.2%, IIA \n87.0%, IIB 78.1%, IIC \n72.6%).   2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 219 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE  \nstaged patients with \ncutaneous \nmelanoma (CM) with \nthe aim of defining \nsubgroups of \npatients who are at \nhigher risk for \nrecurrences and \nwho should be \nconsidered for \nadjuvant clinical \ntrials.   \n5-year OS in \npatients with \nmicrometastases \n(stage IIIA/B): 70.9% \nwhich was clearly \nless favorable than \nfor stages I -II. \nMultivariate analysis \nrevealed tumor \nthickness, \nulceration, body \nsite, histopathologic \nsubtype and SLNB \nstatus as \nindependent \nsignificant \nprognostic factors.  \nQuaglino et al. \n(2011 ) to evaluate which \nprognostic variables \ncould predict NSLN \ninvasion in SLN -\npositive patients \nand their impact on \nthe overall survival \n(OS). Cohort study  \n 603 patients who \nhad undergone \nSLNB for melanoma  OS \n \nprognostic variables \non CLND results \nand disease course.  Breslow thickness, \nulceration and \nmicro/macrometast\natic pat tern of SLN \ninvasion carried a \nsignificantly \nindependent higher \nlikelihood of NSLN \ninvolvement; Starz Retrospective chart \nreview  2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 220 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE  \nclassification did \nnot maintain a \nstatistical \nsignificance in \nmultivariate \nanalysis.  \n \nNSLN involvement, \nwas found in 33.3% \nof patients with one \nand 55.9%  with \n\u2265adverse \nparameters (p = \n0.0001).  \nVan der Ploeg et al. \n(2011)  To determine the \nrole of tumor load \nand tumor site in \nthe SN as \nprognostic factors \nfor survival and as \npredictive factors \nfor NSN positivity.  Cohort study  \n \n 1080 patients with \npositive SLN  NSN status  \n \nOverall survival  Significant factors \nregarding NSN \nstatus: age, study \ncenter, histology \nand location of the \nprimary, Clark level, \nBreslow thickness, \nRotterdam criteria, \nRotterdam criteria \nII, III, and IV, Dewar  \ncriteria, Dewar \ncriteria II, and RDC \ncriteria  Retrospective \ndesign  \n \nLarge patient cohort  \n \nFor de tailed survival \nrates see original \narticle  2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 221 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE  \n \nRate of additional \npositive lymph \nnodes in the group \nof patients with \nsubmicrometastases \n(\uf0a3 0.1 mm, \nRotterdam criteria): \n9% \nPatients with 0.1 to \n1.0 mm: 16%  \nMurali et al (2011)  To investigate in \ndetail the influence \nof SN tumor \ncharacteristics and \nclinical and primary \ntumor  \nparameters on \nregional lymph \nnode recurrence, \ndistant metastasis,  \nand survival.  Cohort stud y \n 409 patients with \nprimary cutaneous \nmelanoma who \nunderwent  \nSNB  DFS \n \nmelanoma -specific \nsurvival (MSS)  Primary tumor \nfeatures (presence \nof ulceration and \nsatellites) and \npresence of ENS in \nSNs were \nindependent \npredictors of DFS, \nDMFS, and MSS. In \nadditio n, poorer \nDFS was \nindependently \nassociated with \nprimary tumor site \n(head/neck and \nlimbs vs. trunk), SN  Same patient cohort \nas Murali et al. \n(2010): Non -\nSentinel Node Risk \nScore ( N-SNORE): A \nScoring System for \nAccurately \nStratifying Risk of \nNon-Sentinel Node \nPositivity in Patients \nWith Cutaneous \nMelanoma With \nPositive Sentinel \nLymph Nodes  2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 222 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE  \ntumor features \n(MaxSize >2 mm, \npresence of PLI) and \npositive NSN in \nCLND; other factors \nindependently \npredictive of DMFS \nwere male sex, \nprimary tumor \nfeatures (absence of \nTILs), and SN tumor \nMaxSize >10 mm; \nand age \u226550 years \nwas an additional \nindependent \npredictor of MSS. \nCLND status was \nnot an independent \npredictor of DMFS \nor MSS.  \nBalch et al. (2 010) To determine the \nsurvival rates and \nindependent \npredictors of \nsurvival  using a \ncontemporary \ninternational cohort Cohort study  \n \n 2313 patients with \nstage III disease  Overall survival  5-year survival for \npatients with \nmicrometastases: \n67% \n \nWhen stratified by \ntumor thickness, Patient cohort \npartially identical \nwith Balch et al. \n2004 and 2009  \n \nFor survival curves \nsee original article  2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 223 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE  \nof patients with \nstage III melanoma.  ulceration, an d \nnumber of involved \nnodes, 5 -year-\nsuvival rates were: \n87% for a single \nnodal \nmicrometastasis \narising from a \nnonulcerated \nprimary melanoma \n\uf0a3 2.0 mm in \nthickness, 23% for \npatients with four or \nmore nodal \nmacrometastases \nfrom an ulcerated \nprimary melanoma \ngreater than 6.0 \nmm in thickness  \n \nFor patients with \nnodal \nmicrometastases \nindependent \npredictors of \nsurvival were \npatient age, sex,  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 224 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE  \ntumor thickness, \nulceration, primary \nanatomic site, and \nnumber of tumor -\nbearing lymph \nnodes  \n \nFor patients with \nnodal \nmacrometa stases, \nage, ulceration, \nanatomic site, and \nnumber of tumor -\nbearing lymph \nnodes \nindependently \npredicted survival  \nMeier et al. (2010)  To compare  the RFS \nand OS of 697 \nmelanoma patients \nas predicted by \nvarious \nclassification \nsystems.  Cohort study  \n \n 697 consecutive \npatients with \nprimary cutaneous \nmelanoma (Bresl ow \ntumor thickness \u2265 1 \nmm) Recurrence -free \nsurvival  \n \nOverall survival  CLND positivity rate \n15.4%  \n \n21% recurrence rate  \n \n14% mortality rate \n(causes related to \nmelanoma)  \n \nIn multivariate Suggestion of new \nclassification \nsystem Hannover II  2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 225 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE  \nanalysis, \nindependent \npredictors for RFS \nwere greatest \ndimension of the \nlargest tumor cell \ndeposit (cutoff \npoint, <0.1 mm vs \n\u2265 0.1 mm), TPD \n(cutoff point, \uf0a3 2 \nmm vs >2 mm), and \ncapsular \ninvolvement; TPD \nand capsular \ninvolvement also for \nOS \nBalch et al. (2009)  To revise th e \nstaging system for \ncutaneous \nmelanoma on the \nbasis of data from \nan expanded \nAmerican Joint \nCommittee on \nCancer (AJCC) \nMelanoma Staging \nDatabase.  Cohort study  \n \n 3,307 stage III \npatients.  Overall survival  Independent \npredictors for \nsurvival: number of \ntumo r-bearing \nnodes, tumor \nburden at the time \nof staging (ie, \nmicroscopic v \nmacroscopic), \npresence or absence \nof primary tumor For stage III survival \ncurves, see Fig. 1 in \nthe publication.  \n \nPatient cohort \npartially identical \nwith Balch et al. \n2004  2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 226 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE  \nulceration, and \nthickness of the \nprimary melanoma  \n \n5-year survival \nrates: 70% for \npatients with T1 -\n4N1M0 melanomas,  \n39% for patient s \nwith T1 -4N3M0 \nmelanomas  \nvan Akkooi et al. \n(2008 ) to evaluate the \nsurvival rate of  \nminimal SN tumor \nburden  Cohort study  388 SN po sitive \npatients  overall survival (OS)  SN tumor burden \nincreased \nsignificantly with \ntumor thickness.  \n \nestimated 5 -year \noverall survival:  \n- for SUB -\nmicrometastases  \n<0.1 mm SN tumor \nburden: 91%  \n- for 0.1 - to 1.0 -\nmm SN tumor \nburden:  61%  \n- for >1 mm SN \ntumor burden: 51%  Retrospective \ndesign  2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 227 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE  \n- for </=0.2 mm: \n89%. \n \nIndependent \nprongostic factors \nin OS (multivariate \nanalysisi):  \n- SN tumor burden  \n- T4 primary \ntumors  \nSatzger et al. \n(2008)  To compare \ndifferent \nparameters of the \nSLN and to identify \nthe paramet ers that \nare most important \nfor the prediction of \nnon-sentinel lymph \nnode (NSLN) \ninvolvement.  Cohort study  \n \n 180 patients with \nprimary cutaneous \nmelanoma  NSLN involvement  NSLN involvement \nin the CLND \nspecimen in 16.0% \nof patients  \n \nPrimary melanomas \nsignif icantly thicker, \nmore often \nulcerated, and \nregressive in \npatients with NSLN \ninvolvement \ncompared with \npatients without \nNSLN involvement  \n \nUpon multivariate Patient population \nsubgroup of Meier \net al. (2010)  2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 228 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE  \nanalysis, the three \nsignificant \nparameters were \npositivity by H&E \n(versus \nimmunohistochemis\ntry alone) , relative \ntumor area > 10%, \nand presence of \nperinodal \nintralymphatic \ntumor  \nDebarbieux e t al. \n(2007)  To confirm the \nprognostic value of \nSLN biopsy (SLNB); \nto correlate patient \nprognosis to the \nmicromor phometric \nfeatures of SLN \nmetastasis in SLN -\npositive patients; \nand to correlate \nthese \nmicromorphometric \nfeatures to the \nlikelihood of \npositive completion Cohort study  \n \n 455 patients  Overall survival  \n \nDisease -specific \nsurvival  SLN positivity rate \n22% \n \nSurvival significantly \nshorter in SLN -\npositive than in \nSLN-negative \npatients  \n \nPrognostic factor of \ndisease -free \nsurvival: \nextracapsular \ninvasion  \n 10 patients lost to \nfollow -up 2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 229 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE  \nlymph node \ndissection (CLND).  Prognostic factors \nof disease -specific \nsurvival: ulceration, \nmaximum diameter \nof lar gest \nmetastasis  \nSatzger et al. \n(2007 a) To determine the \nprognostic \nrelevance of \nhistopathological \ncharacteristics of \nmicrometastases in \nthe SLN.  Cohort study  \n 169 patients with \nprimary cutaneous \nmelanoma \n(Breslow\u2019s tumour \nthickness \u2265 1 mm) \nand positive SLN \ndiagnosed from \nApril 2000 to \nDecember 2004.  Overall survival (OS)  \n \nRelapse -free \nsurvival (RFS)  Relapse rate 30%  \n \nMortality rate 20% \n(15% melanoma -\nrelated, 5% \nunrelated)  \n \nIndependent \nprognostic factors \nin multivariate \nanalysis:  \ninvasion of capsule \n(present versus \nabsent), tumor \npenetrative depth \n(TPD) with a cut -off \nof 2 mm (< 2 mm \nversus \u2265 2 mm) and \ndeposit size (< 30 \ncells versus \u2265 30 \ncells)  Patient population \nsubgroup of Meier \net al. (2010)  2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 230 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE  \nvan Akkooi et al. \n(2006)  to identify  a SN \npositive patient \ngroup, which can be \nspared CLND  Cohort study  \n 77 SN -positive \npatients  \n Disease -free \nsurvival  \n \nEstimated 5 -year \nsurvival  \n \nNon-SN-positivity  \n Estimated 5 -year \nOS rates:  \n<0.1 mm SN tumor \nburden: 100%  \n0.1\u20131.0 mm SN \ntumor burden:  \n63%  \n>1.0 mm SN tumor \nburden: 35%  \n \nDistant metastases \nin <0,1 mm SN -\npositive patients:  \n1/16 = 6.3%  \n \nDistant metastasis -\nfree survival in <0,1 \nmm SN positive \npatients: 91%  \n(identical to the 5 -\nyr OS of SN negative \npatients)  \n \nno additional non -\nSN positivity for S N-\nmicro -metastases \n<0.1 mm.  Retrospective \ndesign  2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 231 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE  \n \nmultivariate \nanalysis: SN tumor \nburden was the \nmost important \nprognostic factor \nfor DFS (P = 0.005) \nand OS (P = 0.03).  \nShivers et al. (2007)  To determine the \nrelevance of low -\nvolume disease of \nthe sent inel lymph \nnode detected only \nby RT -PCR-based \nassays.  Cohort study  \n \n 311 Patients with \nmelanoma  Overall survival  \n \nRelapse -free \nsurvival  \n \nSensitivity and \nspecificity of \nhistology and PCR \nregarding the \nprediction of \nrecurrence/death  SLN positivity rate: \n19% in histology, \n67% by PCR  \n \nRecurrence rate:  \n42% of histologically \nand PCR positive \npatients  \n22% of histologically \nnegative, but PCR \npositive patients  \n6.6% for \nhistologically and \nPCR negative \npatients  \n \nPrediction of death:  \nSensitivity of \nhistology 47%, Very long follow -up \ntime (up to 15 \nyears)  \n \nChange in \ntechnique during \nthe course of time  2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 232 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE  \nspecificity 87%  \nSensitivity of PCR \n88%, specificity 38%  \nBaehner et al. \n(2012 ) To (1) quantitate \ntumor burden in \nsentinel lymph \nnodes (SLNs), and \n(2) assess the \nindepe ndent \ncontributions of SLN \ntumor burden and \nprimary melanoma \nthickness (PMT) \nwith respect to \nprogression -free \nsurvival (PFS) and \noverall survival (OS).  Cohort study  \n 63 patients with \none or more \npositive SLNs were \navailable  Progression -free \nsurvival (PFS)  \n \nOS Cox proportional -\nhazard regression \nmodel: After \nadjusting for age \nand gender, both \nMMS maximum \nmetastasis size \n(MMS)and PMT \nprimary melanoma \nthickness were \nhighly significant \nand provided \nindependent \nprognostic \ninformation.   2b- \nFink et al. (2011 ) to predict the  \nlikelihood of further \nnon-SN metastases \non the basis of  \nearlier published \nmicromorphometric \nclassifications of SN  \nmetastases  Cohort study  Specimens of 124 \npositive -SN basins \nand subsequent  \ncomplete lymph \nnode dissection \n(121 patients)  NSN-posit ivity metastases in non -\nSNs were found in \n30 lymph node  \nbasins (24.2%).  \n \nClassification \naccording to Dewar:  \nSignificant Retrospective study  2b-  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 233 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE  \ncorrelation between \nthe microanatomic \nlocation of the \nmetastases and \nnon-SN involvement \n(P=0.004).  \n \nClassification \naccording to Starz:  \nSignificant \ncorrelation between \nS.classification of \nSN and non -SN \nstatus (P<0.001)  \n \nClassification of the \nsize of the SN \nmetastases \naccording  \nto the Rotterdam \ncriteria for SN \ntumor burden: \nsignificant \ncorrelation with \nadditional non -SN \ninvolvement  \n(P=0.00 7)   \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 234 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE  \n \nno statistically \nsignificant \ndifference between \nthe three \nclassifications \n(P=0.6).  \nMurali et al. (2010)  To investigate \nclinicopathologic \nfactors that predict \nNSN positivity in an \nattempt to identify \npatients who may \nbe safely spared \ncompletion lymph \nnode dissection \n(CLND).  Cohort study  \n \n 409 patients  NSN positivity  \n \n Predictive of NSN \nstatus in \nmuultivariate \nanalysis:  \nclinical \ncharacteristics (sex), \nprimary tumor \ncharacteristics \n(ulceration and \nregression), and \n%PosSN  Retrospe ctive \ndesign  \n \nFor details of the \nscore, see original \narticle  2b- \nRiber -Hansen et al. \n(2009)  To use objective \nstereological \ntechniques to \ncorrelate accurately \ntotal SLN tumour \nburden with \nrecurrence and \npatient survival.  Cohort study  \n \n 335 consecutive \nmelanoma patients  Recurrence rate  \n \nOverall survival  SLN positivity rate \n30.3%  \n \nBenign naevus \ninclusions in 36.1% \nof  SLN patients  \n \nRecurrence rate Description of study \ndrop-outs \ndescribed in \nanother publication  2b-  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 235 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE  \n10.4% (25.3% for \npatients positive in \nhistology, 3.9% for \nnegative patients)  \n \nMortality rate from \nmetastatic dis ease \n6.7% (14.1% for \npatients positive in \nhistology, 3.5% for \nnegative patients)  \nVan der Ploeg et al. \n(2009)  To evaluate the \nmicromorphometric  \nStarz classification \nin melanoma \npatients.  Cohort study  \n \n 70 patients with a \ncutaneous \nmelanoma  Disease -free \nsurvival (DFS)  Lymph node \nrecurrence rate:  \n0% in S -I, S-II \n12% in S -III \n \nOverall 3 -year \nsurvival:  \n100% in S -I, S-II  \n80% in S -III  \n \n3-year disease -free \nsurvival rates: were \n83% in S -I, S-II  \n60% in S -III  Small patient cohort  2b- \nFrankel et al. (2008)  To examine whether Cohort study  144 melanoma Presence of Independent Design not 2b-  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 236 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE  \nthe size and \nlocation of the \nmetastases within \nthe SLN may help \nfurther stratify the \nrisk of additional \npositive NSLN.   \n patients  metas tatic non -\nsentinel nodes  predictors of \nadditional disease \nin CLND:  \nprimary location on \nthe head and neck \nor lower extremity, \nBreslow thickness > \n4 mm, the presence \nof angiolymphatic \ninvasion, \nsatellitosis, \nextranodal \nextension, three or \nmore po sitive SLN \nand tumor burden \nwithin the SLN>1% \nsurface area  consequently \nprospective  \nSatzger et al. \n(2007b)  To determine the \nprognostic \nsignificance of \nisolated HMB45 \nand/or Melan A \npositive cells \n(immunhistochemic\nally positive cells, \nIPC) i n melanoma \nSLN. Cohort study  \n \n 477 patients with \nprimary cutaneous \nmelanoma  Overall survival (OS)  \n \nRelapse -free \nsurvival (RFS)  3 groups were \ndifferentiated \naccording to the \nfindings in the SLN: \nGroup 1 included \n308 patients with \nhistologically and \nimmunoh istochemic\nally negative SLN, \ngroup 2 included 47 Patient population \nsubgroup of Meier \net al. (2010)  2b-  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 237 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE  \npatients with IPC, \nand group 3 \nincluded 122 \npatients with \nmicrometastases.  \n \nRelapse rate: 11.7% \nof SLN negative \npatients, 12.8% of \nIPC+ patients, \n37.7% of histology+ \npatients  \n \nMortality rate: 5.5% \nof SLN neg ative \npatients, 6.4% of \nIPC+ patients, \n23.8% of histology+ \npatients  \nNamikawa et al. \n(2012 ) to re-evaluate \nmicroscopic \nclassifications of \nmetastatic sentinel \nlymph nodes (SLN) \nin the Japanese \npopulatio n Cohort study  \n 450 patients, \nincluding the 149 \ncases with SLN \nmetastasis,  LN positivity -rate additional LN \npositivity rate of 0% \nonly in patients with \na maximum \ndiameter category \nof less than 0.1 \nmm.  \n retrospect ive study  3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 238 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE  \nAs compared with \nthat in the SLN \nmetastasis -negative \ncases, the \nprognosis was \npoorer in cases with \nSLN metastasis, \neven those with \nlesions falling under \nthe maximum \ndiameter category \nof less than 0.1 \nmm, invasion depth \ncategory of SI \n(</=0.3 mm) and \nmicroanatomic \nlocation category of \nsubcapsular.  \nStarz et al. (2004 ) to identify the \nrelevant predictors \nfor the presence \nversus absence of \nnonsentinel lymph \nnode metastases in \nCLND specimens  Cohort study  \n SLNE cohort: 324 \npatients  \n \npre-SLNE \ncohort:274 \nconsecutive \nmelanoma patients  Overall  survival  \n \nsurvival without \ndistant metastases  S-classification  \nwas the most \nsignificant \nindependent \npredictor of the  \npresence/absence \nof NSN -metastases \nin binary logistic \nregression: (P = Patients who \nunderwent SLNE \uf0e0 \nsame population as \nin Starz et al. 2001 \n(see above)  3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 239 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE  \n.010; adjusted \nrelative risk = 3.31).  \n \nsurvival without \ndistant met astases: \nHighly significant \ndivergence of the  \nKaplan -Meier \ncurves of the pre -\nSLNE- and SLNE -\ncohort (P = .0057 \nby log rank test).  \n \nOverall survival:  \nKaplan -Meier \ncurves diverge after \nabout 4 years of \nfollow -up (P -= .03).  \n \nCox regressions: S -\nclassificatio n is a \nsignificant \nindependent \npredictor for distant \nmetastasis (P = \n.014) and overall \nsurvival (P = .009)   \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 240 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE  \nBogenrieder et al. \n(2011 ) to predict the \nabsence of non -SN \nmetastases  \nin a multicentre \nstudy of patients \nwith a positive SN  \nbased on primary \nmelanoma features \nand SN tumour  \nload.  Cohort study  \n 70 SN positive \npatients  NSN-positivity  18/70 patients had \nnon-SN metastases.  \n \nNo non -SN-\nmetastases in \npatients with:  \n- a Bres low \nthickness <2.0 mm \nand an SN  \ntumour load <0.2 \nmm2  \n- a Breslow  \nthickness <2.0 mm \nand SN penetrative \ndepth <600 lm  \n- a Breslow \nthickness <2.0 mm \nand a diameter of \nthe largest SN \ndeposit <500 lm  \n \nlogistic regression: \nthe SN metastatic  \narea was the only \nindependent factor \npredicting the  \npresence of non -SN Differences in \nsurvival between \ndifferent \nmicroanatomic \nlocations of sentinel \nnode metastases \nnot investigated  \n \nNo follow -up \n 3b-  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 241 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE  \nmetastases  \nDewar et al. (2004)  to identify criteria \nthat might be used  \nin selecting patients \nwho should \nundergo CLND  Cohort study  \n \n \n \n 146 SN -positive \npatients  \n NSN-positivity   evidence of \nmelanoma \nmetastases in NSN \nin 24 of CLND \nspecimens (16.4%)  \n \nsignificant \ncorrelation between \nthe microanatomic \nlocation and NSN \ninvolvement \n(subcapsular \nmetastatic deposits \nin 26%: no NSN -\ninvolvement.  \nSN-metastases  \nwith different \nmicroanatomic \nlocation: NSN -\ninvolvement in \n22,2%)  \n \nstrong correlation \nbetween depth of \nmetastatic deposit \nfrom the capsule of Retrospective study  \n \ndifferences  \nin survival between \ndifferent \nmicroanatomic \nlocations of sentinel \nnode metastases \nnot investigated  \n \nNo follow -up \n \n 3b-  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 242 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE  \nthe SN and NSN \ninvolvement (3/24 \npatien ts (12.5%) \nwith positive NSNs \nhad deposits less \nthan 1mmin depth.)  \nStarz et al. (2001)  predictive capac ity \nof S-classification  \n Cohort study  \n \n \n \n 342 patients with \nprimary melanoma \nand SLNE (389 \nlymph node  \nRegions)  \n \n62 patients with \npositive SLNs:  \n \n42 received RCLND  \n \n \n Presence of \nmetastases  \n \nsurvival  325 SLNs: S0  \n24 SLNs: S1  \n22 SLNs: S2  \n18 SLNs: S3.  \n \nCorre lation of the S \ncategories with the \nT categories (of the  \npTNM classification) \n(Spearman \ncorrelation; P = \n0.0001),  \n \noccurrence of \nmelanoma -positive \nnon-SLN \nsignificantly \nincreased from 0 of \n12 in S1 SLNs to 2 \nof 13 in S2 SLNs \nand 9 of 15 in S3 Short follow -up \n \nUlceration of the \nprimary melanoma \nnot included in this \nanalysis  \n \n(multivariate \nanalysis directly \nusing the T and S \nclassifications as \nvariables was not \npossible)  \n \n \n \n 3b-  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 243 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE  \nSLNs (P = 0.0 01; \nchi-square test).  \n \nThe risk of \ndeveloping distant \nmetastases was \ndependent on the T \nclassification (P < \n0.0001; log rank \ntest) and S -\nclassification (P < \n0.0001)  \n \nT classification of \nthe primary \nmelanoma and S -\nclassification= \nhighly significant \npredic tor for distant \nmetastasis (P < \n0.001).  \n \nIt turned out to be \nan independent \nfactor of influence \non distant \nmetastasis and  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 244 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE  \nsurvival in \nmultivariate Cox \nanalyses, which \nincluded tumor \nthickness, primary \ntumor site, patient \ngender, and patient \nage as covaria tes. \n \n2.2.4.  Literatur  \n \nBaehner FL, Li R, Jenkins T, et al. The Impact of Primary Melanoma Thickness and Microscopic Tumor Burden in Sentinel Lymph Nodes on Melanoma Patient Survival. Ann Surg \nOncol 2011  \nBalch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009;2 7:6199 -6206  \nBalch CM, Gershenwald JE, Soong SJ, et al. Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases  \nversus macrometastases. J Clin Oncol 2010;28:2452 -2459  \nBogenrieder T, van D ijk MR, Blokx WA, et al. No non -sentinel node involvement in melanoma patients with limited Breslow thickness and low sentinel node tumour load. \nHistopathology 2011;59:318 -326 \nDebarbieux S, Duru G, Dalle S, et al. Sentinel lymph node biopsy in melanoma: a micromorphometric study relating to prognosis and completion lymph node dissection. Br J \nDermatol 2007;157:58 -67 \nDewar DJ, Newell B, Green MA, et al. The microanatomic location of metastatic melanoma in sentinel lymph nodes predicts nonsentinel lymph node involvement. J Clin Oncol \n2004;22:3345 -3349  \nElsaesser O, Leiter U, Buettner PG, et al. Prognosis of Sentinel Node Staged Patients with Primary Cutaneous Melanoma. PLoS One 2012;7:e29791  \nFink AM, Weihsengruber F, Duschek N, et al. Value of micromorphometric  criteria of sentinel lymph node metastases in predicting further nonsentinel lymph node metastases \nin patients with melanoma. Melanoma Res 2011;21:139 -143 \nFrankel TL, Griffith KA, Lowe L, et al. Do micromorphometric features of metastatic deposits within sentinel nodes predict nonsentinel lymph node involvement in melanoma? \nAnn Surg Oncol 2008;15:2403 -2411  \nMeier A, Satzger I, Volker B, et al. Comparison of classification systems in melanoma sentinel lymph nodes --an analysis of 697 patients from a single ce nter. Cancer \n2010;116:3178 -3188  \nMocellin S, Hoon DS, Pilati P, et al. Sentinel lymph node molecular ultrastaging in patients with melanoma: a systematic review and meta -analysis of prognosis. J Clin Oncol \n2007;25:1588 -1595  \nMurali R, Desilva C, Thompson JF,  et al. Factors predicting recurrence and survival in sentinel lymph node -positive melanoma patients. Ann Surg 2011;253:1155 -1164  \nMurali R, Desilva C, Thompson JF, et al. Non -Sentinel Node Risk Score (N -SNORE): a scoring system for accurately stratifying r isk of non -sentinel node positivity in patients with \ncutaneous melanoma with positive sentinel lymph nodes. J Clin Oncol 2010;28:4441 -4449   \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 245 von 732 Namikawa K, Yamazaki N, Nakai Y, et al. Prediction of additional lymph node positivity and clinical outcome of microm etastases in sentinel lymph nodes in cutaneous \nmelanoma: A multi -institutional study of 450 patients in Japan. J Dermatol 2012;39:130 -137 \nQuaglino P, Ribero S, Osella -Abate S, et al. Clinico -pathologic features of primary melanoma and sentinel lymph node p redictive for non -sentinel lymph node involvement and \noverall survival in melanoma patients: A single centre observational cohort study. Surg Oncol 2011;20:259 -264 \nRiber -Hansen R, Nyengaard JR, Hamilton -Dutoit SJ, et al. Metastatic melanoma volume in senti nel nodes: objective stereology -based measurement predicts disease recurrence \nand survival. Histopathology 2009;54:796 -803 \nSatzger I, Volker B, Al Ghazal M, et al. Prognostic significance of histopathological parameters in sentinel nodes of melanoma patien ts. Histopathology 2007;50:764 -772 \nSatzger I, Volker B, Meier A, et al. Criteria in sentinel lymph nodes of melanoma patients that predict involvement of nonsen tinel lymph nodes. Ann Surg Oncol 2008;15:1723 -\n1732  \nShivers S, Jakub J, Pendas S, et al. Molecul ar staging for patients with malignant melanoma. Expert Rev Anticancer Ther 2007;7:1665 -1674  \nStarz H, Balda BR, Kramer KU, et al. A micromorphometry -based concept for routine classification of sentinel lymph node metastases and its clinical relevance for p atients with \nmelanoma. Cancer 2001;91:2110 -2121  \nStarz H, Siedlecki K, Balda BR. Sentinel lymphonodectomy and s -classification: a successful strategy for better prediction and improvement of outcome of melanoma. Ann Surg \nOncol 2004;11:162S -8S \nvan Akkooi AC,  de Wilt JH, Verhoef C, et al. Clinical relevance of melanoma micrometastases (<0.1 mm) in sentinel nodes: are these nodes to be considered negative? Ann \nOncol 2006;17:1578 -1585  \nvan Akkooi AC, Nowecki ZI, Voit C, et al. Sentinel node tumor burden according  to the Rotterdam criteria is the most important prognostic factor for survival in melanoma \npatients: a multicenter study in 388 patients with positive sentinel nodes. Ann Surg 2008;248:949 -955 \nvan der Ploeg AP, van Akkooi AC, Rutkowski P, et al. Prognosis  in Patients With Sentinel Node -Positive Melanoma Is Accurately Defined by the Combined Rotterdam Tumor Load \nand Dewar Topography Criteria. J Clin Oncol 2011  \nvan der Ploeg IM, Kroon BB, Antonini N, et al. Is completion lymph node dissection needed in case of minimal melanoma metastasis in the sentinel node? Ann Surg \n2009;249:1003 -1007  \n \n \n \n \n \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 246 von 732 3. AG Chirurgische Therapie  \n3.1. Frage III.1. Sicherheitsabst\u00e4nde bei Prim\u00e4rexzision  \u2013 De-novo-Recherche  \nFrage III.1 . Welche Sicherheitsabst\u00e4nde sollen bei radikaler Exzision de s Prim\u00e4rtumors eingehalten werden?  \n3.1.1.  PICO, Suchw\u00f6rter  \n \nSuchw\u00f6rter  \nStichwort  melanoma  therapy, treatment, management, surgery, surgical procedures, excision  \nSynonyme  melanoma  safety margin, excision margin, surgical ma rgin, narrow, wide  \nOber -/Unterbegriffe , Mesh Term  s. Such sstrategie  \n \n3.1.2.  Datenbanken, Suchstrategien, Trefferzahlen  \nDatenbank  Suchstrategie  Datum  Treffer \n1. Suche     \nMedline  \"melanoma\"[tiab] AND (\u201ctherapy\u201d[all fields] OR \u201ctreatment\u201d[all fields] OR \n\u201cmanag ement\u201d[all fields] OR \" surgery \"[all field s] OR \u201csurgical\u201d[all fields] OR \u201csurgical \nprocedures, operative\u201d[mesh] OR \"excision\"[all fields]) AND (\u201csafety margin\u201d[all fields] \nOR \u201cexcision margin\u201d[all fields] OR \u201csu rgical margin\u201d[all fields] OR \u201cnarrow\u201d[all fields] \nOR \u201cwide\u201d[all fields])  26.01.2012  1235 \nCochrane Library  (melanoma and (therapy or treatment or management or surgery or surgical or \nexcision) and (\"safety margin\" or \"excision margin\" or \"surgical margin\" or narrow or 19.01.2012  51  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 247 von 732 wide)).ti,ab.  \nEmbase  (melanoma and (therapy or treatment or management or surgery or surgical or \nexcision) and (\"safety margin\" or \"excision margin\" or \"surgical margin\" or narrow or \nwide)).ti,ab.  23.01.2012  1642  \nBemerkungen:  \nEine erste Literaturrecherche in Medline und und Cochrane erfolgte am 06.09.2010 bzw.  f\u00fcr Embase am 11.05.2011. Die Update -Recherche wurde am \n23.01.2012 (Embase) bzw. am 26.01.2012 f\u00fcr Medline und am 19.01.2012 f\u00fcr Cochrane durchgef\u00fchrt. In der Tabelle angegeben sind  die Treffe rzahlen der \nletzten Recherche.  \n \n3.1.3.  Auswahlkriterien  \nAuswahl der L iteratur  \nGesamttreffer  2928  \nEinschlusskriterien  Thematische \u00dcbereinstimmung  \nSprachen: e,dt  \nVer\u00f6ffentlichung ab 1970  \nAusschlusskriterien  Case Reports  (Case series included) , narrative Reviews  \nAnzahl nach Abstractscreening  61 \nAnzahl ausgew\u00e4hlter Volltex te, vorges ehen f\u00fcr Bewertung  12 \n \n \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 248 von 732 3.1.4.  Evidenztabelle  \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nMocellin et al.  \n(2011 ) To quantify the \nimpact of excision \nmargins on disease -\nspecific survival of \npatients with \nprimary cutaneous \nmelanoma  syste matic review of \nRCT with Meta -\nanalysis  5 eligible RCT  \n \nA total of 3295 \npatients enrolled  \n(1633 (49.5%) were \nallocated to narrow \nexcision and 1662  \n(50.5%) to wide \nexcision)  locoregional \ndisease -free (LDFS)  \n \ndisease -free (DFS)  \n \ndisease -specific \n(DSS)  \n \novera ll survival  \n \n. Narrow margins: \nrisk of both \nlocoregional disease \nrecurrence (HR: \n1.30, CI: 1.07 \u2014\n1.57; P = 0.01) and \ndeath by disease \n(HR: 1.28, CI: 1.07 \u2014\n1.53, P = 0.01). As \nregards DFS, the \nborderline \ndisadvantage (HR: \n1.13, CI: 0.995 \u2014\n1.28; P = 0.06) \nbecomes significant \nwhen considering \nRCT that enrolled \npatients with thicker \nmelanoma (HR: \n1.19, CI: 1.02 \u2014\n1.39, P = 0.03). \nWhen death by any \ncause (OS) was \nanalyzed: narrow vs. \nwide excision \nmargins (HR: 1.05, The lack of DSS data \nfrom all the \navailable RCT  \n \n \n4 of the 5 RCT \nincluded in \nsystematic review of \nSladden et al. 2010 \n(Cohn -Cedermark et \nal (2000), Balch et al \n(2001), Khayat et al \n(2003), Thomas et \nal (2004)  1a  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 249 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \n95%CI: 0.95 \u2013 \n1.16, P = 0.32  \nSladden et al. \n(2010)  To assess the \neffects of different \nexcisio n margins for \nprimary cutaneous \nmelanoma.  \n Systematic review of \n5 randomised \ncontrolled trials \n(RCTs) of surgical \nexcision of \nmelanoma \ncomparing different \nwidth excision \nmargins  \n 1633 participants in \nthe narrow excision \nmargin group and \n1664 in the wide \nexcision margin \ngroup  Primary outcomes:  \n1. Time to death \n(any cause)  \n2. Time to \ncombined endpoint \nof death (any cause) \nor recurrence  \n(local, in transit, \nregional, distant)  \n \nSecondary \noutcomes:  \n1. Quality of Life  \n2. Adverse \nevents/outcomes  No significant \ndifference in overall \nsurvival when \ncomparing narrow \nwith wide excision  \n \nOverall survival wide \nexcision: Hazard \nRatio 1.04 \ncompared with \nnarrow excision; not \nsignificant  \n \nRecurrence -free \nsurvival wide \nexcision: Hazard \nRatio 1.13 \ncompared with \nnarrow excision; not \nsignificant  Limited RCT data \nassessing treatment \nof thin melanomas \n< 1 mm and thick \nmelanomas \u2265 4 \nmm. \n \n \nMelanomas in \nspecific body sites \nnot sufficiently \ninvestigated  \n \n 1a \n \nGillgren et al. (2011 )  to test whether \nsurvival was diff \nerent for a wide \nlocal excision  randomised,  \nmulticentre trial  936 patients with \ncutaneous \nmelanoma thicker \nthan 2 mm, at Overall survival  5-year overall  \nsurvival was 65% \n(95% CI 60 \u201369) in \nthe 2 -cm group and  1b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 250 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \nmarg in of 2 cm \ncompared with a 4 -\ncm excision margin  clinical stage IIA \u2013C \n \n(465 were randomly \nallocated to \ntreatment with a 2 -\ncm resection \nmargin, 471 to \nreceive treatment \nwith a 4 -cm \nresection margin)  65% (60 \u201370) in the \n4-cm group \n(p=0\u00b769)  \n \nSubtopic: Margins in \nspecial localizations         \nJahn et al. (2006)  To define \nprognostic fact ors \nfor melanoma of the \near and to evaluate \nsurgical strategies \nfor excision \nmargins, \nhistological \nevaluation and \nsentinel lymph node \nbiopsy (SLNB) in \norder to achieve \nbetter cosmetic and \nfunctional results.  Prognostic study  \n \n 161 patients with \nstage I and  II \nmelanoma of the \nexternal ear.  \n Recurrence -free and \ndisease -specific \nsurvival  Recurrence -free \nsurvival rate 83% \nover 3 years and \n79% over 5 years  \n \nTumour thickness \nand Clark invasion \nlevel were the only  \nsignificant risk \nfactors for disease -\nspecific surv ival in  \nKaplan \u2013Meier \nunivariate analysis.  Prospective study \ndesign  \n \nPatients not \nrandomized \nbetween groups \nwith different \nexcision margins; \nrecommendations \nfor excision margins \nwere reduced during \nthe observation \nperiod (1976 \u2013 \n2004); confounding 2b-  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 251 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \nby other historical \nfactors possible.  \n \nFor details on \nrecurrence -free \nsurvival in relation \nto surgical margin, \nsee Fig. 2 in full -\ntext of the article.  \nHazan et al. (2008)  To review clinical \nand histologic \nfeatures of lentigo \nmaligna (LM) and \nlentigo maligna \nmelanoma (LMM) \nand determine \nsurgical margin \nnecessary for \ncomplete excision.  Cross -sectional \nstudy  \n \n 117 patients  Required surgical \nmargin and number \nof stages for \ncomplete excision \nof LM and LMM  Mean total surgical \nmargin required for \nexcision of LM: 7.1  \nmm and 10.3 mm \nfor LMM  \n \nMean number of \nstages required to \ncompletely excise a \nlesion: 1.67  Small number of \ninvasive melanoma  \n \nNo data about \nrecurrence rates  3b \nFurukawa et al. \n(2007)  To evaluate how \namputation level \nand cutaneous \nmargin affects \nprognos is and \nreconstructive \nchoice.  Prognostic study  \n \n 15 patients (6 men, \n9 women) with \nmelanoma of the \nthumb between  Disease -free \nsurvival  \n \n Significant \nprognostic factors: \nstage and thickness  \n \nLevel of amputation \nand excision margin \nnot significant  Small pat ient \nsample  \n \n 3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 252 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \nMohrle et al. (2003)  To evaluate clinical \nparameters and \nsurgical strategies \ninfluencing the \nprognosis of \npatients with facial \nmelanoma.  Prognostic study  \n \nSurvival and history \nof 3960 patients in \nstages I and II were \nprospectively \nrecord ed between \n1980 and 1999. Of \nthese, 368 \nmelanomas were \nlocalized in the face, \n140 on the \ncapillitium and 76 \non the neck.  \n \nSurgical margins \nwere successively \nreduced during the \nobservation period, \nstarting from 5 cm \nin 1980.  \n \nFor functional and \naesthetic re asons, \nrecommendations \nfor surgical margins \ncould not always be 368 patients with \nfacial melanoma  Overall survival (5 \nyears)  \n \nRecurrence -free \nsurvival (5 years)  Significant \npredictors for \nsurvival: tumour \nthickness, C lark \nlevel and ulceration, \nsurgery with 3D \nhistology and \nhistological tumour \nsubtype  \n Patients not \nrandomized \nbetween groups \nwith different \nexcision margins; \nrecommendations \nfor excision margins \nwere reduced during \nthe observation \nperiod (1976 \u2013 \n2004); co nfounding \nby other historical \nfactors possible.  3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 253 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \nfollowed in the head \nand neck regions.  \nPockaj et al. (2003)  To evaluate the \nprognostic variables \nand clinical \nramifications of \nmelanoma of the \near. Prognostic study, \nretrospective design  \n \n 84 patients with \ninvasive melanoma \nof the external ear  \n Lymph node \ninvolvement  \n \nLocal, regional and \nsystemic recurrence  Local recurrence in \n13% \n \nRecurrence of \nmelanoma in the \nlymph nodes in 12%  \n \nSystemic metastases \nin 22%  \n \nType of resection \ndid not influence \nsystemic recurrence \n(P=0.41)  Retrospective \ndesign  \n \nPatient numbers not \nsufficient for an \nevaluation of the \ninfluence of \ndifferent surgical \nprocedures on \nrecurrences  3b \nTseng et al. (1997)  The purpose of the \nstudy was to \ninvestigate the \nsurgical \nmanagement of \ncutaneous \nmelanomas of the \nhands and feet.  Prognostic study  \n \n 116 patients with \nmelanomas of the \nhands (n = 26) and \nfeet (n = 90)  Recurrence rate  In melanomas <1.5 \nmm thickness, no \nlocal recurrences  \n \nMetastases \ndeveloped in 5%  \n \nNo local recurrence \nor metastasis in \npatients with < 1.5 No control groups  \n \nData on elective \nlymph node \ndissection biased \n(decision about \nELND was left to the \nsurgeon) and not \nsufficient (small \nnumbers of 3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 254 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \nmm acral -\nlentigino us \nmelanoma  \n \nOf 79 patients with \nmelanoma \u2265 1.5 \nmm, 15 (19%) \npresented with \nregional node \ndisease  \n \nAll 13 patients with \nsubungual \nmelanomas had \nlesions \u22651.5 mm in \nthickness; 6 (46%) \nof 13 had evidence \nof nodal disease at \nthe time of \npresentation or at \nELND or had \nregional node \nmetastases develop \nwithin 1 year of \ninitial diagnosis  \n \nIn patients with patients)   \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 255 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \nALM, 71% presented \nwith lesions \u22651.5 -\nmm thick and were \ntreated with wide \nexcision or \namputation; local \nrecurrence in two \n(6%) of these \npatients, but nodal \nmetastases or \nsyste mic disease or \nboth in 19 (56%) of \n34 patients  \nHudson et Krige \n(1995)  To analyse the \noutcome of local \ntreatment and \npatient survival \nusing a 3 cm local \nexcision margin and \nsplit skin grafting  Prognostic study  \n \n 16 men and 3 \nwomen  Overall survival  \n \nTime to progression  12 patients with \nstage I disease: \nmean Breslow depth \n2.7 mm  \n \nAll 12 had local \nexcision of the \nprimary lesion with \n3 cm margins and \nskin grafts applied \nto the galea; 6 \ndeveloped regional \nlymph node \nmetastases, 3 Very small patient \nnumbers  \n \nNo control group  3b-  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 256 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \ndeveloped systemic \nmetastases (all of \nwhom died)  \n \nOne patient \npresented with \nstage II disease and \ndeveloped local \nrecurrence  \n \n5 patients in stage \nIII disease were \ntreated by wide \nlocal excision and \ntherapeutic lymph \nnode dissection; all \ndied after a mean of \n9.6 months (range 3 \n\u2013 22 months)  \nThen et al. (2009)  To report early cure  \nrates for periocular \nmelanoma using \nSlow-Mohs surgery \nwith en -face margin \nsectioning.  Retrospective, \nmulticenter, \nnoncomparative \ncase series  \n \n. 14 patients with \nperiocular MM  Number of stages \nneeded for \ncomplete excision  \n \nRecurrence rate  most common site : \nlower eyelid (8/14, \n57.1%). Breslow \nthickness ranged \nfrom 0.27 to 1.70 \nmm, with four cases \nless than 0.76mm \nand one case Very low LoE (case \nseries, retrospective \ndesign)  4  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 257 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \ngreater than \n1.5mm. Five cases \nwere a Clark level II \nor greater. \nComplete excision \nwas achieved with \none level (6 cases) \nor two or thr ee \nlevels (8 cases), with \n2- to 3-mm \nmargins at each \nlevel in all but one \ncase. With median \nfollow -up of 36 \nmonths, there were \ntwo local \nrecurrences (2/14, \n14.3%).  \nSubtopic: Vertical \nmargins         \nKenad y et al. (1982 ) To determine \nwhether the \npresence oor \nabsence of muscle \nfasciae in patients \nwith stages 0 and I Retrospective \nprognostic study  \n \n 202 patients with \nprimary melanoma \nof the trunk and \nproximal limb s  Recurrence rate  \n \nSurvival rate  Sites of first \nrecurrence or \nsurvival not \nsignificantly \naffected by the \nexcision of fasciae  AJCC 1978 staging \nsystem used \nretrospectively  \n \nPossible \nconfounding by the 2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 258 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \nmalignant \nmelanoma \ncorrelates with \nprognosis.  fact that the control \ngroup is historical \n(other poten tial \nchanges in \nmelanoma \nmanagement in the \nmeantime)  \n \n3.1.5.  Literatur  \nFurukawa H, Tsutsumida A, Yamamoto Y, et al. Melanoma of thumb: retrospective study for amputation levels, surgical margin an d reconstruction. J Plast Reconstr Aesthet Surg \n2007;60:24 -31 \nGillgren P, Drzewiecki KT, Niin M, et al. 2 -Cm Versus 4 -Cm Surgical Excision Margins for Primary Cutaneous Melanoma Thicker than 2 Mm: a Randomised, Multicentre Trial. \nLancet 2011;378:1635 -1642  \nHazan C, Dusza SW, Delgado R, et al. Staged excision for lentig o maligna and lentigo maligna melanoma: A retrospective analysis of 117 cases. J Am Acad Dermatol \n2008;58:142 -148 \nHudson DA, Krige JE. Results of 3 cm excision margin for melanoma of the scalp. J R Coll Surg Edinb 1995;40:93 -96 \nJahn V, Breuninger H, Garbe C, et al. Melanoma of the ear: prognostic factors and surgical strategies. Br J Dermatol 2006;154:310 -318 \nKenady DE, Brown BW, McBride CM. Excision of underlying fascia with a primary malignant melanoma: effect on recurrence and su rvival rates. Surgery 198 2;92:615 -618 \nMocellin S, Pasquali S, Nitti D. The impact of surgery on survival of patients with cutaneous melanoma: revisiting the role o f primary tumor excision margins. Ann Surg \n2011;253:238 -243 \nMohrle M, Schippert W, Garbe C, et al. Prognostic paramete rs and surgical strategies for facial melanomas. J Dtsch Dermatol Ges 2003;1:457 -463 \nPockaj BA, Jaroszewski DE, DiCaudo DJ, et al. Changing surgical therapy for melanoma of the external ear. Ann Surg Oncol 2003;10:689 -696 \nSladden MJ, Balch C, Barzilai DA, et al. Surgical excision margins for primary cutaneous melanoma. Cochrane Database Syst Rev 2009;(4):CD004835  \nThen SY, Malhotra R, Barlow R, et al. Early cure rates with narrow -margin slow -Mohs surgery for periocular malignant melanoma. Dermatol Surg 2009; 35:17 -23 \nTseng JF, Tanabe KK, Gadd MA, et al. Surgical management of primary cutaneous melanomas of the hands and feet. Ann Surg 1997;225:544 -50; discussion 550 -3 \n \n \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 259 von 732 3.2. Frage III. 2. Prophylaktische Lymphadenektomie  - Adaptation  \nFrage III.2.  In welchen F\u00e4llen ist eine elektive (prophylaktische) LAD indiziert?  \n3.2.1.  Synopse Quellleitlinien  (kurz)  \nThema/Fragestellung  LL Austr alien  \nNew Zealand Guidelines \nGroup 2008  LL GB  \nNICE 2006  LL Frankreich  \nFrench National Authority \nfor Health 2005  LL Kanada  \nCancer Care O ntario 2 007 \nIn welchen F\u00e4llen ist die \nadjuvante (prophylaktische) \nLAD ind iziert?  Nicht empfohlen (I)  Keine Angaben  Prophylaktische LAD bringt \nkeinen Vorteil (A)  (nur relevant f\u00fcr \nmedikament\u00f6se Therapien ) \n \n3.2.2.  Empfehlung,  Hintergrundstext und Literatur Australische  Quell Leitlinie  \n(mit Seitenangaben der Quellleitlinie)  \n LL Austr alien  \nNew Zealand Guidelines Group \n2008  LL GB  \nNICE 2006  LL Frankreich  \nFrench National Authority for \nHealth 2005  \nSchl\u00fcsselempfe hlungen  keine  \n \n keine  \n S. 42  \n \nStandard  \nLe curage prophylactiqu e syst \u00e9matique \nest contre -indiqu\u00e9.  \n \nStandard  \nDie prophylaktische LAD ist  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 260 von 732  LL Austr alien  \nNew Zealand Guidelines Group \n2008  LL GB  \nNICE 2006  LL Frankreich  \nFrench National Authority for \nHealth 2005  \nkontr aindiziert.  \nHintergrundtexte  S. 83  \n \nA systematic review of rando mised \ncontrolled trials comparing elective \nlymph node dissection with surgery \ndelayed until the time of clinical \nrecurrence showed no significant \noverall survival benefit for patients \nundergoing ele ctive lymph node \ndissection. [12]  \nTherefore, except in rare \ncircumstances, elective lymph node \ndisse ction is not recommended for \nmelanoma pat ients.  \n \nS. 84  \n \nEvidence summar y  \nElective lymph node dissection is not \nrecommended, regardless of the \nBreslow thic kness of the primary \ntumour  \nLoE: I  \nReferences: 7, 12  S. 93  \n \nLymph node clearance  \nOne systematic review found no \nstatistically significant a dvantage in \nterms of overall mor tality ari sing from \nelective lymph node dissection \ncompared to delayed lymph node \ndissection at the onset of clinical \nsymptoms.  \nOne RCT of elective versus delayed \nregional lymph node dissection in \npatients with melanoma found that the \nroutine use of immedi ate node \ndissection had no signif icant impact on \nsurvival, while the status of regional \nnodes significantly pr edicted survival.  \n \nS. 232 \u2013 234 (NICE Guideline Ev idence \nReview)  \n \nSummary of the supporting evidence \nfor the recomme ndations  \nObservational study e vidence su ggests S. 30 \u2013 31 \n \nCurage ganglionnaire prophyla ctique \nsyst\u00e9ma tique  \n \nDESCRIPTION DES \u00c9TUDES  \nLa m\u00e9ta -analyse de Lens et al. a \u00e9valu\u00e9 \nl\u2019impact sur la survie globale du curage \nganglionnaire prophyla ctique chez les \npatients porteurs d\u2019un m\u00e9lanome sans \nm\u00e9tastases gangl ionnaires \ncliniquement d\u00e9celables [84]. Quatre \nessais randomis\u00e9s ont \u00e9t\u00e9 inclus, soit \nun total de 1 704 p atients [84 -89]. \nL\u2019un de ces essais n\u2019a pas pu \u00eatre \nutilis\u00e9 pour l\u2019analyse quantitative, car \nles donn\u00e9es disponibles dans la \npublication, et apr\u00e8s v\u00e9rification \naupr\u00e8s des auteurs, \u00e9taient \ninsuffisantes [87 ]. \n \nSURVIE GLOBALE  \nAucun des quatre essais random is\u00e9es \nn\u2019a montr\u00e9 de b\u00e9n\u00e9fice   \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 261 von 732  LL Austr alien  \nNew Zealand Guidelines Group \n2008  LL GB  \nNICE 2006  LL Frankreich  \nFrench National Authority for \nHealth 2005  \nthat the status of the regional node \nbasin is a strong pr edictor of survival, \nalong with primary t umour \ncharacteristics such as Breslow \nthickness and ulceration. Syst ematic \nreview and RCT evidence does not \ndemonstrate that elective lymph n ode \ndissection carries a survival benefit \nover a policy of observing patients with \nprimary mel anoma after wide excision. \nHowever the syste matic review by Lens \net al. (2002a) suggests that some \npatients will benefit from elective \nlymph node dissection.  \n \nEvidence based clinical guidelines from \nthe UK reco mmend that in  \npatients with melanoma, the pre sence \nof disease in one node indicates radical \nlymph node disse ction but that elective \nlymph node disse ction in the absence \nof lymph node disease should not be \nperformed.  \nObservational study evidence su ggests \nthat the prevalence of lymphoedema en faveur du curage [85 -89] (Tableau \nIX). La m\u00e9ta -analyse n\u2019a retrouv\u00e9 \naucune diff\u00e9rence de survie \u00e0 5 ans \nentre le curage ganglionnaire et \nl\u2019absence de curage gangl ionnaire (odd  \nratio = 0,86 [IC95 : 0,68 -1,09]) [84] \n(Tableau X) . \n \nCOMPLICATIONS  \nAucune information concernant les \ncomplications n\u2019est disponible dans la \nm\u00e9ta -analyse.  \nCe type de curage a toujours une \ncertaine morbidit\u00e9, plus importante \npour le membre inf\u00e9rieur que pour  le \nmembre sup\u00e9rieur. La fr\u00e9quence des \ncompl ications pr\u00e9coces est de 10 \u00e0  \n15 % dans les meilleures s\u00e9ries lors de \ncurages inguinaux [90, 91]. Le taux de \nlymphoed\u00e8mes ta rdifs varie de 6 \u00e0 15 \n% au membre inf\u00e9rieur, 6 % au membre \nsup\u00e9rieur [90, 92].  \n \nCOMMENTA IRES M\u00c9THODOLOGIQUES \nET CLINIQUES   \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 262 von 732  LL Austr alien  \nNew Zealand Guidelines Group \n2008  LL GB  \nNICE 2006  LL Frankreich  \nFrench National Authority for \nHealth 2005  \namongst p atients who have undergone \ncomplete level I -III \naxillary lymph node disse ction for \nmelanoma is 10%, and 53% after \nadditional axillary radiothe rapy. \n\u2022 The systematic r eview by Lens et al. \n(2002a), calculated a pooled odds  \nratio for overall mortality as 0.86 in  \nfavour of elective lymph node \ndissection over delayed lymph node \ndissection at the onset of clinical \nsymptoms (95% CI 0.68 -1.09). The \nauthors concluded that alth ough the \nresult was not statistically signif icant \nand although the pr imary studies had \nflaws, the possibi lity exists that some \nsubgroups of patients with melan oma \nwill benefit from elective lymph node \ndissection.  \n\u2022 The RCT by Cascinelli et al. (1998) \ncompa red elective ve rsus delayed  \nregional lymph node dissection in \npatients with melanoma and found  \nthat the routine use of immed iate node \ndissection had no impact on survival La validit\u00e9 clinique des essais \nrandomis\u00e9s inclus dans la m\u00e9ta -\nanalyse est critiquable, en raison de la \nr\u00e9alisation du curage ganglionnaire sur \nla seule base de l\u2019examen clinique.  \nL\u2019int\u00e9r\u00eat du curage prophylactique \nreste c ontrovers\u00e9 et le curage \nganglionnaire ne peut s\u2019envisager que \ndans les localis ations o\u00f9 il existe une \nvoie de drainage unique, soit \nessentiellement les l\u00e9sions des \nmembres.   \n \nCONCLUSION DE LA LITT\u00c9RATURE  \nAucun b\u00e9n\u00e9fice du curage \nganglio nnaire prophylactiqu e apr\u00e8s \nex\u00e9r\u00e8se de m\u00e9lanome n\u2019a \u00e9t\u00e9 \nd\u00e9montr\u00e9. Le curage ganglionnaire \nprophylactique syst\u00e9matique \nn\u2019am\u00e9liore pas la survie globale par \nrapport au curage ga nglionnaire \nretard\u00e9 ou \u00e0 l\u2019absence de curage \nganglionnaire chez les patients atteints \nd\u2019un m\u00e9lanome c utan\u00e9 cliniquement \nNO (niveau de preuve A).   \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 263 von 732  LL Austr alien  \nNew Zealand Guidelines Group \n2008  LL GB  \nNICE 2006  LL Frankreich  \nFrench National Authority for \nHealth 2005  \n(hazard ratio 0.72, 95% CI 0.5 -1.02), \nwhilst the status of regio nal nodes \naffected su rvival significantly. The \nauthors co ncluded  \nthat regional node dissection o ffers \nincreased survival in patients with node \nmetastases only.  \n\u2022 The retrospective, case series study \nby Kretschmer et al. (2005) found that \noverall survival at 5 years in patients  \nwho underwent d elayed  \nlymph node dissection following in itial \nwide excision of melanoma was  \n37.4%. Disease free survival in this \ngroup of patients was 11.6%.  \n\u2022 Evidence based guidelines pr oduced \nby Roberts et al. (2002) on behalf of \nthe British Associatio n of \nDermatologists state that ele ctive \nlymph node dissection is not indica ted \nin patients with melanoma and \nclinically negative lymph n odes. \n\u2022 Evidence based guidelines produced \nby the Scottish Intercoll egiate  \nGuidelines Network (2003) reco mmend  \nS. 30 - 31 \nSystematische prophylaktische \nLymphadenektomie (LAD)  \n \nBESCHREIBUNG DER STUDIEN  \nDie Metaanalyse von Lens et al. hat den \nEinfluss der prophylaktischen LAD auf \ndas Gesamt\u00fcberleben bei P atienten mit \nMelan om ohne klinisch nachweisbare \nLymphknotenmet astasen ausgewertet \n[84]. \nVier randomisierte Studien mit einer \nGesamtzahl von 1 704 Patienten sind \ndabei eingeschlossen worden [84 -89]. \nEine dieser Studien konnte nicht f\u00fcr die \nquantitative Analyse verwendet \nwerd en, da die Daten in der Publik ation \nauch nach Verifikation bei den Autoren \ninsuffizient waren [87].  \n \nGESAMT\u00dcBERLEBEN  \nKeine der vier randomisierten St udien \nkonnte einen Vorteil der LAD zeigen \n[85-89] (Tabelle IX) .   \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 264 von 732  LL Austr alien  \nNew Zealand Guidelines Group \n2008  LL GB  \nNICE 2006  LL Frankreich  \nFrench National Authority for \nHealth 2005  \nthat in p atients with melan oma, the \npresence of disease in one node \nindicates radical lymph node dissection \nbut that elective lymph node dissection \nin the a bsence of lymph node disease \nshould not be performed.  Die Metaanalyse ergab keinen \nUnterschied i n der 5 -Jahres - \n\u00dcberl ebensrate zwischen Durchf\u00fchrung \nund Nicht -Durchf\u00fchrung der ele ktiven \nLAD (Odds -Ratio = 0,86 [IC95 : 0,68 -\n1,09]) [84] (Tabelle X) . \n \nKOMPLIKATIONEN  \nIn der Metaanalyse sind keine \nInformationen \u00fcber Komplikationen \nverf\u00fcgbar.  \nDiese Art der  LAD geht immer mit einer \ngewissen Morbidit\u00e4t einher, an der \nunteren Extremit\u00e4t ausgepr\u00e4gter als an \nder oberen Extremit\u00e4t.  \nDie H\u00e4ufigkeit der Fr\u00fchkomplikati onen \nreicht von 10 bis 15% in den besseren \nSerien der inguinalen \nLymphadenektomien [90, 91].  \nDie R ate der sp\u00e4ten Lymph\u00f6deme \nreicht von 6 bis 15% an den unteren \nExtremit\u00e4ten und betr\u00e4gt ca. 6% an den \noberen Extremit\u00e4ten [90, 92].  \n \nMETHODOLOGISCHE UND KLINISCHE  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 265 von 732  LL Austr alien  \nNew Zealand Guidelines Group \n2008  LL GB  \nNICE 2006  LL Frankreich  \nFrench National Authority for \nHealth 2005  \nKOMMENTARE  \nDie klinische Validit\u00e4t der in die M eta-\nAnalyse eingeschlossenen \nrandomisierten St udien ist fragw\u00fcrdig, \nda die Durchf\u00fchrung der LAD allein mit \ndem Ergebnis der klinischen \nUntersuchung begr\u00fcndet wurde.  \nDie Frage der prophylaktischen LAD \nbleibt kontrovers. Sie kann zudem nur \nbei Tumorlokalisationen in B etracht \ngezogen werden, an denen nur ein \nlymphatischer Abflussweg existiert, \nd.h. im Wesentlichen bei L\u00e4sionen an \nden Extremit\u00e4ten.   \n \nSCHLUSSFOLGERUNG AUS DER \nLITERATUR  \nEs konnte nach Exzision des Mel anoms \nkein Vorteil der prophylaktischen LAD \ngezeigt werden. Sie ve rbessert im \nVergleich zur sp\u00e4ten LAD oder zum \nVerzicht auf LAD nicht das \u00dcberleben \nbei Patienten mit mali gnem Melanom \nim klinischen Stadium N0 (Evidenzlevel \nA).   \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 266 von 732  LL Austr alien  \nNew Zealand Guidelines Group \n2008  LL GB  \nNICE 2006  LL Frankreich  \nFrench National Authority for \nHealth 2005  \nBemerkungen   Diese Leitlinie bezieht sich auf MM und \nauf NMSC.  \n \nReferenzen und ausf\u00fchrliche \nEvidenztabellen dieser Leit linie werden \nwegen ihres Umfangs als separates \nDokument zur Ve rf\u00fcgung gestellt:  \nGB NICE Guideline Evidence R eview, S. \n232 bis 238.  Im Volltext der Leitlinie tabellarische \nDarstellung der einbezogenen St udien \n(S. 30).  \n \nLiteratur:  \nLL Austr alien New Zealand Guidelines Group 2008  \n7. National Comprehensive Cancer Network. Melanoma: Clinical Practice Guidelines in Oncology. version 2. 2007. National Compr ehensive Cancer Network  \n12. Lens MB, Dawes M, Goodacre T, et al. Elective lymph node dissection in patients w ith melanoma: systematic review and meta -analysis of randomized controlled trials. Arch \nSurg 2002;137:458 -461 \n \nLL GB NICE 2006  \nCascinelli N, Morabito A, Santinami M, et al. Immediate or delayed dissection of regional nodes in patients with melanoma of the trunk: a randomised trial. WHO Melanoma \nProgramme. Lancet 1998;351:793 -796 \nLens MB, Dawes M, Goodacre T, et al. Elective lymph node dissection in patients with melanoma: systematic review and meta -analysis of randomized controlled trials. Arch Surg \n2002;13 7:458 -461  \nRoberts DL, Anstey AV, Barlow RJ, et al. U.K. guidelines for the management of cutaneous melanoma. Br J Dermatol 2002;146:7 -17 \nScottish Intercollegiate Guidelines Network. Cutaneous m elanoma. A national clinical guideline. 2003 http://www.sign.ac.uk/pdf/sign72.pdf  \nStarritt EC, Joseph D, McKinnon JG, et al. Lymphedema after complete axillary node dissection for melanoma: assessment using a new, objective definition. Ann Surg \n2004;240:866 -874 \nWhite RR, Stanley WE, Johnson JL, et al. Long -term survival in 2,505 patients with melanoma with regional lymph node metastasis. Ann Surg 2002;235:879 -887 \n \nLL Frankreich  French National Authority for Health 2005 ) \n90. Baas PC, Schraffordt Koops H, Hoekstra HJ , et al. Groin dissection in the treatment of lower -extremity melanoma. Short -term and long -term morbidity. Arch Surg \n1992;127:281 -286  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 267 von 732 86. Balch CM, Soong SJ, Bartolucci AA, et al. Efficacy of an elective regional lymph node dissection of 1 to 4 mm thick m elanomas for patients 60 years of age and younger. Ann \nSurg 1996;224:255 -63; discussion 263 -6 \n91. Beitsch P, Balch C. Operative morbidity and risk factor assessment in melanoma patients undergoing inguinal lymph node di ssection. Am J Surg 1992;164:462 -5; discussion \n465-6 \n85. Cascinelli N, Morabito A, Santinami M, et al. Immediate or delayed dissection of regional nodes in patients with melanoma  of the trunk: a randomised trial. WHO Melanoma \nProgramme. Lancet 1998;351:793 -796 \n92. Karakousis CP, Heiser MA, Mo ore RH. Lymphedema after groin dissection. Am J Surg 1983;145:205 -208 \n84. Lens MB, Dawes M, Goodacre T, et al. Elective lymph node dissection in patients with melanoma: systematic review and meta -analysis of randomized controlled trials. Arch \nSurg 2002;137 :458-461  \n87. Sim FH, Taylor WF, Pritchard DJ, et al. Lymphadenectomy in the management of stage I malignant melanoma: a prospective ra ndomized study. Mayo Clin Proc 1986;61:697 -\n705 \n88. Veronesi U, Adamus J, Bandiera DC, et al. Inefficacy of immediate node  dissection in stage 1 melanoma of the limbs. N Engl J Med 1977;297:627 -630 \n89. Veronesi U, Adamus J, Bandiera DC, et al. Delayed regional lymph node dissection in stage I melanoma of the skin of the lower extremities. Cancer 1982;49:2420 -2430  \n  \n \n \n \n \n \n \n \n \n \n \n \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 268 von 732 3.3. Frage III.3. Therapeutische Lymphadenektomie  \u2013 De-novo-Recherche  \nFrage III.3 . In welchen F\u00e4llen ist die therapeutische LAD indiziert?  \n3.3.1.  PICO-Unterfragen  \n- Hat die therapeutische LAD bei Patienten mit klinisch feststellbaren LK -Metastasen einen Einfluss auf d as \u00dcberleben?  \n- Hat die therapeutische LAD bei Patienten mit klinisch feststellbaren LK -Metastasen einen Einfluss auf die rezidivfreie Zeit?  \n- Hat die therapeutische LAD bei Patienten mit klinisch feststellbaren LK -Metastasen einen Einfluss auf die Lebensquali t\u00e4t? \n \nSuchw\u00f6rter  \nStichwort , Synonyme,  Ober-\n/Unterbegriffe , Mesh Term  s. Suchsstrategie  \n \n3.3.2.  Datenbanken, Suchstrategien, Trefferzahlen  \nDatenbank  Suchstrategie  Datum  Treffer \n1. Suche     \nMedline  melanoma AND (\"lymph node \nexcision\"[MeSH Terms] OR (\"lymph\"[Al l \nFields] AND \"node\"[All Fields] AND \n\"excision\"[All Fields]) OR \"lymph node \nexcision\"[All Fields] OR \n\"lymphadenectomy\"[All Fields] OR \n\u201clymph node dissection\u201d[All Fields] OR \n\u201clymphonodectomy\u201d[All Fields])  08.03.2011  3408  \nMedline Update -Recherche  melanoma A ND (\"lymph node 11.01.2011  3754   \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 269 von 732 excision\"[MeSH Terms] OR (\"lymph\"[All \nFields] AND \"node\"[All Fields] AND \n\"excision\"[All Fields]) OR \"lymph node \nexcision\"[All Fields] OR \n\"lymphadenectomy\"[All Fields] OR \n\u201clymph node dissection\u201d[All Fields] OR \n\u201clymphonodectomy\u201d[All Fields])  \nCochrane Library  (melanoma and ((lymph and node and \nexcision) or lymphadenectomy or \n\"lymph node disse ction\" or \nlymphonodectomy)).ti,ab.  08.03.2011  93 \nEmbase  (melanoma and ((lymph and node and \nexcision) or lymphadenectomy or \n\"lymph node di ssection\" or \nlymphonodectomy)).ti,ab.  11.05.2011  2148  \n2. Suche/Erg\u00e4nzungen     \n    \nBemerkungen: Eine erste Literaturrecherche in Medline und und Cochrane erfolgte am 08.03.2010 bzw. f\u00fcr Embase am 11.05.2011. Zweite Medlin e-Recherche \n(Update -Recherche) er folgte am 11.01.2011.  Da die Frage III.3. letztendlich konsensbasiert beantwortet wurde (s.3.3.3.) ,  wurde a uf eine Update -Recherche \nAnfang 2012 verzic htet. \n \n \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 270 von 732 3.3.3.  Auswahlkriterien  \nAuswahl der Literatur  \nGesamttreffer  5995  \nEinschlusskriterien  Thematische \u00dcbe reinstimmung  \nSprachen: e,dt  \nAusschlusskriterien  Case Reports, narrative Reviews  \nAnzahl nach Abstractscreening  61 \nAnzahl ausgew\u00e4hlter und bewerteter Volltexte, vorges ehen f\u00fcr Bewertung  27 \nBemerkungen: Aufgrund des Fehlens von Studien, die das Outcome vo n Patienten, die eine therapeutische LAD erhalten haben, mit dem von Patienten vergleicht, \ndie diese LAD trotz bestehender LK -Metastasen nicht erhalten haben, entschieden sich die Experten der AG chirurgische Therapie f\u00fcr eine konsensbasierte statt \nevidenz basierte Beantwortung der Frage.  \n \n3.3.4.  Evidenztabelle  \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE  \nPilko et al. (2011)  To compare the \noverall survival of \ndifferent groups of \nstage III cutaneous \nmelanoma patients  Prognostic study  \n \nCohort stu dy  \n \n 325 patients with \nstage III melanoma  \n Overall survival (OS)  \n \nDisease -free \nsurvival (DFS)  The mean follow -up \nwas 44 months \n(range 1 \u2013 168 \nmonths).  \n \nThe 5 -year DFS for \nthe whole group \nwas 36.6%, 5 -year \nOS was 52.6%.  \n Retrospective \ndesign (prospective \ndatabase)  \n \nShort follow -up in \nsome patients  \n \nNo control group \n(comparison of \nlymph node 3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 271 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE  \nOn multivariate \nanalysis, age, \nBreslow thickness, \npresence of \nulceration, number \nof involved lymph \nnodes, type of \nlymph node \ndissection and size \nof SN metastasis \nwere independent \nprognostic factors \nfor OS.  dissection vs. no \nlymph node \ndissection not \npossible)  \n \nPasquali et al. \n(2010)  To investigate \nwhether patients \nwith melanoma who \nundergo \nlymphadenectomy \nafter a positive \nsentinel  \nlymph node (SN) \nbiopsy (SNB) have a  \nbetter prognosis \ncompared with \npatients who are \ntreated for clinically \nevident disease.  Systematic review  The included 6 \nstudies \nencompassed 2633 \npatients who had \nAJCC stage III \nmelanoma.  \n \n Overall survival  Hazard ratio for \noverall survival \n(TLND vs. CL ND): \nSummary measure \n1.602  Study included here \nfor the data on \ntherapeutic node \ndissection (not \ncompletion node \ndissection after SNB)  \n \nSystematic review \nand original data, \nbut different \nobjective of the \nstudy (therapeutic \nvs. completion node \ndissection, no t 3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 272 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE  \ntherapeutic vs. \ncontrol group), \ntherefore lower level \nof evidence \nconcerning the \nquestion of \nindication for \ntherapeutic node \ndissection  \nRutkowski et al. \n(2010)  To compare \noutcomes of \npatients with clinical \nnodal melanoma \nmetastases without \na detectab le primary \ntumor (MUP) with \nthose with a known \nprimary site (KPM).  Prognostic study  \n \nCohort study  \n \n 459 consecutive \nmelanoma patients, \nstages IIIB and IIIC  Overall survival  \n \nDisease -free \nsurvival  \n \nRecurrence rates  3-year and 5 -year \nOS rates: 48.0% and \n41.4%, respectively, \nfor the MUP group \n(median 36.2 \nmonths) and 42.0% \nand 36.0%, \nrespectively, for the \nKPM group (median \n25.7 months).  \n \n3-year and 5 -year \nDFS rates: 47.0% \nand 44.0%, \nrespectively, for the \nMUP group (median \n14.9 months) and \n31.1% and 28.3%, Retrospective \ndesign  \n \nNo control group \n(comparison of \nlymph node \ndissection vs. no \nlymph node \ndissection not \npossible)  \n 3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 273 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE  \nrespectively, for the \nKPM group (median \n11.7 months).  \n \nDisease \nrecurrences:in the \nMUP group 31 \npatients; 52.5%, in \nthe KPM group 299 \ncases; 74.8%  \nAllan et al. (2008)  To review the \nexperience of \nroutine ilioinguinal \ndissection for all \npatients presenting \nwith palpable \nmetastatic \nmelanoma in the \ngroin.  prognostic and \ndiagnostic study  \n \nCohort study  \n \n 72 patients  \n Disease -free \ninterval  \n \nDisease -free \nsurvival  \n \nOverall survival  \n \nPelvic lymph node \nstatus  \n \nDiagnostic value of \npreoperative CT  \n \nComplication rate \n(lymphoedema)  22 (30.6%) of 72 \npatients with \nhistologically \ninvolved pelvic \nlymph nodes.  \n \nPreoperative CT \naccuracy for pelvic \nlymph no de \ninvolvement:  \nsensitivity 60.0% \nspecificity 100.0%, \nPPV 100.0%  \nNPV 86.2%.  \n \nMedian time to first \nrecurrence: 8.7 Retrospective \ndesign  \n \nSmall patient cohort  \n \nNo control group \n(comparison of \nlymph node \ndissect ion vs. no \nlymph node \ndissection not \npossible)  \n \nConfounder: \nadjuvant therapy  3b-  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 274 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE  \nmonths (0.8 \u201369.7 \nmonths). Regional \nrecurrence in 6 \n(8.3%) of 72 patients \n(at a median of 4.9 \nmonths (0.9 \u201332.0 \nmonths).  \n \nExtranodal spread \nadversely associated \nwith disease -free \nsurvival.  \n \n5-year DFS: 38% \n(95% CI 26 \u201350), OS \n47% (95% CI 33 \u2013 \n60). \n \nLymphoedema was \nreported in 32 \n(44.4%) of 72 \npatients.  \nLee et al. (2008)  Clinical outcomes of \npatients with MUP \nand known primary \nmelanoma (MKP) \nwith regional nodal Prognostic study  \n \nCohort study  \n 1,571 patients who \nunderwent \ntherapeutic regional \nlymphadenectomy  \n Overall survival  \n \nDisease -free \nsurvival  significant factors \non multivariate \nanalysis: age, sex, \nnodal tumor \nburden, de cade of Retrospective \ndesign  \n \nNo control group \n(comparison of 3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 275 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE  \nmetastases were \ncompared to \ninvestigate the \nprognostic \nsignifica nce of MUP.  (262: MUP, 1,309: \nMKP)  \n diagnosis, status of \nprimary.  \n \nGreater risk was \nassociated with age \n\u2265 60 years, male \nsex, increased \nnumber of tumor -\ninvolved nodes (>1), \nand MKP. The risk of \ndeath was 40% \nlower in the MUP \ngroup than the MKP \ngroup (HR = 1.507).  \n \n5-year and 10 -year \nrates of OS for \npatients with MUP \nversus patients with \nMKP were 58% \uf0b1 7% \nversus 40% \uf0b1 7%, \nrespectively, and \n52% \uf0b1 7% versus \n36% \uf0b1 7%, \nrespectively.  \n \nMedian OS was also lymph node \ndissection vs. no \nlymph node \ndissection not \npossible)  \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 276 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE  \nsignificantly longer \nin the MUP group \nthan the MKP group \n(165 months vs. 34 \nmonths).  \nVan Akkooi et al. \n(2007)  To evaluate \nmorbidity and \nmortality following \nTLND, and disease -\nfree (DFS) and \noverall survival (OS) \nfollowin g TLND.  Prognostic study  \n \nCohort study  \n 236 melanoma \npatients who \nunderwent TLND  Overall survival  \n \nDisease -free \nsurvival  \n \nRegional control \nrate \n \nComplication rate  \n mean follow -up \nafter TLND: 29 \nmonths (range 0 \u2013 \n280 months).  \n \nestimated 5 -year \nDFS and OS  for the \n236 patients after \nTLND: 19% and 26%.  \n \nestimated 5 -year \nregional control rate \nafter TLND: 79%.  \n \nMedian time to \ndisease progression: \n7 months.  \n \nestimated 5 -year \nDFS according to \nsite of tumor: 23% \n(extremities) and 9% Retrospective \ndesign  \n \nNo follow -up in \nsome patients  \n \nNo cont rol group \n(comparison of \nlymph node \ndissection vs. no \nlymph node \ndissection not \npossible)  \n \nFor data on \ncomplications, see \noriginal article  3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 277 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE  \n(central tumors)  \n \nestimated  5-year \nDFS for different \ncategories of nodal \nstatus (N1, N2, N3): \n31%, 15% and 10%, \nrespectively.  \n \nsignificant different \nestimated 5 -year OS \nrate for different \nintervals of \ndiagnosis until \nTLND.  \nYoung et al. (2006)  To investigate rates \nof long -term \nsurvival for patients \nwith regional (nodal) \nmelanoma.  Progn ostic study  \n \nCohort study  \n 1422 patients with \nstage III melanoma \nwho received \ncomplete \nlymphadenectomy   \n \n Overall survival  \n \nMelanoma -specific \nsurvival  maximum follow -\nup: 386 months (32 \nyears)  \n \nrates of 15 -, 20- \nand 25 -year \nmelanoma -specific \nsurvival: 36 % \uf0b1 1%, \n35% \uf0b1 1%, and 35% \uf0b1 \n1%, respectively.  \n \nMedian melanoma -Retrospective \ndesign  \n \nLong follow -up \n \nNo control group \n(comparison of \nlymph node \ndissection vs. no \nlymph node \ndissection not \npossible)  3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 278 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE  \nspecific OS: 28.1 \nmonths in the \npalpable and 90 \nmonths in the non -\npalpable group.  \n \nWhen stratified by \nclinical status of \nregional nodes, \nsurvival rates were \nsignificantly lower if \nnodes were \npalpable.   \nPienkowski et al. \n(2005 ) to perform a single -\ninstitution analysis \nof factors \ninfluencing the \nclinical out comes of \ncutaneous \nmelanoma (CM) \npatients undergoing \ntherapeutic \nlymphadenectomy \n(LND).  Cohort study  353 consecutive \nmelanoma patients \nwith metastases to \nregional lymph \nnodes  Overall survival  \n \nDisease -free \nsurfvival  Estimated 5 -year \noverall survival \nratio: 44%   \n \n5-year disease free \nsurvival rate: 35%  \n \nindependent \npredictors of poor \nOS (multivariate \nanalysis):  \n- extracapsular \nmelanoma invasion \n(p 3mm (p = 0.007)  Retrospective \ndesign  3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 279 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE  \n- male sex \n(p=0.011)  \n- CM site in \nhead/neck region (p \n= 0.05)  \n \nnegative factors for \nDFS:  \n- noda l \nextracapsular \nmelanoma \nextension (p < \n0.0001)  \n- male sex (p < \n0.0001).  \nSerpell et al. (2003)  To review regional \ndisease control and \nmorbidity in a series \nof \nlymphadenectomies  Cohort study  \n \n 64 melanoma \npatients have \nundergone 7 3 RLND \nfor metastatic \nregional melanoma  Overall survival  \n \nRecurrence rate  \n \nComplication rate  \n \n median time to \ndiagnosis of \nregional lymph node \ndisease: 11.2 \n(interquartile range \n2\u201348) months.  \n \nregional control:  \n92% \nlocal recurrences \n(LR): 8%  \n Retrospective \ndesign  \n \nSmall patient cohort  \n \nNo control group \n(comparison of \nlymph node \ndissection vs. no \nlymph node \ndissection not \npossible)  3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 280 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE  \nLR all occurr ed \nwithin 12 months of \nlymphadenectomy, \nall but 1 patient \nwith LR have died \nwithin 12 months.  \n \nrate of LR local \nrecurrence was \nsimilar with or \nwithout \npostoperative \nradiotherapy.  \n \n34/64 patients died, \nmedian time to \ndeath=12 months \n(range 2 \u201335 \nmonths).   \nFor data on \ncomplications, see \noriginal article  \nFisher (2002)  To evaluate the \neffects on survival, \ndisease -free \ninterval, and \nrecurrence patterns \nfor patients \nundergoing elective, \ntherapeutic, and Cohort study  \n \n 1444 melanoma \npatients:  \n- 219 patients with \nELND, histologically \nproven negative  \nlymph nodes  \n- 27 patients with \nELND, histologically Disease -free \nsurvival  \n \nOverall survival  overall rate of nodal \nrecurrence for all \npatients: 129/1045 \npatients 12%.  \n \nsignificant \nimprovement in \nsurvival for DLND Retrospectiv e \ndesign  \n \nStudy included here \nfor data on delayed \nlymph node \ndissection (DLND); \nfor further data on 3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 281 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE  \ndelayed lymph node \ndissection for \nmalignant \nmelanoma of the \nhead and neck.  proven positive \nlymph nodes  \n- 106 patients with \nDLND for regional \nlymph node \nrecurrence  \n- 112 patients with \nTLND for clinically \npositive lymph \nnodes  when compared \nwith patients  \nundergoing ELNDQ \nor TLND (P=0.01).  \n \nFive-year survival \nafter DLND and \nTLND was 56% and \n36%, respectively.  \n \n ELND and TLND see \noriginal article  \n \nNo control group for \nDLND (comparison \nof lymph node \ndissection vs. no \nlymph node \ndissection not \npossible)  \n \nPathak et  al. (2002)  To determine the \nrates of regional \nrecurrence for \nnode -positive \nmelanoma after \nneck dissection \nalone.  Cohort study  \n \n 31 patients who \nunderwent neck \ndissection for node -\npositive melanoma  Recurrence rate  \n \nMean time to \nrecurrence  \n \nOverall survi val \n mean follow -up: \n45.3 months with a \nSD of 35.3 months \nand a range of 1 to \n108 months.  \n \nregional recurrence \nrate at 5 years for \nmelanoma: 31%.  \n \nmean time to \nrecurrence: 78 \nmonths (95% CI: 63 \nto 93 months).  \n \nmean survival for Small patient cohort  \n \nVery short follow -\nup in some patients \n(recurrence rate may \nbe underestimated)  \n \nNo control group \n(comparison of \nlymph node \ndissection vs. no \nlymph node \ndissection not \npossible)  \n 3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 282 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE  \npatients undergoing \nneck dissection: 61 \nmonths.  \nWhite et al. (2002)  To examin e the \nlong-term \noutcomes of \npatients with \nmelanoma \nmetastatic to \nregional lymph \nnodes.  Cohort study  \n \n 2,505 patients  Overall survival  \n \nRecurrence -free \nsurvival  For regional lymph \nnode metastases:  \nmedian overall \nsurvival: 3.4 years,  \n \nmedian recurrence -\nfree survival: 1.5 \nyears.  \n \nEstimated overall \nsurvival rates(95% \nCI) at 5, 10, 15, 20, \nand 25 years: 43% \n(41\u201345%), 35% (33 \u2013 \n37%), 28% (25 \u201330%), \n23% (20 \u2013 \n26%), and 19% (13 \u2013\n24%), respectively.  \n \nEstimated \nrecurrence -free \nsurvival rates at 5, \n10, 15, and 20 \nyears: 33% (31 \u2013Retrospective \ndesign  \n \nMissing data led to \nexclusion of \npatients  \n \nNo control group \n(comp arison of \nlymph node \ndissection vs. no \nlymph node \ndissection not \npossible)  \n \n 3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 283 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE  \n35%), 28% (26 \u201330%), \n25% (23 \u201327%), and \n22% (18 \u201326%) \nrespectively,  \n \nBoth curves \nappeared to plateau \nat approximately \n20%, no first \nrecurrences after 21 \nyears.  \nHughes et al. (2000 ) to identify disease - \nand treatment -\nrelated factors that \ninfluence the \noutcome of patients \nundergoing \ntherapeutic groin \ndissection for \nclinically detectabl e \nmelanoma lymph \nnode metastases  132 patients  \nWith clinically \ndetectable LN -\nmetastases  \n \n60 patients: \nsuperficial inguinal \nlymph node \ndissection (SLND)  \n \n72 patients: \ncombined \nsuperficial inguinal \nand pelvic lymph \nnode dissection \n(CLND)   Morbidity  \n \nOverall survival  \n \nRecurrence rate  no difference in \npostoperative \nmorbidity or major \nlymphoedema \nbetween SLND and \nCLND  \n \noverall 5 -year-\nsurvival -rate:  \n- 34% \n \n5-year-survival -\nrate: \n-pelvic lymph node \nmetastases (CLND): \n19% Retrospective study  3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 284 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE  \n- no pelvis lymph \nnode metastases \n(CLND): 1 7% \n(P = 0.015)  \n \n \nFactors with \nsignificant impact \non survival \n(univariate analysis):  \n- age (P = 0.003)  \n- number of \ninvolved superficial \nlymph nodes (P = \n0.001)  \n- presence of \nextracapsular \nspread (P = 0.003)  \n \nSystemic recurrence \nrate:  \n62% \n \nMedian time to \nsystemic recurrence: \n9 months  \n.  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 285 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE  \nCascinelli et al. \n(1998)  To evaluate the \nefficacy of \nimmediate node \ndissection in \npatients with \nmelanoma of the \ntrunk and without \nclinical evidence of \nregional node and \ndistant metastases.  Randomized \ncontrolled trial  \n \n Of 240 patients  \n \n122: wide excision \nand immediate node \ndissection  \n \n118: wide excision \nand dissection \ndelayed until the \ntime of appearance \nof clinically \ndetectable node \nmetastases.  \n Time to first \nrecurrence  \n \nOverall survival  36/118 patie nts \n(30.5%) developed \nregional node \nmetastases  \n \nmedian lag between \nexcision of primary \ntumour and the \ndiagnosis of \nregional node \nmetastases: 8.3 \nmonths \n(interquartile range \n3.7\u201316.2). minimum \ndelay: 0.43 months, \nmaximum 55.0 \nmonths  \n \n\u201cDelayed\u201d patients \nhad a survival rate \nat 5 years of 51.3% \n(95% CI 41.7 \u201360.1).  Study included here \nfor the data on \ndelayed node \ndissection (not \nimmediate node \ndissection)  \n \nProspective, \nrandomized design, \nbut different \nobjective of the \nstudy (elective vs. \ntherapeutic node \ndissect ion, not \ntherapeutic vs. \ncontrol group), \ntherefore lower level \nof evidence \nconcerning the \nquestion of \nindication for \ntherapeutic node \ndissection  3b \nJonk et al. (1998)  To identify \nprognostic factors \ndetermining overall \nsurvival in patients Cohort study  \n \n 70 surgically treated \nwith curative intent \nfor cervical lymph \nnode metastasis  Overall survival  overall survivals \nafter 5 and 10 \nyears: 23% and 20%, \nrespectively. Median Retrospective \ndesign  \n \nSmall patient cohort  3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 286 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE  \nwith surgically \ntreated neck node \nmetastases of \ncutaneous \nmelanoma   \n- radical neck \ndissection: 64 \npatient -  - \nmodified radical \nneck dissection: 4 \npatients  \n- postero -lateral \nneck dissection:2 \npatients.  survival: 22 months.  \n \nFollowing a \ntherapeutic neck \ndissection, 5 -year \nsurvival rate: 22%  \n \nfollowing elective \ndissection, 5 -year \nsurvival ra te: 29%  \n (difference not \nsignificant).   \nPatients \npredominantly male  \n \nNo control group \n(comparison of \nlymph node \ndissection vs. no \nlymph node \ndissection not \npossible)  \n \nKarakousis and \nDriscoll (1996)  To report the \nexperience with \ngroin dissection for \nmelanoma  Cohort study  \n \n 205 patients who \nunderwent groin \ndissection  \n \n Overall survival  \n \nDisease -free \nsurvival  \n \nComplication rate  Estimated -overall \n5-year survival and \ndisease -free \nsurvival rates for \npatients with \nhistologically \nproven negative \nnodes: 73% and 67% \nrespectively, rates \nfor those with \npositive nodes: 39% \nand 29%, \nrespectively. 10 -\nyear survival rate for \npatients with Retrospective \ndesign  \n \nNo control group \n(comparison of \nlymph node \ndissection vs. no \nlymph node \ndissection not \npossible)  \n 3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 287 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE  \nnegative nodes was \n63% and for those \nwith positive nodes \n33%.  \n \nmedian length of \nsurvival for patients \nwith clinically \npositive nodes: 29 \nmonths, for the 40 \nwith negative nodes: \n52 months. 5 - and \n10-year survival \nrates: in the former \ngroup: 37% and 32% \nrespectively, in the \nlatter group: 43% \nand 35%.  \n \nFor patients with \npositive nodes only \nin the inguinal \nregion: 5 -year \noverall and disease -\nfree survival rates \nwere 43% and 35% \nrespectively; for  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 288 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE  \npatients with \npositive nodes in \nboth the inguinal \nand deep node \ngroups: 34% and \n21%. Estimated 10 -\nyear survival rate for \nthe former group: \n39%. for the lat ter \ngroup: 25% at 92 \nmonths.  \nKarakousis et al. \n(1994)       Patient cohort is a \nsubset of \nKarakousis and \nDriscoll (1994); see \nabove   \nGadd and Coit \n(1992)  To analyze the \npatterns of initial \nrecurrence and \noutcome of patients \nwith recurrence of \nmelanoma following \naxillary or inguinal \nlymphadenectomy  Cohort study  \n \n 403 patients with \nrecurrences after \nlymphadenectomy;  Disease -free \ninterva l \n \nsurvival  The median \ndisease -free \ninterval: 11.2 \nmonths, range from \n1 to 157 months.  \n \nMedian survival of \npatients with:  \n \n- single -site Retrospective \ndesign  \n \nMissing tumor \ncharacteristics for \ncirca half of the \npatient population; \nalso missing \ntreatment \ninformation in some 3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 289 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE  \nrecurrence: 11 \nmonths, with a 5 -\nyear survival rate of \n10% \n \n- multiple sites: 3 \nmonths, no 5 -year \nsurvivors  \n \n- nonvisc eral \nsingle -site \nrecurrence: 18.5 \nmonths with a 5 -\nyear-survival rate of \n14%  \n \n- single visceral \nrecurrence: 6 \nmonths with a 5 -\nyear-survival rate of \n3%  \n \n- surgical resection \nof single -site \nrecurrences: 17 \nmonths with a 5 -\nyear survival rate of patients  \n \nNo separate analysis \nfor elective and \ntherapeutic \ndissections  \n \nComparison \nbetween surgical \nand nonsurgi cal \ntherapy, but groups \nnot randomized   \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 290 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE  \n14% (Complete  \nresection: median \nsurvival: 19 months, \npartial resection: 6 \nmonths)  \n \n- nonsurgical \ntherapy: 5 months \nwith a 5 -year \nsurvival rate of 2%  \n \n- surgical resection \nof multiple site \nrecurrences:  \n7 months  \n \n- nonsurgical \ntherapy of multiple \nsite recurrences: 3 \nmonths \n  \nMorton et al. (1991)  To evaluate the \nimportance of \nvarious prognostic \nfeatures after \nlymphadenectomy.  Cohort study  \n \n. 1134 patients with \nlymph node \nmetastases  \n \n737 patients in \nwhom complete Overall survival  5-, 10- and 15 -year \nsurvival: 46%, 41%, \nand 38%, \nrespectively.  \n \nMultivariate Missing information \nin many patients, \nwho were excluded \nfrom the analysis  \n \nRetrospective 3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 291 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE  \ninformation was \navaila ble  analysis:the number \nof involved nodes (p \n= 0.001), the \nlocation on an \nextremity (p = \n0.0059), the depth \nof the primary (p = \n0.0334), the \npatient's sex (p = \n0.0627), and clinical \nstage (p = 0.0942) \nwere significantly \ncorrelated with \nsurvival.  design  \n \nNo control group \n(comparison of \nlymph node \ndissection vs. no \nlymph node \ndissection not \npossible)  \n \nFor mathematical \nmodel of prognosis, \nsee original article  \nKarakousis et al. \n(1990 ) To report on results \nand complications \nof axillary node \ndissection in \nmelanoma  Cohort study  \n  133 melanoma \npatients who \nunderwent axillary \nnode d issection  \n \n Overall survival  \n \nDisease -free \nsurvival  \n \nComplication rate  estimated 5 -year \ndisease -free \nsurvival rate for \npatients with:  \n \n- histologically \nnegative nodes: 80%  \n \n- histologically \npositive nodes: 23%.  \n \n- palpable nodes: \n13% For data on \ncomplications, see \noriginal article  \n \nRetrospective \ndesign  \n \nNo control group \n(comparison of \nlymph node \ndissection vs. no \nlymph node \ndissection not 3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 292 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE  \n \n- clinically negativ e \nnodes: 60%.  \n \nIn patients with \nclinically & \nhistologically \ninvolved nodes: the \ngreater the number \nof involved nodes, \nthe shorter was the \ndisease -free \nsurvival time after \nnode dissection.  \n \nConsidering all \npatients with \nelective and \ntherapeutic node \ndissec tions: \nrecurrence in 53 \npatients (40%), 74% \nof them within 2 \nyears.   possible)  \n \nKarakousis et  al. \n(1986)       Patient cohort is a \nsubset of \nKarakousis and   \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 293 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE  \nDriscoll (1994); see \nabove  \nFinck et al. (1982)  To review the \nresults of \nilioinguinal \ndissection and to \ncompare results for \npatients with \ninguinal and iliac \nnode involvement \nwith those with onl y \ninguinal \ninvolvement.  Cohort study  \n \n 82 melanoma \npatients with \ninguinal lymph node \nmetastases.  \n Disease -free \ninterval  \n \nOverall survival  Significant \ndifference in \ndisease -free interval \nfor patients with \ninguinal and iliac \nnode metastases \nand patients who  \nhad only inguinal \ninvolvement.  \n(p < 0.01).  \n \nDisease recurrence: \n- 20/24 (83.3%) \npatients with \npositive iliac nodes  \n- 32/58 (55.2%) \npatients with \nnegative iliac nodes.  \n \nMedian disease -free \ninterval:  \n- 5.8 months for \npatients with iliac \nmetastases  \n- 25.6 months for Retrospective \ndesign  \n \nSmall patient cohort  \n \nMissing information \non primary tumo ur \ncharacteristics in \nmany patient files  \n \nNo control group \n(comparison of \nlymph node \ndissection vs. no \nlymph node \ndissection not \npossible)  \n 3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 294 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE  \npatients without \niliac nodal \ninvolvement.  \n \nMedian survival:  \n- for patients with \niliac metastases: \n20.0 months  \n- for patients with \nnegative iliac \nnodes:52,1 months  \nVeronesi et al. \n(1982)  To investigate \nwhether regional \nlymph nodes should \nor should not be \nremoved in stage I \nmelanoma patients \n(elective dissection).  Randomized \ncontrolled trial  \n \n 553 stage I \nmelanoma patients  Overall survival  The type of \ntreatment given did \nnot modify the \nchances of cure for \nthe patients, even if \nadjusted by single \nsignificant factors \nor by all o f them.  \n \n5-year overall \nsurvival rates for \ndelayed dissection:  \n57.9% for males  \n76.5% for females  \n \n10-year overall Prospective design  \n \nStudy included here \nfor the data on \ntherapeutic  node \ndissection (not \nelective dissection)  \n \nDifferent objective \nof the study \n(therapeutic vs. \ncompletion node \ndissection, not \ntherapeutic vs. \ncontrol group), \ntherefore lower level 3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 295 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE  \nsurvival rates for \ndelayed dissection:  \n48.7% for males  \n62.0% for females  \n \n of evidence \nconcerning the \nquestion of \nindication for \ntherapeutic node \ndisse ction  \n \nPredominantly \nwomen in study \ngroup  \nSandeman (1966)  To review the \nresults of radical \nsurgery and other \nmethods in the \ntreatment of \nregionally advanced \nmelanoma  Cohort study  \n \n 113 patients with \nmalignant \nmelanoma in stages \nI-III  Overall survival  5-year OS survival \nfor patients who \noriginally presented \nin stage I, \ndepending on \ntreatment method:  \nSurgery 27%  \nIrradiation 23%  \nCombined 67%  \n \n5-year overall \nsurvival for patients \nwho originally \npresented in stage \nII, depending on \ntreatment method:  \nSurgery 27% Retrospective \ndesign  \n \nInsufficient control \ngroup of patients \nwho did not receive \ntreatment  \n 3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 296 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE  \nIrradiation 33%  \nCombined 0/4  \n \nStage III: 5 -year \nsurvival for \nirradiation 33%  \n \nInsufficient data for \n\u201cno treatment\u201d \ngroup and stage III \nwith other treatment \nmodalities  \nPrice and Duval \n(1963)  To determine \nwhether or not \nprognosis in \nmalignant \nmelanoma is \naffected by regional \nlymph node \nexcision  Cohort study  \n \n 50 patients with \nmalignant \nmelanoma arising \non an extremity  Overall survival  27 of 50 patients \nhad cli nically \npositive nodes on \npresentation. Of \nthese 2 refused \ntreatment (0% \nsurvivors) and  \n \n27/25 patients with \nclinical positive \nnodes received  \nregional lymph node \ndissection: 20% \nsurvivors  \n Retrospective \ndesign  \n \nSmall patient cohort  \n \nVery old patient \ncohort (1931 \u2013 \n1956), questionable \ntransferability to \ncurrent situation  \n \nVery small, probably \nbiased control \ngroup (2 patients \nwith clinically 3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 297 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE  \n14/23 patients with \nhad clinically \nnegative nodes; \nreceived regi onal \nlymph node \ndissection: 43% \nsurvivors   \n \n involv ed nodes who \nrefused treatment)  \n \nBowsher et al. \n(1986)  To evaluate short \nand long term \npostoperative \nmorbidity, mortality \nand local recurrence \nrate after regional \nnode dissection for \nmelanoma  Cohort study  \n \n 86 patients who \nreceived regional \nnode disse ction for \nmelanoma  \n(28% prophylactic, \n72% therapeutic)  Recurrence rate  \n \n Local recurrence \nafter dissection:  \n \n- cervical: 33%  \n- axillary: 13%  \n- inguinal: 9%  \n- axillary for trunk \nlesions: 21%  \n- axillary for arm \nlesions: 6%  \n \n Retrospective \ndesign  \n \nSmall pat ient cohort  \n \nNo control group \n(comparison of \nlymph node \ndissection vs. no \nlymph node \ndissection not \npossible)  \n \nFor data on \nprophylactic RND \nand complications, \nsee original article  3b-  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 298 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE  \nFortner et al. (1964)  To present results \nof groin dissection \nin maligna nt \nmelanoma  Cohort study  \n \n 220 patients who \nhad undergone a \ngroin dissection for \nmalignant \nmelanoma  Overall survival  \n \nRecurrence rate  \n \nComplication rate  5-year-survival -rate \nof patients with \ndissection:  \n- unilateral groin \ndissection: 33,5%  \n- histologically  \npositive nodes: 23,3 \n% \n- histological \nnegative nodes: \n78,8%  \n-radical groin \ndissection: 31,6%  \n- nodal involvement \nby metastatic cancer \nconfined to the \nsuperficial groin: \n41,6%  \n- positive nodes in \nboth superficial and \ndeep groups: 8,7%  \n \nComplication -rate \n- during operation:  \n3% \n- postoperative:  \nApproximately 60%  Very old patient \ncohort (1931 \u2013 \n1956),  questionable \ntransferability to \ncurrent situation  \n \nNo control group \n(comparison of \nlymph node \ndissection vs. no \nlymph node \ndissection not \npossible)  \n \nFor further \nprognostic data see \noriginal article  3b-  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 299 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE  \n \nMortality rate within \n30 days after \noperation: <0,5%  \n \nMorbidity rate \n(relative to other \nthan wound \nproblems: 19,4%)  \n \nRecurrence rate \ntotal for first year: \n55,8%  \n \n3.3.5.  Literatur  \nAllan CP, Hayes AJ, Thomas JM. Ilioinguin al lymph node dissection for palpable metastatic melanoma to the groin. ANZ J Surg 2008;78:982 -986 \nBowsher WG, Taylor BA, Hughes LE. Morbidity, mortality and local recurrence following regional node dissection for melanoma. Br J Surg 1986;73:906 -908 \nCascin elli N, Morabito A, Santinami M, et al. Immediate or delayed dissection of regional nodes in patients with melanoma of the tr unk: a randomised trial. WHO Melanoma \nProgramme. Lancet 1998;351:793 -796 \nFinck SJ, Giuliano AE, Mann BD, et al. Results of ilioingu inal dissection for stage II melanoma. Ann Surg 1982;196:180 -186 \nFisher SR. Elective, therapeutic, and delayed lymph node dissection for malignant melanoma of the head and neck: analysis of 1444 patients from 1970 to 1998. Laryngoscope \n2002;112:99 -110 \nFORT NER JG, BOOHER RJ, PACK GT. Results of Groin Dissection for Malignant Melanoma in 220 Patients. Surgery 1964;55:485 -494 \nGadd MA, Coit DG. Recurrence patterns and outcome in 1019 patients undergoing axillary or inguinal lymphadenectomy for melano ma. Arch Su rg 1992;127:1412 -1416  \nHughes TMD, A'Hern RP, Thomas JM. Prognosis and surgical mananagement of patients with palpable inguinal lymph node metastase s from melanoma. Br J Surg 2000;87:892 -\n901 \nJonk A, Strobbe LJ, Kroon BB, et al. Cervical lymph -node metastasi s from cutaneous melanoma of the head and neck: a search for prognostic factors. Eur J Surg Oncol \n1998;24:298 -302 \nKarakousis CP, Driscoll DL. Groin dissection in malignant melanoma. Br J Surg 1994;81:1771 -1774  \nKarakousis CP, Driscoll DL, Rose B, et al. Gro in dissection in malignant melanoma. Ann Surg Oncol 1994;1:271 -277 \nKarakousis CP, Emrich LJ, Rao U. Groin dissection in malignant melanoma. Am J Surg 1986;152:491 -495 \nKarakousis CP, Hena MA, Emrich LJ, et al. Axillary node dissection in malignant melanoma:  results and complications. Surgery 1990;108:10 -17  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 300 von 732 Lee CC, Faries MB, Wanek LA, et al. Improved survival after lymphadenectomy for nodal metastasis from an unknown primary melanoma. J Clin Oncol 2008;26:535 -541 \nMorton DL, Wanek L, Nizze JA, et al. Improved  long-term survival after lymphadenectomy of melanoma metastatic to regional nodes. Analysis of prognostic factors in 1134 \npatients from the John Wayne Cancer Clinic. Ann Surg 1991;214:491 -9; discussion 499 -501 \nPasquali S, Mocellin S, Campana LG, et al. Ea rly (sentinel lymph node biopsy -guided) versus delayed lymphadenectomy in melanoma patients with lymph node metastases : \npersonal experience and literature meta -analysis. Cancer 2010;116:1201 -1209  \nPathak I, Gilbert R, Yoo J, et al. Outcome of neck dissecti on for node -positive melanoma. J Otolaryngol 2002;31:147 -149 \nPienkowski A, Nowecki ZI, Rutkowski P, et al. Analysis of survival and prognostic factors in patients with cutaneous melanoma  after therapeutic lymphadenectomy. Nowotwory \n2005;55:207 -212 \nPilko G,  Besic N, Zgajnar J, et al. Prognostic heterogeneity after the excision of lymph node metastases in patients with cutaneous melanoma. Surg Oncol 2011;20: 26-34 \nPRICE WE, DUVAL MK,Jr. Regional Lymph Node Dissection and Malignant Melanoma. Effect of Survival.  Arch Surg 1963;87:747 -750 \nRutkowski P, Nowecki ZI, Dziewirski W, et al. Melanoma without a detectable primary site with metastases to lymph nodes. Derm atol Surg 2010;36:868 -876 \nSandeman TF. The radical treatment of enlarged lymph nodes in malignant melano ma. Am J Roentgenol Radium Ther Nucl Med 1966;97:967 -979 \nSerpell JW, Carne PW, Bailey M. Radical lymph node dissection for melanoma. ANZ J Surg 2003;73:294 -299 \nvan Akkooi AC, Bouwhuis MG, van Geel AN, et al. Morbidity and prognosis after therapeutic lymph node dissections for malignant melanoma. Eur J Surg Oncol 2007;33:102 -\n108 \nVeronesi U, Adamus J, Bandiera DC, et al. Delayed regional lymph node dissection in stage I melanoma of the skin of the lower extremities. Cancer 1982;49:2420 -2430  \nWhite RR, Stanley WE, Johnson JL, et al. Long -term survival in 2,505 patients with melanoma with regional lymph node metastasis. Ann Surg 2002;235:879 -887 \nYoung SE, Martinez SR, Faries MB, et al. Can surgical therapy alone achieve long -term cure of melanoma metastatic to re gional nodes? Cancer J 2006;12:207 -2 \n \n \n \n \n \n \n \n \n \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 301 von 732 3.4. Frage II I.7. Operative Therapie bei Fernmetastasen  \u2013 De-novo-Recherche  \nFrage III.7 . Wann ist bei Fernmetastasen eine operative Therapie indiziert?  \n \n3.4.1.  Datenbanken, Suchstrategien, Trefferzahlen  \nDatenbank  Suchstra tegie  Datum  Treffer \n1. Suche     \nMedline  (\u201cmelanoma\u201d[tiab] AND (\"neoplasm metastasis\"[MeSH Terms] OR (\"metastasis\"[tiab])) \nAND (\"surgery\"[All Fields] OR \u201cmetastasectomy\u201d[All Fields])  26.01.2012  3878  \n2. Suche/Erg\u00e4nzungsrecherche     \nMedline  (\u201cmelanoma\u201d[t iab] AND (\"neoplasm metastases\"[MeSH Terms] OR (\"metast ases\"[tiab]) \nOR (\u201cmetastatic\u201d[tiab])) AND (\"surgery\"[All Fields] OR \u201cmetastase ctomy\u201d[All Fields])  26.01.2012  4137  \nCochrane Library  (melanoma and (metastasis or metastases) and (surgery or metastasecto my)).ti,ab.  19.01.2012  89 \nEmbase  (melanoma and metastasis and (surgery or metastasectomy)).ti,ab.  \n(melanoma and metastases and (surgery or metastasectomy)).ti,ab.  23.01.2012  806 \n1342  \nBemerkungen: Eine erste Literaturrecherche in Medline und und Cochrane erfolgte am 26.04.2011 bzw. f\u00fcr Embase am 11.05.2011. Eine Erg\u00e4nzungsrecherche in \nMedline erfolgte am 08.12.2011. Die Update -Recherche wurde am 23.01.2012 (Embase) bzw. am 26.01.2012 ( Medline) und am 19.01.2012 (Cochrane) \ndurchgef\u00fchrt. In der Tabelle ange geben sind die Trefferzahlen der letzten R echerche.  \n \n \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 302 von 732 3.4.2.  Auswahlkriterien  \nAuswahl der Literatur  \nGesamttreffer  inkl. Dupletten  10252  \nEinschlusskriterien  Thematische \u00dcbereinstimmung  \nSprachen: e,dt, ab Erscheinungsjahr 1978  \npopulation \u2265 20 patients  \nAusschl usskriterien  narrative Reviews, Case Reports, gemischte Kollektive mit anderen Krebsarten, Studien au sschlie\u00dflich zu Gehirn -\nMetastasen (andere AG)  \nAnzahl nach Abstractscreening  93 \nAnzahl ausgew\u00e4hlter Volltexte, vorges ehen f\u00fcr Bewertung  31 \n \n3.4.3.  Evidenztabell e \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE  \nSubtopic Pulm onary \nMetastases         \nPetersen et al. \n(2007)  to discriminate  \npredictors of \nsurvival for patients \nwith pulmonary \nmetastatic \nmelanoma.  Cohort study  \n \n 1720 patients with \nmetastati c \npulmonary \nmelanoma  \n \n318 patients \nunde rwent resection \n(with curative \nintent)  Survival  \n \n1-, 2- and 5 -year-\nsurvival  \n \n OS (n=1720)  \n- 1 year: 34%  \n- 2-year: 14%  \n- 5 years: 6%.  \n \nmedian survival: 7.3 \nmonths.  \n \ncomplete vs Retrospective \ndesign \n \ncomplete follow -up \non all patients  \n \nlarge sample  \n \ndata collection 2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 303 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE  \n  incomeplete \npathologic \nresection:  \n- median su rvival: \n19 vs. 11 months  \n- 5-year survival: \n21 vs. 3% \n(P<0.0001).  \n \nsingle vs. r epeated \nmetastase ctomy:  \n- median su rvival: \n17 vs.15 months \n(P<0.9). \n \nSignificant \npredi ctors of \nsurvival \n(multivariate \nmodel):  \n- nodular hi stologic \ntype ( P=0.033)  \n- disease -free \ninterval (P<0.001)  \n- number of \npulmonary \nmeta stases during a span of 35 \nyears.   \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 304 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE  \n(P=0.012)  \n- presence of \nextrathoracic \nmetast asis \n(P<0.001)  \n- performance of \npulmonary \nmeta stasectomy \n(P<0.001).  \n \n \ndisease-free \ninterval after \nsurgery > 5 years: \nSurvival: 19 months \n(vs 7 mont hs, \nP<0.01)  \n \nPatients without \nextrathoracic \nmeta stasis: 18 (vs 8  \nmonths, P<0.01). \nLeo et al (2000)  To evaluate the \nlong-term results of \nlung \nmetastasect omy for \nmelanoma and to Cohort study  \n \n. 328 patients who \nunde rwent lung \nmetastase ctomy  \n \nSurgical patients Overall survival  \n \nMortality  \n \nProgn ostic factors 5-year-survival: \n18% 10 -year-\nsurvival: 14%  \nmedian su rvival 17 \nmonths.  Retrospective \ndesign \n \n \nOld patient cohort 2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 305 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE  \ndefine a su bset of \npatients with better \nprognosis.  underwent resection \nwith cur ative intent \nonly \n of survival   \nR0-resection:  \n 5- and 10 -year \nsurvival: 22% and \n16%(m edian \nsurvival 19 months)  \n \nR1/R2 -resection: 5 -\nyear-survival: 0%  \n(median survival 11 \nmonths).  \n \nLong - term survival \naccor ding to the \nradicality of \nmeta stasectomy \n(16% vs 0% at 10 \nyears, P < 0.01)  \n \nindependent \nunfavou rable \nprognostic factors:  \n- time to pulmonary \nmeta stases (TPM) \n<36 months  \n- presence of \nmultiple metast ases  (1945 -1995) \n/questionable \ntransferability to \ncurrent situation  \n \nBias: chemo -\n/radiotherapy  \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 306 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE  \n \nPatients without \nthese risk fa ctors: \n5-year-survival \nrate:29%  \n \nPatients with 1 risk \nfactors: 5 -year-\nsurvival rate:20%  \n \nPatients with 2 risk \nfactors or \nincomplete \nresection: 5 -year-\nsurvival  \nrate:7%  \n \n- mortality rate 67%  \n- in the R0 group: \n65% \n- in the R1 \u20132 group: \n80%).  \n \n5-year-survival \ninpatients with \nintrathoracic \nrecurrence and  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 307 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE  \nfurther surgery: 19%  \nHarpole et al. \n(1992)  To analyse patients \nfrom a melanoma \ndata base  \n- overall risk of \npulmonary \nmeta stastic disease?  \n- pulmonary \nresection as a \nprimary therapy for \nmetast ases? \n- multivariate risk \nfactors for survival?  Cohort study  945 patients \nwithpulmonary \nmetases.  \n 1-, 3- and 5 -year \nsurvival -rates  \n \nsurvival  1-, 3- and 5 -year \nsurvival -rates: 30%, \n9% and 4%  \n \nMultivariate \npredictors of \nimproved survival \n(p<0,001):  \n-complete resection \nof pulmonary \ndisease \n- longer time for \nformation of \nmeta stases  \n-treatment with \nchemotherapy  \n-1 or 2 pulmonary \nnodules  \n- lymph nodes \nnegative for \nmetastases \n(p<0,005)  \n-histologic type \n(p<0,04)  \n \ncurative resection Retrospective \nanalysis \n \nNo information \nabout follow up  \n \n 2b- \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 308 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE  \nfor a sol itary nodule \n(n=84) vs. no \noperation (n=142): \n2-year and 5 -year \nsurvival: 42% versus \n20% (p<0,001)  \nNeuman et al. \n(2007)  to evaluate the  \nnatural history of \nstage -IV melanoma \nmetastatic to the \nlung and identify \nfactors predi ctive of \nsurvival.  Cohort study  \n 122 patients with \nstage -IV mel anoma \nand pulmonary \nmetastases  \n  factors pedicitive of \nsurvival  \n \nsurvival  \n \ntime to recurrence  \n \n5-year-survival  Median survival: 14 \nmonths  \n5-year su rvival: 8%  \n \nFactors \nindependently \npredictive of \nsurvival:  \n- solitary \npulmonary \nmetast asis (HR 2.7, \nCI 1.6 \u20134.4, \np<0.0005)  \n- absence of extra -\npulmonary disease \n(HR 1.9, CI 1.2 \u20133.1, \nP=0.01).  \n- metastase ctomy \n(HR 0.42, CI 0.21 \u2013\n0.87, P = 0.02).  \n Retrospective \ndesign \n \nNo information \nabout staging  \n \nSmall number of \npatients who \nreceived \nmetastase ctomy \n(n=26)  \n \nPatients with \npulmon ary \nmetastases a nd \nconcurrent  \nskin/subcutaneous/\ndistant nodal \ndisease were \nincluded  \n 3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 309 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE  \nmedian survival of \npatients with \nmeta stasectomy vs. \nno surg ical \ntreatment:  \n- 40 vs. 13 months  \n \nMedian time to \nrecurrence: 5 \nmonths  \n \nestimated 5 -year \nsurvival of patients \nundergoing \nmeta stasect omy: \n29%.  \n \nPatient who were \nfollowed up 3 \nand/or 5 years:  \n3-year- survival: \n50%  \n5-year- survival: \n23%  Bias: systemic \ntherapy \nAndrew et al.(2006)  To describe the  \nexperience with \npulmonary cohort study  \n \n 86 patients 1-4 \npulmonary \nmetastases.  relapse -free \nsurvival  \n overall median time \nto relapse: 8.4 \nmonths  Retrospective \ndesign \n 3b   \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 310 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE  \nmetastase ctomy   \n(10 patients with \nunknown p rimary \nsite) \n overall -survival  \n \n5-year-survival  \n \n  \nmedian survival: 35 \nmonths.  \n \n5-year survival rate: \n33% \n \n48/86 patients died  \n(median survival \ntime = 24 months),  \n \n16% of patients \nwere re lapse -free at \na median fo llow-up \nof 35 months.  \n \nmedian survival of \npatients with a \nsolitary vs. multiple \nlesions: 41 vs. 25 \nmonths  \n(P = .05)  Short follow -up \n \nPatients received \ndifferent \npostsurg ical \ntherapies  \n \n \nSchuhan et al. \n(2011) to determine the \nclinical course, \noutcome and \nprogno stic factors in \na subset of patients Cohort study  30 patients with \npulmonary \nmetast ases from \nmalignant \nmelanoma who 5-year survival rate  \n \nMedian survival  \n \nprognostic Cumulative 5 -year \nsurvival rate after \npulmonary \nresection: 35.1%, \nmedian survival: Small patient cohort  3b-  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 311 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE  \nrecently tre ated by \nmetastase ctomy.  underwent \npulmonary \nresection \n \nComplete \npulm onary \nresection in 27 \npatients  param eter for OS  18.3 months.  \n \npatients with \ncomplete \npulmonary vs. \npatients with \nincomplete \nresection: median \nsurvival: 20.5 \nmonths vs. 13.0 \nmonths  \n \ncompleteness of \nresection=no \nstatistically \nprogno stic factor \nfor survival.  \n \nMultivariate \nanalysis: only \nsignificant \nprognostic \nparam eter for \noverall survival: \ngender (9.4 months \nvs. 25.0 months for \nthe female and male  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 312 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE  \ngroup, respe ctively ( \nP = 0.022).  \nDelaunay et al. \n(1991 ) to assess the value \nof surgery in terms \nof survival and to \ndelimit its \nindications  cohort study  \n \n \n 38 patients with \npulmonary \nmetast ases of \nmalignant \nmelanoma  \n Overall -survival  \n \nDisease -free \nsurvival \n \n5-year survival rate  median survival: 15 \nmonths (range 2 -\n144 months).  \n \n5-year-survival: \n20% \n \nmedian disease -\nfree-survival: 10,5 \nmonths.  \n \nStatistical \nsignif icance in \nsurvival (incomplete \nvs. rad ical surgery: \np<0,0001)  \n Retrospective \nmulticenter study  \n \nNo information \nabout follow -\nup/recruitment \nperiod \n \n10 patients received \nneo-adjuvant \ntreatment  \n 3b- \nPogrebniak et al. \n(1988 ) To update and \nreexamine the \nefficacy of excision \nof pulmonary \nmelan oma \nmetastases  Cohor t study  \n \n 49 patients with \nresection of \npresumed \npulmonary \nmetastases from \nmalignant \nmelan oma survival  Benign disease \n(n=13), metasta stic \ndisease (n=32), \nlung ca ncer (n=1)  \n \nSurvival (benign vs. \nmalignant disease): retrospective study  \n \nscreening met hods \nout of use, \nquestionable \ntransferabi lity to \ncurrent situ ation 3b-   \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 313 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE  \n \n \n \n 169 vs. 22 months  \n \nMedian survival \nafter thoracotomy \n(malignant di sease): \n13 months.  \n \nNo diffe rence in \nsurvival after \ncomplete vs. \nincomplete \nresection. \n \n2-year-survival for \npatients with 1 vs. \n>1 nodule resected: \n30% vs. 10%  \nMathisen et al \n(1979)  To determine the \nefficacy of resection \nof pulmonary \nmetastases from \nmalignant \nmelanoma  Cohort study  33 patients who \nunderwent \nthoracotomy for \nresection of \nsuspected \npulmonary \nmetast ases from \nmalignant \nmelanoma  survival  11 patients: non -\nmalignant disease  \n \n10 unresectable \ndisease: median \nsurvival: 10,5 \nmonths (3 -20) \n \n12 were rendered \ndisease -free, Retrospective study  \nSmall population  \n \nPopul ation not \ndescribed  \n \nOld patient cohort \n(1957 -1978) \nquestionable \ntransferabi lity to 3b-   \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 314 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE  \nmedian survival: 12 \nmonths (3 -35).  \n \n5-year survival: 0%  current data  \n \n10 patients r eceived \npostoperative \nchemotherapy  \nSubtopic \nAbdominal/ \nretroperitoneal \nmeta stases         \nSanki et al. (2009 ) To assess survival, \nmorbidity  and \nmortality following \ntherapeutic or \npalliative resection \nof gastr ointestinal \n(GI) tract melanoma \nmetast ases retrospective \nprognostic cohort \nstudy  117 patients who \nunderwent \noperations for acute \nand/or sub -acute \nsymptoms or for \nimminently \nsymptomatic GI  \nmetast ases detected \nradiolog ically Mortality  \n \nPostoperative \ncomplications  \n \nsurvival  Mortality rate after \nGI resection: 1.4%  \n \npost-operative \ncompl ications -rate: \n2,5% \n \n1-, 2- and 5 -year \nsurvival rates:  \n-  for all p atients: \n57%, 39% and 27%  \n- for patients \nhaving palliative \nresect ions: 34%, \n19% and 0%.  \n \nThe median  2b \n \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 315 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE  \nsurvival: \n- after surgical \nresection: 16.4 mo.  \n- after resection \nwith cur ative intent: \n22.6 mo.  \n-  following \npalliative resection: \n7.7 mo.  \n \nsignificant \nprogno stic \nindicators of \nsurvival (on \nmultiva riate \nanalysis):  \n- presence of \nresidual \nintraabdominal \ndisease \n- presence of non -\nGI meta stases at the \ntime of surgery or \nafter su rgery were \nthe  \nOllila et al. (1996 ) To evaluate the role \nof surgery in the Retrospective \nprognostic c ohort 124 patients with \nmetastatic Operative morbi dity \nand mortality  median DFI : 23.2 \n(range, 1 -154)  2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 316 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE  \nsurvival of patients \nwith melanoma \nmetastat ic to the \ngastrointe stinal (GI) \ntract study  melanoma in the \nstomach, small \nintestine, colon, or \nrectum  \nrelief of sym ptoms  \n \nmedian and 5 -year \nsurvival months.  \n \n1 operative death  \n \n1 major oper ative \ncompl ication  \n \nAfter surgery r elief \nof sym ptoms in 97%  \n \nmedian su rvival in \npatients with \ncurative resection \nvs. palliative \nprocedures and \nnonsurgical \ninterventions: 48.9 \nvs 5.4 and 5.7 \nmonths, \nrespe ctively  \n \nprogno stic factors \nfor long -term \nsurvival \n(multivariate \nanalysis):  \n- complete  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 317 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE  \nresection of GI tract \nmetast ases \n- GI tract as the \ninitial site of distant \nmetast ases.  \nHodgson et al. \n(2007)  To determine the \nrole of resectional \nsurge ry in \nmeta stastic \nmelanoma of the \nabdomen  Cohort study  \n \n 25 patients  \n \n(5 patients had \noccult tumours)  \n \n Survival  \n \nmorbidity  \n \nmorta lity median survival \nafter abdominal \nresection: 8.3 \n(range 0.4 \u201341.1) \nmonths.  \n \n1-year survival: 36%  \n \n1-year-survival \nafter s urgery with \ncurative vs. \npalliative intend:  \n89 vs 10%, P < \n0.0001)  \n \nSuperior survival in \npatients with \u22642 \nmetastases \ncompared with \u22652 \n(P = 0.0001)  \n \nIntent of surgery Retrospective study  \n \nSmall population  \n \nNo information \nabout follow -up 2b-  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 318 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE  \n(curative vs \npalliative) was the \nonly factor \nsignif icant \non multivariate \nanalysis (P = \n0.001).  \n \nRelief of \npreoper ative \nsymptoms: 87%  \n \nOper ative \nmorbidity: 12%  \n \n30-day morta lity: \n4%. \nMittendorf et al. \n(2008)  to determine the \nnatural history of \nmelanoma \nmetast asis to th e \nadrenal gland and \nthe a ppropriate role \nfor surgical \nintervention  Cohort study  154 patients with \nadrenal metastasis  \n \n22 patients \nunde rwent surgical \nresection  \n \n \n surgical treatment  \n \nsurvival median OS:6.4 \nmonths (range 0,2 -\n97 months).  \n \nmedian OS for \npatients with:  \n- synchronous \nmetastatic di sease: \n6.6 months  \n- isolated adrenal Retrospective \ndesign \n \nSmall population  3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 319 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE  \nmeta stasis: 18.7 \nmonths (p<0,0001)  \n \nmedian OS for \npatients with a \ndisease-free \ninterval of:  \n- <1 year: 7 months  \n- >1 year: 11 \nmonths ( P=0,35 ). \n \nAfter a median \nfollow-up of 12.6 \nmonths, 9/22 (41%)  \nPatients who \nunderwent surgical \nresection were alive, \nincl. 7 without \nrecurrence.  \n \nSurvival of patients \nwho u nderwent \nsurgery vs. those \nmanaged \nnonoper atively \n(p<0,0001).  \nPawlik et al. (2006)  To ev aluated the Cohort study  40 patients with Survival  median time to Retrospective 3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 320 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE  \nefficacy of hepatic \nresection in p atients \nwith metastatic \nocular and \ncutaneous \nmelanoma and to \nassesse fa ctors that \ncould affect su rvival \nafter rese ction  \n metastatic \nmelan oma involving  \nthe liver who were \ntreated w ith hepatic \nresection with  \ncurative intent  \n \n  \n5-year-survival  \n \nTime to recurrence  recurrence: 8.3 \nmonths  \n \nmedian survival: \n28.2 months \n(range,4.6 \u201393 .7 \nmonths)  \n \n5-year su rvival rate: \n10.9%.  \n \n5-year survival rate \nfor patients with a  \nprimary ocular \nmelanoma: 20.5%.  \n \n5-year survival rate \nfor patients with \ncutaneous \nmelan oma (P=0.03).  \n \nNo clinicopathologic \nfactors predictive of \nsurvival after \nhepatic resection  design \n \nPatients with oc ular \nmelanoma i ncluded  \n \nSome patients  had \nother metastatic \nsites (not only liver) \nwhich were not \noperated  \n \nBias: 17 patients \n(70.8%) received \nsome form of \nsystemic therapy  \nRicaniadia et al. \n(1995)  to investigate the  \nrole of surgical Cohort study  \n 68 patients with \nclinical indic ations Complication rate  \n median survival for \npatients unsuitable Retrospective \ndesign 3b   \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 321 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE  \nintervention in  \npatient with GI \nmetastasis and to \ndefine the group of \npatients who would \nbenefit surgical \nresection.   of involvement of \nthe gastrointest inal \n(GI) tract with \nmetastatic \nmelanoma  \n \n47 patients \nunde rwent \nabdominal surgery  Survi val \n \n5-year-survival  for surgery: 2.9 \nmonths.  \n \nRelief of \npreoper ative \nsymptoms after \nsurgery: 73%  \n \nPostoperative \ncomplications: 29%  \n \nDeath within 30 \ndays of surgery: \n11% \n \nmedian survival:  \n- after surgery vs. \nno surg ery: 5.66 vs. \n2.9 months \n(P=0.0035)  \n- after complete \nresection and no \nother disease vs. \nresection and other \nmetastasis present: \n27,6 vs. 5.1 months  \n- after by -pass  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 322 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE  \nprocedure: 1,9 \nmonths  \n \n5-year survival:  \n- after co mplete \nresection and no \nother ev idence of  \ndisease: 28.3%  \n(the other groups \nhad only 1 -year \nsurvivors) \nSzynglarewicz et al. \n(2012 ) To asses the role of \ncolorectal su rgery in \nthe treatment of \nmetastatic \nmelan oma and to \nidentify p atients who \ncan most benefit \nfrom surgical \nresection. Cohort study  34 consecutive \npatients with skin \nmelanoma  \nwho underwent \nsurgical resection of \nlarge bowel \nmeta stasis  \n \n9 patients: \nemergency surgery \nfor obstruction, 25 \npatients had an \nelective proc edure.  \n \nIntend of surgery: \ncurative in 14 Mortality  \n \nMorbidity  \n \nMedian survival  \n \n1-, 2-, and 5 -year \nsurvival rates  \n \nPrognostic factors  postoperative \nmortality: 0%  \n \npostoperative \nmorbidity: 9%.  \n \nMedian survival \nfollowing surgery: \n11.5 (4 -68) \nmonths. 1 -, 2-, and \n5-year survival \nrates:  \n50%, 32%, and 17% \nrespectively.  \n \nMedian survival Small patient cohort  \n \nNo information \nabout R1 -Status  3b-  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 323 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE  \npatients, palliative \nin 20 patients  \n significantly \nincreased in \npatients without \nextra -abdominal \nmetastases, with no \nevidence of non -\nlarge bowel \nmetastases, if the \nDFI >24 months \nand when curative \nresection was \nperformed.  \n \nmost important \nprognostic factors \non mu ltivariate  \nanalysis: appa rently \ncomplete or \npalliative resection \nand the absence or \npresence of \nextraabdominal \nmeta stases  \nde Wilt et al. (2003)  To analyse \nindications for \nsurgery, \ncomplications, and Cohort study  \n \n 15 patients who \nunderwent surgical \ntreatment of \nmeta stases  Postoperative \nmorbidity  \n \nOverall survival  patients with \nsplenectomy: \nmedian OS: 11 \nmonths  retrospective design  \n \nSmall patient \nnumber 3b-  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 324 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE  \noverall survival with \nthe aim of clarifying \nthe indications for \nsurgical treatment in \nsuch patients   \n98 patients were \ntreated \nconserv atively \n \n.  \n1-year-survival rate  \n \n2-year-survival rate  \n 1-year survival rate: \n35%, 2 -year-\nsurvival -rate 21%  \n \npatients with single \nsplenic lesion and \nsplenectomy: \nmedian OS : 23 \nmonths.  \n1-year survival rate: \n70%, 2 -year-\nsurvival -rate: 50%  \n \nconservatively \ntreated patients:  \nmedian OS: 4 \nmonths. 1 -year \nsurvival rate: 13%, \n2-year-survival -\nrate 3%  \n \nsurvival of patients \nwith splenic \nmeta stases treated \nsurgically vs. \nconserv atively: \nP=0.02   \nMedical/conservativ\ne treatment not \ndescribed in detail,  \n4 patients who \nunderwent \nsplenect omy were \nincluded in clinical \ntrials.  \n \nNo information \nabout follow -up  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 325 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE  \n \nSurvival after \nsplenectomy with \npalliative vs. \ncurative intent: \nP=0,07  \nBerger et al. (1999 ) \n To determine \nwhether surgery \ninfluences ou tcomes  Retrospective \ncohort study  Fifty patients with \nmelanoma \nmetasta tic to the GI \ntract Mortality rate  \n \nsurvival  operative mortality \nrate: 2.5%  \n \nmean survi val times \nfor the unexplored \nand unrese cted \ngroups: 4.1 months  \n \nsignificantly \nincreased survival:  \n- in the pa rtial-\nresection group (8.9 \nmonths) co mpared \nwith the \nunrese ctable group \n(P<0. 001).   \n- in the co mplete -\nresection group \n(23.5 months) than \nin the le ss than \ncomplete r esection - 3b-  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 326 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE  \ngroup ( P<0.0001).  \nKhadra et al. (1990)  To examine if a \nsurgical approach of \nmetatases in the GIT \nis justified.  Cohort study  \n \n 56 patients with \nsymptomatic \nmelanoma of the \ngastr ointestinal \ntract (GIT) treated \nsurgically  \n \n(13 occult primary)  \n \n complication rate  \n \npostoperative \nsurvival  \n \noverall survival  \n \ntime to recurrence  relief of symptoms \nin 44 p atients post  \npostoper atively.  \n \npostoperative \ncomplications: 8/56 \npatients (2 died)  \n \nmean postoperative \nOS after 1st vs. 2nd \nmetastases: 11 .7 \n(range 1 -60) vs. 3,6 \nmonths (range 0 -12 \nmonths)  \n \nmedian time of \nrecurrence: 12 \nmonths (range 3 -47 \nmonths)  \n \nmean OS for \nulcerated vs. non -\nulcerated tumor: \n46,6 vs. 84,9 \nmonths.  \n Retrospective \ndesign \n \nMethods of follow -\nup not described  \n \nNo information \nabout metastases \nother than in GIT -\ntract \n \nBias: Adjuvant \ntherapy \n(chemotherapy in \n26 patients, \nradiotherapy in 1 \npatients, \nimmunothe rapy in 4 \npatients)  \n 3b-  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 327 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE  \nmean OS when \nprimary t umor <1,5 \nmm vs. >1,5 mm: \n11,7 vs. 9,5 \nmonths. \nChua et al. (2010 ) To evaluate the \nefficacy of surgical \nmetastase ctomy on \nsurvival ou tcomes.  Retrospective \ncohort study  23 patients with \nvisceral metast ases \nfrom mel anoma (15 \nunderwent surgical \nresection)  disease -free \ninterval  \n \nOverall survival  DFI: 49 (range, 5 to \n559) mon ths \n \nMedian OS: 9 \nmonths. 1 - and 3 -\nyear su rvival: 39% \nand 30%, \nrespe ctively.  \n \nSurvival was \ninfluenced by - the \nnumber of \nmetastases ( P = \n0.05) and the \ntreatment r eceived \n(P = 0.03).  \n \nAfter \nmetastasect omy: \nDFI and OS: 14 and \n21 months, \nrespe ctively. 1 - and Small patient cohort  4  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 328 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE  \n3-year su rvival: 60% \nand 40%, \nrespe ctively.  \n \nSignificant longer \nsurvival for patients \nwith single site vs. \n>1 site of \nmetast asis (P = \n0.005)  \nBranum et al. \n(1991) To evaluate the role \nof resection in the \nmanag ement of \nmelanoma  \nmetastatic to the \nadrenal gland  Retrospective \ncohort study  28 patients with \nmelanoma  \nmetasta tic to the \nadrenal gland  Survival  \n \n5-year-survival  Mean survival in the \ngroup that \nunderwent r esection \nfor cure: 59 months \n(3 to 112 months)  \n \nsurvival in the \ngroup wit h \nunresectable \ntumors: 15 months \n(1.5 to 132 \nmonths).  \n \n5-year-survival:  \n- 4/8 patients who \nunderwent rese ction \nfor cure   4  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 329 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE  \n1/14 p atients with \nunresectable \ntumors  \nSubtopic di fferent \nmetasta tic sites         \nWasif et. (2011)  to study the  \nimpact of \nmeta stasectomy on \nsurvival in these \npatients.  Prognostic factors  4229 patients with \nstage IV melanoma  \n \npatients were \nsubdivided into M1a \ndisease (cutaneous \nmetastases) and \nMbc disease \n(visceral \nmetast ases). Median survival  \n \n5-year-survival  median survival of \nthe study \npopul ation: 7 \nmonths.  \n \nPatients who \nunderwent \nmeta stasectomy \n(33.6%) vs. patients \nwithout \nmetastasectomy:  \nmedian OS: 12 \nmonths vs 5 \nmonths  \n5-yeas OS: 16% vs. \n7% (P < 0.001).  \n \nIn patients with M1a \ndisease (n = 1,994): \nmedian survival of \n14 months vs. 6 Those who had \nmeta stasectomy \nperformed were \ncompared with \npatients that did \nnot. 2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 330 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE  \nmonths, 5 -year OS: \n20% vs. 9% (P < \n0.001).  \n \nYounger age and  \ndiagnosis from \n2001 to 2006 were \npredi ctors of \nmetastase ctomy. \nMetastase ctomy \nwas an ind ependent \nand signif icant \npredictor of survival \nfor the e ntire cohort \n(HR 0.59, 95% CI \n0.55\u20130.63).  \nEssner et al (2004)  to evaluate the \noutcome of p atients \nwith a dvanced -stage \nmelanoma treated \nby surgical resection \nwith cur ative intent.  Cohort study  \n 4426 patients stage \nIV melanoma,  \n1574 (35%) \nunde rwent surgical \nresection with \ncurative i ntent; \n 5-year-survival rate  \n \npredictive factors \non survival  5-year survival rate: \npatients who \nunderwent surg ical \nresection vs. \nnonsurgical \ntreatment: \nmean\u00b1SD, 23%\u00b12% \nvs. 6%\u00b15% \n(P<0.001)  \n \n5-year survival rate:  retrospective study  \n \nNo information \nabout adjuvant \ntherapies  2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 331 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE  \npatients with a \nsolitary vs. >/=4 \nmeta stases: 29%\u00b1 \n2% vs. 11%\u00b13% \n(P<0.001)  \n \nmedian su rvival is \nslightly higher for \npatients with skin or \nsubcutaneous sites \n(alone) than for LN, \nGIT or lung sites, no \nsignificant \ndifferences in the \nestimated 5 -year \nsurvival rate \n(P=0.29)  \n \npredictive factors \non multivariate \nanalyses:  \n- earlier primary \ntumor stage (I vs II) \n(P<0.001)  \n- absence of \nintervening stage III \nmetastases  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 332 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE  \n(P=0.02)  \n- solitary metastasis \n(P<0.001)  \n- disease -free \ninterval >36 \nmonth s from AJCC \nstage I or II to stage \nIV (P=0.005)  \nBrand et al. (1997 ) \n to identify impo rtant \nprognostic factors \nassociated with \nStage IV melanoma . Retrospective \nprognostic c ohort \nstudy  3258 melanoma  \npatients  \n \n442 melanoma \npatients with \ndistant metastases  Overall survival  \n \nPrognostic factors  median su rvival \ntime: 7 months  \n \n2-year, 5 -year, and \n10-year su rvival \nrates: 11.9%, 6.7%, \nand 4.7%, \nrespe ctively.  \n \nOf the modalities of \ntherapy given, onl y \nsurgery  was \nassoc iated with \nprolonged su rvival \n(P< 0.0001)  \n \nFactors significantly \nrelated to short \nterm su rvival:   2b \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 333 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE  \n- primary \nmetast asis to the \nskin (P = 0.006)  \n- - the brain (P = \n0.015)  \n- >1 meta static site \n(P = 0.002)  \n- Karnofsky \nperfo rmance status \n<80 ( P = 0.0035)  \n- subsequent >/=2 \nnew m etastatic sites \n(P = 0.0025)  \nTauceri et al (2009)  to agree on the  \nrole of surgery in \npatients with \nmetastatic \nmelanoma  cohort study  \n \n 84 consecutive \npatients ope rated \non for stage IV \nmelanoma  \n \n survival  \n \n1-, 3- and 5-year-\nsurvival rate  \n \nMortality  \n \nmorbid ity postoperative \nmortality: 0  \n \noverall morbidity: \n15%. \n \nminimal and \nmaximal survival: \n1.5 and 142.5 \nmonths, \nrespectively.  \n \nmean OS: 56.7 \nmonths (1 year: retrospective d esign \n \nbias: 90.5% \nunde rwent adjuvant \ntherapies  \n 2b-  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 334 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE  \n72.1%, 3 years: \n46.5%, 5 years: \n23.16%).  \n \nsurvival of \nreiter ative surgery \nvs. single \nsurgery:62.7 vs \n42.4 months, \nmedian 50.9 vs \n16.0, p=0.03.  \n \nReiter ative \nsurgery was shown \nas an independent \nprognostic factor  \n(p<0.05).  \nOllila et al. (1999 ) To exa mine whether \na 2nd \nmetastasect omy \ncould prolong the \nsurvival of p atients  \nwith recurrent stage \nIV melanoma.  Retrospective \ncohort study  131 patients who \ndeveloped recurrent \nstage IV diseas  DFI to recurrence  \n \nSurvival  \n \n5-year-survival  Median DFI: 8 \n(range 0.6 \u201391.8) \nmonths.  \n \nMedian survival:  \n18.2 months after \ncomplete \nmeta stasectomy vs. \n12.5 months or 5.9 \nmonths after Possibly \noverlapping \npopulation/ Ollila et \nal. 1996  \n \n \n2 gynecologic \ntumor sites \nincluded  2b-  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 335 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE  \npalliative surgical  \nprocedure or \nnonsurgical \nmanag ement, \nrespectively.  \n \n5-year survival: \n20.0% after \ncomplete surgical \nmetastase ctomy vs. \n7.0% and 2.1% a fter \npalliative surgical \nand nonsurgical \nintervention, \nrespe ctively.  \n \nprognostic fa ctors \nfor survival:  \n- prolonged DFI \n(P=0,0001)  \n- complete surgical \nmeta stasectomy  \n(P=0,0001)  \nGohl et al. (1996)  To examine the \nvalue of surgical \ntreatment of distant \nmetastases of Cohort study  \n \n In 174 cases \nsurgery was \nperfomed, in 70 \npatients with Survival  Median survival  \n- after R0 (curative \nsurgery): 13 months  \n- R1/R2: 6 months.  Retrospective \ndesign \n \nNo information 3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 336 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE  \nmalignant \nmelanoma  curative intent. 15 \npatients with occult \nmelanoma.  \n \n - Patients without \ntreatment: 3 \nmonths  \n \nstatistically \nsignificant \ndifference in 1 -\nyear-survival for \npatients who \nunde rwent curative \nsurgery vs.palliative \nsurgery.  \n \n5-year-survival and \n10-year-survival \nafter curative \nsurgery: 24% and \n7% respe ctively  about adjuvant \ntherapy \n \nStaging of patients \nnot described  \n \n \nKarakousis CP et al. \n(1994)  To evaluate surgical \ntreatment during the \nmanage ment of \npatients with a small \nnumber of \nresectable lesions in \nan effort to prolong \ntheir life  Cohort study  \n 114 with \ndisseminated \nmelanoma \namenable to \nsurgical resection  \n \n \n Survival  \n \nEstimated 5 -year-\nsurvival  \n \n5-year-survival rate  Median survival \nafter \nmetastasect omy: 19 \nmonths  \n \nestimated 5 -year \nsurvival rate: 22%.  \n \n5-year su rvival rate Retrospective \ndesign \n \nbilateral nodal \nmetastasis or \nspread from one \ngroin  to the \ncontr alateral groin \nwas consi dered 3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 337 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE  \nfor those with:  \n-distant \nsubcutan eous \nmetast ases: 33% \n- distant LN \nmeta stases: 22% \n- pulmonary \nmeta stases: 74%  \n(P=0.72).  \n \n5-year survival rate \nfor : \n- combined group \nof s.c. and nodal \nmetast ases: 28% \n- pulmonary and \nvisceral sites: 17%  \n \nSignificant \nprognostic \nparam eters:  \n- thickness of the \nprimary mel anoma  \n(p=0.05)  \n- number of \nmetastatic lesions \n(p=0.03)  likely to be r egional \nspread and these \npatients were \nexcluded  \n \n \n93% underwent \nchemotherapy, 27% \nradiotherapy, 5% no \nfurther therapy  \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 338 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE  \n- prior di sease-free \ninterval (p=0.05) .  \nOverett et al. \n(1985)  To revi ew \nclinic opathologic \nfactors that \ndetermine the \nsuccessful rese ction \nof tumor, survival, \nand quality of life  Cohort study  \n \n 176 patients who \nunde rwent surgical \nintervention for \ndistant metastases  \nof  \n \n Survival  \n \n2- and 5 -year-\nsurvival -rate \n \nMortality  \n \nRelapse rate  estimated 2 - and \n5-year survival rate: \n2 1 % and 13%, \nrespectively  \n \nmedian su rvival \ntime: 8.5 months.  \n \nEstimated 2 -year \nand 5-year \nsurvival -rate after \ncomplete resection \nof single-site- vs. \nmultiple-site \nlesions: 47% and \n33% vs. 17% and 9%, \nrespectively (P < \n0.01).  \n \nOperative mortality  \nRate: 1.4%  \n \nrelapse -rate: 66%  \n \nMedian interval to Retrospective \ndesign \n \nOld patient cohort \n(1965 -1979), \nquestionable \ntransferabi lity to \ncurrent situ ation \n \n 3b   \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 339 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE  \nrelapse in case of \nincomplete vs. \ncomplete rese ction: \n3 vs. 9 months (P = \n0.07).  \n \n5-years survival \nafter repeated \nresection: 20%  \n \nmedian su rvival in \ncase of repeate d \nresection vs. \nincomplete \nresection of new \ndisease: 26 vs. 8 \nmonths (P<0.0005)  \nGarbe (1996)  to identify patients \nwith prolonged  \nsurvival in stag e IV \ndisease and to  \nanalyse the possible \nimpact of therapy  \non the course of the \ndisease.  Retrospective \nreview \n \n 263 patients ha ving \nstage IV mel anoma  \n \n111 patients: \nsurgery and/or \nradiation therapy. \n(17 surgery alone)  \n \n89 patients: \nsyste mic treatment  Survival  22 patients treated \nwith multimodality \nsurvived > 24 \nmonths (m edian \nSurvival: 33 \nmonths)  \n \n16: both systemic \ntreatment and \nsurgery and/or Confounder \nadjuvant the rapy 3b-  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 340 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE  \n \n48 patients: both \nsystemic and local \ntherapy. \n \n111 patients: no \ntreatment.  radiation, 3: \nsystemic drug \ntherapy, 3:only local \ntreatment.  \n \n 12/22 patients \nbecame tumour  \nfree after initial \nsurgery or \nradiation.  \n \n2-year-survival for \npatients wit hout \ntreatment:0%  \nKarakousis et al. \n(1983 ) to identify, or \nconfirm, favorable \ncharacteri stics that \nmay improve \npalliation  Cohort study  79 consecutive \npatients with \nresectable, \nrecurrent malignant \nmelanoma were \ntreated with \nsurgical exc ision \n \n Survival  \n \n significant survival \ndifference between \nStage IV su rvivors \n(36 months) and \nthose who \nmanifes ted disease \nprogre ssion (12 \nmonths) (P < 0.02).  \n \nCharacteristic of \nthose patients who \nremain diseas e free: \n- initial presence Retrospective \ndesign \n \nSmall population  \n \nNo information \nabout staging  \n \nPoor information \nabout follow -up \n 3b-  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 341 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE  \n</=3 m etastatic \nlesions  \n- long prior \ndisease-free \ninterval  \nWornom et al. \n(1983) To examine the \nefficacy of surgery \nas palliative \ntreatment in 65 \npatients with distant \nmetastatic \nmelanoma amenable \nto surgical exc ision Cohort study  \n 65 patients with \ndistant metastatic \nmelanoma \namenable to \nsurgical  \n Survival  \n \nmorta lity overall operative \nmortality: 11%  \n \nRelief of symptoms \nafter excision of:  \n- 77% of brain \nmetastases,  \n- 100% of lung \nmetastases  \n- 88% of di stant LN \nand s.c. metast ases \n- 100% of \nabdom inal \nmetastases  \n \nMedian survival \nafter exc ision of:  \n- brain metast ases: \n8 months  \n-  lung m etastases: \n9 months  \n- abdominal Retrospective \ndesign \n \nMost patients \nreceived \nchemother apy \n \nNo information \nabout staging  \n \nNo detailed \ninformation about \npopulation  3b- \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 342 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE  \nmeta stases 8 \nmonths  \n- distant s.c., LN \nmeta stases: 15 \nmonths.  \n \nmedian survival of \npatients with  \n- combined visceral \nand resected \nsuperficial \nmetast ases: 14 \nmonths, 5 -year \nsurvival: 0%  \n- resection of \nsuperficial \nmetastases  \nand no detec table \nevidence of visceral \nmetastasis: 17 \nmonths. 5 -year \nsurvival: 14%  \n \n2-year su rvival: 29% \nfor both groups.  \nFeun et al. (198 2) To discuss the \nnatural hi story of Cohort study  \n 102 patients with \nmalignant survival  \n median survival: 18 \nmonths.  Retrospective \ndesign 3b-  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 343 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE  \nStage IVA mel anoma  \nand the role of \nadjuvant therapy   melan oma who had \ndistant metastases \nsurgica lly resected \nand were judged to \nbe clinically free of \ndisease  \n \n disease -free-\nsurvival   \nsurvival d epending \non site of r esected \nmetastases:  \n- brain: 15 m onths  \n- lung: 16 months  \n- intraa bdominal 18 \nmonths  \n- skin and/or LN 23 \nmonths  \n \nDisease -free \ninterval not \ninfluenced by site  \n \nSimilar survival of \npatients who had \nmetastases resec ted \nfrom se veral organs \nat the same time \nand patients with \none resected site  \n \ngroup treated with \nsurgery only vs. \nadjuvant group:  \nmedian disease - \n35 patients who had \nsurgery vs. 67 \npatients who \nreceived adj uvant \ntherapy   \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 344 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE  \nfree interval and \nsurvival:  \n6 and 16 months \nvs. 6 and 21 \nmonths, \nrespe ctively  \n \n3.4.4.  Literatur  \nAndrews S, Robinson L, Cantor A, et al. Survival after surgical re section of isolated pulmonary metastases from malignant melanoma. Cancer Control 2006;13:218 -223 \nBerger AC, Buell JF, Venzon D, et al. Management of symptomatic malignant melanoma of the gastrointestinal tract. Ann Surg Oncol 1999;6:155 -160 \nBrand CU, Ellwa nger U, Stroebel W, et al. Prolonged survival of 2 years or longer for patients with disseminated melanoma. An analysis of related prognostic factors. C ancer \n1997;79:2345 -2353  \nBranum GD, Epstein RE, Leight GS, et al. The role of resection in the management  of melanoma metastatic to the adrenal gland. Surgery 1991;109:127 -131 \nChua TC, Saxena A, Morris DL. Surgical metastasectomy in AJCC stage IV M1c melanoma patients with gastrointestinal and liver metastases. Ann Acad Med Singa pore \n2010;39:634 -639 \nde Wilt J H, McCarthy WH, Thompson JF. Surgical treatment of splenic metastases in patients with melanoma. J Am Coll Surg 2003;197:38 -43 \nDelaunay MM, Amici JM, Avril MF, et al. Surgery of pulmonary metastasis from malignant melanoma. Results and criteria of surgical  excision]. Ann Dermatol Venereol \n1991;118:287 -295 \nEssner R, Lee JH, Wanek LA, et al. Contemporary surgical treatment of advanced -stage melanoma. Arch Surg 2004;139:961 -6; discussion 966 -7 \nFeun LG, Gutterman J, Burgess MA, et al. The natural history of res ectable metastatic melanoma (Stage IVA melanoma). Cancer 1982;50:1656 -1663  \nGarbe C. Increased survival in distant melanoma metastasis and the effect of treatments. Analysis of the disease course of pa tients with a survival of 2 years or more]. Hautarzt \n1996;47:35 -43 \nGohl J, Meyer T, Haas C, et al. Is surgical therapy of distant metastases of malignant melanoma worthwhile?]. Langenbecks Arc h Chir Suppl Kongressbd 1996;113:122 -126 \nHarpole DH,Jr, Johnson CM, Wolfe WG, et al. Analysis of 945 cases of pulmonary metastatic melanoma. J Thorac Cardiovasc Surg 1992;103:743 -8; discussion 748 -50 \nHodgson R, Fink MA, Jones RM. The role of abdominal resectional surgery in metastatic melanoma. ANZ J Surg 2007;77:855 -859 \nKarakousis CP, Moore R, Holyoke ED. Surgery in recurr ent malignant melanoma. Cancer 1983;52:1342 -1345  \nKarakousis CP, Velez A, Driscoll DL, et al. Metastasectomy in malignant melanoma. Surgery 1994;115:295 -302 \nKhadra MH, Thompson JF, Milton GW, et al. The justification for surgical treatment of metastatic mel anoma of the gastrointestinal tract. Surg Gynecol Obstet 1990;171:413 -416 \nLeo F, Cagini L, Rocmans P, et al. Lung metastases from melanoma: when is surgical treatment warranted? Br J Cancer 2000;83:569 -572 \nMathisen DJ, Flye MW, Peabody J. The role of thora cotomy in the management of pulmonary metastases from malignant melanoma. Ann Thorac Surg 1979;27:295 -299 \nMittendorf EA, Lim SJ, Schacherer CW, et al. Melanoma adrenal metastasis: natural history and surgical management. Am J Surg 2008;195:363 -8; discussio n 368 -9 \nNeuman HB, Patel A, Hanlon C, et al. Stage -IV melanoma and pulmonary metastases: factors predictive of survival. Ann Surg Oncol 2007;14:2847 -2853  \nOllila DW, Essner R, Wanek LA, et al. Surgical resection for melanoma metastatic to the gastrointestin al tract. Arch Surg 1996;131:975 -9; 979 -80 \nOllila DW, Hsueh EC, Stern SL, et al. Metastasectomy for recurrent stage IV melanoma. J Surg Oncol 1999;71:209 -213 \nOverett TK, Shiu MH. Surgical treatment of distant metastatic melanoma. Indications and results. C ancer 1985;56:1222 -1230   \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 345 von 732 Pawlik TM, Zorzi D, Abdalla EK, et al. Hepatic resection for metastatic melanoma: distinct patterns of recurrence and prognosis for ocular versus cutaneous disease.  Ann Surg \nOncol 2006;13:712 -720 \nPetersen RP, Hanish SI, Haney JC, et  al. Improved survival with pulmonary metastasectomy: an analysis of 1720 patients with pulmonary metastatic melanoma. J Thora c \nCardiovasc Surg 2007;133:104 -110 \nPogrebniak HW, Stovroff M, Roth JA, et al. Resection of pulmonary metastases from malignant mel anoma: results of a 16 -year experience. Ann Thorac Surg 1988;46:20 -23 \nRicaniadis N, Konstadoulakis MM, Walsh D, et al. Gastrointestinal metastases from malignant melanoma. Surg Oncol 1995;4:105 -110 \nSanki A, Scolyer RA, Thompson JF. Surgery for melanoma met astases of the gastrointestinal tract: indications and results. Eur J Surg Oncol 2009;35:313 -319 \nSchuhan C, Muley T, Dienemann H, et al. Survival after pulmonary metastasectomy in patients with malignant melanoma. Thorac Cardiovasc Surg 2011;59:158 -162 \nSzynglarewicz B, Ekiert M, Forgacz J, et al. The role of surgery in the treatment of colorectal metastases from primary skin mel anoma. Colorectal Dis 2012  \nTauceri F, Mura G, Roseano M, et al. Surgery and adjuvant therapies in the treatment of stage IV melanom a: our experience in 84 patients. Langenbecks Arch Surg \n2009;394:1079 -1084  \nWasif N, Bagaria SP, Ray P, et al. Does metastasectomy improve survival in patients with Stage IV melanoma? A cancer registry analysis of outcomes. J Surg Oncol  \n2011;104:111 -115 \nWornom IL,3rd, Smith JW, Soong SJ, et al. Surgery as palliative treatment for distant metastases of melanoma. Ann Surg 1986;204:181 -185 \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 346 von 732 4. AG Adjuvante Therapie  \n4.1. Frage IV.1. Adjuvante Chemotherapie - Adaptation  \n4.1.1.  Synopse Quellleitlinien  \n LL Austr alien  \nNew Zealan d Guidelines \nGroup 2008  LL GB  \nNICE  2006  LL Frankreich  \nFrench National Authority \nfor Health 2005   LL Kanada  \nCancer Care O ntario  \n2007  \nBeeinflusst eine \nadjuvante Chemo therapie \ndas Ge samt\u00fcberleben \nund/oder die rezidivfreie \nZeit von \nMelanompatien ten?  Nein  \n \nKein zytotoxisches \nMedikament hat eine \n\u00dcberle genheit gege n\u00fcber \nBeobachtung gezeigt  Nein  \n \nKeine Evidenz f\u00fcr \nadjuvante Chemotherapie \nnach erfol gter \nchirurgischer Therapie  Nein  \n \nDacarbazin verbessert \nnicht das \u00dcberleben in \nadjuvanter Situ ation  \n Nein  \n \nKeine Verbesserung des \nGesamt\u00fcberlebens durch \nadjuvante Chemotherapie  \n \nZugrunde li egende \nEvidenz  S. 93, keine Verkn\u00fcpfung \nmit zugrundeliegender \nEvidenz  \n Manual: S. 81, keine \nVerkn\u00fcpfung mit \nzugrundeli egender \nEvidenz Evidenz R eview: \nS. 537 (\u201ekeine Rolle im  \nadjuvan ten Setting\u201c) 10 \nStudien zitiert  Niveau A 5 randomisierte \nStudien wur den \nuntersucht + B ezug auf \nCancer Care Ontario \n2002  \n Ergebnis aus 9 random. \nStudien  \n \n \nUpdate Recherche am 11.01.201 1 \nSuchstrategie Medline: (melanoma[tiab] OR melanoma[MeSH]) AND (chemotherapy[tiab] OR vindesine[tiab] OR dacarbacine[tiab] AND \nadjuvant[tiab])   \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 347 von 732 Treffer: 483, Auswahl: Eigentler et al. 2008, Retsas et al. 1994  \nLiteratur:  \n \nEigentler TK, Radny P, Hauschild A, et al. Adjuvant treatment with vindesine in comparison to observation alone in patients with metastasized melanoma after complete \nmetastasectomy: a randomized multicenter trial of the German Dermatologic Cooperative Oncology Group. Melanoma Res 2008;18:35 3-358 \nRetsas S, Quigley M, Pectasides D, et al. Clinical an d histologic involvement of regional lymph nodes in malignant melanoma. Adjuvant vindesine improves survival. Cancer \n1994;73:2119 -2130  \n \n4.1.2.  Empfehlung und Hintergrundstext franz\u00f6sische Quell Leitlinie  \nQuellleitlinie: Recommandations pour la Pratique Clinique :  Standards, Options et Recommandations 2005  \nOriginaltext (Evidenztabellen und Text siehe Quell LL ab S.39)  \u00dcbersetzung  \nDESCRIPTION DES \u00c9TUDES  \nAu total, 5 essais randomis\u00e9s ont \u00e9t\u00e9 retenus pour l\u2019analyse critique. Aucun nouvel essai \nrandomis\u00e9 n\u2019a \u00e9t\u00e9 retro uv\u00e9 dans le cadre de la mise \u00e0 jour 2005. Deux essais ont compar\u00e9 \nl\u2019administration de dacarbazine versus observation *114, 130+, un essai a compar\u00e9 la \ndacarbazine versus placebo [127] et 1 essai a \u00e9valu\u00e9 l\u2019association de dacarbazine \u00e0 d\u2019autres \nsubstances v ersus observ ation *131+. Un seul essai a \u00e9tudi\u00e9 le m\u00e9thyl -CCNU [116]. Le CCOPGI \na r\u00e9vis\u00e9 en 2002 la synth\u00e8se m\u00e9thodique avec analyse quantitative initialement pu bli\u00e9e en 1997 \n[12].  \n \nSURVIE GLOBALE  \nAucune des 4 \u00e9tudes qui ont \u00e9valu\u00e9 la dacarbazine (DITC) n \u2019a rapport\u00e9 de diff\u00e9rence \nsignificative en termes de su rvie globale [114, 117, 127, 130, 131]. L\u2019analyse pool\u00e9e des \ndonn\u00e9es r\u00e9alis\u00e9e par le CCOPGI sur 7 essais randomis\u00e9s n\u2019a pas retrouv\u00e9 de diff\u00e9rence \nsignific ative sur la survie globale \u00e0 3 ans (odd ratio  = 1,03 [IC95 : 0,74 -1,43] [12]. L\u2019\u00e9tude de \nFisher et al. qui a compar\u00e9 m\u00e9thyl -CCNU versus observation n\u2019a pas retrouv\u00e9 de diff\u00e9rence \nsignificative entre les deux bras compar\u00e9s [116].  \n \n \nCOMMENTAIRES M\u00c9THODOLOGIQUES ET CLINIQUES  \nLa dacarbazine est la mol\u00e9cu le qui a \u00e9t\u00e9 la plus \u00e9tudi\u00e9e, seule ou association avec le BCG. Un \nseul essai randomis\u00e9 a \u00e9t udi\u00e9 \u2019efficacit\u00e9 du m\u00e9thyl -CCNU sur une population de 136 patients, \nce qui limite la port\u00e9e des conclusions qui pourront \u00eatre \u00e9tablies concernant cette mol\u00e9cule.  \n Beschreibung der Studien  \nInsgesamt wurden 5 randomisierte Studien f\u00fcr eine kritische Analyse ausg ew\u00e4hlt. Im Rahmen \ndes Update 2005 wurde keine neue randomisierte Studie gefunden. Zwei Studien haben \nDacarbazin versus Beobachtung verglichen [114,130], eine St udie hat Dacarbazin gegen \nPlacebo verglichen [127] und 1 Studie hat Dacarbazin in Kombination mit anderen Substanzen \nversus B eobachtung evaluiert. [131] Nur eine Studie untersuchte Methyl -CCNU [116]. Die \nCCOPGI hat 2002 ein systematisches Review von 1997mi t Metaanalyse \u00fcberarbeitet [12].  \n \n \nGesamt\u00fcberleben  \nKeine der 4 Studien, die Dacarbazin untersucht haben, haben einen signifika nten Unterschied in \nBezug auf das Gesamt\u00fcberleben gezeigt [114, 117, 127, 130, 131]. Die gepoolte Analyse der \nDaten, die durch die  CCOPGI aus 7 randomisierten Studien durchgef\u00fchrt wurde, fand keinen \nsignifikanten Unte rschied bezogen auf das Gesamt\u00fcberleben nach 3 Jahren (odds ratio = 1,03 \n[IC95 : 0,74 -1,43] [12 ]. Die Studie von Fisher et al. , die Methyl -CCNU ve rsus Beobachtung \nverglic hen hat, fand keinen signifikanten Unterschied zw ischen den Vergleichsarmen [116].  \n \n \nMethodologische und Klinische Kommentare  \nDacarbazin ist die am meisten untersuchte Substanz, allein oder zusammen mit BCG. Nur eine \nrandomisierte Sudie \u00fcberpr\u00fcfte die Wirk samkeit von M ethyl-CCNU an einer Population von 136 \nPatienten, dies beschr\u00e4nkt die Auss agekraft dieser Substanz.  \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 348 von 732 Originaltext (Evidenztabellen und Text siehe Quell LL ab S.39)  \u00dcbersetzung  \nCONCLUSIONS DE LA LITT\u00c9RATURE  \nLa dacarbazine en situation adjuvante n\u2019am\u00e9liore pas la survie des patients porteurs d\u2019un \nm\u00e9lanome cutan\u00e9 op\u00e9r\u00e9 (niveau de preuve A). Les donn\u00e9es dispo -nibles sont insuffisantes pour \nconclure sur le b\u00e9n\u00e9fice/risque du methyl - CCNU en situation adjuvante chez les patients \nporteurs d\u2019un m\u00e9l anome cutan\u00e9.  \n \nStandards, Options et Recommandations  \nLes traitements adjuvants syst\u00e9miques \u00e0 base de levamisole, BCG ou dacarbazine ne sont pas \nrecommand\u00e9s en dehors d\u2019essais th\u00e9rapeutiques.  \n Schlussfolgerungen aus der Literatur  \nDacarbazin verbessert nicht das \u00dcberleben von Patienten mit operiertem k utanem Melanom in \nadjuvanter Situ ation (Level A). Die Daten f\u00fcr Methyl -CCNU sind insuffizient um \u00fcber \nBenefit/Risiko in adjuvanter Situation bei P atienten mit kutanem Melanom zu entscheiden.  \n \n \nStandard, Optionen und Empfehlungen  \nEine adjuvante systemische Therapie mit Levamisole, BCG oder  Dacarbazin wird ausserhalb von \nTherapiestudien nicht empfohlen.  \n \nLiteratur:  \n \n12.CCOPGI, (Cancer Care Ontario Practice Guidelines Initiative). Systemic adjuvant therapy for patients at high risk for recu rrent melanoma. Practice Guideline Report No 8 -1 \n[online]. 2002. Available: URL: http://www.cancercare.on.ca/index_practiceGuidelinesandEvidencesum maries.htm#list  \n131. Randomized controlled trial of adjuvant chemoimmunotherapy with DTIC and BCG after complete excision of primary melanoma with  a poor progn osis or melanoma \nmetastases. Can Med Assoc J 1983;128:929 -933 \n116. Fisher RI, Terry WD, Hodes RJ, et al. Adjuvant immunotherapy or chemotherapy for malignant melanoma. Preliminary report of th e National Cancer Institute randomized \nclinical trial. Surg Clin  North Am 1981;61:1267 -1277  \n130. Hill GJ,2nd, Moss SE, Golomb FM, et al. DTIC and combination therapy for melanoma: III. DTIC (NSC 45388) Surgical Adjuvant St udy COG PROTOCOL 7040. Cancer \n1981;47:2556 -2562  \n127. Lejeune F, Macher E, Kleeberg UR, Rumke P, Pr ade M, Thomas D, et al. An asses sment of DTIC versus levamisole or placebo in the treatment of high risk stage I patients \nafter removal of a primary melanoma of the skin: a phase III adjuvant study (EORTC protocol 18761). Eur J Cancer 1988;24:S81 -90.  \n114. Veronesi U, Adamus J, Aubert C, et al. A randomized trial of adjuvant chemotherapy and immunotherapy in cutaneous melanoma. N Engl J Med 1982;307:913 -916 \n \n \n4.1.3.  Empfehlung und Hintergrundstext kanadische  Quell Leitlinie  \nQuellleitlinie : Systemic Adjuvant Therap y for Patients at High Risk for Recurrent Melanoma: Updated Guideline Recommend ations (Cancer \nCare Ontario) 2009  \nKEY EVIDENCE  Chemotherapy  \nData from randomized controlled trials do not suggest an improvement in OS with adjuvant chemotherapy alone for p atients with \nresected high -risk melanoma (10 trials).   \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 349 von 732 OUTCOMES  Chemotherapy  \nTen trials of chemotherapy are summarized in Table 9 (33,41,45 -52). None of the trials were limited to high -risk patients. Two trials \ncompared dacarbazine with observation (45,46),  one compared dacarbazine with placebo (33), and five trials evaluated dacarbazine in \ncombination with other agents (including immunomodulatory agents such as BCG) that are not commonly used at present, against \nobservation alone (47 -51). There was also a t rial of methyl lomustine (methyl -CCNU) versus control (41) and a trial of carmustine (BCNU) \ncombined with actinomycin -D and vincristine versus control (52). In the largest study of chemoth erapy (46), 47% of patients treated with \ndacarbazine were alive afte r three years compared with 42% of control (p=0.64). Only the study by Hansson et al (49) reported a \nstatistically significant survival benefit for patients who received chemotherapy as adjuvant treatment (p<0.025). That was t he smallest \nof the chem otherap y trials, with only 26 patients randomized to three treatment groups. Data from the two active -treatment arms (da -\ncarbazine alone and dacarbazine in combination with CCNU and vincristine) were co mbined and compared with results for nine patients \nin the con trol group, but that trial is far too small to permit any conclusions. Three -year mortality rates, from the text or from survival \ncurves in the published reports from seven studies, were pooled and are presented in Figure 3. Three studies were not include d in the \nmeta -analysis because the number of deaths at three years could not be ascertained (45,51) or because no survival data were r eported \n(47). The mortality risk ratio from the pooled analysis (0.94; 95% CI, 0.84 to 1.06; p=0.3) does not demonstrate an y difference between \nchemotherapy and control. No heterogeneity was found among the results from these st udies (p=0.52). Because response rates to \nchemotherapy in advanced disease have been unsatisfactory, there is no current interest in pursuing chemother apy alone in the adjuvant \nsetting.  \nLiteratur:  \n48. Randomized controlled trial of adjuvant chemoimmunotherapy with DTIC and BCG after complete excision of primary melanoma with  a poor prognosis or melanoma \nmetastases. Can Med Assoc J 1983;128:929 -933 \n41. Fisher RI, Terry WD, Hodes RJ, et al. Adjuvant immunotherapy or chemotherapy for malignant melanoma. Preliminary report of the  National Cancer Institute randomized \nclinical trial. Surg Clin North Am 1981;61:1267 -1277  \n49. Hansson J, Ringborg U, Lagerlof B, e t al. Adjuvant chemotherapy of malignant melanoma. A pilot study. Am J Clin Oncol 1985;8:47 -50 \n45. Hill GJ,2nd, Moss SE, Golomb FM, et al. DTIC and combination therapy for melanoma: III. DTIC (NSC 45388) Surgical Adjuvant St udy COG PROTOCOL 7040. Cancer \n1981;47:2556 -2562  \n47. Jacquillat C, Banzet P, Maral J. Clinical trials of chemotherapy and chemoimmunotherapy in primary malignant melanoma. Recent  Results Cancer Res 1982;80:254 -258 \n52. Karakousis C, Blumenson L. Adjuvant chemotherapy with a nitrosourea -based protocol in advanced malignant melanoma. Eur J Cancer 1993;29A:1831 -1835  \n50. Karakousis CP, Emrich LJ. Adjuvant treatment of malignant melanoma with DTIC + estracyt or BCG. J Surg Oncol 1987;36:235 -238 \n33. Lejeune FJ, Macher E, Kleeberg U, Rumke P, Prad e M, Thomas D, et al. An assessment of DTIC versus levamisole or placebo in the treatment of high risk stage I patients \nafter surgical removal of a primary melanoma of the skin. Eur J Cancer Clin Oncol. 1988;24 Suppl 2:S81 -S90.  \n46. Veronesi U, Adamus J, A ubert C, et al. A randomized trial of adjuvant chemotherapy and immunotherapy in cutaneous melanoma. N Engl J Med 1982;307:913 -916 \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 350 von 732 4.2. Frage IV.2. Adjuvante Vak zinierung \u2013 Adaptation  \n4.2.1.  Synopse Quellleitlinien  \n LL Australien  \nNew Zealand Guidelines \nGroup 2008  LL GB  \nNICE 2006  LL Frankreich  \nFrench National Authority \nfor Health 2005  LL Kanada  \nCancer Care Ontario 2007  \nBeeinflusst eine adjuvante \nVakzinationstherapie das \nGesamt\u00fcberleben und/oder \ndie rezidivfreie Zeit von \nMelanompatienten?  \n Nein \n \nKeine \u00dcberlegenheit von \nVakzinierungen gegen\u00fcber \nBeobachtung  \n \n Nein \n \nVerwendung von \nImpfstoffen ist \nexperimentell  \n \n Nein \n \nAucun des proc\u00e9d\u00e9s de \nvaccination utilis\u00e9s jusqu\u2019\u00e0 \nce jour  \nn\u2019a mis en \u00e9vidence une \ndiff\u00e9rence significative sur \nla survie  \nsans r\u00e9cidive ou sur la \nsurvie g lobale des patients \natteints  \nd\u2019un m\u00e9lanome cutan\u00e9 \nr\u00e9s\u00e9qu\u00e9 avec ou sans \nenvahissement  \nganglionnaire et dont \nl\u2019\u00e9paisseur est sup\u00e9rieure \u00e0 \n1,5 mm  \n(niveau de preuve B1).  \nKeine Vakzinierung hat \neinen signifikanten Nein \n \n \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 351 von 732  LL Australien  \nNew Zealand Guidelines \nGroup 2008  LL GB  \nNICE 2006  LL Frankreich  \nFrench National Authority \nfor Health 2005  LL Kanada  \nCancer Care Ontario 2007  \nUnterschied zwischen \nrezidivfreiem \u00dcberleben \noder Gesamt\u00fcberleben \nzeigen k\u00f6nnen (Td >1,5 N0 \nund N+)  \n \nNiveau BI  \nEntspricht in etwa Level of \nEvidence nach Oxford 1b  \n \nSchl\u00fcsselempfehlung  Zur Vakzinierung keine \nSchl\u00fcsselempfehlung  Zur Vakzinierung keine \nSchl\u00fcsselempfehlung  Les proc\u00e9d\u00e9s de vaccina tion \nne sont pas indiqu\u00e9s dans le  \ntraitement adjuvant des \npatients op\u00e9r\u00e9s d\u2019un \nm\u00e9lanome  \ncutan\u00e9 en dehors d\u2019essais \nth\u00e9rapeutiques.  \nRecommandation: Option  \n \nVakzinierungstherapien sind \nals adjuvante Behandlung \nbei Patienten nach \nOperation eines kutanen \nMelano ms ausserhalb von Zur Vakzinierung keine \nSchl\u00fcsselempfehlung   \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 352 von 732  LL Australien  \nNew Zealand Guidelines \nGroup 2008  LL GB  \nNICE 2006  LL Frankreich  \nFrench National Authority \nfor Health 2005  LL Kanada  \nCancer Care Ontario 2007  \nklinischen Studien nicht \nindiziert.  \nZugrunde liegende Evidenz  S. 93, keine Verkn\u00fcpfung \nmit zugrundeliegender \nEvidenz  Manual:  \nS. 81, keine Verkn\u00fcpfung \nmit zugrundeliegender \nEvidenz  \nEvidenz Review : \nS.538, kein verbessertes OS, \nmanche zeigen verbessertes \nrezidivfreies \u00dcberleben, \nVakzinierung wichtiges \nForschungsfeld  \n7 Studien  Diskutiert werden Studien \nmit:BCG, GMK, \nMelanomzell -Lysat (VMCL), \nMelanom Oncolysat (VMO), \nallogenes Melanomvakzin, \npolyvalen tes \nMelanomvakzin, GM2 -KLH, \nTIL 9 randomisierte Studien \nwurden zusammengefasst \n(virales Oncolysat, \nGanglioside, polyvalentes \nVakzin, Melanomzell -Lysat, \n\u201ewhole -cell\u201cVakzin) \naufgrund der Heterogenit\u00e4t \nder Studien wurden die \nDaten nicht gepoolt. Keine \nStudie konnte ein \nverbessertes \u00dcberleben \nzeigen.  \nEine Subgruppenanalyse \nSWOG 9035 zeigte einen \n\u00dcberlebensbenefit f\u00fcr HLA -\nA2 und/oder HLA -C3 \npositive Patienten der \nVakzin -Gruppe, dazu wurde \njedoch keine klinische \nEmpfehlung abgeleitet  \nIm Update 10 Studien: \nEORTC1 8961, signifikant  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 353 von 732  LL Australien  \nNew Zealand Guidelines \nGroup 2008  LL GB  \nNICE 2006  LL Frankreich  \nFrench National Authority \nfor Health 2005  LL Kanada  \nCancer Care Ontario 2007  \nschlechteres \nGesamt\u00fcberleben f\u00fcr GM2 -\nKLH21 Arm  \n \n4.2.2.  Empfehlung und Hintergrundstext franz\u00f6sische Quell Leitlinie  \nQuellleitlinie : Recommandations pour la Pratique Clinique : Standards, Options et Recommandations 2005  \nOriginaltext (Evidenztabe llen und Text siehe Quell LL ab S.36)  \u00dcbersetzung  \nVACCINATION  \n \nBCG th\u00e9rapie  \n\u2022 Description des \u00e9tudes  \nDeux essais randomis\u00e9s ont \u00e9t\u00e9 retenus et ont compare l\u2019administration \nde BCG versus observation d\u2019une part, et BCG versus l\u2019association BCG et \ndacarbazin e (Tableau XV) [114, 115]. L\u2019\u00e9tude de L\u2019OMS a concern\u00e9 761 \npatients randomis\u00e9s en 4 bras (observation versus BCG seul versus \ndacarbazine seule versus association BCG et dacarbazine) [114] L\u2019\u00e9tude de  \nAgarwala et al. pr\u00e9sente les r\u00e9sultats \u00e0 long terme d\u2019un essai sur 734 \npatients men\u00e9 entre 1974 et 1978 [115]. Les patients ont \u00e9t\u00e9 randomis\u00e9s \nselon 4 bras constituant 2 cohortes. La premi\u00e8re cohorte a compar\u00e9 BCG \nversus observ ation et la seconde BCG et dacarbazine versus BCG seul.  \n\u2022 Survie globale  Vakzinierung  \n \nBCG Therapie  \n\u2022Beschreibung der Studien  \nZwei randomisierte Studien wurden ausgew\u00e4hlt und haben die Gabe von \nBCG versus Beobachtung einerseits und BCG versus gemeinsame Gabe von \nBCG und Dacarbazin verglichen (Tab. XV) [114, 115]. Die Stud ie der WHO \nbetraf 761 randomisierte Patienten in 4 Armen (Beobachtung versus BCG \nallein ve rsus DTIC allein versus BCG plus DTIC) [114]. Die Studie von \nAgarwala et al. pr\u00e4sentierte die Langzeitergebnisse einer Studie an 734 \nPatienten, die zw ischen 1974 und 1978 durchgef\u00fchrt wurde [115]. Die \nPatienten wurden in 4 Arme randomisiert die Teil zweier Kohorten waren. \nDie erste Kohorte verglich BCG versus Beobac htung, die zweite BCG plus \nDTIC versus BCG allein.   \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 354 von 732 Originaltext (Evidenztabe llen und Text siehe Quell LL ab S.36)  \u00dcbersetzung  \nAucun des 2 e ssais n\u2019a mis en \u00e9vidence une diff\u00e9rence significative en \ntermes de survie globale dans les diff\u00e9rents bras compar\u00e9s [114, 115]. \nDans une an alyse en sous -groupe, l\u2019\u00e9tude de l\u2019OMS a observe une \ndiff\u00e9rence significative sur la survie globale en faveur du tra itement par \nBCG pour les patients pr\u00e9sentant 2 \u00e0 3 ganglions envahis (45 % versus \n31,7 % \u00e0 3 ans ; p = 0,01).  \n\u2022 Survie sans r\u00e9cidive  \nAucun des 3 essais n\u2019a mis en \u00e9vidence une diff\u00e9rence significative en \ntermes de survie globale dans les diff\u00e9rents bras co mpar\u00e9s [114 -116].  \n\u2022 Toxicit\u00e9  \nLes r\u00e9sultats de toxicit\u00e9 ont \u00e9t\u00e9 rapport\u00e9s dans les 2 \u00e9tudes [114, 115], \nmais seule l\u2019\u00e9tude de Agarwala et al. a pr\u00e9sent\u00e9 des r\u00e9sultats d\u00e9taill\u00e9s. \nAucune toxicit\u00e9 l\u00e9tale n\u2019a \u00e9t\u00e9 ra pport\u00e9e. Des ad\u00e9nopathies r\u00e9gionales et \ndes r\u00e9 actions syst\u00e9miques corr\u00e9l\u00e9es au traitement par le BCG ont \u00e9t\u00e9 \nobserv\u00e9es dans 10 \u00e0 13 % des cas [115].  \n\u2022 Commentaires cliniques et m\u00e9thodologiques  \nLes r\u00e9sultats de l\u2019analyse en sous -groupes r\u00e9alis\u00e9e dans l\u2019\u00e9tude de l\u2019OMS \nsont m\u00e9thodologiquement tr\u00e8s critiq uables [114]. D\u2019une part, l\u2019analyse en \nsous-groupe n\u2019\u00e9tait pas pr\u00e9vue initialement dans le protocole et, d\u2019autre \npart, l\u2019existence de ce r\u00e9sultat isol\u00e9 n\u2019a pas de coh\u00e9rence clinique, \npuisque la di fference de survie n\u2019est significative que pour le sous -groupe \nde patients avec 2 ou 3 ganglions envahis, ce qui rend ces r\u00e9sultats \ndifficilement i nterpr\u00e9tables.  \nVaccins m\u00e9laniques  \n\u2022 Description des \u00e9tudes  \nQuatre essais randomis\u00e9s sont disponibles :  \u2022Gesamt\u00fcberleben  \nKeine der zwei Studien hat einen sign ifikanten Unterschied in Bezug auf \ndas Gesamt\u00fcberleben in den Vergleichsarmen gezeigt[114, 115].  In einer \nSubgruppenanalyse fand sich in der Studie der WHO einen signifikanten \nUnterschied f\u00fcr das G esamt\u00fcberleben zugunsten einer Behandlung mit \nBCG f\u00fcr Pati enten mit 2 -3 positiven Lymphknoten. (45 % versus 31,7 % \nnach 3 Jahren ; p = 0,01).  \n\u2022Rezidivfreies \u00dcberleben  \nKeine der drei Studie zeigte einen signifikanten Unterschied in Bezug auf \ndas Gesamt\u00fcberleben in den unterschiedlichen Vergleichsarmen [114 -\n116].  \n\u2022Toxizit\u00e4t  \nErgebnisse zur Toxizit\u00e4t wurden in beiden Studien berichtet [114, 115], \naber nur die Studie von Agarwala et al. pr\u00e4sentiere detaillierte Ergebnisse. \nKeine letale Toxizit\u00e4t wurde berichtet. Regionale Adenopathien und \nSystemreakti onen wurden korell ierten in 10 bis 13% mit einer Behandlung \nmit BCG [115].  \n\u2022Klinische und Methodische Kommentare  \nDie Ergebnisse der Subgruppenanalyse die in der Studie der WHO \ndurchg ef\u00fchrt wurde sind methodisch sehr kritisierbar [114]. Zum einen \nwar die Su bgruppenanalyse ur spr\u00fcnglich nicht im Protokoll vorgesehen \nund, zum anderen hat dieses isolierte Ergebnis keinen klinischen \nZusammenhang, da der Unte rschied im \u00dcberleben nur f\u00fcr die Subgruppe \nmit 2 oder 3 positiven Lymphkn oten signifikant war, wodurch diese \nErgebnisse schwi erig zu interpretieren sind.  \nMelanom Impfstoffe   \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 355 von 732 Originaltext (Evidenztabe llen und Text siehe Quell LL ab S.36)  \u00dcbersetzung  \n\u2013 2 essais ont compar\u00e9 un vaccin m\u00e9lanique versus observation [117 -119] \n(Tableau XVI),  \n\u2013 2 essais ont compar\u00e9 l\u2019administration d\u2019un vaccin m\u00e9lanique versus \nplacebo [120 -122] (Tableau XVII).  \nAu total, 1 677 patients ont \u00e9t\u00e9 randomis\u00e9s dont 1 230 \u00e9valuables. \nAucune des 4 \u00e9tudes n\u2019a inclus de patients porteurs d\u2019un m\u00e9lanome  dont \nl\u2019\u00e9paisseur \u00e9tait inf\u00e9rieure \u00e0 1,5 mm. Les interventions \u00e9valu\u00e9es dans les 4 \nessais rand omis\u00e9s ont \u00e9t\u00e9 :  \n\u2013 lysat cellulaire de vaccin m\u00e9lanique (VMCL) [117],  \n\u2013 lysat de cellules tumorales irradi\u00e9es (Melacine\u00ae) provenant de deux \nlign\u00e9es allog\u00e9niques +  un adjuvant [118, 119],  \n\u2013 vaccin issu de quatre lign\u00e9es allog\u00e9niques + virus de la variole att\u00e9nu\u00e9 \n[120, 121],  \n\u2013 vaccin issu de trois lign\u00e9es allog\u00e9niques et une lign\u00e9e x\u00e9nog\u00e9nique + un \nadjuvant (aluminium) [122]  \n \n \n \n\u2022 Survie globale  \nTrois des 4 essais ran domis\u00e9s disponibles ont \u00e9valu\u00e9 l\u2019impact sur la survie \nd\u2019un vaccin m\u00e9lanique versus placebo ou observation [117, 120 -122]. La \nsurvie globale \u00e9tait le crit\u00e8re de jugement secondaire pour ces \u00e9tudes. \nAucune difference de survie globale n\u2019a \u00e9t\u00e9 mise en \u00e9videnc e apr\u00e8s un \nsuivi m\u00e9dian variable selon les \u00e9tudes compris entre 2,5 ans et 8 ans. \nDans le quatri\u00e8me essai, le suivi n\u2019a pas \u00e9t\u00e9 suffisant pour permettre \nl\u2019analyse de la survie gl obale [118, 119].  \u2022Beschreibung der Studien  \nVier randomisierte Studien stehen zur Verf\u00fcgung:  \n-Zwei Studien haben einen Melanom Impfstoff versus Beobachtung \nverglichen observation [117 -119] (Tab. XVI),  \n-Zwei Studien haben die G abe eines Melanom Impfstoffes versus Placebo \nverglichen [120 -122] (Tab. XVII).  \nInsgesamt wurden 1 677 Patienten randomisiert, von denen 1 230 \nauswertbar waren. Keine der vier Studien hat Melanompatienten mit einer \nTumordicke von weniger als 1,5mm eingeschl ossen. Die untersuchten \nInterventionen in den vier randomisierten Studien waren:  \nZelllysat Impfstoff (VMCL) [117]  \nLysat aus bestrahlten Tumorzellen (Melacine\u00ae) aus zwei allogenen L inien \nplus ein Adjuvant [118, 119],  \nImpfstoff aus vier allogenen Linien plus  abgeschw\u00e4chtes Varizellen V irus \n[120,121],  \nImpfstoff aus drei allogenen Linien und einer xenogenen Linie plus ein \nAdjuvant (Aluminium) [122]  \n \n\u2022Gesamt\u00fcberleben  \nDrei der vier randomisierten verf\u00fcgbaren Studien haben den Einfluss auf \ndas \u00dcberleben eines Mela nom Impfstoffes versus Placebo oder \nBeobachtung u ntersucht [117, 120 -122]. Das Gesamt\u00fcberleben war der \nsekund\u00e4re Endpunkt dieser Studien. Einen Unterschied im \nGesamt\u00fcberleben konnte in keiner der Studien nachgewiesen werden, die \nein medianes Follow up zwis chen 2,5 und 8 Jahren hatten. In der vierten \nStudie war das Follow up f\u00fcr eine Analyse des Gesamt\u00fcberlebens nicht  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 356 von 732 Originaltext (Evidenztabe llen und Text siehe Quell LL ab S.36)  \u00dcbersetzung  \n \n\u2022 Survie sans r\u00e9cidive  \nLes 4 essais randomis\u00e9s disponibles  ont \u00e9valu\u00e9 l\u2019impact sur la survie sans \nrechute d\u2019un vaccin m\u00e9lanique versus placebo ou observation. La survie \nsans rechute \u00e9tait le crit\u00e8re de jugement principal pour 3 \u00e9tudes ; le \ncrit\u00e8re de jugement principal n\u2019\u00e9tait pas pr\u00e9cis\u00e9 pour la quatri\u00e8me \u00e9tude.  \nAucune difference significative de survie sans rechute n\u2019a \u00e9t\u00e9 r etrouv\u00e9e. \nDes analyses en sous -groupes ont \u00e9t\u00e9 propos\u00e9es dans certaines \u00e9tudes. \nL\u2019\u00e9tude SOGT -9035 a notamment \u00e9valu\u00e9 l\u2019interaction entre antig\u00e8nes HLA \net la survie sans r\u00e9cidive [119]. La sur vie sans r\u00e9cidive a \u00e9t\u00e9 augment\u00e9e \ndans le groupe vaccin chez les patients qui exprimaient 2 ou plus de 5 \nantig\u00e8nes de classe I (97 patients trait\u00e9s par vaccin versus 78 patients \ndans le groupe observation ; p = 0,0002). Avec les antig\u00e8nes HLA A2 et \nC3, la survie sans rechute a \u00e9t\u00e9 de 77 % dans le groupe vaccin versus 64 % \ndans le groupe observation (p = 0,004).  \n \n \n\u2022 Toxicit\u00e9  \nLa toxicit\u00e9 a \u00e9t\u00e9 \u00e9valu\u00e9e dans les 4 \u00e9tudes [117, 118, 121, 122]. Les \ndonn\u00e9es de toxicit\u00e9 sont clairement pr\u00e9sent\u00e9es dans 2 des 4 \u00e9tude s. \nGlobalement, peu d\u2019effets ind\u00e9sirables ont \u00e9t\u00e9 observ\u00e9s. Dans l\u2019\u00e9tude de \nSondak et al., 9 % des patients ont pr\u00e9sent\u00e9 une toxicit\u00e9 de grade 3 \n(r\u00e9actions locales s\u00e9v\u00e8res, m alaises et fatigue, troubles visuels, fi\u00e8vre, \ndiarrh\u00e9es, thrombop\u00e9nies et \u00e9ru ptions cutan\u00e9es), 64 % ont pr\u00e9sent\u00e9 des \ntoxicities de grade 2 et 23 % ont pr\u00e9sent\u00e9 des toxicit\u00e9s de grade 1 [118]. \nL\u2019\u00e9quipe de Hersey et al. a esse ntiellement observ\u00e9 des toxicit\u00e9s de grade ausreichend. [118, 119].  \n \n\u2022Rezidivfreies \u00dcberleben  \nDie vier verf\u00fcgbaren randomisierten Studien haben den Einfluss auf das \nrezidivfreie \u00dcberleb en eines Melanom Impfstoffes versus Placobo oder \nBeobac htung untersucht. Das rezidivfreie \u00dcberleben war der prim\u00e4re \nEndpunkt in Drei Studien, f\u00fcr die vierte Studie war der prim\u00e4re Endpunkt \nnicht klar. Es wurde kein signifikanter Unterschied im rezidivfreie n \n\u00dcberleben gefunden. In einigen Studien wurden Subgruppenanalysen \nvorgeschlagen. Die Studie SOGT -9035 beinhaltet eine Untersuchung der \nInteraktion zwischem HLA Ant igenen und rezidivfreiem \u00dcberleben [119]. \nEin verl\u00e4ngertes rezidivfreies \u00dcbe rleben wurde in der Impfstoff Gruppe \nunter den Patienten die 2 oder mehr als 5 Antigene der Klasse I \nexprimierten, beobachtet (97 mit Impfstoff behande lte Patienten versus 78 \nPatienten im Beobachtungsarm; p = 0,0002). Mit den Antigenen HLA A2 \nund C3 war das rezidivfreie \u00dc berleben 77% in der Impfstoff Gruppe veruss \n64% im Beobachtungsarm (p = 0,004).  \n\u2022Toxizit\u00e4t  \nDie Toxizit\u00e4t wurde in allen vier Studien untersucht [117, 118, 121, 122]. \nDaten zur Toxizit\u00e4t sind in zwei der vier Studien klar dargestellt. \nInsgesamt wu rden nur w enig Nebenwirkungen beobachtet. In der Studie \nvon Sondak et al. zeigten 9% der Patienten eine Grad 3 Toxizit\u00e4t (schwere \nLokalreaktion, U nwohlsein und Fatigue, visuelle Probleme, Fieber, \nDurchf\u00e4lle, Thrombopenien und Hautausschl\u00e4ge), 64% zeigten eine Grad 2  \nToxizit\u00e4t und 23% eine Grad 1 Toxizit\u00e4t [118]. Das Team von Hersey et al. \nbeobachtete im Wesentlichen Grad 2 Toxizit\u00e4ten (Erytheme und  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 357 von 732 Originaltext (Evidenztabe llen und Text siehe Quell LL ab S.36)  \u00dcbersetzung  \n2 (\u00e9ryth\u00e8mes et ulc\u00e9ration au site d\u2019injection chez 47 % des patients ;  \nlymphop\u00e9nie pour 33 % d\u2019entre eux) et de grade 1 (malaises et fi\u00e8vre \nrespectivement chez 35 % et 20 % des patients).  \n \n\u2022 Commentaires m\u00e9thodologiques et cliniques  \nToutes les \u00e9tudes ont r\u00e9alis\u00e9 les analyses en intention de traiter. Trois des \n4 \u00e9tudes pr\u00e9sen tent clairement le calcul du nombre de patients a priori \n(sur la survie sans rechute) [117 -119, 122]. L\u2019\u00e9tude de Bystryn et al. a \u00e9t\u00e9 \narr\u00eat\u00e9e pr\u00e9matur\u00e9ment et n\u2019a port\u00e9 que sur 38 patients au lieu des 210 \npatients i nitialement pr\u00e9vus. De ce fait, le suivi n\u2019a pas \u00e9t\u00e9 suffisant \n(inf\u00e9rieur \u00e0 2 ans pour la majorit\u00e9 des patients) et n\u2019a pas permis l\u2019analyse \nde la survie globale [122]. Pour 3 des 4 \u00e9tudes, les populations \u00e9tudi\u00e9es \npeuvent \u00eatre appl iqu\u00e9es \u00e0 la pratique courante [117 -119, 122]. En \nrevanche, dans l \u2019\u00e9tude de Wallack et al. la population trait\u00e9e est un peu \ncomplexe et h\u00e9t\u00e9rog\u00e8ne par rapport \u00e0 la pratique courante bien que \ncorrespondant \u00e0 des types cliniques d\u00e9finis et reconnus par la \nclassification AJCC. Toutes les variables pertinentes n\u2019ont pas \u00e9t\u00e9 prises \nen compte lors de la randomisation, puisque seul le nombre de ganglions \nenvahis a \u00e9t\u00e9 condid\u00e9r\u00e9 [120 -121].  \n \n \nIFN alpha  versus GMK \n\u2022 Description des \u00e9tudes  \nUne seule \u00e9tude randomis\u00e9e est disponible [123] (Tableau XVIII) . Cette \n\u00e9tude a compar\u00e9 l\u2019IFN  alpha 2b hautes doses versus vaccine GMK \n(ganglioside GM2 co njugu\u00e9 avec de l\u2019h\u00e9mocyanine (KLH) combin\u00e9e \u00e0 une Ulzerationen am Injektionsortbei 47% der Patienten; Lymph openie bei 33%) \nund Grad 1 Toxizit\u00e4ten (Unwohlsein und Fieber b ei 35% und 20% der \nPatienten)  \n \n\u2022Klinische und Methodische Kommentare  \nAlle Studien haben eine Intent to treat (ITT) Analyse durchgef\u00fchrt. Drei der \nvier Studien pr\u00e4sentieren eine klare Fallzahlberechnung a priori f\u00fcr das \nrezidivfreie \u00dcberleben [117 -119, 122] . Die Studie von Bystryn et al. wurde \nvorze itig beendet und wurde nur an 38 statt der 210 urspr\u00fcnglich \ngeplanten Patienten durchgef\u00fchrt. Aus diesem Grund war die Dauer der \nNachbeobac htung nicht ausreichend (weniger als 2 Jahre f\u00fcr die Mehrheit \nder Patiente n) und erlaubt keine Analyse des Gesamt\u00fcberlebens [122]. In \ndrei der vier Stud ien wurden Populationen untersucht, die auf die \nderzeitige Praxis \u00fcbertragen werden k\u00f6nnen [117 -119, 122]. \nDemgegen\u00fcber ist die in der Studie von Wallack et al. behandelte \nPatien tenpopulation recht komplex und heterogen im Vergleicht zur \nderzeitigen Praxis obwohl die klinischen Stadien durch die AJCC \nKlassifikation angegeben wurden. F\u00fcr die Randomisierung wurden nicht \nalle Variablen sondern nur die Anzahl der beteiligten Lymphknot en \nber\u00fcc ksichtigt wurde [120 -121].  \n \nIFN\u03b1 versus GMK \n\u2022Beschreibung der Studien  \nEine einzige randomisierte Studie ist verf\u00fcgbar [123]. Diese Studie hat \nHochdosis IFN\u03b12b versus GMK Vakzin (Ganglioside GM2 konjugiert mit \nKLH komb iniert mit einem adjuvanten Mol ek\u00fcl QS -21) verglichen. Diese  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 358 von 732 Originaltext (Evidenztabe llen und Text siehe Quell LL ab S.36)  \u00dcbersetzung  \nmol\u00e9cule adjuvante QS -21). Cette \u00e9tude a port\u00e9 sur des patients atteints \nd\u2019un m\u00e9lanome de stades IIB ou III r\u00e9s\u00e9qu\u00e9s.  \n\u2022 Survie globale  \nLa survie gl obale a \u00e9t\u00e9 \u00e9valu\u00e9e apr\u00e8s un suivi m\u00e9dian de 16 mois. Une \ndiff\u00e9rence statist iquement significative a \u00e9t\u00e9 mise en \u00e9vidence en faveur \ndes patients trait\u00e9s par l\u2019IFN  alpha  2b. La survie globale \u00e0 2 ans a \u00e9t\u00e9 de \n78 % dans le bras IFN \u03b12b versus 73 % dans le bras GMK (p = 0,035) [123].  \n\u2022 Survie sans r\u00e9cidive  \nLa survie sans r\u00e9cidive a \u00e9t\u00e9 \u00e9valu\u00e9e apr\u00e8s un suivi median de 16 mois. \nUne diff\u00e9rence statistiquement significative a \u00e9t\u00e9 mise en \u00e9vidence en \nfaveur des patients trait\u00e9s par l\u2019IFN  alpha  2b. La survie sans r\u00e9cidive \u00e0 2 \nans a \u00e9t\u00e9 de 62 % dans le bras IFN  alpha  2b versus 49 % dans le bras GMK \n(p = 0,027) [123].  \n\u2022 Toxicit\u00e9  \nLes toxicit\u00e9s les plus fr\u00e9quemment observ\u00e9es dans le bras IFN  alpha  2b \nont \u00e9t\u00e9 des toxicit\u00e9s de grade 3 de type fat igue, cytop\u00e9nies, \u00e9l\u00e9vation du \ntaux des e nzymes du foie et symptoms neurologiques. Quarante -cinq \npour cent des p atients traits par l\u2019IFN  alpha  2b ont arr\u00eat\u00e9 le traitement en \nraison des effets ind\u00e9s irables. Les toxicit\u00e9s ont \u00e9t\u00e9 globalement moins \nfr\u00e9quentes  dans le bras GMK. La toxicit\u00e9 la plus rapport\u00e9e chez les \npatients trait\u00e9s par GMK a \u00e9t\u00e9 une r\u00e9a ction locale au niveau du site \nd\u2019injection. Aucun d\u00e9c\u00e8s toxique n\u2019a \u00e9t\u00e9 ra pport\u00e9.  \n\u2022 Commentaires m\u00e9thodologiques et cliniques  \nLes analyses ont toutes \u00e9t\u00e9 r\u00e9alis \u00e9es en intention de traiter. Les auteurs se \nsont bas\u00e9s sur les r\u00e9sultats positifs de l\u2019\u00e9tude ECOG1684 pour d\u00e9finir le \nprotocole de leur essai d\u00e9finissant ainsi l\u2019interf\u00e9ron -alpha \u00e0 haute dose Studie wurde an Melanom Patienten im resezierten Stadium IIB oder III \ndurchgef\u00fchrt.  \n\u2022Gesamt\u00fcberleben  \nDas Gesamt\u00fcberleben wurde nach einer medianen Nachbeobachtung von \n16 Monaten evaluiert. Ein statistisch signifikanter Un terschied wurde f\u00fcr \ndie mit IFN alpha  2b behandelten Patienten gesehen. Das \nGesamt\u00fcberleb en nach 2 Jahren war 78% im IFN alpha  2b Arm versus 73% \nim GMK Arm (p = 0,035) [123].  \n\u2022 Rezidivfreies \u00dcberleben  \nDas rezidivfreie \u00dcberleben wurde nach einer medianen Nachbeo bachtung \nvon 16 Monaten evaluiert. Ein statistisch signifikanter Un terschied wurde \nf\u00fcr die mit IFN alpha  2b behandelten Patienten gesehen. Das rezidivfreie \n\u00dcberleben nach 2 Jahren war 62% im IFN\u03b12b Arm versus 49% im GMK Arm \n(p = 0,027) [123].  \n\u2022Toxizit\u00e4t  \nDie am h\u00e4ufigsten beobachteten Toxizit\u00e4ten im IFN alpha  2b Arm waren \nGrad 3 Toxizit\u00e4ten vom Typ Fatigue, Zytopenie, Anstieg der Leberenzyme \nund neur ologische Sym ptome. 45% der Patienten im IFN alpha  2b Arm \nhaben die Therapie aufgrund von Nebenwirkungen gesto ppt. Die \nNebenwirkungen waren insg esamt weniger h\u00e4ufig im GMK Arm. Die am \nh\u00e4ufigsten berichtete Nebenwi rkung im GMK Arm waren Lokalreaktionen \nam Injektionsort. Es wurde keine t\u00f6dliche Nebenwirkung berichtet.  \n\u2022Klinische und Methodische Kommentare  \nAlle Analy sen wurden als Intent to treat Analyse durchgef\u00fchrt. Die Autoren \nhaben sich auf die positiven Ergebnisse der Studie ECO1684 gest\u00fctzt, um \ndie Hochdosis Interferon -alpha Therapie in ihrem Protokoll als Kontrollarm  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 359 von 732 Originaltext (Evidenztabe llen und Text siehe Quell LL ab S.36)  \u00dcbersetzung  \ncomme contr\u00f4le [104], bien que ces r\u00e9sultats n\u2019aient pas \u00e9t\u00e9 con firm\u00e9s \npar la suite. De ce fait, l\u2019absence de vrai bras contr\u00f4le invalide \nconsid\u00e9rablement les co nclusions. La population \u00e9tudi\u00e9e est mixte (77 % \nde patients pr\u00e9sentaient un envahissement ganglionnaire) et la \nstadification NO (23 %) est h\u00e9t\u00e9rog\u00e8ne (45 % de s patients ont \u00e9t\u00e9 \u00e9valu\u00e9s \ncliniquement et 46 % ont eu une \u00e9valuation histologique). L\u2019interpr\u00e9tation \ndes r\u00e9sultats est donc rendue plus complexe, puisque dans les autres \n\u00e9tudes, la proportion de patients sans envahissement est g\u00e9n\u00e9ralement \nmajor itaire. Pa r ailleurs, le suivi m\u00e9dian n\u2019\u00e9tant que de 16 mois, \nl\u2019\u00e9valuation de la survie doit \u00eatre interpr\u00e9t\u00e9e avec pr\u00e9caution.  \n \n \nTumor infiltrating lymphocytes (TIL)  \n\u2022 Description des \u00e9tudes  \nUne \u00e9tude est disponible [124, 125] (Tableau XIX) . Il s\u2019agitd\u2019une \u00e9tude \nprospective rand omis\u00e9e comparant un traitement par TIL+ IL -2 versus IL-\n2 seule chez 88 patients porteurs d\u2019un m\u00e9lanome de stade III (AJCC) apr\u00e8s \ncurage ganglionnaire. Le suivi m\u00e9dian a \u00e9t\u00e9 de 46,9 mois.  \n\u2022 Survie globale, survie sans r\u00e9cidive  \nAucune diff\u00e9rence  significative en termes de survie globale et de survie \nsans r\u00e9cidive n\u2019a \u00e9t\u00e9 mise en \u00e9vidence entre les 2 groupes. N\u00e9anmoins, \nune diff\u00e9rence significative a \u00e9t\u00e9 observ\u00e9e entre les deux bras de \ntraitement dans un sous groupe de patients (avec un seul gangl ion envahi, \nmais pas de pr\u00e9c ision sur la rupture capsulaire), notamment sur la survie \nglobale et le taux de rechute.  \n\u2022 Toxicit\u00e9  zu definieren [104], obwohl sich diese Ergeb nisse nachtr\u00e4glich nicht \nbest\u00e4tigt haben. Da dadurch ein echter Kontrollarm fehlt, ist es nicht \nm\u00f6glich g\u00fcltige Schlussfolgerungen zu ziehen. Die untersuchte Population \nist gemischt (77% der Patienten haben eine Lymphknotenbeteiligung) und \ndie Stadieneinte ilung NO (23%) ist heterogen (45% der Patienten wurden \nklinisch klassifiziert und 46% der Patienten wurden histologisch \nklassifiziert). Die Interpretation der Ergebnisse ist daher komplex, da in \nanderen Studien die Mehrzahl der Patie nten keine \nLymphknotenb eteiligung hat. Da auch die Nachbeobachtungszeit nur 16 \nMonate betrug, m\u00fcssen die \u00dcberlebenszeitanalysen mit Vorsicht \ninterpretiert werden.  \n \nTumor infiltrating lymphocytes (TIL)  \n\u2022Beschreibung der Studien  \nEine Studie steht zur Verf\u00fcgung [124, 125]. Es ist e ine prospektive \nrandom isierte Studie die eine Therapie mit TIL+IL -2 versus IL -2 allein bei \n88 Melanom Patienten im Stadium III (AJCC) nach einer \nLymphknotenausr\u00e4umung ve rgleicht. Die mediane Nachbeobachtungszeit \nbetrug 46,9 Monate. \u2022Gesamt\u00fcberleben, Rezidi vfreies \u00dcberleben  \nIn Bezug auf das Gesamt\u00fcberleben und das rezidivfreie \u00dcberleben wurde \nkein signifikanter Unterschied zwischen den 2 Gruppen beobachtet. \nDennoch wu rde bei einer Subgruppe (bei Beteiligung nur eines \nLymphknoten aber ohne Angaben zur Kapsel\u00fc berschreitung) zwischen den \nBehandlungsarmen ein signifikanter Unterschied bezogen auf Gesamt - \nund rezifivfreies \u00dcberleben gesehen.  \n\u2022Toxizit\u00e4t   \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 360 von 732 Originaltext (Evidenztabe llen und Text siehe Quell LL ab S.36)  \u00dcbersetzung  \nGlobalement, le traitement par TIL a \u00e9t\u00e9 tr\u00e8s bien tol\u00e9r\u00e9. Aucune toxicit\u00e9 \nde grades 3 ou 4 n\u2019a \u00e9t\u00e9 observ\u00e9e. Les principaux eff ets ind\u00e9sirables ont \n\u00e9t\u00e9 une inflammation au site  \nde l\u2019injection et une asth\u00e9nie.  \n \n\u2022 Commentaires m\u00e9thodologiques et cliniques  \nLa m\u00e9thode de randomisation n\u2019est pas d\u00e9crite dans les articles et \nl\u2019absence de r\u00e9el bras contr\u00f4le limite consid\u00e9rablement la por t\u00e9e des \nconcl usions qui pourront \u00eatre \u00e9tablies. Les analyses en sous -groupes \nconduites a posteriori (non pr\u00e9vues initialement lors de la randomisation) \nne permettent pas d\u2019extrapoler des conclusions sur les crit\u00e8res de \njugement. Il est \u00e9galement important de relever les contraintes techniques \nli\u00e9es \u00e0 ce proc\u00e9d\u00e9 dont le succ\u00e8s est conditionn\u00e9, dans un premier temps, \npar la production de TIL chez les patients concern\u00e9s.  \n \nConclusions de la litt\u00e9rature  \nAucun des proc\u00e9d\u00e9s de vaccination utilis\u00e9s jusqu\u2019\u00e0 ce jour n\u2019a mis en \n\u00e9vidence une diff\u00e9rence significative sur la survie sans r\u00e9cidive ou sur la \nsurvie globale des patients attaints d\u2019un m\u00e9lanome cutan\u00e9 r\u00e9s\u00e9qu\u00e9 avec \nou sans env ahissement ganglionnaire et dont l\u2019\u00e9paisseur est sup\u00e9rieure \u00e0 \n1,5 mm (niveau de preuve B1). \n Insgesamt wurde die Behandlung mit TIL sehr gut toleriert. Keine Grad 3  \noder 4 Toxizit\u00e4ten wurden beobachtet. Di e haupts\u00e4chlichen \nNebenwirkungen w aren Entz\u00fcndungen am Injektionsort und Asthenie.  \n \n\u2022Klinische und Methodische Kommentare  \nDie Methode der Randomisation wurde im Artikel nicht berichtet und das \nFehlen eines echten Kontrollarms machen es schwierig g\u00fcltige \nSchlussfolg erungen zu ziehen. Nachtr\u00e4glich durchgef\u00fchrte \nSubgruppenanalysen (die zum Zeitpunkt der Randomisierung nicht \nvorgesehen waren) machen Schlussfolg erungen aus den Ergebnissen nicht \nm\u00f6glich. Es ist auch wichtig die technischen Zw\u00e4nge zu bedenken, da in \neinem ersten Schritt die Produktion von TIL bei den betroffenen Patienten \nerfolgen muss.   \n \nSchlussfolgerung aus der Literatur  \nKeine der Impfverfahren die bis heute verwendet wurden haben einen \nsignif ikanten Unterschied f\u00fcr das Gesamt\u00fcberleben oder rezid ivfreie \n\u00fcberleben bei Patienten mit reseziertem Melanom, oder ohne \nLymphknotenbeteil igung und mit einer Tumordicke gr\u00f6sser als 1,5mm \nerbracht (niveau de preuve B1).  \nEntspricht in etwa Level of Evidence nach Oxford 1b  \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 361 von 732 4.2.3.  Empfehlung und Hintergrundstext kanad ische Quell Leitlinie  \nQuellleitlinie : Systemic Adjuvant Therapy for Patients at High Risk for Recurrent Melanoma: Updated Guideline Recommend ations (Cancer \nCare Ontario) 2009  \nNine randomized trials of vaccines are summarized in Table 8, one of a viral onc olysate ,  one of a ganglioside , \none of a polyvalent vaccine , one of vaccinia melanoma cell lysate , and five of whole -cell vaccines . Six RCTs \ncompared vaccine with observation, while three trials were double -blind . Seven of the nine trials were confined \nto patients with nodal involvement, and the majority of patients in one of the other trials were node positive . \nNone of the reported trials have shown a statistically significant improvement in overall survival for patients \ntreated with vaccines, an observati on co nfirmed in a recent update of the SWOG 9035 trial . However, in that \nstudy, the subset analysis of patients who were positive for human leukemic antigen (HLA) -A2 and/or HLA -C3 \ndemonstrated a significant five -year overall survival benefit of 93% for vac cine patients compared with 74% for \npatients in the obse rvation group (p=0.009). This clearly hypothesis -generating observation cannot be used to \ndirect clinical decisions. For obvious reasons attesting to heterogene ity of the studies and vaccines employed , \nwe have elected not to pool those data in our analysis.  \nLiteratur:  \nLL Frankreich  French National Authority for Health 2005 ) \n115. Agarwala SS, Neuberg D, Park Y, et al. Mature results of a phase III randomized trial of bacillus Calmette -Guerin (BCG) versu s observation and BCG plus dacarbazine versus \nBCG in the adjuvant therapy of American Joint Committee on Cancer Stage I -III melanoma (E1673): a trial of the Eastern Oncology Group. Cancer 2004;100:1692 -1698  \n122. Bystryn JC, Zeleniuch -Jacquotte A, Oratz R, et al. Double -blind trial of a polyvalent, shed -antigen, melanoma vaccine. Clin Cancer Res 2001;7:1882 -1887  \n124. Dreno B, Nguyen JM, Khammari A, et al. Randomized trial of adoptive transfer of melanoma tumor -infiltrating lymphocytes as adjuvant therapy for  stage III melanoma. \nCancer Immunol Immunother 2002;51:539 -546 \n116. Fisher RI, Terry WD, Hodes RJ, et al. Adjuvant immunotherapy or chemotherapy for malignant melanoma. Preliminary report of th e National Cancer Institute randomized \nclinical trial. Surg Cli n North Am 1981;61:1267 -1277  \n117. Hersey P, Coates AS, McCarthy WH, et al. Adjuvant immunotherapy of patients with high -risk melanoma using vaccinia viral lysates of melanoma: results of a randomized \ntrial. J Clin Oncol 2002;20:4181 -4190  \n123. Kirkwood JM, Ibrahim JG, Sosman JA, et al. High-dose interferon alfa -2b significantly prolongs relapse -free and overall survival compared with the GM2 -KLH/QS -21 \nvaccine in patients with resected stage IIB -III melanoma: results of intergroup trial E1694/S9512/C509801. J  Clin Oncol 2001;19:2370 -2380  \n125. Labarriere N, Pandolfino MC, Gervois N, et al. Therapeutic efficacy of melanoma -reactive TIL injected in stage III melanoma patients. Cancer Immunol Immunother \n2002;51:532 -538  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 362 von 732 118. Sondak VK, Liu PY, Tuthill RJ, et al. Adjuvant immunotherapy of resected, intermediate -thickness, node -negative melanoma with an allogeneic tumor vaccine: overall \nresults of a randomized trial of the Southwest Oncology Group. J Clin Oncol 2002;20:2058 -2066  \n119. Sosman JA, Unger JM, Liu PY, et al . Adjuvant immunotherapy of resected, intermediate -thickness, node -negative melanoma with an allogeneic tumor vaccine: impact of \nHLA class I antigen expression on outcome. J Clin Oncol 2002;20:2067 -2075  \n114. Veronesi U, Adamus J, Aubert C, et al. A randomi zed trial of adjuvant chemotherapy and immunotherapy in cutaneous melanoma. N Engl J Med 1982;307:913 -916 \n120. Wallack MK, Sivanandham M, Ditaranto K, et al. Increased survival of patients treated with a vaccinia melanoma oncolysate vaccine: second interim  analysis of data from a \nphase III, multi -institutional trial. Ann Surg 1997;226:198 -206 \n121. Wallack MK, Sivanandham M, Whooley B, et al. Favorable clinical responses in subsets of patients from a randomized, multi -institutional melanoma vaccine trial. Ann Surg \nOncol 1996;3:110 -117 \n \nLL Kanada  Cancer Care O ntario 2007  \nEggermont AM, Suciu S, Ruka W, Marsden J, Testori A, Corrie P. EORTC 18961: Post -operative adjuvant ganglioside GM2 -KLH21 vaccination treatment vs observation in stage II \n(T3-T4N0M0) melanoma:  2nd interim analysis led to an early disclosure of the results. J Clin Oncol. 2008;26(May 20 suppl):9004.  \n \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 363 von 732 4.3. Frage IV.3. Adjuvante Extremit\u00e4tenperfusion - Adaptation  \n4.3.1.  Synopse Quellleitlinien  \n LL Austr alien  \nNew Zealand Guidelines \nGroup 2008  LL GB  \nNICE 20 06 LL Frankreich  \nFrench National Authority \nfor Health 2005  LL Kanada  \nCancer Care O ntario \n2007  \nBeeinflusst eine adjuvante \nExtremit\u00e4tenperfusion das \nGesamt\u00fcberleben und/oder \ndie rezidivfreie Zeit von \nMelanompatienten?  Adjuvant regional drug \ntherapy improve s disease \nfree interval but does not \nimprove overall survival  \nLevel II  \n - \n La perfusion de melphalan \nsur membre isol\u00e9 ne semble \npas am\u00e9liorer la survie \nglobale des patients atteints \nd\u2019un m\u00e9lanome cutan\u00e9 \nNiveau de preuve C  \nEine adjuvante \nExtremit\u00e4tenperfus ion mit \nMelphalan scheint das \nGesam t\u00fcberleben von \nMelanompatienten nicht zu \nverbe ssern.  \nNiveau C  - \nSchl\u00fcsselempfe hlung Prophylactic isolated limb \nperfusion (ILP) is not \nrecommen ded \nGrade A  - La perfusion de membre \nisol\u00e9 n\u2019est pas \nrecommand\u00e9e en dehors \nd\u2019essais th\u00e9rapeutiques et \ndoit \u00eatre r\u00e9alis\u00e9e par des  \n\u00e9quipes e ntra\u00een\u00e9es.  \nRecommandation: Option  -  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 364 von 732  LL Austr alien  \nNew Zealand Guidelines \nGroup 2008  LL GB  \nNICE 20 06 LL Frankreich  \nFrench National Authority \nfor Health 2005  LL Kanada  \nCancer Care O ntario \n2007  \nEine Extr emit\u00e4tenperfusion \nwird ausserhalb klinischer \nStudien nicht empfohlen \nund soll durch erfahrene \nTeams durc hgef\u00fchrt \nwerden.  \nZugrunde li egende Evidenz  1 Studie  \nKoops, H.S. et al. 1998  \n - 2 Studien  \nKoops, H.S. et al. 1998  \nGhussen, F. et al. 1989  - \n \n4.3.2.  Empfehlung und Hintergrundstext franz\u00f6sische Quell Leitlinie  \nQuellleitlinie: Recommandations pour la Pratique Clinique : Standards, Options et Recommandations 20 05 \nOriginaltext (Evidenztabelle und Text siehe Quell LL ab S.40)  \u00dcbersetzung  \nPerfusion de melphalan sur membre isol\u00e9  \n \nDESCRIPTION DES \u00c9TUDES  \nDeux \u00e9tudes randomis\u00e9es ont \u00e9tudi\u00e9 l\u2019effet d\u2019une perfusion sur membre \nisol\u00e9 de melphalan apr\u00e8s ex\u00e9r\u00e8se d\u2019un melano ma primitif isol\u00e9 [134, 135] \n(Tableau XXI). Les 2 essais ont \u00e9valu\u00e9 respectivement 107 et 832 patients \ndont l\u2019\u00e9paisseur de la tumeur \u00e9tait sup\u00e9rieure \u00e0 1,5 mm. Dans l\u2019\u00e9tude de \nGhussen et al. la perfusion de melphalan a \u00e9t\u00e9 associ\u00e9e \u00e0 une Isolierte Extermit\u00e4tenperfusion mit Melphalan  \n \n\u2022Beschreibung der Studien  \nZwei randomisierte Studien haben den Effekt einer isolierten \nExtre mit\u00e4tenperfusion mit Melphalan nach Exizision des Prim\u00e4rmelanoms \nuntersucht. Die beiden Studien haben 107 und 832 Patienten mit einer \nTumordicke ab 1,5 mm eingeschlossen. In der Studie von Ghussen et al. \nwar die Perfusion mit Melphalan mit Hyperthermie kom biniert.   \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 365 von 732 Originaltext (Evidenztabelle und Text siehe Quell LL ab S.40)  \u00dcbersetzung  \nhyperthermie.  \n \nSURVIE GLOBALE, SURVIE SANS R\u00c9CIDIVE  \nSeule une des deux \u00e9tudes randomis\u00e9es a montr\u00e9 un avantage en termes \nde contr\u00f4le local et de survie globale en faveur du traitement sur membre \nisol\u00e9 par une association hyperthermie -melphalan apr\u00e8s ex\u00e9r\u00e8se d\u2019un \nmelanoma pr imitif isol\u00e9 [134]. L\u2019\u00e9tude de Koops et al. n\u2019a pas montr\u00e9 de \ndiff\u00e9rence sign ificative en termes de survie globale [135]. Une analyse en \nsous-groupe a c ependant mis en \u00e9vidence une survie sans r\u00e9cidive plus \n\u00e9lev\u00e9e chez les p atients qui ont eu un curage gan glionnaire (RR = 0,75 \n[IC95 : 0,55 -0,98]) et plus particuli\u00e8rement chez les patients dont la \ntumeur \u00e9tait inf\u00e9rieure \u00e0 3 mm (RR = 0,56 [IC95 : 0,36 -0,88]) [135]. \nAucune diff\u00e9rence en termes de survie globale n\u2019a \u00e9t\u00e9 observ\u00e9e dans les \nanalyses en sousgroupe s. \n \nTOXICIT\u00c9  \nLes toxicit\u00e9s ont \u00e9t\u00e9 principalement de grade 1 et globalement plus \nimpo rtantes dans les groupes de patients perfus\u00e9s [134, 135]. Les \ntoxicit\u00e9s les plus fr\u00e9quentes ont \u00e9t\u00e9 la douleur et les infections du \nmembre, souvent localis\u00e9es au niveau du  site de la perfusion. La plupart \ndes complications ont cependant \u00e9t\u00e9 r\u00e9versibles.  \n \nCOMMENTAIRES M\u00c9THODOLOGIQUES ET CLINIQUES  \nL\u2019\u00e9tude de Ghussen et al. a \u00e9t\u00e9 arr\u00eat\u00e9e pr\u00e9matur\u00e9ment en raison d\u2019une \nanalyse interm\u00e9diaire qui a montr\u00e9 l\u2019existence d\u2019un b\u00e9n\u00e9fice  \u00e9vident en \ntermes de survie sans r\u00e9cidive en faveur des patients qui ont re\u00e7u une  \n\u2022Gesamt\u00fcberleben, Rezidivfreies \u00dcberleben  \nNur eine der beiden Studien zeigte einen Vorteil in Bezug auf lokale \nKontrolle und Gesamt\u00fcberleben zugunsten einer Therapie mit isolierter \nExtremit\u00e4tenperfusion mit Hyperthermie -Melphalan nach Exzision ei nes \nPrim\u00e4rmelanoms. Die Studie von Koops et al. zeigte keinen signifikanten \nUnterschied in Bezug auf das Gesamt\u00fcberleben. Eine Subgruppenanalyse \nzeigte jedoch ein verl\u00e4ngertes rezidivfreies \u00dcberleben bei Patienten mit \nLymphknotendissekt ion (RR = 0,75 [IC95  : 0,55 -0,98])  \n[Kommentar: in der Originalarbeit bezieht sich das verl\u00e4ngerte rezidivfreie \n\u00dcberleben auf Patienten OHNE Lymphknotendisse ktion: \u201c\u2026The difference \nwas significant for patients who did not undergo ele ctive lymph node \ndissection (ELND).\u201d]   \nund besonders bei P atienten mit einem Tumordicke unter 3mm (RR = 0,56 \n[IC95 : 0,36 -0,88]). Die Subruppenanalysen ergaben keine Unterschiede in \nBezug auf das Gesa mt\u00fcberleben.  \n \n\u2022Toxizit\u00e4t  \nToxizit\u00e4ten waren haupts\u00e4chlich Grad 1 und insgesamt am wichtigsten in \nden Gruppen der perfundierten Patienten. Die h\u00e4ufigsten Toxizit\u00e4ten \nwaren Schmerzen und Infektionen in der Extremit\u00e4t, h\u00e4ufig am Ort der \nInfusion. Die meisten Komplikationen waren jedoch reversibel.  \n \n\u2022Klinische und Methodische Kommentare  \nDie Studie von Ghusse n et al. wurde vorzeitig beendet, da eine \nZwischenan alyse einen Benefit in Bezug auf das rezidivfreie \u00dcberleben  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 366 von 732 Originaltext (Evidenztabelle und Text siehe Quell LL ab S.40)  \u00dcbersetzung  \nperfusion hyperthermique de melphalan (p < 0,001). Au total, 115 \npatients ont \u00e9t\u00e9 i nclus, dont 107 \u00e9valuables. Le calcul a priori du nombre \nde sujets n\u00e9cessaires n\u2019\u00e9tant pas  pr\u00e9sent\u00e9, la puissance de l\u2019\u00e9tude ne peut \n\u00eatre recalcul\u00e9e et la fiabilit\u00e9 des r\u00e9sultats est limit\u00e9e. Les analyses en \nsous-groupes d\u00e9finies a posteriori ne permettent pas d\u2019\u00e9tablir de \nconclusions fiables en regard de ces r\u00e9sultats. Les populations des 2 \n\u00e9tudes ne sont pas comparables. \u00c0 noter \u00e9galement que pr\u00e8s de 10 ans \ns\u00e9parent les 2 \u00e9tudes et que les protocoles de traitement ont \u00e9t\u00e9 \ndiff\u00e9rents (hyperthermie dans l\u2019\u00e9tude de Ghussen et al.).  \n \nCONCLUSIONS DE LA LITT\u00c9RATURE  \nLa perfusion de melphalan sur memb re isol\u00e9 ne semble pas am\u00e9liorer la \nsurvie globale des patients atteints d\u2019un melanoma cutan\u00e9 (niveau de \npreuve C).  zugunsten einer hype rthermen Perfusion mit Melphalan gezeigt hat (p < \n0,001). Insgesamt wurden 115 Patienten eingeschlossen, davon waren 107 \nauswertbar. Die erforderliche Fal lzahlberechnung wurde nicht dargestellt, \ndie Power der Studie konnte nicht berechnet werden und die \nVerl\u00e4sslichkeit der Daten ist limitiert. Die nachtr\u00e4glich definierten \nSubgruppenanalysen lassen keine verl\u00e4sslichen Schlus sfolgerungen aus \nden Ergebnissen zu. Die Populationen aus den beiden Studien sind nicht \nvergleichbar. Es ist zu beachten, dass fast 10 Jahre zwischen den beiden \nStudien lag und die Behandlungsprotokolle unterschiedlich waren \n(Hyperthermie in der Studie von Ghu ssen et al.)  \n \n\u2022Schlussfolgerung aus der Literatur  \nEine adjuvante Extremit\u00e4tenperfusion mit Melphalan scheint das \nGesamt\u00fcberleben von Melanompatienten nicht zu verbe ssern. (Niveau de \npreuve C)  \n \nLiteratur:  \n \nGhussen F, Kruger I, Smalley RV, et al. Hypertherm ic perfusion with chemotherapy for melanoma of the extremities. World J Surg 1989;13:598 -602 \nKoops HS, Vaglini M, Suciu S, et al. Prophylactic isolated limb perfusion for localized, high -risk limb melanoma: results of a multicenter randomized phase III tri al. European \nOrganization for Research and Treatment of Cancer Malignant Melanoma Cooperative Group Protocol 18832, the World Health Organ ization Melanoma Program Trial 15, and \nthe North American Perfusion Group Southwest Oncology Group -8593. J Clin Oncol 1998;16:2906 -2912  \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 367 von 732 4.4. Frage IV.4. Adjuvante Immunstimulation - Adaptation  \n4.4.1.  Synopse Quelleitlinien  \n LL Austr alien  \nNew Zealand Guidelines \nGroup 2008  LL GB  \nNICE 2006  LL Frankreich  \nFrench National Authority \nfor Health 2005  LL Kanada  \nCancer Care O ntario \n2007  \nBeeinflusst eine \nunspezifische \nImmunstimulation (BCG, \nLevamisol) das \nGesamt\u00fcberleben und/oder \ndie rezidivfreie Zeit von \nMelanompatie nten? - \n - \n Le levamisole en situation \nadjuvante n\u2019am\u00e9liore pas la \nsurvie  \ndes patients porteurs d\u2019un \nm\u00e9lanome cutan\u00e9 op\u00e9r\u00e9 \n(niveau de preuve A).  \n \nEine adjuvante Therapie mit \nLevamisole ve rbessert nicht \ndas \u00dcberleben von  \nMelanompatienten. (Niveau \nde pre uve A)  After the review of the \navailable information with \nrespect to levamisole, we \nhave concl uded that, if \nlevamisole has an i mpact on \nthe clinical course of \nmalignant melanoma when \ngiven in the adjuvant \nsetting, that effect is \nmarginal  \n \n(BCG wurde nicht in die \nLiteratursuche \neingschlossen)  \nSchl\u00fcsselempfe hlung - - Les traitements adjuvants \nsyst\u00e9miques \u00e0 base de \nlevam isole, BCG ou \ndacarbazine ne sont pas \nrecommand\u00e9s en d ehors \nd\u2019essais th\u00e9rapeutiques.  Keine Empfehlung zu \nLevamisole enthalten   \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 368 von 732  LL Austr alien  \nNew Zealand Guidelines \nGroup 2008  LL GB  \nNICE 2006  LL Frankreich  \nFrench National Authority \nfor Health 2005  LL Kanada  \nCancer Care O ntario \n2007  \n \nAdjuvante  systemische \nTherapien mit Levamisol, \nBCG oder Dacarbazine \nwerden  ausse rhalb von \nklinischen Studien nicht \nempfohlen.  \nZugrunde li egende Evidenz  - \n - 4 Studien, 1 Metaanalyse \naus der kanadischen LL \n2002  \n \nLoutfi et al 1987, Lejeune et \nal. 1988, Quirt et al 1991, \nSpitler et al. 1991, Cancer \nCare Ontario Practice \nGuidelines Initiative 2002  4 Studien  \n \nSpitler et al 1980, Loutfi et \nal 1987, Lejeune et al. 1988, \nQuirt et al 1991, Spi tler et \nal. 1991  \n \nUpdate Recherche am 07.03.20 11 \nSuchstrategie Medline:  melanoma [tiab] AND levamisole [tiab], Treffer: 50 , Darunter seit 2005 keine neuen randomisierten Studien zu \nLevamisol  \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 369 von 732 4.4.2.  Empfehlung und Hinte rgrundstext franz\u00f6sische Quell Leitlinie  \nQuellleitlinie: Recommandations pour la Pratique Clinique : Standards, Options et Recommandations 2005  \nOriginaltext (Evidenztabelle siehe Quell LL ab S.38)  \u00dcbersetzung  \n LEVAMISOLE  \n \n\u2022Description des \u00e9tudes  \nQuatre es sais randomis\u00e9s ont \u00e9valu\u00e9 l\u2019efficacit\u00e9 du levamisole  \n(immunomodulateur) en situation adjuvante chez les patients  \nporteurs d\u2019un m\u00e9lanome cutan\u00e9 op\u00e9r\u00e9 [126 -129]. Aucun nouvel  \nessai randomis\u00e9 n\u2019a \u00e9t\u00e9 retrouv\u00e9 dans le cadre de la mise \u00e0 jour  \n2005. Trois essai s ont compar\u00e9 levamisole versus placebo [126,  \n127, 129] et 1 essai a \u00e9valu\u00e9 levamisole versus observation [128].  \n \n\u2022Survie globale  \nAucun des 3 essais contre placebo n\u2019a rapport\u00e9 de diff\u00e9rence  \nsignificative en termes de survie globale [126, 127, 129].  \nL\u2019\u00e9tud e du NCIC a observ\u00e9 une diff\u00e9rence significative de la  \nsurvie \u00e0 5 ans en faveur des patients trait\u00e9s par levamisole  \npar rapport \u00e0 l\u2019absence de traitement (78 % versus 62 % ;  \np = 0,027) [128]. L\u2019analyse pool\u00e9e des donn\u00e9es r\u00e9alis\u00e9e par le  \nCCOPGI n\u2019a pas retr ouv\u00e9 de diff\u00e9rence significative (odd  \nratio = 0,90 [IC95 : 0,63 -1,30]) [12].  \n \n\u2022Commentaires m\u00e9thodologiques et cliniques  \nLes doses de levamisole administr\u00e9es dans les 4 \u00e9tudes sont  \ntr\u00e8s h\u00e9t\u00e9rog\u00e8nes, ce qui ne permet pas d\u2019\u00e9tablir de conclusions  LEVAMISOLE  \n \n\u2022Beschreibung der Studien  \nVier randomisierte Studien haben den Effekt von Levamisole \n(Immunmodul ator) bei Patienten in der adjuvanten Situation nach Exzision \neines kutanen Melanoms u ntersucht [126-129].  Keine neue randomisierte \nStudie wurde im Rahmen der Aktualisierung 2005 gefunden. Drei Studien \nhaben Levamisole gegen Placebo verglichen [126, 127, 129]  und eine \nStudie hat Levamisole gegen Beobachtung unte rsucht [128].  \n \n \n\u2022Gesamt\u00fcberle ben \nKeine der drei Studien versus Placebo berichtete einen signifikanten \nUnterschied in Bezug auf das Gesamt\u00fcberleben [126, 127, 129].  \nDie Studie der  NCIC (National Cancer Institute of Canada Clinical Trials \nGroup) hat einen signifikanten Unterschied des \u00dcberlebens nach 5 Jahren \nf\u00fcr Pataienten die mit Levamisole behandelt wurden  im Vergleich zu \nunbehandelten Patienten gezeigt. Die Metaanalyse durch die CCOPGI hat \nkeinen sign ifikanten Unterschied gezeigt. (odd ratio = 0,90 [IC95 : 0,63 -\n1,30]) [12].  \n \n\u2022Klinische und Methodische Kommentare  \nDie in den vier Studien verabreichten Dosierungen von Levamisole waren  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 370 von 732 concernant la relation effet -dose. La population incluse  \ndans l\u2019\u00e9tude du NCIC est h\u00e9t\u00e9rog\u00e8ne (seuls 50 % des  \npatients sont des patients \u00e0 haut risque de r\u00e9cidive).  \n \n\u2022Conclusions de la litt\u00e9rature  \nLe levamisole en situation adjuvante n\u2019am\u00e9liore pas la survie  \ndes patie nts porteurs d\u2019un m\u00e9lanome cutan\u00e9 op\u00e9r\u00e9 (niveau  \nde preuve A).  sehr heterogen, daher lassen sich keine Schlussfolgerungen zur \ndosisabh\u00e4ngigen Wirkung ziehen. Die eingeschlossene Population in der \nNCIC Studien ist seh r heterogen (nur 50% der Patienten sind \nHochrisikopatienten)  \n \n\u2022Schlussfolgerung aus der Literatur  \nEine adjuvante Therapie mit Levamisole verbessert nicht das \u00dcberleben \nvon  Melanompatienten. (Niveau de pre uve A)  \n \nLiteratur :  \n \n12. CCOPGI, (Cancer Care Onta rio Practice Guidelines Initiative). Systemic adjuvant therapy for patients at high risk for recurrent melanoma. Practice Gui deline Report No 8 -1 \n[online]. 2002. Available: URL: http://www.cancercare.on.ca/index_practiceGuidelinesandEvidencesummaries.htm#list . \n127. Lejeune F, Macher E, Kleeberg UR, Rumke P, Prade M, Thomas D, et al. An assessment of DTIC versus levamisole or placebo in the treatment of high ri sk stage I patients \nafter removal of a primary melanoma of the skin: a phase III adjuvant study (EORTC protocol 18761). Eur J Cancer 1988;24:S81 -90.  \n126. Loutfi A, Shakr A, Jerry M, et al. Double blind randomized prospective trial of levamisole/placebo in  stage I cutaneous malignant melanoma. Clin Invest Med 1987;10:325 -\n328 \n128. Quirt IC, Shelley WE, Pater JL, et al. Improved survival in patients with poor -prognosis malignant melanoma treated with adjuvant levamisole: a phase III study by the \nNational Canc er Institute of Canada Clinical Trials Group. J Clin Oncol 1991;9:729 -735 \n129. Spitler LE. A randomized trial of levamisole versus placebo as adjuvant therapy in malignant melanoma. J Clin Oncol 1991;9:736 -740 \n \n4.4.3.  Empfehlung und Hintergrundstext kanadische  Quell Leitlinie  \nQuellleitlinie: Systemic Adjuvant Therapy for Patients at High Risk for Recurrent Melanoma: Updated Guideline Recommend ations (Cancer \nCare Ontario) 2009  \nLevamisole is an anti-helminthic with disputed immunostimulatory properties in vitro. On  the basis of that activity, levamisole has been \ninvestigated as adjuvant therapy in a number of cancers. Apart from results as adjuvant therapy in colon cancer when combined  with a \ncytotoxic agent, the trials in other cancers have been negative.  \nThere are  four randomized controlled trials of levamisole in melanoma, of which three are placebo -controlled (30 -33). The (NCIC) study \n(34) enro lled a heterogeneous group of patients with 50% being at high risk of recurrence (personal communication, B. Zee). The to tal \ndose of levamisole used in this level I study was 800 mg over a two -week period for an 80 kg individual. Three smaller trials evaluated  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 371 von 732 total doses of 450 mg (31,31), 600 mg (32), and 600 to 1000 mg (33) over a two -week period. Whether those difference s in dose are \nsubstantive is difficult to know in the absence of any data that demonstrate a dose -response relationship for levamisole with any \nmeasure of activity.  \nAlthough the initial report by Spitler et al (31) described a survival trend in favour of l evam isole compared with placebo in the subgroup \nof patients without lymph node disease (p=0.07, two -sided), there was no survival difference between trea tments for the total study \npopulation. That lack of benefit was confirmed by a subsequent report of lon g-term follow -up (30). Loutfi et al (32) and Lejeune et al \n(33) co ncluded that there was no meaningful impact on survival with levamisole compared with placebo. The only study in which \nlevamisole had an i mpact, albeit a marginal one, was the study from the  NCIC (34) in which there was a statistically significant difference \nin the survival rate in favour of levam isole when the five -year point estimates of overall survival were assessed (78% for levamisole \nversus 62% for control, p=0.027, 2 -sided). However, w hen the whole survival exp erience was compared between the groups, the \ndifference in survival was not significant (p=0.08, two -sided). That difference represented a risk reduction in mortality of 29% and was \nobserved in all risk groups, including the group  to which this systematic review is directed.  \nWithout an intermediate marker of activity for levamisole, it is impossible to categorically state whether or not there are s ubstantive \ndifferences in the reg imens used in those four trials. This systematic rev iew is directed at a specific segment of the population involved \nin those trials. While a meta -analysis r estricted to data from the high -risk subgroup might help to reconcile the seemingly disparate \nfindings, survival results are not reported separately fo r that p atient subgroup, and data for individual cases are generally not available. \nHowever, it is our belief that the regimens evaluated are unlikely to be substantially different in their clinical activity a nd that the impact \nof levamisole does not diffe r across risk groups. A meta -analysis of five -year death rates (Figure 2), a bstracted from survival curves in \npublished reports, yields a risk ratio of 0.94 (95% CI, 0.75 to 1.20; p=0.6). No heterogeneity was found among the r esults from these \nstudies (p=0 .19). \nAfter the review of the available information with respect to levamisole, we have concluded that, if levamisole has an impact  on the \nclinical course of m alignant melanoma when given in the adjuvant setting, that effect is marginal.  \nAdverse effects  \nMorbidity from levamisole is generally mild, although it was severe enough to result in discontinuation of therapy in 41% of pa tients in \nthe NCIC study (34), 44% in the Loutfi et al study (compared with 16% in the placebo group) (32), and 17% in the Lejeune et al study \n(compared with no patients in the placebo group) (33). Data on toxicity was reported for two of the placebo -controlled trials (32,33). In  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 372 von 732 the study by Loutfi et al, 22% of patients on levamisole repo rted a flu -like syndrome (compared with 3% on  placebo), 14% reported \nnausea and vomiting (compared with 8% on placebo), and 14% reported musculosk eletal symptoms (compared with no patients on \nplacebo) (32). The most commonly reported adverse events in the Lejeune et al study were nausea and v omiting (27% with levamisole \nversus 10% with placebo), weakness (27% versus 14%), and anorexia (22% versus 8%) (33). Hematologic abnormalities were noted for 7% \nof patients on levamisole and none of the placebo group in the Loutfi et al study (32), and for 16% and  5%, respectively, of those groups \nin the Lejeune et al study (33). No treatment -related mortality has been observed in the four levamisole studies summarized here.  \n \nLiteratur : \n \n33. Lejeune FJ, Macher E, Kleeberg U, Rumke P, Prade M, Thomas D, et al. An assessment of DTIC versus levamisole or placebo in the treatment of high risk stage I patients \nafter surgical removal of a primary melanoma of the skin. Eur J Cancer Clin Oncol. 1988;24 Suppl 2:S81 -S90. \n32. Loutfi A, Shakr A, Jerry M, et al. Double blind ra ndomized prospective trial of levamisole/placebo in stage I cutaneous malignant melanoma. Clin Invest Med 1987;10:325 -\n328 \n34. Quirt IC, Shelley WE, Pater JL, et al. Improved survival in patients with poor -prognosis malignant melanoma treated with adjuvant levamisole: a phase III study by the \nNational Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1991;9:729 -735 \n30. Spitler LE. A randomized trial of levamisole versus placebo as adjuvant therapy in malignant melanoma. J Clin Oncol 1991;9:73 6-740 \n31. Spitler LE, Sagebiel R. A randomized trial of levamisole versus placebo as adjuvant therapy in malignant melanoma. N Engl J M ed 1980;303:1143 -1147  \n \n \n \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 373 von 732 4.5. Frage IV.5. und IV.6. Adjuvante Interferon alpha  Therapie  \u2013 De novo Recherche  \nFrage IV. 5. Beeinfl usst eine Therapie mit IFN -alpha das Gesamt\u00fcberleben und/oder die rezidivfreie Zeit von Melanomp atienten?  \nFrage IV. 6. Welche Patientengruppe profitiert von einer Interferon -alpha -Therapie?  \n4.5.1.  PICO, Suchw\u00f6rter  \n \nPICO - Schema  \nPopulation  Intervention  Comparison  Outcome  \nMelanoma patients, clinical stage II and \nIII IFN-alpha treatment  Observation  OS, PFS  \n \nSuchw\u00f6rter  \nStichwort  melanoma  Interferon -alpha  adjuvant   \nSynonyme   Interferon  alpha, Interferon \nalpha,  IFN -\u03b1, IFN-alpha    \nOber -/Unterbegriffe   interferon -alpha -2b, \ninterferon -alpha -2a, \nmultiferon    \nMesh Term  melanoma  Interferon -alpha    \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 374 von 732 4.5.2.  Datenbanken , Suchstrategien , Trefferzahlen  \nDatenbank  Suchstrategie  Datum  Treffer (Auswahl)  \n1. Suche     \nMedline  (melanoma[ tiab] OR melanoma[MeSH]) AND (Interferon -alpha[tiab] OR \nInterf eron-alpha[MeSH] OR \u201cInterferon alpha\u201d[tiab] OR IFN -alpha  [tiab] OR \nIFN-alpha[tiab] OR interf eron-alpha -2b[tiab] OR interferon -alpha -2a[tiab] \nOR multiferon[tiab]) AND (adj uvant[tiab])  12.04.11  404 (25)  \nCochrane Library  (melanoma and interferon alpha and adjuvant).mp.  12.04.11  46 (8, davon 7 Dubletten, 1 Studie dazu \nRudolf Z 1994)  \nEmbase  (melanoma and (Interferon alpha or IFN alpha or interferon alpha 2b or \ninterferon alpha 2a or multiferon) and  (adjuvant)).ti,ab.  11.05.11  301 (nach Dublettenelimination 0 d azu) \nUpdate Suche     \nMedline  s.o. 30.01.12  427 (2 dazu: Petrella, Egge rmont)  \nCochrane Library  s.o. 30.01.12  47 (0 dazu)  \nEmbase  s.o. 23.01.12  308 (0 dazu)  \n \n \n \n \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 375 von 732 4.5.3.  Auswahlkriterien  \nAuswahl der  Literatur  \nGesamttreffer  782 \nEinschlusskriterien  system. Reviews , klinische Studien  zu adjuvanter Therapie mit Interferon alpha bei Patienten mit Rezidivrisiko, \ntumorfreies St adium I -III \nIntervention: IFN alpha Monotherapie, Vergleichsgruppe: Beobachtung  \nSprachen: e,dt  \nAusschlusskriterien  Nicht systematische Reviews  \nKohorten Studien, Case Reports  \nKombinationstherapien  \nVergleichsgruppe Chemotherapie, andere Systemtherapien  \nTherapiestudien mit Interferon alpha im Stadium IV  \nKollektive mit gemischten Tumore ntiti\u00e4ten  \nAnzahl ausgew\u00e4hlter Studien (8 Reviews, 16 RCTs, davon 2 nur als Abstract vorliegend ) 24 \nAnzahl in Reviews zus\u00e4tzlich ber\u00fccksichtigter Studien (E2696+E1694 kein Obs Arm, Kokoschka, Rusciani mangelnde \nQualit\u00e4t)  4 \nAnzahl der ausgeschlossenen Stu dien nach Bewertung (Rudolf)  1 \n \n \n \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 376 von 732 4.5.4.  Evidenztabelle - Kurzfassung  \nRCT No. of patients  OS p RFS p LoE \nLow Dose        \nPehamberger, AMCG, 1998  311 no benefit, HR n.r.  - benefit, HR n.r.  <0.2  1b \nGarbe, DeCOG, 2008  444 HR = 0.62  0.0045  HR = 0.69  0.018  1b \nKleeberg, EORTC 18871, 2004  484 HR = 0.96  0.72 HR = 1.04  0.71 1b \nHancock, UKCCCR, 2004  674 OR = 0.94  0.6 OR = 0.91  0.3 1b \nCascinelli, WHO, 2001  444 no benefit, HR n.r.  0.72 no benefit, HR n.r.  0.5 1b \nCameron, SMG, 2001  95 no benefit, HR n.r.  >0.2  no bene fit, HR n.r.  - 1b \nKirkwood, E1690, 2000  642 HR = 1.04\u00a7 0.813  HR = 1.19\u00a7 0.171  1b \nGrob, FCGM, 1998  489 no benefit, HR n.r.  0.059  benefit, HR n.r.  0.035  1b \nIntermediate Dose        \nHansson, Nordic trial, 2011  855 HR = 0.91  0.642  HR = 0.80  0.030  1b \nEggerm ont, EORTC 18952, 2005  832 \n835 HR = 1.00*  \nHR = 0.85*  0.96 \n0.11 HR = 0.95*  \nHR = 0.83*  0.59 \n0.05 1b \nHigh Dose        \nAgarwala, E1697, 2011  1150  no benefit, HR n.r.  - no benefit, HR n.r.  -  \nMcMasters, Sunbelt Trial, 2008  218 HR = 1.07  0.79 HR = 0.82  0.46  \nKirkwood, E1690, 2000  642 HR = 1.0\u00a7 0.995  HR = 1.28\u00a7 0.054  1b \nKirkwood, E1684, 1996/2004  287 Upd.: HR = 1.22\u00a7 \nbenefit, HR n.r.  0.18 \n0.0237  Upd.: HR = 1.38\u00a7 \nbenefit, HR n.r.  0.02 \n0.0023  1b \nCreagan, NCCTG, 1995  262 HR = 0.9  0.53 HR = 0.83  0.37 1b \nPegylate d       \nEggermont, EORTC 18991, 2008  1256  HR = 0.98  0.78 HR = 0.82  0.01 1b \n*13 month, 25 month interferon; DMFS not RFS was calculated, \u00a7 HR relates to proportion alive and proportion relapsfree (> 1 = Favour IFN)  \nAgarwala 2011, Mc Masters 2008: only ab stract available   \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 377 von 732 4.5.5.  Hochdosis versus Niedrigdosis Interferon alpha  \n \nRandomisierte Studie HDI versus LDI versus Beobachtung: kein signifikanter Un terschied  \nRCT No. of patients  OS p RFS p LoE \nKirkwood et al. 2000  HDI n=215, HDI vs. Obs  \nLDI n=215, LDI vs. Obs  \nHDI vs. LDI*  HR = 1.0\u00a7 \nHR = 1.04\u00a7 \nRR = 1.02*\u00a7   \nFavour LDI, n.s.  n.s. \nn.s. \n0.92*  HR = 1.28\u00a7 \nHR = 1.19\u00a7 \nRR = 0.93*\u00a7, \nFavour HDI, n.s.  n.s. \nn.s. \n0.50*  1b \n* Data not reported, calculated based on event data RR=(events/group A)/(events group B), p value: Fishe r's exact test ; \u00a7 HR relates to proportion alive and proportion relapsfree  \n \n \nSubgruppenvergleich Metaanalyse Mocellin et al. 2010: 6 HDI Studien versus 7 LDI und IDI Studien, kein signifikanter Untersch ied \nStudy  No. of trials \n/ patients  OS \nHR (95% CI)  \n No. of trials \n/ patients  PFS \nHR (95% CI)  \n No. of trials \n/ patients  OS \nHR (95% CI)  \n No. of trials \n/ patients  PFS \nHR (95% CI)  \n Subgroup  \ncomparison  LoE \nMocellin et \nal. 2010  HDI LDI or IDI  OS p=0.99  \nPFS p=0.05  2b \n 5/3114  0.89 \n(0.77 \u2013 1.02)  6/3221  0.75 \n(0.68 \u2013 0.83) 7/4590  0.89 \n(0.81 \u2013 0.98)  8/4901  \n 0.85 \n(0.78 \u2013 0.93)    \n \n \n \n \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 378 von 732 Vergleich Hochdosis versus Niedrigdosis Interferon alpha Studien im Stadium der lokoregion\u00e4ren Metastasierung  (AJCC 2009: St.  III) \nRCT \nLow Dose  Anteil Patienten \nmit lokoreg. \nMet. OS p RFS p RCT \nHigh Dose  Anteil Patienten \nmit lokoreg. \nMet. OS p RFS p \nCascinelli, \nWHO, 200 1 97%  no \nbenefit, \nHR n.r.  0.72 no \nbenefit, \nHR n.r.  0.5 Kirkwood, \nE1684,  \n2004 (U pdate), \n1996  89% Upd.: no \nbenefit: HR \n= 1.22\u00a7  \nbenefit, HR \nn.r. 0.18 \n \n \n \n0.0237  Upd.: HR = \n1.38\u00a7 \n \n \nbenefit, HR \nn.r. 0.02 \n \n \n \n0.0023  \nHancock, \nUKCCCR, 2004  81% OR = \n0.94 0.6 OR = \n0.91 0.3 Kirkwood, \nE1690, 2000  74%  HR = 1.0\u00a7 0.995  HR = 1.28\u00a7 0.054  \nKirkwood, \nE1690, 2000  74%  HR = \n1.04\u00a7 0.813  HR = \n1.19\u00a7 0.171  Creagan, \nNCCTG, 1995  61%  HR = 0.9  0.53 HR = 0.83  0.37 \nGarbe, DeCOG, \n2008  61% HR = \n0.62 0.0045  HR = \n0.69 0.018        \nKleeberg, \nEORTC 18871, \n2004  60% HR = \n0.96 0.72 HR = \n1.04 0.71       \nCameron, SMG, \n2001  St II + III  \nAnteil n.r.  no \nbenefit, \nHR n.r.  >0.2  no \nbenefit, \nHR n.r.  -       \nPehamberger, \nAMCG, 1998  0% no \nbenefit, \nHR n.r.  - benefit, \nHR n.r.  <0.2        \nGrob, FCGM, \n1998  0% no \nbenefit, \nHR n.r.  0.059  benefit, \nHR n.r.  0.035        \n\u00a7 HR relates to proportion alive and proportion relapsfree  \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 379 von 732 4.5.6.  Evidenztabelle n \u2013 Langfassung  \n4.5.6.1.  Evidenztabelle \u2013 Systemati sche Reviews and Metaanalyse n \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nPetrella et al. 2012  To conduct another \nupdate of the \nevidence and \nrecommendations. \nThis report \nsumm arises the \nevidence pu blished \nbetween July 2005 \nand June 2010 that  \ninformed the \ndevelopment of \nrevised \nrecomme ndations \nfor adjuvant \ninterf eron therapy \nby the Melanoma \nDSG. Systematic review \n(Update)  \n \nadjuvant treatment \nfor stage AJCC stage \nIIB, IIC and III.  7 new RCTs:  \n \nEORTC 18991  \nSunbelt Trial  \nPectasides et al. \n2009  \nEORTC 18952  \nStadler et al. 2006  \nDeCOG 2008  \nDeCOG 2010  \n \nMetaanalyses:  \nMocellin et al.  \nWheatley et al.  OS \n \n \n \n \nDFS HDI vs. Obs: no \nsign. ben efit \nHazard Ratio:  \n0.93 [0.78,1.12]  \n \nHDI vs. Obs: sign. \nBenefit \nHazard Ratio:  \n0.77 [0.65, 0.92]  \nP = 0.004; 9% \nabsolute r isk \nreduction at 5 years  most LDI studies \nnot included  \n \nConflict of Interest:  \nThe first author \nreceived consulting \nfees or honoraria \ngreater than $5000 \nfrom Schering -\nPlough in the past 2 \nyears.  1a- \nEggermont et al. \n2011  To present a meta -\nanalysis of the t wo \nlargest adjuvant \nIFN/PEG -IFN \nrandomised trials in \na combined total of Metaanalysis of 2 \nstudies  \n EORTC 18991  \nEORTC 18952  \n \n2644 patients with \nhigh-risk melanoma \nstage IIb/III  OS \n \n \n \n \nRFS IDI+peg IFN vs. \nObs: no sign. \nbenefit \nHazard Ratio:  \n0.94 [0.80, 1.11]  \n Conflict of Inte rest: \nAlexander M.M. \nEggermont: \nConsu ltant in \nadvisory boards f or \nmelan oma for 1a-  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 380 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \n2644 patients with \nhigh-risk melanoma \n(stage IIb/III)   \n \n \n \nDMFS  \n \n sign. benefit  \nHazard Ratio:  \n0.85 [0.76, 0.95]  \np=0.004  \n \nsign. benefit  \nHazard Ratio:  \n0.89 [0.79, 1.00]  \np=0.36  Merck, BMS, Roche, \nGSK. Poulam Patel: \nAd hoc adv isory \nboards for \nSchering -Plough \nResearch Institute \u2013 \nhonor aria paid.  \nGarbe et al. 2011  to present the \nsuccess of current \ntreatments and the \npromise of those \nstill in clinical \ndevelopmen t that \nmay yield \nincremental \nimprovements in \nthe treatment of \nadvanced, \nmetasta tic \nmelanoma  Systematic review  \n \nadjuvant and \npalliative treatments  Interferon alpha:  \n11 RCTs  \n \nNCCTG  \nECOG 1684  \nECOG 1690  \nEORTC 18952  \nSMG  \nWHO  \nDeCOG  \nFCGM  \nUKCCCR  \nAMCG  \nEORTC  18991  \n \n Metaanalysis  \n \nOverall survival (OS)  \n \n \n \n \n \nDisease free su rvival \n(DFS)  12 RCTs  \n \nSignificant \nimprovement  \nodds ratio = 0.88, \n95% CI = 0.79 \u20130.99, \np<0.03  \n \nSignificant \nimprovement  \nodds ratio = 0.83, \n95% CI = 0.75 \u20130.92 \np<0.0001  Number needed to \ntreat not reported  \n \nNo quality \nasses sment of \nstudies  \n \nupdated data of \nE1684 (Kir kwood \n2004) and EORTC \n18871 (Kleeberg \n2004) not i ncluded  \n \nConflict of Interest: \nClaus Garbe: \nConsultant/advisory \nrole: Roche Pharma, \nMSD, Bristol -Myers 1a- \n(SR with \nheterogen eit\ny)  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 381 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \nSquibb, Swedish \nOrphan, Genta, \nGlaxoSmithKline; \nResearch \nfunding/contracted \nresearch: Roche \nPharma, MSD, \nBristol-Myers \nSquibb, Swedish \nOrphan, Genta, \nGlaxoSmit hKline;  \nAxel Hauschild: \nConsu ltant/advisory \nrole: Abraxis \nOnco logy, Bayer \nSchering, Bristol -\nMyers Squibb, Essex \nPharma/Schering -\nPlough; Honoraria: \nGlaxoSmithKline, \nMerck, Onyx \nPharmaceuticals, \nPfizer, Roche \nPharma, Synta \nPharm aceuticals \nCorp.; John M. \nKirkwood:  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 382 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \nConsu ltant/advisory \nrole: Schering (for \nFDA review of \nPegIFN), \nGlaxoSmit hKline (for \nchairma nship of \nvaccine steering \ncommi ttee). \nMocellin et al. 2010  to examine the \neffect of IFN -alpha \non DFS and OS in \npatients with high -\nrisk cutaneous \nmelan oma Systematic review  \n \nAdjuvant treatment \nwith interferon \nalpha 14 RCTs ( pu blished \n1990 \u2013 2008)  \n8122 p atients \n \nNCCTG  \nECOG 1684  \nAMCG  \nFCGM  \nECOG 1690  \nSMG  \nWHO  \nECOG 1694  \nE2696  \nUKCCCR  \nEORTC 18871  \nEORTC 18952  \nDeCOG  \nEORTC 18991  \n OS  \n \n \n \n \n \n \n \n \nDFS Significant \nimprovement  \nHR for death = \n0.89, 95% CI = \n0.83\u20130.96;  \nP=.002  \n \nNumber needed to \ntreat 29 patients  \n \nSignificant \nimprovement  \nHR for disease \nrecurrence = 0.82, \n95% CI = 0.77 \u20130.87;  \np<.001  \n \n \n absolute risk \nreduction not \nreported  \n \nReported hazard \nratio were used for \nmeta -analysis  \n \n \nupdated data of \nE1684 (Kirkwood \n2004) not i ncluded  \nData of E1694 and \nE2696 (co ntrol \nvaccination arm \nwith p otentially \nworse outcome) \nwere included  \n 1a- \n(SR with \nheterogen eit\ny)  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 383 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \nOS benefit was \nobserved only when \ntrials that used low \nor interm ediate IFN -\na doses were \nconsidered  \n \nFunding: no funds \ninvolved  \nAll authors declared \nno conflict of \ninterest. \nVerma et al. 2006  To examine the role \nof systemic \nadjuvant therapy  Systematic review  Interferon alpha:  \n13 RCTs, published \n1980 -2004  \n \nMetaanalysis:  \nE1684, E1690, \nE1694  \n OS \n \n \n \n \n \n \n \n \n \n \n \n \n Metaanalysis  \nE1684, E1690, \nE1694:  \nsignificant \nImprovem ent  \nRR (2 years) 0.85, \n95% CI = 0.73 \u20130.99;  \nP=.03  \nnot significant after \nexclusion of E1694:  \nHR 0.87, 95% CI = \n0.71\u20131.07;  \nP=.18  Number needed to \ntreat not reported  \n \nNo quality \nasses sment of \nstudies  \n \nonly 3 RCTs were \nincluded into \nmetaanalysis  \n \nother RCTs and \npublished \nmetaanalyses were \nreported na rratively  1a- \n(SR with \nheterogen eit\ny)  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 384 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \n \nFunding: Su pported \nby Cancer Care \nOntario and the \nOntario Ministry of \nHealth and Long -\nTerm Care.  \nPirad et al. 2004  to evaluate the \neffect of IFN -alpha \non the relapse rate \n(RR) and the overall \nsurvival (OS).  Systematic review  9 RCTs  \n2 880 p atients  \n \nECOG 1684  \nNCCTG  \nECOG 1690  \nRusciani  \nFCGM  \nAMCG  \nSMG  \nKokoschka  \nWHO  Metaanalysis  \n \nOS \n \n \n \n \n \nRR \n  \n \nno significant \nbenefit \nOR = 0.87; 95% CI \n=0.74 \u20131.02; p = \n0.1029  \n \nSignificant lower  \nOR = 0.74; 95% CI \n= 0.64 \u20130.86; p = \n0.0001  Number needed to \ntreat not reported  \n \nNo quality \nasses sment of \nstudies  \n \nheterogeneity tests \nare non -significant \n(=homogeneous \neffects of studies),  \nbut studies were \nheterogeneous in \nregard to the \nschedules, the \nclassification used \nand the m edian \ntime of follow -up \n \nFunding/Conflict of 1a- \n(SR with \nheterogen eit\ny)  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 385 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \ninterest: not \nmentioned  \nWheatley et al. 2003  To assess all the \navailable evidence \nfor adjuvant \ninterf eron-alpha  Metaanalysis  12 RCTs  \n \nECOG 1684  \nECOG 1690  \nNCCTG  \nE2696  \nEORTC 18952  \nWHO  \nUKCCCR  \nFCGM  \nAMCG  \nSMG  \nKleeberg (18871)  \nKleeberg (DKG -80)  Metaanalysis  \n \nOS \n \n \n \n \nRFS \n  \n \nno significant \nbenefit \nHR = 0.93; 95% CI \n0.85-1.02; p=0.1  \n \nsignificant benefit  \nHR = 0.83; 95% CI \n0.77-0.90; \np=0.000003  \n \n Number needed to \ntreat not reported  \n \nfew studies were \nused without \nexisting publication, \ndata of EORTC \n18871 + DKG -80 \nwere not \nreprodu cible within \nthe later publication \n(Kleeberg et al. \n2004)  \n \nFunding/Conflict of \ninterest: not \nmentioned  1a- \n(SR with \nheterogen eit\ny) \nLens et al. 2002  to assess the \nbenefit of IFN alpha \ntherapy in \nmalignant \nmelanoma  Systematic review  9 RCTs, 8 RCTs \nincluded, 3 178 \npatients  \n \nAMCG  \nFCGM  \nECOG 1684  OS \n \n \n \n \n \n analysis on avail able \ndata for 2 7 71 \npatients from 6 \ntrials  \nno study with \nbenefit \n High quality SR  \n \nNumber needed to \ntreat reported for \neach individual trial  \n \nno metaanalysis due 1a- \n(SR with \nheterogen eit\ny)  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 386 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \nECOG 1690  \nNCCTG  \nSMG  \nUKCCCR  \nWHO   \n \n \n \nRFS \n \n \n \n \n \n \n \n \n \n \n ECOG 1684: \nsignif icant benefit, \nnot co nfirmed  \n \n \nanalysis on avail able \ndata for 2 020 \npatients from 4 \ntrials  \n1 study with benefit  \n \nECOG 1684 \nsignif icant benefit, \nconfirmed  \nECOG 1690: \nsignif icant benefit, \nnot confirmed  \n \n to heterogene ity of \nstudies, the authors \nstate that any \nrecommendation \nshould be made on \nthe basis of an \nevaluation of the \nindividual studies.  \n \n \n \n \n \n \n \nFunding: Center for \nEvidence -Based \nMedicine, Univers ity \nof Oxford  \n \n \n \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 387 von 732 4.5.6.2.  Evidenztabelle \u2013 Niedrigdosis  IFN alpha  \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nGarbe et al. 2008  \n \nDeCOG  to improve disease -\nfree survi val (DFS) \nand overall survival \n(OS) with interferon \n(IFN) a2a with or \nwithout dacarbazine \n(DTIC) compared \nwith o bservation \nalone  RCT \n \nTreatment groups  \nLDI \n(LDI plus DTIC)  \nOBS 444 patients, \nresected Stage III  \n \nn=148  \n(n=148)  \nn=148   \nOS \n \n \n \n \n \n \nDFS \n LDI vs OBS  \nsignificant benefit  \nHR 0.62; 97.5% CI: \n0.42-0.89; \np=0.0045;  \nevents: 65/148 vs \n88/148  \n \nsignificant benefit  \nHR 0.69; 97.5% CI: \n0.49-0.96; \np=0.018;  \nevents: 84/148 vs \n102/148  \n \n Jadad Score 3 of 5  \nnot placebo \ncontrolled, not \nblinded  \n \nFunding:  \nGerman Cancer Aid  \n(Deutsche \nKrebshilfe); German \nCancer Society \n(Frankfurt, \nGermany); \nHoffmann -LaRoche \nAG (Grenzach -\nWhylen, Ge rmany).  1b \nHancock et al. 2004  \n \nUKCCCR  To evaluate low -\ndose extended \nduration interferon \nalfa-2a RCT \n \n \nTreatment groups  \nLDI \nOBS 674 patients, \nresected stage IIB \nand stage III  \n \nn=338  \nn=336   \n \nOS \n \n \n \n \n \nRFS LDI vs OBS  \nno benefit  \nOR 0.94; 95% CI: \n0.75-1.18; p=0.6;  \nevents: 151/338 vs \n156/336  \n \nno benefit  \nOR 0.91; 95% CI: Jadad Score 3 of 5  \nnot placebo \ncontrolled, not \nblinded  \n \nFunding: The study \nwas supported by a \ngrant from Roche \nProducts  1b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 388 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \n0.75-1.10; p=0.3;  \nevents: 211/338 vs \n215/336  Ltd \nKleeberg et al. 2004  \n \nEORTC 18871  to evaluate the \nefficacy and toxi city \nof low dose \nrecombinant \ninterferon -alpha 2 b \n(rIFN-alpha2b) (1 \nMU) or recombinant \ninterferon gamma  in \ncomparison with an \nuntreated control \ngroup  RCT \n \nTreatment groups  \nOBS \nvery LDI alpha  \n(very LDI gamma)  \n 728 p atients Stage \nII-III \n \nn=244  \nn=240  \n(n=244)  \n  \n \nOS \n \n \n \n \n \nRFS LDI vs. OBS  \nno benefit  \nHR 1.04; 95% CI: \n0.84-1.30;  \nevents: 137/240 vs \n148/244  \n \nno benefi t \nHR 0.96; 95% CI: \n0.76-1.21;  \nevents: 159/240 vs \n158/244  \n Jadad Score 2 of 5  \nnot placebo \ncontrolled, not \nblinded, \nrandomization \nscheme not \ndescribed  \n \nFunding:Essex and \nBoeri nger-\nIngelheim, grant \nnumber 3U10 -\nCA11488 -18S1 \nthrough 5U10 -\nCA11488 -33 from \nthe Nat ional Cancer \nInstitute  1b \nCascinelli et al. \n2001  \n \nWHO  to see whether \ninterferon alpha -2a \nincreased survival \nprospects in stage \nIII melanoma \npatients  RCT \n \n \nTreatment groups  \nOBS \nLDI 444 patients with \nlymph node \ninvolvement  \n \nn=219  \nn=225   \n \nOS \n \n \n LDI vs. OBS  \nno be nefit \nHR n.r., p=0.72  \nevents: 146/225 vs \n138/219  \n Jadad Score 3 of 5  \nnot placebo \ncontrolled, not \nblinded  \n \nFunding: not 1b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 389 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \n \nRFS no benefit  \nHR n.r., p=0.5; \nevents: 162/225 vs \n158/219  mentioned  \nCameron et al. 2001  \n \nSMG To test the possible \ndisease -free and \noverall survival \nadvantage of a \nshort, 6 -month \ncourse of low -dose \nIFN for p atients with \nhigh-risk, surgically \nresected, malignant \nmelan oma. RCT \n \n \n \nTreatment groups  \nOBS \nLDI 95 patients with at \nleast 3mm Breslow \nthickness or lymph \nnode involvement  \n \nn=49  \nn=46   \n \nOS \n \n \n \n \nRFS LDI vs. OBS  \nno benefit  \nHR n.r., p>0.2; \nevents: 31/46 vs \n36/49  \n \nno benefit  \nHR n.r., p>0.1; \nevents: 32/46 vs \n35/49  Jadad Score 2 of 5  \nnot placebo \ncontrolled, not \nblinded, \nrandomization \nscheme not \ndescribed  \n \nFunding: not \nmentioned, IFN \nsuppl ied by \nSchering -Plough  1b \nKirkwood et al. \n2000  \n \nE1690  To evaluate the \nefficacy of high -\ndose IFNalpha2b \n(HDI) for 1 year and \nlow-dose \nIFNalpha2b (LDI) for \n2 years versus OBS  RCT \n \nTreatment groups  \nOBS \n(HDI)  \nLDI 642 patients, 75% \nnodal involvement  \n \nn=212  \n(n=215) \nn=215   \n \nOS \n \n \n \n \n \nRFS LDI vs. OBS  \nno benefit  \nHR 1.04\u00a7; 95% CI: \n0.78-1.38; \np=0.813;  \nevents: 96/215 vs \n93/212  \n \nno benefit  \nHR 1.19\u00a7; 95% CI: Jadad Score 3 of 5  \nnot placebo \ncontrolled, not \nblinded  \n \nFunding: n ot \nreported  \nassistance of \nSchering-Plough \nResearch Institute 1b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 390 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \n0.93-1.53; \np=0.171;  \nevents: 122/215 vs \n127/212  and Schering -\nPlough Oncol ogy \nBiotech with \nposttrial data \ncollection \nGrob et al. 1998  \n \nFCGM  To assess the \nefficacy of adjuvant \nlow dose interferon \nalpha RCT \n \n \n \n \nTreatment groups  \nOBS \nLDI 489 pa tients, tumor \nthickness > 1.5mm \nwithout clinically \ndetectable node \nmetastases  \n \nn=245  \nn=244   \n \nOS \n \n \n \n \nRFS LDI vs. OBS  \nno benefit  \nHR n.r., p=0.059  \nevents: 59/244 vs \n76/245  \n \nsignificant benefit  \nHR n.r., p=0.035  \nevents: 100/244 vs \n119/245  Jadad Score 3 of 5  \nnot placebo \ncontrolled, not \nblinded  \n \nFunding: grant from \nHoffman -La Roche \nLtd, also pr ovided \nthe interferon \u0001 -2a \n(Roferon -A). 1b \nPehamberger et al. \n1998  \n \nAMCG  To investigate \nwhether adjuvant \nIFNalpha2a \ndiminishes the \noccurrence of \nmetastases and \nthus prolong s \ndisease -free \nsurvival in \nmelanoma p atients  RCT \n \nTreatment groups  \nOBS \nLDI 311 patients, tumor \nthickness > 1.5mm  \n \nn=157  \nn=154   \n \nOS \n \n \n \n \nRFS LDI vs. OBS  \nno benefit  \nHR n.r.,  \nevents: 17/154 vs \n21/157  \n \nsignificant ben efit \nHR n.r., p=<0.2  \nevents: 37/154 vs \n57/1 57 Jadad Score 2 of 5  \nnot placebo \ncontrolled, not \nblinded, \nrandomization \nscheme not \ndescribed  \n \nFunding:  \nin part by \nHoffmann -La 1b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 391 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \nRoche, Vienna, \nAustria.  \nRusciani et al. 1997  to study the use of \nrecombinant \ninterferon -alpha \n(IFN-alpha) as \nadjuvant therapy  for \npatients with Stage I \nand Stage II \nmelanoma  RCT \n \nTreatment groups  \nObs  \nLDI 84+ 70 patients, \nstages I+II,  \n \nn=70  \nn=84  DFS Significant ben efit \nevents LDI vs. OBS  \n11/84 vs 21/70  \n Jadad Score 0 of 5  \nmatched controlls, \nno randomis ation, \nnot placebo \ncontrolled, not \nblinded, no \ndescri ption of \ndropouts  \nStudy excluded  \n 2b  \nlow qua lity \nRCT \n \nstudy \nexcluded  \nKokoschka et al. \n1990  To evaluate the \nefficacy of rIFN \nalpha 2b therapy in \nhigh-risk mel anoma \npatients stage I and \nstage II  \n Cohort Study  \n \nTreatment groups  \nOBS \nLDI 135 patients, stages \nI+II \n \n \nn=82  \nn=53  \n OS \nDFS no significant \nbenefit Cohort Study  \nOnly included in SR \nby Pirad et al.  2b \n \nstudy \nexcluded  \n\u00a7 HR relates to proportion alive and proportion relapsfree (> 1 = Favour IFN)  \n \n \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 392 von 732 4.5.6.3.  Evidenztabelle - Mittlere Dosis IFN alpha  \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nHansson et al. 2011  \n \nNordic IFN trial  To investigate \nwhether adjuvant \ntherapy with \nintermediate -dose \ninterferon alfa -2b \nfor 1 or 2 years \nwould improve \noutcomes in \npatients with stage \nIIB-IIC or III resected \ncutaneous \nmelanoma  RCT  \n \nTreatment groups  \nOBS \nIDI 12 months  \nIDI 24 months  \n  855 p atients stage \nIIB-IIC \n \nn=284  \nn=285  \nn=286   \n \nOS \n(12 months + 24 \nmonths)  \n \n \n \nPFS \n(12 months + 24 \nmonths)  \n \n \n \n \n24 months alone  IDI vs. OBS  \nno benefit  \nHR 0.91; 95% CI: \n0.74-1.10; \np=0.642;  \nevents: 285/571 vs \n148/284  \n \nsignificant benefit  \nHR 0.80; 95% CI: \n0.67-0.96; \np=0.030;  \nevents: 338/571 vs \n183/284  \n \nno benefit  \n \n Jadad Score 3 of 5  \nnot placebo \ncontrolled, not \nblinded  \n \nFunding: Schering -\nPlough; the \nRadiumhemmet \nResearch Funds, \nStockholm; and the \nStockholm County \nCouncil  1b \nEggermont et al. \n2005  \n \nEORTC 18952  to assess the effect \nof two reg imens of \ninterferon of \nintermediate dose \nversus o bservation \nalone  RCT \n \nTreatment groups  \nIntermediate IFN, 13 \nmonths  \nIntermediate  IFN, 25 \nmonths  1388 patients  \n \n \nn=553  \n \nn=556  \n  \n \nOS \n13 months  \n \n25 months  \n IDI vs. OBS  \nno benefit  \nHR 1.00; 95% CI: \n0.79-1.25; p=0.96;  \nHR 0.85; 95% CI: \n0.67-1.07; p=0.11;  \nevents: 535/1109 Jadad Score 3 of 5  \nnot placebo \ncontrolled, not \nblinded  \n \nFunding: not \nmentioned  1b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 393 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \nOBS n=279   \n \n \nDFS \n13 months  \n \n25 months  vs 146/279  \n \nno benefit  \nHR 0.97;  95% CI: \n0.78-1.20; p=0.72;  \nHR 0.83; 95% CI: \n0.67-1.03; p=0.05;  \nevents: 679/1109 \nvs 183/279  The authors  \ndeclared that they \nhave no conflict of \ninterest.  \n \n4.5.6.4.  Evidenztabelle - Hochdosis  IFN alpha  \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nKirkwood et al. \n2004/1996  \n \nUpdate E 1684  \nInitial Data E1684  \n \n \n To update the \nanalyses  \n \nTo evaluate \nInterf eron alfa -2b \nas an adjuvant \ntherapy  \n \n RCT \n \nTreatment groups  \nOBS \nHDI  287patients, stages \nIIb and III  \n \nn=137  \nn=143   \n \nOS \n \n \n \n \n \n \n \nRFS \n \n HDI vs. OBS  \nUpdate: no benefit  \nHR 1.22; 95% CI: \nn.r.; p=0.18;  \nInitial: significant \nbenefit \nHR n.r., p=0.0237  \nevents 81/143 vs \n90/137  \nsignificant ben efit \nUpdate: HR 1.38, \np=0.02  \nInitial: HR n.r. , Jadad Score 3 of 5  \nnot placebo \ncontrolled, not \nblinded  \n \nFunding: grants \nfrom the National \nInstitutes of  \nHealth, Bethesda, \nMD. \nUpdate: Grant CA -\n23318, awarded by \nthe National Cancer 1b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 394 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \n \n p=0.0023  \nevents HDI vs. OBS  \n90/143 vs 103/137  Institute, United \nStates De partment \nof Health and \nHuman Services.  \nKirkwood et al. \n2000  \n \nE1690  To evaluate the \nefficacy of high -\ndose IFNalpha2b \n(HDI) for 1 year and \nlow-dose \nIFNalpha2b (LDI) for \n2 years versus OBS  RCT \n \nTreatment groups  \nOBS \nHDI \n(LDI) 642 patients, 75% \nnodal involv ement  \n \nn=212  \nn=215  \n(n=215)   \n \nOS \n \n \n \n \n \nRFS HDI vs OBS  \nno ben efit \nHR 1.00; 95% CI: \n0.75-1.33; \np=0.995;  \nevents HDI vs. OBS  \n98/215 vs 93/212  \n \nno ben efit \nHR 1.28; 95% CI: \n1.00-1.65; \np=0.054;  \nevents HDI vs. OBS  \n114/215 vs \n127/212  \nevents LDI vs. OBS  \n122/215 vs \n127/212  Jadad Score 3 of 5  \nnot placebo \ncontrolled, not \nblinded  \n \nImpact on RFS only \nsignif icant by Cox \nmultivariable \nanalysis \n \nFunding: not \nreported  \nassistance of \nSchering-Plough \nResearch Institute \nand Schering -\nPlough Oncol ogy \nBiotech with \nposttrial data \ncollection 1b \nCreagan et al. 1995  \n To report a \nprospe ctive RCT \n 262 patients, stages \nI and II   \n HDI vs OBS  \nno ben efit Jadad Score 2 of 5  \nnot placebo 1b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 395 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \nNCCTG  randomized trial \ndesigned  \nto determine the \nclinical efficacy in \nterms of recurrence  \nrates, time to \nrecurrence, and \npatient survival \nfollowing  \nIFN-a2a given as \npostsurgical \nadjuvant therapy to \nselected  \npatients with high -\nrisk stage I and II \nmalignant  \nmelanoma  Treatment groups  \nOBS \nHDI  \nn=131  \nn=131  OS \n \n \n \n \n \nRFS HR 0.83; 95% CI: \n0.61-1.13; p=0.24;  \nevents: 68/131 vs \n72/131  \n \nno ben efit \nHR 0.90; 9 5% CI: \n0.64-1.25; p=0.53;  \nevents: 77/131 vs \n85/131  \n controlled, not \nblinded, \nrandomization \nscheme not \ndescribed  \n \nFunding:  \nsupported in part by \nPublic Health  \nAgarwala et al. \n2011  \n \nE1697  To assess the \nbenefit of 4 weeks \nof HDI compared \nwith O bservation in \nrelation to the RFS \nand OS of patients \nwith resectable \ninterm ediate and \nhigh-risk melanoma  RCT \n \n \nTreatment groups  \nOBS \nHDI 4 weeks  1150 patients  \nT2N0, T3N0, T4N0, \nT1-4N1a -2a \n \nn=596  \nn=581   \n \n \n5-year survival rate  \n \nRFS \n no be nefit \nIFN vs OBS  \n \n0.82 vs 0.85  \n \n6.8 vs 7.3 years  \n only ASCO a bstract \navailable    \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 396 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \nMcMasters et al. \n2008  \n \nSunbelt Trial  To evaluate the role \nof high -dose \ninterf eron alfa -2b \n(IFN) or completion \nlymph node \ndisse ction (CLND) in \npatients with \nmelanoma staged \nby sentinel lymph \nnode (SLN) biopsy  RCT \n \n \nTreatment groups  \nObservation  \nHDI \n 218 patients, after \nSLN biopsy, 1 \npositive node  \n \nn=106  \nn=112  OS \n \n \n \nRFS no benefit  \nHR 1.07; CI: 0.65 -\n1.78; p=0.79  \n \nno benefit  \nHR 0.82; 95% CI: \n0.47-1.40; p=0.46  only ASCO a bstract \navailable  \nKirkwood et al. \n2001  \n \nE 1694  To evaluate the \nefficacy of HDI for 1 \nyear versus \nvaccin ation with \nGM2 RCT \n \nTreatment groups  \nHDI  \nvacination  874 p atients, stages \nIIB/III  \n \nn=385  \nn=389  OS \n \n \n \n \nRFS significant ben efit \nevents IFN vs. Vacc.  \n52/385 vs 81/389  \n \nsignificant ben efit \nevents IFN vs. Vacc.  \n98/385 vs 151/389  Included in SR \nalthough no OBS \nArm \n \nFunding: Eastern \nCooperative \nOnco logy Group \ngrant no. NIH CA \n39229 -16 and R03 \ngrant no. CA75950 -\n02.  \nKirkwood et al. \n2001  \n \nE2696  To evaluate the \ntoxicity and other \neffects of the \nestablished \nadjuvant high -dose RCT \n \nTreatment groups  \nVacc+HDI day 1  \nVacc+HDI day 28  107 patients, stages \nIIB, III, and IV  \n \nn=36  \nn=36  RFS  \n \n \n \nno OS analysis due significant ben efit \nevents IFN+Vacc vs. \nVacc.  \n28/72 vs 19/35  Included in SR \nalthough no OBS \nArm \n \nFunding:   \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 397 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \nIFNalpha2b regimen \nin relation to \nimmune responses \nto GMK  Vacc \n n=35  to sho rt follow up  unrestricted grant \nfrom Dr Craig \nTendler of Schering \nPlough Research \nInstitute, provision \nof the vaccine by \nDrs R obert Israel \nand Paul Ma ddon of \nProge nics, Inc.  \n \n \n \n \n \n \n \n \n \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 398 von 732 4.5.6.5.  Evidenztabelle - Pegyliertes  IFN alpha  \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nEggermont et al. \n2008/2011  \n \nUpdate EORTC \n18991  \nInitial Data EORTC \n18991  To present the \nlong-term results at \n7.6-years fol low up  \n \nTo determine \nwhether pegylated \ninterf eron alfa -2b \ncan facilitate \nprolonged exposure \nwhile maintaining \ntolerability  RCT \n \nTreatment groups  \nObservation  \nPeylated IFN alfa -2b 1256 patients, \nresected Stage III  \n \nn=629  \nn=627   \n \nOS \n \n \n \n \n \n \n \n \n \n \n \nRFS PegIFN vs. OBS \nno benefit  \nUpdate:  \nHR 0.96; 95% CI \n0.82-1.11; p=0.57  \nEvents: 332/627 vs \n336/629  \n \nInitial:  \nHR 0.98; 95% CI \n0.82-1.16.; p=0.78  \nevents: 262/627 vs \n263/629  \n \nsignificant benefit  \nUpdate:  \nHR 0.87; 95% CI \n0.76-1.00, p=0.05  \nevents: 384/627 vs \n406/629  \nInitial :  \nHR 0.82; 95% CI \n0.71-0.96; p=0.01  \nevents: 328/627 vs \n368/629  Jadad Score 3 of 5  \nnot placebo \ncontrolled, not \nblinded  \n \nFunding: Schering \nPlough Research \nInternational.  1b \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 399 von 732 4.5.7.  Subgruppenanalysen  \n \nSubgruppenvergleich Metaanalyse Mocellin et al. 2010: Stadium  II versus Stadium III, kein signifikanter Unterschied  \nStudy  No. of trials \n/ patients  OS \nHR (95% CI)  No. of trials \n/ patients  PFS \nHR (95% CI)  \n No. of trials \n/ patients  OS \nHR (95% CI)  \n No. of trials \n/ patients  PFS \nHR (95% CI)  \n Subgroup  \ncomparison  LoE \nMocel lin et \nal. 2010  Stadium II  Stadium III  OS p=0.36  \nPFS p=0.42  2a \n 1/499  0.70  \n(0.50 \u2013 0.98)  2/810  0.70  \n(0.55 \u2013 0.88)  3/2144  0.87  \n(0.68 \u2013 1.11)  3/2144  0.82  \n(0.72 \u2013 0.93)    \n \n \nSubgruppenanalysen der eingeschlossenen randomisierten Studien  \nStudy  Subgroup / No. of patients  OS, HR  p PFS, HR  p LoE \nHansson et al. 2011  \n \n(Intermediate Dose)  All patients / n=855  0.91 0.642  0.80 0.030  1b \nStage IIB -IIC / n=166  n.r. - Favour IFN, n.s.  0.082  3b \nStage III, palpable nodes / n=554  n.r. - Favour IFN  0.015  3b \nStage I II, 1 pos. node / n=374  n.r. - Favour IFN, n.s.  - 3b \nStage III, 2 -3 pos. node, n=201  n.r. - Favour IFN, n.s.  - 3b \nStage III, >/= 4 pos. node / n=114  n.r. - Favour IFN  0.038  3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 400 von 732 Study  Subgroup / No. of patients  OS, HR  p PFS, HR  p LoE \nUlzeration, n=238  1.05, Favour Obs, n.s.  0.809  1.04, Favour Obs, n.s.  0.829 3b \nEggermont et al. 2011  \n \n(Intermediate Dose+ \nPegylated Interferon \nalpha)  2 studies, all patients, n = 2644  0.94 0.36 0.85  0.004  1a- \nN1, n=1154  0\u00b781  0.07 0.78 0.01 3b \nN2, n=1031  1\u00b701  0.92 0.91  0.25 3b \nNo Ulceration, n=1336  1\u00b711  0\u00b720  0.92  0.30 3b \nUlceration, n=849  0.72  0.001  0\u00b775  0.001  3b \nUlceration + N1, n=484  0.58  0.0003  0.69  0.003  3b \nUlceration + N2, n=365  0.89  0.41 0.83 0.15 3b \nMcMasters et al. 2010  \n \n(High Dose)  SN-, Ulceration, n=127  n.s.  n.s.  3b \nSN+, Ulceration, n=75  n.s.   0.0169  3b \nSN+, no Ulceration, n=147  n.s.  n.s.   \nKleeberg et al. 2004  \n \n(Low Dose)  St. IIb vs. St. III  IFN benefit: similar  3b \nHancock et al. 2004  \n \n(Low Dose)  stage, age, sex  IFN benefit: n.s. differences  3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 401 von 732 Study  Subgroup / No. of patients  OS, HR  p PFS, HR  p LoE \nKirkwood et al. 2000  \n \n(Benefit of High Dos e) \n T4 N0 M0    1.46 0.20 3b \nT1-4 N1 M0    1.16 0.74 3b \nT1-4 N1-2 M0    1.57 0.20 3b \nRecurrent N+    1.27 0.18 3b \nN0   1.46 0.19 3b \nN1   1.0 0.99 3b \nN2-3   1.92 0.02 3b \nN>=4    1.15 0.58 3b \nCreagan et al. 1995  \n \n(High Dose)  Stage I    n.s. 0.93 3b \nStage II    Favour IFN, n.s.  0.09 3b \n \n \n \n \n \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 402 von 732 4.5.8.  Toxizit\u00e4t  \nStudy  Treatment \ngroups  \n(number of \npatients)  Treatment  \nrelated deaths  Discontinuation \nbecause of \ntoxicity  Number of \npatients with  \nGrade 3 or 4 \nToxicities (%) Fatigue  \nNumber of \npatients with \nany Grade Tox. \n(%) / with Grade \n3 or 4 Tox. (%)  Depression  \nNumber of \npatients with \nany Grade Tox. \n(%) / with Grade \n3 or 4 Tox. (%)  Neutropenia  \nNumber of \npatients with \nany Grade Tox. \n(%) / with Grade \n3 or 4 Tox. (%)  Hepatotoxicity  \nNumber of \npatients with \nany Grade To x. \n(%) / with Grade \n3 or 4 Tox. (%)  \nAgarwala et al. \n2011  OBS (n=596)  \n \nHDI 4 weeks \n(n=581)  n.r. n.r. n.r. n.r. n.r. n.r. n.r. \nEggermont et al. \n2008 \n \n OBS (n=629)  \nPeylated IFN \nalfa-2b (n=627)  n.r.  \n n.r.  \n n.r.  \n n.r.  \n n.r.  \n n.r.  \n n.r.  \n \nHansson et al.  \n2011  \n \nNordic IFN trial  OBS \n(n=284)  \n \nIDI 12 months \n(n=285)  \n \nIDI 24 months \n(n=286)  \n n=0  \n \n \nn=72 (25%)  \n \n \nn=72 (25%)  \n n.r. n=106 (37%) /  \nn=5 (2%)  \n \nn=267 (94%) / \nn=28 (10%)  \n \nn=266 (93%) / \nn=32 (11%)  n=108 (38%) / \nn=1 (<1%)  \n \nn=210 (74%) / \nn=17 (6%)  \n \nn=214 (75% ) n.r. n=41 (14%) / \nn=2 (1%)*  \n \nn=118 (41%) / \nn=2 (1%)*  \n \nn=122 (43%) / \nn=6 (2%)*  \n*ALAT  \nKirkwood et al. \n1996  OBS (n=140)  \nHDI (n=146)  n.r.  \n n.r. n.r. n.r. n.r. n.r. n.r.  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 403 von 732 Study  Treatment \ngroups  \n(number of \npatients)  Treatment  \nrelated deaths  Discontinuation \nbecause of \ntoxicity  Number of \npatients with  \nGrade 3 or 4 \nToxicities (%) Fatigue  \nNumber of \npatients with \nany Grade Tox. \n(%) / with Grade \n3 or 4 Tox. (%)  Depression  \nNumber of \npatients with \nany Grade Tox. \n(%) / with Grade \n3 or 4 Tox. (%)  Neutropenia  \nNumber of \npatients with \nany Grade Tox. \n(%) / with Grade \n3 or 4 Tox. (%)  Hepatotoxicity  \nNumber of \npatients with \nany Grade To x. \n(%) / with Grade \n3 or 4 Tox. (%)  \nEggermont et al. \n2008  \n \nEORTC 18991  OBS (n=629, \nTox. assessed \nn=613)  \n \nPeylated IFN \nalfa-2b (n=627, \nTox. assessed \nn=608)  n.r.  \n \n \n \nn=191 (31%)  n=74 (12%)  \n \n \n \nn=278 (46%)  n=252 (41%) / \nn=7 (1%)  \n \n \nn=574 (94%) / \nn=97 (16%)  n=153 (25%) / \nn=3 (<1%)  \n \n \nn=360 (59%) / \nn=39 (6%)  n.r. n=221 (36%) / \nn=10 (2%)*  \n \n \nn=479 (79%) / \nn=66 (11%)*  \n*Liver function \ntest \nGarbe et al. \n2008  \nDeCOG LDI (n=148)  \n(LDI plus DTIC)  \nOBS (n=148)  n.r. n=20 (14%)  n=13 (9%)  n.r. n.r. n.r. n.r. / n=0  \nEggermont et al. \n2005  \n \nEORTC 18952  Intermediate \nIFN, 13 months \n(n=553, tox. \nassessed n= \n521) \n \nIntermediate \nIFN, 25 months \n(n=556, tox . \nassessed n= n=0 n=87 (16%)  \n(N=539)  \n \n \n \n \nn=108 (20%) \n(N=539)  n.r. \n \n n.r. / 78 (15%)  \n \n \n \n \n \nn.r. / n=67 \n(13%)  \n \n n.r. / n=62 \n(12%)  \n \n \n \n \nn.r. / n=56 \n(11%)  \n \n n.r. n.r. / n=16 (3%)  \n \n \n \n \n \nn.r. / n=21 (4%)  \n \n \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 404 von 732 Study  Treatment \ngroups  \n(number of \npatients)  Treatment  \nrelated deaths  Discontinuation \nbecause of \ntoxicity  Number of \npatients with  \nGrade 3 or 4 \nToxicities (%) Fatigue  \nNumber of \npatients with \nany Grade Tox. \n(%) / with Grade \n3 or 4 Tox. (%)  Depression  \nNumber of \npatients with \nany Grade Tox. \n(%) / with Grade \n3 or 4 Tox. (%)  Neutropenia  \nNumber of \npatients with \nany Grade Tox. \n(%) / with Grade \n3 or 4 Tox. (%)  Hepatotoxicity  \nNumber of \npatients with \nany Grade To x. \n(%) / with Grade \n3 or 4 Tox. (%)  \n532) \n \nOBS (n=279, \ntox. assessed \nn= 252)   \n \nn.r. / n=5 (2%)   \n \nn.r. / n=9 (4%)   \n \nn.r. / n=1 (<1%)  \nHancock et al. \n2004  \n \nUKCCCR  LDI (n=338, tox. \nassessed range \n322-327))  \n \nOBS (n=336)  n=0 n=50 (15%)  n=56 (17%)  n=265 (78%) / \nn=22 (7%)  \n \n \nn=116 (38%) / \nn=4 (1%)  n=179 (55%) / \nn=11 (3%)  \n \n \nn=94 (31%) / \nn=5 (2%)  n.r. n=113 ( 35%) / \nn=7 (2%)  \n \n \nn=65 (22%) / \nn=1 (<1%)  \nKleeberg et al. \n2004  \n \nEORTC 18871  OBS (n=244)  \n \nvery LDI alpha \n(n=240)  \n \n(very LDI \ngamma, n=244)  \n n.r.  \n \nn=11 (5%)  n.r. n.r. n.r. n.r. n.r. \nCascinelli et al. \n2001  OBS (n=219)  \n n.r. n=0 n.r. n.r. n.r. n.r. n.r.  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 405 von 732 Study  Treatment \ngroups  \n(number of \npatients)  Treatment  \nrelated deaths  Discontinuation \nbecause of \ntoxicity  Number of \npatients with  \nGrade 3 or 4 \nToxicities (%) Fatigue  \nNumber of \npatients with \nany Grade Tox. \n(%) / with Grade \n3 or 4 Tox. (%)  Depression  \nNumber of \npatients with \nany Grade Tox. \n(%) / with Grade \n3 or 4 Tox. (%)  Neutropenia  \nNumber of \npatients with \nany Grade Tox. \n(%) / with Grade \n3 or 4 Tox. (%)  Hepatotoxicity  \nNumber of \npatients with \nany Grade To x. \n(%) / with Grade \n3 or 4 Tox. (%)  \n \nWHO  LDI (n=225)  \nCameron et al. \n2001  \n \nSMG OBS \n \nLDI n=0 n=0 n.r. n.r. n.r. n.r. n.r. \nKirkwood et al. \n2000  \n \nE1690  OBS (n=212)  \n \nHDI (n=215)  \n \nLDI (n=215)  n=0 n.r. n.r. n.r. / n=0  \n \nn.r. / n=51 \n(24%)  \nn.r. / n=7 (3%)  n.r. / n=0  \n \nn.r. / n=20 (9%)  \n \nn.r. / n=5 (2%)  n.r. / n=0  \n \nn.r. / n=94 \n(44%)  \nn.r. / n=12 (6%)  n.r. / n=6 (3%)  \n \nn.r. / n=61 \n(29%)  \nn.r. / n=9 (4%)  \nGrob et al. 1998  \n \nFCGM  OBS (n=245)  \n \nLDI (n=244)  n=0 n=35 (14%)  n.r. \n \nn=24 (10%)  n.r. \n \nn=118 (48%) / \nn=5 (2%)  n.r. \n \nn=40 (16%) / \nn=3 (1%)  n.r. \n \nn.r. / n=6 (2%)  n.r. \n \nPehamberger et \nal. 1998  \n \nAMCG  OBS (n=157)  \n \nLDI (n=154)  n.r. n=5 (3%)  n.r. n.r. n.r. n.r. n.r. \nKirkwood et al. OBS (n=137)  n=2 (lethal 26% 67% n.r. n.r. n.r. n.r.  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 406 von 732 Study  Treatment \ngroups  \n(number of \npatients)  Treatment  \nrelated deaths  Discontinuation \nbecause of \ntoxicity  Number of \npatients with  \nGrade 3 or 4 \nToxicities (%) Fatigue  \nNumber of \npatients with \nany Grade Tox. \n(%) / with Grade \n3 or 4 Tox. (%)  Depression  \nNumber of \npatients with \nany Grade Tox. \n(%) / with Grade \n3 or 4 Tox. (%)  Neutropenia  \nNumber of \npatients with \nany Grade Tox. \n(%) / with Grade \n3 or 4 Tox. (%)  Hepatotoxicity  \nNumber of \npatients with \nany Grade To x. \n(%) / with Grade \n3 or 4 Tox. (%)  \n1996  \n \nE 1684   \nHDI (n=143)  hepatic toxic ity)  \nn=140 (100%) / \nn=69 (48%)*  \n*constitutional \nsymptoms \nincluding fatigue   \nn=118 (83%) / \nn=40 (28%)*  \n*neurologic   \n  \nn=89 (62%) / \nn=20 (14%)  \nCreagan et al. \n1995  \n \nNCCTG  OBS (n=131)  \n \nHDI (n=131)  n.r. \n n.r. \n n.r. \n n.r. \n \nn=117 (89%) / \nn=26 (20%)  n.r. \n n.r. \n n.r. \n \n \n \n \n \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 407 von 732 4.5.9.  Metaanalysen  \nEine Metaanalyse wurde mit 13 Studien  (14 Vergleiche)  unter Einschluss der in bisher igen Metaanalysen  nicht erfassten Studie von \nHansson et al. 2011  wurden nach den definierten Ein - und Ausschlusskriterien durchgef\u00fchrt  (kein Einschluss bei fehlendem \nBeobachtungsarm, damit Aussch luss E1694 und E26 96: Vergleichsarm jew. Vakzine).  \nAufgrund der Heterogenit\u00e4t der Studien keine Metaanalyse \u00fcber alle 14 Vergleiche, sondern getrennt nach verschiedenen Dosis \nSchemata:  \n- Hochdosis Interferon alpha  \n- Mittlere Dosis Interferon alpha  \n- Niedrigdosis  Interferon alpha  \n \nLimit ation : unterschiedliche  Follow up Perioden innerhalb der Studien  \nAuswertung durch Review Manager 5.1, The Cochrane Collaboration  \n \n \n \n \n \n \n \n \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 408 von 732 Abbildung 1:  Hochdosis  Interferon alpha versus Beobachtung  \nOutcome: Mortalit\u00e4t  Risk Ratio: 0 .98 CI [0.87, 1.10] n.s       \n \n \n \n \n \n \n \n \nOutcome: Progression  Risk Ratio: 0.88 CI [0.80, 0.97] sign.  \n \n \n \n \n \n \n \n \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 409 von 732 Abbildung 2:  Mittlere Dosis Interferon alpha versus Beobachtung  \nOutcome: Mort alit\u00e4t  Risk Ratio: 0.94 CI [0.85, 1.03] n.s  \n \n \n \n \n \n \n \n \nOutcome: Progressio n Risk Ratio: 0.93 CI [0.86, 1.00] sign.  \n \n \n \n \n \n \n \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 410 von 732 Abbildung 3:  Niedrigdosis Interferon alpha versus Beobachtung  \nOutcome:  Mortalit\u00e4t  Risk Ratio: 0.93 CI [0.86, 1.00]  sign. \n \n \n \n \n \n \n \n \nOutcome:.  Progression Risk Ratio: 0.93 CI [0.88, 0 .99] sign. \n \n \n \n \n \n \n \n \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 411 von 732 4.5.10.  Literat ur \n \nAgarwala SS, Lee SJ, Flaherty LE, et al. Randomized phase III trial of high -dose interferon alfa -2b (HDI) for 4 weeks induction only in patients with intermediate - and high -risk \nmelanoma (Intergroup trial E 1697) . ASCO Meeting Abstracts 2011;29:8505  \nCameron DA, Cornbleet MC, Mackie RM, et al. Adjuvant interferon alpha 2b in high risk melanoma - the Scottish study. Br J Cancer 2001;84:1146 -1149  \nCascinelli N, Bufalino R, Morabito A, et al. Results of adjuvant interferon study in WHO melanoma programme. L ancet 1994;343:913 -914 \nCreagan ET, Dalton RJ, Ahmann DL, et al. Randomized, surgical adjuvant clinical trial of recombinant interferon alfa -2a in selected patients with malignant melanoma. J Clin \nOncol 1995;13:2776 -2783  \nEggermont AM, Suciu S, MacKie R, et al. Post -surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III mela noma \n(EORTC 18952): randomised controlled trial. Lancet 2005;366:1189 -1196  \nEggermont AM, Suciu S, Santinami M, et al. EORT C 18991 phase III trial: Long -term adjuvant pegylated interferon -{alpha}2b (PEG -IFN) versus observation in resected stage III \nmelanoma: Long -term results at 7.6 -years follow -up. ASCO Meeting Abstracts 2011;29:8506b  \nEggermont AM, Suciu S, Santinami M, et al . Adjuvant therapy with pegylated interferon alfa -2b versus observation alone in resected stage III melanoma: final results of EORTC \n18991, a randomised phase III trial. Lancet 2008;372:117 -126 \nEggermont AM, Suciu S, Testori A, et al. Ulceration and stage are predictive of interferon efficacy in melanoma: Results of the phase III adjuvant trials EORTC 18952 and EORTC \n18991. Eur J Cancer 2012;48:218 -225 \nGarbe C, Eigentler TK, Keilholz U, et al. Systematic review of medical treatment in melanoma: current stat us and future prospects. Oncologist 2011;16:5 -24 \nGarbe C, Radny P, Linse R, et al. Adjuvant low -dose interferon {alpha}2a with or without dacarbazine compared with surgery alone: a prospective -randomized phase III DeCOG \ntrial in melanoma patients with regi onal lymph node metastasis. Ann Oncol 2008;19:1195 -1201  \nGrob JJ, Dreno B, de la Salmoniere P, et al. Randomised trial of interferon alpha -2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically \ndetectable node metastases.  French Cooperative Group on Melanoma. Lancet 1998;351:1905 -1910  \nHancock BW, Wheatley K, Harris S, et al. Adjuvant interferon in high -risk melanoma: the AIM HIGH Study --United Kingdom Coordinating Committee on Cancer Research \nrandomized study of adjuvant l ow-dose extended -duration interferon Alfa -2a in high -risk resected malignant melanoma. J Clin Oncol 2004;22:53 -61 \nHansson J, Aamdal S, Bastholt L, et al. Two different durations of adjuvant therapy with intermediate -dose interferon alfa -2b in patients with  high-risk melanoma (Nordic IFN \ntrial): a randomised phase 3 trial. Lancet Oncol 2011;12:144 -152 \nKirkwood JM, Ibrahim J, Lawson DH, et al. High -dose interferon alfa -2b does not diminish antibody response to GM2 vaccination in patients with resected melanom a: results of \nthe Multicenter Eastern Cooperative Oncology Group Phase II Trial E2696. J Clin Oncol 2001;19:1430 -1436  \nKirkwood JM, Ibrahim JG, Sondak VK, et al. High- and low -dose interferon alfa -2b in high -risk melanoma: first analysis of intergroup trial  E1690/S9111/C9190. J Clin Oncol \n2000;18:2444 -2458  \nKirkwood JM, Ibrahim JG, Sosman JA, et al. High-dose interferon alfa -2b significantly prolongs relapse -free and overall survival compared with the GM2 -KLH/QS -21 vaccine in \npatients with resected stage IIB -III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol 2001;19:2370 -2380  \nKirkwood JM, Manola J, Ibrahim J, et al. A pooled analysis of eastern cooperative oncology group and intergroup trials of adj uvant high -dose interferon for melano ma. Clin \nCancer Res 2004;10:1670 -1677  \nKirkwood JM, Strawderman MH, Ernstoff MS, et al. Interferon alfa -2b adjuvant therapy of high -risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial \nEST 1684. J Clin Oncol 1996;14:7 -17 \nKokoschka EM, Trautinger F, Knobler RM, et al. Long -term adjuvant therapy of high -risk malignant melanoma with interferon alpha 2b. J Invest Dermatol 1990;95:193S -197S  \nLens MB, Dawes M. Interferon alfa therapy for malignant melanoma: a systematic review of randomize d controlled trials. J Clin Oncol 2002;20:1818 -1825  \nMcMasters KM. The Sunbelt Melanoma Trial. Ann Surg Oncol 2001;8:41S -43S \nMocellin S, Pasquali S, Rossi CR, et al. Interferon alpha adjuvant therapy in patients with high -risk melanoma: a systematic review and meta -analysis. J Natl Cancer Inst \n2010;102:493 -501 \nPehamberger H, Soyer HP, Steiner A, et al. Adjuvant interferon alfa -2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative \nGroup. J Clin Oncol 1998;16:142 5-1429  \nPetrella T, Verma S, Spithoff K, et al. Adjuvant Interferon Therapy for Patients at High Risk for Recurrent Melanoma: An Upda ted Systematic Review and Practice Guideline. Clin \nOncol (R Coll Radiol) 2012   \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 412 von 732 Pirard D, Heenen M, Melot C, et al. Interferon  alpha as adjuvant postsurgical treatment of melanoma: a meta -analysis. Dermatology 2004;208:43 -48 \nRudolf Z. Adjuvant treatment of malignant melanoma with interferon after radical surgery - Part II. Effect of recombinant alpha interferon. Radiology and Onc ology \n1994;28:183 -187 \nRusciani L, Petraglia S, Alotto M, et al. Postsurgical adjuvant therapy for melanoma. Evaluation of a 3 -year randomized trial with recombinant interferon -alpha after 3 and 5 \nyears of follow -up. Cancer 1997;79:2354 -2360  \nVerma S, Quirt I, McCready D, et al. Systematic review of systemic adjuvant therapy for patients at high risk for recurrent melanoma. Cancer  2006;106:1431 -1442  \nWheatley K, Ives N, Hancock B, et al. Does adjuvant interferon -alpha for high -risk melanoma provide a worthwhil e benefit? A meta -analysis of the randomised trials. Cancer \nTreat Rev 2003;29:241 -252 \n \n \n \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 413 von 732 5. AG Medikament\u00f6se Therapie bei Metastasierung  \n5.1. Frage V.1 . Lokale medikament\u00f6se Therapie  Intransitmetastasen \u2013 De novo Recherche  \nFrage V.1.  Welche therapeutischen (au\u00dfe r operativen) Ma\u00dfnah men sind bei Satelliten - und In transit -Metastasen effektiv?  \n5.1.1.  PICO, Suchw\u00f6rter  \nPICO \u2013 Schema   \nPopulation  Intervention  Comparison  Outcome  \nMelanoma patients with locoregional \nmetastases  Local therapies (except surgery, \nradiotherapy, extre mity perfusion)  Standard of care  Efficacy  \n \nSuchw\u00f6rter  \nStichwort  melanoma  Satellite Metastasis  \nIn-Transit Metastasis  therapy  interleukin -2, IL-2 \nrose bengal  \nimiquimod  \nDNCB, dinitrochlorobenzene  \nDPCP, diphencyprone  \ninterferon beta, interferon -\u00df \nelectroche motherapy  \nSynonyme   Local recurrence  \nLocoregional spread  treatment   \nOber -/Unterbegriffe      \nMesh Term  melanoma  Neoplasm Recurrence, Local  therapeutics    \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 414 von 732 5.1.2.  Datenbanken, Suchstrategien, Trefferzahlen  \nDatenbank  Suchstrategie  Datum  Treffer \n1. Suche     \nMedli ne (\"melanoma\"[tiab] OR \"melanoma\"[MeSH])  \nAND (\"Satellite metastases\"[tiab] OR \"Satellite metastasis\"[tiab]  \nOR \"In -transit metastases\"[tiab] OR \"In -transit metastasis\"[tiab]  \nOR \"Intransit metastases\"[tiab] OR \"Intransit metastasis\"[tiab]  \nOR \"Local recu rrence\"[tiab] OR \"Locoregional recurrence\"[tiab]  \nOR \"Locor egional spread\"[tiab] OR \"Locoregional metastases\"[tiab]  \nOR \"Locoregional metastasis\"[tiab] OR intratumo*[tiab] OR \"intralesional\"[tiab]  \nOR \"Neoplasm Recurrence, L ocal\"[MeSH])  \nAND (\"therapy\"[tia b] OR \"treatment\"[tiab] OR \"therapeutics\"[MeSH]  \nOR \"interleukin -2\"[tiab] OR \"IL -2\"[tiab] OR \"rose bengal\"[tiab] OR \"imiquimod\"[tiab]  \nOR \"dinitrochlor obenzene\"[tiab] OR \u201eDNCB\u201c[tiab] OR\u201cdiphencyprone\u201c[tiab]  \nOR \"DPCP\"[tiab] OR \"interferon beta\"[tiab] OR \"i nterferon -\u00df\u201c[tiab]  \nOR \"electrochem otherapy\"[tiab])  16.12.10  2322  \nEmbase  (melanoma and (\"satellite metast*\" or \"In -transit metast*\" or \"Intransit metast*\" or \n\"local recurrence\" or \"locoregional recurrence\" or \"locoregional spread\" or \"locoregio nal \nmetast* \" or \"locoregional metast*\") and (therapy or treatment)).ti,ab.  12.10.10  579 \nMedline - Erweiterung der \nSuchstrategie  (\"melanoma\"[tiab] OR \"melanoma\"[MeSH])  \nAND (\"Satellite metastases\"[tiab] OR \"Satellite metastasis\"[tiab]  \nOR \"In -transit metastases\"[tiab ] OR \"In -transit metastasis\"[tiab]  \nOR \"Intransit metastases\"[tiab] OR \"Intransit metastasis\"[tiab]  \nOR \"Local recurrence\"[tiab] OR \"Locoregional recurrence\"[tiab]  \nOR \"Locoregional spread\"[tiab] OR \"Locoregional metastases\"[tiab]  \nOR \"Locoregional metasta sis\"[tiab] OR intratumo*[tiab] OR \"intralesional\"[tiab]  06.04.11  2467   \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 415 von 732 Datenbank  Suchstrategie  Datum  Treffer \nOR \"Neoplasm Recurrence, Local\"[MeSH] OR \"cutaneous metastases\"  \nOR \"skin metastases\" OR \"cutaneous melanoma metastases\"  \nOR \"skin melanoma metastases\")  \nAND (\"therapy\"[tiab] OR \"treatment\"[tiab]  \nOR \"therapeutics\"[MeSH] OR \"i nterleukin -2\"[tiab] OR \"IL -2\"[tiab]  \nOR \"rose bengal\"[tiab] OR \"imiquimod\"[tiab] OR \"dinitrochlorobenzene\"[tiab]  \nOR \u201eDNCB\u201c[tiab] OR\u201cdiphencyprone\u201c[tiab] OR \"DPCP\"[tiab] OR \"interferon beta\"[tiab] OR \n\"interferon -\u00df\u201c[tiab] OR \"elec trochem otherapy\"[tiab])  \nUpdate Suche     \nMedline  s.o. 31.01.12  2586  (3 dazu: \nBoyd et al. 2011 , \nFlorin  et al. 2011 , \nKis et al. 2011 ) \nCochrane Library  s.o. 31.01.12  13 (0 dazu)  \nEmbase  s.o. 23.01.12  668 (0 d azu) \n \n \n \n \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 416 von 732 5.1.3.  Auswahlkriterien  \nAuswah l der Literatur  \nGesamttreffer  3267  \nEinschlusskriterien  Thematische \u00dcbereinstimmung (gemeinsame Berichte verschiedener Tumorentit\u00e4ten wurden ausgeschlossen)  \nSprachen: e, dt  \nKlinische Studien  \nBei nicht Vorhandensein von Studien Einschluss von Fallserien ab  3 Patienten  \nAusschlusskriterien  Nicht systematische Reviews  \nCase Reports  \nIntratumorale Therapie als Systemtherapie  \nAnzahl nach Abstractscreening, vorges ehen f\u00fcr Bewertung  63 \nAnzahl ausgew\u00e4hlter Volltexte  36 \nDie ausgew\u00e4hlten Arbeiten wurden wie folgt zusammengefasst:  \nImmunmodulation ( Interleukin -2, Imiquimod, BCG, Interferon beta, GM -CSF, Interferon gamma, Mycobacterium smegmatis ) \nAblative  Therapien ( Elektrochemotherapie, lokale  Chemo therapie, Bengal Rosa, Carbon Laser)  \nContac t Sensitizer ( Dinitrochlor obenzene, Diphencyprone)  \n \n \n \n \n \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 417 von 732 5.1.4.  Evidenztabelle  \n \nImmunmodulation (Interleukin -2, Imiquimod, Interferon alpha, Interferon beta, Interferon gamma, BCG)  \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nBoyd et al. 2011  To document the  \nresponse of in -\ntransit metasta ses \nto intra -lesional IL -\n2 inje ction Case Series  \n \nTreatment:  \nIL-2 intralesional \nbiweekly  39 patients with \n629 intransit \nmeta stases  Response  \n \n \n \n \n \n \n \n5 year survival  \n Patients:  \nCR 51%  \nPR 31%  \nNo response 18%  \n \nLesions:  \nResponserate 76%  \n \nComplete  \nrespon ders versus \npartial responder  \n80% versus 33% (p= \n0.012)  Response was \nevaluated for \npatients and for \ntreated lesions \nseparately.  \nLimitations:  \nLack of control \ngroup  \n 4 \nFlorin et al. 2011  To treat cutaneous \nmetastases of \nmalignant \nmelanoma in a  \nseries  of patients \nwith imiquimod and \n5-fluorouracil \ncreams  Case Series  \n \nTreatment:  \n5-fluorouracil  \ncream in the \nmorning and 5% \nimiqu imod cream at \nnight, 5 days per \nweek, until \nresponse  5 patients with 45 \nintransit meta stases  Response  CR = 19 lesions  \nPR = 25 lesi ons \nSD = 1 lesion  \n \n \n Lack of control \ngroup  \n 4  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 418 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \nWeide et al. 2010  To confirm the \nprevious results \nwith intralesional Il -\n2 in a larger cohort \nand to ide ntify \nrelevant patient or \nregimen \ncharacteristics \nassociated with \nresponse to \ntreatment and with \noverall s urvival. Phase II prospective \nopen label study  \n \nTreatment was \ninitiated at 3 MIU \nIL-2 daily,  \ndose escalation 1.5 \nMIU each treatment  \nday. Schedule: 3 \ntimes weekly  51 patients \nenrolled, 48 \npatients evaluable  \nwith injectable \ndermal or \nsubcut aneous \nmetast ases, Stage III \n(69%) or Stage IV \n(31%)  \nno concomitant \nsystemic \nchemoth erapeutic  \n \n894 of 917 \nseparately treated \nmetastases (97.5%)  \nwere evaluable for \nlocal tumor \nresponse  Clinical Response  \n \n \n \n \n \n \n \n \n \nOverall Survival  \n \n \n \nToxicity  Patients:  \nComplete local \nrespons e 33 \npatients (69%), \n(Stage III 82%, Stage \nIV 40%)  \nLesions: 78.7% CR \nrate, 0.7% PR rate,  \n16.3% stable \nmeta stases, and \n4.3% progressive \nlesions.  \nOverall Survival \nafter 2 years:  \nStage III 77%, Stage \nIV 53%)  \nToxicity: only grad \n1 and 2 toxicity, \n(injection si te \nreaction, injection \npain, fever, nausea, \nfatigue)  Response was \nevaluated for \npatients and for \ntreated lesions \nseparately.  \nResponse for \npatients applied to \nlocal r esponse.  \nLimitations:  \nLack of control \ngroup  \n 4 \nDehesa et al. 2009  To describe the \nexperien ce over 2 \nyears with the use  \nof intralesional IL -2 \nto treat cutan eous Case Series  \n \nTreatment: twice \nweekly, starting \nwith 3 MIU Il -2 7 melanoma \npatients with \nsatellit osis an \ncutaneous \nmetastases   Response  \n \n \n \n Lesions:  \nComplete remission \n95.9% of treated \nlesions  \nPartial remission:  Limitations:  \nCase Series,  \nsmall sample size  4  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 419 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \nmetastases of \nmalignant \nmelanoma in 7 \npatients.  244 les ions \n \nno other organs \ninvolved   \n \nToxicity  3.7% of treated \nlesions  \nToxicitiy: few mild \nside e ffects (grade \n1-2). \nFujimura et al . 2009  To report 3 patients \nwho were treated \nwith peritumoral \ninjection of \ninterf eron beta  Case Series  \n \nTreatment: \nperitumoral \ninterf eron beta  3 melanoma \npatients Stage IV \nM1a Reponse  Target lesion: 1 CR, \n2 PR \n Limitations:  \nCase Series,  \nsmall sample size  4 \nGreen et al. 2006  To investigate the \ncombination of \ntopical imiquimod \nand intralesional IL -\n2, to treat a small \ncohort of patients \nwith accessible \nmelan oma \nmetastases r esistant \nto other treatments  Phase I/II \nprospe ctive open \nlabel study  \n \nTreatment: after  4 \nweeks of 5% \nimiquimod cream \ndaily, start of IL -2 \nintralesional or \nsubcut aneously in \naddtion to \nimiquimod cream  13 patients, Stage III \nor IV with cutan eous \nand/or \nsubcutaneous \nlesions  \n \n182 lesions  Response  Lesions:  \nCR:  74 lesions \n(40,7%)  \nPR: 18 lesions \n(9,9%)  \nSD: 53 lesions \n(29,1%)  \nPD:  33 lesions \n(18,1%)  \n4 lesions were not \nassessable (2,2%)  Regressed lesions \nwith remained \npigmentation were \nclassified as PR \n(possible \nexplan ation for low \nCR rates compared \nto other stu dies) \nLimitations:  \nheterogenous \ntreatment sch edules  4 \nKhorana et al. 2003  To determine the \nsafety and \ntolerabi lity of \nintratumoral Phase I single -\ncenter dose -\nescalation study  \n 11 patients with \nhistologically \nconfirmed locally  \nrecurrent or Safety  \nToxicity  \n \n No treatment \nrelated  death, no  \ngrade 4 or dose -\nlimiting toxicities Limitations:  \nLack of control \ngroup  4  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 420 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \ninjection with \nadeno-IFN-g, and \nto determine the \nmaximum tol erated \ndose Treatment: 4 \nsuccessive dose \nlevels: 107 \ninfectious units (iu) \n(n=3), 108 iu (n=3), \n109 iu (n=3), and \n1010 iu (n=2) per \ninjection per week \nfor 3 weeks.  meta static \nmalignant \nmelanoma   \n \n \n \n \n \n \n \nResponse  Most frequently \nobserved \ntoxicitie sgrade 1 \npain and/or redness \nat the i njected site \nin 8/11 (72%) \npatients, and grade \n1 fatigue in 5/11 \n(45%) p atients.  \nLocal response:  \n5 of 11 patients:  \nminor d ecrease in \nsize (<25%) of the \ninjected lesion  \nDistant response:  \nSD: 1 of 11 patients  \nPD: 10 of 11 \npatients  \nPaul et al. 2003  To examine the \neffect of \nintral esional beta -\ninterferon injections \ncombined with \nradiotherapy in \npatients wi th \nmeta static \nmalignant Case Series  \n \nTreatment:  \nsimultaneous  \nexternal beam \nradiotherapy and \nintralesional \ninjection of beta -\ninterferon. 3\u2013 20 patients with  \ninoperable \nmelanoma \nmetast ases Response  17 patients \nevalu able \nCR: 12 pat ients \n(70%)  \nPR: 5 patients (30%)  Limitations:  \nLack of control \ngroup  \nCombined \ntreatment with \nradioth erapy 4  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 421 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \nmelan oma 5 Mio IE / 3x/week  \nRadny et al. 2003  To investigate the  \nfeasibility, efficacy, \nand safety of \nintralesionally \ninjected IL -2 in 24 \nmelanoma pat ients \nwith skin and soft -\ntissue metast ases Phase II prospective \nopen label study  \n \nTreatment: 2 -3 \ntimes weekly, 1 -57 \nweeks, max. daily \ndose 12 MIU IL -2 24 melanoma \npatients with skin \nand soft -tissue \nmeta stases  \n16 patients Stage III  \n8 patients Stage IV  \n \n245 lesions  Response  \n \n \n \n \n \n \n \n \n \n \nSafety  Lesions:  \nCR: 209 lesions \n(85%)  \nPR: 21 lesions (6%)  \nPD: 7 lesions (3%) 8 \nlesions (3%) were \nnot a ssessable  \nPatients, local \nresponse:  \nCR: 15 patients  \nPR:  3 patients  \nMain toxicities \n(grade I+II): Local \nreaction, Fever, Flu -\nlike sym ptoms, \nPain, Fat igue, \nNausea/vomiting  Response was \nevaluated for \npatients and for \ntreated lesions \nseparately.  \nResponse for \npatients applied  \nto local r esponse.  \nLimitations:  \nsingle centre study, \nlack of control \ngroup  4 \nBong et al. 2002  to study imiquimod \nas an adjuvant f or \ntreating cutaneous \nmetastases of \nmalignant \nmelanoma  Case Series  \n \nTreatment: Twice \ndaily application of \nimiquimod 5% \ncream, 21 -28 \nweeks  3 melanoma \npatients with \nmultiple cutaneous \nin-transit \nmetastases  Response  >90% regression in \n2 patients, in one \npatie nt complete \nresponse after \naddition of \nintralesional Il -2 Limitations:  \nSmall series  4 \nSi et al. 1996  To examine whet her Phase I study  13 melanoma Response  Local resp onse:  - 4  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 422 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \nintralesional \ninjections of GM -\nCSF induce \nregression of \nsubcutanuous \nmetastases in \npatients with \nmelanoma and \ninfluence lymphoid \ninfiltrates in and \naround the \nmeta stases   \nTreatment: weekly \ninjections of 15 -\n50mg GM -CSF into \ntwo subcut aneous \nmetastases up to 6 \nmonths  patients with at \nleast 3 \nsubcutaneous \nmetastases Stage III \nor IV (6 patients)   PR 1 patient  \nSD 8 patients  \nPD 4 patients  \n \nTan et al. 1993  To determine the \nrole of BCG \nimmunotherapy in \nmalignant \nmelanoma  Systematic review  \n \nStage I and II: RCTs \nof BCG (adjuvant \ntherapy)  \n \nStage III: RCTs \n(combination BCG -\nchemother apy) + \ntrials on \nintralesio nal and \noral BCG \nmonotherapy  Stage III, \nintral esional therapy \n(local therapy):  \n15 non placebo \ncontrolled trials of \nintralesional BCG \nwere ident ified  \n Response  Stage III, \nintral esional BCG \ntrials:  \nPooled average \ncomplete response: \n19%, PR 26 %, \nextended survival \n13% of patients. \nThreefold greater \nrate of regression \nwith intralesional \nBCG for intrade rmal \nmetastases \ncompared with \nsubcutaneous Selected \nintral esional BCG \ntrials were not \ndescribed in detail:  \nnumber of tr eated \nlesions and lesions \nresponse not \nindicated, control \ngroups not \nindicated  4*  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 423 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \nand/or visceral \nmetastases  \nFierlbeck et al. 1992  To compare the \neffect of \nintralesional b eta-\ninterferon at \ndifferent dosages  Case Series  \n \nTreatment:  \nGroup 1: 5x106 I.E. \nrIFN-beta 3x/week  \nGroup 2:  5x1 06 I.E. \nrIFN-beta 1x/week  \nGroup 3:  3x106 I.E. \nrIFN-beta 1x/week  10 pat ients with \ncutaneous or \nsubcutaneous \nmelanoma \nmetast ases \n \n19 lesions  Lesion Response  Group 1 (n=8)  \nCR:2, PR:1, SD:3, \nPD:2 \nGroup 2 (n=8)  \nCR:3, PR:2, SD:2, \nPD:1 \nGroup 3 (n=3)  \nCR:0, PR:0,  SD:1, \nPD:2 Limitations:  \nSmall sample size  \n 4 \nVon Wussow et al. \n1988  To study the effects \nof higher IFN \nconcentrations on \nmalignant \nmelanoma \nmetastases, p atients \nwere treated with \nintalesional IFN \ninjections.  Retrospective \nevaluation  \n \nTreatment:  \nSystemic  and \nintralesional \nInterferon alpha  51 patients  Lesion Response  Intralesional \ntreatment (lesions \nn= 51)  \nCR n=16  \nPR n=7  \nNC n=26  \nPD n=2  26 patients were \ntreated with human \ninterferon alpha and \n25 patients with \nrecombinant \ninterferon alpha  4 \nLokich et al. 1 979 To describe the \ntreatment with \nintralesional \nmethanol extraction \nresidue of bacillus \nCalmette Guerin Case Series  \n \nTreatment:  \nSingle injection with \nMER-BCG 6 patients with \ncutaneous or \nsubcut aneous \nmelanoma \nmetastases  \n9 lesions  Lesion response  Complete \nregression: 3 \nlesions  \nPartial regression: 2 \nlesions  \nErythema/no - 4  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 424 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \n(MER-BCG) regression: 4  \nVosika et al. 1979  To investigate the \nclinical \npharmacol ogy and \nefficacy of \nintralesional \nimmonotherapy \nutilizing a vaccine \ncomposed of \nMycobacterium \nsmegmatis ce ll wall \nskeleton and the \nmycobacterial \nglypolipid fraction  Phase I study  \n \nTreatment: every 1 \nor 2 weeks CWS/P3  15 melanoma \npatients Stage III \nand IV (8 patients)  Response injected \nand non -injected \nlesions  In 6 (40%) of the 15 \npatients, response  \n(CR+PR) of at least \none injected lesion \nwas observed. In 4 \nof these 6 patients, \nnoninjected disease \nalso responded. 1 \npatient had PR of \npulmonary \nmetastasis in \naddition to CR of \ninjected lesion.  Limitations:  \nSmall series, lack of \ncontrol group  4 \nNathanson et al. \n1979 To compare the \nefficacy of \ntreatment with BCG \nwhen it was \naltern atively \nadministered either \nby intral esional \ninjection, or \nintradermally in a \nnontumor bearing \nsite, using the \nmultipuncture (Tine) Randomised \nprospective study  \n \nTreatment:  \nIL-BCG Group: BCG \nintralesiona lly in the \nbase of each lesion \nonce a week for 6 \nweeks (up to 5 \nlesions)  \nMPV-BCG: Multiple \npuncture BCG once 59 patients with \nhistologically \nproven, surgically  \nincurable \nmelan oma, with \nmeasur able lesions \nin or as sociated \nwith the skin   \n \n \n \nResponse  Rate \n \nSurvival  \n \n \nToxicity  \n IL-BCG vs. MPV -\nBCG \n(44 patients \nevalu able)  \n \n45% vs.  9% for  \n \n21.1 vs. 13.3 \nmonths  \n \nMore severe toxicity \nwas observed in the the study design \ndoes not cover the \nquestion of \nliterature search \n(efficacy of local \ntreatments \ncompared to \nstandard treatment), \nthe study is \ntherefore \ndownclass ified as \nlevel 4 study  4*  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 425 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \ntechnique  a week for 6 weeks  IL-BCG group, but \nno deaths were seen \ndue to toxicity in \neither gro up  \nLimitations:  \nImbalance of \ngroups: more male \npatients in the IL -\nBCG group, \nrandomization \nscheme not \ndescribed  \nStorm et al. 1979  To describe the \ntreatment with \nintralesional bacille \nCalmette Guerin and \nhyperthermic \nperfusion  Case Series  \n \nTreatment: Inje ction \nof lesions with \nGlaxo strain bacille \nCalmette Guerin \nevery 2 -3 weeks  27 melanoma \npatients with locally \nrecurrent disease  Response  Complete or \ntransient local \ndisease control: 20 \nof 27 patients  \n number of treated \nlesions not \nindicated  4 \nKrown et al. 1978  To determine the \noptimal dose, \nschedule and \ntoxicity of MER \n(methanol \nextraction residue \nof bacillus \nCalmette -Guerin) \ngiven by the il \nroute, and to Phase I study  \n \nTreatment: 1 -5 \nlesions were \ninjected with 0.1 - \n0.5 mg of MER on \nthe first day, the \ndose was adjusted \ndaily, d epending \nupon the degree of 22 patients with \nskin and \nsubcutan eous \nmetastases without \nvisceral metastases   \n \nResponse  \n \n \n \n \nToxicity  18 patients \nevalu able \nCR of all injected \nlesions: 8 patients  \nPR: 4 pa tients  \n6 patients did not \nrespond  \nFever (100%), Chills \n(45%), Malaise \n(50%), Hea dache number of treated \nlesions not \nindicated  4  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 426 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \ncompare it with BCG \nin terms of tumor \nregression and side \neffects.  local reaction and \nsystemic effects  (45%), Nausea and \nvomiting (18%), \nHypotension (14%),  \nLethargy (14%), \nCyanosis (9%), \nConfusion (5%)  \n \nAblative Therapien (Elektr ochemotherapie, lokale Chemotherapie, Bengal Rosa, Carbon Laser)  \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nKis et al. 2011  To investigate ECT \ntreatment in \nmelanoma patients  Case Series  \n \nTreatment:  \nECT with i.v. \nbleomycin (15 \nmg/m2) under  \ngeneral sed ation 9 patients with 158 \ncutaneous and \nsubcutaneous \nmeta stases  Response  CR 23%  \nPR 39%  \nNo change 30%  \nPD 8%  - 4 \nFoote et al. 2009  To report three \ncases of \nintralesio nal rose \nbengal treatment \nfollowed by \nradiotherapy  Case Ser ies 3 patients with   \ncutaneous \nmetas tastes  Response  Local complete \nresponse in all 3 \npatients  - 4 \nThompson et al. \n2008  To investigate the \ntherapeutic \npotential of PV -10 Open label phase II \nstudy  \n 11 patients with \nlocoregionally \nrecurrent lesion response  \noverall response  \nbystander effect  25 le sions \nevalu able: \nCR 36% (n=9)  - 4  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 427 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \n(Rose Bengal) in \npatients with stage \nIII metastatic \nmelanoma.  Treatment:  \nOne s ingle IL \ninjection of PV -10 \nin 1-3 target lesions  melanoma, Stage III  \n \n26 lesions treated  \n28 lesions untreated \n(to assess potential \nbystander effect)  toxicity  PR 12% (n=3)  \nSD 28% (n=7)  \nPD 24% (n=6)  \nPatients:  \nCR 27% (n=3)  \nPR 27% (n=3)  \nSD 27% (n=3)  \nPD 18% (n=2)  \nApparent bystander \neffect in untreated \ntumours in 27% of \npatients  \nToxicity:  \ntransient mild to -\nmoderate pain at \nthe treatment site \n(n=8), local \ninflammation (n=4),  \ntreatment site \npruritus (n=3), mild \nphotosensitivity \nreaction (n=1), mild \ninsomnia  \nsecondary to \ninjection site pain \n(n=1)  \nQuaglino et al. 2008  To prospectively Prospective Phase II 14 patients, Stage III  Response (8 weeks Patients(n=14):  - 4  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 428 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \nevaluate clinical \nactivity and \ntolerability of ECT \nwith i.v. bleomycin  study  \n \nTreatment:  \nECT with i.v. \nbleomycin  after ECT)  \nLocal tumor control \nrate CR n=7 (50%)  \nPR n= 6 (43%)  \nPD n= 1 (7%)  \nLesions (n=160):  \nCR 62%  \nPR 33%  \n2 years loc al \ntumor control rate: \n74.5%  \nGaudy et al. 2006  To assess whether \nEP therapy i mproves \nthe local control of \nskin m etastases of \nmelanoma by \nintralesional \nbleomycin  A prospective \ninternally controlled \nstudy with \nrandom ization of \nmelanoma skin \nmetastases i n each \nindividual to \nintralesional \ninjections of \nbleomycin alone or \nto intral esional \ninjections of \nbleomycin with EP  12 patients Stage III \n(4 patients) and \nStage IV (8 patients \nunder \nchemother apy)  \n54 lesions   \n \n \n \nLocal response \n(lesions)  \n \n \nTolerance  Lesion s treated with \nbleomycin + EP \n(n=30) versus \nbleomycin alone \n(n=24):  \nCR  36% (11 of 30) \nvs. 8% (2 of 24)  \np = 0.016  \n \nAll patients reported \ndiscomfort during \nthe EP procedure, \nincluding local pain \nfor 9 p atients (75%) \nat the treatment site \nand muscle spasm \nwith myocl onia in 3 \ncases (25%). No the study design \ndoes not cover the \nquestion of \nliterature search \n(efficacy of local \ntreatments \ncompared to \nstandard treatment), \nthe study is \ntherefore \ndownclass ified as \nlevel 4 stud y \n \nLimitations:  \nNo comparison to \nstandard trea tments \n(e.g. surgery, \nradiotherapy)  4*  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 429 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \nclinical or biologic \nsystemic toxi city. \nByrne et al. 2005  to evaluate the \neffect of EPT after \nintratumoral \ninjection of \nbleomycin, and to \ncompare this with \nthe effect of \nintratumoral \ninjection of \nbleomycin alon e Phase II, \nrandomized, open -\nlabel \nstudy comparing \nintralesional \nbleomycin + EPT \nwith intralesional  \nbleomycin alone.  \n \nTreatment:  \nInjectin of \nbleom ycin followed \nby electrical pulses, \npossible \nretrea tment at wek \n4, 8 or 12  19 patients, stage III \nor IV with a t least 2 \ncutaneous and/or \nsubcutaneous \nmetastases  \n \n36 evaluable \nlesions, lesions \nwere randomized to \ntreatment  lesion response  \n bleomycin only (19 \nLesions)  \nCR  26% (n=5)  \nPR 5% (n=1)  \nSD 15% (n=3)  \nPD 53% (n=10)  \n \nbleomycin plus EPT \n(17 lesions, plus 1 \nlesion crossed over)  \nCR  72% (n=13)  \nPR 5% (n=1)  \nSD 18% (n=3)  \nPD 5% (n=1)  \n \np=0.002  Response was \nevaluated for \ntreated lesions. No \ndata available for \nduration of \nresponse  \nLimitations:  \nNo comparison to \nstandard trea tments \n(e.g. surgery, \nradiotherapy)  4* \nOratz et al . 2003  To evaluate the use \nof a novel \nintral esional \nchemother apy \u2013 \ncisplatin / \nadrenaline \ninject able gel \u2013 for \nthe treatment of open -label, \nmulticentre study  \n \nTreatment: up to six \nweekly  intratumoral \ninjections of \ncisplatin/adrenaline \ngel within an 8 week 25 patients with \n244 lesions were \nevaluable for \nefficacy  Response  \nToxicity  CR was achieved in \n114 tumours (47%), \nPR in 16 t umours \n(7%). Median time to \nan indivi dual \ntumour response \nwas 62 days (range \n1\u2013534 days).  4  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 430 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \nrefractory or \nrecurrent cut aneous \nand soft tissue \nmelan oma \nmetastases  period or until \ncomplete response  Median duration of \nan individual \ntumour r esponse (n \n= 124)  \nwas 347 days (range \n30\u2013783 days).  \nRols et al. 2000  To apply the \nelectrochemotherap\ny method  Case Series  \n \nTreatment:  \n10 mg/m2 dose o f \nbleomycin i.v. \nfollowed by short, \nintense electric \npulses  4 patients  \n55 metastases  Response  Objective responses \nof treated \nmeta stases:  more \nthan 90%  \nComplete response \nrate 9%  Small series  4 \nSersa et al. 2000  To evaluate the \nantitumor \neffectiveness of \nelectrochemother ap\ny using intratumoral \ncisplatin \nadministration  \non cutaneous tumor \nnodules in \nmalignant \nmelanoma  \npatients  Phase II open -label \nStudy  \n \nTreatment:  \nIntratumoral \ncisplatin followed by \nelectrical pulses \nversus cisplatin \nalone ve rsus electric \npulses alone versus \ncontrol  10 patients with \ncutaneous \nmeta stases, Stage III \nor IV \n \nECT group: 82 \nlesions  \ncisplatin group:  \n27 lesions  \nelectric pulses  \ngroup: 2 lesions  \nuntreated controls: Lesion response  ECT group (n=82): \nCR 68% (n=56), PR \n10% (n= 8), SD 15% \n(n=12), PD 7% (n=6)  \nCisplatin group \n(n=27):  \nCR 19% (n=5), PR \n19% (n=5), SD 30% \n(n=8), PD 33% (n=9)  \nElectric pulses \n(n=2):  \nSD 50% (n=1), PD No details given \nhow l esions are \nallocated to \ndifferent treatment \ngroups  \nLimitations:  \nNo comparison to \nstandard trea tments \n(e.g. surgery, \nradiotherapy)  \nSmall sample size  4  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 431 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \n22 lesions  50% (n=1)  \nControl group \n(n=22):  \nSD 36% (n=8), PD \n64% (n=14)  \nGlass et al. 1996  To report the e ffects \nof ECT in 5 patients \nwith m etastatic \nmalignant \nmelanoma  Case Series  \n \nTreatment:  \nIntrale sional \nbleomycin followed \nby pulses of \nelectricity delivered \nvia needle \nelectrodes or cal iper 5 patients with \ncutaneous \nmetastatic \nmelanoma  \n \n23 lesions treated \nwith ECT  \n3 lesions with \nelectic pulses alone  \n9 lesions bleomycin \nalone  Lesion response  ECT: \nCR 78% (n=18)  \nPR 17% (n=4)  \nSD 4% (n=1)  \nElectric pulses \nalone: No response  \nBleomycin alone: No \nresponse  \n - 4 \n \nContact Sensitizer (Dinitrochlorobenzene, Diphencyprone)  \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nTerheyden et al. \n2006  To gain mor e \ninsight to criteria of \nresponse to \ncombined treatment \nwith ep ifocal DNCB \nand intravenous retrospective study  \n \nTreatment:  \nepifocal DNCB and  \nintravenous DTIC  72 evaluable \npatients with \nrecurrent melanom a \nStage III n=39  \nStage IV n=33  Response  \n \n \n \n \n Stage III, patients \nn=39  \nResponse  \nCR n=15 (39%)  \nPR n=9 (23%)  \nSD n=9 (23%)  - 4  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 432 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \nDTIC, data were \ncollected in this \nretrospective study   \nProgression free \nsurvival  \n \nOverall survival  PD n=6 (15%)  \nMedian PFS: 10 \nmonths (range 3 \u2013 \n120 months)  \nmedian OS 14 \nmonths (range 3 \u2013 \n120 months)  \nDamian et al. 2009  To report DPCP \ntreatment of 7 \npatients with \ncutan eous \nmetastastic \nmelanoma  Case Series  \n \nTreatment:  \n2 weeks after \nsensitization weekly \napplicatio of DPCP \ncream to all \ncutan eous \nmetastases  7 patients with  \ncutaneous \nmetas tastes Response  CR 4 patients  \nPR 3 patients  - 4 \nTrcka et al. 1998  To describe an \nimmunochemothera\npy for metastatic \nmelanoma  \n Case Series  \n \nTreatment:  \nepifocal DNCB and  \nintravenous DTIC  15 evaluable \nmelanoma p atients  Response  n=15  \nCR n=4  \nPR n=3  - 4 \nStrobbe et al. 1997  To describe the \nexperience with a \ncombination of \nDNCB and DTIC in \nselected patients Case Series  \n \nTreatment:  \nLocal DNCB 2% \nsolution in acetone 59 patients wi th the \npresence of \nlocoregional \nmetastases, Stage III \n63% (n=37) or Stage Response  Overall Response \n(patients)  \nCR 25% (n=15)  \nPR+SD 12% (n=7)  \nPD 63% (n=37)  No detailed data \nregarding local \nrespons e available  \nLimitations:  \nCombination 4  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 433 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \nwith regional \ncutaneous \nmetastases  alone for 4 weeks, \nstart of DTIC i.v. \nafter 4 weeks  IV 37% (n=22).  \n \n Local Response \n(patients)  \nCR+PR 68% (n=40)  therapy \nCohen et al. 1978  To compare efficacy \nand toxicity of \nintralesional BCG \nversus intralesional \nDNCB in patients \nwith locoregional \nmetastatic \nmelanoma  Randomized \nprospective Study  \n \nTreatment:  \nBCG group: \nintrales ional BCG \ninjecitons every 4 -6 \nweeks  \nDNCB group: topical \napplication until \nhypersensitivity \noccured (within 2 \nweeks) thereafter \nintralesional \ninjections every 4 -6 \nweeks  18 patients with \nintradermal or \nsubcutaneous \nmelan oma \nmetastases, Stage III  \n \nRandomisa tion in \ntwo treatment \ngroups: 9 patients \nreveived BCG with \n177 dermal and 22 \nsubcutaneous \nlesions, 9 patients \nreveived DNCB with \n504 dermal and 63 \nsubcutaneous \nlesions  Response  \n \n \n \n \n \n \n \n \n \n \n \n \nSurvival  \n \n \nToxicity  Lesion response:  \nBCG group  \nRegression dermal \nlesions: 90% \n(n=157), \nsubcut aneous \nlesions: 45% (n=10)  \nDNCB group  \nRegression dermal \nlesions: 90% \n(n=453), \nsubcutaneous \nlesions: 43% (n=27)  \nOverall Survival at \n39 months: 33% in \nboth groups.  \nToxicity BCG vs. \nDNCB  \nFever (88% vs. 0%), \nChills (84% vs. 0%), \nNause a 1(40% vs. \n0%), Major \nulcer ation (44% vs. \n4%), Cellulitis the study design \ndoes not cover the \nquestion of \nliterature search \n(efficacy of local \ntreatments \ncompared to \nstandard treatment), \nthe study is \ntherefore \ndownclass ified as \nlevel 4 study  4*  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 434 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \n(antibi otics) (16% vs. \n2%), Distant \ninfection (8% vs. 0%) \nDisseminated \nintravascular \ncoagul ation, \nincluding one near \nfatality. (12% vs. 0%)  \n* the study design does not cover the question of literature search (efficacy of local treatments compared to standard treatm ent), the study is therefore \ndownclass ified as level 4 study  \n \n5.1.5.  Literatur  \n \nBong AB, Bonnekoh B, Franke I, et al. Imiquimod, a topical immune response modifier, in the treatment of cutaneous metastases of malignant melanoma. Dermatology \n2002;205:135 -138 \nBoyd KU, Wehrli BM, Temple CL. Intra -lesional interleukin -2 for the treatment of in -transit melanoma. J Surg Oncol 2011;104:711 -717 \nByrne CM, Thompson JF, Johnston H, et al. Treatment of metastatic melanoma using electroporation therapy with bleomycin (elec trochemotherapy). Melanoma Res 2005;15:45 -\n51 \nCohen MH, Jessup JM, Felix EL, et al. Intralesional treatment of recurrent metastatic cutaneous malignant melanoma: a randomized prospective study of intralesional  Bacillus \nCalmette -Guerin versus intralesional dini trochlorobenzene. Cancer 1978;41:2456 -2463  \nDamian DL, Shannon KF, Saw RP, et al. Topical diphencyprone immunotherapy for cutaneous metastatic melanoma. Australas J Dermatol 2009;50:266 -271 \nDehesa LA, Vilar -Alejo J, Valeron -Almazan P, et al. Experience in t he treatment of cutaneous in -transit melanoma metastases and satellitosis with intralesional interleukin -2]. \nActas Dermosifiliogr 2009;100:571 -585 \nFierlbeck G, d'Hoedt B, Stroebel W, et al. Intralesional therapy of melanoma metastases with recombinant inte rferon -beta]. Hautarzt 1992;43:16 -21 \nFlorin V, Desmedt E, Vercambre -Darras S, et al. Topical treatment of cutaneous metastases of malignant melanoma using combined imiquimod and 5 -fluorouracil. Invest New \nDrugs 2011  \nFoote MC, Burmeister BH, Thomas J, et al . A novel treatment for metastatic melanoma with intralesional rose bengal and radiotherapy: a case series. Melanoma Res \n2010;20:48 -51 \nFujimura T, Okuyama R, Ohtani T, et al. Perilesional treatment of metastatic melanoma with interferon -beta. Clin Exp Derm atol 2009;34:793 -799 \nGarcia MS, Ono Y, Martinez SR, et al. Complete regression of subcutaneous and cutaneous metastatic melanoma with high -dose intralesional interleukin 2 in combination with \ntopical imiquimod and retinoid cream. Melanoma Res 2011  \nGaudy C,  Richard MA, Folchetti G, et al. Randomized controlled study of electrochemotherapy in the local treatment of skin metastases of melanoma. J Cutan Med Surg \n2006;10:115 -121 \nGlass LF, Pepine ML, Fenske NA, et al. Bleomycin -mediated electrochemotherapy of met astatic melanoma. Arch Dermatol 1996;132:1353 -1357   \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 435 von 732 Green DS, Bodman -Smith MD, Dalgleish AG, et al. Phase I/II study of topical imiquimod and intralesional interleukin -2 in the treatment of accessible metastases in malignant \nmelanoma. Br J Dermatol 2007;156 :337-345 \nKhorana AA, Rosenblatt JD, Sahasrabudhe DM, et al. A phase I trial of immunotherapy with intratumoral adenovirus -interferon -gamma (TG1041) in patients with malignant \nmelanoma. Cancer Gene Ther 2003;10:251 -259 \nKis E, Olah J, Ocsai H, et al. Electro chemotherapy of Cutaneous Metastases of Melanoma -A Case Series Study and Systematic Review of the Evidence. Dermatol Surg 2011  \nKrown SE, Hilal EY, Pinsky CM, et al. Intralesional injection of the methanol extraction residue of Bacillus Calmette -Guerin (MER ) into cutaneous metastases of malignant \nmelanoma. Cancer 1978;42:2648 -2660  \nLokich JJ, Garnick MB, Legg M. Intralesional immune therapy: methanol extraction residue of BCG or purified protein derivativ e. Oncology 1979;36:236 -241 \nNathanson L, Schoenfeld D, Regelson W, et al. Prospective comparison of intralesional and multipuncture BCG in recurrent intradermal melanoma. Cancer 19 79;43:1630 -1635  \nOratz R, Hauschild A, Sebastian G, et al. Intratumoral cisplatin/adrenaline injectable gel for the treatment of pat ients with cutaneous and soft tissue metastases of malignant \nmelanoma. Melanoma Res 2003;13:59 -66 \nPaul E, Muller I, Renner H, et al. Treatment of locoregional metastases of malignant melanomas with radiotherapy and intralesional beta -interferon injection. Melanoma Res \n2003;13:611 -617 \nQuaglino P, Mortera C, Osella -Abate S, et al. Electrochemotherapy with intravenous bleomycin in the local treatment of skin melanoma metastases. Ann Surg Oncol \n2008;15:2215 -2222  \nRadny P, Caroli UM, Bauer J, et al. Phase II tria l of intralesional therapy with interleukin -2 in soft -tissue melanoma metastases. Br J Cancer 2003;89:1620 -1626  \nRols MP, Bachaud JM, Giraud P, et al. Electrochemotherapy of cutaneous metastases in malignant melanoma. Melanoma Res 2000;10 :468-474 \nSersa G, S tabuc B, Cemazar M, et al. Electrochemotherapy with cisplatin: clinical experience in malignant melanoma patients. Clin Cancer Res 2000;6:863 -867 \nSi Z, Hersey P, Coates AS. Clinical responses and lymphoid infiltrates in metastatic melanoma following treatm ent with intralesional GM -CSF. Melanoma Res 1996;6:247 -255 \nStorm FK, Sparks FC, Morton DL. Treatment for melanoma of the lower extremity with intralesional injection of bacille Calmett e Guerin and hyperthermic perfusion. Surg \nGynecol Obstet 1979;149:17 -21 \nStrobbe LJ, Hart AA, Rumke P, et al. Topical dinitrochlorobenzene combined with systemic dacarbazine in the treatment of recurrent melanoma. Melanoma Res 1997;7:5 07-512 \nTan JK, Ho VC. Pooled analysis of the efficacy of bacille Calmette -Guerin (BCG) immunot herapy in malignant melanoma. J Dermatol Surg Oncol 1993;19:985 -990 \nTerheyden P, Kortum AK, Schulze HJ, et al. Chemoimmunotherapy for cutaneous melanoma with dacarbazine and epifocal contact sensitizers: results of a nationwide survey o f \nthe German Dermato logic Co -operative Oncology Group. J Cancer Res Clin Oncol 2007;133:437 -444 \nThompson JF, Hersey P, Wachter E. Chemoablation of metastatic melanoma using intralesional Rose Bengal. Melanoma Res 2008;18:405 -411 \nTrcka J, Kampgen E, Becker JC, et al. Immunoche motherapy of malignant melanoma. Epifocal administration of dinitrochlorobenzene (DNCB) combined with systemic \nchemotherapy with dacarbazine (DTIC)]. Hautarzt 1998;49:17 -22 \nvon Wussow P, Block B, Hartmann F, et al. Intralesional interferon -alpha therapy in  advanced malignant melanoma. Cancer 1988;61:1071 -1074  \nVosika GJ, Schmidtke JR, Goldman A, et al. Intralesional immunotherapy of malignant melanoma with mycobacterium smegmatis cel l wall skeleton combined with trehalose \ndimycolate (P3). Cancer 1979;44:495 -503 \nWeide B, Derhovanessian E, Pflugfelder A, et al. High response rate after intratumoral treatment with interleukin -2: results from a phase 2 study in 51 patients with \nmetastasized melanoma. Cancer 2010;116:4139 -4146  \nWeide B, Eigentler TK, Pflugfelder A,  et al. Survival after intratumoral interleukin -2 treatment of 72 melanoma patients and response upon the first chemotherapy during follow -\nup. Cancer Immunol Immunother 2011;60:487 -493 \n \n \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 436 von 732 5.2. Frage V.2. und V.3. Systemtherapie Einzelsubstanzen  \u2013 De novo Recher che \nFrage V.2. : F\u00fcr welche Substanzen konnten objektive Remissionen im metastasierten Stadium (First - und S econdline) gezeigt werden?  \nFrage V.3. : F\u00fcr welche Substanzen konnte eine Verbesserung des Gesamt\u00fcberl ebens im metastasierten Stadium (First - und Seco ndline) \ngezeigt werden?  \n \n5.2.1.  PICO, Suchw\u00f6rter  \nPICO \u2013 Schema   \nPopulation  Intervention  Comparison  Outcome  \nAdvanced m elanoma patients  stage IV, \nunresectable stage III  Systemic treatment  Standard of care/Placebo/Standard of \ncare+Placebo  Overall Survival, Respons e, Duration of \nResponse  \n \nSuchw\u00f6rter  \nStichwort  melanoma  phase III  \nphase 3  Chemotherapy  Stage IV  \nStage 4  \nSynonyme   random*   Palliative  \nOber -/Unterbegriffe    Systemic thera py Salvage  \nmetastatic  \nDisseminated  \nMesh Term  melanoma  Clinical Trial, Phase III  \nRandomized Co ntrolled Trial  Drug Therapy   \n \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 437 von 732 5.2.2.  Datenbanken, Suchstrategien, Trefferzahlen  \nDatenbank  Suchstrategie  Datum  Treffer \n1. Suche     \nMedline  (melanoma[tiab] OR melanoma[MeSH]) AND (Clinical Trial, Phase III [Publication Type] OR \nRandomized Controll ed Trial [Publication Type] OR \u201cphase 3\u201d OR \"phase III\"[tiab] OR \nrandom*[tiab]) AND (\u201csystemic therapy\u201d[tiab] OR chemotherapy[tiab] OR \"drug \ntherapy\"[MeSH] OR metastatic[tiab] OR palliative[tiab] OR advanced[tiab] OR \"stage IV\"[tiab] \nOR \"stage 4\"[tiab] OR salvage[tiab])  26.07.11  1091 (Auswahl: 38)  \nMedline \u2013erweiterte \nSuchstr ategie  (melanoma[tiab] OR melanoma[MeSH]) AND (Clinical Trial, Phase III [Publication Type] OR \nRandomized Controlled Trial [Publication Type] OR \u201cphase 3\u201d OR \"phase III\"[tiab] OR \nrando m*[tiab]) AND (\u201csystemic therapy\u201d[tiab] OR chemotherapy[tiab] OR \"drug \ntherapy\"[MeSH] OR disseminated [tiab] OR metastatic[tiab] OR palliative[tiab] OR \nadvanced[tiab] OR \"stage IV\"[tiab] OR \"stage 4\"[tiab] OR sa lvage[tiab])  05.12.11  1142 (Avril et al. 2004 \ndazu)  \nCochrane Library  (melanoma and (random* or phase 3) and (systemic therapy or chemotherapy or m etastatic \nor palliative or advanced or salvage)).ti,ab.   17.10.11  385 (Auswahl: 2 5, abz. \nDuble tten: 2 dazu ) \nEmbase  (melanoma and (random* or phase 3) an d (systemic therapy or chemotherapy or metastatic \nor palliative or advanced or sa lvage)).ti,ab.  04.10.11  894 (Auswahl: 33, abz. \nDuble tten: 3 dazu)  \nUpdate Suche     \nMedline  s.o. 30.01.12  1145  (2 dazu : Kim et al. \n2012, Kirkwood et al. \n2012)  \nMedline  s.o. 01.08.12  1221  (2 dazu: Flaherty et \nal. 2012, Hauschild et al. \n2012)   \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 438 von 732 Cochrane Library  s.o. 30.01.12  389 (0 dazu)  \nEmbase  s.o. 23.01.12  937 (0 dazu)  \n \n5.2.3.  Auswahlkriterien  \nAuswahl der Literatur  \nGesamttreffer  2547 \nEinschlusskriterien  RCTs zur medikament\u00f6sen Sys temtherapie bei Melanompatienten im Stadium IV / nicht resektables Stadium III  \nInterventionsarm: Monotherapie oder Monotherapie + Standardtherapie  \nBeobachtungsarm: Placebo, Standardtherapie oder Placebo + Standardtherapie  \nPublikationsjahr ab 1980  \nAusschlu sskriterien  Case Reports, Kohortenstudien  \nDosisfindungsstudie  \nKolle ktive mit gemischten Tumorentit \u00e4ten \nAnzahl nach Abstractscreening, vorges ehen f\u00fcr Bewertung  48 \nAnzahl der ausgeschlossenen Studien nach Sichtung der Volltexte  8 \nAnzahl ausgew\u00e4hlter Vollt exte 40 \nDie ausgew\u00e4hlten Arbeiten wurden wie folgt zusammengefasst:  \nZielgerichtete Therapien  /small molecules   (Trametinib, Dabrafenib, Selumetinib, Bevacizumab, Vemurafenib, Intetumumab, Bosentan, Sorafenib, Elesclomol, \nTamoxifen)  \nImmuntherapien , Immunmo dulation  (Ipilimumab, Vakzine, Lenalidomide, Thymosin, PF -3512676, Interferon alpha, Thalidomide, Histamine)  \nChemotherapien/ Chemosensitizer  (DHA -paclitaxel, Dacarbazine, Temozolomide, Lomeguatrib, Oblimersen, Cisplatin, Fotemustine, Vindesine, Detorubicin)  \n \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 439 von 732 5.2.4.  Evidenztabelle  \n \nZielgerichtete Therapien  / small molecules  \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nFlaherty et al. 2012  To compare \ntrametinib (MEK \nInhibitor) with \ndacarbazine  or \nTaxol  in patients \nwith metastatic \nmelanoma with the \nBRAF V600E or BRAF \nV600K mut ation RCT, open label  \n \nTreatment:  \nGroup A  \ntrametinib  (2 mg \norally twice daily)  \n \nGroup B  \ndacarb azine, 1000 \nmg/m\u00b2 i.v.  \nor paclitaxel \n175mg/m\u00b2 i.v.  \non day 1 every 3 \nweeks  322 patients with \nmetastatic \npreviously untreated \nor treated  \nmelanoma with the \nBRAF V600E or BRAF \nV600K mut ation  \n \n \nOverall Survival \u2013 6 \nmonths  \n \n \nProgression free \nsurvival  \n \n \n \nOverall Response \nrate \n \nDuration of \nResponse  trametinib vs. \nchemotherapy  \n \n81% vs. 67% (HR \n0.54; 95% CI, 0.32 \nto 0.92; p = 0.01)  \n \n4.8 vs. 1.5 months \n(HR 0.45; 95% CI, \n0.33 to 0.63; \nP<0.001)  \n \n22% vs. 8% (p=0.01)  \n \n \n5.5 months vs. \nnot yet reached  Jadad Score 4 \nIndependent review \nof tumor \nassessment  \n \nFunding:  \nGlaxoSmithKline.  1b \nHauschild et al. \n2012  To compare  \ndabrafenib with \ndacarbazine \nchemothe rapy in \npreviously untreated \nmel anoma patients RCT, open label  \n \nTreatment:  \nGroup A  \ndabrafenib  (150 mg \norally twice da ily) 250 patients with \npreviou sly \nuntreated, \nmetastatic \nmelanoma with the \nBRAF V600E  \n \n \nOverall Survival  \n \n dabrafenib vs. \ndacarb azine \n \nHR 0,61 (95% CI, \n0,25\u20131,48)  \n Jadad Score 4  \nIndependent review \nof tumor \nassessment  \n \nFunding:  1b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 440 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \nwhose tumours \nharboured a \nBRAF V600E \nmutation.   \nGroup B  \ndacarb azine, 1000 \nmg/m\u00b2 i.v. on day 1 \nevery 3 weeks  mutation  Progression free \nsurvival  \n \n \n \nOverall Response \nrate  \n \nDuration of \nResponse  5,1 vs. 2,7 months \n(HR 0,30; 95% CI, \n0,18\u20130,51; \np<0\u20220001)  \n \n50% vs. 6%  \n \n \n5.5 months vs. not \nyet reached  GlaxoSmithKline.  \nChapman et al. \n2011  To compare \nvemurafenib with \ndacarbazine in 675 \npatients with \npreviously \nuntreated, \nmetastatic \nmelanoma with the \nBRAF V600E \nmutation RCT, open label  \n \nTreatment:  \nGroup A  \nvemurafenib (960 \nmg orally twice \ndaily) \n \nGroup B  \ndacarb azine, 1000 \nmg/m\u00b2 i.v. on day 1 \nevery 3 weeks  \n 675 patients with \npreviously \nuntreated, \nmetastatic \nmelanoma with the \nBRAF V600E   \n \n \nOverall Survival \u2013 6 \nmonths  \n \n \n \n \n \n \n \nOverall Response \nrate  \n \nDuration of \nResponse  Vemurafenib vs. \nDTIC \n \n84% (95% CI, 78 to \n89) vs. 64% (95% CI, \n56 to 73), HR for \ndeath in the \nvemurafenib group \n0.37 (95% CI, 0.26 \nto 0.55; P<0.001), \nsign. \n \n48% vs.  5%, \np<0.001, sign.  \n \nnot yet estimated  Jadad Score 2  \nno description of \ndropouts, tumor \nassessment not \nblinded, only 439 \npatients (65%) were \nevaluated for tumor \nresponse, 48 \npatients in the DTIC \nGroup received no \nstudy treatment  \n \nFunding:  \nHoffmann \u2013La Roche  1b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 441 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \nO\u00b4day et al. 2011  To evaluate the \nsafety and efficacy \nof Intetumumab \n(CNTO 95), a fully \nhuman anti -\nalpha(v) -integrin \nmonoclonal \nantib ody RCT, double -blind \n(Group A+B)  \n \nTreatment q3w:  \n \nGroup A  \n1000 mg/m\u00b2 \ndacarbazine + \nplacebo, (n=32)  \n \nGroup B  \n1000 mg/ m\u00b2 \ndacarbazine + 10 \nmg/kg \nintetumumab \n(n=32)  \n \nGroup C  \n10 mg/kg \nintetumumab \n(n=33)  \n \nGroup C  \n5 mg/kg \nintetum umab \n(n=32)  129 c hemotherapy -\nnaive patients   \n \n \n \n \n \nMedian Overall \nSurvival \n \nOverall Response \nRate \n \n \nDuration of \nResponse  DTIC vs. DTIC+ \nintetumumab vs.  \nintetumumab 10mg \nvs. intetumumab \n5mg \n \n8 vs. 11 vs. 15 vs. \n9.8 months, n.s.  \n \n10% (n=3) vs. 3% \n(n=1) vs. 6% (n=2) \nvs. 0%, n.s.  \n \n3.9, 7.3, and 10.3+ \nmonths vs. 7.0 \nmonths vs. 6.3 and \n8.2+ months  Jadad Score 5  \n \nFunding:  \nCentocor Ortho \nBiotech, Inc., \nMalvern, \nPA, USA.  \n 1b \nKefford et al. 2010  To evaluate the RCT, double -blind  80 patients with  DTIC+Bosentan vs. Jadad Score 4  1b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 442 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \neffects of bosentan \n- a dual endothelin \nreceptor antagonist \n- in patients \nreceiving first -line \ndacarbazine ther apy \nfor stage IV \nmetastatic \ncutaneous \nmelan oma  \nTreatment:  \n \nGroup A  \nDTIC 1 000 mg/m2 \nevery 3 weeks  \nstarting on Day 1 \n+Bosentan 500 mg \ntwice a day (n=40)  \n \n \nGroup B  \nDTIC 1000 mg/m2 \nevery 3 weeks  \nstarting on Day \n1+Placebo (n=40)  previously u ntreated \nmetastatic \nmelanoma   \n \nMedian Overall \nSurvival \n \n \n \n \n \n \nOverall Respon se \nRate \n \nDuration of \nResponse  DTIC+Placebo  \n \n13.0 months (95% \nCI, 7.8 -16.6) vs. \n10.6 months (95% \nCI, 6.9 -14.7), n.s., \n(HR, 1.044; 95%  \nCI, 0.584 -1.865; p \n= 0.8841)  \n \nnot reported  \n \n \nnot reported  tumor assessment \nnot described as  \nblinded  \n \nFunding:  \nActelion \nPharm aceuticals \nLtd., \nAllschwil, \nSwitzerland.  \nHauschild et al. \n2009  To evaluate the \nefficacy and safety \nof sorafenib with \ncarboplatin and \npaclitaxel (CP) in \npatients with \nadvanced melanoma  RCT, double -blind  \n \nTreatment:  \n \nGroup A  \npaclitaxel 225 \nmg/m2 plus \ncarbo platin (AUC 6) \n+ sor afenib 400mg \n(n=135)  \n 270 patients with \nadvanced melan oma \n(unresectable stage \nIII or stage IV) that \nhad progressed \nduring or af ter \nreceiving at least \none cycle of a \nregimen containing \ndacarb azine or \ntemozol omide in  \n \n \nMedian Overall \nSurvival \n \n \n \n \n \nOverall Response C/P + Sorafenib vs. \nC/P + Placebo  \n \n42.0 weeks (9.7 \nmonths) vs. 42.0 \n(9.7 months), n.s.,  \nHR 1.01 (95% CI, \n0.76 to 1.36; \np=0.92)  \n \n12% (n=16) vs. 11% Jadad Score 5  \n \nFunding:  \nBayer AG and Onyx \nPharmaceut icals, \nInc. 1b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 443 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \nGroup B  \npaclitaxel 225 \nmg/m2 plus \ncarbo platin (AUC 6) \n+ placebo (n=135)  the advanced \nsetting \n \n Rate \n \nDuration of \nResponse  (n=15), n.s., p=1.0  \n \nnot reported  \nO\u00b4Day et al. 2009  To evaluate whether \nthe add ition of \nelesclomol to \nweekly paclitaxel \ncould i mprove \nefficacy in patients \nwith stage IV \nmetastatic \nmelanoma  RCT, double -blind  \n \nTreatment:  \n \nGroup A  \nelesclomol 213 \nmg/m\u00b2 plus \npaclitaxel 80 \nmg/m(2) (E + P) (n= \n53) \n \nGroup B  \npaclitaxel 80 \nmg/m\u00b2 alone  \n(n= 28)  \n 81 metastatic \nmelanoma p atients \nwith one or fewer \nprior standard \nchemotherapy \nregimens   \n \n \n \nMedian Overall \nSurvival \n \nProgression Free \nSurvival  \n \n \nOverall Response \nRate \n \n \n \nDuration of \nResponse  Elesclomol \n+Paclitaxel vs. \nPaclitaxel  \n \n11.9 vs. 7.8 months  \n \n \n3.7 months vs. 1.8 \nmonths, sig n., \np=0.035  \n \n15.1% (n=8) vs. \n3.6% (n=1) \n(p=0.153) ,n.s., \np=0.153  \n \nrange 58+ to 188+ \ndays (censored \npatients), 107, 136 \ndays vs. 115 days  Jadad Score 4  \nTumor assessment \nby investigators, \nRandomization \nwithout \nstratification, M1c \npatients unbalanced \n(25.8% v s. 75%)  \n \nFunding:  \nSynta \nPharmaceut icals, \nLexington, MA.  1b \nMcDermott et al. To evaluate the RCT, double -blind  101 chemotherapy - Sorafenib + DTIC Jadad Score 5  1b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 444 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \n2008  efficacy and safety \nof sorafenib plus \ndacarbazine in \npatients with \nadvanced melanoma   \nTreatment:  \n \nGroup A  \nsorafenib plus \ndacarbazine (n = \n51)  \n \nGroup B  \nplacebo plus \ndacarbazine (n = \n50)  \n naive patients with \nstage III \n(unresect able) or IV \nmelanoma   \n \n \nMedian Overall \nSurvival \n \n \nOverall Response \nRate \n \n \nDuration of \nResponse  vs. \nPlacebo + DTIC  \n \n45.6 weeks vs. 51 .3 \nweeks, n.s., \np=0.927  \n \n24% (n=12) vs. 12% \n(n=6), n.s., \np=0.193  \n \n26.9 vs. 23.0 \nmonths, n.s., \np=0.194  \n  \nFunding:  \nBayer HealthCare \nPharmaceuticals  \nand Onyx \nPharm aceuticals Inc.  \nAgarwala et al. \n1999  To test the benefit \nof adding tamo xifen \nto dacarbazine and \ncarboplatin \nchemotherapy for \npreviously u ntreated \npatients with \nmetastatic \nmelanoma  RCT, open label  \n \nTreatment:  \n \nGroup A  \ncarboplatin 300 \nmg/m\u00b2 and \ndacarbazine 1g/m\u00b2 \nplus tamoxifen 20 \nmg/day (D+C+T)  \n \nGroup B  56 metastatic \nmelanoma  patients, \nwithout prior \nchemotherapy  \n  \n \nMedian Overall \nSurvival \n \n \nOverall Response \nRate \n \n \nDuration of \nResponse  D+C+T vs. D+C  \n \n4.6 months vs. 7 \nmonths, n.s., \np=0.1377  \n \n14.3% (n=4) vs. \n10.7% (n=3), n.s., \n(p=1.0)  \n \n3, 3, 6, and 6 \nmonths vs. 2, 16 Jadad Score 2  \nunblinded tumor \nassessment, no \ndescription of \ndropouts and \nwithdrawals, small \nsample size  \n \nFunding:  \nNot declared  1b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 445 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \n(D+C)  \n months + los t to \nfollow up at 31 \nmonths  \n \n \nImmuntherapien, Immunmodulation  \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nHersh et al. 2011  To evaluate the \nsafety and efficacy \nof ipilimumab  alone \nand in combination \nwith d acarbazine \n(DTIC) in patients \nwith u nresectable, \nmetastatic \nmelanoma  RCT, open label  \n \nTreatment:  \nGroup A  \nipilimumab at 3 \nmg/kg every 4 \nweeks for four \ndoses alo ne (n=37)  \n \nGroup B  \nipilimumab at 3 \nmg/kg every 4 \nweeks for four \ndoses with up to six \n5-day courses of \nDTIC at 250 \nmg/m\u00b2/day (n=35)  72 chemotherapy -\nnaive patients  \n \n  \n \n \nMedian Overall \nSurvival \n \n \n \nOverall Response \nRate \n \n \n \nDurable Complete \nResponse  Ipi alone ( n=32) vs. \nIpi+DTIC (n=32)  \n \n11.4 months (95% \nCI, 6.1 -15.6) vs. \n14.3 months (95% \nCI, 10.2 -18.8), n.s.  \n \n5.4% (95% CI, 0.7 -\n18.2) vs. 14.3% (95% \nCI, 4.8 -30.3), n.s.  \n \nn=2 (1.6+/1.85+ \nyears) vs. n=2 \n(1.73+/1.76+ \nyears)  Jadad Score 2  \nsmall sample size  \nrandomizatio n \nscheme not \ndescribed, tumor \nassessment not \nblinded  \n \nFunding:  \nBristol -Myers \nSquibb Co.  \n 1b \nRobert et al. 2011  To evaluate RCT, double -blind  502 patients with  Ipi+DTIC vs.  Jadad Score 5  1b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 446 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \nipilimumab  (10 mg \nper kilogram) plus \ndacarbazine in \npatients with \npreviously untreated \nmetastatic \nmelanoma   \nTreat ment:  \n \nGroup A  \nIpilimumab (10 mg \nper kilogram) plus \ndacarbazine (850 \nmg/m\u00b2)  \n \nGroup B  \ndacarbazine (850 \nmg/m\u00b2) plus \nplacebo previously u ntreated \nmetastatic \nmelanoma   \n \nMedian Overall \nSurvival \n \n \n \n \n \n \nOverall Survival  \n1 year  \n2 years  \n3 years  \n \nOverall Response \nRate \n \nDuration of \nResponse  Placebo+DTIC  \n \n11.2 months (95% \nCI, 9.4 to 13.6) vs. \n9.1 months (95% CI, \n7.8 to 10.5)  \n(hazard ratio for \ndeath with \nDITC+Ipi,  \n0.72; p<0.001)  \n \n47.3% vs. 36.3%  \n28.5% vs. 17.9%  \n20.8% vs. 12.2%  \n \n15.2% vs . 10.3%, \nn.s. (p = 0.09)  \n \n19.3 months (95% \nCI, 12.1 to 26.1) vs. \n8.1 months (95% CI, \n5.19 to 19.8) \n(p=0.03)   \nFunding:  \nBristol -Myers \nSquibb.  \n \nSchwar tzentruber et \nal. 2011  To investigate if the \ncombination of a \nmelanoma va ccine \nwith interl eukin-2, RCT, open label  \n \nTreatment:  \n 185 patients with \nstage IV or locally \nadvanced stage III \ncutaneous  \n \nMedian Overall \nSurvival IL-2 vs. IL -\n2+Vaccine  \n \n11.1 months (95% Jadad Score 4  \ntumor assessment \nblinded  \n 1b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 447 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \nan immune \nactiva ting agent, \ncould i mprove \noutcomes  Group A  \ninterleukin -2 alone \n(720,000 IU per \nkilogram of body \nweight per dose)  \n \nGroup B  \ngp100: 209 -\n217(210M) plus \nincomplete Freund's \nadjuvant (Mont anide \nISA-51) once  per \ncycle, followed by \ninterleukin -2 \n \n \n melanoma, \nexpression of \nHLA*A0201, an \nabsence of brain \nmetastases, and \nsuitability for high -\ndose inte rleukin -2 \ntherapy   \n \n \n \n \nOverall Response \nRate \n \nDuration of \nResponse  CI, 8.7 to 16.3); vs. \n17.8 months (95% \nCI, 11.9 to 25.8) \nn.s. (p=0.06)  \n \n6% vs. 16%, p=0.03  \n \n \nnot reported  Funding:  \nNational Cance r \nInstitute, Indiana \nUniversity Health \nGoshen, Goshen \nHospital and Health \nCare Foundation, \nChiron, and \nNovartis  \n \nHodi et al. 2010  To compare \nipilimumab , \nadmini stered with \nor without a \nglycoprotein 100 \n(gp100) pe ptide \nvaccine with gp100 \nalone in patient s \nwith pr eviously \ntreated metastatic RCT, double -blind  \n \nTreatment:  \n \nGroup A  \nipilimumab plus \ngp100 (n=403)  \n \nGroup B  \nipilimumab alone 676 HLA -A*0201 -\npositive patients \nwith previously \ntreated unresect able \nstage I II or IV \nmelanoma   \n \n \n \nMedian Overall \nSurvival \n \n \n \n ipilimumab  +gp100 \nvs. ipilimumab vs. \ngp100  \n \n10.0 months vs. \n10.1 months vs. 6.4 \nmonths, sign., \n(hazard ratio for \ndeath, 0.68 ; \np<0.001).  Jadad Score 5  \ntumor assessment \nby investigators  \n \nFunding:  \nMedarex and \nBristol-Myers \nSquibb  1b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 448 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \nmelanoma  (n=137)  \n \nGroup C  \ngp100 alone \n(n=136)   \nOverall Response \nRate \n \n \n \nMedian Duration of \nResponse  \n \n \nTreatment related \ndeaths   \n5.7% (n=23) vs. 11% \n(n=15) vs. 1.5% \n(n=2), sign., p=0.04  \n \n \n11.5 (5.4 \u2013NR) vs. NR \n(28.1 \u2013NR) vs. NR \n(2.0\u2013NR) months  \n \nn=14  \nEisen et al. 2010  To compar e the \ntreatment with \nlenalidomide  to \nplacebo in 306 \npatients with \nmetastatic \nmalignant \nmelan oma RCT, double -blind  \n \nTreatment:  \n \nGroup A  \nlenalidomide (25 \nmg/d on Days 1 -21 \nof a 28 -day cycle  \n(n=154)  \n \n \nGroup B  \nplacebo  \n(n=152)  \n 306 patients with \npreviously tre ated \nmetastatic \nmalignant \nmelanoma   \n \n \nMedian Overall \nSurvival \n \n \n \n \nOverall Response \nRate \n \nDuration of \nResponse  lenalidomide  vs. \nplacebo  \n \nmedian 5.9 months \n(range 5.1 -7.7) vs. \n7.4 months range \n5.5-8.2); n.s., \np=0.32  \n \n5.3% vs 5.8%; n.s., \np=0.82  \n \nnot reported  Jadad Score 5  \n \nFunding:  \nCelgene \nCorpor ation, \nSummit, New Jersey.  1b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 449 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \nMaio et al. 2010  To evaluate the \nefficacy and safety \nof combining \nThymosin alpha 1  \nwith daca rbazine \nand interferon alfa \nin patients with \nmetastatic \nmelanoma  RCT, open label  \n \nTreatment:  \nGroup A: DTIC+IFN \nalpha+ Thymosin \nalpha 1 (1.6mg)  \n \nGroup B: DTIC+IFN \nalpha+ Thymosin \nalpha 1 (3.2mg)  \n \nGroup C: DTIC+IFN \nalpha+ Thymosin \nalpha 1 (6.4mg)  \n \nGroup D: \nDTIC+Thymosin \nalpha 1 (3.2mg)  \n \nGroup D: DTIC+IFN \nalpha  \n 571 chemotherapy -\nnaive patients    \n \n \n \nMedian Overall \nSurvival \n \n \n \n \n \n \nOverall Response \nRate \n \n \nMedian duration of \nResponse  \n \n \nClinical benefit \n(CR+PR+SD)  \n DIT1.6 vs. DIT3.2 \nvs. DIT6.4 vs. DT3.2 \nvs. DI  \n \n9.3 vs. 8.6 vs. 10.3 \nvs. 9.3 vs. 6.6 \nmonths, n.s.  \nDTI+DT vs. DI, PP \npopul ation: HR = \n0.74; 95% CI , 0.57 - \n0.95; p=0.02 \n \n7.2% vs. 10.3% vs. \n6.1% vs. 12.1% vs. \n4.1%, n.s.  \n \n7.4 vs. 8.3 vs. 7.9 \nvs. 7.7 vs. 6.3 \nmonths  \n \nDT3.2 vs. DI:  \n49.5% vs. 32.0%  \nP=0.009  \n \n \n Jadad Score 4  \ntumor assessment \nblinded  \n \nFunding: Sigma -Tau \nSpA, Pomezia, Italy  \n 1b \nWeber et al. 20 11 To assess the RCT, open label  184 patients with  PF-3512676 10mg Jadad Score 3  1b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 450 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \nobjective response \nrate of PF-3512676 , \na CpG \noligodeoxynucle otid\ne, alone in 2 doses \nor in combination \nwith daca rbazine \n(DTIC) in patients \nwith unr esectable \nstage IIIB/C or stage \nIV malignant \nmelanoma   \nTreatment:  \n \nGroup A  \nPF-3512676 10 mg  \n(n=46)  \n \nGroup B  \nPF-3512676 40 mg  \n(n=46)  \n \nGroup C  \nPF-3512676 40 mg \nplus DTIC (850 \nmg/m\u00b2)  \n(n=45)  \n \nGroup D  \nDTIC (850 mg/m\u00b2)  \nalone  \n(n=39)  previously u ntreated \nmetastatic \nmelanoma   \n \n \n \n \nMedian Overall \nSurvival \n \n \nOverall Respon se \nRate \n \nDuration of \nResponse  vs. PF -3512676 \n40mg vs. PF -\n3512676 40 mg + \nDTIC vs. DTIC  \n \n9.4 vs. 8.4 vs. 9.0 \nvs. 11.7 months, \nn.s. \n \n2% vs. 0% vs. 16% \nvs. 8%, n.s.  \n \nnot estimated \n(number to small)   \nFunding:  \nnot declared  \nSchadendorf et al. \n2006  To demonstrate the \nsuperiority of \nautologous \npeptide -loaded \ndendritic cell (DC) \nvaccin ation over RCT, open label  \n \nTreatment:  \n \nGroup A  \nDC vaccines loaded 108 metastatic \nmelanoma patients \nwith no prior \nsystemic \nchemother apy  \n \n \nMedian Overall \nSurvival \n DC vaccination  vs. \nDTIC \n \n9.3 months vs. 11.6 \nmonths n.s.  \n Jadad Score 3  \n \nFunding:  \nGerman Cancer Aid  \n 1b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 451 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \nstandard \ndacarbazine (DTIC) \nchemoth erapy in \nstage IV melanoma \npatients  with MHC c lass I \nand II -restricted \npeptides (n=53)  \n \nGroup B  \nDTIC 850 mg/m\u00b2 \n(n=55)  Overall Response \nRate \n \n ITT: 3.8% (n=2) vs. \n5.5% (n=3), n.s.  \n(PP:4.9 vs. 4.8%)  \nKaufmann et al. \n2005  To compare TMZ \nalone and TMZ plus \nIFN-alpha  in terms \nof objective \nresponse (OR), \noverall survival, and \nsafety  RCT, open label  \n \nTreatment:  \n \nGroup A  \nTMZ alone (n=146)  \n \nGroup B  \nTMZ + s.c. IFN -\nalpha (n=148)  294 patients with \nuntreated stage IV \nmetastatic \nmelanoma   \n \n \nMedian Overall \nSurvival \n \n \n \n \nResponse Rate  \n \n \n \n \n \nDuration of \nResponse  TMZ vs. TMZ + s.c. \nIFN-alpha  \n \n8.4 months (95% CI, \n7.07 to 9.2 7) vs. 9.7 \nmonths (95% CI, \n8.26 to 11.18), n.s., \np=0.16  \n \n13.4% (n=18 of 134 \npatients) vs. 24.1% \n(n=33 of 137 \npatients, sign., \np=0.036  \n \nLonger in Group B  Jadad Score 3  \nunblinded tumor \nassessment by \ninvestigators  \n \nFunding:  \nEssex Pharma \nGmbH (Munich, \nGermany)  1b \nDanson et al. 2003  To determine \nresponse rates, RCT, open label  \n 181 patients   \n TMZ vs. TMZ+IFN \nvs. Jadad Score 2  \ndropouts and 1b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 452 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \noverall survival, and \ntolerability of the \nregimens \ntemoz olomide with \ninterf eron alfa -2b \nand, separately, \nwith thalidomide in \npatients with \nadvanced metasta tic \nmelanoma.  Treatment:  \n \nGroup  A \nTMZ (n=59)  \n \nGroup B  \nTMZ + Interferon \nalfa-2b (n=62)  \n \nGroup C  \nTMZ + Thalidomide  \n(n=60)   \n \nMedian Overall \nSurvival \n \nOverall Response \nRate \n \nResponse duration  TMZ+Thalidomide  \n \n5.3 vs. 7.7 vs. 7.3 \nmonths  \n \n9% vs. 18% vs. 15%  \n \n \nrange 2.4 - 21.2 \nmonths  withdrawals not \ndescribed  \n \nAgarwala et al. \n2002  To determine \nwhether the \naddition of \nhistamine  to a \nsubcutaneousr egim\nen of interle ukin-2 \n(IL-2) would \nimprove the survival \nof metastatic \nmelanoma patie nts RCT, open label  \n \nTreatment:  \n \nGroup A  \nIL-2 plus histamine \n(n=152)  \n \nGroup B  \nIL-2 alone  (n=153)  305 metastatic \nmelanoma patients \nwith or without \nprevious systemic \ntherapy except IL -2  \n \n \nMedian Overall \nSurvival \n \n \n \nOverall Response \nRate \n IL-2 + histamine  vs.  \nIL-2 alone  \n \n272 days (9.1 \nmonths) vs. 245 \ndays (8.2 months), \nn.s., p=0.125  \n \n3% (n=5) vs. 3% \n(n=5), n.s.  Jadad Score 2  \nunblinded tumor \nassessment  \ndropouts and \nwithdrawals not \ndescribed  \n \nFunding:  \nnot declared  1b \nYoung et al. 2001  To evaluate DTIC \n+IFN-alpha in \npatients with RCT, open label  \n \nTreatment:  61 advanced \nmelanoma patients \nwithout pr evious  \n \n DTIC + IFN-alpha  \nVs. DTIC  \n Jadad Sco re 3 \nunblinded tumor \nassessment, small 1b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 453 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \nmeta static \nmelanoma   \nGroup A  \nDTIC +IFN -alpha  \n(n=30)  \n \nGroup B  \nDTIC \n(n=31)  \n DTIC or IFN  \n \n \n Median Overall \nSurvival \n \n \n \n \nSurvival 6 months  \n \nOverall Response \nRate \n \nDuration of \nResponse  4.8 months (95% CI \n2.0-8.0) vs. 7.2 \nmonths (95% CI \n4.4-9.0), n.s., \np=0.70  \n \n40% vs. 58%  \n \n18% (n=4) vs. 23% \n(n=6), n.s., p=0.59  \n \nmedian 212 days \n(95% CI 140 \u2013648) \nvs. median 180 days \n(95% CI 131 \u2013349) sample size  \n \nFunding:  \nCancer Research \nCampaign and \nRoche \nPharmaceut icals \nFalkson et al. 1998  To investigate the \nresponse rate, time \nto treatment fai lure \n(TTF), overall \nsurvival, and \ntoxicity in patients \nwith m etastatic \nmelanoma treated \nwith dacarbazine \nalone, dacarbazine \nplus interferon \n(IFN), dacarbazine RCT, open label  \n \nTreatment:  \n \nGroup A  \nDTIC alone (n=69)  \n \nGroup B (n=68)  \nDTIC + IFN  \n \nGroup C (n=66)  \nDTIC + T MX 271 metastatic \nmelanoma patients \nwith no pnor \nchemotherapy \nexcept for adjuvant \nIFN  \n \n \n \n \nMedian Overall \nSurvival \n \n \n \n \nOverall Response DTIC alone vs. DTIC \n+ IFN vs. DTIC + \nTMX vs. DTIC + IFN \n+ TMX  \n \npooled over the 4 \nGroups: 8.90 \nmonths (95% CI, \n8.08 -10.8), n.s., \np=0.85  \n \n15% vs. 21% vs. 18% Jadad Score 3  \nunblinded tumor \nassessment  \n \n \nFunding:  \nin part by Public \nHealth grants no. \nCA 21692, CA \n23318, CA 07190, \nCA 18663, CA \n16395, CA 66636, 1b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 454 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \nplus tamoxifen \n(TMX), or \ndacarbazine plus \nIFN plus TMX   \nGroup D  \nDTIC + IFN + TMX \n(n=68)  Rate vs. 19% (of 250 \npatients)  and CA 21115 from \nthe National Cancer \nInstitute, National \nInstitutes of Health, \nand the Department \nof Health and \nHuman Services, \nBethesda. MD  \nSparano et al. 1993  To compare the \nresponse rate, \nsurvival, and \ntoxicity of treatment \nwith high -dose \nintrave nous bolu s \ninterle ukin-2 (IL-2) \nplus interf eron alfa -\n2a (IFN-alpha) with \nhigh-dose IL -2 \nalone in patients \nwith advanced \nmelan oma \n RCT, open label  \n \nTreatment:  \n \nGroup A  \nIL-2 + Interf eron \nalfa-2a  \n \nGroup B  \nIL-2 alone  85 patients   \n \n \nMedian Overall \nSurvival \n \nResponse R ate \n \n \n \n \nDuration of \nResponse  IL-2 + IFN alpha  vs. \nIL-2 alone  \n \n9.7 months vs. 10.2 \nmonths, n.s.  \n \n10% (4 of 41 \npatients) vs. 5% (2 \nof 44 patients), n.s., \np=0.30  \n \n11.5 months (ra nge, \n2.0 to 15.7+)  Jadad Score 3  \nunblinded but \nindependently \nreviewed tumor \nasses sment  \n \nFunding:  \nNational Institutes \nof Health, Bethesda, \nMD, contracts no. \nNO1-CM73702, \nNO1-CM73703, \nN01-CM73704, \nNO1-CM73705, \nNO1-CM73706, and \nNO1-CM73707; \nNational Institutes \nof Health Clinical \nResearch Center 1b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 455 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \ngrant no. MOI -\nRR00054 to Tufts \nUniversity Sc hool \nofMedicine; and by \nHoffman La -Roche, \nInc \nThompson et al. \n1993  To assess the \ncombination of \ndacarb azine and \ninterferon -alpha 2a  \nversus d acarbazine \nalone as systemic \ntherapy for \nmetastatic \nmalignant \nmelan oma RCT, open label  \n \nTreatment:  \n \nGroup A  \nDTIC plus IFN a lpha \n2a \n \nGroup B  \nDTIC alone  170 patients   \n \n \nMedian Overall \nSurvival \n \nResponse Rate  \n \n \n \nDuration of \nResponse  DTIC + IFN alpha2a  \nvs. DTIC  \n \n229 vs. 269 days  \n \n \n21% (95% CI 13 -\n31%) vs. 17% (95% \nCI 10 -27%) \n \n258 vs. 286 days   1b \nFalkson et al. 1991  To assess if results \nwith DTIC could be \nimproved by using a \ncombin ation of \nDTIC and IFN alfa -\n2b in metastatic \nmalignant \nmelanoma.  RCT, open label  \n \nTreatment:  \n \nGroup A  \nDTIC plus interf eron \nalfa-2b (n=30)  \n 64 metastatic \nmelanoma p atients  \n \n \nMedian Overall \nSurvival \n \n \nOverall Response DTIC + IFN alfa -2b \nvs. DTIC  \n \n17.6 months vs. 9.6 \nmonths, sign.,  \np < 0.01  \n \n53% (n=16) vs. 20% Jadad Score 2  \nRandomization \nscheme not \ndescribe d, \nunblinded tumor \nassessment, small \nsample size, \nimbalance of groups 1b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 456 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \nGroup B  \nDTIC alone (n=31)  Rate \n \n \nDuration of \nResponse  (n=6), sign., \np=0.007  \n \nNot reported  (more male patients \nin Group B)  \nFunding:  \nIFN alfa -2b was \nsupplied by Scherag \nSouth Africa, \nJohannesburg.  \n \nChemotherapy/Chemosensitizer  \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nBedikian et al. 2011  To compare the \nefficacy and toxic ity \nprofiles of \nDocos ahexaenoic \nacid (DHA) -\npaclitaxel with \nthose of \ndacarb azine RCT, open label  \n \nTreatment:  \nGroup A  \nDHA-paclitaxel, 900 \nmg/m\u00b2 i.v. on day 1 \nevery 3 weeks \n(n=194)  \n \nGroup B  \nDacarb azine, 1000 \nmg/m\u00b2 i.v. on day 1 \nevery 3 weeks \n(n=199)  393 chemonaive \npatients with \nmetastatic \nmelanoma  \n  \n \n \nMedian Overall \nSurvival \n \n \n \n \n \nOverall Response \nrate \n \nDuration of \nResponse  DHA-paclitaxel vs. \nDTIC \n \n267 days (8.8 \nmonths) (95% CI \n220\u2013297) vs. 226  \ndays (7.4months) \n(95% CI 192 \u2013263), \nn.s. \n \n5.2% (n=10) vs. \n5.5% (n=11), n.s.  \n \n134 days (4.4 \nmonths) (95% CI 77 \nto not estimated) Jadad Score 3  \ntumor assessment \nnot d escribed as \nblinded  \n \nFunding:  \nLuitpold \nPharmaceu ticals, \nInc. 1b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 457 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \nvs. not est imated \ndue to censoring \npattern  \nPatel et al. 2011  To compare the \nefficacy of an \nextended schedule \nescalated dose of \ntemozolomide \nversus standard \ndose dacarbazine  RCT, open label  \n \nTreatment:  \n \nGroup A  \noral temozolomide \n150mg/m\u00b2/day for \nseven consecutive \ndays every 2weeks \n(n=429)  \n \nGroup B  \nDacarbazine, i.v. \n1000mg/m\u00b2/day on \nday 1 every 3 weeks \n(n=430)  859 chemotherapy -\nnaive patients   \n \n \nMedian Overall \nSurvival  \n \n \nOverall Response \nRate \n \n \nDuration of \nResponse  TMZ vs. DTIC  \n \n \n9.1 months vs. \n9.4months, n.s. \n(p=1.0)  \n \n14.5% (n=58) \nvs.9.8% (n=38), \np=0.05  \n \n4.6 vs. 11.2 \nmonths, p=0.015, \nsign. Jadad Score 3  \n \ntumor assessment \nwas not blinded  \n \nFunding:  \nSchering Plough, UK \nNational Cancer \nResearch Network  \n 1b \nRanson et al. 2007  To evaluate tumor \nresponse, \npharmacodynamic \neffects, and safet y \nof a combination of \nlomeguatrib (LM), \nan O6 -RCT, open label  \n \nTreatment:  \n \nGroup  A  \nlomeguatrib \n40mg/d, 2h later 104 patients with \nunresectable stage \nIII or IV cutaneous \nmelanoma who had \nno prior systemic \nchemotherapy  \n  \n \n \n \nMedian Overall \nSurvival  \n LM/TMZ vs. TMZ  \n \n \n \n7.6 months (95% CI, \n6.9 - 10.3 months) \nvs. 7.7 months (95% Jadad Score 2  \nRandomization \nscheme not \ndescribed, tumor \nassessm ent not \nblinded  \n 1b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 458 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \nmethylguanine \nDNA-\nmethyltransferase \n(MGMT) inactivator, \nand temozolomide \n(TMZ), TMZ alone, \nand LM/TMZ after \ndisease progression \non TMZ alone in \npatients with \nadvanced melanoma  TMZ 125mg/m2/d, \norally, 5 days every \n4 weeks (n=52)  \n \nGroup B  \nTMZ 125mg/m2/d, \norally, 5 days every \n4 weeks (n=52)   \n \n \nOverall Response \nRate \n CI, 6.3 - 10.7 \nmonths), n.s.  \n \n13.5% (n=7) vs. \n17.3% (n=9), n.s.  \n Funding:  \nKudos \nPharmaceuticals, \nowned by \nAstraZeneca.  \nBedikian et al. 2006  To evaluate whether \ntargeting Bcl -2 \nusing an antisense \noligonucleotide \n(oblimersen sodium) \ncould improve the \nefficacy of systemic \nchemotherapy in \npatients with \nadvanced \nmelanoma.  RCT, open label  \n \nTreatment:  \n \nGroup A  \nOblimersen (7 \nmg/kg/d by \ncontinuous \ni.v.infusion for 5 \ndays) + DTIC \n(n=386)  \n \nGroup B  \nDTIC (n=385)  771 chemotherapy -\nna\u00efve patients   \n \n \nMedian Overall \nSurvival  \n \nPFS \n \n \nOverall Response \nRate \n \nDurableRespo nse Oblimersen + DTIC  \nvs. DTIC  \n \n9.0 v 7.8 months; \np=0.077  \n \n2.6 v 1.6 months; \np=0.001  \n \n13.5% vs. 7.5% \np=0.007  \n \n7.3 vs. 3.6% \np=0.027  Jadad Score 4  \nIndependent \nblinded tumor \nassessment  \n \nFunding: Genta, Inc.  1b \nBafaloukos et al. To evaluate and RCT, open label  132 metastatic  TMZ vs. TMZ + Jadad Score 2  1b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 459 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \n2005  compare t he activity \nand safety profile of \nthe combination \nCisplatin + TMZ \nversus single -agent \nTMZ in patients with \nadvanced melanoma   \nTreatment:  \n \nGroup A  \nTMZ 200 \nmg/m\u00b2/day orally \nd1-5q28 (n=66)  \n \nGroup B  \nTMZ + Cisplatin 200 \nmg/m\u00b2 daily on \ndays 1 -5 and 75 \nmg/m\u00b2 of cisplatin \non day 1 (n=66)  melanoma patients \nwith no previous  \nchemotherapy   \n \nMedian Overall \nSurvival  \n \nOverall Response \nRate \n \n \nDuration of \nResponse  Cisplatin  \n \n11.5 months vs. 12 \nmonths, n.s.  \n \n16 patients (26%) \nvs. 19 patients \n(29%), n.s.  \n \n5.7 months vs. 9.4 \nmonths, n.s., \np=0.35  \n Randomization \nscheme not \ndescribed, tumor \nassessment not \nblinded  \n \nFunding:  \nKudos \nPharmaceuticals, \nowned by \nAstraZeneca.  \nAvril et al. 2004  To compare \nfotemustine and \ndacar bazine (DTIC) \nin patients with \ndisseminated \ncutaneous \nmelanoma.  RCT, open label  \n \nTreatment:  \n \nGroup A  \nFotemustine \n100mg/m\u00b2; weekly, \n3 weeks, (n = 112)  \n \nGroup B  \nDTIC 250 mg/m\u00b2/d; \n5d every 4 weeks, (n \n= 117)  229 patients   \n \n \nMedian Overall \nSurvival  \n \nResponse Rate \n \n \nDuration of \nResponse  Fotemustine vs. \nDTIC \n \n7.3 vs. 5.6 months, \np = 0.067  \n \n13.4% vs. 6.0% (p= \n0.057)  \n \nn.s. difference  Jadad Score 3  \n \nFunding:  \nInstitut de \nRecherches \nInternationales \nServier, Courbevoie, \nFrance  1b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 460 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \nMiddleton et al. \n2000  To compare \ntemo zolomide and \ndacarbazine (DTIC) \nin terms of overall \nsurvival, \nprogression -free \nsurvival (PFS), \nobjective response, \nand safety  RCT, open label  \n \nTreatment:  \n \nGroup A  \nTemozolomide \n(n=156)  \n \nGroup B  \nDTIC (n=149)  305 advanced \nmelanoma patients \nwithout previous \ntreatment for \nmetastatic disease   \n \nMedian Overall \nSurvival  \n \n \n \n \nPFS \n \n \n \nOverall Response \nRate \n \n \nDuration of \nResponse  TMZ vs. DTIC  \n \n7.7 months vs. 6.4 \nmonths, n.s., HR \n1.18 (95% CI, 0.92 \nto 1.52), p=0.20 \n(ITT population)  \n \n1.9 vs. 1.5 months; \nHR 1.37; sign., \np=0.012  \n \n13.5% (21 of 156) \nvs. 12.1% (18 of \n149), n.s.  \n \nlonger in the TMZ \ngroup; 18 of the 21 \nTMZ responders \nsurvived longer than \n12 months vs. 11 of \nthe 18 DTIC \nresponders  Jadad Score 3  \nunblinded tumor \nassessment, \ndifferent time \npoints for \nassessment \nbetwee n groups  \n \nFunding:  \nNot declared  1b \nKeilholz et al. 1997  To determine \nwhether the \naddition of Cisplatin \nto a cytokine RCT, open label  \n \nTreatment:  \n 138 metastatic \nmelanoma patients, \nno pr ior therapy \nwith Cisplatin   \n \n \n IFN alpha + IL -2 vs. \nIFN alpha + IL -2 + \nCisplatin  \n Jadad Score 3  \ntumor assessment \nnot blinded  \n 1b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 461 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \ntreatment regimen \nwith IFN alpha and \nhigh-dose IL -2 \ninfluences survival \nof patients with \nmetastatic \nmelanoma  Group A  \nIFN alpha 10 x 106 \nU/m2 sc. on days 1 \nthrough 5 + IL -2 on \ndays 3 through 8  \n(18 mIU/m2/6 h,  \n18 mIU/m2/12 h,  \n18 mIU/m2/24 h, \nand 4.5 mIU/m2/24 \nh x 3)  \n \nGroup B  \nIFN alpha + IL -2 + \nCisplatin 100 \nmg/m2 on day 1  Median Overall \nSurvival  \n \n \nOverall Response \nRate \n \nDuration of \nResponse  all patients: 9 \nmonths, n.s. \nbetween groups  \n \n18% vs. 33%, sign., \np=0.04  \n \n17 vs. 6 months, \nn.s., p=0.057  Funding:  \nChiron BV, \nAmsterdam, the \nNetherlands and  \nHoffmann -La Roche \nAG, Grenzach, \nGermany  \nJungnelius et al. \n1998  To investigate if the \naddition of Cisplatin \nto the combination \nDTIC and Vindesine \ncould incr ease \nsurvival.  RCT, open label  \n \nTreatment:  \n \nGroup A  \ndacarbazine + \nvindesine + \ncisplatin (DVP) \n(n=161)  \n \nGroup B  \ndacarbazine + 326 metastatic \nmelanoma patients, \nno prior \nchemotherapy   \n \nMedian Overall \nSurvival  \n \n \nOverall Response \nRate \n \nDuration of \nResponse  DVP vs. DV  \n \n7.2 months vs. 5.9 \nmonths, n.s., \np=0.22  \n \n31.4% vs. 21%, n.s.  \n \n \n6.0 months for the \nwhole study \npopulation  Jadad Score 2  \nRandomization \nscheme not \ndescribed, \nunblinded tumor \nassessment  \n \nFunding:  \nNot declared  1b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 462 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \nvindesine (DV) \n(n=165)  \nRingborg et a l. \n1989  To evaluate \ntreatment with \ndacarbazine alone \nor in combination \nwith vindesine in \npatients with \ndisseminated \nmalignant \nmelanoma  \n RCT, open label  \n \nTreatment:  \n \nGroup A  \ndacarbazine + \nvindesine (n=59)  \n \nGroup B  \ndacarbazine alone \n(n=51)  \n 119 patients (11 0 \nevaluable)  \n \n \n  \n \n \n \nMedian Overall \nSurvival  \n \nOverall Response \nRate \n \nDuration of \nResponse  dacarbazine + \nvindesine vs. \ndacarbazine alone  \n \n5.8 months vs. 4.7 \nmonths, n.s.  \n \n25% vs. 18%, n.s., \np>0.20  \n \n171 days vs. 123 \ndays, n.s.  Jadad Score 1  \nNo description of \ndropouts, \nrandomization \nscheme not \ndescribed, \nunblinded tumor \nassessment  \n \nFunding:  \nSwedish Cancer \nSociety and Eli Lilly \nCompany  1b \nChauvergne et al. \n1982  To evaluate the \nefficacy of \ndetorubicin in \ncombination with \nDTIC versus DTIC \nalone  RCT, open label  \n \nTreatment:  \n \nGroup A  \nDTIC (250 mg/m2, \ni.v., over 4 days \nevery three weeks) \n+ detorubicin (120 \nmg/m2, i.v. every \nthree weeks)  51 patient  \n  \n \n \nMedian Overall \nSurvival  \n \nOverall Response \nRate \n \n \nDuration of DTIC + detorubicin \nvs. DTI C alone  \n \n8 months vs. 5 \nmonths, n.s.  \n \n36% (n=8 of 22 \npatients) vs. 15% \n(n=4 of 26), n.s.  \n \n6 months vs. 5 Jadad Score 2  \nRandomization \nscheme not \ndescribed, \nunblinded tumor \nassessment, small \nsample size  \n \nFunding:  \nNot declared  1b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 463 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \n \nGroup B  \nDTIC alone  Response  months,n.s.  \n \n5.2.5.  Literatur  \n \nAgarwala SS, Ferri W, Gooding W, et al. A phase III randomized trial of dacarbazine and carboplatin with and without tamoxifen in  the treatment of patients with metastatic \nmelanoma. Cancer 1999;85:1979 -1984  \nAgarwala SS, Glaspy J, O'Day SJ, et al. Results from a randomized phase III study comparing combined treatment with histamine dihydrochloride plus interleukin -2 versus \ninterleukin -2 alone in patients with metastatic melanoma. J Clin Oncol 2002;20:125 -133 \nAvril MF, Aamdal S, Grob JJ, et al. Fotemustine compar ed with dacarbazine in patients with disseminated malignant melanoma: a phase III study. J Clin Oncol 2004;22:1118 -\n1125  \nBafaloukos D, Tsoutsos D, Kalofonos H, et al. Temozolomide and cisplatin versus temozolomide in patients with advanced melano ma: a rando mized phase II study of the \nHellenic Cooperative Oncology Group. Ann Oncol 2005;16:950 -957 \nBedikian AY, DeConti RC, Conry R, et al. Phase 3 study of docosahexaenoic acid -paclitaxel versus dacarbazine in patients with metastatic malignant melanoma. Ann Onco l \n2011;22:787 -793 \nBedikian AY, Millward M, Pehamberger H, et al. Bcl -2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study \nGroup. J Clin Oncol 2006;24:4738 -4745  \nChapman PB, Hauschild A, Robert C,  et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364:2507 -2516  \nChauvergne J, Bui NB, Cappelaere P, et al. Chemotherapy in advanced malignant melanoma. Results of a controlled trial comparing a combination o f dacarbazine (DTIC) and \ndetorubicin with dacarbazine alone. Sem Hop 1982;58:2697 -2701  \nDanson S, Lorigan P, Arance A, et al. Randomized phase II study of temozolomide given every 8 hours or daily with either interferon alfa -2b or thalidomide in metastatic \nmalignant melanoma. J Clin Oncol 2003;21:2551 -2557  \nDummer R, Garbe C, Thompson JA, et al. Randomized dose -escalation study evaluating peginterferon alfa -2a in patients with metastatic malignant melanoma. J Clin Oncol \n2006;24:1188 -1194  \nEisen T, Trefzer U, H amilton A, et al. Results of a multicenter, randomized, double -blind phase 2/3 study of lenalidomide in the treatment of pretreated relapsed or refractory \nmetastatic malignant melanoma. Cancer 2010;116:146 -154 \nFalkson CI, Falkson G, Falkson HC. Improved re sults with the addition of interferon alfa -2b to dacarbazine in the treatment of patients with metastatic malignant melanoma. J \nClin Oncol 1991;9:1403 -1408  \nFalkson CI, Ibrahim J, Kirkwood JM, et al. Phase III trial of dacarbazine versus dacarbazine with in terferon alpha -2b versus dacarbazine with tamoxifen versus dacarbazine with \ninterferon alpha -2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Group study. J Clin Oncol 1998;16:1743 -1751  \nGlaspy J, Atkins MB, R ichards JM, et al. Results of a multicenter, randomized, double -blind, dose -evaluating phase 2/3 study of lenalidomide in the treatment of metastatic \nmalignant melanoma. Cancer 2009;115:5228 -5236  \nFlaherty KT, Robert C, Hersey P, et al.  Improved survival wi th MEK inhibition in BRAF -mutated melanoma. 2012;  N Engl J Med 367: 107 -114 \nHauschild A, Agarwala SS, Trefzer U, et al. Results of a phase III, randomized, placebo -controlled study of sorafenib in combination with carboplatin and paclitaxel as second -\nline treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol 2009;27:2823 -2830   \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 464 von 732 Hauschild A, Grob JJ, Demidov LV , et al. Dabrafenib in BRAF -mutated metastatic melanoma: a multicentre, open -label, phase 3 randomised controlled trial. Lancet 2012; 380: \n358-365 \nHersey P, McLeod GR, Thomson DB. Treatment of advanced malignant melanoma with recombinant interferon alfa -2a in combination with DTIC: long -term follow -up of two \nphase II studies. Br J Haematol 1991;79 Suppl 1:60 -66 \nHersey P, Sos man J, O'Day S, et al. A randomized phase 2 study of etaracizumab, a monoclonal antibody against integrin alpha(v)beta(3), + or - dacarbazine in patients with \nstage IV metastatic melanoma. Cancer 2010;116:1526 -1534  \nHersh EM, O'Day SJ, Powderly J, et al. A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy -naive patients with advanced melanoma. Invest \nNew Drugs 2011;29:489 -498 \nHodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastat ic melanoma. N Engl J Med 2010;363:711 -723 \nJungnelius U, Ringborg U, Aamdal S, et al. Dacarbazine -vindesine versus dacarbazine -vindesine -cisplatin in disseminated malignant melanoma. A randomised phase III trial. \nEur J Cancer 1998;34:1368 -1374  \nKaufmann R, Spieth K, Leiter U, et al. Temozolomide in combination with interferon -alfa versus temozolomide alone in patients with advanced metastatic melanoma: a \nrandomized, phase III, multicenter study from the Dermatologic Cooperative Oncology Group. J Clin Oncol 2 005;23:9001 -9007  \nKefford RF, Clingan PR, Brady B, et al. A randomized, double -blind, placebo -controlled study of high -dose bosentan in patients with stage IV metastatic melanoma receiving \nfirst-line dacarbazine chemotherapy. Mol Cancer 2010;9:69  \nKeilholz U , Goey SH, Punt CJ, et al. Interferon alfa -2a and interleukin -2 with or without cisplatin in metastatic melanoma: a randomized trial of the European Organization for \nResearch and Treatment of Cancer Melanoma Cooperative Group. J Clin Oncol 1997;15:2579 -2588 \nKim KB, Sosman JA, Fruehauf JP, et al. BEAM: A Randomized Phase II Study Evaluating the Activity of Bevacizumab in Combination With Carboplatin Plus Paclitaxel in P atients \nWith Previously Untreated Advanced Melanoma. J Clin Oncol 2012;30:34 -41 \nKirkwood J M, Bastholt L, Robert C, et al. Phase II, Open -Label, Randomized Trial of the MEK1/2 Inhibitor Selumetinib as Monotherapy versus Temozolomide in Patients with \nAdvanced Melanoma. Clin Cancer Res 2012;18:555 -567 \nKirkwood JM, Lee S, Moschos SJ, et al. Immunog enicity and antitumor effects of vaccination with peptide vaccine+/ -granulocyte -monocyte colony -stimulating factor and/or \nIFN-alpha2b in advanced metastatic melanoma: Eastern Cooperative Oncology Group Phase II Trial E1696. Clin Cancer Res 2009;15:144 3-1451 \nMaio M, Mackiewicz A, Testori A, et al. Large randomized study of thymosin alpha 1, interferon alfa, or both in combination with dacarbazine in patients with metasta tic \nmelanoma. Journal of Clinical Oncology 2010;28:1780 -1787  \nMcDermott DF, Sosman JA, Gon zalez R, et al. Double -blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a \nreport from the 11715 Study Group. J Clin Oncol 2008;26:2178 -2185  \nMiddleton M, Hauschild A, Thomson D, et al. Resul ts of a multicenter randomized study to evaluate the safety and efficacy of combined immunotherapy with interleukin -2, \ninterferon -{alpha}2b and histamine dihydrochloride versus dacarbazine in patients with stage IV melanoma. Ann Oncol 2007;18:1691 -1697  \nMiddleton MR, Grob JJ, Aaronson N, et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of pati ents with advanced metastatic malignant \nmelanoma. J Clin Oncol 2000;18:158 -166 \nO'Day S, Gonzalez R, Lawson D, et al. Phase II, rand omized, controlled, double -blinded trial of weekly elesclomol plus paclitaxel versus paclitaxel alone for stage IV metastatic \nmelanoma. J Clin Oncol 2009;27:5452 -5458  \nO'Day S, Pavlick A, Loquai C, et al. A randomised, phase II study of intetumumab, an anti -alpha(v) -integrin mAb, alone and with dacarbazine in stage IV melanoma. Br J Cancer \n2011  \nPatel PM, Suciu S, Mortier L, et al. Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: Final results of a randomised phase III s tudy \n(EORTC 18032). Eur J Cancer 2011;47:1476 -1483  \nPolyzos A, Legha SS, Burgess AM, et al. Phase II study of AMSA alone and in combination with DTIC in patients with metastatic  melanoma. Invest New Drugs 1988;6:57 -61 \nPresant CA, Bartolucci AA, Balch C, et al. A randomized comparison of cyclophosphamide, DTIC with or without piperazinedione in metastatic malignant melanoma. Cancer \n1982;49:1355 -1357  \nRanson M, Hersey P, Thompson D, et al. Randomized trial of the combination of lomeguatrib and temozolomide comp ared with temozolomide alone in chemotherapy naive \npatients with metastatic cutaneous melanoma. J Clin Oncol 2007;25:2540 -2545  \nReichle A, Vogt T, Coras B, et al. Targeted combined anti -inflammatory and angiostatic therapy in advanced melanoma: a randomized  phase II trial. Melanoma Res \n2007;17:360 -364  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 465 von 732 Ringborg U, Rudenstam CM, Hansson J, et al. Dacarbazine versus dacarbazine -vindesine in disseminated malignant melanoma: a randomized phase II study. Med Oncol Tumor \nPharmacother 1989;6:285 -289 \nRobert C, Thomas  L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011;364:2517 -2526  \nSchadendorf D, Ugurel S, Schuler -Thurner B, et al. Dacarbazine (DTIC) versus vaccination with autologous peptide -pulsed dendr itic cells (DC) in first -line treatment of patients \nwith metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG. Ann Oncol 2006;17:563 -570 \nSchwartzentruber DJ, Lawson DH, Richards JM, et al. Gp100 Peptide Vaccine and Interleuk in-2 in Patients with Advanced Melanoma. N Engl J Med 2011;364:2119 -2127  \nSparano JA, Fisher RI, Sunderland M, et al. Randomized phase III trial of treatment with high -dose interleukin -2 either alone or in combination with interferon alfa -2a in \npatients wit h advanced melanoma. J Clin Oncol 1993;11:1969 -1977  \nTarhini AA, Millward M, Mainwaring P, et al. A phase 2, randomized study of SB -485232, rhIL -18, in patients with previously untreated metastatic melanoma. Cancer \n2009;115:859 -868 \nThomson DB, Adena M, McLe od GR, et al. Interferon -alpha 2a does not improve response or survival when combined with dacarbazine in metastatic malignant melanoma: \nresults of a multi -institutional Australian randomized trial. Melanoma Res 1993;3:133 -138 \nWeber JS, Zarour H, Redman B,  et al. Randomized phase 2/3 trial of CpG oligodeoxynucleotide PF -3512676 alone or with dacarbazine for patients with unresectable stage III \nand IV melanoma. Cancer 2009;115:3944 -3954  \nYoung AM, Marsden J, Goodman A, et al. Prospective randomized comparison  of dacarbazine (DTIC) versus DTIC plus interferon -alpha (IFN -alpha) in metastatic melanoma. Clin \nOncol (R Coll Radiol) 2001;13:458 -465 \n \n \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 466 von 732 5.3. Frage V.4. Biochemotherapie  - Adaptation  \nFrage V.4.  F\u00fchrt die Gabe von Biochemo therapien im metastasierten Stadium z u mehr objektiven Remissionen  / zu einer Verbesserung \ndes Gesamt\u00fcberlebens  ?  \n5.3.1.  Synopse Quellleitlinien  \n LL Austr alien  \nNew Zealand Guidelines \nGroup 2008  LL GB  \nNICE 2006  LL Frankreich  \nFrench National Authority \nfor Health 2005  LL Kanada  \nCancer Care O ntario 2007  \nF\u00fchrt die Gabe von \nBiochemo therapien im \nmetastasierten Stadium zu \nmehr objektiven \nRemissionen?  \n Ja \n \nInterferon -alpha und IL -2 \nverbe ssern Ansprechen von \nMonother apien aber nicht das \nGesamt\u00fcberl eben allein oder in \nKombination mit \nChemother apien. Ja \n \nDacarbazin plus Interferon \nalpha f\u00fchrt zu besserem \nAnsprechr aten, nicht zu einer \nVerl\u00e4ngerung des \nGesamt\u00fcbe rlebens.  \n  \n \nLeitlinie enth\u00e4lt keine \nEmpfe hlungen zu Therapien im \nfernmetastasierten St adium  Ja \nZugrunde li egende Evidenz  level of evidenz II  \n(4 Studie n) Evidenz Review, S.315  \n(1 Metaanalyse)   9 Studien zu \nBiochemotherapien  \n(Standardchemotherpie mit Il -\n2 oder IFN)  \n7 Studien geben A nsprechraten \nan, 2 Studien mit verbessertem \nAnsprechen, 5 Studien kein \nUnterschied, gepoolt: besseres \nAnspr echen \nF\u00fchrt die Gabe von Nein Nein - Nein  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 467 von 732  LL Austr alien  \nNew Zealand Guidelines \nGroup 2008  LL GB  \nNICE 2006  LL Frankreich  \nFrench National Authority \nfor Health 2005  LL Kanada  \nCancer Care O ntario 2007  \nBiochemo therapien im \nmetastasierten Stadium zu \neiner Verbesserung des \nGesamt\u00fcberlebens?  \n  \nInterferon -alpha und IL -2 \nverbe ssern Ansprechen von \nMonother apien aber nicht das \nGesamt\u00fcberl eben allein oder in \nKombination mit \nChemother apien.   \nDurch Verwendung einer \nPolychemotherapie wird das \nGesamt\u00fcbe rleben nicht \nverl\u00e4ngert  \n  \nZugrunde li egende Evidenz  level of evidenz II  \n(4 Studien)  Evidenz Review, S.315  \n(1 Metaanalyse, 1 Review, 1 \nLeitlinie)  9 Studien zu \nBiochemother apien \n(Standardchem otherapie mit Il -\n2 oder IFN).  \nKeine Studie zeigt ein \nverbessertes Gesam t\u00fcberleben  \n5.3.2.  Empfehlung,  Hintergrundstext und Literatur Kanadische Quell Leitlinie  \nQuellleitlinie: Biochemotherapy for the Treatment of Metastatic Malignant Melanoma: A Clinical Practice  Guideline (Cancer Care Ontario) \n2007  \nQuestion: What is the role of biochemotherapy in the treatment of metastatic malignant melanoma?  \nFor the purposes of this report, \"biochemotherapy\" is defined as a therapeutic regimen that includes, at a minimum, chem otherapy \n(either single agent or combination) and interleukin -2. Outcomes of interest include response rate, disease -free survival, overall \nsurvival, quality of life, and incidence of grade 3 and 4 toxicities.  \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 468 von 732 Recommendation  \nDue to the inconsistent result s of the available studies with regard to benefit (response, time -to-progression, and survival) and \nconsistently high toxicity rates, biochemotherapy is not recommended for the treatment of metastatic melanoma.  \nKey Evidence  \nNine randomized controlled tria ls of biochemotherapy for patients with metastatic malignant melanoma were eligible for inclusion in this \nsystematic review of the evidence. Six randomized controlled trials compared chemotherapy alone to chemotherapy combined with  \ninterleukin -2 and interf eron, two randomized trials compared a combination of chemotherapy and interferon with chemotherapy \ncombined with interleukin -2 and interferon, and one trial compared inte rferon and interleukin -2 with versus without chemotherapy.  \nSeven of the nine trials reporting on response rate outcomes provided statistical comparisons. Only two trials reported statistically \nsignificant response rates favouring treatment with biochemotherapy, while five trials failed to detect any significant diffe rences. None of \nthe ni ne trials detected a statist ically significant survival improvement with biochemotherapy.  \nWhen data were pooled, biochemotherapy was superior to chemotherapy in terms of better response (relative risk, 1.52; 95% con fidence \ninterval, 1.24 to 1.87; p<0.0001)  and delayed progression at six months (relative risk, 0.85; 95% confidence interval, 0.75 to 0.96; \np=0.008) but not decreased morta lity at 12 months (relative risk, 0.98; 95% confidence interval, 0.84 to 1.16; p=0.85).  \nBiochemotherapy is a toxic therapy,  and patients are likely to e xperience serious hematologic, gastrointestinal, cutaneous, and \nconstitutional toxicities. In addition, there are risks of cardiovascular toxicities such as myocardial events and arrhyt hmias, hypotension, \ncapillary leak syndrom e, hepatotoxicity, and renal toxicity. When conducted in the correct setting, grade 3 and 4 toxicities appear to be \nmanageable, and treatment -related death can be min imized.  \n \n \n \n \n \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 469 von 732 Literatur : \n4. Atkins MB, Lee S, Flaherty LE, Sosman JA, Sondak VK, Kirkwood JM. A prospective randomized phase III trial of concurrent biochemotherapy (BCT) with ci splatin, vinblastine, \ndacarbazine (CVD), IL -2 and interferon alpha -2b (IFN) versus CVD alone in patients with metastatic melanoma (E3695): An ECOG -coordinated intergrou p trial [abstract]. Proc \nAm Soc Clin Oncol 2003;22:A2847.  \n6. Atzpodien J, Neuber K, Kamanabrou D, et al. Combination chemotherapy with or without s.c. IL -2 and IFN -alpha: results of a prospectively randomized trial of the \nCooperative Advanced Malignant Mel anoma Chemoimmunotherapy Group (ACIMM). Br J Cancer 2002;86:179 -184 \n5. Bajetta E, Del Vecchio M, Nova P, et al. Multicenter phase III randomized trial of polychemotherapy (CVD regimen) versus the same chemotherapy (CT) plus subcutaneous \ninterleukin -2 and i nterferon -alpha2b in metastatic melanoma. Ann Oncol 2006;17:571 -577 \n8. Eton O, Legha SS, Bedikian AY, et al. Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial. J Clin Oncol \n2002;20:2045 -2052  \n11. Hauschild A, Garbe C, Stolz W, et al. Dacarbazine and interferon alpha with or without interleukin 2 in metastatic melanoma: a randomized phase III multicentre tri al of the \nDermatologic Cooperative Oncology Group (DeCOG). Br J Cancer 2001;84:1036 -1042  \n12. Keilholz U, Goey SH, Punt CJ, et al. Interferon alfa -2a and interleukin -2 with or without cisplatin in metastatic melanoma: a randomized trial of the European Organization \nfor Research and Treatment of Cancer Melanoma Cooperative Group. J Clin Oncol 199 7;15:2579 -2588  \n10. Keilholz U, Punt CJ, Gore M, et al. Dacarbazine, cisplatin, and interferon -alfa-2b with or without interleukin -2 in metastatic melanoma: a randomized phase III trial (18951) \nof the European Organisation for Research and Treatment of Canc er Melanoma Group. J Clin Oncol 2005;23:6747 -6755  \n7. Ridolfi R, Chiarion -Sileni V, Guida M, et al. Cisplatin, dacarbazine with or without subcutaneous interleukin -2, and interferon alpha -2b in advanced melanoma outpatients: \nresults from an Italian multicen ter phase III randomized clinical trial. J Clin Oncol 2002;20:1600 -1607  \n9. Rosenberg SA, Yang JC, Schwartzentruber DJ, et al. Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, \ndacarbazine,  and tamoxifen alone or in combination with interleukin -2 and interferon alfa -2b. J Clin Oncol 1999;17:968 -975 \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 470 von 732 5.4.  Frage V.5. Polychemotherapie \u2013 De novo Recherche  \nFrage V. 5. F\u00fchrt die Gabe von Polychemo therapien im metastasierten Stadium zu mehr objektiven  Remissionen  / zu einer Verbesserung \ndes Gesamt\u00fcberlebens als die Gabe von Dacarbazin?  \n5.4.1.  PICO, Suchw\u00f6rter  \nPICO \u2013 Schema  \nPopulation  Intervention  Comparison  Outcome  \nAdvanced melanoma patients stage IV, \nunresectable stage III  Polychemotherapy  DTIC Response, Overall Survival  \n \nSuchw\u00f6rter  \nStichwort  melanoma  review  Chemotherapy  Stage IV  \nStage 4  \nSynonyme     palliative  \nOber -/Unterbegriffe    Systemic thera py Salvage  \nmetastatic  \nMesh Term  melanoma  Review [Publication Type]  Drug Therapy   \n \n \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 471 von 732 5.4.2.  Datenbanken, Suchstra tegien, Trefferzahlen  \nDatenbank  Suchstrategie  Datum  Treffer \nMedline  (melanoma[tiab] OR melanoma[MeSH]) AND  \n(review [ti] AND system*[ti]) AND (\u201csystemic therapy\u201d[tiab] OR \nchemotherapy[tiab] OR \"drug therapy\"[MeSH] OR metastatic[tiab] OR \npalliative[tiab] O R disseminated[tiab] OR advanced[tiab] OR \"stage IV\"[tiab] \nOR \"stage 4\"[tiab] OR sa lvage[tiab])  05.12.2011  27  \n(Auswahl 2 \nReviews)  \nUpdate Suche     \nMedline  s.o. 07.02.2012  28 (0 dazu)  \nCochrane Library  (melanoma and (random* or phase 3) and (systemic ther apy or \nchemotherapy or  \nmetastatic or palliative or advanced or salvage)).ti,ab. and (review).ti.  07.02.2012  14  \n(Auswahl 3 \nReviews)  \n \n5.4.3.  Auswahlkriterien  \nAuswahl der Literatur  \nGesamttreffer  69 \nEinschlusskriterien  Systematische Reviews zur medikament\u00f6se n Systemtherapie bei Melanompatienten im Stadium IV, nicht resektables \nSt. III, die Studien zu Kombinationschemotherapien versus DTIC enthalten  \nAusschlusskriterien  Nicht systematische Reviews, RCTs, Kohortenstudien, Case Reports,  \nDosisfindungsstudie  \nKolle ktive mit gemischten Tumorentit \u00e4ten \nAnzahl nach Abstractscreening, vorges ehen f\u00fcr Bewertung  5 \nAnzahl ausgew\u00e4hlter Volltexte  4  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 472 von 732 5.4.4.  Evidenztabelle  \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nEigentler et al. 2003  To investigate rates \nof response t o \nvarious treatment \nmodalities and the \noutcome for the \nmelanoma patients  Systematic Review  41 RCTs, p atients \nwith meta static \nmelanoma  \n7 RCTs \nPolychem otherapy \nvs. DTIC included  \nChiarion Sileni et al. 2001  \nChapman et al. 1999  \nRingborg et al. 1989  \nLuikart et al. 1984  \nChauvergne et al. 1982  \nCarter et al. 1976  \nMoon et al. 1975   \n \n \n \n \nResponse Rate  \n \nOverall Survival  DTIC vs. \nPolychem otherapy \n(without IFN), 7 \nRCTs  \n \nbenefit  \n \nNo difference  quality asses sment \nof studies reported  \nSearch terms and \ndatabases not \nmentioned  1a \nHuncharek et al. \n2001  To report the \nresults of a meta -\nanalysis comparing \nthe response rates \nof DTIC as single \nagent therapy for \nmetastatic \nmelanoma with \ncomb ination \nchemother apy Systematic Review  \n \nTreatment:  \nDTIC versus \nCombination \ntherapies  \n 20 RCT s, 3273 \npatients with \nmetastatic \nmelanoma  \n  \n \n \n \n \nResponse Rate  \n \n \nOverall Survival  DTIC versus \nCombination \ntherapies (without \nIFN) 10 RCT\u00b4s  \n \nOR 1.33 (95% CI \n0.99-1.78)  \n \nNo difference  Literature search \nreported  \nno quality \nasses sment of \nstudies  1a \n \n \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 473 von 732 Ausgesch lossene Studien  \nStudy  Aims  Design  Population  Outcomes  Results  Comments  L\no\nE \nGarbe et al. 2011  To present the \nsuccess of current \ntreatments and the \npromise  \nof those still in \nclinical development \nthat may yield  \nincremental \nimprovements in \nthe treatment of \nadvanced, \nmetastatic \nmelanoma  Systematic Review  \n \nTreatment:  \nAdjuvant and \npalliative treatment  \n RCTs Adjuvant and \npalliative treatment  \n \nNo RCTs for \nPolychemotherapy \nvs. DTIC included    No RCTs for \nPolychemotherapy \nvs. DTIC included \uf0e0 \nstudy excluded   \nSasse et  al. 2009  To compare the \neffects of \nchem otherapy alone \nversus combined \ntherapy with \nchemoth erapy and \nimmun otherapy \n(chemoimmunoth er\napy) in people with \nmeta static Systematic Review  \n \nTreatment:  \nChemotherapy \nversus \nChemoimmun othera\npy \n 18 RCTs, 2625 \npatients with \nmeta static \nmelanoma  1 year Survival  \n \n \n \nResponse Rates  \n n.s. \nRR  1.06 (95% CI \n0.91 -1.24) p = \n0.48 \n \nsign. diffe rence \nin favor of \nchemoimmunothera\npy  \nRR  1.40 (95% CI No RCTs for \nPolychemotherapy \nvs. DTIC inclu ded \uf0e0 \nstudy excluded    \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 474 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  L\no\nE \nmalignant \nmelanoma.  1.20 -1.63), p < \n0.0001  \nCrosby et al. 2009  To review the \nbenefits from the \nuse of systemic \ntherapies in \nmetastatic \ncutaneous \nmelanoma \ncompared to best \nsupportive \ncare/placebo, and \nto establish whether \na 'standard' therapy \nexists which is \nsuperior to other \ntreatments  Systematic Review  \n \nTreatment:  \nSystemic therapies \nversus best \nsupportive \ncare/placebo  0 RCTs  Overall survival  \nMedian survival  \nProgression free \nsurvival  \n \n No RCTs were \nretrieved, so no \nanalysis of the \neffects of the \ninterventions  \nwas carried out.  No RCTs for \nPolychemotherapy \nvs. DTIC included \uf0e0 \nstudy excluded   \n \n5.4.5.  Literatur  \nCarter RD, Krementz ET, Hill GJ,2nd, et al. DTIC (nsc -45388) and combination therapy for melanoma. I. Studies with DTIC, BCNU (NSC -409962), CCNU (NSC -79037), vincristine \n(NSC-6757 4), and hydroxyurea (NSC -32065). Cancer Treat Rep 1976;60:601 -609 \nChapman PB, Einhorn LH, Meyers ML, et al. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin \nOncol 1999;17:2745 -2751 \nChauvergne J, Bui NB, Cappelaere P, et al. Chemotherapy in advanced malignant melanoma. Results of a controlled trial comparing a combination of dacarbazine (DTIC) and \ndetorubicin with dacarbazine alone. Sem Hop 1982;58:2697 -2701   \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 475 von 732 Chiarion Sileni V, Nor tilli R, Aversa SM, et al. Phase II randomized study of dacarbazine, carmustine, cisplatin and tamoxifen versus dacarbazine alone in advanced melanoma \npatients. Melanoma Res 2001;11:189 -196 \nCrosby T, Fish R, Coles B, et al. Systemic treatments for metastat ic cutaneous melanoma. Cochrane Database of Systematic Reviews 2009;1  \nEigentler TK, Caroli UM, Radny P, et al. Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials. Lancet Oncol 2003;4:748 -\n759 \nGarbe C,  Eigentler TK, Keilholz U, et al. Systematic review of medical treatment in melanoma: current status and future prospects. Oncologist 2011;16:5 -24 \nHuncharek M, Caubet JF, McGarry R. Single -agent DTIC versus combination chemotherapy with or without immunoth erapy in metastatic melanoma: a meta -analysis of 3273 \npatients from 20 randomized trials. Melanoma Res 2001;11:75 -81 \nLuikart SD, Kennealey GT, Kirkwood JM. Randomized phase III trial of vinblastine, bleomycin, and cis -dichlorodiammine -platinum versus dacar bazine in malignant melanoma. J \nClin Oncol 1984;2:164 -168 \nMoon JH, Gailani S, Cooper MR, et al. Comparison of the combination of 1,3 -bis(2 -chloroethyl) -1-nitrosourea (BCNU) and vincristine with two dose schedules of 5 -(3,3-\ndimethyl -1-triazino) imidazole 4 -carboxamide (DTIC) in the treatment of disseminated malignant melanoma. Cancer 1975;35:368 -371 \nRingborg U, Rudenstam CM, Hansson J, et al. Dacarbazine versus dacarbazine -vindesine in disseminated malignant melanoma: a randomized phase II study. Med Oncol T umor \nPharmacother 1989;6:285 -289 \nSasse AD, Sasse EC, Clark GOL, et al. Chemoimmunotherapy versus chemotherapy for metastatic malignant melanoma. Cochrane Database of Systematic Reviews 2011;1  \n \n \n \n \n \n \n \n \n \n \n \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 476 von 732 5.5. Frage V.7. Lebermetastasen \u2013 De novo Recherche  \nFrage V.7.  Welche medikament\u00f6sen Ther apien k\u00f6nnen bei Lebermetastasierung empfohlen werden?  \n \n5.5.1.  PICO, Suchw\u00f6rter  \nPICO \u2013 Schema  \nPopulation  Intervention  Comparison  Outcome  \nMelanoma patients with liver \nmetastases  Local therapies, specific therapies  Standard chemo therapy  Response, Overall Survival  \n \nSuchw\u00f6rter  \nStichwort  melanoma  liver metast asis/metastases  treatment   chemoembolizatio n, perfusion , \nTACE, i mmunoembolization, \nIHP, HAI, resection, surgery , \n\u201eradiofrequency ablation\u201c , RFA, \nradioembolization , \nbrachythera py \nSynonyme   hepatic metast asis/metastases  therapy   \nOber -/Unterbegriffe      \nMesh Term  melanoma     \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 477 von 732 5.5.2.  Datenbanken, Suchstrategien, Trefferzahlen  \nDatenbank  Suchstrategie  Datum  Treffer \n1. Suche     \nMedline  (\u201cmelanoma\u201d[tiab] OR \u201cmelanoma\u201d[MeSH]) AND ((liver [tiab] AND metastas*[tiab]) OR \n(hepatic[tiab] AND metastas*[tiab])) AND (treatment[tiab] OR therapy[tiab] OR \n\u201cchemoembolization\u201c[tiab] OR TACE[tiab] OR immunoembolization[tiab] OR IHP[tiab] OR \nHAI[tiab] OR perfusion[tiab] OR resection[tiab] OR surgery[tiab ] OR \u201cradiofrequency \nablation\u201d[tiab] OR RFA[tiab] OR radioembolization[tiab] OR brachytherapy[tiab])  18.01.11  722 \nEmbase  (melanoma and (liver or hepatic) and (treatment or therapy or chemoembolization or TACE or \nimmunoembolization or IHP or HAI or perfusi on or resection or  surgery or r adiofrequency \nablation or RFA or radioembolization or brachytherapy)). ti,ab.  11.05.11  1579  \nCochrane Library  (melanoma and (liver or hepatic) and (treatment or therapy or chemoembolization or TACE or \nimmunoembolization or I HP or HAI or perfusion or resection or  surgery or r adiofrequency \nablation or RFA or radioembolization or brachytherapy)). ti,ab.  21.07.11  35  \nUpdate Suche     \nMedline  s.o. 30.01.12  792 ( 3 dazu : \nHeusner  et al. \n2011 , Farolfi  et \nal. 2011 , \nGonsalves  et al. \n2011 ) \nEmbase  s.o. 23.01.12  1691 (0 dazu)  \nCochrane Library  s.o. 30.01.12  37 (0 dazu)  \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 478 von 732 5.5.3.  Auswahlkriterien  \nAuswahl der Literatur  \nGesamttreffer  2520  \nEinschlusskriterien  Studien zur medikament\u00f6sen Therapie von Lebermetastasen bei Melanompatienten  \nMangels RCT s: Einschluss von Phase I/II Studien, Fallserien ab 10 Patienten  \nMangels ausreichender Daten zu Lebermetastasen kutaner Melanome, Einschluss von Studien mit Lebermetastasen \nuvealer Melanome  \nSprachen: e,dt  \nAusschlusskriterien  Case Reports  \nNicht systematisc he Reviews  \nStudien zu Lebermetastasen anderer Tumorentit\u00e4ten  \nAnzahl Volltexte  36 \nAusgeschlossene Studien  6 \nAusgew\u00e4hlte Studien  30 \nDie ausgew\u00e4hlten Arbeiten wurden wie folgt zusammengefasst:  \n- Resektion  \n- Isolierte hepatische Perfusion (IHP)  \n- Hepatische art erielle Infusion (HAI)  \n- Hepatische arterielle Chemoembolisation (HACE) / Trans -arterielle Chemoembolisation (TACE)  \n- Radioembolisation (selektive interne Radio -Therapie \u2013 SIRT)  \n \n \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 479 von 732 5.5.4.  Evidenztabelle  \n \nResektion  \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nCaralt et al. 2010  To analyze the \noutcome of pat ients \nundergoing hep atic \nresection for \nmelanoma liver \nmeta stases.  Case Series  \n \nTreamtent:  \nLiver resection  14 patients  \nOcular melanoma \nn=6 \nCutaneous \nmelanoma n=8  Recurrence  \n \n \n \nSurvival  liver recu rrence \n46.2%  \nsystemic recurrence \n76.9%  \n1- and 3 -year \nsurvivals: 77 and \n49% Small series  4 \nFrenkel et al. 2009  To evaluate the \nposthepatectomy \nsurvival of uveal \nmelanoma patients \nwith liver \nmetasta ses. Retrospective \ncohort study  \n \nTreamtent:  \n\u2010 Liver resection  \n\u2010 No liver resection  74 uveal melan oma \npatients with \nmetastases  \n \noperated patients  \nn=35  \nnon\u2010operated \npatients n=39  Survival  median survival \noperated patients: \n23 months (95% CI: \n13.3 \u2013 41.3) \nnon\u2010operated \npatients:  \n6.8 (95% CI: 3.6 \u2013 \n12.5)  No cutaneous \nmelanoma patients \nRisk of selection \nbias Although \nsimilar demographic \nand ocular \nchara cteristics \nbetween the groups \nare me ntioned, no \nbaseline data are \npresented.  4* \n \nPoor qualitiy \ncohort study  \nMariani et al. 2009  To review the \nsurgical \nmana gement of \nliver metastases \nfrom uveal Retrospective \nevaluation  \n \nTreamtent:  \n\u2010 Surgery  798 uveal \nmelan oma patients \nwith liver metastase  \n \nsurgical resection  Survival  \n \n \n \n median overall   \npostoperative \nsurvival    \nAll patients n=255:   \n14 months  No cutaneous   \nmelanoma patients   \nMultivariate anal ysis \nincluded    \nLack of control   4  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 480 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \nmelanoma in a \nsingle institution \nwith regard to \nsurvival and the \ndetermin ation of \npredictive factors \nfor the o ptimal \nsurgical cand idate  n= 255   \n \n \n \n \n \n \nPredictive factors  R0 resection n=76:   \n27 months  \nR1 rese ction n=22:   \n17 month  \nR2 resection   \nn=157: 11 months  \n \n4 variables \nindependently \ncorrelate   with \nprolonged survival:    \ninterval from \nprimary diagnosis \nto liver   m etastases \n>24 months  \ncompr ehensiveness   \nof surgical resection   \n(R0) \nnumber of \nmetastases r esected \n(< or  =   4)  \nabsence of  ffect s   \ndisease  group  \nWoon et al. 2008  To assess the \nsurvival of \nmelanoma patients \nwith hepa tic Retrospective \nevaluation  \n \nTreatment:  15 patients with \nhepatic melanoma \nmetastases, 9 \npatients suitable for Survival  Median survival for \nall patients: 7 \nmonths.  \nCurative su rgical Small series  4  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 481 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \nmetastases who \nunderwent surgery  Lobectomy  \nCryoth erapy  surgical  \n  ffect s tion group: 22 months  \npalliat ive group: 6 \nmonths.   \nHerman et al. 2007  To evaluate the \nexperience of liver \nresection for \npatients with \nmeta static \nmelanoma  Case Series  \n \nTreatment:  \nLiver resection  18 patients with \nmetastatic \nmelanoma, 10 were \noperated  \n \nOcular melanoma \nn=5 \nCutaneous \nmelanoma n=5 Survival  Overall median \nsurvival: 22 months  \n \nCutaneous \nmelanoma n=5 \n(Follow up 46 \nmonths):  \n3 dead, 1 alive, \ndisease free, 1 alive, \nrecurrent disease  Small series  4 \nPawlik et al. 2006  To evaluate the \nefficacy of hepatic \nresection in patients \nwith metas tatic \nocular versus \ncutaneous \nmelanoma and to \nassess add itional \nfactors that may \naffect survival after \nresection of \nmelanoma \nmeta static to the Retrospective \nevaluation  \n \nTreatment:  \nLiver resection  40 patients with \nhepatic melanoma \nmetastasis \nunde rwent resection \nat 4 major \nhepatobiliary \ncenters  \n \nOcular m elanoma  \nn=16  \n \nCutaneous \nmelanoma n=24   \n \nRecurrence  \n \n \nMedian time to \nrecurrence  \n \n \nSurvival  Cutaneous \nmelanoma N=24  \nTumor recurre nce \nn=18 (75.0%)  \n \nMedian time to \nrecurrence:  \n4.7 months  \n \nMedian Survival:  \n23.6 months  \n \n2\u2010year\u2010survival rate: 17 of 24 patients \nwith cutaneous \nmelanoma received \nsystemic therapy  4  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 482 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \nliver.  20.5%  \n \n5\u2010year\u2010survival rate: \n0% \nRose et al. 2001  To identify patients \ntreated by surgical \nresection for \nmeta static \nmelanoma to the \nliver and to \ndetermine if any \nfactors would be \nuseful for \nidentifying p atients \nwho should be \ntreated with surgery  Retrospective \nevaluation  \n \nTreatment:  \nLiver resection  1750 patients with \nhepatic metastase s  \n \nsurgery n=34  \n \nextensive \nintraa bdominal \ndisease identified at \nexploratory \ncelioto my, no \nresection n=10  \n \ncurative resection \nn=18 (75%)  \n \npalliative debulking \nn=6 (25%)  median disease -free \nsurvival (DFS)  \n \nOverall su rvival (OS)  Median DFS  \n12 months  \n \nMedian OS 28 \nmonths  \n \n5\u2010year DFS and OS: \n12% and 29%.  \n \nMacroscopically, \ncomplete r esection \nof disease (P =.001) \nand histolo gically \nnegative r esection \nmargins (P =.03) \nsignificantly \nimproved DFS by \nunivariate analysis  Uveal or cutaneous \norigin not \nmentioned  4 \nSalmon et al. 1998  To present the \npreliminary results \nof the therapeutic \napproach of Prospective study  \n \nTreatment:  \nsurgical approach 75 uveal melanoma \npatients with liver \nmetastases  Survival  Median overall \nsurvival \nall patients: 9 \nmonths.  No cutaneous \nmelanoma patients \nCombined \ntreatment  4  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 483 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \nlaparotomy with \nhepatic resection \n(whene ver possible), \nimpla ntation of an \nintraa rterial catheter \nand intraarterial \nchemoth erapy \n(IACH).  remov ing as much \nliver disease as \npossible and \nintraarterial \nchemoth erapy for 6 \nmonths   Surgery plus \nchem otherapy \n(n=61): 10 months  \ncurative resection \n(n=1 9): 22 months  Lack of control \ngroup  \n \nIsolierte hepatische Perfusion (IHP)  \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nHeusner et al. 2011  To assess the \noverall survival time \nof patients suffering \nfrom metastasized  \nuveal melanoma \nundergoing \nconventional \ntransa rterial hepatic \nchemope rfusion \nusing me lphalan  Case series  \n 61 uveal melanoma \npatients with liver \nmetastases   \n \nResponse  \n \n \n \nSurvival  Response after first \nsession (N=61)  \nPR n=5 (8%)  \nSD n=29 (49%)  \nPD n=26 (43%)  \n \nMedian OS  \n10 months  Lack of control  \ngroup  \n 4 \nRizell et al. 2008  To analyze the \noutcome of three \ntreatment strat egies \nusing isolated Case series  \n \nTreatment:  \nIHP with 27 melanoma \npatients with live r \nmetastases  \n Response  \n \n \n Response (N=27):  \nCR n=2  \nPR n=17  \nSD n=2  Lack of control  \ngroup  \n 4  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 484 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \nhyperthermic liver \nperfusion (IHP) with \nmelphalan for liver \nmetastases of \nmalignant \nmelanoma  modific ations \nduring 3 different \ntime p eriods (IHP I, \nIHP II and IHP III), in \ntechnique and \ntemperature \n(amount of \nmelph alan: 0.5, 1.0 \nand 2 mg/kg body \nweight in the \nperfusate; 41, 40 \nand 40\u00b0C)   Ocular melanoma  \nn=20  \nCutaneous \nmelanoma n=5  \nAnal melanoma n=2   \n \nMortality  \n \nSurvival  Overall response \nrate 70%  \nPostoperative \nmortality n=6  \nMedian Survival: 7.5 \nmonths (range 0 \u2010 \n57), postopera tive \ndeaths excluded: \n12.6 months (range \n2.5\u201057 months)  \nAlexander et al. \n2003  To evaluate isol ated \nhepatic perf usion \n(IHP) for patients \nwith unresectable \nliver m etastases \nfrom ocular \nmelanoma  Case series  \n \nTreatment:  \n60-min \nhyperth ermic IHP \nusing 1.5 mg/kg of \nmelphalan  29 patients with \nunresectable liver \nmetastases from \nocular melanoma  Response  \n \n \n \nProgression -free \nsurvival (PFS)  \n \nOverall Survival (OS)  \n \n \nToxicity  Response (N=29)  \nCR n=3 (10%)  \nPR n=15 (52%)  \n \nMedian PFS: 8 \nmonths  \n \nmedia n OS: 12.1 \nmonths  \n \nGrade 3 or greater \nhepatic toxicity \n(reversible) n=19 \n(65%)  No cutaneous \nmelanoma patients  4 \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 485 von 732 Hepatische arterielle Infusion (HAI)  \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nFarolfi et al. 2011  To investigate direct \nhepatic intra -\narterial \nchemoth erapy of \nfotemustine or \ncarboplatin in \nmelanoma patients \nwith liver \nmetasta ses Case Series  \n \nTreatment:  \nHai, \nFotemustine, \nCarboplatin  23 melanoma \npatients with \nunresectable liver \nmetastases  \n78% uvea melan oma  Response  \n \n PR n=3 ( 16.7%)  \nSD n=4 (22.2%)  \nPD n=11 (61.1%)  - 4 \nMelichar et al. 2009  To evaluate hepatic \narterial infusion of \nthe combination of \ncisplatin, vinblastine \nand dacarbazine in \npatients with liver \nmetastases of uveal \nmelanoma.  Case Series  \n \nTreatment:  \nhepatic arterial  \ninfusion (HAI) of the \ncombination of \ncisplatin, vinblastine \nand dacarbazine  \n 10 patients with \nhepatic metastases \nof uveal melan oma Response  \n \n \n \nSurvival  Response (n=10)  \nPR n=2  \nSD n=4  \nPD n=4  \nMedian survival 16  \nmonths (range 5  \u2010 \n69) Small series  4 \nSiegel e t al. 2007  To compare the \neffectiveness of \nhepatic arterial \nFotemustine \ninfusion between \nliver m etastases \nfrom ocular and Retrospective \nevaluation  \n 36 patients with \nhepatic metastases \nfrom ocular or \ncutaneous \nmelanoma, 30 \npatients wer e \ntreated   \n \n \nResponse  \n \n \nSurvival  cutaneous \nmelan oma patients \n(N=12)  \nPR n=4 (33%)  \nSD n=4 (33%)  \nPD n=4 (33%)  \nMedian survival: 12  4  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 486 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \ncutaneous \nmelanoma.  \n  \nOcular melanoma  \nn=18  \nCutaneous \nmelanoma n=12   \nToxicity  months.  \nToxicity (all p atients \nN=30) grade III\u2010IV \nthrom -bocytop enia: \n30% grade III\u2010IV \nneutropenia: 7% \nnausea/vomiting:  \n17% (max. gr. I\u2010II)  \nabdominal pain 7% \n(max. gr. I\u2010II)  \nPeters et al. 2006  To investigate the \nuse of fot emustine \nvia direct intra -\narterial hepatic \n(i.a.h.) \nadministration i n \npatients with uveal \nmelanoma \nmetastases  Retrospective \nevaluation  \n \nTreatment: \nfotemustine, \nadmini stered intra -\narterially weekly for \na 4-week i nduction \nperiod, and then as \na mai ntenance \ntreatment every 3 \nweeks  101 uveal \nmelan omapatients \nfrom 7 centers with  \nliver m etastases  Response  \n \n \n \n \nSurvival  CR n=15 (15%)  \nPR n=21 (21%)  \nSD n=48 (48%)  \nPD n=17 (17%)  \n \nMedian overall \nsurvival: 15 months  \n(95% CI: 12.1 \u201017.6)  \n1\u2010year survival rate  \n67%, 3\u2010 year survi val \nrate 12%  No cutaneous  \nmelanoma patients  \n \n 4 \nAgarwala et al. \n2004  To evaluate the \naddition of \nembol ization to \nchemoth erapy and Phase I/II trial  \n \nescalating doses \nofintrahepatic 19 patients with \nocular melanoma \nand liver metast ases Toxicity  \n \n \n Toxicity:  \nGrade 3 n=7  \nGrade 4 n=9  \n No cutaneous \nmelanoma patients  \n 4  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 487 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \nto dete rmine the \nrole of escalation of \nintrahepaticarterial \ncisplatin dose, \neither alone or as \npart of \nchemoemboliz ation. chemotherapywithci\nsplatin with \norwithout \npolyvinyl sponge \n(PVS)  Response  PR n=3 (16%)  \nSD n=13 (68%)  \nPD n=1 (5%)  \nNot evaluable n=2  \n(11%)  \nBecker et al. 2002  To evaluate the \nactivity of \nseque ntial \nfotemustine, \ninterferon alpha, \nand i nterleukin 2 for \nmetastatic uvea \nmelanoma \npatien tsin a \nprospectiv ephase II \ntrial. Phase I/II study  \n \nTreatment:  \nFotemustine \n100mg/m\u00b2 via \nhepatic artery or i.v. \nfollowed by s.c. IL\u20102 \non day 31 and s.c. \ninterferonalpha o n \nday 36  48 pat ients with \nmetastatic ocular \nmelanoma  Response  \n \n \n \n \n \n \n \nSurvival  \n CR n=1 (2%)  \nPR n=6 (12.5%)  \nSD n=18 (37.5%)  \n \nIntraarterial versus \ni.v. fotemustin  \nResponses  \n21.7% vs 8%  \nOverall survival  \n369 vs 349 days  No cutaneous \nmelanoma p atients  \nStudy stratifi ed \naccording to \npresence or a bsence \nof extrahepatic \nmeta stases,resultin\ng in different \nprogno stic factors \nbetween th e groups.  4 \nLeyvraz et al. 1997  To evaluate the \neffectiveness and \ntoxicity of hepatic \nintraarterial \nfotemustine when \nadministered \nthrough the hepatic \narterial route in the Phase II study  \n \nTreatment:  \n intraarterial \nfotemustine 100 \nmg/m2  \n(4 hour infusion)  31 patients with \nliver metastases \nfrom ocular \nmelanoma  Response  \n \n \n \n \n \n \n Response liver \nmetastases (30 \npatients asses sable) \nCR n=4 (13%)  \nPR n=8 (27%)  \nMinor Response  \nn=2 \nSD n=13  No cutaneous \nmelanoma patients  \n \nNo overall response  \ndata 4  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 488 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \ntreatment of liver \nmeta stases from \nocular melanoma   \nSuvival  \n PD n=3  \nMedian overall \nsurvival 14 months  \nKhayat et al. 1991  To evaluate hep atic \nintra-arterial \ninfusion (HIAI) of \nfotemustine  Phase II Study  \n \nTreatment:  \nintraarterial \nfotemustine 100 \nmg/m \u00b2 (4 hour \ninfusion)  17 patients with \nexclusive or \npredominant liver \nmetastases from \nmalignant \nmelanoma.  \n13 patients \nevaluable  Response  \n Hepatic Response  \n(N=13)  \nCR n=2  \nPR n=6  \nMR n=1  \nSD n=3  \nPD n=1  \nOverall extrahepatic  \nresponse  \nrate 6/14 (42.8%)  Uveal or cu taneous \norigin not \nmentioned  \n 4 \nStorm et al. 1982  To evaluate \ncombined trea tment \nwith intraarterial \nDTIC infusion and \nlocalized \nhyperthermia of \npatients with \nadvanced liver \nmetastases  Case Series  \n \nTreatment: IA -DTIC \nplus heat  10 melanoma \npatients with li ver \nmetast ases \n \nOcular melanoma \nn=3 \nCutaneous \nmelanoma n=4  \nUnknown primary \nn=2 Response  \n \n \n \n \nSurvival  Response  \nCR n=1  \nPR n=2  \nSD n=5  \nPD n=2  \nMedian survival 8.5  \nmonths (range 3.5\u2010  \n18) Small series  4 \n \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 489 von 732 Hepatische arterielle Chemoembolisation (HACE) / Trans -arterielle Chemoembolisation (TACE)  \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nAhrar et al. 2011  To evaluate the \nresponse rates and \nsurvival durations of \npatients with \nmetastatic \ncutaneous \nmelanomas who \nunderwent \nchemoembolization.  Retrospe ctive \nevaluation  \n \nTreatment:  \nIntra\u2010arterial \nembo lic agent \nfollowed by cisplatin \n(100 \u2010 150mg)  42 patients with \ncutaneous \nmelan oma \nmetastatic to the \nliver \n \nextrahepatic disease  \nn=36  \nno extrahepatic  \ndisease n=6  \nEvaluable n=36  Response  \n \n \n \n \n \nOverall Survival (OS)  \n \nTime to progression \n(TTP) Response (N=36)  \nCR n=0  \nPR n=5 (13.9%)  \nMR n=9 (25%)  \nSD n=17 (47.2%)  \nPD n=5(13.9%)  \nMedian overall \nsurvival: 7.69 \nmonths  \nTTP of liver disease: \n6.01 months  Mulitvariate anal ysis \nincluded  \nLack of control \ngroup  4 \nHuppert et al. 2010  To evaluate \nresponse and \nsurvival in patients \nwith liver \nmetastases from \nuveal melanoma \ntreated by \nchemoembolization \nfollowing an \ninvar iable treatment \nprotocol over a \nperiod of more than \n6 years.  Phase II Study  \n \nTreatment:  \nHepatic transarter ial \nchemoemboliz ation \n(TACE) 100mg/m\u00b2 \nof cisplatine was \ncontinuously \ninfused by means of \na power injector \npreceding \nembolization by \nmanual injection of \npolyvinyl alcohol \nparticles  14 patients with \nhepatic metastases \nfrom uveal \nmelanoma  \n34 TACE\u00b4s were \nperformed  Response  \nTime to progression  \nSurviv al Response (N=14)  \nCR n=0  \nPR n=8 (57%)  \nSD n=4 (29%)  \nPD n=2(14%)  \n \nMedian time to  \nprogression 8.5  \nmonths (5 \u201035 \nmonths)  \nMedian survival:  \n14.5 months in  \nresponders versus  \n10 months in \nnonresponders  No cutaneous \nmelanoma patients  4  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 490 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \n(p=0.18,  \nnot significant)  \nSchuster et al. 2010  To report the \nexperience with \ntransa rterial \nchemoembol ization \n(TACE) in uveal \nmelanoma  patients \nwith pr etreated liver \nmeta stases  Case Series  \n \nTreatment:  \nfotemustine -based \nor cisplatin -based \nTACE after \ntreatment failure of \nsystemic therapy  25 uveal melan oma \npatients with liver \nmetast ases Toxicity  \n \n \n \n \nResponse  \n \n \n \n \n \nprogression\u2010free \nsurvival ( PFS) \n \nOverall survival (OS)  Toxicity:  \nNo grade IV toxicity \nor \ncatheterass ociated \ncomplic ations  \nResponse (N=25)  \nCR n=0  \nPR n=4 (16%)  \nSD n=14 (56%)  \nPD n=7 (28%)  \n \nPFS: 3 months (95% \nCI: 2\u20104 months)  \n \nOS: 6 months (95%  \nCI: 5\u20107 months)  No cutaneous \nmelanoma patie nts \n 4 \nYamamoto et al. \n2009  To retrospectively \nevaluate prognostic \nfactors for survival \nin patients with \nuveal melanoma \nwho received \nchemoembolization \n(CE) with 1,3 -bis Retrospective \nevaluation  \n(of patients treated \nwithin 2 different  \nPhase II studies)  \n \nTreatment:  \nChemoembolization  53 patients with \nuveal mel anoma  \n \nCE n=19  \nIE n=34  Overall survival (OS)  \n \n \n \n \n \n \nProgre ssion-free Median OS  \nCE: 9.8 months  \nLow\u2010dose IE: 13.0 \nmonths  \nHigh\u2010dose IE: 20.4 \nmonths  \n \nMedian Liver PFS CE: No cutaneous \nmelanoma patients  4  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 491 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \n(2-chloroethyl) -1-\nnitrosourea or \nimmunoemboliz atio\nn (IE) with \ngranul ocyte-\nmacrophage \ncolony-stimulating \nfactor (GM -CSF) for \nhepatic m etastases  with BCNU or with  \nGM\u2010CSF survival (PFS)  6.4 months  \nLow\u2010dose IE: 4.2 \nmonths  \nHigh\u2010dos e IE: 9.3 \nmonths  \nFiorentini et al. \n2009  To assess the safety \nand efficacy of TACE \nwith irin otecan as \ndrug-eluting beads  Phase II study  \n \nTreatment: TACE -\ncontaining beads \npreloaded with IRI \n(100 mg)  10 patients with \nliver m etastases \nfrom uveal \nmelanoma  Response  \n Partial response: 10 \npatients  No cutaneous \nmelanoma patients  4 \nSharma et al. 2008  To present the \noutcomes with \nhepatic arterial \nchemoe mbolization \nfor m etastasis of \nstage 4 mel anoma  Retrospective \nevaluation  \n \nTreatmen t:  \nhepatic arterial \nchemoembolization  20 patients with \nliver\u2010dominant \nmetastasis of ocular \nor cutaneous \nmelan oma  \n \nOcular melan oma \nn=17  \nCutaneous \nmelanoma n=3  Response  \n \n \n \n \nOverall survival  \n \n \n \n \nProgression\u2010free Response  \nCR n=0  \nPR n=0  \nSD n=13 (65% ) \nPD n=7 (35%)  \nmedian overall \nsurvival:  \n271 days no deaths \nwithin 30 days of \ntreatment  \nmedian Presence or a bsence \nof extrah epatic \nmetastases not \nmentioned  4  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 492 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \nsurvival  progression\u2010free \nsurvival:  \n185 days  \nVogl et al. 2006  To evaluate results \nin the palliative \ntreatme nt of \npatients with liver \nmetastases of uveal \nmalignant \nmelan oma using \ntransa rterial \nchemoembol ization \n(TACE)  Case Series  \n \nTreatment:  \ntransarterial \nchemoembolization \n(TACE) embolization \nsuspension: 10 \nmg/m\u00b2 Mitom ycin \nC, 10 ml Lipiodol, \nand an inje ction of  \n200-450 mg \nresor bable \nmicrospheres for \nvascular occl usion 12 patients with \nliver metastases of \nuveal malignant \nmelanoma  Side effects  \n \nResponse  \n \n \n \nSurvival  no relevant side \neffects.  \nResponse  \nPR n=3  \nSD n=5  \nPD n=4  \nMean survival after \nfirst embolization \n19.5 months. Lower \nsurvival rates for \nthe progressive \ngroup (16.5 \nmonths).  No cutaneous \nmelanoma patients  4 \nPatel et al. 2005  To evaluate \nchemoembolization \nof the hepatic artery \nwith BCNU for \nmetastatic uveal \nmelanoma  phase II study  \n \nTreatment: \nchemoembolizati on \nof the hepatic artery \nwith 1,3 -bis(2 -\nchloroethyl) -1-\nnitrosourea (BCNU) \ndissolved in 30 patients with \nhepatic metastases \nfrom uveal \nmelanoma, 24 \npatients evaluable  respo nses in \nhepatic metastases  \n \n \n \nOverall survival  \n Response (n=24)  \nCR n=1  \nPR n=4  \nSD n=13  \nPD n=6  \nMedian Survival  \nITTP 5.2 months  \nCR+PR 21.9 months  \nSD 8.7 months  No cutaneous \nmelanoma patients  4  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 493 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \nethiodized oil. \nGelatin sponge \nparticles were used \nas a tra nsiently \nocclusive agent.  PD 3.3 month  \n \nRadioembolisation (selektive interne Radio -Therapie  \u2013 SIRT)  \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nGonsalves et al. \n2011  to assess the safety \nand efficacy of \nradioembolization \nin the management \nof hepatic \nmetastasis of uveal \nmelanoma after \nfailure of \nimmunoembolizatio\nn or \nchemoemboliz ation Retrospective \nevaluation  32 patients with \nhepatic metastases \nfrom uveal \nmelanoma  responses in \nhepatic metastases  \n \n \n \nMedian overall \nsurvival \n CR n=1  \nPR n=1  \nSD n=18  \nPD n=12  \n \n10 months  \nCR+PR+SD 14.7 \nmonths  \nPD 4.9 months  No cutaneous \nmelanoma patients  4 \nKennedy et al. 2009  To evaluate \nYttrium-90 \nmicrosph eres \n(radioembol ization) \ndelivered via the \nhepatic artery  Case Series  \n \nTreatment:  \nYttrium\u201090 \nmicrospheres \n(radioe mbolization) 11 patients with \nliver metastases \nfrom uveal \nmelanoma  Toxicity  \nResponse  \nSurvival  Toxicity:  \nGrade 3: n=1  \nResponse  \nCR n=1  \nPR n=6  \nSD n=1  No cutaneous \nmelan oma patients  4  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 494 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \ndelivered via the \nhepatic a rtery PD n=1  \n1 year survival 80%  \n \n5.5.5.  Literatur  \n \nAgarwala SS, Panikkar R, Kirkwood JM. Phase I/II randomized trial of intrahepatic arterial infusion chemotherapy with cisplat in and chemoembolization with cisplatin and \npolyvinyl sponge in patients with ocular melanoma metastati c to the liver. Melanoma Res 2004;14:217 -222 \nAhrar J, Gupta S, Ensor J, et al. Response, survival, and prognostic factors after hepatic arterial chemoembolization in patients with liver metastases from cu taneous melanoma. \nCancer Invest 2011;29:49 -55 \nAlexan der HR,Jr, Libutti SK, Pingpank JF, et al. Hyperthermic isolated hepatic perfusion using melphalan for patients with ocular m elanoma metastatic to liver. Clin Cancer Res \n2003;9:6343 -6349  \nBecker JC, Terheyden P, Kampgen E, et al. Treatment of disseminated o cular melanoma with sequential fotemustine, interferon alpha, and interleukin 2. Br J Cancer \n2002;87:840 -845 \nCantore M, Fiorentini G, Aitini E, et al. Intra-arterial hepatic carboplatin -based chemotherapy for ocular melanoma metastatic to the liver. Report  of a phase II study. Tumori \n1994;80:37 -39 \nCaralt M, Marti J, Cortes J, et al. Outcome of patients following hepatic resection for metastatic cutaneous and ocular melanoma. J Hepatobiliary Pancreat Sci 2010  \nEgerer G, Lehnert T, Max R, et al. Pilot study of  hepatic intraarterial fotemustine chemotherapy for liver metastases from uveal melanoma: a single -center experience with seven \npatients. Int J Clin Oncol 2001;6:25 -28 \nFarolfi A, Ridolfi L, Guidoboni M, et al. Liver metastases from melanoma: hepatic intra -arterial chemotherapy. A retrospective study. J Chemother 2011;23:300 -305 \nFiorentini G, Aliberti C, Del Conte A, et al. Intra-arterial hepatic chemoembolization (TACE) of liver metastases from ocular melanoma with slow -release irinotecan -eluting \nbeads. Ear ly results of a phase II clinical study. In Vivo 2009;23:131 -137 \nFrenkel S, Nir I, Hendler K, et al. Long -term survival of uveal melanoma patients after surgery for liver metastases. Br J Ophthalmol 2009;93:1042 -1046  \nGonsalves CF, Eschelman DJ, Sullivan KL , et al. Radioembolization as salvage therapy for hepatic metastasis of uveal melanoma: a single -institution experience. AJR Am J \nRoentgenol 2011;196:468 -473 \nHerman P, Machado MA, Montagnini AL, et al. Selected patients with metastatic melanoma may benefit  from liver resection. World J Surg 2007;31:171 -174 \nHeusner T -, Antoch G, Wittkowski -Sterczewski A, et al. Transarterial hepatic chemoperfusion of uveal melanoma metastases: Survival and response to treatment. RoFo \nFortschritte auf dem Gebiet der Rontgenst rahlen und der Bildgebenden Verfahren 2011;183:1151 -1160  \nHuppert PE, Fierlbeck G, Pereira P, et al. Transarterial chemoembolization of liver metastases in patients with uveal melanom a. Eur J Radiol 2010;74:e38 -44 \nKennedy AS, Nutting C, Jakobs T, et al. A first report of radioembolization for hepatic metastases from ocular melanoma. Cancer Invest 2009;27:682 -690 \nKhayat D, Cour V, Bizzari JP, et al. Fotemustine (S 10036) in the intra -arterial treatment of liver metastasis from malignant melanoma. A phase II S tudy. Am J Clin Oncol \n1991;14:400 -404 \nLeyvraz S, Spataro V, Bauer J, et al. Treatment of ocular melanoma metastatic to the liver by hepatic arterial chemotherapy. J Clin Oncol 1997;15:2589 -2595  \nLeyvraz S, Zografos L, Bauer J, et al. Phase II study of hepat ic intraarterial fotemustine in patients with hepatic metastases from uveal malignant melanoma: Preliminary results. \nRegional Cancer Treatment 1992;5:ate of Pubaton: 1992  \nMariani P, Piperno -Neumann S, Servois V, et al. Surgical management of liver metastas es from uveal melanoma: 16 years' experience at the Institut Curie. Eur J Surg Oncol \n2009;35:1192 -1197  \nMelichar B, Dvorak J, Jandik P, et al. Intraarterial chemotherapy of malignant melanoma metastatic to the liver. Hepatogastroenterology 2001;48:1711 -1715   \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 495 von 732 Melichar B, Voboril Z, Lojik M, et al. Liver metastases from uveal melanoma: clinical experience of hepatic arterial infusion of cisplatin, vinblastine and dacarbaz ine. \nHepatogastroenterology 2009;56:1157 -1162  \nNoter SL, Rothbarth J, Pijl ME, et al. Isolat ed hepatic perfusion with high -dose melphalan for the treatment of uveal melanoma metastases confined to the liver. Melanoma Res \n2004;14:67 -72 \nPatel K, Sullivan K, Berd D, et al. Chemoembolization of the hepatic artery with BCNU for metastatic uveal melano ma: results of a phase II study. Melanoma Res 2005;15:297 -\n304 \nPawlik TM, Zorzi D, Abdalla EK, et al. Hepatic resection for metastatic melanoma: distinct patterns of recurrence and prognosis for ocular versus cutaneous disease.  Ann Surg \nOncol 2006;13:712 -720 \nPeters S, Voelter V, Zografos L, et al. Intra-arterial hepatic fotemustine for the treatment of liver metastases from uveal melanoma: experience in 101 patients. Ann Oncol  \n2006;17:578 -583 \nRizell M, Mattson J, Cahlin C, et al. Isolated hepatic perfusion f or liver metastases of malignant melanoma. Melanoma Res 2008;18:120 -126 \nRose DM, Essner R, Hughes TM, et al. Surgical resection for metastatic melanoma to the liver: the John Wayne Cancer Institute and Sydney Melanoma Unit experience.  Arch Surg \n2001;136:95 0-955 \nSalmon RJ, Levy C, Plancher C, et al. Treatment of liver metastases from uveal melanoma by combined surgery -chemotherapy. Eur J Surg Oncol 1998;24:127 -130 \nSchuster R, Lindner M, Wacker F, et al. Transarterial chemoembolization of liver metastases fro m uveal melanoma after failure of systemic therapy: toxicity and outcome. \nMelanoma Res 2010;20:191 -196 \nSharma KV, Gould JE, Harbour JW, et al. Hepatic arterial chemoembolization for management of metastatic melanoma. AJR Am J Roentgenol 2008;190:99 -104 \nSiegel R, Hauschild A, Kettelhack C, et al. Hepatic arterial Fotemustine chemotherapy in patients with liver metastases from cutaneous melanoma is as effective as in ocu lar \nmelanoma. Eur J Surg Oncol 2007;33:627 -632 \nStorm FK, Kaiser LR, Goodnight JE, et al. Thermochemotherapy for melanoma metastases in liver. Cancer 1982;49:1243 -1248  \nvan Etten B, de Wilt JH, Brunstein F, et al. Isolated hypoxic hepatic perfusion with melphalan in patients with irresectable ocular melanoma metastases. Eur J Surg Oncol \n2009;35:5 39-545 \nVogl T, Eichler K, Zangos S, et al. Preliminary experience with transarterial chemoembolization (TACE) in liver metastases of uveal malignant melanoma: local tum or control and \nsurvival. J Cancer Res Clin Oncol 2007;133:177 -184 \nWoon WW, Haghighi KS, Zuckerman RS, et al. Liver resection and cryotherapy for metastatic melanoma. Int Surg 2008;93:274 -277 \nYamamoto A, Chervoneva I, Sullivan KL, et al. High-dose immunoembolization: survival benefit in patients with hepatic metastases from uveal melanoma. Radiology \n2009;252:290 -298 \n \n \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 496 von 732 5.6. Frage V.8. L ebensqualit\u00e4t \u2013 De novo Recherche  \nFrage V.8.  Welche  medikament\u00f6sen Ther apieverfahren haben im metastasierten Stadium einen (positiven) Effekt auf die Lebensqualit\u00e4t?  \n5.6.1.  PICO, Suchw\u00f6rter   \nPICO \u2013 Schema  \nPopulation  Intervention  Comparison  Outcome  \nMelanoma patients , clinical stage III \nand IV  Systemic treatment  Observation, other systemic treatments  Quality of life  \n \nSuchw\u00f6rter  \nStichwort  melanoma  Quality of life    \nSynonyme   Qol   \nMesh Term  melanoma  Quality of life    \n \n5.6.2.  Datenbanken, Suchstrategien, Trefferzahlen  \nDatenbank  Suchstrategie  Datum  Treffer \n1. Suche     \nMedline  (\u201cmelanoma\u201d[tiab] OR \u201cmelanoma\u201d[MeSH]) AND (\u201cQuality of life\u201d \nOR \u201cQol\u201d OR \u201cQuality of life\u201d [Mesh])  24.02.11  399 \nUpdate Suche     \nMedline  s.o. 31.01.12  435 (3 dazu: Hofmann et al. 2011, Robinson et al.  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 497 von 732 Datenbank  Suchstrategie  Datum  Treffer \n2011, Ziefle et al. 2011, Bran dberg et al. 2011)  \nCochrane Library  (melanoma and (\u201cquality of life\u201d or \u201cQoL\u201d)).ti,ab.  31.01.12  42 (0 dazu)  \nEmbase  (melanoma and (\u201cquality of life\u201d or \u201cQoL\u201d)).ti,ab.  24.01.1 2 497 (0 dazu)  \n \n5.6.3.  Auswahlkriterien  \nAuswahl der Literatur  \nGesamttreffer  974 \nEinschlusskriterien  Studien / System. Reviews zu Lebensqualit\u00e4t bei Melanompatienten unter Therapie  \nKlinische adjuvante und palliative Therapiestudien / system. Reviews zum Melanom , die Lebensqualit\u00e4t als prim\u00e4ren oder \nsekund\u00e4ren Endpunkt messen  \nSprachen: e,dt  \nAusschlusskriterien  Case Reports  \nNicht systematische Reviews  \nKollektive mit gemischten Tumorentiti\u00e4ten  \nLebensqualit\u00e4t bei Melanompatienten nach/w\u00e4hrend chirurgischer Therapi e \nLebensqualit\u00e4t bei Melanompatienten ohne Therapie  \nAnzahl nach Abstractscreening, vorges ehen f\u00fcr Bewertung  28 \nAnzahl ausgew\u00e4hlter Studien nach Handsuche (Durchsicht der Literaturlisten)  3 \nAnzahl der ausgeschlossenen Studien nach Sichtung der Volltexte  10 \nAnzahl ausgew\u00e4hlter Volltexte  21 \nDie ausgew\u00e4hlten Arbeiten wurden wie folgt zusammengefasst:    \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 498 von 732 Auswahl der Literatur  \n- Reviews zu QoL bei Melanompatienten unter Therapie  \n- Adjuvante Therapienstudien die QoL als Endpunkt enthalten  \n- Palliative Therapienstudien die QoL als Endpunkt enthalten  \n \n5.6.4.  Evidenztabelle  \n \nReviews zu QoL bei Melanompatienten unter Therapie  \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nCashin et al. 2008  To examine all of \nthe information \npublished so far on \nthe impact of \ninterventions on \nQoL, includi ng all \navailable treatment \nstrategies or \nscreening programs \nfor MM  Systematic review  \n \nInclusion criteria:  \nreports of original \nresearch related to \nQoL in MM and/or \neconomics  \nof MM  13 QoL studies  \n(5 economic \nstudies) \n QoL Instruments  \nMain QoL Results  \n(Interv entions, \nClinical Outcome, \nAdverse Events)  \n QoL Instruments \nused:  \nEORTC, EORTC \nQLQ-36, QLQ C30, \nQWB-SA, Lin ear \nanalog self -\nassessment scale \nincluding the GLQ -\n8, GLQ -8, SF-36, \nRotterdam Checklist \nSymptom \nquesti onaire, QWB -\nSA \nQOL Results:  \nno significant \nimprovements in Detailed description \nof studies and \nresults  1a  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 499 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \nQoL for any \nalternative for \ntreating MM  \nCornish et al. 2009  To systematically \nreview the avail able \nliterature on health -\nrelated qua lity of \nlife (HRQOL) and \nmelanoma  Systematic review  \n \nInclusion c riteria:  \n(HR)QOL \nasses sment in \ncutaneous \nmelanoma  13 selected st udies HRQOL in patients \nwith cutaneous \nmelanoma  - 20 different \ninstruments were \nused within the 13 \nstudies  \n- 3 distinct periods \nof HRQOL impact: \ndiagnosis, \ntreatment and \nfollow -up \n- systemic drugs \ndecreased pat ients\u00b4 \nHRQOL during \ntreatment.  Results of QoL \nmeasurements \nwithin the studies \nare not pr esented in \ndetail . \n \nMethodological \nquality of included \nstudies was \nmeasured by 14 not \nvalidated criteria  1a- \n \nAdjuvante Therapiestudien die QoL als Endpunkt enthalten  \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nZiefle et al. 2011  To evaluate QoL in \npatients with \nmelanoma using the  \nEuropean \nOrganiz ation for \nResearch and QoL evaluation \nwithin a phase III \ntrial \n \nQoL instrument:  \nEORTC QLQ -C30 QoL Assessment  \n \nno. of forms \nreceived (e xpected)  \nBaseline  \nn=725 (850)  HRQOL at baseline  \n \n \n \n \nHRQOL during HRQoL co mpared \nwith the healthy \nreference \npopulation  \n \nsignificant decrease No assessment of \nlong term QoL Data \n(Group 2)  1b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 500 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \nTreatment of  \nCancer Quality of \nLife Questionnaire \n(EORTC QLQ -C30) \nbefore and during \nthe first 12 months \nof adjuvant \ntreatment with IFN -\na-2a Time points: \nbaseline, month 3, \n6 and 12  \n \nTreatment:  \nGroup 1: IFN -a-2a \n18 months  \nGroup 2: IFN -a-2a \n60 months   \nall timepoints  \nn=282 (850)  \n treatment  of 9 of 15 QLQ -C30 \nsubscales  \npeaked at 3 months  \n \n \n \nBrandbert et al. \n2011  To compare health -\nrelated  quality  of \nlife (HRQoL) and \nside-effects in \npatients  with high-\nrisk melanoma  \nparticipating in a \nrandomised  phase  \nIII trial of adjuvant  \ninterf eron alfa-2b QoL evaluation \nwithin a phase III \ntrial \n \nQoL instrument:  \nEORTC QLQ -C30 \nTime points: \nbaseline, month 3, \n6 and 12  \n \nTreatment:  \nArm  A: Observation  \nArm B: 1 year \nintermediate Dose \nIFN-a-2b  \nArm C: 2 years \nintermediate Dose \nIFN-a-2b  QoL Assessment  \n \nno. of forms \nreceived > 80%  \n \nall timepoints  \nn=282 (850)  \n HRQOL during \ntreatment compared \nto bas eline \n \n \n \n \n \nHRQOL diffe rences \nbetween groups  \n significant \nintera ctions \nbetween \nrandomisation arm \nand time after \nrandom isation for \nalmost all EORTC \nQLQ-30 variables \n \nArm A improved or \nremained at \nbaseline levels  \nARM B+C significant \nnegative impact on \nHRQoL of IFN \ntreatment.  \n \nthe impact were - 1b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 501 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \nreversible when \ntreatment was \nstopped.  \nBottomley et al. \n2009  To examine the \nhealth -related \nquality of life effects \nof ad juvant \npegylated IFN -\nalpha -2b (PEG -IFN-\nalpha -2b) versus \nobservation in \npatients with stage \nIII melanoma  QoL evaluation \nwithin a phase III \ntrial \n \nQoL instrument:  \nEORTC QLQ -C30 \nTime points: \nbaseline, month 3, \n12, 24, 36, 48, 60.  \n \nTreatment:  \nGroup 1 observ ation \n(n = 629)  \nGroup 2 PEG -IFN-\nalpha -2b (n = 627)  QoL Assessment  \n \nno. of forms \nreceived (e xpected)  \nBaseline  \nGr. 1: n=521 (629)  \nGr. 2: n=520 (627)  \n \n36 months  \nGr. 1: n=158 (352)  \nGr. 2: n=134 (347)  \n \n60 months  \nGr. 1: n=10 (26)  \nGr. 2: n=9 (30)  \n \nof 1,256 patients  \nwith stage III \nmelanoma  \n HRQOL at month 3  PEG-IFN-alpha -2b \ntreatment arm:  \n-decreased global \nHRQOL at month 3 \n(-11.6 points; 99% \nCI, -8.2 to -15.0) \nand year 2 ( -10.5 \npoints; 99% CI, -6.6 \nto -14.4)  \n-statistically \nsignif icant impaired \n(P< 0.0001) at 3 \nmonths  after \nbaseline: \nSocial functioning  \nRole functioning  \n(at other timepoints \nno clinically \nmeaningful \ndifferences between \nboth treatment \ngroups)  \n-statistically \nsignif icant impaired Analysis was \nrestricted to the \nfirst 3 years, as \nlimited data existed \nat years  4 and 5.  \n \nConflict of interest \n5 of 18 authors \nreceived funding, \nhonoria or had \nconsultant/advisory \nrole (Schering \nPlough)  1b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 502 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \n(P<.0001) over \ntime:  Appetite loss  \nFatigue  \nGarbe et al. 2008  To evaluate \nadjuvant Interferon \nalpha and DTIC  \nin terms of over all \nsurvival, \nrecurrence -free \nsurvival and \noccurrence of  \nadverse events. \nHealth -related \nquality of life (QoL)  \nwas measured by a \nquestionnaire.  QoL Evaluation \nwithin a RCT  \n \nQoL Instrument:  \nEORTC QLQ -C30 \n \nTime points:  \nBaseline +  6 \nmonths  \n \nTreatment:  \nArm A: Interferon \nalpha (n=146)  \nArm B: Interferon \nplus Dacarbazine \n(n=148)  \nArm C: Observ ation \n(n= 147)  \n HRQOL assessment  \n  \nNo. of patients= \n238 (54%)  \n \n HRQOL at month 6  better outcome for \nthe general \ndime nsions of QoL  \nfor patients with \nadjuvant therapy  \nphysical  functioning \n(Arm A vs. Arm C: p \n= 0.007)  \nrole functioning \n(Arm A vs.  Arm C: p \n= 0.008)  \nemotional \nfunctio ning (Arm A \nvs. Arm C: p = \n0.048)  \n \nmore drug -related \nsymptoms  \nfatigue symptom \nscale (Arm A vs. \nArm C: p = 0.036)  \nnausea and \nvomiting scale (Arm \nB vs. Arm C: p = Baseline HRQOL \ndata not presented  \n 1b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 503 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \n0.037)  \nDixon et al. 2006  To evaluate data on \nhealth -related \nquality of life \n(HRQoL) and costs \nof low -dose \nextended duration \nadjuvant interf eron-\nalpha therapy in the \ntreatment of \nmalignant \nmelanoma  \n QoL E valuation \nwithin a RCT  \n \nQoL Instrument:  \nEORTC QLQ -C30 \n \nTime points:  \nBaseline, 3, 6, 12, \n24, 36, 48, 60 \nmonths  \n \nTreatment:  \nGroup 1: IFN low \ndose, 60 months  \nGroup 2: \nObserv ation (OBS)  QoL assessment (%)  \n \nGroup 1  \nn= 211 (68%)  \n \nGroup 2  \nn= 187 (56%)  \n \nof 674 mel anoma \npatients (clinical \nstage not ind icated)  \n HRQoL over time \nbetween groups  \n \n(Costs)  OBS group:  \nsignificantly be tter \nmean follow -up \nQoL on 5 of 6 \ndimensions of the \nfunctional scales: RF \n(role functioning), \nEF (emotional f.), CF \n(cognitive f.), SF \n(social  f.) and QL  \nsignificantly better \nmean follow -up \nQoL symptom \nscores on 7 of 9 \ndime nsions: FA, NV, \nDY, AP, CO, DI and \nFI (after adjustment \nfor baseline QoL \nand overall survival \nstatus (dead or \ncensored)  due to mis sing data, \nfollow -up QoL \nresponses for each \nindividual subject \nwere su mmarised \nby taking the \naverage of their \nfollow -up QoL \nresponses over \ntime.  \n 1b \nLoquai et al. 2011  To evaluate the \nimpact on quality of \nlife (QOL) in \npatients treated Retrospective \nevaluation  \n \nQoL Instrument:  30 patients  \n QOL changes  \n \n \n impairment in most \nQOL single \ndime nsions  \n Small sample size  4  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 504 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \nwith once weekly \n2\u200a\u03bcg/kg PEG -IFN-\n\u03b12b and to e xamine \nwhether there is a \ndifference in \npatients' and \nphysicians' \nperce ption of QOL  EORTC QLQ -C30 \n \nTime points:  \nBaseline, every 3 \nmonths  \n \nTreatment: 2 \u200a\u03bcg/kg \nPEG-IFN-\u03b12b  Patients \nquestio nnaires \ncompared to \nphysician \nasses sment  QOL documented by \nphysicians was \nsignificantly hig her \nthan QOL from the \npatients' \nquestio nnaires in all \nQOL dimens ions \nRatai  et al. 2005  to evaluate the \nimpact of interferon \n(IFN) trea tment on \npatients' quality of \nlife (QoL) after \nradical surgery of \ncutaneous \nmelanoma  Comparative St udy \n \nQoL Instrument:  \nEORTC QLQ -C30  \n \nTime points:  \nBaseline und during \ntreatment  \n \nTreatment:  \nGroup  1: INF -alpha -\n2b \nGroup 2: \nObserv ation 220 patients  \nGroup 1 n=110  \nGroup 2 n=110  \n \n QoL The IFN -alpha -2b \ntreatment \nsignif icantly \naffected p atients' \nphysical co ndition, \nmental health, and \nsocial life. In spite \nof se veral adverse \neffects, the patients \nassessed their QoL \nas good  Allocation to groups \nnot indicated \nBaseline data not \npresented  \nTimepoints of \nassessment not \nindicated  \n 4 \nTrask et al. 2004  To assess the the \nlongitudinal cou rse \nof depression, \nfatigue, and QoL Observ ational study  \n \nQoL Instruments:  \n-BSI 16 patients  \n Depression  \nQoL \nFatigue  \n 6-month post high -\ndose assessment: \nsignificantly \nincreased somati c Small sample size  \ndata presented in \ndetail  \n 4  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 505 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \nbefore and during \ninterf eron therapy  -FACT -BRM \n-RPFS \n-BDI \n \nTime points:  \nBaseline, 1, 2, 3, 6 \nmonths post \ntreatment  \n \nTreatment: high \ndose interf eron-\nalpha  complaints, \ndepre ssion, and \nfatigue, reductions \nin QoL in the areas \nof Physical Well -\nBeing, Fun ctional \nWell-Being, and \nAdditional \nSymptoms.  \nQoL did not i mprove \nover the course of \ntherapy  \n \nCohen et al. 2002  To prospectively \nassess QoL in \npatients with \nmalignant \nmelan oma \nparticipating in a \nphase Ib \nimmun otherapy \ncancer cli nical trial \nof an autolo gous \ntumour -derived \nvaccine  QoL Evaluation \nwithin a Phase Ib \nstudy  \n \nQoL Instruments:  \n-SF-36 (RAND \nscoring method, 8 \nscales, range 0 \n(worst) to 100 \n(best). Physical \nComponent \nSummary (PCS) and \nMental Component \nSummary (MCS)  QoL assessment  \nBaseline n=29  \nWeek 3 n=28  \nFollow up n=27  \n \nof 30 evaluable \npatients with stage \nIII or IV malignant \nmelan oma \n Changes of PCS, \nMCS and IES over \ntime \n \nAssociation b etween \nIES, PCS and MCS \nScores  \n \n QoL remained \nstable during \ntreatment, no \nsignific ant time \neffect for the PCS \nscore, MCS  \nscores or the IES \nscores  \n \nsignificant negat ive \nassociation between \nIES sc ores at \nbaseline and mental \nhealth sc ores at Missing data at all 3 \ntimepoints. 2 of 3 \nmissing \nassessments a t \nfollow up due to \nprogressive disease.  \n \nMixed model \nregression analyses, \nanalyses using the \nlast observation \ncarried forward and \nanalyses using a \ncomplete cases 4  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 506 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \nScores, computed \nby using items from \nthe 8 subscales  \n-Impact of Event \nScale (IES)  \n \nTime points:  \nbaseline, week 3 \nand follow -up  \n \nTreatment: vaccine  each time point ( < \n0.002 for all).  \n approach were \nperformed.  \nBender et al. 2000  To describe short - \nand long -term \nchanges in cog nitive \nfunction and quality \nof life in patients \nwith m elanoma \nreceiving interferon \n(IFN) alpha -2b Pilot Study  \n \nQoL instrument:  \nFACT -G scale  \nTime points: \nbaseline, 3, 6, 9, 12 \nand 15 months  \n \nTreatment:  \nGroup A: high dose \nIFN a lpha-2b n=6, \nGroup B: low dose \nIFN a lpha-2b n=6, \nGroup C: control \ngroup n=6  18 melanoma \npatients (part of \nECOG EST 1690 \ntrial) \n \nbaseline  \nGroup A: n=6  \nGroup B: n=6  \nGroup C: n=6  \n \n15 months  \nGroup A: n=2  \nGroup B: n=3  \nGroup C: n=2  \n QoL \n(cognitive function)  significant \ndifference on the \nphysical wellbeing \ndime nsion of quality \nof life from T1 to T2 \nin Goup A  \nGroup A and B: \ntrend to diminished \noverall quality of life  Limitations: small \nsample size  \nBaseline \ncharact eristics (e.g. \ngender, age) are not \npresented  4 \nPoor \nquality \ncase \ncontrol \nstudy  \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 507 von 732 Palliative Therapiestudien die QoL als Endpunkt enthalten  \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nRobinson et al. \n2012  To \ndeterminepatient -\nreported signs, \nsymptoms, and \nfunctioning, HRQoL \nquestionnaire \npsychometrics, and \ntreatment im pact on \nHRQoL  QoL Evaluation \nwithin a randomized \nphase II study  \n \nQoL instrument:  \nMelanoma Subscale \n(MS) of the \nFunctional \nAssessment of \nCancer Therapy -\nMelanoma  \nBrief Pain Inventory \n(BPI) \n \nTreatment: DTIC + \nIntetumumab versus \nDTIC + Placebo  QoL Assessment  \n \n127 patients  \n Baseline QoL  \n \n \n \n \nQoL at week 3  \n Baseline HRQoL \nscores differed \naccording to ECOG  \nperformance status  \n \ntrend for HRQoL  \nresponse in the  \ndacarbazine+ 10 \nmg/kg \nintetumumab arm \nversus dacarbazine \n+ placebo:  \n \nMS 22 versus 10%,  \nBPI 23 versus 5%  no. of forms \nreceived not \nindicated  \n 1b \nHofmann et al. \n2011  To compare best \nsupportive care \n(BSC) alone with \ncisplatin, vindesine \nand dacabazine -\nbased (CVD) \nchemotherapy and \nBSC in terms of \noverall survival, QoL Eva luation \nwithin a cohort \nstudy  \n \nQoL instrument:  \nEORTC QLQ -C30 \n \nTreatment:  \nArm A: BSC (n=34)  QoL Assessment  \n \nno. of forms \nreceived (expected)  \nBaseline  \nn=83 (117)  \nArm A: 58.8%  \nArm B: 75.9%  \n  \n \nBaseline QoL  \n \n \n \n \nQoL at week 8  Arm A versu s Arm B  \n \nno significant \ndifferences  \nin the function and \nsymptom scales  \n \nincrease in \ndyspnoea and Initial protocol: \nrandom assignment. \nDue to lack of \npatients  consent for \nrandomization the \nprotocol was \nchanged to \ntreatment \nassignment based 2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 508 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \ndisease control rate \nand quality of life  Arm B: BSC+CVD \n(n=83)  \n \n fatigue Arm B, not \nsignificant  \nreduction in the \nGlobal Health status \nin both arms, not \nsignificant  on patients choice  \nAvril et al. 2004  To compare \nfotemustine and \ndacarbazine (DTIC) \nin terms of overall \nresponse rate (ORR) \nas primary end -\npoint and overall \nsurvival, dura tion of \nresponses, time to \nprogression, time to \noccurrence of brain \nmetastases (BM), \nand to assess safety \nand quality of life  QoL Evaluation \nwithin a randomized \nphase III study  \n \nQoL instrument:  \nEORTC QLQ -C30 \nTime points: \nbaseline and after \ninduction period  \n \nTreatment: \nFotemustine versus \nDTIC \n QoL assessment \nN=156  \nFotemustine group \nn=83 (of 112)  \nDTIC group n=73  \n(of 117)  \n \nof 229 Stage IV \nmelanoma patients  \n Quality of life  \n \n(overall response \nrate, overall \nsurvival, duration of \nresponses, time to \nprogression,  time to \noccurrence of brain \nmetastases)  \n QoL: \nno statistically \nsignificant \ndifference between \ngroups.  \ngeneral tendency: \ndegradation for all \n(presented) \nfunctional and \nsymptom scales \nover time in both \ngroups.  \n \ndisease progression \nand performance \nstatus wer e the \nmain factors for \nQoL impairment.  QoL analysis only \navailable for \ninduction phase due \nto high number of \nmissing \nquestionnaires  \nData are presented \nfor 7 scales only.  \nMissing scales: \nEmotional \nfunctioning, \nCognitive \nfunction ing, \nDyspnoea, \nInsomnia, Appe tite \nloss, Constipation , \nDiarrhoea, Financial \ndifficulties  1b \nChiarion -Sileni et al. \n2003  To analyse the \nhealth related QoL Evaluation \nwithin a randomized Available QoL \nscores HRQOL difference  \nHRQOL at baseline between treatment \narms over time:   1b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 509 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \nquality of life \n(HRQOL) of \nadvanced melanoma \npatients, in a \nrandomised trial \ncomparing bio -\nchemotherapy (bio -\nCT) versus \nchemotherapy (C T) phase III study  \n \nQoL Instrument:  \nRotterdam Symptom \nChecklist (RSCL)  \nTime points:  \nBaseline, Cycle 1, 2, \n3, 4, 5 and 6  \n \nTreatment:  \nCT: cisplatin and  \nDTIC alone  \nBio-CT: cisplatin, \nDTIC, IL -2 and IFN \na-2b  \nBaseline n=140 (of \n178) \nCycle 6 n=16 (of \n57)  \n as prognostic factor  \n statistically \nsignificant \ndifference in the \noverall quality of life \nscore (P=0.03) , \ndecrease of 6.28 \npoints in the bio -CT \narm \nno significant \ndifference between \ntreamtents:  \nactivity level \n(P=0.20)  \nphysical symptom \ndistress (P=0.08)  \npsychological \ndistress (P=0.25)  \n(values always \nslightly inferior in \nthe bio -CT arm)  \n \ndeterioration over \ntime:  \nbio-CT arm: \nsignificantly in all \ndomains (most \nimportant reduction  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 510 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \nin the activity level)  \nCT arm: significant \nonly for the activity \nlevel and the \nphysical symptom \ndistress (P<0.001).  \n \nPrognostic Factors: \noverall quality of life \nscore, the physical \nsymptom  \ndistress score, and \nthe se rum LDH level \nwere confirmed  \nas independent \nprognostic factors \nin in mulitvariate \nanalysis.  \nKiebert et al. 2003  To report detailed \nHRQL results of a \nphase III clinical trial \ncomparing \ntemozolomide \n(TMZ) to \ndacarbazine (DTIC) \nin patients with \nmetastati c QoL Evaluation \nwithin a Phase III \nstudy  \n \nQoL Instrument:  \nEORTC QLQ -C-30 \n \nTime points:  \nbaseline, week 12, Available HRQL \nscores  \nBaseline TMZ \nn=110  \nBaseline DTIC \nn=110  \nWeek 12 TMZ n=50  \nWeek 12 DTIC n=31  \nWeek 24 TMZ n=22  HRQL differences  \n-Between groups  \n-Over time  between groups:  \nbaseline: no \nsignificant \ndifferences  \n12 weeks: TMZ \ngroup significantly \nbetter physical \nfunctioning, less \nfatigue and sle ep At week 24 not \nenough data for \ninterpretations.  \nMore missing data \nin the DTIC group.  \nLimited external \nvalidity:  \nPrivilege of \nreceiving the new, 1b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 511 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \nmelanoma  24 \nTreatment:  \nGroup 1 DTIC  \nGroup 2 \nTemozolomide  Week 24 DTIC n=8  \n(of 305 advanced \nmelanoma patients)  \n disturbances, \ncognitive \nfunctioning \nequivalent, worse \non nausea and \nvomiting.  \n24 weeks: all \nsubscales \n(exception diarrhea) \nbetter for TMZ \npatients  \n \nOver time:  \nTMZ patients: \nclinically meaningful \nimprovements in \nemotional \nfunctioning, \ncognitive \nfunction ing, and \nsleep disturbances \nat week 12. DTIC \npatients: poorer \nphysical \nfunctioning, \nimproved emotional \nwell-being, and less maybe \u201cbetter\u201d drug \nin the TMZ group \nmay influence the \nfunctioning scales \nmore than the drug \nitself.  \np-values are only \nindicated for \nbaseline \ncharacteristics.   \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 512 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \nnausea and \nvomiting, pain, \nappetite loss, and \ndiarrhea at week 12. \n(not statistically \nsignificant or \nconsidered clinically \nmeaningfu l) \nYoung et al. 2001  To report the \nresults of DTIC \n+IFN-alpha in \npatients with \nmetastatic melanom  QoL evaluation \nwithin a phase III \nstudy  \n \nQoL instrument:  \nEORTC QLQ C30 \n(+3)  \nTime points: \nbaseline, at ea ch \nvisit \n \nTreatment:  \nGroup 1 DTIC  \nGroup 2 DTIC + \nIFN-alpha  41 (of 57) advanced \nmelanoma patients \ncompleted at least 1 \nquestionnaire  \n \nBaseline n=38  \nTimepoint of tumor \nassessment n=27  \n \n QoL \n-between groups  \n-over time  -no significant \ndifferences between \nthe g roups, both at \nbaseline (z =70.82, \nP=0.41) and for the \nchange in scores \nover time (z = \n71.29, P=0.20)  \n-for both groups \nthe level of \nsymptoms \nworsened over time, \nbut patients\u2019 \nfunctioning ability \nappeared to be \nstable  Limitations: missing \ndata \n 1b \nMiddlet on et al. \n2000  To compare \ntemozolomide and Randomized p hase \nIII study  QoL Scores available  \n QoL (secondary \nobjective)  TMZ group: \nsignificant better QoL data are not \nshown in detail  1b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 513 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \ndacarbazine (DTIC) \nin terms of overall \nsurvival, \nprogression -free \nsurvival (PFS), \nobjective response, \nand safety, and to \nassess health -\nrelated quality of \nlife (QoL) and \npharmacokinetics of \nboth drugs.   \nQoL Instrument:  \nEORTC QLQ -C30 \n \nTimepoints: \nbaseline, week 12  \n \nTreatment:  \nGroup 1 \nTemozolomide \n(TMZ)  \nGroup  2 DTIC  \n Baseline n=251  \nWeek 12  \nTMZ group n=51  \nDTIC group n=31  \n \nof 305 patients with \nadvanced metastatic \nmelan oma -Differences of \nScores at week 12 \nbetween groups  \n-Differences of \nmaintenance or \nimprovement of \nscores compared to \nbaseline between \ngroups  \n \n(primary objective: \noverall survival, \nfurther secondary \nobjectives: PFS, \nResponse Rates , \nSafety)  scores for physical \nfunctioning, fatigue, \ninsomnia.  \nSimilar results for \nresponder subgroup \nanalysis between \ngroups.  \nTMZ group: \nsignificant more \npatients with \nmaintenance or \nimprovement of \nphysical and \ncognitive \nfunct ioning  \n Sample size seems \nto be too small for \nresponder subgroup \nanalysis (exact \nnumbers not \nindicated, DTIC \ngroup: QoL Scores \navailable n=31 of \n149, responders \nn=18 of 149)  \nSigurdardottier et \nal. 1996  to describe QoL o f \npatients with \nadvanced melanoma \nduring \nchemotherapy and \nto compare the \nclinical outcome \nvariables and \npatients' self -\nassessed QoL  Longitudinal QoL \nstudy  \n \nQoL Instruments:  \n- EORTC QLQ -C36 \n- study -specific \nmelanoma module  \n- Hospital Anxiety \nand Depression  \n(HAD) scale  \n 95 patients with \nadvanced melanoma  \n \n(73 patients of a \nrandomized clinical \ntrial, 22 non -\nrandomized \npatients with \nchemotherapy)  QoL \n-score differences \nbetween baseline \nand week 9  \n - significant \ndeterioration in all \nQoL measurements, \nwith the exception \nof pain and \nemotional \nfunctioning at week \n9 No randomized \ndesign  \n 4  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 514 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \nTreatment: DTIC \nplus vindesine with \nor without cisplatin  \nThomson et al. \n1993  To describe the \nprognostic \nassociations of QL \nscores obtained \nduring a multicentre \nrandomised clinica l \ntrial comparing \nDTIC plus \nrecombinant \ninterferon -alfa 2a \nversus DTIC alone \nfor patients with \nmetastatic \nmalignant \nmelanoma.  QoL assessment \nwithin a Phase III \nstudy  \n \nQoL instrument:  \nlinear analog self \nassessment (LASA) \nscales, GLQ -8 \nby physician: QL  \nIndex  questionnaire  \nTime points:  \nBaseline, week 12  \n \nTreatment:  \nGroup 1: DTIC  \nGroup 2 DTIC + \nIFN-alpha -2a 176 advanced \nmelanoma patients  \n \nNumber of QoL data \nnot indicated  QoL \n(Response rate, \nResponse duration, \nTime to disease \nprogression, \nToxicity, Overall \nSurvival) Quality of life was \nnot significantly \ndifferent in either \ngroup, except that \nfatigue, as \nmeasured at week \n12 by LASA scales, \nand activity, as \nmeasured by the \nfunctional living \nindex, were both \nimproved in the \ncombination  QoL data not \npresented in det ail. \nNot clear, if score \nchanges between \nbaseline and week \n12 or if absolute \nscores at week 12 \nare compared \nbetween the groups.  \nNumber of received \nquestionnaires not \nmentioned.  2b poor \nquality  \n \n \nAusgeschlossene Studien  \nStudy  Aims  Design  Population  Outcome s Results  Comments  LoE \nAdamina et al. 2008  To assess the safety \nand immunogenicity multi -centre ph ase \nI/II open lab eled 20 resected AJCC \nstages IIb -IV   QoL data are not \npresented    \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 515 von 732 Study  Aims  Design  Population  Outcome s Results  Comments  LoE \nof heterologous \nprime -boost \nimmunotherapy of \nmelanoma patients \nwith Influenza \nvirosomes, and \nrecombinant \nVaccinia virus.  \nQuality of life will \nbe assessed with a \ndedicated F ACT-\nBRM 4 questio nnaire  study  \n \nLQ instrument:  \nFACT -BRM 4 \nquestionna ire melanoma patients  excluded  \nBeguerie et al. 2010  Tamoxifen vs. non -\ntamoxifen \ntreatment for \nadvanced \nmelanoma: a meta -\nanalysis  metaanalysis  9 randomized \ncontrolled trials  Secondary outcome \nquality of life  \n \n(Response, \nmortal ity,  toxicity, \ntreatment -related \nmortality)  None of the trials \nreported QoL  excluded   \nNoorda et al. 2007  To assess the long-\nterm health -related \nquality of life \n(HRQL) of \nmelan oma survivors \nwho had undergone \nisolated limb Comparative St udy \n \nQoL Instrument:  \nmailed \nquestio nnaire SF -36  \nTime point: after \nILP, at least 6 QoL assessment \nn=51 (89%) of  \n \n51 patients after \nisolated limb \nperfusion \nmedian follow up SF-36 scores  SF-36 scores of the \npatient group were \nequal to or better \nthan that of the \ngeneral population, \nsignifican tly for \nbodily pain, general Assessment after \ntherapy, no baseline \ndata \nStudy excluded    \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 516 von 732 Study  Aims  Design  Population  Outcome s Results  Comments  LoE \nperfusion (ILP) of \nthe extrem ities, and \nto identify the \npatient -, tumour - \nand ILP -related \nfactors a ssociated \nmost strongly with \nthe patients\u2019 self -\nreporte d HRQL.  months disease free  \n \nComparison: \nnorm ative sample of \nthe Dutch general \npopulation of SF -36 \nscores  after ILP 14 years \n(range 3 -25 years)  health pe rceptions, \nand the physic al \nand mental health \ncomponent scores  \nPetrella et al. 2007  To determine the \nrole of single -agent \ninterleukin -2 in the \ntreatment of adults \nwith metastatic \nmelanoma. \nOutcomes: objective \nand complete  \nresponse rates, \nduration of \nresponse, tox icity \nand quality of life  systematic review  1 systematic review, \n5 RCTs, 12 Phase II \ntrials, 1 QoL report    excluded  \n(only 1 QoL report)   \nQuirt et al. 2007  To examine the role \nof temozol omide in \npatients with \nmetastatic \nmelanoma  systematic review  \n \n \n Two randomized \nphase III trials and \nthree randomized \nphase II trials  \n  only 2 studies with \nQoL data  excluded    \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 517 von 732 Study  Aims  Design  Population  Outcome s Results  Comments  LoE \nOutcomes: r esponse \nrate, progression -\nfree survival, overall \nsurvival, quality of \nlife, and adverse \neffects   \nSchallreuter et al. \n1991  A quite promising \nclinical trial was \nconducted using the \nnew nitroso urea \nfotemustine  phase II study  19 patients   quality of life of the \npatients during and \nafter ch emotherapy \nwas not severely \naffected  no QoL assessment \nstudy exclu ded  \nVerma et al. 2006  To examine the role \nof systemic \nadjuvant therapy in \npatients with high -\nrisk, resected, \nprimary melan oma \nOutcomes: ove rall \nsurvival, dise ase-\nfree survival, \nadverse effects, and \nquality of life  systematic review  37 randomized \ncontroll ed trials, 2 \nmeta-analyses, and \n1 systematic review \nwere identified that \ninvestigated \ninterf eron, \nlevamisole, vaccine, \nor chem otherapy as \nadjuvant ther apy   only Q -TWiST data, \nno QoL data \npresented  \nstudy exluded   \nSigurda rdottier et \nal. 1993  To assiss the QoL of \npatients with \nmelanoma before \nthe start of quality of life (QoL) \nstudy  \n \nQoL instruments:  89 patients   Before treatment \nthe patients \nreported  a relatively \nlow symptom No assessment \nunder therapy  \nstudy excluded    \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 518 von 732 Study  Aims  Design  Population  Outcome s Results  Comments  LoE \ntreatment  - EORTC QLQ -C36 \n- study -specific \nmelanoma (MM) \nmodule \n-Hospital Anxiety \nand Depre ssion \n(HAD) scale  burden, good \nphysical and social \nfunctio ning, \nmoderate \npsychol ogical \ndistress and a high \noverall QoL r ating \nduring the past \nweek  \nCoates 1993  To measure aspects \nof qu ality of life (QL) \nprospe ctively by \npatients using l inear \nanalogue self \nassessment (LASA) \nscales including the \nGLQ-8 and by \ndoctors using \nSpitzer's QL Index \nwithin a clinical trial \ncompa ring \ndacarbazine (DTIC) \nplus recombinant \ninterf eron-alfa2a \n(IFN) versus DTIC \nalone  QoL ev aluation \nwithin a phase III \nstudy  \n \nQoL instruments:  \npatients: 5 linear \nanalog self \nasses sment (LASA) \nscales, GLQ -8 \nphysician: Spitzer's \nQL Index  \n \nTreatment:  \nDTIC plus \ninterf eron-alfa2a \nversus DTIC alone  Baseline QoL data \navailable of 152 \npatients  \n Prognost ic value of \nQuality of Life \nScores at Baseline  \n In univariate \nanalyses, Spitzer QL \nIndex assessed by \nthe doctor and LASA \nscores for physical \nwellbeing (PWB), \nmood, pain, \nappetite, nausea \nand v omiting, GLQ -\n8 total and overall \nQL were significant \n(P < 0.01) \npredictors of \nsubsequent su rvival Only baseline QoL \ndata  \n \nStudy excluded    \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 519 von 732 Study  Aims  Design  Population  Outcome s Results  Comments  LoE \nKilbridge et al. 2002  To analyse quality -\nof-life-adjusted \nsurvival of the high -\ndose adjuvant \ninterferon alpha -2b \nregimen  A quality -of-life--\nadjusted survival \n(QAS) analysis \nanalysi s of two \ncooper ative group \nphase III trials, \nE1684 and E1690, \nwas pe rformed    E1684: increase in \nQAS for all sets of \npatient utilities, \nsignificant for 16%  \nE1690: increase in \nQAS 77%, decrease \n23%, not significant  Utility weights were \nobtained in a \nseparate study of \n95 low -risk \nmelanoma patients \nand were combined \nwith su rvival and \ntoxicity data of \nE1684 and E1690  \n \nQoL data of the \ntrials are not \npresented  \n \nStudy excluded   \n5.6.5.  Literatur  \n \nAdamina M, Weber WP, Rosenthal R, et al. Heterologous prime -boost immunothe rapy of melanoma patients with Influenza virosomes, and recombinant Vaccinia virus encoding \n5 melanoma epitopes and 3 co -stimulatory molecules. A multi -centre phase I/II open labeled clinical trial. Contemp Clin Trials 2008;29:165 -181 \nAvril MF, Aamdal S, G rob JJ, et al. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study. J Clin Oncol 2004; 22:1118 -\n1125  \nBeguerie JR, Xingzhong J, Valdez RP. Tamoxifen vs. non -tamoxifen treatment for advanced melanoma: a met a-analysis. Int J Dermatol 2010;49:1194 -1202  \nBender CM, Yasko JM, Kirkwood JM, et al. Cognitive function and quality of life in interferon therapy for melanoma. Clin Nurs Res 2000;9:352 -363 \nBottomley A, Coens C, Suciu S, et al. Adjuvant therapy with pegyla ted interferon alfa -2b versus observation in resected stage III melanoma: a phase III randomized controlled \ntrial of health -related quality of life and symptoms by the European Organisation for Research and Treatment of Cancer Melanoma Group. J Clin  Oncol 2009;27:2916 -2923  \nBrandberg Y, Aamdal S, Bastholt L, et al. Health -related quality of life in patients with high -risk melanoma randomised in the Nordic phase 3 trial with adjuvant intermediate -\ndose interferon alfa -2b. Eur J Cancer 2011  \nCashin RP, Lui P, Ma chado M, et al. Advanced cutaneous malignant melanoma: a systematic review of economic and quality -of-life studies. Value Health 2008;11:259 -271 \nChiarion -Sileni V, Del Bianco P, De Salvo GL, et al. Quality of life evaluation in a randomised trial of chemot herapy versus bio -chemotherapy in advanced melanoma patients. \nEur J Cancer 2003;39:1577 -1585   \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 520 von 732 Coates A, Thomson D, McLeod GR, et al. Prognostic value of quality of life scores in a trial of chemotherapy with or without interferon in patients with metastatic  malignant \nmelanoma. Eur J Cancer 1993;29A:1731 -1734  \nCohen L, Parker PA, Sterner J, et al. Quality of life in patients with malignant melanoma participating in a phase I trial of an autologous tumour -derived vaccine. Melanoma Res \n2002;12:505 -511 \nCornish D,  Holterhues C, van de Poll -Franse LV, et al. A systematic review of health -related quality of life in cutaneous melanoma. Ann Oncol 2009;20 Suppl 6:vi51 -8 \nDixon S, Walters SJ, Turner L, et al. Quality of life and cost -effectiveness of interferon -alpha in m alignant melanoma: results from randomised trial. Br J Cancer 2006;94:492 -\n498 \nGarbe C, Radny P, Linse R, et al. Adjuvant low -dose interferon {alpha}2a with or without dacarbazine compared with surgery alone: a prospective -randomized phase III DeCOG \ntrial i n melanoma patients with regional lymph node metastasis. Ann Oncol 2008;19:1195 -1201  \nHofmann MA, Hauschild A, Mohr P, et al. Prospective evaluation of supportive care with or without CVD chemotherapy as a second -line treatment in advanced melanoma by \npatie nt's choice: a multicentre Dermatologic Cooperative Oncology Group trial. Melanoma Res 2011;21:516 -523 \nKiebert GM, Jonas DL, Middleton MR. Health -related quality of life in patients with advanced metastatic melanoma: results of a randomized phase III study  comparing \ntemozolomide with dacarbazine. Cancer Invest 2003;21:821 -829 \nKilbridge KL, Cole BF, Kirkwood JM, et al. Quality -of-life-adjusted survival analysis of high -dose adjuvant interferon alpha -2b for high -risk melanoma patients using intergroup \nclinica l trial data. J Clin Oncol 2002;20:1311 -1318  \nLoquai C, Schmidtmann I, Beutel M, et al. Quality of life in melanoma patients during adjuvant treatment with pegylated inter feron -alpha2b: patients' and doctors' views. Eur J \nDermatol 2011  \nMiddleton MR, Grob JJ , Aaronson N, et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant  \nmelanoma. J Clin Oncol 2000;18:158 -166 \nNoorda EM, van Kreij RH, Vrouenraets BC, et al. The health -related qua lity of life of long -term survivors of melanoma treated with isolated limb perfusion. Eur J Surg Oncol \n2007;33:776 -782 \nPetrella T, Quirt I, Verma S, et al. Single -agent interleukin -2 in the treatment of metastatic melanoma: a systematic review. Cancer Trea t Rev 2007;33:484 -496 \nQuirt I, Verma S, Petrella T, et al. Temozolomide for the treatment of metastatic melanoma: a systematic review. Oncologist 2007;12:1114 -1123  \nRataj D, Jankowiak B, Krajewska -Kulak E, et al. Quality -of-life evaluation in an interferon therapy after radical surgery in cutaneous melanoma patients. Cancer Nurs \n2005;28:172 -178 \nRobinson DW,Jr, Cormier JN, Zhao N, et al. Health -related quality of life among patients with metastatic melanoma: results from an international phase 2 multicenter s tudy. \nMelanoma Res 2012;22:54 -62 \nSchallreuter KU, Wenzel E, Brassow FW, et al. Positive phase II study in the treatment of advanced malignant melanoma with fotemustine. Cancer Chemother Pharmacol \n1991;29:85 -87 \nSigurdardottir V, Bolund C, Brandberg Y, et al . The impact of generalized malignant melanoma on quality of life evaluated by the EORTC questionnaire technique. Qual Life Res  \n1993;2:193 -203 \nSigurdardottir V, Bolund C, Sullivan M. Quality of life evaluation by the EORTC questionnaire technique in patien ts with generalized malignant melanoma on chemotherapy. Acta \nOncol 1996;35:149 -158 \nThomson DB, Adena M, McLeod GR, et al. Interferon -alpha 2a does not improve response or survival when combined with dacarbazine in metastatic malignant melanoma: \nresults of a multi -institutional Australian randomized trial. Melanoma Res 1993;3:133 -138 \nTrask PC, Paterson AG, Esper P, et al. Longitudinal course of depression, fatigue, and quality of life in patients with high risk melanoma receiving adjuvant interferon. \nPsychoo ncology 2004;13:526 -536 \nVerma S, Quirt I, McCready D, et al. Systematic review of systemic adjuvant therapy for patients at high risk for recurrent m elanoma. Cancer 2006;106:1431 -1442  \nYoung AM, Marsden J, Goodman A, et al. Prospective randomized comparison  of dacarbazine (DTIC) versus DTIC plus interferon -alpha (IFN -alpha) in metastatic melanoma. Clin \nOncol (R Coll Radiol) 2001;13:458 -465 \nZiefle S, Egberts F, Heinze S, et al. Health -related quality of life before and during adjuvant interferon -alpha treatme nt for patients with malignant melanoma (DeCOG -trial). J \nImmunother 2011;34:403 -408 \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 521 von 732 5.6.6.  \u00dcbersicht Frageb\u00f6gen  zur Erhebung der Lebensqualit\u00e4t  \n \nEORTC QLQ -C30 ( Version 3.0 is currently the standard version of the QLQ -C30) \nThe QLQ -C30 is a questionnaire for patie nt self -completion, composed of multi -item and single scales. These include five functional \nscales (physical, role, emotional, social, and cognitive), three symptom scales (fatigue, nausea and vomiting and pain) and a  global \nhealth status/QOL scale and six  single items (dyspnoea, insomnia, appetite loss, constipation, diarrhea and financial difficu lties). \n(http://groups.eortc.be/qol/index.htm)  \n \nEORTC QLQ -C36  \nfirst generation core questionnaire. The 36 -item questionnaire was designed 1987 to be (1) cancer s pecific, (2) multidimensional in \nstructure, (3) appropr iate for self -administration (i.e. brief and easy to complete), and (4) applicable across a range of cultural settings.  \n(http://groups.eortc.be/qol/index.htm)  \n \nHADE  Scale  \nDimensionen: Angst, Depressiv it\u00e4t; je 7 Items.  \n \nSF-36 (Short Form (36) Health Survey)  \nEntwickelt in den USA, Kurzform eines urspr\u00fcnglich aus 149 Items bestehenden Fragebogens, der in den 60er und 70er -Jahren \nentwickelt wurde.  \nDeutsche \u00dcbersetzung durch M. Bullinger, I. Kirchberger , Hogrefe Verlag, G\u00f6ttingen   \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 522 von 732 Krankheits\u00fcbergreifendes Me\u00dfinstrument zur Erfassung der gesundheitsbezogenen Lebensqualit\u00e4t von Patienten.  \n2 Bereiche: k\u00f6rperliche Gesundheit und psychische Gesundheit  \n8 Dimensionen: K\u00f6rperliche Funktionsf\u00e4higkeit, K\u00f6rperliche Ro llenfunktion, K\u00f6rperliche Schmerzen, Allgemeine \nGesundheitswahrnehmung, Vitalit\u00e4t, Soziale Funktionsf\u00e4higkeit, Emotionale Rollenfunktion und Psychisches Wohlb efinden.  \n \nQWB-SA \nThe Quality of Well -Being Scale (QWB) has been used in numerous clinical trials and studies over the years to evaluate medical and \nsurgical therapies in conditions such as chronic obstructive pulmonary disease, HIV, cystic fibrosis, diabetes mellitus, atri al fibrillation, \nlung transplantation, arthritis, end stage renal disease, cance r, depression, and several other conditions. Further, the instrument has \nbeen used for health resource allocation modeling and served as the basis for an innovative experiment in the allocation of h ealth care \nby the State of Oregon. Studies have also demon strated that the QWB is respo nsive to clinical change derived from surgery or medical \nconditions such as rheumatoid arthritis, AIDS, and cystic fibrosis.  \nThe self -administered form of the QWB (QWB -SA) was developed more recently. It has been shown to be hi ghly correlated with the \ninterviewer -administered QWB and to retain its psychometric properties. The QWB -SA combines preference -weighted values for \nsymptoms and functioning. Symptoms are assessed by questions that ask about the presence or absence of diffe rent symptoms or \nconditions. Functioning is assessed by a series of questions d esigned to record functional limitations over the previous three days, \nwithin three separate domains (mobility, physical activity, and social activity). The four domain scores a re combined into a total score \nthat provides a numerical point -in-time expression of well -being that ranges from zero (0) for death to one (1.0) for asymptomatic \noptimum functioning.  \nhttp://www.healthmeasurement.org/Measures.html  \n \nGLQ-8 \nTo measure quality  of life in cancer patients receiving chemotherapy   \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 523 von 732 Number of items: 8 plus one optional write -in \nAdministration mode:  Self-administered  \nAuthor: Coates Alan S  \nhttp://www.proqolid.org/instruments/glq_8_glq_8  \n \nLASA scale  \n5 linear analog self assessment (LASA)  scales , measuring physical wellbeing, mood,  pain, nausea and vomiting and appetite  \nIES (Impact of Event Scale)  \na 15-item, self -report scale that assesses two  categories of cognitive responses to stressful events:  intrusion (intrusively experienced \nideas,  images,  feelings or bad dreams) and avoidance (consciously  recognized avoidance of certain ideas, feelings or  situations). The \nscale was originally developed to  assess cu rrent distress associated with a specific  trauma. Patients in the present study were asked to  \nrate the frequency of intrusive thoughts and avoidance  behaviours in relation to their current health  status using a 4 -point scale (0, \u2018not \nat all\u2019; 1, \u2018rarely\u2019;  2, \u2018sometimes\u2019; 3, \u2018often\u2019), with higher scores representing  \nworse functioning. The I ES total score  is the sum of the two subscale scores . \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 524 von 732 5.7. Frage V.9. Medikament\u00f6se Therapie Hirnmetastasen \u2013 De novo Recherche  \n5.7.1.  PICO, Suchw\u00f6rter  \nPICO \u2013 Schema  \nPopulation  Intervention  Comparison  Outcome  \nMelanoma patients with brain \nmetastases  Systemic treat ment  Observation, other systemic treatments  Survival, progression free survival, \nQuality of Life  \n \nSuchw\u00f6rter  \nStichwort  melanoma  Therapy  brain  Temo*, fotemustin  \nSynonyme   treatment  Cerebral, CNS   \nMesh Term      \n \n5.7.2.  Datenbanken, Suchstrategien, Trefferzahl en \nDatenbank  Suchstrategie  Datum  Treffer \n1.Suche     \nMedline  (melanoma[tiab] OR melanoma[MeSH]) AND (treatment[tiab] OR therapy[tiab] OR \ntherapy[MeSH] OR temo*[tiab] OR fotemustin[tiab]) AND (brain[tiab] OR cerebral[tiab] OR \nCNS[tiab] or Brain Neoplasms[M eSH])  30.05.11  1553 (Auswahl 19)  \nEmbase  (melanoma and (treatment or therapy) and (brain or cerebral or CNS)).ti,ab.  11.05.11  1247  \n(Dedubliziert : 346 , 0 dazu )  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 525 von 732 Datenbank  Suchstrategie  Datum  Treffer \nCochrane Library  (melanoma and (treatment or therapy) and (brain or cerebral or CNS)).ti,ab.  20.05.11  28 (Auswahl 3 Dubletten,  0 \ndazu)  \nUpdate Suche     \nMedline  s.o. 31.01.12  1625 (1 dazu , W eber et al. \n2011)  \nEmbase  s.o. 23.01.12  1349 (1 dazu, Heller et al.  \n2011 -Abstr akt) \nCochrane Library  s.o. 31.01.12  31 (0 dazu)  \n \n5.7.3.  Auswahlkriterien  \nAuswahl der L iteratur  \nGesamttreffer  3005  \nEinschlusskriterien  Systematische Reviews oder klinische Studien zur medikament\u00f6sen Therapie bei Melanompatienten mit Hirnmetastasen  \nRCT\u00b4s die Patienten mit Hirnmetastasen eingeschlossen haben  \nSprachen: e,dt  \nAusschlusskriteri en Case Reports  \nNicht systematische Reviews  \nKollektive mit gemischten Tumorentiti\u00e4ten  \nKombination mit Radiotherapie  \nAnzahl nach Abstractscreening, vorges ehen f\u00fcr Bewertung  22 \nAnzahl ausgew\u00e4hlter Studien nach Handsuche (Durchsicht der Literaturlisten)  0  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 526 von 732 Auswahl der L iteratur  \nAnzahl der ausgeschlossenen Studien nach Sichtung der Volltexte  9 \nAnzahl ausgew\u00e4hlter Volltexte  13 (davon 1 Asco Abstract  \n \n5.7.4.  Evidenztabelle  \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nHodi et al. 2010  To compare \nipilimumab, \nadmini stered wit h \nor without a \nglycoprotein 100 \n(gp100) pe ptide \nvaccine with gp100 \nalone in patients \nwith pr eviously \ntreated metastatic \nmelanoma  RCT \n \nTreatment:  \n \nGroup A ipilimumab \nplus gp100 (n=403)  \nGroup B ipilimumab \nalone (n=137)  \nGroup C gp100 \nalone (n=136)  676 HLA -A*0201-\npositive patients \nwith previously \ntreated unresect able \nstage III or IV \nmelanoma  \n \n82 patients with \nbrain metastases   \n \n \n \n \nMedian Overall \nsurvival  \n \n \n \n \nOverall Response \nRate \n All patients \n(ipilimumab \n+gp100 vs. \nipilimumab vs. \ngp100)  \n \n10.0 months vs. \n10.1 m onths vs. 6.4 \nmonths, sign., \n(hazard ratio for \ndeath, 0.68; \np<0.001).  \n \n5.7% (n=23) vs. 11% \n(n=15) vs. 1.5% \n(n=2), sign., p=0.04  Outcomes of \npatients with brain \nmeta stases not \nreported separately  \n 4 \nAvril et al. 2004  To compare \nfotemustine and \ndacarbazine  (DTIC) RCT \n \nTreamtent:  229 patients with \nmetastatic \nmelanoma   \n \n Patients with brain \nmetastases n=43  \nArm A Fotemustin Outcomes of \npatients with brain \nmeta stases not 4  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 527 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \nin in patients with \ndisseminated \ncutan eous \nmelanoma  Arm A: Fotemustine  \nArm B: DTIC   \n43 patients with \nbrain m etastases \n(Arm A n=22, Arm B \nn=21)   \n \nResponse  \n \n vs. Arm B DTIC  \n \nCR n=0 versus n=0  \nPR n=1 versus n=1  \nSD not reported  \nPD not reported  \n reported in detail.  \n \nAuthor contacted, \nno reply  \nWeber et al. 2011  To further evaluate \nthe efficacy and \nsafety of ipilimumab \nat 10 mg/kg in \nmelanoma patients \nwith stable brain \nmetastases.  Retrospective \nanalysis of data \nfrom a phase II \nstudy  12 patients with \nstable brain \nmeta stases  Response  \n \n \nSurvival  PR n=2 of 12  \nSD n=3 of 12  \n \nMedian OS: 14 \nmonths  \n \nBoth pati ents with a \npartial response and \none with stable \ndisease were alive at \nthe last follow -up, \nwith survival time of \nmore than 4 years  Lack of control \ngroup  4 \nAmaravadi et al. \n2009  To evaluate the \ncombination of the \noral alkylating agent \ntemozol omide and \nthe oral multikinase \ninhib itor sorafenib Phase II study  \n \nTreatment:  \nSorafenib 400mg \ntwice daily  \n+ temozolomide  167 patients with \nmetastatic \nmelanoma  \n \n53 patients with \nbrain m etastases Response rates  \n \n \n \n \n Evaluable patients \n(Arm D with brain \nmetastases) n=52  \n \nCR rate: 0%  \nPR rate: 15%  Response assessed \naccording RECIST \ncriteria, CT every 8 \nweeks  \n \nLack of control 4  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 528 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \nin advanced \nmelanoma patients   \n (Arm D)   \n \n \n6-month PFS  rate \nMedian PFS  \nMedian OS  SD rate: 48%  \nPD rate: 37%  \n \n23% \n3.5 months  \n8 months  group  \nVestermark  et al. \n2008  To evaluate single \nagent antitumour \nactivity and toxic ity \nof Thalidomide in a \nphase II se tting in \npatients with brain \nmetastases \nassociated with \nmeta static \nmelanoma  Phase II study  \n \nTreatment:  \nthalidomide  36 patients with \nbrain metastases  CNS Response  \n \n \nCR+PR  \nSD \nPD \n \nMedian PFS  \nMedian OS  Evaluable patients: \nn=35  \n \nn=0 \nn=5 \nn=30  \n \n1.7 months  \n3.1 months  Response assessed \naccording RECIST \ncriteria, CT or MRI \nevery 3 months  \n \nLack of control \ngroup  4 \nLarkin et al. 2007  To assess the \nmaximum -tolerated \ndose (MTD), saf ety \nand efficacy of the \ncombination of \ntemozolomide and \nlomustine in \nmelanoma \nmeta static to the \nbrain  Phase I/II study  \n \nTreatment:  \ntemozolomide + \nlomustine  26 patients with \nbrain metastases  CNS Response  \n \n \nCR+PR  \nSD \nPD \n \nMedian OS  Evaluable patie nts: \nn=20  \n \nn=0 \nn=10, 50%  \nn=10, 50%  \n \n2 months  Response assessed \naccording WHO \ncriteria, CT or MRI \nafter 3.+ 6. cycle \n(28days/cycle)  \n \nonly 10% of patients \nreceived more than \n2 cycles of therapy  \n 4  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 529 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \nLack of control \ngroup  \nSchade ndorf et al. \n2006  To test a dose -\nintensified regimen \nof temozolomide in \nmelanoma patients \nwith brain \nmeta stases in a \nprospe ctive, open -\nlabel, multicentre \nphase II trial  Phase II study  \n \nTreatment:  \ntemoz olomide  \n \n 45 patients with \nasymptomatic brain \nmetastases  CNS Response  \n \n \n \n \nCR \nPR \nSD \nPD \n \nMedian OS  Evaluable patients: \nn=40 (5 missing \npatients: no clinical \nresponse)  \n \nn=0 \nn=2, 4.4%  \nn=5 \nn=33  \n \n4.1 months  Response assessed \naccording RECIST \ncriteria, CT or MRI, \nweek 8 and week \n20, responses were \nconfirmed 4 weeks \nlater.  \n \nLack of control \ngroup  4 \nHwu et al. 2005  To examine the \nefficacy and safety \nof temozolomide \nplus thalidomide in \nchemother apy-\nnaive patients with \nbrain meta stases  Phase II study  \n \nTreatment:  \ntemozolomide + \nthalidomide  26 patients with \nbrain metastases, \n16 with \nsymptoma tic brain \nmetastases  CNS Response  \n \n \nCR \nPR \nSD \nPD \n \nMedian OS  Evaluable patients: \nn=14  \n \nn=2 \nn=1 \nn=7 \nn=4 \n \n5 months  Response assessed \naccording WHO \ncriteria, CT or MRI \nevery 8 weeks  \n \n11 patients did not \ncomplete first cycle  \n \nLack of control \ngroup  4 \nBafaloukos et al. \n2004  To evaluate the \nefficacy and toxicity \nof temozol omide -Analyses of patients \nwith brain \nmeta stases within 2 25 patients with \nbrain metastases  CNS Response  \n \n Evaluable patients: \nn=24  \n Response assessed \naccording WHO \ncriteria, CT or MRI 4  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 530 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \nbased \nchemotherapy in \npatients with \ncerebral metastases \nfrom melanoma.  Phase II studies  \n \nTreatment:  \ntemozolomide + \ndocetaxel n=10, \ntemozol omide + \ncisplatin n=9,  \ntemozolomide alone \nn=6 CR \nPR \nSD \nPD \n \nMedian OS  \n1-year survival rate  n=0 \nn=6 \nn=5 \nn=13  \n \n4.7 months  \n20.9%  \n every second cycle \n(28 days/cycle)  \n \nLack of control \ngroup  \nAgarwala et al. \n2004  To assess the saf ety \nand efficacy of \ntemozolomide in \npatients with brain \nmetastases from \nmetastatic \nmelanoma  Phase II study  \n \nTreatment:  \ntemozolomide  \n \n 151 patients with \nbrain metastases  \n \nn=117 no prior \nchemotherapy  \nn=34 prior \nchem otherapy  CNS Response  \n \n \nCR \nPR \nSD \nPD \n \n \nMedian OS  Evaluable patients: \nn=132  \n \nn=1 \nn=8 \nn=40  \nn=73  \n \nall patients (n=151)  \n3.2 months  \n Large study  \n \nResponse assessed \naccording WHO \ncriteria, \ngadolinium -\nenhanced MRI every \nsecond cycle (28 \ndays/cycle), \nresponses were \nconfirmed 4 weeks \nlater.  \n \nLack of control \ngroup  4 \nChang et al. 1994  To investigate the \nsequential Phase II study  \n 34 patients with \nbrain metastases  Response  \n Evaluable patients: \nn=34  Tumour response \nwas defined 4  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 531 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \nadmini stration of \ndacarb azine and \nfotemustine in the \ntreatment of \ncerebral metastases \nfrom malignant \nmelan oma Treatment:  \nDTIC + fotemustine   \nCR \nPR \nSD \n \n \n \n \n \nMedian OS   \nn=2  \nn=2 \nn=9 \n \nduration of \ncomplete response: \n12, 36+ months  \n \n4.5 months  accor ding to Worl d \nHealth  \nOrganisation criteria  \n \nLack of control \ngroup  \nJacquillat et al. \n1990  To investigate the \nactivity of \nfotemu stine against \ncerebral metastases \nof disseminated \nmalignant \nmelan oma Phase II study  \n \nTreatment:  \nfotemustine  42 patients with \nbrain metastas es \n  \n16 patients with \nonly brain \nmeta stases, 23 \npatients with  brain \n+  extracerebral \nmetastases  Response  \n \n \nCR \nPR \nSD \nPD \n \nMedian OS  \n \n1-year survival  Evaluable patients: \nn=39  \n \nn=2 \nn=9 \nn=9 \nn=19  \n \n26 weeks (6 \nmonths)  \n21% Tumor assessment \naccording WHO \ncriteria  \n \nLack of control \ngroups  4 \nHeller et al. 2011  To report safety and \nefficacy  data of \ntreatment with \nIpilimumab in \npatients with brain open -label study  \n \nTreatment:  \nipilimumab 3 or 10 \nmg/kg  165 with brain \nmetastases at \nbaseline  (of 869 \npatients)  Toxicity  \n \n \n \n drug-related \nserious adverse \nevents of any grade : \n26.1%  \n(similar rate to pts only asco abstract \navailable    \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 532 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \nmeta stases   \n \n1 year survival  without brain \nmetastases)  \n \n20% \n \n5.7.5.  Literatur  \n \n \nAgarwala SS, Kirkwood JM, Gore M, et al. Temozolomide for the treatment of  brain metastases associated with metastatic melanoma: a phase II study. J Clin Oncol \n2004;22:2101 -2107  \nAmaravadi RK, Schuchter LM, McDermott DF, et al. Phase II Trial of Temozolomide and Sorafenib in Advanced Melanoma Patients w ith or without Brain Metast ases. Clin Cancer \nRes 2009;15:7711 -7718  \nAvril MF, Aamdal S, Grob JJ, et al. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study. J Clin Oncol 2004; 22:1118 -\n1125  \nBafaloukos D, Tsoutsos D, Kalofonos H, et al. Temozolomide and cisplatin versus temozolomide in patients with advanced melanoma: a randomized phase II study of the \nHellenic Cooperative Oncology Group. Ann Oncol 2005;16:950 -957 \nChang J, Atkinson H, A'Hern R, et al. A phase II study of the sequentia l administration of dacarbazine and fotemustine in the treatment of cerebral metastases from malignant \nmelanoma. Eur J Cancer 1994;30A:2093 -2095  \nHeller KN, Pavlick A.C., Hodi F.S., et al. Safety and survival analysis of ipilimumab therapy in patients with stable asymptomatic brain metastases. Journal of  Clinical Oncology, \n2011 ASCO Annual Meeting Proceedings (Post -Meeting Edition). 2011;Vol 29:8581  \nHodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanom a. N Engl J Med 2010;363:711 -723 \nHwu WJ, Lis E, Menell JH, et al. Temozolomide plus thalidomide in patients with brain metastases from melanoma: a phase II study. Cancer 2005;103:2590 -2597  \nJacquillat C, Khayat D, Banzet P, et al. Final report of the French  multicenter phase II study of the nitrosourea fotemustine in 153 evaluable patients with disseminated malignant \nmelanoma including patients with cerebral metastases. Cancer 1990;66:1873 -1878  \nLarkin JM, Hughes SA, Beirne DA, et al. A phase I/II study of lo mustine and temozolomide in patients with cerebral metastases from malignant melanoma. Br J Cancer \n2007;96:44 -48 \nSchadendorf D, Hauschild A, Ugurel S, et al. Dose -intensified bi -weekly temozolomide in patients with asymptomatic brain metastases from malign ant melanoma: a phase II \nDeCOG/ADO study. Ann Oncol 2006;17:1592 -1597  \nVestermark LW, Larsen S, Lindelov B, et al. A phase II study of thalidomide in patients with brain metastases from malignant melanoma. Acta Oncol 2008;47:1526 -1530  \nWeber JS, Amin A, Mino r D, et al. Safety and clinical activity of ipilimumab in melanoma patients with brain metastases: retrospective analysis of data from a phase 2 trial. \nMelanoma Res 2011;21:530 -534  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 533 von 732 6. AG Radiotherapie  \n6.1. Frage VI.1. Radiotherapie Prim\u00e4rtumor  \nFrage VI.1. Hat ein e Radiotherapie von inoperablen Prim\u00e4rtumoren oder eine postoperative Radiotherapie nach R1 oder R2 -Resektion \nvon Prim\u00e4rtumoren bzw. bei Vorhandensein anderer Risikofaktoren (nicht einhaltbare Sicherheitsabst\u00e4nde) einen Einfluss auf da s \nprogressionsfreie \u00dc berleben oder Gesamt\u00fcberl eben? \n6.1.1.  PICO, Suchw\u00f6rter  \nPICO - Schema  \nPopulation  Intervention  Comparison  Outcome  \nMelanoma patients with pr imary \ntumor, prior or after (partial) \nresection  radiotherapy  no radiotherapy  PFS, OS  \n \nSuchw\u00f6rter  \nStichwort  melanoma  radiot herapy  primary  margin  \nSynonyme   Radiation, irradiation    \nOber -/Unterbegriffe  Lentigo maligna, cutaneous, \nskin   Resection, R1, R2, inoperable, \nunresectable, adjuvant, \npostoperative  \nMesh Term  melanoma  radiotherapy, radiation    \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 534 von 732 6.1.2.  Datenbanken, Suchstrategi en, Trefferzahlen  \nDatenbank  Suchstrategie  Datum  Treffer  (Auswahl)  \n1. Suche     \nMedline  (melanoma[tiab] OR melanoma[MeSH]) AND (radiotherapy[tiab] OR radiother apy[MeSH] \nOR radiation[tiab] OR radiation[MeSH]) AND (primary OR \"lentigo mali gna\" OR margin* \nOR resection OR R1 OR R2 OR inoperab* OR unresectab*) NOT (uvea*[ti] OR \nanorectal[ti] OR mucosal[ti])  20.04.11  1836 (Auswahl 22 \nStudien)  \nMedline -Erweiterte \nSuchstr ategie  \n (melanoma[tiab] OR melanoma[MeSH]) AND (radiotherapy[tiab] OR radiother apy[MeSH] \nOR ra diation[tiab] OR radiation[MeSH] OR irradiation) AND (skin OR cutan eous OR \nprimary OR \"lentigo maligna\" OR margin* OR resection OR R1 OR R2 OR postoperative \nOR inoperab* OR unresectab*) NOT (uvea*[ti] OR anorectal[ti] OR muco sal[ti])  16.05.11  5435 (Auswahl  8 Studien)  \nCochrane Library  (melanoma  and (radiotherapy  or radiation or irradiation) and (skin or cutaneous or \nprimary or \"lentigo maligna\" or margin* or resection or R1 or R2 or adjuvant or \npostoperative or inoperab* or unresectab*) not (uvea* or anor ectal or mucosal)) .ti,ab.  20.04.11  42 (0)  \nEmbase  (melanoma  and (radiotherapy  or radiation or irradiation) and (skin or cutaneous or \nprimary or \"lentigo maligna\" or margin* or resection or R1 or R2 or adjuvant or \npostoperative or inoperab* or unresectab* ) not (uvea* or anorectal or mucosal)) .ti,ab.  11.05.11  3272 (Auswahl 3 Studien)  \nUpdate Suche     \nMedline  s.o. 31.01.12  5613 (1Studie dazu, \nHedblad et al. 2011)  \nCochrane Library  s.o. 31.01.12  42 (0  dazu ) \nEmbase  s.o. 23.01.12  3475 (0  dazu ) \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 535 von 732 6.1.3.  Auswahlkriter ien \nAuswahl der Literatur  \nGesamttreffer  8721  \nEinschlusskriterien  Mangels RCT\u00b4s Einschluss von Kohortenstudien und Fallserien ab 20 Patienten  \nSprachen: e,dt  \nAusschlusskriterien  Case Reports  \nNicht systematische Reviews  \nKombinationstherapien  \nArbeiten zu RT  von nicht invasiven Melanomen (Melanoma in situ/Lentigo maligna)  \nKollektive mit gemischten Tumorentit\u00e4ten  \nArbeiten \u00e4lter als 1980  \nAnzahl nach Abstractscreening, vorges ehen f\u00fcr Bewertung  34 \nAnzahl der ausgeschlossenen Studien nach Sichtung der Volltexte  19 \nAnzahl ausgew\u00e4hlter Volltexte  15 \n \n6.1.4.  Evidenztabelle  \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nWasif et al. 2011  To study the \nsurgical \nmanag ement of \ndesmoplastic \nmelanoma (DM), \nidentify prognostic \nfactors, and impact Retrospective \ncohort study  \n 1735 patients with \ndesmoplastic \nmelanoma  \n \n143 (8%) of p atients \nin the cohort \nreceived adjuvant survival  adjuvant radiation \ntherapy: \nnegative impact on \nsurvival [HR 1.65 \n(95% CI 1.17 -2.31)]  Adverse impact of \nRT pro bably reflects \nselection bias  3b \n \nCohort \nstudy with \nimba lance of \ngroups   \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 536 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \nof treatment \noptions  radioth erapy \nChen et al. 2008  To describe the \nclinicopathologic \nfeatures of  \ndesmoplastic \nneurotropic \nmelanoma (DNM), \nto update \noutcomes, and to \nexplore the role of \nadjuvant radi ation \ntreatment in the \nmanagement of this \nentity  Retrospective \ncohort study  \n \nTreatment:  \nSurgery + different \nRT modalities and \nschedules  128 patients with \nDNM \n27 patients received \nradiotherapy after \nlocal excision  Local recurrence  \n \n \n \n \nPrognostic factors  RT group, N=27:  \nn=2 (7.4%)  \nSurgery only, \nN=101: n=6 (5.9%)  \n \nsignificant \npredi ctors of local \nrecurrence:  \n-a positive margin \n(P < .001)  \n-head and neck \nlocation (P = .03)  Imbalance of \ngroups: RT group \nincluded more \npatients with worse \nprogno stic factors \n(closer exicision \nmarg in, higher \ntumor thicknes, \nmore head and neck \ntumors)  \n 3b \n \nCohort \nstudy with \nimba lance of \ngroups  \nHedblad et al. 2011  To evaluate Grenz \nray treatment in a \nstructured way for \ntreatment of Lentigo \nmaligna melanoma \nas an alternative to \nsurgery Retrospective \ncohort study  \n \nTreatment:  \nGrenz ray treatment  593 patients with \nLentigo maligna or \nearly lentigo \nmaligna mel anoma  Complete clearance  88% Lack of control \ngroup  4 \nVongtama et al. \n2003  To address the role \nof radi ation therapy \nin local control of \ndesmoplastic Retrospective \ncohort study  \n (1976 \u2013 1999)  \n 44 patients with \nDMM  \n14 patients with \npostoperative RT Local recurrence  \n \nLocal control in re \ncurrent DMM  Overall: n=21 (48%)  \n \nSurgery +RT (15 \npts) Possible selection \nbias, Imbalance of \ngroups, small \nsample size  4 \n \nCohort \nstudy wi th  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 537 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \nmalignant \nmelanoma (DMM)  Treatment:  \nSurgery alone  \nSurgery + RT, \nmedian dose 50 Gy  after local \nrecurrence  \n1 patient with \npreoperative RT   \n \n \nDistant metastasis  n=15  \nSurgery alone (7pts)  \nn=3 \nnonirradiated \npatients 35%  \nirradiated patients \n40% imba lance of \ngroups and \nsmall \nsample size  \nFoote et al. 2008  To address the role \nof radiotherapy in \nthe local control of \ndesmoplastic \nmelanoma  Retrospective \nevaluation  \n \nTreatment:  \nSurgery + wide  \nfield radiotherapy \nwith a 3 - to 4-cm \nmargin  \n 24 patients with DM \nreceived surgical \nexcision as initial \ntreatment followed \nby pos toperative \nradiotherapy  3-year in -field \nrelapse -free \nsurvival  \n \n \n3-year relapse -free \nsurvival  \n \n \n3-year overall \nsurvival 91% (95%  \nconfidence interval \n68.1\u201397.6%)  \n \n 86% (95% \nconfidence int erval \n63.2\u201395.4%)  \n \n83% (95% \nconfidence interval \n54.9\u201394.3%).  Lack of control \ngroup  4 \nArora et al. 2005  To determine local \nrecurrence rates for \npatients with \ndesmoplastic \nmelanoma who \nunde rwent wide \nexcision alone  Retrospective \nevaluation  \n \nTreatment: sur gery \nalone  \n 65 Patients with  \nDM received \nsurgi cal excision \nalone  \n \n Local recurrence \nrate n=2 ( 4% )  \nof 49 patients with \nminimum of 2 years \nof follow -up Lack of control \ngroup  4 \nFarshad et al. 2002  To perform a Retrospective 150 patients with Local recurrence n=7 (7%)  Lack of control 4  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 538 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \nretrospective study \nof 150 patients with \nlentigo maligna (LM) \nand lentigo maligna \nmelanoma  (LMM) \ntreated with \nradiotherapy using \nGrenz or soft X -\nrays. evaluation  \n \nTreatment:  \nGrenzrays (12 kV)  \nX-rays (20 or 30 kV)  \n \nLM: 10 -12 Gy x 10 \nfractions  \nLMM 7 -9 Gy x 6 \nfractions  LM or LMM  \ntreated at the skin \ncancer unit of the \nDepartment of  \nDermatology, \nUniversity of Zurich \n(Switze rland)  \nbetween 1950 and \n2000   rate of 101 patients \nfollowed up for at \nleast 2 years  group  \nSchmid -Wendtner \net al. 2000  To present the \nresults of a \nfractionated \nradiation therapy \n(modified \nMiescher\u2019s \ntechnique) in 64 \npatients with LM or \nLMM treated \nbetween 1987 and \n1998.  Retrospective \nevaluation  \n \nTreatment:  \nsuperficial x -ray \nunit (Dermopan, \nSiemens, Erlangen, \nGerm any)  \n100 Gy applied in \n10 fractions, safety \nmargin: 0.5 - 2.0 \ncm  64 patients  \nwith LM (n =42)  \nand LMM (n= 22)  Local recurrence \nrate LM n=0 (0%)  \nof 42 patients  \nLMM n=2 (9%)  \nof 22 patients  \n \nmedian fo llow up \n15 months  \n Lack of control \ngroup  4 \nStevens et a l. 2000  To assess local \nrecurrence and \nsurvival of patients \ntreated with surgery Retrospective \nevaluation  \n \nTreatment:  174 Stage I \u2013III \nmelanoma patients \nreceived \npostoperative Local recurrence \nrate  \n \n n=20 (11%) (Group \nA and B)  \n \n Lack of control \ngroup  \nNo baseline \nchara cteristics 4  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 539 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \nand postoperative \nhypofractionated \nradiation therapy  TD 30 \u201336 grays \n(Gy), 5 \u20137 fractions, \ntwice wee kly radiation the rapy \n \nGroup A n=32: \nprimary tumor site  \n(Group B n=142: \nlymph node \ninvolvement)  3-years metastasis \nfree survival  60% (Group A)  presented  \nPanizzon et al. \n1999  To report radiation \ntreatment results of \n129 patients with \nthe precursor lesion \nlentigo m aligna and \n27 patients with \nlentigo maligna \nmelan oma Retrospective \nevaluation  \n \nTreatment:  \nRT alone  27 patients with \nlentigo m aligna \nmelanoma  Complete response  n=25 (92.8%)  Lack of control \ngroup  \n 4 \nAng et al. 1994  To assess the \nefficacy and toxicity \nof elective -\nadjunctive \nradiotherapy given \nin five 6 -Gy \nfractions to patients \nwith cut aneous \nmelanoma of the \nhead and neck at \nhigh r isk for l ocal-Retrospective \nevaluation  \n \nTreatment:  \n(most patients) \nelectrons, mostly 9 -\n12 MeV, 6 -Gy dose \nper fra ction, twice a \nweek, total dose \n30Gy  \n 174 melanoma \npatients  \n \nGroup 1 (n=79) RT \nafter wide excision  \nGroup 2 (n=32) \nRT+limited n eck \ndissection  \nGroup 3 (n=63) RT \nafter neck \n ecur ttion for 5-year local -\nregional control  \n \nSurvival  \n \n \nPattern of failure \n(after median \nfollow-up of 35 \nmonths)  88% (all patients)  \n87% (Group 1)  \n \n47% (all patients)  \n62% (Group 1)  \n \nGroup 1  \nNED n= 51  \nDermal r  ecur. N=2  \nNodal relapse n=2  \nD+N n=1  Lack of control \ngroup  \n 4  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 540 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \nregional relapse  nodal r elapse  \n Distant met. N=21  \nStorper et al. 1993  To elucidate the \nefficacy of external \nbeam irradi ation in \nthe treatment of \nhead and neck \nmalignant \nmelanoma, in \ncompar ison with the \nefficacy of  surgical \nexcision and the \nefficacy of su rgical \nexcision co mbined \nwith external beam \nirradiat ion Retrospective \nevaluation  \n \nTreatment:  \n-surgery (SE), n=26  \n-primary external \nbeam irra diation \n(XRT), n=10  \n-adjuvant external \nbeam irra diation \n(SE+XRT), n=8  44 m elanoma \npatients with \nrecurrent disease  \n \n Survival  SE 19%  \nXRT 20%  \nSE+XRT 37%  Imbalance of \nprognostic factors \nbetween groups  \nSite of RT not \nmentioned  \n 4 \nPhipps et al. 1992  To examine  the \neffect of \nimmediat ely \npreoperative \nadjuvant \nradiotherapy in the \nsurgi cal treatment \nof primary \ncutaneous \nmalignant Retrospective \nevaluation  \n(1958 -1970)  \n \nTreatment:  \nAll patients: 400 \ncGy external beam \nradiotherapy, 52 \npatients add itional \nsingle -fraction 77 melanoma \npatients,  \nclinical Sta ge I \n 5-years survival  \n10-year survival  \nLocal recurrence  \n 68% \n57% \n14% \n \nFollow -up minimum \n10 years  Lack of control \ngroup  \nTumor thickness \nnot mentioned  4  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 541 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \nmelanoma  2000 cG y \nSurgery within 24h  \nElsmann et al. 1991  To facilitate clinical \ndecisions the \nauthors report on \ntheir results using \nsoft X -ray therapy \nof primary \nmelan omas Retrospective \nevaluation  \n(1974 -1989)  \n \nTreatment:  \nSoft X -ray 30 -\n100kV  \nTD 48 \u2013 105 Gy, \nfraction size 3.5 \u2013 7 \nGy \n \nafter total excision \nn=23  \nafter partial \nexcision n=41  \nwithout prior \nexcision n=19  83 melanoma \npatients  \nLMM n= 64 \nSSM n=8  \nNMM n=6  \nNot classified n=5  \n \npT1 n=17  \npT2 n=13  \npT3 n=19  \npT4 n=13  \npT classification not \navailable n=2  \nnot biopsied n=19  Local recurrence  \n \n \n \n \n \n \n \n \n \nSurvival  n=1 (skin \nmetast asis) \nRT after total \nexcision \n \nn=1 (recurrent \ntumor nodule)  \nRT without total  \nexcision \n \n60%,  (melanoma \ndeaths 9.6%, other \ndiseases 30.1%)  \n \nFollow -up median \n42 months  Lack of control \ngroup  4 \nHarwood et al. \n1983  To review the \nresults of radiation \ntreatment of 51 \npatients with LM \nand LMM.  Retrospective \nevaluation (1958 -\n1982)  \n \nTreatm ent: \nLMM 125, 140 or \n175 KEV  28 patients with \nLentigo maligna \nmelanoma  Local recurrence or \nresidual tumor  \nNo local recurrence  \nNot assessable  n=2 (7%)  \n \nn=23 (82%)  \nn=3 (11%)  Lack of control \ngroup  4  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 542 von 732 Ausgeschlossene Studien  \nStudy  Aims  Design  Population  Outcom es Results  Comments  LoE \nZygogianni et al. \n2011  To assess the \npotential impact of \nradiotherapy (RT) on \nlocal control, quality \nof life and overall \nsurvival  Review  Pubmed 1978 - \n2010    Non systematic \nReview, excluded   \nNewlin et al. 2005  To report our \nexperi ence with \nneurotropic \nmelanoma  Case Series  \n \nTreatment:  \nSurgery + x -rays (6 \nMV) \n 3 patients with \nneurotropic \nmelanoma  \nreceived RT after \nincomplete excision \n(n=2) and adjuvant \nRT after complete \nexcision (n=1)  Local control  1 patient: \nrecurrence in a \nregional  lymph \nnode after 30 \nmonths  \n2 patients disease -\nfree (after 34 and \n14 months)  <20 patients, study \nexcluded   \nCooper et al. 2001  To report our in itial \nresults with elective \nradiation therapy \nafter definitive \nsurgery for selected \npatients who have \nhigh-risk m alignant \nmelanomas.  Retrospective \nevaluation  \n \nTreatment:  \nSurgery + 6Gy per \nfraction, 5 or 6 \nfractions  40 patients with \nhigh-risk mali gnant \nmelanomas  \n \n29 patients with \nrecurrent primary or \nregional disease  \n \n9 patients: close or \nmicroscopically \ninvolved su rgical \nmargins  5-year local -\nregional control rate  \n \n 84% majority of p atients \nreceived RT for \nrecurrent disease. \nAnalyses were \nperformed together \nfor the very \nheteroge nous \ngroup , \nstudy excluded  \n  \nSeege nschmiedt et To analyze relevant Retrospective 2 917 melanoma Response at 3 CR n=7 (64%)  <20 patients RT   \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 543 von 732 Study  Aims  Design  Population  Outcom es Results  Comments  LoE \nal. 1999  endpoints (tu mor \nresponse, local \ntumor control, \nsurvival) and to \nidentify prognostic \nfactors for \nachievement of \nthese endpoints in \nlong-term follow -\nup (FU)  evaluation  \n \nTreatment:  \nlinac 6 \u201310 MV  \nphotons  \nor 4\u201318 MeV \nelectrons  patients  \n121 rec eived RT, \nthereof  \n11 patients with \nrelapsed/residual \nMM (UICC IIB)  \n months  \n \nRecurrence rate  \n \nIn-field local \nrelapse  \n \nRegional in -transit \nmetastases  \n PR n=4 (36%)  \n \nn=3 (27%)  \n \nn=2 (18%)  \n \nn=1 (9%)  \n \nof 11 patients  primary tumor, \nstudy e xcluded  \nTsang et al.  To report the \nexperience with \nradiotherapy for \nlentigo maligna  Retrospective \nevaluation  \n \n 54 patients with \nlentigo maligna    No patients with \nlentigo maligna \nmelanoma  \nstudy excluded  4 \nUmebay ashi et al \n1995  To answer whet her \nor not the proton \nbeam can pr ovide \nuseful trea tment for \ncutaneous \nmelan oma Case series  \n \nTreatment:  \nproton beam, t otal \ndose of around 100 \nGy, fracti onated \ninto single doses of \nappro ximately 10 \nGy 7 patients  \n \nwith 5 primary \nmelanomas and 3 \nmetastatic lymph \nnodes  Regression primary \nmelanoma  100%   n=1  \n90%     n=2  \n80%     n=1  \n85%     n=1  <20 patients, study \nexcluded   \nRounsaville et al. \n1988  Radiotherapy in the \nmanagement of \ncutaneous \nmelan oma: effect of \ntime, dose, and Review     Non systematic \nReview, excluded    \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 544 von 732 Study  Aims  Design  Population  Outcom es Results  Comments  LoE \nfraction ation \nVon Rottkay et  al. \n1987  Radiation therapy in \nmalignant \nmelan oma using \naccel erated \nfractionation. \nRemission and \npreliminary results \nof local tumor \ncontrol  Retrospective \nevaluation  \n(1982 -1985)  \n 14 patients at \ndifferent clini cal \nstages    <20 patients, \ndifferent stages, \nstudy e xcluded   \nBlake et al. 1985  To report the \nresults of treatment \nof malignant \nmelanoma by fast \nneutrons  Retrospective \nevaluation  \n \nTreatment:  \n156OcGy in 12 \nfractions (4 weeks) \nor 1395cGy in 6  \nfractions (2 w eeks)  7 patients with \nprimary m elanomas  \n \n(of 48 melanoma \npatients with 87 \ntumors)  \n Response  CR n=6 (86%) of 7 \nprimary melanomas  <20 patients, study \nexcluded   \nOvergaard et al. \n1980  Radiation Trea tment \nof malignant \nmelanoma  Retrospective \nevaluation (1970 -\n1980) \n \nTreatment:  \nDifferent fractions \nand dose schedules  36 patients with  \n24 skin lesions and \n25 lymph node \nmetastases  Response  \nCR \nPR \nNo response  \nProgression  \n \n \n \nCR \nPR skin lesions n=24  \nn=7 \nn=10  \nn=6 \nn=1 \n \nlymph node \nmeta stases n=25  \nn=5 \nn=10  Baseline \ncharact eristics \nmissing  \nprimary melanomas \nand skin metastases \nare not \ndistinguished  \n \nstudy e xcluded    \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 545 von 732 Study  Aims  Design  Population  Outcom es Results  Comments  LoE \nNo response  \nProgression  n=8 \nn=2 \nTonak et al. 1976  To present the \ntreatment results of \n195 melanoma \npatients (clinical \nstages I and II)       published before \n1980,  study \nexcluded   \nVon Lieven et al. \n1976  To investigate the \ncorrelation b etween \nthe total dose \nneeded for a local \nhealing and the \nperiod of treatment      published before \n1980, study \nexcluded   \nK\u00f6nig et al. 1970  Problems in the \nradiological \ntreatment of \nmalignant \nmelan omas of the \nskin. Report on 136 \npatients followed -\nup over long p eriod \nof time      published before \n1980, study \nexcluded   \nStein et al. 1965  The avoiding of a \ncombination -effect \nin combined \nsurgi cal-\nradiological \ntreatment of     published before \n1980, study \nexcluded    \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 546 von 732 Study  Aims  Design  Population  Outcom es Results  Comments  LoE \nmalignant skin \ntumors \nHellriegel et al. \n1963  To present \nradioth erapentic \nimprov ements and \nresults in malignant \nmelan omas     published before \n1980, study \nexcluded   \nWernsdoe rfer et al. \n1960  On the treatment \nand prophylaxis of \nmalignant \nmelan oma skin \ntumors      published before \n1980, study \nexcluded   \nSpoljar et al. 1959  The treatment of \nmalignant \nmelan oma     published before \n1980, study \nexcluded   \nNitter et al. 1956  The treatment of \nmalignant \nmelan oma with \nspecial reference to \nthe possible effect \nof radiotherapy      published before \n1980, study \nexcluded   \nGreve et al. 1952  Roentgen irradi ation \nof skin tumors      published before \n1980, study \nexcluded   \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 547 von 732 6.1.5.  Literatur  \n \nAng KK, Peters LJ, Weber RS, et al. Postoperative radiotherapy for cu taneous melanoma of the head and neck region. Int J Radiat Oncol Biol Phys 1994;30:795 -798 \nArora A, Lowe L, Su L, et al. Wide excision without radiation for desmoplastic melanoma. Cancer 2005;104:1462 -1467  \nBlake PR, Catterall M, Errington RD. Treatment of malignant melanoma by fast neutrons. Br J Surg 1985;72:517 -519 \nChen JY, Hruby G, Scolyer RA, et al. Desmoplastic neurotropic melanoma: a clinicopathologic analysis of 128 cases. Cancer 2008;113:2770 -2778  \nCooper JS, Chang WS, Oratz R, et al. Elective radiat ion therapy for high -risk malignant melanomas. Cancer J 2001;7:498 -502 \nElsmann HJ, Ernst K, Suter L. Radiotherapy of primary human melanomas --experiences and suggestions. Strahlenther Onkol 1991;167:387 -391 \nFarshad A, Burg G, Panizzon R, et al. A retrospec tive study of 150 patients with lentigo maligna and lentigo maligna melanoma and the efficacy of radiotherapy using Grenz or \nsoft X -rays. Br J Dermatol 2002;146:1042 -1046  \nFoote MC, Burmeister B, Burmeister E, et al. Desmoplastic melanoma: the role of radio therapy in improving local control. ANZ J Surg 2008;78:273 -276 \nGREVE W. Roentgen irradiation of skin tumors. Strahlentherapie 1952;89:401 -408 \nHarwood AR. Conventional fractionated radiotherapy for 51 patients with lentigo maligna and lentigo maligna melano ma. Int J Radiat Oncol Biol Phys 1983;9:1019 -1021  \nHedblad MA, Mallbris L. Grenz ray treatment of lentigo maligna and early lentigo maligna melanoma. J Am Acad Dermatol 2011  \nHELLRIEGEL W. Radiation therapy of primary and metastatic melanoma. Ann N Y Acad Sc i 1963;100:131 -141 \nKoenig H. Problems in the radiological treatment of malignant melanomas of the skin. Report on 136 patients followed -up over long period of time. Z Arztl Fortbild (Jena) \n1970;64:770 -779 \nNewlin HE, Morris CG, Amdur RJ, et al. Neurotropic melanoma of the head and neck with clinical perineural invasion. Am J Clin Oncol 2005;28:399 -402 \nNitter L. The treatment of malignant melanoma with special reference to the possible effect of radiotherapy. 1956.  \nOvergaard J. Radiation treatment of maligna nt melanoma. Int J Radiat Oncol Biol Phys 1980;6:41 -44 \nPanizzon R.G. Radiotherapy of lentigo maligna and lentigo maligna melanoma. 1999.  \nPhipps AR, Godfrey AM, Durrant KR, et al. The effect of immediately preoperative adjuvant radiotherapy in the surgical  treatment of primary cutaneous malignant melanoma. Br \nJ Plast Surg 1992;45:30 -33 \nRounsaville MC, Cantril ST, Fontanesi J, et al. Radiotherapy in the management of cutaneous melanoma: effect of time, dose, and fractionation. Front Radiat Ther Oncol \n1988;22 :62-78 \nSchmid -Wendtner MH, Brunner B, Konz B, et al. Fractionated radiotherapy of lentigo maligna and lentigo maligna melanoma in 64 patients. J Am Acad Dermatol 2000;43:477 -\n482 \nSeegenschmiedt MH, Keilholz L, Altendorf -Hofmann A, et al. Palliative radiothe rapy for recurrent and metastatic malignant melanoma: prognostic factors for tumor response \nand long -term outcome: a 20 -year experience. Int J Radiat Oncol Biol Phys 1999;44:607 -618 \nSpoljar M., Franicevic N., Kubovic M. The treatment of malignant melanoma.  1959.  \nStein G. The avoiding of a combination -effect in combined surgical -radiological treatment of malignant skin tumors. Strahlentherapie 1965;128:347 -350 \nStevens G, Thompson JF, Firth I, et al. Locally advanced melanoma: results of postoperative hypofr actionated radiation therapy. Cancer 2000;88:88 -94 \nStorper IS, Lee SP, Abemayor E, et al. The role of radiation therapy in the treatment of head and neck cutaneous melanoma. Am J Otolaryngol 1993;14:426 -431 \nTonak J, Hermanek P, Hornstein OP, et al. Treatme nt of malignant melanoma (clinical stages I and II) (author's transl)]. Dtsch Med Wochenschr 1976;101:435 -450 \nTsang RW, Liu FF, Wells W, et al. Lentigo maligna of the head and neck. Results of treatment by radiotherapy. Arch Dermatol 1994;130:1008 -1012  \nUmebayashi Y, Uyeno K, Tsujii H, et al. Proton radiotherapy for malignant melanoma of the skin. Dermatology 1995;190:210 -213 \nvon Lieven H, Skopal D. Radiosensitivity of malignant melanoma]. Strahlentherapie 1976;152:1 -4 \nvon Rottkay P. Radiation therapy in mal ignant melanoma using accelerated fractionation. Remission and preliminary results of local tumor control. Strahlenther Onkol \n1987;163:139 -143 \nVongtama R, Safa A, Gallardo D, et al. Efficacy of radiation therapy in the local control of desmoplastic maligna nt melanoma. Head Neck 2003;25:423 -428 \nWasif N, Gray RJ, Pockaj BA. Desmoplastic melanoma - the step -child in the melanoma family? J Surg Oncol 2011;103:158 -162 \nWERNSDOERFER R. On the treatment and prophylaxis of malignant melanoma skin tumors. Strahlenthe rapie 1960;Suppl 46:43 -48 \nZygogianni A, Kyrgias G, Kouvaris J, et al. Melanoma: The Radiotherapeutic Point of View; Review of the Current Literature. Rev Recent Clin Trials 2011  \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 548 von 732 6.2. Frage VI.2. und VI.3. Radiotherapie Intransit - und Fernmetastasen  \nFrage VI.3.  Welche Radiotherapie -Indikationen bestehen im Stadium der Fernmetastasierung?  \nFrage VI.2. Hat eine Radiotherapie von Satelliten - und In -transit -Metastasen einen Einfluss auf das Progressionsfreie \u00dcberl eben oder \nGesamt\u00fcberleben?  \n6.2.1.  PICO, Suchw\u00f6rter  \nPICO \u2013 Schema (Intransitmetastasen)  \nPopulation  Intervention  Comparison  Outcome  \nMelanoma patients with sate llite or \nintransit metastases  radiotherapy  no radiotherapy  PFS, OS  \n \nSuchw\u00f6rter (Instransitmetastasen)  \nStichwort  Melanoma  radiotherapy  Satellite metastases  salvage  \nSynonyme   Radiation, irradiation  Satellite metastasis, In -transit \nmetastases, In -transit \nmetastasis, Intransit \nmetastases, Intransit \nmetastasis   \nOber -/Unterbegriffe  cutaneous, skin, subcutaneous   Local recurrence, Locoregional \nrecurrence, Locoregi onal \nspread, Locoregional \nmetastases, Locoregional \nmetastasis, relapse  relapse  \nMesh Term  melanoma  radiotherapy, radiat ion Neoplasm Recurrence, Local    \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 549 von 732  \nPICO \u2013 Schema (Fernmetastasen)  \nPopulation  Intervention  Comparison  Outcome  \nMelanoma patients with di stant \nmetastases, Stage IV  radiotherapy  no radiotherapy  Lesion response, overall response, \nsurvival, toxicity, qua lity of life  \n \nSuchw\u00f6rter (Fernmetastasen)  \nStichwort  melanoma  radiotherapy  Postoperative  \npalliative  metastases  \nSynonyme   Radiation, irradiatio n  Stage IV  \nOber -/Unterbegriffe   radiosurgery  \n  lung, pulmonal  \nbone  \nspinal cord  \nspine  \nliver, hepatic  \nvisceral  \nskin, dermal  \nMesh Term  melanoma     \n \n \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 550 von 732 6.2.2.  Datenbanken, Suchstrategien, Trefferzahlen  \nDatenbank  Suchstrategie (Instransitmetastasen)  Datum  Treffer \n1. Suche     \nMedline  (melanoma[tiab] OR melanoma[MeSH]) AND (radiotherapy[tiab] OR radiother apy[MeSH] OR \nradiation[tiab] OR radiation[MeSH]) AND (\"Satellite metastases\" OR \"S atellite metastasis\" OR \"In -\ntransit metastases\" OR \"In -transit metastasis\" OR \"In transit metastases\" OR \"Intransit metastasis\" OR \n\"Local recurrence\" OR \"Locoregional recurrence\" OR \"Locoregional spread\" OR \"Locoregional \nmetastases\" OR \"Locoregional m etastasis\" OR \u201cNeoplasm Recurrence, Local\u201d[MeSH]) NOT (uvea*[ti] \nOR anorectal[ti] OR mu cosal[ti])  14.04.11  477  \nMedline \u2013 erweiterte \nSuchstr ategie  (melanoma[tiab] OR melanoma[MeSH]) AND (radiotherapy[tiab] OR radiother apy[MeSH] OR \nradiation[tiab] OR radiation[MeSH] OR irradiation) AND (skin OR cutaneous OR subcutaneous OR \n\"Satellite metasta ses\" OR \"S atellite metastasis\" OR \"In -transit metastases\" OR \"In -transit metastasis\" \nOR \"Intransit metastases\" OR \"Intransit metastasis\" OR \"Local recurrence\" OR \"Locoregional \nrecurrence\" OR \"Locoregional spread\" OR \"Locoregional metastases\" OR \"Locoregion al metastasis\" \nOR \u201cNeoplasm Recurrence, Local\u201d[MeSH] OR salvage OR relapse) NOT (uvea*[ti] OR anorectal[ti] OR \nmucosal[ti])  04.07.11  4872  \nCochrane Library  (melanoma and (radiotherapy or radiation or irradiation) and (skin or cutaneous or su bcutaneous or \nSatellite metastases or Intransit metastases or Locoregional metastases or salvage or relapse or \nrecurrence or locoregional spread)).ti,ab.  10.06.11  33  \nEmbase  (melanoma and (radiotherapy or radiation or irradiation) and (skin or cutaneous or su bcutaneous or \nSatellite metastases or Intransit metastases or Locoregional metastases or salvage or relapse or \nrecurrence or locoregional spread)).ti,ab.  11.05.11  2710   \n \n \nUpdate Suche     \nMedline  s.o. 31.01.12  4980 (0 \ndazu)   \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 551 von 732 Datenbank  Suchstrategie (Instransitmetastasen)  Datum  Treffer \nCochrane Library  s.o. 31.01.12  33 (0 dazu ) \nEmbase  s.o. 23.01.12  2889 (0 \ndazu)  \nGesamttreffer   7902  \n \nDatenbank  Suchstrategie (Fernmetastasen)  Datum  Treffer \n1. Suche     \nMedline  (melanoma[tiab] OR melanoma[MeSH]) AND (radiotherapy[tiab] OR radiation[MeSH] OR \nradiosurgery[tiab] OR irradiation[tia b]) AND (postoperative[tiab] OR palli ative[tiab] OR \nmetastas*[tiab] OR \"stage IV\"[tiab] OR lung[tiab] OR pulmonal[tiab] OR bone[tiab] OR \"spinal \ncord\"[tiab] OR \"spine\"[tiab] OR liver[tiab] OR hepatic[tiab] OR visceral[tiab] OR skin[tiab] OR \ndermal[tiab])  16.05.11  3273  \nCochrane Library  (melanoma and (radiotherapy or radiation or irradiation or radiosurgery) and (pos toperative or \npalliative or metastasases or \"stage IV\" or lung or  pulmonal or bone or \"spinal cord\" or \"spine\" or \nliver or hepatic or visceral  or skin or dermal)).ti,ab.  19.05.11  28 \nEmbase  (melanoma and (radiotherapy or radiation or irradiation or radiosurgery) and (pos toperative or \npalliative or metastasases or \"stage IV\" or lung or  pulmonal or bone or \"spinal cord\" or \"spine\" or \nliver or hep atic or visceral or skin or dermal)).ti,ab.  11.05.11  2915  \n \nUpdate Suche     \nMedline  s.o. 31.01.12  3359 (0 \ndazu)  \nCochrane Library  s.o. 31.01.12  28 (0 dazu)   \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 552 von 732 Datenbank  Suchstrategie (Fernmetastasen)  Datum  Treffer \nEmbase  s.o. 23.01.12  3032 (0 \ndazu) \nGesamttreffer   6419  \n \n6.2.3.  Auswahlkriterien  \nAuswahl der Literatur ( Intransit - und Fernmetastasen)  \nGesamttreffer (Intransit - und Fernmetastasen)  14321  \nEinschlusskriterien  Arbeiten die d ie Radiotherapie  von Fern - und Intransit metastasen  bei Patienten mit metastasiertem M elanom beschreiben  \nMangels RCT\u00b4s Einschluss von Koho rtenstudien und Fallserien ab 20 Patienten , bzw. ab 20 L\u00e4sionen (bei Angabe von \nl\u00e4sionsbezogenen Re sponsedaten)  \nSprachen: e,dt  \nAusschlusskriterien  ausschliesslich ZNS Metastasen (siehe Frage VI.4.)  \nKollektive mit gemischten Tumorentiti\u00e4ten  \nNicht systemati scher Review  \nPublikation vor 1980  \nAnzahl ausgew\u00e4hlter Volltexte  23 \nBermerkungen:  \nDa zum Thema keine ranomisierten Studien existieren, wurden Fallberichte aufgenommen (Level 4). Kollektive mit ausschliesslic her ZNS Metastasierung wurden \nausgeschlossen.  Arbeiten mit historischen Verfahren (Bremer et al. 1999) wurden ausgeschlossen. Aufgrund der \u00dcberlappung der gefundenen Arbeite n aus beiden \nSuchen wu rden diese in einer gemeinsamen Evidenztabelle zusammengefasst  \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 553 von 732 6.2.4.  Evidenztabelle  \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nOvergaard et al. \n2009  \n \n(original public ation \n1996)  To investigate the \nvalue of \nhyperthe rmia as an \nadjuvant to \nradiotherapy in \ntreatment of \nmalignant \nmelanoma  RCT \n \nTreatment  \nRT vs \nRT+Hyperthermia \n(HT) \n \nRT; high voltage \nphotons  or \nelectrons  70 patients, 134 \nlesions, skin \nlesions: n=93   \n \n \n \nResponse  \n \n \n \n \nOverall 5 -year \nSurvival Rate  \n 128 evaluable \ntumors, RT vs RT + \nHT \n \nCR: 35% vs 62% , \nsign.,  p=0.003  \nPR: 37% vs 27% n.s.  \nNR: 28% vs 11% n.s.  \n \n68 evaluable \npatients: 19%  Randomisatio n \nbased on lesions, \nnot on patients  \nResponse \nasses sment was not \nblinded  \nresponse was not \nanalyzed separately \nfor node and \ncutaneous l esions  4 \n \n1b (question \nRT vs RT + \nHT) \nRichtig et al. 2005  To evaluate t he \norgan -specific \nresponse rate, local \nresponse rat e of \neach therape utic \nmeasure and \nsurvival of 68 \npatients with stage \nIV disease Retrospective \nevaluation  \n \nTreatment:  \nRT: TD 30 \u2013 50 Gy, \nfraction size 2 - 4 \nGy \nGama knife Surgery  \nLocal hyperthe rmia \nChemotherapy  68 patients with \nunresectable stage \nIV disease  \n \n46 treatment \nperiods \nradiother apy \n(total: 410 \ntreatment periods)  Respo nse  \n CR+PR (in regard to \ntreatment p eriods):  \nTotal 12/46 (26%)  \nLymph N ode 3/9  \nBone 0/10  \nCutaneous / \nsubcutaneous 2/3  \nOther 2/3  \nBrain 5/21  No patient r elated \nresponse data \navailable 4 \nKirova et al. 1999  To assess the \nresponse rate and \nefficacy of palli ative Retrospective \nevaluation  \n 28 patients, 35 \nsites,  \nbone an d soft ti ssue Response  \n Clinical response  \nbone metast ases \n67%  Response was \ndefined as relief of \nsymptoms  4  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 554 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \nradiation th erapy in \npatients with \nmetastatic \nmelanoma  Treatment (most \npatients): TD 30 or \n20 Gy, fraction size \n3 or 4 Gy  metastases n=20,  \nbrain m etastases \nn=8   Lack of response \nand survival data  \nSeege nschmiedt et \nal. 1999  To analyze diff erent \nendpoints and \nprognosti c factors \nin patients with \nlocally advanced, \nrecurrent or \nmetastatic \nmelanoma  Retrospective \nevaluation  \n \nTreatment: median \nTD 48 (range 20 - \n66) Gy, fraction size \n2\u20136 Gy 121 patients of a \nmelanoma registry \nwith 2,917 patients  \n \nStage IV n=53 \n(distant LN, SK , ST \nmets n=7, visceral \norgan mets n=46)  \n Response  \n \n \n \n \n \n \n \n \n \n \n \n \nSuvival Rate (mean \nfollow up 7.8 years)  Stage IV (n=53), at  \n3 months  \nCR n=9 (17%)  \nPR n=17 (32%)  \nNC n=12 (23%)  \nPD n=15(28%)  \n \nStage III (n= 57)  \nCR n=25 (44%)  \nPR n=19 (33%)  \nNC n=5 (9%)  \nPD n=8 (1 4%) \n \nStage IV 6%  \nStage III 30%) Detailed analyses,  \nlarge cohort,  \nResults are reported \nseparately for \ndifferent stages, \nstage III i ncludes \nlymph node and \nintransit -\nmetastases  \nresponse was not \nanalyzed separately \nfor node and \ncutaneous l esions  4 \nEngin et al. 1993  To present the \nexperience with \nhyperthermia \ncombined with \nradiation in \nadvanced melanoma \npatients b etween Retrospective \nevaluation  \n \nTreatment:  \nRT mean TD 37 \n(range 13 - 66) Gy, \nmean fra ction size 40 melanoma \npatients with 48 \nlesions, Stage IV \nlesions n=26  Response  Evaluable lesions \n(n=33)  \nCR n=12 (36%)  \nPR n=17 (52%)  \n WHO/UICC criteria \nwere used to assess \ntumor response  4  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 555 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \n1980 -1988  3.6 Gy (range 2 - \n5.5) combined with \nhyperthermia  \nPyrh\u00f6nen et al. \n1992  To present 15 \npatients with \nhistolo gically \nproven recu rrent or \nmetast atic \ncutaneous \nmelan omas treated \nwith large fractions \nbetween April 1987 \nand May 1991  Case Series  \n \nTreatment:  \nElectron beams at \nappropriate \nenergies (6 -15 \nMeV). A total dose \nof 40 Gy was given \nin 8 fra ctions \n(fraction size 5 Gy) \nover 23 days.  15 melanoma \npatients, 89 treated \nlesions  \nskin n=68 (76%)  \n transplanted skin \nn=3 (3 %)  \n subcut aneous \nn=11 (12%)  \nlymph nodes n=7 \n(8%) Response  Evaluable lesions \n(n=89)  \n \nCR n=61 (69%)  \nPR n=25 (28%)  \nNo response n=3 \n(3%)  4 \nHerbert et al. 1991  To eva luate the \nefficacy of palli ative \nradiation therapy in \nthe treatment of \nspinal cord and  \ncauda equina \ncompression due to \nmetastatic \nmalignant \nmelanoma  Retrospective \nevaluation  \n \nTreatment:  \nRT (all patients), \ndecompressive \nlaminectomy \n(n=11), st eroids \n(n=32)  \n \nRT: cobalt -60, 6 or \n15 MV, median TD 35 patients with \nspinal cord and \ncauda equina \ncompression, 38 \nsites treated  Response  \n \n \n \n \n \n \nMedian Overall \nSurvival (OS)  28 sites (in 26 \npatients) evalu able \n \nCR 11 sites (39%)  \nPR 13 sites (46%)  \nORR 24 sites (86%)  \n \nOS all patients: 11 \nweeks (range 4 \u2013 35 \nweeks)  multivariate ana lysis \nperformed but not \npresented in detail, \nsmall sa mple size  \n 4  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 556 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \n2850 cGy (range, \n500 to 4000 cGy), \nfraction size 200 -\n800 cGy  \nChadha et al. 1990  To evaluate the role \nof brach ytherapy in \nthe ma nagement of \nlocally advanced \nmalignant \nmelan oma. Retrospective \nevaluation  \n(1979 -1986)  \n \nTreatment:  \nbrachytherapy, \ntemporary and \npermament \nimplants, different \ndoses  33 melanoma \npatients with locally \nadvanced disease \nwith/without nodal \ndisease or distant \nmetast ases \n  \n \nLocal \ncontrol/Implant \nsite: \n \n \n 33 patients  \n \n80% at 6 months \n42% at 1 year  \n \nExtremity vs. \nIntrathoracic and \nchest wall vs. \nGynecologic & \nintra-abdominal vs. \nHead and neck  \n \nn=13 of 14 vs. n=4 \nof 9 vs. n=3 of 7 vs. \nn=0 of 2  Baseline \ncharact eristics ar e \nnot pr esented in \ndetail, clinical \nstages not indicated  4 \nKonefal et al. 1988  To see if the use of \nlarger dose \nfractions increased \nthe rate of palliation \nof visceral \nmelan oma \nmetastases  Retrospective \nevaluation  \n \nTreatment:  \nTD range <2000  - \n5000 cGy, fr action \nsize < 200 to  > 63 patients, 89 \nvisceral m etastases \ntreated, 65 \nevalu able Response  40 of 65 lesions \n(62%)  \n19 of 28 bone \nmetastases (68%)  response was \ndefined as the \nsignif icant relief \nfrom sym ptoms for \nat least 2 months  4  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 557 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \n600 \nRate et al. 1988  To present the \nexperience with \npalliative \nradioth erapy for \nmalignant \nmelanoma \nmetastatic to brain, \nto bone, or with \nspinal cord \ncompre ssion. Retrospective \nevaluation  \n \nTreatment:  \nTD 1100 - 4000 \ncGy, fraction size \n115 cGy - 1100 cGy  26 patients with 39 \nbone me tastases, \n17 patients with \nspinal cord \ncompression  Response  Bone:  \n33 of 39 l esions \n(85%)  \nSpinal cord \ncompression:  \n(8/17) 47%  \nPartial palliation \n24% (4/17).  response was \ndefined as pain \nrelief  4 \nRounsaville et al. \n1988  To review the \nexperience of three \nSan Francisco \nradiation oncology \ndepar tments  Retrospective \nevaluation  \n \nTreatment: TD \nrange 600 \u2013 7700 \ncGy, fra ction size \n180 - 1000  81 patients  \n29 patients (51 \nsites) with \nmeasu rable tumor \n(Lymph node, skin, \nliver, mucosa, \nspleen)  \n15 patients (28 \nsites) wi th bone \nmetastes  Response  Measurable tumor:  \nCR 4 of 51 sites (8%)  \nPR 22 of 51 sites \n(43%)  \nBone metastases:  \n24 of 28 sites (86%)  Definition re sponse \nin bone m etastases: \nmarked regression \nor elimination of \npain 4 \nMameghan et al. \n1988  To assess the acute \nskin reaction after \ntreatment and to \nmeasure the \nresponse of the Case Series  \n \nTreatment:  \nRadiotherapy alone \n(15 lesions)  12 melanoma \npatients with 32 \nlesions  \nsubcutaneou s tissue \nn=26  Response  All lesions (n=32)  \n \nCR n=14(44%)  \nPR n=10(31%)  \nNo response  4  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 558 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \nmelanoma  Heat therapy alone \n(6 lesions)  \nCombined radiation \nand heat therapy \n(11 lesions)  Lymph node n=5  \nCheek n=1  n=2(6%)  \nNot evaluable n=6 \n(19%)  \n \nLesions treated with \nradiotherapy alone \n(n=15)  \nCR n=8  \nPR n=2  \nNo response n=1  \nNot evaluable n=4  \nKonefal et al. 1 987 To retrospectively \nanalyze the results \nof 67 cutaneous or \nlymph node \nmeta static lesions, \nfocusing on \ndoset ime \nfractionation and \ntumor respo nse Retrospective \nevaluation  \n(1970 -1985)  \n \nTreatment:  \nTD 18 -66 Gy, \nfraction size 1.5 - 8 \nGy, intervals daily to \nweekly  \n 35 melanoma \npatients with 67 \ncutaneous or lymph \nnode metastatic \nlesions, 30 \ncutaneous l esions  \n \n Response  \n All lesions (n=67)  \n \nOverall Tumor \nControl n=14  \nCR n=16  \nPR n=23  \nNo response n=28  \n \n Overall tumor \ncontrol indicates \nthat lesions were \ncontrolled at the \ntime of patient\u00b4s \ndeath or at last \nfollow -up \nPR was defined as \n>50% reduction of \ntumor size  4 \nOvergaard et al. \n1987  To present the \nexperience with \nhyperthermia and \nradiotherapy in \nmetastatic Retrospective \nevaluation  \n \nTreatment:  \n- Radiation alone 36 patients, many \npatients with \ndisseminated \ndisease,  \n118 lymph node Response  \n 102 lesions \nevaluable \nCR n=57 (56%)  \nPR n=32 (31%)  \nNR n=13 (13%)  Patient baseline \ncharacteristics are \nmissing, no \nresponse data \navailable for tumors 4  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 559 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \nmelanoma patients  (TD 15 -30 Gy) \nn=62 sites  \n- Simultaneous heat \nplus radiation n=26  \n- Sequential \nradiation plus heat \nn=27  \n- heat alone n=3  and cutaneous \nmeta stases  \n treated with \nradiation alone.  \nPR was def ined as \n>50% redu ction of \ntumor size  \nOvergaard et al. \n1986  Some factors of \nimpo rtance in the \nradiation trea tment \nof malignant \nmelanoma  Retrospective \nevaluation  \n \nTreatment:  \nTD median 40 Gy, \nrange 8 -77, fraction \nsize median 5 Gy, \nrange 2 \u2013 11, \nnumber of fra ctions \nmedian 10, range \n1-27. \n 204 cutaneous or \nlymph node lesions \nin 114 patie nts with \nrecurrent or \nmeta static \nmelanoma, 45 \npatients with only \nlocal or regional \ndisease   \n \n \nLocal tumor control  \n \n3 year survival  45 patients with \nregional disease  \n \nn=26 of 45 (58%)  \n \n56% Baseline \ncharact eristics are \nnot pr esented in \ndetail, clinical \nstages not \nindicated,  \nresponse for node \nand cutaneous \nlesions was not \nanalyzed separately  4 \nBlake et al. 1985  Treatment of \nmalignant \nmelanoma by fast \nneutrons  Retrospective \nevaluation  \n \nTreatment:  \n75 MeV neutron \nbeam, TD 156O or 48 patients, 87 \nprimary, recurrent \nor metastatic \ntumors   \n \nResponse  \n \nRecurrence  \n All sites n= 87  \n \nCR n=62 (71%)  \n \nn=8 (9%)  \n Baseline \ncharact eristics are \nnot pr esented in \ndetail, clinical \nstages not \nindicated,  4  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 560 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \n1395 cGy in 12 or 6 \nfractions  Complications  n=19 (22%)  response for \nprimary, recurrent \nor metastatic \nlesions was not \nanalyzed separately  \nKhan et al. 1984  To evaluate the \nresults of different \nmodes of trea tment \nthe records of 182 \nmelanom pat ients, \nreferred to the \nRegional \nRadiother apy \nCentre, Newcastle \nupon Tyne be tween \nJanuary 1 975 and \nDece mber 1980 \nhave been revi ewed Retrospective \nevaluation  \n \nTreatment:  \nexternal beam \nradiotherapy \n(collimated beam \nfrom cobalt -60 and \ncaesium -137 \ntelether apy units, or \n100-250 keV or 4 -8 \nMeV X -rays)  \ndifferent \nfraction ation \nregimes and tumor \ndoses  63 melanoma \npatients (42 Stage \n2, 21 Stage 3) with \n74 sites of dise ase \n(skin and lymph \nnodes, 58; bone, 8; \nbrain, 8)  \n Response  \nDuration of \nremiss ion Overall response \nrate 73%  \nCR 47%  \nPR 26%  \n \nSites with skin and \nlymph node \nmeta stases (58):  \nCR 35 (60%)  \nPR 8 ( 14%) \n \nBone metastases \n(8): \nCR 0 \nPR 6 (75%)  \n \nMedian duration of \nremission 7 months \n(range 1 -72)  4 \nJohanson et al. \n1983  To report the the \nexperience of the Retrospective \nevaluation  23 patients with \nrecurrent melan oma  \n n= 23 patients  \n clinical stages not \nindicated,  4  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 561 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \nPrincess Margaret \nHospital with large \ndose per fraction \n(800 rad) \nradioth erapy in the \ncurative and \npalliative treatment \nof nod ular \nmelanoma  (1975 -1980)  \n \nTreatment: TD 2400 \nrad, fraction size \n800 rad, given on \nday 0, day 7, and \nday 21  Response  \n \n CR, no local \nrecurrence n=7  \nCR, local r ecurrence \nn=2 \nPR n=5  \nSD n=3  \nno response n=6  \n response was not \nanalyzed separately  \nDoss et al. 1982  To review the \ninstitutional \nexperience  Retrospective \nevaluation  \n \nTreatment: TD \nrange 500 to <4500 \ncGy, fraction si ze \n100 - 1250  27 patients, 41 \nlesions  Response  CR 15/41 (37%)  \n \n Definition complete \nresponse: \ndisappearance of \nmeasurable lesions, \nsymptoms ceased \nwithin 2 months \nafter RT  4 \nAdam et al. 1982  Response rate of \nmalignant \nmelan oma to large \nfraction irradi ation  22 patients, 24 \nsites, visceral sites \nn=2     \nKatz et al. 1981  To determine if \nresults in the \nirradiation of soft \ntissue, visceral, and \nbone metastases \nwere comparable to Retrospective \nevaluation  \n \nTreatment: TD \nrange 1000 to 6000 \nrad, fraction size 86 patients  \n \n16 patients with \nvisceral m etastases \n(20 lesions)  \n Response  \n \n Visceral lesions  \n13 of 20 lesion s \n(65%)  \nBone lesions  \n37 of 48 l esions \n(77%)  Definition response:  \nsubjective decrease \nin bone pain, \nreduction in size to \na degree which \nsignif icantly relieved 4  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 562 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \nthose previously \nreported in the \nliterature  200 \u2013 1000 rad  32 patients with \nbone metastases \n(48 lesions)  \n \n8 patients with skin \nmetastases (14 \nlesions)   \n the local tumor -\nassociated \nsymptoms  \nLobo et al. 1981  To evaluate the \nexperience in the \nradio therapeutic \nmanagement of \npatients with \nmalignant \nmelanoma  Retrospective \nevaluation  \n \nTreatment:  \n(bone lesions) TD \nrange 2700 -3000 \nrad, fra ction size \n300 rad  45 patients, 69 \nlesions  \nBone n=22, lung \nn=3, liver n=3  \n Response  bone: 15 of 22 \n(68%)  \nlung: 1 of 3 \nliver 0 of 3  Response was \ndefined as \nimprov ement of \nsymptoms  \n 4 \nStrauss et al. 1981  To evaluate clinical \nresponses of \nmeta static \nmelanoma to four \nradiation  \ndose fractionation \nschemes.  Retrospective \nevaluation  \n \nTreatment: fraction \nsize 180 rad to 800 \nrad 48 patients, 83 sites  Response  Soft tissue:29 of 46 \nsites (63%)  \nBone: 7 of 9 sites  \n \n  Response was \ndefined as \nimprov ement of \nsymptoms  \n 4 \n \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 563 von 732 6.2.5.  Literatur  \n \nAdam JS, Habeshaw T, Kirk J. Response rate of malignant melanoma to large fraction irradiation. Br J Rad iol 1982;55:605 -607 \nBlake PR, Catterall M, Errington RD. Treatment of malignant melanoma by fast neutrons. Br J Surg 1985;72:517 -519 \nChadha M, Hilaris B, Nori D, et al. Role of brachytherapy in malignant melanoma: a preliminary report. J Surg Oncol 1990;43 :223-227 \nDoss LL, Memula N. The radioresponsiveness of melanoma. Int J Radiat Oncol Biol Phys 1982;8:1131 -1134  \nEngin K, Tupchong L, Waterman FM, et al. Hyperthermia and radiation in advanced malignant melanoma. Int J Radiat Oncol Biol Phys 1993;25:87 -94 \nHerbert SH, Solin LJ, Rate WR, et al. The effect of palliative radiation therapy on epidural compression due to metastatic mali gnant melanoma. Cancer 1991;67:2472 -2476  \nJohanson CR, Harwood AR, Cummings BJ, et al. 0 -7-21 Radiotherapy in Nodular Melanoma. Canc er 1983;51:226 -232 \nKatz HR. The results of different fractionation schemes in the palliative irradiation of metastatic melanoma. Int J Radiat On col Biol Phys 1981;7:907 -911 \nKhan MS, Ross WM. Management of malignant melanoma: a retrospective analysis of 182  patients. Clin Radiol 1984;35:151 -154 \nKirova YM, Chen J, Rabarijaona LI, et al. Radiotherapy as palliative treatment for metastatic melanoma. Melanoma Res 1999;9:611 -613 \nKonefal JB, Emami B, Pilepich MV. Analysis of dose fractionation in the palliation of  metastases from malignant melanoma. Cancer 1988;61:243 -246 \nKonefal JB, Emami B, Pilepich MV. Malignant melanoma: analysis of dose fractionation in radiation therapy. Radiology 1987;164 :607-610 \nLobo PA, Liebner EJ, Chao JJ, et al. Radiotherapy in the manag ement of malignant melanoma. Int J Radiat Oncol Biol Phys 1981;7:21 -26 \nMameghan H, Knittel T. Response of melanoma to heat and radiation therapy --a review of the literature and experience from The Prince of Wales Hospital, Sydney. Med J Aust \n1988;149:474 -6, 478 -81 \nOvergaard J, Gonzalez Gonzalez D, Hulshof MC, et al. Hyperthermia as an adjuvant to radiation therapy of recurrent or metastatic malignant melanoma. A multicentre \nrandomized trial by the European Society for Hyperthermic Oncology. 1996. Int J Hype rthermia 2009;25:323 -334 \nOvergaard J, Overgaard M. Hyperthermia as an adjuvant to radiotherapy in the treatment of malignant melanoma. Int J Hyperthermia 1987;3:483 -501 \nOvergaard J, Overgaard M, Hansen PV, et al. Some factors of importance in the radiation  treatment of malignant melanoma. Radiother Oncol 1986;5:183 -192 \nPyrhonen SO, Kajanti MJ. The use of large fractions in radiotherapy for malignant melanoma. Radiother Oncol 1992;24:195 -197 \nRate WR, Solin LJ, Turrisi AT. Palliative radiotherapy for metastat ic malignant melanoma: brain metastases, bone metastases, and spinal cord compression. Int J Radiat Oncol \nBiol Phys 1988;15:859 -864 \nRichtig E, Ludwig R, Kerl H, et al. Organ - and treatment -specific local response rates to systemic and local treatment modal ities in stage IV melanoma. Br J Dermatol \n2005;153:925 -931 \nRounsaville MC, Cantril ST, Fontanesi J, et al. Radiotherapy in the management of cutaneous melanoma: effect of time, dose, a nd fractionation. Front Radiat Ther Oncol \n1988;22:62 -78 \nSeegenschmiedt M H, Keilholz L, Altendorf -Hofmann A, et al. Palliative radiotherapy for recurrent and metastatic malignant melanoma: prognostic factors for tumor response \nand long -term outcome: a 20 -year experience. Int J Radiat Oncol Biol Phys 1999;44:607 -618 \nStrauss A, D ritschilo A, Nathanson L, et al. Radiation therapy of malignant melanomas: an evaluation of clinically used fractionation sch emes. Cancer 1981;47:1262 -1266  \n \n \n \n \n \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 564 von 732 6.3. Frage VI.4. Radiotherapie und Chirurgie Hirnmetastasen  \nFrage VI.4. Wie ist der Einfluss unters chiedlicher Behandlungsmodalit\u00e4ten und deren Kombinationen (Operation, Ganzhirnbestrahlung, \nEinzeitbestrahlung) auf das Gesamt\u00fcberleben, die lokale Kontrolle, die intrakranielle Kontrolle, Verl\u00e4ngerung der symptomfrei en Zeit und \nLebensqualit\u00e4t bei Patiente n mit cerebralen Metastasen?  \n \n6.3.1.  PICO, Suchw\u00f6rter  \nPICO \u2013 Schema   \nPopulation  Intervention  Comparison  Outcome  \nMelanoma patients with cerebral \nmetastases  Radiotherapy, surgery, stereotactic \nradiosurgery, combinations  no therapy  OS, local control, time without \nsymptoms, QoL  \n \nSuchw\u00f6rter  \nStichwort  Melanoma  radiotherapy  surgery  brain  \nSynonyme   Radiation, irradiation  resection, excision  Cerebral  \nCNS \nCentral Nervous System  \nOber -/Unterbegriffe   Stereotactic  \nradiosurgery    \nMesh Term  melanoma  radiotherapy, radiati on   \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 565 von 732 6.3.2.  Datenbanken, Suchstrategien, Trefferzahlen  \nDatenbank  Suchstrategie  Datum  Treffer  \n1. Suche     \nMedline  (melanoma[tiab] OR melanoma[MeSH]) AND (radiotherapy[tiab] OR radiotherapy[MeSH] OR \nradiation[tiab] OR radiation[MeSH] OR \u201cIrradiation\u201d[tiab] OR S tereotatic[tiab] OR \nradiosurgery[tiab] OR surgery[tiab] OR resection[tiab] OR excision[tiab]) AND (brain[tiab] OR \ncerebral[tiab] OR CNS[tiab] OR \"Central Nervous System\"[tiab])  \n 19.09.11  874 (Auswahl \n64) \nCochrane Library  (melanoma and (radiotherapy or rad iation or irradiation or stereotatic or radiosurgery or \nsurgery or resection or excision) and (brain or cerebral or CNS)).ti,ab.  19.09.11  10 (Auswahl: \nMornex, \nDublette, \nzus\u00e4tzliche \nAuswahl 0)  \nEmbase  (melanoma and (radiotherapy or radiation or irradiation or stereotatic or radiosurgery or \nsurgery or resection or excision) and (brain or cerebral or CNS)).ti,ab.  10.05.11  823 \n(zus\u00e4tzliche \nAuswahl 0)  \nUpdate Suche     \nMedline  s.o. 31.01.12  889 (0 dazu)  \nCochrane Library  s.o. 31.01.12  10 (0 dazu)  \nEmbase  s.o. 23.01.12  903 (0 dazu)  \n \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 566 von 732 6.3.3.  Auswahlkriterien  \nAuswahl der Literatur  \nGesamttreffer  1802  \nEinschlusskriterien  Studien, die mind. einen der Parameter Gesamt\u00fcberleben, lokale Kontrolle, symptomfreie Zeit oder Lebensqualit\u00e4t bei \nMelanompatienten nach Radiotherapie o der Operation von Hirnmetastasen beschreiben  \nSprachen: e,dt  \nAusschlusskriterien  Case Reports  \nNicht systematische Reviews  \nKollektive mit gemischten Tumorentiti\u00e4ten  \nErweitertes \nAusschlusskriterium  Studien ohne Vergleichsgruppe  \nRetrospektive Kohortenstudie ohne Multivariatanalyse  \nPublikation vor 1980  \nAnzahl nach Abstractscreening, vorgesehen f\u00fcr Bewertung  64 \nAnzahl der ausgeschlossenen Studien nach Sichtung der Volltexte  57 \nAnzahl ausgew\u00e4hlter Volltexte  7 \n \n6.3.4.  Evidenztabelle  \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nEigentler et al. 2011  To identify \nprognostic factors \nin patients with \nbrain metastases \n(BM) from malignant Retrospective \nsurvival analysis  \n \nTreatment:  \nSRS + Surgery 692 patients  Median Survival  \n(from date of \ndiagnosis of brain \nmetastases)  \n Entire cohort \n(n=672)  \n5 months  \n \nSRS + Surgery vs.  Retrospective study  \nlarge coho rt \nSRS vs. Surgery was \nnot compared  \n 3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 567 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \nmelanoma  (n=122)  \nWBRT + \nChemotherapy \n(n=92)  \n WBRT + \nChemotherapy  \nSingle BM:  \n9 vs. 6 months, \np=0.036  \n \n<3 BM:  \n6 vs. 7 months,  \np=0.448  \n \nmultivariate analysis  \nindependent \nprognostic factors  \n- entire cohort:  \nsingle vs. multiple \nBM,  HR 1.6, 95% CI \n1.3-2.7, p=0.002  \n \nLDH not elevated vs. \nelevated, HR 1.6, \n95% CI 1.1 -2.4, \np=0.01  \n \n- Single BM:  \nSRS or surgery vs. \nWBRT and/or \nchemotherapy, HR Funding: in part by \nan educational \ngrant from \nEssex/Schering -\nPlough.   \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 568 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \n1.5, 95% CI 1.1 -1.9, \np=0.0061  \nStaudt et al. 2010  To identify \nprognostic factors \nin patients with \nbrain metastases \nfrom cutaneous \nmelanoma  Retrospective \nsurvival analysis  \n \nTreat ment:  \nSurgery (n=63)  \nSRS (n=31)  \nWBRT (n=122)  \nchemotherapy \n(n=28)  \nno therapy (n=12)  265 patients  \n \n36.7% had local \ntreatment \n(neurosurgery or \nstereotactic \nradiosurgery (SRS)  Median Survival  \n(from date of \ndiagnosis of brain \nmetastases)  \n \n \n \n \n \n \n \n \n \n \n Entire coho rt \n(n=265)  \n5 months, 95% CI \n4.3\u20135.7 months  \n \nsurgery vs. SRS vs. \nWBRT vs. \nchemotherapy vs. \nno therapy  \n9 vs. 9 vs. 4 vs. 3 \nvs. 1 month(s)  \n \nmultivariate analysis  \nindependent \nfavourable \nprognostic factors: \nLDH level, type of \ntherapy, number of \nbrain metastases , \npresence of bone \nmetastasis  \nsurgery (n=63) vs. \nSRS (n=31):  \nHR 1.0, 95% CI 0.6 \u2013 \n1.8 Retrospective study  \ndetailed data, few \nmissing cases  \n \nfollow up time not \nmentioned (but at \ntime of analysis \nalready 253 deaths)  \n \nFunding: not \nmentioned  3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 569 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \nRaizer et al. 2008  To gain a better \nunderstanding of \npatient and disease \ncharacteristics that \nhave the greatest \nimpact on overall \nsurvival in \nmelanoma patients \nwith brain \nmetastases  Retrospective \nsurvival analysis  \n \nTreatment:  \nSurgery (n=126)  \nSRS (n=78)  \nTemozolomide \n(n=1 13) \nWBRT (n=190)  \n 355 patients  Median Survival  \n(from date of \ndiagnosis of brain \nmetastases)  \n \n \n \n \n \n \n \n \n Entire cohort \n(n=335)  \n5.2 months (range \n0.1 \u2013 155 months)  \n \nsurgery vs. SRS vs. \nTemozolomide vs. \nWBRT  \n \n9.3 vs. 10.0 vs. 7.9 \nvs. 6.1 months  \n \nmultivariate a nalysis  \nsurgery: RR 0.56, \n95% CI 0.43 \u2013 0.75 \nSRS:  RR 0.69, 95% \nCI 0.50 \u2013 0.94 Retrospective study  \n \nMedian follow up \namong surviving \npatients 18.4 \nmonths  \n \nFunding: Schering -\nPlough International  3b \nFife et al. 2004  To analyze \nprognostic factors, \neffects o f treatment, \nand survival for \npatients with \ncerebral metastases \nfrom melanoma.  Retrospective \nsurvival analysis  \n \nTreatment:  \nsurgery+RT \n(n=158)  \nsurgery (n=47)  \nradiotherapy \n(n=236)  \nsupportive care 1137 patients with \ncerebral metastases; \n686 wi th therapy  Median survival \n(from date of \ndiagnosis of brain \nmetastases)  \n \n \n \n \n \n Entire cohort \n(n=1137)  \n4.1 months (range, \n0 to 17.2 years)  \n \nSurgery+RT vs. \nsurgery vs. RT vs. \nsupp.care  \n \n8.9 vs. 8.7 vs. 3.4 Retrospective study \nLarge cohort  \nresults of univariate \nanalyses not shown, \nonly 578 of 686 \npatients in cluded  \nmissing data not \nadressed  \n \nFunding:  3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 570 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \nalone (n=210)  \n  \n \n vs. 2.1 months  \n \nmultivariate analysis  \nPrognostic factors:  \nsurgical treatment \n(p<0.0001), no \nconcurrent \nextracerebral \nmetastases \n(p<0.0001), \nyounger age \n(p=0.0007), longer \ndisease -free \ninterval (p=0.036)  Supported by the \nMelanoma \nFoundation of the \nUniversity of Sydney \nand the Melanoma \nand Skin Cancer \nResearch Institute  \nMornex et al. 2003  To compare a \ncombined regimen \nof fotemustine plus \nwhole brain \nirradiatio n with \nfotemustine alone  RCT \n \nTreatment:  \n \nGroup A: \nFotemustine (n = \n39) \n \nGroup B: \nfotemustine + WBRT \n(n = 37)  \n 76 patients  \n   \n \n \nMedian survival  \n \n \n \n \ncerebral response \nafter 7 weeks  \n \n \ncontrol rates Group A vs. B (ITT \npopulation)  \n \n86 days (2.8 \nmonths) vs. 105 \ndays (3.4 months) \nn.s.  \n \n5.1% (95% CI 1 \u201317%) \nvs. 8.1% (95% CI 2 \u2013\n22%), p=0.60  \n \n23.1% (95% CI 10 \u2013Early termination of \nstudy, small sample \nsize \nIndependent tumor \nassessment  \n \nFunding: not \nmentioned  1b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 571 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \n(objective responses \n+ stable disease) \nafter 7 weeks  \n \ntime to cerebral \nprogression  36%) vs. 37.8% (95% \nCI 22 \u201354%), p=0.16  \n \n \n49 days (1.6 \nmonths) vs. 80 days \n(2.6 months), \np=0.030  \nWronski et al. 2000  To review the \nsurgical experience \nin a series of \npatients with brain \nmetastases from \nprimary melanoma  Retrospecti ve \nsurvival analysis  \n \nTreatment:  \nSurgery alone \n(n=29)  \n \nSurgery + WBRT \n(n=49)  91 patients  Median survival \nfollowing \ncraniotomy  \n \nsurvival rates  \n1 year  \n2 years  \n3 years  \n5 years  \n \n \n \n \n \n \n \n Entire cohort (n=91)  \n6.7 months  \n \n \n \n36.3%  \n18.7%  \n13.2%  \n6.6% \n \nSurgery alone  \n(n=29) vs. \nSurgery+WBRT \n(n=49)  \n8.3 vs. 9.5 months, \np = 0.67  \n \nmultivariate analysis  \nnegative impact on Retrospective study, \nsmall sample size,  \nresults of \nmultivariate \nanalyses not \npresented in detail  \n \nFunding: not \nmentioned  3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 572 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \nsurvival: lack of \nresection of \nrecurrent brain \ntumor (p =0.0003) \nand infratentorial \nlocation of brain \nmetastases (p = \n0.0013)  \nStevens et al. 1992  To analyze factors \naffecting survival in \n129 patients with \ncerebral metastases \nfrom malignant \nmelanoma  Retrospective \nsurvival analysis  \n \nTreatment:  \nRadiotherapy \n(n=74)  \nSurgery + \nRadiotherapy \n(n=45)  129 patients  Median survival \nafter detection of \ncerebral metastases  \n \n \n \n \n \n \n Entire cohort \n(n=127) 5 months  \n \nRadiotherapy vs. \nSurgery + \nRadiotherapy  \n4 vs. 9 months \n(p<0.001)  \n \nmultivariate analysis  \nIndependently \nassociated with a \nprolonged survival:  \nSurgery, p=0.004  Retrospective study,  \nmultivariate analysis \nnot presented in \ndetail  \n \nFunding: not \nmentioned  3b \n \n \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 573 von 732 Ausgeschlossene Studien  \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nLonser et al. 2011  to determine the \neffectiveness of \nresection and the \neffects of \nimmunotherapy on \nbrain metastasis \nmanagement  Retrospective \nanalyses  \n \nTreatment:  \nSurgery, \nImmunotherapy, \nwhole brain \nradiation  41 patients   Duration of survival \nfrom brain \nmetast asis \ndiagnosis was not \nsignificantly \ndifferent between \npatients who \nreceived WBRT \n(mean 24.9 months) \nand those who did \nnot (mean 23.3 \nmonths) (p > 0.05)  Combination  with \nImmunotherapy \uf0e0 \nstudy excluded   \nSalvati et al. 2011  To report on 84 \npatients with si ngle \nmelanoma brain \nmetastasis \nsurgically treated \nfrom 1997 to 2007  Retrospective \nanalysis  \n \nTreatment:  \nSurgery  84 patients with \nsingle melanoma \nbrain metastasis  1-year survival rate  \n \n2 years survival rate  \n 52% (32 patients)  \n \n14% (12 patients)  Lack of com parison \ngroup \uf0e0 study \nexcluded   \nSkeie et al. 2011  To review a series of \npatients who \nunderwent Gamma \nKnife surgery (GKS)  Retrospective \nanalysis  \n \nTreatment:  \nGamma Knife  77 patients  with a \ntotal of 143 \nmetastases  Growth control  \n \n \nmedian survival \nafter GKS  \n 59 of 70 (84.3%) \npatients  \n \n7 months (range 0 -\n73 months)  Lack of comparison \ngroup \uf0e0 study \nexcluded   \nRades et al. 2010  To investigate a Retrospective 51 patients   Standard vs. high Lack of comparison   \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 574 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \npotential benefit \nfrom escalation of \nthe whole -brain \nradiotherapy (WBRT) \ndose beyond the \n\"standard\" regimen \n30 Gy in 10  \nfractions  analysis, Cohort \nstudy  \n \nTreatment:  \nWBRT  \n \n10x3 Gy (n = 33)  \n40 Gy/20 fractions \n(n = 11)  \n45 Gy/15 fractions \n(n = 7)   \n  \n \n6 months survival \n(OS)  \n \n12 months OS  \n \n6 months local \n(intracerebral) \ncontrol (LC)  \n12 months LC  dose \n \n27% vs. 50%  \n(p = 0.009)  \n \n4% vs. 20%  \n \n23% vs. 50%  \n \n \n0% vs.13%.  group \uf0e0 study \nexcluded  \nRedmond et al. \n2008  To investigate which \npatient - or \ntreatment -specific \nfactors influence \nsurvival of patients \nwith melanoma \nbrain metastases  Retrospective \nanalysis, Prognosis \nstudy  \n \nTreatment:  \nGKS 59 patients   Survival was \nsignificantly better \nin patients with \nsolitary metastasis \n(p = 0.04), lesions \nwithout evidence of \npre-GKS \nhemorrhage (p = \n0.004), and in \npatients with total \ntumo r volume \ntreated < 4 cm(3) (p \n= 0.02)  Lack of comparison \ngroup \uf0e0 study \nexcluded   \nMathieu et al. 2007  to assess clinical \noutcomes and Retrospective \nanalysi s, Prognosis 244 patients  median survival  \n 5.3 months  \n Lack of comparison \ngroup \uf0e0 study   \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 575 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \nidentify prognostic \nfactors for survival \nand cerebral disease \ncontrol after \nGamma knife \nradiosurgery  study  \n \nTreatment:  \nGKS \n Sustained local \ncontrol  86.2% of tumors  excluded  \nHofmann et al. \n2007  To examine \nprognostic factors \nand the evaluation \nof different \ntreatment  options  Retrospective \nsurvival analysis  \n \nTreatment:  \nSurgery (n=34)  \nSRS (n=43)  \nWBRT (n=33)  \ncorticosteroids \n(n=63)  \n \n 133 patients  Median Survival  \n(from date of \ndiagnosis of brain \nmetastases)  \n Entire cohort \n(n=133)  \n24 weeks (5.1 \nmonths) (range 1 \u2013\n196 weeks)   \n \nsurgery vs. SRS vs. \nWBRT vs. \ncorticosteroids:  \n57 vs. 40 vs. 24 vs. \n17 weeks  \n univariate analysis \nis missing, small \nsample size \uf0e0 study \nexcluded   \nSamlowski et al. \n2007  To report a \nretrospective \nanalysis of our \ninstitutional \nexperience of \nmultimodality \ntreatment utilizing \nlinear accelerator Retrospective \nanalysis  \n \nTreatment:  \nstereotactic \nradiosurgery (SRS)  44 patients  median survival with \nbrain metastases  \n \n \n \n1-year survival  \n2-year survival  \n 11.1 months ( 95% \nconfidence interval \n[CI]: 8.2 -14.9 \nmonths) from \ndiagnosis  \n47.7%  \n17.7%  \n Lack of comparison \ngroup \uf0e0 study \nexcluded    \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 576 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \n(Linac) -based \nstereotactic \nradiosurgery (SRS)   \n \n \n Addition of WBRT to \nmaintain control of \nbrain metastases in \na subset of patients \ndid not improve \nsurvival  \nChristopoulou et al. \n2006  To investigate the \neffect of gamma \nknife surgery on the \nlocal control of \ncerebral metastases \nfrom melanoma and \nto assess survival  Retrospective \nanalysis  \n \nTreatment:  \nGKS 29 patients  local control  \n \n \n \n \n \n \n \n \nmedian survival \nfrom gamma knife \nsurgery  61.5% of 96 \nmetastases \nregressed by more \nthan 50% of the \npretreatment \nvolume, 25% \nregressing by more \nthan 90% and 13.5% \ncompletely  \n5.7 months  Lack of comparison \ngroup \uf0e0 study \nexcluded   \nGaudy -Marqueste \neta l. 2006  To assess \nretrospectively a \nstrategy that uses \nGamma -Knife \nradiosurgery in the \nmanagement of \npatients with brain \nmetastases of Retrospective \nanalysis  \n \nTreatment:  \nGKS 106 patients , 221 \nbrain metastases  Median survival \nfrom the time of \nGKR \n \nControl rate  \n \ncomplete response \npartial response  5.09 months  \n \n \n \n83.7%  \n \n14% (14 BMs)  \n42% (41 BMs)  Lack of comparison \ngroup \uf0e0 study \nexcluded    \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 577 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \nmalignant \nmelanoma  stabilization  43% (43 BMs)  \nKoc et al. 2005  To evaluate \nretrospectively the \neffectiveness of \nGamma Knife \nradiosurgery for \nintracranial \nmetastatic \nmelanoma and to \nidentif y prognostic \nfactors related to \nsurvival  Retrospective \nanalysis  \n \nTreatment:  \nGKS \n 26  patients, 72 \nbrain metastases  Overall median \nsurvival after GKS  \n \n1-year survival  6 months  \n \n \n25% \n Lack of comparison \ngroup \uf0e0 study \nexcluded   \nMeier et al. 2004  to determin e the \nfactors influencing \nsurvival in a \nretrospective review \nof patients with \nmelanoma brain \nmetastases to \npermit more \nspecific \nrecommendations \nregarding therapy  Retrospective \nsurvival analysis  \n \nTreatment:  \nWBRT (n=54)  \nsurgery (n=37)  \nSRS (n=17)  \nchemotherap y \n(n=38)  100 patients  median overall \nsurvival  \n \n \n6-month survival  \n1-year survival  \n2-year survival  \n \n \n \n \n \n Entire cohort \n(n=100)  \n4.8 months  \n \n36% \n14% \n5% \n \nWBRT vs. surgery vs. \nradiosurgery vs. \nchemotherapy vs. \ntemozolomide  \n < 20 patients in one \nof the treatment \ngroups  \n\uf0e0 study excluded  \n \nOnly 63 patients \nincluded in \nmultivariate analysis \ndue to missing data  \n \n   \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 578 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \n \n 5.5 vs. 10.6 vs. 10.3 \nvs. 6.6 vs. 10 .1 \nmonths  \nMorris et al. 2004  To determine the \noutcome of patients \nwith metastatic \nmalignant \nmelanoma (MMM) \ntreated wi th \npalliative whole \nbrain radiotherapy \n(WBRT)  Retrospective \nanalysis  \n \nTreatment:  \nWBRT  \n 112 patients  median survival \nafter WBRT  51 days (range 3 -\n1386)  Lack of comparison \ngroup \uf0e0 study \nexcluded   \nRadbill et al. 2004  To identify \nassociated \nprognostic \nindica tors for \npatients receiving \ngamma knife (GK) \nradiosurgery in the \ninitial treatment of  \nintracranial \nmelanoma \nmetastases  Retrospective \nanalysis  \n \nTreatment:  \nGKS \n 51 patients, 188 \nbrain metastases  median overall \nsurvival from time \nof GKS  26 weeks  \n \nSubgroup a nalysis: \n77 weeks for \npatients presenting \nwith a single lesion, \ncompared with 20 \nweeks for patients \npresenting with \nmultiple lesions (P \n= 0.003)  Lack of comparison \ngroup \uf0e0 study \nexcluded   \nStone et al. 2004  To evaluate overall \nsurvival in patients \nwith bra in Retrospective \nsurvival analysis  \n 91 patients  Overall Survival  A survival benefit of \n7.3 months (p = \n0.05) was found to < 20 patients in one \nof the treatment \ngroups    \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 579 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \nmetastases from \nmalignant \nmelanoma  Treatment:  \nSRS+WBRT (n=8)  \nSurgery + WBRT \n(n=16)  \nWBRT (n=59)  be associated with \ngamma knife \nradiosu rgery or \nsurgical excision \nplus radiation \ntherapy over \nradiation therapy \nalone after \ncontrolling for \ndifferences in age, \nnumber of brain \nlesions, and \npresence of \nsymptoms.  \uf0e0 study excluded  \n \nSelek et al. 2004  To report on the \noutcome of patients \nwith melanoma \nbrain metastases \ntreated with \nstereotactic \nradiosurgery (SRS)  Retrospective \nanalysis  \n \nTreatment:  \nSRS alone (61 \npatients), SRS + \nwhole -brain \nradiotherapy (WBRT) \n(12 patients), and \nsalvage SRS after \nWBRT (3 0 patients)  103 patients, 153 \nintracranial \nmelanoma \nmetastases  1-year local control \n(LC) for all patients \ntreated with SRS  49% < 20 patients in one \nof the treatment \ngroups  \n\uf0e0 study excluded  \n  \nHerfarth et al. 2003  Stereotactic Retrospective 64 patients, 122 Median survival  10.6 months  Lack of compa rison   \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 580 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \nradiosurgery is an \nalternativ e option to \nneurosurgical \nexcision in the \nmanagement of \npatients with brain \nmetastases.  analysis  \n \n \nTreatment:  \nStereotactic \nradiosurgery  brain metastases   \n1 year local control   \n81% group \uf0e0 study \nexcluded  \nBuchsbaum et al. \n2002  To determine \nwhether various \ntherapies provided \nany benefit at all in \na population of \npatients with brain \nmetastases from \nmelanoma  Retrospective \nanalysis  \n \nTreatment:  \nsurgical resection, \nWBRT, stereotact ic \nradiosurgery, or \nWBRT combined \nwith local therapy  74 patients with \nbrain metastases  median survival was \nfor all patients  5.5 months  \n \ncombined treatment \noffered significantly \nbetter survival (P < \n0.0001; combined \nvs. other)  \n \nmedian survival was \n8.8 month s (range, \n1.8-99.2 months) \nfor the combined \ntherapy group, 4.8 \nmonths (range, 1.2 -\n27.8 months) for \nthe local therapy \nalone group, 2.3 \nmonths (range, 0.2 -\n9.6 months) for the \nWBRT alone group, < 20 patients in one \nof the treatment \ngroups  \n\uf0e0 study excluded  \n   \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 581 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \nand 1.1 months \n(0.1-3.0 months) \nfor the group that \nreceived no th erapy  \nGonzales -Martinez \net al. 2002  to evaluate \nretrospectively the \neffectiveness of \nstereotactic \nradiosurgery for \nintracranial \nmetastatic \nmelanoma and to \nidentify prognostic \nfactors  Retrosp ective \nanalysis  \n \nTreatment:  \nstereotactic radio \nsurgery  24 patients, 115 \nlesions  mean survival after \nradiosurgery  5.5 months  \n \nno difference in \nterms of survival \nbetween patients \nwho underwent \nWBRT or \nchemotherapy and \nthose who did not  \n \nsignificant \ndifferen ce (p < \n0.05) in mean \nsurvival was \nobserved between \npatients receiving \nimmunotherapy or \nthose with a \nKarnofsky \nPerformance Scale \n(KPS) score of \ngreater than 90  Lack of comparison \ngroup \uf0e0 study \nexcluded    \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 582 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \nMingione et al. \n2002  To evaluate the \nusefulness and \nlimitations of \ngamma surgery in \nthe treatment of \nbrain metastases \nfrom melanoma.  Retrospective \nanalysis  \n \nTreatment:  \nGKS 45 patients, 92 \nbrain metastases  Follow -up imaging \nstudies available:  \n35 patients, 66 \nlesions  24% percent of the \nlesions disappeared, \n35% shrank, 23% \nremained \nunchanged, and \n18% increased in \nsize. Lack of comparison \ngroup \uf0e0 study \nexcluded   \nNoel et al. 2002  To evaluate the \nefficacy and toxicity \nof stereotactic \nradiotherapy in the \ntreatment of brain \nmetastases of \nmelanoma.  Retrospective \nanalysis  \n \nTreatment:  \nstereotactic \nradiotherapy  25 patients, 61 \nmetastases  Median survival   \n \noverall survival rates  \n3- month  \n6- month  \n12-month  \n \nProgression  \n \nlocal control rates  \n3- month  \n6- month  \n12-month  8 months  \n \n \n75 +/ - 9% \n53 +/ - 10% \n 29 +/ - 10% \n \nn=5 (9.8%)  \n \n \n95 +/ - 3% \n90 +/ - 5% \n84 +/ - 7% Lack of comparison \ngroup \uf0e0 study \nexcluded   \nYu et al. 2002  To identify \nimportant \nprognostic factors \npredictive of \nsurvival and tumor \ncontrol in patients Retrospective \nanalysis  \n \nTreatment:  \nGKS \n 122 patients, 332 \nintracranial \nmelanoma \nmetastases  median overall \nsurvival from time \nof radiosurgery  7.0 months  Lack of comparison \ngroup \uf0e0 study \nexcluded    \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 583 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \nwith metastatic \nmelanoma to the \nbrain who \nunderwent gamma \nknife radiosurgery  \nZacest et al. 2002  to review the \noutcome of pa tients \nwho underwent \nsurgery for \ntreatment of \ncerebral metastatic \nmelanoma  Retrospective \nanalysis  \n \nTreatment:  \nsurgery  147 patients  median survival \nfrom the time of \nsurgery  \n 8.5 months  \n \n \n \n Lack of comparison \ngroup \uf0e0 study \nexcluded   \nEllerhorst et al. \n2001  To obtain a \ndescription of the \npopulation offered \nWBRT  Retrospective \nanalysis  \n \nTreatment:  \nWBRT  87 patients  median survival  19 weeks  \n Lack of comparison \ngroup \uf0e0 study \nexcluded   \nKonstadoulakis et \nal. 2000  To evaluate the \nprognostic \nparameters and \ntreatment  \nmodalities of \nmalignant \nmelanoma patients \nwith brain \nmetastases  Retrospective \nanalysis  \n \nTreatment:  \nSurgery  \nsurgery + \nradiotherapy (n=2)  \nsurgery + \nchemotherapy 136 patients  1-year survival rate  surgery  \n28.3%  \nradiotherapy and/or \nchemotherapy  \n6.67%  \nno treatment 3.45%  \n (p=0.006)  Subgroups < 20 \npatients \uf0e0 study \nexcluded    \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 584 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \n(n=17)  \nLavine et al. 1999  To analyze the \neffectiveness of \nLeksell gamma unit \ntherapy for \nmetastatic \nmelanoma to the \nbrain  Retrospective \nanalysis  \n \nTreatment:  \nGKS \n 45 patients, 59 \nLeksell gamm a unit \ntreatment sessions  Median overall \nsurvival from the \ntime of gamma \nknife treatment  \n \nimproved or stable \nneurological \nsymptomatology  \n \nlocal tumor control \nrate 8 months (range, 1 -\n20 mo nths) \n \n \n \n78% \n \n \n \n97% Lack of comparison \ngroup \uf0e0 study \nexcluded   \nFrieh s et al. 1998  To determine the \neffectiveness of \ngamma knife \nradiosurgery in \npatients with \nmalignant \nmelanoma \nmetastases  prospective \nmulticenter study  \n \nTreatment:  \nGKS 45 patients, 96 \nlesions  median overall \nsurvival  \n \ntumor control  4.2 months  \n \n \n86% of lesio ns Lack of comparison \ngroup \uf0e0 study \nexcluded   \nSampson et al. 1998  To identify \ndemographic \nfactors associated \nwith the \ndevelopment of \nclinically significant Retrospective \nsurvival analysis  \n \nTreatment:  \nSurgery (n=52)  \nSurgery+WBRT 702 patients  median overall  \nsurvival  \n Entire cohort \n(n=702) 3.7 months  \n \nsurgery vs. \nsurgery+WBRT vs. \nWBRT vs. no multivariate \nanalysis included \uf0e0 \nstudy excluded    \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 585 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \nbrain metastases in \n702 of these \npatients and to \ndetermine the \nfactors influencing \nthe prognosis of  \nthis population to \npermit more \ninformed \nrecommendations \nregarding surgical \ntherapy  (n=87)  \nWBRT (n=180)  \nChemotherapy \n(n=205)  \nSymptomatic \ntreatment (n=178)  \n chemotherapy:  \n8.8 vs. 6.4 vs. 3.9 \nvs. 1.3 months  \n \nFletcher et al. 1998  To reviewe the \nresults of surgical \nresection  Retrospective \nanalysis  \n \nTreatment:  \nsurgery  77 patients,  \ndifferent sites,  \nbrain n = 12    <20 patients with \nbrain metastases  \n\uf0e0 study excluded   \nGrob et al. 1998  To evaluate the \neffectiveness of \nradiosurgery \nwithout whole brain \nradiotherapy in the \npalliative t reatment \nof melanoma brain \nmetastases  Retrospective \nanalysis  \n \nTreatment:  \nradiosurgery  35 patients  Median overall \nsurvival  \n \n \n \n \n \n \nlocal control rate at 22 months (solitary \nbrain metastasis)  \n7.5 months ( single \nbrain metastasis + \nmetastases \nelsewh ere) \n4 months ( multiple \nbrain metastases)  \n98.2% (55/56 Lack of comparison \ngroup \uf0e0 study \nexcluded    \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 586 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \n3 months   metastases)  \nMori et al. 1998  To evaluate results \nafter stereotactic \nradiosurgery (SR) \nfor patients with \nmetastastic \nmelanoma to \nidentify patient \noutcomes an d \nfactors for survival  Retrospective \nanalysis  \n \nTreatment:  \nSR alone n=9  \nSR+WBRT n=51  60, 118 melanoma \nbrain metastases  Median survival \nafter SR  \n \nlocal control rate of \nevaluable tumors (n \n= 72)  \ndisappearance \nshrinkage  \nstable  7 months  \n \n \n90% \n \n \n11% \n44% \n35% < 20 patients in one \nof the treatment \ngroups  \n\uf0e0 study excluded  \n  \nSeung et al. 1998  To evaluate the \nefficacy and toxicity \nof gamma knife \nradiosurgery in the \ntreatment of \nmelanoma \nmetastases to the \nbrain  Retrospective \nanalysis  \n \nTreatment:  \nGKS  55 patients, 1 40 \nlesions  median overall \nsurvival  35 weeks  \n \n35 weeks for \npatients with \nsolitary metastases \nversus 33 weeks for \nthose with multiple \nmetastases  Lack of comparison \ngroup \uf0e0 study \nexcluded   \nGupta et al. 1997  To report the \nexperience of 31 \npatients who \npresent ed with \ncerebral metastasis \nof cutaneous \nmelanoma  \n Retrospective \nanalysis  \n \nTreatment:  \nSurgery (n=17)  \nSurgery + \nradiotherapy (n=6)  31 patients  median  overall \nsurvival  \n \n 4 months  \n \n \n < 20 patients in one \nof the treatment \ngroups  \n\uf0e0 study excluded  \n   \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 587 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \n \nGieger  et al. 1997  to determine the \nradiographic \nresponse of \nintracranial \nmetastatic \nmelanomas to SRS  Retrospective \nanalysis  \n \nTreatment:  \nstereotactic \nradiosurgery  12 patients with 21 \nintracranial \nmelanoma \nmetastases    Lack of comparison \ngroup \uf0e0 study \nexcluded   \nIsokangas et al. \n1996  To report the long -\nterm results of the \nirradiation of \nintracranial \nmalignant \nmelanoma  Retrospective \nanalysis  \n \nTreatment:  \nRadiotherapy  \nTD 40 Gy vs. \nnormalized TD at 3 \nGy (NTD3Gy) with \n30 Gy as cutpoints  60 patients  median survival  4.1 months  \n \nThose with higher \ntotal doses to the \ntumour area had \nsignificantly better \n(P = 0.0006) \nsurvival  Lack of comparison \ngroup \uf0e0 study \nexcluded   \nSkibber et al. 1996  To evaluate \npostoperative \nadjunctive cranial \nirradiation in 34 \npatients with \nsolitary brain \nmetastases  Retrospective \nanalysis  \n \nTreatment:  \nSurgery alone n=12  \nSurgery + WBRT \nn=22  34 patients, 34 \nbrain metastases   Overall survival was \nsignificantly \nimproved in the 22 \npatients who \nreceived adjunctive \ncranial irradiation \nversus that in the \n12 patients who had \nsurgery alone  < 20 patients in one \nof the treatment \ngroups  \n\uf0e0 study excluded  \n   \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 588 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \nWillner et al. 1995  To show treatment \nresults and to \ndefine prognostic \nsubgroups in \npatients undergoing \nradiotherapy for \nbrain metastases \nfrom malignant \nmelanom a Retrospective \nanalysis  \n \nTreatment:  \nRadiotherapy  30 patients  \n Overall survival rate  \n6 months  \n1 year   \n39%  \n23% \n Lack of comparison \ngroup \uf0e0 study \nexcluded   \nSomaza et al. 1993  To determine local \ntumor control rates \nand survival of \npatients with \nmelanoma \nmetastases to the \nbrain  Retrospective \nanalysis  \n \nTreatment:  \nstereotactic \nradiosurgery + \nWBRT  23 patients, 32 \ntumors  median survival \nperiod after \ndiagnosis  \n \nlocal tumor control \nrate  9 months (range 3 \nto 38 months)  \n \n \n97% Lack of comparison \ngroup \uf0e0 study \nexcluded   \nDavey et al. 1991  To determine how \nmany patients \nmight be candidates \nfor radiosurgery, a \nretrospective \nanalysis of \ncomputed \ntomographic brain \nscans performed on \n41 patients with  41 patient s   No survival + \nefficacy data \uf0e0 \nstudy excluded    \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 589 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \ncerebral metastases \nfrom malignant \nmelanoma was \nundertaken  \nHagen et al. 1990  To report treatment \nresults of patients \nwith brain \nmetastasis from \nmelanoma  Retrospective \nanalysis  \n \nTreatment:  \nSurgery + \npostoperative \nradiation n=19  \n \nSurgery alone n=16  35 patients   Group A had a \nlonger interval to \nCNS relapse \ncompared with \ngroup B, but \nsurvival was similar.  < 20 patients in one \nof the treatment \ngroups  \n\uf0e0 study excluded  \n  \nOredsson et al. \n1990   Retrospective \nanalysis  \n \nTreatment:  \nSurgery  40 patients  median survival  \n \n3-year survival  \n5-year survival  \n \nNeurological \nimprovement  \n \nsurgical mortality \nrate  8 months  \n \n25% \n15% \n \n25 patients  \n \n \nless than 5%  \n \n \nQuality of life as \njudged by Karnofsky Lack of comparison \ngroup \uf0e0 study \nexcluded    \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 590 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \nindex was improved \nafter surgery and \nmaintained on an \nacceptable level for \nthe remainin g time \nof survival  \nGuazzo et al. 1989   Retrospective \nanalysis  \n \nTreatment:  \nSurgery  31 patients  Significant and life -\nthreatening \ncomplications  \n \nrelief of symptoms:  5 patients (17%)  \n \n \n \n64% had complete \nremission o f \nsymptoms while a \nfurther 20% were \nsubstantially \nimproved  Lack of comparison \ngroup \uf0e0 study \nexcluded  \n  \nMendez et al. 1988   Retrospective \nanalysis  \n \nTreatment:  \nSurgery, \nRadiotherapy  55 patients with \nneurological signs \nand symptoms \nsecondary to \nmetastases t o the \nbrain  6 month survival  58% if surgical \nexcision was \npossible  < 20 patients in one \nof the treatment \ngroups  \n\uf0e0 study excluded  \n  \nRate et al. 1988  To review the \nrecords of all \npatients receiving \npalliative Retrospective \nanalysis  \n \nTreatment:  77 patients with \nbrain metastases  median survival \nfrom the initiation \nof radiotherapy  14 week  Lack of comparison \ngroup \uf0e0 study \nexcluded    \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 591 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \nradiotherapy for \nmalignant \nmelanoma \nmetastatic  to brain, \nto bone, or with \nspinal cord \ncompression  Radiotherapy  \nRetsas et al. 198 8  Retrospective \nanalysis  \n \nTreatment:  \nDifferent treatments  100 patients  Median survival  2.5 months  Lack of comparison \ngroup \uf0e0 study \nexcluded   \nWornom et al. 1986   Retrospective \nanalysis  \n \nTreatment:  \nsurgery  65 patients, 94 \nmetastatic lesions \n(brain, lung , \nabdomen, distant \nsubcutaneous sites, \nand distant lymph \nnodes)  Median survival \nafter excision of \nbrain metastases  \n \nRelief of symptoms  8 months  \n \n \n \n77% of brain \nmetastases  Lack of comparison \ngroup \uf0e0 study \nexcluded   \nZiegler et al. 1986  To examine the \nrecor ds of 72 \npatients who \nreceived various \nregimens of \nradiotherapy for \ncerebral metastases Retrospective \nanalysis  \n \nTreatment:  \nWBRT  \n300 cGy \n(conventional 72 patients   No difference in \nresponse could be \nattributed to dose \nschedules, either \noverall or in the \nsubgroups of \npatients who had Lack of comparison \nbetween different \ntreatments \uf0e0 study \nexcluded    \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 592 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \nfrom malignant \nmelanoma  fractionation, CF) \nvs. 500 -600 cGy \n(high -dose-per-\nfraction, HDF) to a \ntotal of 30 00 cGy  solitary or multiple \nbrain metastases  \nChoi et al.  1985   Retrospective \nanalysis  \n \nTreatment:  \nWBRT  \n \n 194 patients with \nintracranial \nmetastatic \nmelanoma    Lack of comparison \ngroup \uf0e0 study \nexcluded   \nStridsklev et al. \n1984  To analyze patients \nwho completed \nwhole -brain \nirradiation \ntreatment for brain \nmetastas es from \nmalignant \nmelanoma  Retrospective \nanalysis  \n \nTreatment:  \nWBRT  39 patients  Median survival  \n \nclinical \nimprovement  \n \nobjective regression \nof the brain \nmetastases  2 months  \n \nn=21 (53.8%)  \n \n \n6 of 15 evaluable \npatients (40%)  Lack of comparison \ngroup \uf0e0 study \nexcluded   \nMadajewicz et al. \n1984  To review 8 years of \nRoswell Park \nMemorial Institute's \n(RPMI) experience \nwith the \nmanagement of Retrospective \nanalysis  \n \nTreatment:  \n \nNone (n=15)  125 patients with \nbrain metastases \n(73% multiple \nmetastases)  median survival  The median survival \nof the untreated \ngroup of patients \nwas 3 weeks as \ncompared with that \nof 6 weeks for the < 20 patients in one \nof the treatment \ngroups,  no \nmultivariate \nanalysis \uf0e0 study \nexcluded    \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 593 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \nmalignant \nmelanoma CNS \nmetastases ( 1972 -\n1980)  Steroids (n=17)  \nradiotherap y (n=23)  \nsurgery (n=20)  \nchemotherapy  patients maintained \non steroids  \nonly, 9 weeks for \nthose who received \nradiotherapy, 11 \nweeks for the \npatients treated \nwith intraarterial  \nchemotherapy, and \n26 weeks for the \npatients who \nunderwent \nsuccessful surgical \nexcision of a \nsolitary  \nlesion.  \nByrne et al. 1983   Retrospective \nanalysis  \n \nTreatment:  \nGroup 1, multiple \nbrain metastases \ntreated with \nradiation therapy \n(RT) (n = 49)  \n \nGroup 2, single 81 patients with \nbrain metastasis   \n \nMedian survival  Groups 1 vs 2 vs 3  \n \n11, 9 and 41 weeks  No multivariate \nanalysis included \uf0e0 \nstudy excluded    \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 594 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \nbrain metastasis \ntreated with RT (n = \n17) \n \nGroup 3, single \nbrain metastasis \ntreated with surgery \nwith or without RT \n(n = 9).  \nVlock et al. 1982  To examine the \nresults in 4 6 \npatients treated \nwith high - or low -\ndose fractions for \nintracranial \nmetastases  Retrospective \nanalysis  \n \nTreatment:  \n26 patients received \nhigh-dose fraction \ntherapy, generally \n600 \nrad/fraction/week \nto 2400 --3600 rad; \n20 patients received \nlow-dose fraction \nradiotherapy with \n125--400 \nrad/fraction daily  46 patients   \n \n \n \nMedian survival  \n \n \nImprovement  \n \nStability  \n \ndeterioration  high-dose fraction \ngroup vs. low -dose \nfraction group  \n \n3 months vs. 2 1/2 \nmonths  \n \n38 vs. 35%,  \n \n23 vs. 25%  \n \n38 vs. 40%  Lack of comparison \nbetween different \ntreatments  \n \uf0e0 study excluded   \nKatz et al. 1981  To records of all \npatients who Retrospective \nanalysis  63 patients  Response  73% to \ncorticosteroids  < 20 patients in one \nof the treatment   \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 595 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \nreceived \nradiotherapy for \nmelanoma \nmetastatic to brain \n(63 patients   \nTreatment:  \ncorticosteroids, \nradiotherapy, \nsurgery (n=8)  42% to radiotherapy  \n groups  \n\uf0e0 study excluded  \n \nCarella et al. 1980  To determine the \nresponse to whole \nbrain irradiation  Retrospective \nanalysis  \n \nTreatment:  \nWBRT  60 patients  Median sur vival  Study 1 patients 10 \nweeks (range 1 -\n200) vs. Study II \npatients 14 weeks \n(range 1 -76) \n \nsignificant benefit \nfrom radiation \ntherapy in terms of \nsymptomatic and \nneurologic function \nimprovement. \nSymptomatic \nimprovement was \nobserved in 76%, \nwith 31% comple tely \nimproved  Lack of comparison \ngroup \uf0e0 study \nexcluded   \nCooper et al. 1980   Retrospective \nanalysis  \n \nTreatment:  30 patients, 35 \ncourses   Marked \nimprovement in \nneurologic status \noccurred in Lack of comparison \ngroup \uf0e0 study \nexcluded    \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 596 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \nWBRT  approximately 35%. \nSlight to moderate \nimprovement was \nevide nt in an \nadditional 35%.  \nHafstrom et al. \n1980   Retrospective \nanalysis  \n \nTreatment:  \nSurgery  25 patients  median survival  5 months  Lack of comparison \ngroup \uf0e0 study \nexcluded   \nPennington  et al. \n1975   Retrospective  \nanalysis  \n \nTreatment:  \n \nRadiotherapy, \nchemotherapy, \nsurgery and \nimmunotherapy  57 patients    Publication  <1980 \n\uf0e0 study excluded   \n \n \n \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 597 von 732 6.3.5.  Literatur  \n \nBuchsbaum JC, Suh JH, Lee SY, et al. Survival by radiation therapy oncology group recursive partitioning analys is class and treatment modality in patients with brain metastases \nfrom malignant melanoma: a retrospective study. Cancer 2002;94:2265 -2272  \nByrne TN, Cascino TL, Posner JB. Brain metastasis from melanoma. J Neurooncol 1983;1:313 -317 \nCarella RJ, Gelber R, He ndrickson F, et al. Value of radiation therapy in the management of patients with cerebral metastases from malignant melanoma : Radiation Therapy \nOncology Group Brain Metastases Study I and II. Cancer 1980;45:679 -683 \nChoi KN, Withers HR, Rotman M. Intracran ial metastases from melanoma. Clinical features and treatment by accelerated fractionation. Cancer 1985;56:1 -9 \nChristopoulou A, Retsas S, Kingsley D, et al. Integration of gamma knife surgery in the management of cerebral metastases fro m melanoma. Melanoma  Res 2006;16:51 -57 \nCooper JS, Carella R. Radiotherapy of intracerebral metastatic malignant melanoma. Radiology 1980;134:735 -738 \nDavey P, O'Brien P. Disposition of cerebral metastases from malignant melanoma: implications for radiosurgery. Neurosurgery 1 991;28:8 -14; discussion 14 -5 \nEigentler TK, Figl A, Krex D, et al. Number of metastases, serum lactate dehydrogenase level, and type of treatment are progn ostic factors in patients with brain metastases of \nmalignant melanoma. Cancer 2011;117:1697 -1703  \nEllerho rst J, Strom E, Nardone E, et al. Whole brain irradiation for patients with metastatic melanoma: a review of 87 cases. Int J Radiat Oncol Biol Phys 2001;49:93 -97 \nFife KM, Colman MH, Stevens GN, et al. Determinants of outcome in melanoma patients with cereb ral metastases. J Clin Oncol 2004;22:1293 -1300  \nFletcher WS, Pommier RF, Lum S, et al. Surgical treatment of metastatic melanoma. Am J Surg 1998;175:413 -417 \nFriehs GM, Legat J, Zheng Z, et al. Outcomes in patients treated with gamma knife radiosurgery for b rain metastases from malignant melanoma. Neurosurg Focus 1998;4:e1  \nGaudy -Marqueste C, Regis JM, Muracciole X, et al. Gamma -Knife radiosurgery in the management of melanoma patients with brain metastases: a series of 106 patients without \nwhole -brain radioth erapy. Int J Radiat Oncol Biol Phys 2006;65:809 -816 \nGieger M, Wu JK, Ling MN, et al. Response of intracranial melanoma metastases to stereotactic radiosurgery. Radiat Oncol Investig 1997;5:72 -80 \nGonzalez -Martinez J, Hernandez L, Zamorano L, et al. Gamma kn ife radiosurgery for intracranial metastatic melanoma: a 6 -year experience. J Neurosurg 2002;97:494 -498 \nGrob JJ, Regis J, Laurans R, et al. Radiosurgery without whole brain radiotherapy in melanoma brain metastases. Club de Cancerologie Cutanee. Eur J Canc er 1998;34:1187 -\n1192  \nGuazzo EP, Atkinson RL, Weidmann M, et al. Management of solitary melanoma metastasis of the brain. Aust N Z J Surg 1989;59:321 -324 \nGupta G, Robertson AG, MacKie RM. Cerebral metastases of cutaneous melanoma. Br J Cancer 1997;76:256 -259 \nHafstrom L, Jonsson PE, Stromblad LG. Intracranial metastases of malignant melanoma treated by surgery. Cancer 1980;46:2088 -2090  \nHagen NA, Cirrincione C, Thaler HT, et al. The role of radiation therapy following resection of single brain metastasis from melanoma. Neurology 1990;40:158 -160 \nHerfarth KK, Izwekowa O, Thilmann C, et al. Linac -based radiosurgery of cerebral melanoma metastases. Analysis of 122 metastases treated in 64 patients. Strahlenther Onkol \n2003;179:366 -371 \nHofmann MA, Coll SH, Kuchler I,  et al. Prognostic factors and impact of treatment in melanoma brain metastases: better prognosis for women? Dermatology 2007;215:10 -16 \nIsokangas OP, Muhonen T, Kajanti M, et al. Radiation therapy of intracranial malignant melanoma. Radiother Oncol 1996;38 :139-144 \nKatz H.R. The relative effectiveness of radiation therapy, corticosteroids, and surgery in the management of melanoma metasta tic to the central nervous system. 1981.  \nKoc M, McGregor J, Grecula J, et al. Gamma Knife radiosurgery for intracranial m etastatic melanoma: an analysis of survival and prognostic factors. J Neurooncol 2005;71:307 -\n313 \nKonstadoulakis MM, Messaris E, Zografos G, et al. Prognostic factors in malignant melanoma patients with solitary or multiple brain metastases. Is there a role  for surgery? J \nNeurosurg Sci 2000;44:211 -8; discussion 219  \nLavine SD, Petrovich Z, Cohen -Gadol AA, et al. Gamma knife radiosurgery for metastatic melanoma: an analysis of survival, outcome, and complications. Neurosurgery \n1999;44:59 -64; discussion 64 -6 \nLonser RR, Song DK, Klapper J, et al. Surgical management of melanoma brain metastases in patients treated with immunotherapy. J Neurosurg 2011;115:30 -36 \nMadajewicz S, Karakousis C, West CR, et al. Malignant melanoma brain metastases. Review of Roswell Park Memorial Institute experience. Cancer 1984;53:2550 -2552  \nMathieu D, Kondziolka D, Cooper PB, et al. Gamma knife radiosurgery in the management of malignant melanoma brain metastases. Neurosurgery 2007;60:471 -81; discussion \n481-2 \nMeier S, Baumert BG, Maier T , et al. Survival and prognostic factors in patients with brain metastases from malignant melanoma. Onkologie 2004;27:145 -149 \nMendez IM, Del Maestro RF. Cerebral metastases from malignant melanoma. Can J Neurol Sci 1988;15:119 -123  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 598 von 732 Mingione V, Oliveira M, P rasad D, et al. Gamma surgery for melanoma metastases in the brain. J Neurosurg 2002;96:544 -551 \nMori Y, Kondziolka D, Flickinger JC, et al. Stereotactic radiosurgery for cerebral metastatic melanoma: factors affecting local disease control and survival. In t J Radiat Oncol Biol \nPhys 1998;42:581 -589 \nMornex F, Thomas L, Mohr P, et al. A prospective randomized multicentre phase III trial of fotemustine plus whole brain irrad iation versus fotemustine alone in cerebral \nmetastases of malignant melanoma. Melanoma R es 2003;13:97 -103 \nMorris SL, Low SH, A'Hern RP, et al. A prognostic index that predicts outcome following palliative whole brain radiotherapy f or patients with metastatic malignant melanoma. Br \nJ Cancer 2004;91:829 -833 \nNoel G, Simon JM, Valery CA, et al. L inac radiosurgery for brain metastasis of melanoma. Stereotact Funct Neurosurg 2002;79:245 -255 \nOredsson S, Ingvar C, Stromblad LG, et al. Palliative surgery for brain metastases of malignant melanoma. Eur J Surg Oncol 1990;16:451 -456 \nPennington DG, Milton GW. Cerebral metastasis from melanoma. Aust N Z J Surg 1975;45:405 -409 \nRadbill AE, Fiveash JF, Falkenberg ET, et al. Initial treatment of melanoma brain metastases using gamma knife radiosurgery: an evaluation of efficacy and toxicity. Cancer \n2004;101:825 -833 \nRades D, Heisterkamp C, Huttenlocher S, et al. Dose escalation of whole -brain radiotherapy for brain metastases from melanoma. Int J Radiat Oncol Biol Phys 2010;77:537 -541 \nRaizer JJ, Hwu WJ, Panageas KS, et al. Brain and leptomeningeal metastases from cutaneous melanoma: survival outcomes based on clinical features. Neuro Oncol 2008;10:199 -\n207 \nRate WR, Solin LJ, Turrisi AT. Palliative radiotherapy for metastatic malignant melanoma: brain metastases, bone metastases, and spinal cord compression. Int J Ra diat Oncol \nBiol Phys 1988;15:859 -864 \nRedmond AJ, Diluna ML, Hebert R, et al. Gamma Knife surgery for the treatment of melanoma metastases: the effect of intratumo ral hemorrhage on survival. J Neurosurg \n2008;109 Suppl:99 -105 \nRetsas S, Gershuny AR. Central n ervous system involvement in malignant melanoma. Cancer 1988;61:1926 -1934  \nSalvati M, Frati A, D'Elia A, et al. Single brain metastases from melanoma: remarks on a series of 84 patients. Neurosurg Rev 2011  \nSamlowski WE, Watson GA, Wang M, et al. Multimodali ty treatment of melanoma brain metastases incorporating stereotactic radiosurgery (SRS). Cancer 2007;109:1855 -1862  \nSampson JH, Carter JH,Jr, Friedman AH, et al. Demographics, prognosis, and therapy in 702 patients with brain metastases from  malignant melan oma. J Neurosurg 1998;88:11 -\n20 \nSelek U, Chang EL, Hassenbusch SJ,3rd, et al. Stereotactic radiosurgical treatment in 103 patients for 153 cerebral melanoma metastases. Int J Radiat Oncol Biol Phys \n2004;59:1097 -1106  \nSeung SK, Sneed PK, McDermott MW, et al. Gamma knife radiosurgery for malignant melanoma brain metastases. Cancer J Sci Am 1998;4:103 -109 \nSkeie BS, Skeie GO, Enger PO, et al. Gamma knife surgery in brain melanomas: absence of extracranial metastases and tumor vol ume strongest indicators of prolon ged survival. \nWorld Neurosurg 2011;75:684 -91; discussion 598 -603 \nSkibber JM, Soong SJ, Austin L, et al. Cranial irradiation after surgical excision of brain metastases in melanoma patients. Ann Surg Oncol 1996;3:118 -123 \nSomaza S, Kondziolka D, Lunsford LD,  et al. Stereotactic radiosurgery for cerebral metastatic melanoma. J Neurosurg 1993;79:661 -666 \nStaudt M, Lasithiotakis K, Leiter U, et al. Determinants of survival in patients with brain metastases from cutaneous melanoma. Br J Cancer 2010;102:1213 -1218  \nStevens G, Firth I, Coates A. Cerebral metastases from malignant melanoma. Radiother Oncol 1992;23:185 -191 \nStone A, Cooper J, Koenig KL, et al. A comparison of survival rates for treatment of melanoma metastatic to the brain. Cancer  Invest 2004;22:492 -497 \nStridsklev IC, Hagen S, Klepp O. Radiation therapy for brain metastases from malignant melanoma. Acta Radiol Oncol 1984;23:231 -235 \nVlock DR, Kirkwood JM, Leutzinger C, et al. High-dose fraction radiation therapy for intracranial metastases of malignant mela noma: a comparison with low -dose fraction \ntherapy. Cancer 1982;49:2289 -2294  \nWillner J, Bohndorf W. CNS metastases in malignant melanomas. Strahlenther Onkol 1995;171:165 -173 \nWornom IL,3rd, Smith JW, Soong SJ, et al. Surgery as palliative treatment for dist ant metastases of melanoma. Ann Surg 1986;204:181 -185 \nWronski M, Arbit E. Surgical treatment of brain metastases from melanoma: a retrospective study of 91 patients. J Neurosurg 2000;93:9 -18 \nYu C, Chen JC, Apuzzo ML, et al. Metastatic melanoma to the brain : prognostic factors after gamma knife radiosurgery. Int J Radiat Oncol Biol Phys 2002;52:1277 -1287  \nZacest AC, Besser M, Stevens G, et al. Surgical management of cerebral metastases from melanoma: outcome in 147 patients trea ted at a single institution ove r two decades. J \nNeurosurg 2002;96:552 -558 \nZiegler JC, Cooper JS. Brain metastases from malignant melanoma: conventional vs. high -dose-per-fraction radiotherapy. Int J Radiat Oncol Biol Phys 1986;12:1839 -1842   \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 599 von 732 6.4. Frage VI.5. Adjuvante Radiotherapie Regionale L ymphknotenstation  \nFrage VI.5. Beeinflusst eine adjuvante Radiotherapie der Lymphknotenstation das Gesamt\u00fcberleben und/oder die rezidivfreie Zei t von \nMelanompatienten?  \n6.4.1.  PICO, Suchw\u00f6rter  \nPICO \u2013 Schema   \nPopulation  Intervention  Comparison  Outcome  \nmelanoma pat ients after nodal surgery  radiotherapy  no radiotherapy  Overall survival, progression free \nsurvival  \n \nSuchw\u00f6rter  \nStichwort  melanoma  adjuvant radiotherapy  postoperative  lymph node  \nlymph nodes  \nSynonyme   radiation   nodal  \nOber -/Unterbegriffe      \nMesh Term  melanoma  adjuvant radiotherapy   lymphoid tissue  \n \n6.4.2.  Datenbanken, Suchstrategien, Trefferzahlen  \nDatenbank  Suchstrategie  Datum  Treffer \n1. Suche     \nMedline  (\"melanoma\"[tiab] OR \"melanoma\"[MeSH]) AND (\"adjuvant radiotherapy\"[tiab] OR \"Radiation\"[tiab] \nOR \"post operative\"[tiab] OR adjuvant radiotherapy[MeSH Terms]) AND (\"lymph node\"[tiab] OR 04.11.11  455  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 600 von 732 Datenbank  Suchstrategie  Datum  Treffer \n\"lymph nodes\"[tiab] OR \"nodal \"[tiab] OR \"lymphoid ti ssue\"[MeSH])  \nCochrane Library  (melanoma and (\"adjuvant radiotherapy\" or radiation) and lymph*).ti,ab  07.11. 11 7 \nEmbase  (melanoma and (\"adjuvant radiotherapy\" or radiation) and lymph*).ti,ab  12.10. 10 475 \nUpdate Suche     \nMedline  s.o. 31.01.12  459 (0 dazu)  \nCochrane Library  s.o 31.01.12  7 (0 dazu)  \nEmbase  s.o. 23.01.12  590 (0 dazu)  \n \n6.4.3.  Auswahlkriterien  \nAuswahl de r Literatur  \nGesamttreffer  1056  \nEinschlusskriterien  Studien, die das Outcome (regionale Kontrollrate, Gesamt\u00fcberleben) einer adjuvanten Radiotherapie nach erfolgter \nLymphknotendissektion beschreiben  \nMangels RCT\u00b4s Einschluss von Kohortenstudien ab 20 Patie nten \nSprachen: e,dt  \nAusschlusskriterien  Case Reports  \nNicht systematische Reviews  \nKollektive mit gemischten Tumorentit\u00e4ten  \nPublikationen vor 1980  \nAnzahl nach Abstractscreening, vorges ehen f\u00fcr Bewertung  32 \nAnzahl ausgew\u00e4hlte Volltexte  11  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 601 von 732 6.4.4.  Evidenztabelle  \nStudy Aims  Design  Population  Outcomes  Results  Comments  LoE \nBurmeister et al. \n2012  To compare \nadjuvant \nradiotherapy with \nobservation alone \nin patients at high \nrisk of lymph -node \nfield relapse who \nhad undergone \ntherapeutic \nlymphadenectomy \nfor metastatic \nmelanoma in \nregional lymph \nnodes  Multicenter \nrandomized study  \n \nTreatment:  \nGroup A: surgery \nalone n=127  \n \nGroup B: surgery + \nRT (TD 48Gy, 20 \nfractions) after \nlymph adenectomy, \nn=123  250 patients after \nlymphadenectomy  \n  \n \n \nLymph node field \nrelapse  \n \n \n \n \nRelapse -free \nsurvival  \n \n \n \nOverall survival  Surgery alone vs. \nSurgery + RT  \n \n34 patients vs. 20 \npatients r elapsed \n(HR 0.56, 95% CI \n0.32 \u2013 0.98, \np=0.041 ) \n \n73 vs. 70 events, \nn.s. \n(HR 0.91, 95% CI \n0.65 \u2013 1.26, p=0.56)  \n \n47 vs. 59 deaths, \nn.s. \n(HR 1.37, 95% CI \n0.94 \u2013 2.01, p =0.12)  Jadad Score 3  \n \nLimitations: high \nnumber of ineligible \npatients  \n \nFunding: National \nHealth and Medical \nResearch Council of \nAustralia, Cancer \nAustralia, \nMelan oma Insitute \nAustra lia and the \nCancer Council of \nSouth Australia  1b \nGojkovic -Horvat et \nal. 20 11 To determine the \nefficacy of and \ncriteria for \npostoper ative \nradiotherapy (PORT) \nin patients with \npalpable mel anoma \nmetastases to the Retrospective \ncohort study  \n \nTreatment:  \nGroup A: surgery \nalone, n=64  \n \nGroup B: surgery + 101 patients, 103 \nnodal dissections   \n \n \nRecurrence  \n \n \n \n Surgery alone vs. \nSurgery + RT  \n \n14 of 66 dissections \n(21.2%; 95% CI, \n12.1-33.0%) vs. 5 of \n37 (13.5%; 95% CI, \n4.5-28.8%) retrospective study, \nImbalance of \nprognostic factors \nbetween the groups: \nworse prognostic \nfactors in the \nsurgery + RT group  3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 602 von 732 Study Aims  Design  Population  Outcomes  Results  Comments  LoE \ngroin  RT (TD range 50 - \n72 Gy, fraction size \n2 - 3 Gy), n=37   \n \n2-year regional \ncontrol rates  \n \n \n \n \n2 years overall \nsurvival  (p=0.431)  \n \n86% (95% CI, 76 -\n95%) and 91% (95% \nCI, 81 -100%),  \nrespectively \n(p=0.395)  \n \n56% (95% CI, 44 -\n68%) vs. 56% (95% \nCI, 39 -72%), \n(p=0.813)  \n \nBibault et al. 2011  To analyze the \noutcome after \nadjuvant radiation \ntherapy with \nstandard \nfractionation \nregimen in \nmetastatic lymph \nnodes (LN) from \ncutaneous \nmelan oma Retrospective \ncohort study  \n \nTreatment:  \nGroup A: surgery \nalone, n=2 6 \n \nGroup B: surgery  + \nRT (median TD \n50Gy, range 30 -70 \nGy, fraction size 2 - \nGy), n=60  \n \n 86 patients with \nlymphadenectomy  \n \nIndications for \nradiation therapy: \n>/= 4 involved LNs, \nextracapsular \nextension, LN size \n> 3 cm  \n \n  \n \n \nRegional control  \nOverall surviva l \n \n \n \n \n \n \n \n \n Surgery alone vs. \nSurgery + RT  \n \nNo improvement of \nregional control \n(p=0.17) or overall \nsurvival (p=0.18)  \n \nSubgroup RT > 50 \nGy (n=30) vs. no RT \n(n=26):  \n \nbetter regional \ncontrol p=0.004, retrospective study, \nImbalance of \ngroups: worse \nprognostic factors \nin the surgery + RT \ngroup (Ulc eration, \nnumber of positive \nLN, extracapsular \nextension)  3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 603 von 732 Study Aims  Design  Population  Outcomes  Results  Comments  LoE \n  \n \n \n \n \n \n better survival \np=0.005  \ncontrol rates / \nregions:  \nAxillary 90 vs. 70% \ninguinal 80 vs. 72% \ncervical 85 vs. 50%  \n \nSubgroup \nextraca psular \nextension:  \nRT <50Gy vs. RT \n<50Gy  \n5 year regional \ncontrol 80 vs. 35%, \np=0.03  \nStrojan et al. 2010  \n To review \nexperiences in the \ntreatment of \nregionally advanced \nmelanoma to the \nneck and/or parotid \nwith adjuvant \nradioth erapy.  Retrospective \ncohort study  \n \nTreatment:  \nGroup A: surgery \nalone, n=40  \n \nGroup B: surgery  + \nRT (median eqTD2 \n60 Gy, range 47.8 \u2013\n78.8, fraction size 5 83 patients after \nsurgery on \nmeta stases to the \nneck and/or parotid \ngland lymph  \nnodes, no distant \nmetastases  \n  \n \n2-year regional \ncontrol rates  \n \n \n2-year distant \nmetastasis -free \nsurvival rates  \n \n2-year survival Surgery alone vs. \nSurgery + RT  \n56% (CI 40 \u201372%) vs. \n78% (CI 63 \u201392%)  \n(p =0.015)  \n \n55% (CI 40 \u201370%) vs. \n40% (CI 25 \u201356%), \nn.s. \n \n51% (CI 36 \u201366%) vs. retrospective study. \nDue to I mbalance of \ngroups (irrad iated \npatients had more \nextensive surgery, a \nsignificantly higher \nmedian number of \ninvolved nodes, \nmore frequently \nextraca psular tumor \nextension, 3b \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 604 von 732 Study Aims  Design  Population  Outcomes  Results  Comments  LoE \nGy, range 2 \u20136 Gy), \nn=43  rates (all deaths \nconsidered as \nevents)  58% (CI 42 \u201373%), \nn.s.  \n \n nonrad ical surgery, \nless systemi c \nimmun otherapy \nwith inte rferon) a \nrisk factor score \nwas used for \nretrospective \ngrouping of \npatients.  \nAgrawal et al. 2009  To evaluate the \nimpact of adjuvant \nradiation therapy \n(RT) on regional \nrecurrence and \nsurvival after \ntherapeutic \nlymphad enectomy  Retrospective \ncohort study  \n \nTreatment:  \nGroup A: surgery \nalone, n=106  \n \nGroup B: surgery  + \nRT (most patients: \nTD 30 Gy, fraction \nsize 6 Gy, 2.5 \nweeks), n=509  615 patients after \nlymphadenectomy \n(cervical, axillary, \ninguinal)  \n \n \n  \n \n \nRecurrence  \n(at a median fo llow-\nup 60 months)  \n \n \n \n \n \n \n \n5-year regional \ncontrol rate  Surgery alone vs. \nSurgery + RT  \n \nRegional recu rrence: \n43 of 106 pts \n(40.6%) vs. 52 of \n509 pts (10.2%)  \n \ndistant recurrence: \n73.6% (78 of 106 \npts) vs. 55.4% (282 \nof 509 pts)  \n \nall sites 52 vs. 87%, \np<0.000 1 \ncervical 43 vs. 93%, \np<0.0001  \naxillary 48 vs. 91%, retrospective study, \nlarge series. P -\nvalues for \nrecurrence missing.  \ndata for overall \nsurvival not \ncompared between \ngroups  \n 3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 605 von 732 Study Aims  Design  Population  Outcomes  Results  Comments  LoE \np<0.0001  \ninguinal 69 vs. 69%, \nn.s. \n \nmultivariate \nanalysis: DMFS and \nDSS both were \ninfluenced by the \nnumber of positive \nlymph nodes and \nthe number of \nlymph nodes \nremoved. In \naddition, DSS was \ninfluenced b y \nprimary tumor \nthickness and the \nreceipt of adj uvant \nRT. \nThe most common \ncomplication  \nwas symptomatic \nlymphedema  \n \nHamming et al.  \n2009  To examine the \neffect of adjuvant \nradiotherapy on Retrospective \ncohort study  \n 64 patients wit h \nnelanoma neck \nnode metastasis   \n \n Surgery alone vs. \nSurgery + RT  \n retrospective study, \nshort median \nfollow-up (2.5 3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 606 von 732 Study Aims  Design  Population  Outcomes  Results  Comments  LoE \nregional control of \nmelanoma neck \nnode metastasis.  Treatment:  \nGroup A: surgery \nalone, n=24  \n \nGroup B: surgery  + \nRT (TD 24 - 36 Gy, \nfraction size 6 Gy) \nn=40   \n 2-year ipsilateral \nregional recurrence \nrate \n \n \n \n \n \n \n \n \n2-year disease -free \nsurvival (DFS)  \n \n \n2-year overall \nsurvival (OS).  46% vs. 18%, n.s. \n(p=0.16)  \n \nmultivariate \nanalysis: significant \nreduction of the RR \nrate after corre ction \nfor the number of \ninvolved nodes  \n(p=0.04)  \n \n29% vs. 18%, n.s. \n(p=0.30)  \n \n \n58% vs. 26%, n.s. \n(p=0.07)  \n years), small sa mple \nsize,-Imbalance of \nprognostic factors \nbetween the  groups  \nMoncrieff et al. \n2008  To examine the \neffectiveness of \nadjuvant \nradioth erapy in \ncontrolling regi onal \ndisease in high -risk \npatients  Retrospective \ncohort study  \n \nTreatment:  \nGroup A: surgery \nalone, n=587  \n \nGroup B: surgery  + \nRT (median TD 33 716 patients after \ncervical lymph node \nsurgery  \n  \n \n \n6 years regional \nrecurrence rate  \n \nOverall survival  \n \n Surgery alone vs. \nSurgery + RT  \n \n6.1% vs. 10.1%, n.s.  \n \n \nno benefit to \npatients with \nadjuvant retrospective study, \nlarge series, \nimba lance of \ngroups: the surgery \nplus RT group \nincludes \nsignificantly less \npatients with \nmicroscopic than 3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 607 von 732 Study Aims  Design  Population  Outcomes  Results  Comments  LoE \n(range  30 - 60 Gy, \nmost patients: \nfraction size 5.5 Gy, \n2x/week) n=129   \n radiotherapy  \n \nmultivariate \nanalysis: ulceration \nin the primary \ntumor: only \nsignificant \nindepe ndent \npredictor of \nregional recurrence \n(p = 0.005; hazard \nratio, 5.60; 95% \nconfidence interval, \n1.7\u201318.4)  \n \nnodal status, \nextracapsular \nspread and \nulcer ation of the \nprimary tumor: \nsignificant \nindependent \npredi ctors of \nsurvival (p = 0.001, \np = 0.014, and p = \n0.003)  \n macro scopic \ndisease and \nsignificantly more \npatients with \nextensive surgery  \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 608 von 732 Study Aims  Design  Population  Outcomes  Results  Comments  LoE \n \nFuhrmann et al. \n2001  To evaluate the \nusefulness of \nadjuvant \nradiotherapy \nfollowing resection \nof lymph node \nmetastases  Retrospective \ncohort study  \n \nTreatment:  \nGroup A: surgery \nalone,  n=58  \n \nGroup B: surgery  + \nRT (most patients \nTD 50 -65 Gy, \nfraction size 2 \u2013 3.8 \nGy) n=58  116 patients, Stage \nIII after resection of \nlymph node \nmeta stases  \n  \n \n \nLocal r ecurrence \nrate \n \nOverall survival  \n \n(after a follow up of \n12-14 years)  Surgery alone vs. \nSurgery + RT  \n \n79% vs. 84%, n.s.  \n \n \n26% vs. 17% , n.s.  retrospective study, \nImbalance of \ngroups: pairs were \nonly matched for \ngender and number \nof tumour -bearing \nlymph nodes. Group \nB includes more \nhead and neck \nmelan omas and \nthicker tumours. \nGroups were treated \nin 2 diffe rent \ngerman centres \nusing the same \nfollow up schedule.  \nmissing data, e.g. \nmedian follow up, \np-values  \n 3b \nShen et al. 2000  To examine the \nincidence of cervical \nrecurrence among \npatients who did \nnot receive Retrospective \ncohort study  \n \nTreatment:  \nGroup A: surgery 217 patients with  \nhead and neck \nmelanoma after \nregional lymph \nnode d issection   \n \n \nCervical recurrence \nrate Surgery alone vs. \nSurgery + RT  \n \n14% (25/183) vs. \n15% (2/13), n.s.  Baseline \ncharact eristics for \nthe su rgery+RT \ngroup were not \nindicated, no 3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 609 von 732 Study Aims  Design  Population  Outcomes  Results  Comments  LoE \npostoperative \nradioth erapy after \nsurgica l \nmanagement of \nnodeposit ive head \nand neck m elanoma  alone, n=196  \n \nGroup B: surgery  + \nRT (treatment \nSchedule not \nindicated) n=21    \n5 years overall \nsurvival \n5 years disease free \nsurvival  \n  \n32% \n \n21% \n \nmulitvariate \nanalysis: extranodal \ndisease: only \nindependent \npredictor for \ncervical recurrence  \n statistical analyses \nfor this group due \nto small sample \nsize, retrospective \nstudy  \nO'Brien et al. 1997  To analyze the \ninfluence of the \nnumber of positive \nnodes, \nextrac apsular \nspread, and the use \nof adjuvant \nradiotherapy on \nregional control and \nsurvival  retrospective cohort \nstudy \n \nTreatment:  \nGroup A: surgery \nalone, n=107 (sites)  \n \nGroup B: surgery  + \nRT (TD 33 Gy, \nfraction size 5.5 Gy, \n3 weeks) n=45 \n(sites)  \n 143 patients  after \nneck or parotid \ndissection, 152 \nlymphadenec tomy \nsites  \n \n \nLocal recurrence  \n \n \n \n5 years survival  \n \n Surgery alone vs. \nSurgery + RT  \n \n18.7% (20 of 107) \nvs. 6.5% (3 of 45), \np=0.055  \n \n35% vs. 40%, n.s.  \n retrospective study, \nimbalance of \ngroups, difficult to \ncompare data for \nrecurrence with \nother studies as \nthey do not refer to \npatients but to \nirradiated sites.  3b \nCreagan et al. 1978  To assess the role RCT 56 patients after  Surgery alone vs. Limit ations:  2b poor  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 610 von 732 Study Aims  Design  Population  Outcomes  Results  Comments  LoE \nof postoperative \nradiation therapy \ndirected to the \nregional node area \nin patients \nunde rgoing \nlymphadenectomy  \nfor metastatic \nmelanoma   \nTreatment:  \nGroup A: surgery \nalone, n=29  \n \nGroup B: surgery  + \nRT (TD 5000 rad, \nfraction size 2500 \nrad) n=27  lymphadenectomy  \n \n \n  \n \nTime to recurrence  \n \n \n \nSurvival  \n Surgery + RT  \n \n9 months vs. 20 \nmonths, n.s. \n(p=0.07)  \n \n22 months vs. 33 \nmonths, n.s. \n(p=0.09)  randomization \nscheme not \nappropriate (group \nassignment \npredict able), small \nsample size,  \nImbalance of groups \n(more younger \npatients and more \npatients with only \none pos itive node in \nthe RT group  \n quality \nRCT \n6.4.5.  Literatur  \n \nAgrawal S, Kane JM,3rd, Guadagnolo BA, et al. The benefits of adjuvant radiation therapy after therapeutic lymphadenectomy for clinically advanced, high -risk, lymph node -\nmetastatic melanoma. Cancer 2009;115: 5836 -5844  \nBibault JE, Dewas S, Mirabel X, et al. Adjuvant radiation therapy in metastatic lymph nodes from melanoma. Radiat Oncol 2011;6:12  \nCreagan ET, Cupps RE, Ivins JC, et al. Adjuvant radiation therapy for regional nodal metastases from malignant melan oma: a randomized, prospective study. Cancer \n1978;42:2206 -2210  \nBurmeister BH, Henderson MA, Ainslie J, et al. Adjuvant radiotherapy versus observation alone for patients at risk of lymph -node field relapse after therapeutic \nlymphadenectomy for  melanoma: a randomised trial. Lancet Oncol  2012;  13: 589 -597 \nFuhrmann D, Lippold A, Borrosch F, et al. Should adjuvant radiotherapy be recommended following resection of regional lymph n ode metastases of malignant melanomas? Br J \nDermatol 2001;144:66 -70 \nGojkovic -Horva t A, Jancar B, Blas M, et al. Adjuvant Radiotherapy for Palpable Melanoma Metastases to the Groin: When to Irradiate? Int J Radiat Oncol Biol Phys 2011  \nHamming -Vrieze O, Balm AJ, Heemsbergen WD, et al. Regional control of melanoma neck node metastasis afte r selective neck dissection with or without adjuvant radiotherapy. \nArch Otolaryngol Head Neck Surg 2009;135:795 -800 \nHenderson MA, Burmeister B, Thompson JF, et al. Adjuvant radiotherapy and regional lymph node field control in melanoma patie nts after lymph adenectomy: Results of an \nintergroup randomized trial (ANZMTG 01.02/TROG 02.01). J Clin Oncol (Meeting Abstracts) 2009;27:LBA9084  \nMoncrieff MD, Martin R, O'Brien CJ, et al. Adjuvant postoperative radiotherapy to the cervical lymph nodes in cutaneous melan oma: is there any benefit for high -risk patients? \nAnn Surg Oncol 2008;15:3022 -3027   \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 611 von 732 O'Brien CJ, Petersen -Schaefer K, Stevens GN, et al. Adjuvant radiotherapy following neck dissection and parotidectomy for metastatic malignant melanoma. Head Neck \n1997;19:589 -594 \nShen P, Wanek LA, Morton DL. Is adjuvant radiotherapy necessary after positive lymph node dissection in head and neck melanomas? Ann Surg Oncol 2000;7:554 -9; discussion \n560-1 \nStrojan P, Jancar B, Cemazar M, et al. Melanoma metastases to the neck nodes : role of adjuvant irradiation. Int J Radiat Oncol Biol Phys 2010;77:1039 -1045  \n \n \n \n6.5. Frage VI.6. Fraktionierung  \nFrage VI.6. Hat das Fraktionierungsschema einen Einfluss auf die Effektivit\u00e4t der Radiotherapie bei Melanompatienten?  \n6.5.1.  PICO, Suchw\u00f6rter  \nPICO \u2013 Schem a  \nPopulation  Intervention  Comparison  Outcome  \nmelanoma patients  Radiotherapy high dose per fraction  Radiotherapy low dose per fraction  effectiveness  \n \nSuchw\u00f6rter  \nStichwort  Melanoma  radiotherapy  fraction   \nSynonyme   Radiation, irradiation  dose  \nOber -/Unterbegriffe      \nMesh Term  melanoma  radiotherapy, radiat ion   \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 612 von 732 6.5.2.  Datenbanken, Suchstrategien, Trefferzahlen  \nDatenbank  Suchstrategie  Datum  Treffer \n1. Suche     \nMedline  ((melanoma[ti] OR melanoma[MeSH]) AND (radiotherapy[ti] OR radiotherapy[MeSH] OR \nradiat ion[MeSH] OR radiation[ti] or irradiation[ti]) AND (fraction*[ti] OR dose[ti]))  14.07.11  216 (Auswahl 9)  \nCochrane Library  (melanoma and (radiotherapy or radiation or irradiation) and fraction*).ti.  14.07.11  3 (Overgaard, Chang, \nSause \u2013 alles Dubletten , 0 \ndazu ) \nEmbase  (melanoma and (radiotherapy or radiation or irradiation) and fraction*).ti.  11.05.11  49 (Katz - Dublette)  \nUpdate Suche     \nMedline  s.o. 31.01.12  221 (0 dazu)  \nCochrane Library  s.o. 31.01.12  3 (0 dazu)  \nEmbase  s.o. 23.01.12  52 (0 dazu)  \n \n6.5.3.  Auswahlkriterien  \nAuswahl der Literatur  \nGesamttreffer  276 \nEinschlusskriterien  RCT\u00b4s  \nSprachen: e,dt  \nAusschlusskriterien  Case Reports  \nNicht systematische Reviews  \nKombinationstherapien   \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 613 von 732 Auswahl der Literatur  \nKollektive mit gemischten Tumorentiti\u00e4ten  \nArbeiten \u00e4lter als 1980  \nAnzahl nach Abstractscreening, vorges ehen f\u00fcr Bewertung  9 \nAnzahl der ausgeschlossenen Studien nach Sichtung der Volltexte  7 \nAnzahl ausgew\u00e4hlter Volltexte  2 \n \n6.5.4.  Evidenztabelle  \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nSause et al. 1991  To evalu ate the \neffectiveness of \nhigh dose per \nfraction irradi ation \nin the treatment of \nmelan oma RCT \n \nTreatment:  \n \nGroup A: 4 \nfractions, 8.0 Gy, \ndays 0, 7, 12 and \n21 \n \nGroup B: 20 \nfractions, 2.5 Gy, 5 \ndays a week  137 patients with \nskin, soft tissue and \nnodal lesions  \n \nGroup A n=67 \npatients  \n \n \nGroup B n=70 \npatients  Response  \n \n \n \n \n \n Group A vs. Group \nB: no significant \ndifferences  \n \nCR  24.2% vs. 23.4%  \nPR   35.5% vs. 34.4%  \nNC  33.9% vs. 39.1%  \nPD   6.5% vs. 3.1%  \n Randomization \nscheme not \ndescribed  \nassessment not \nblinded  1b \nOvergaard et al. \n1985  To compare two \nhigh-dose per \nfraction radiation RCT \n \nTreatment:  14 patients, 35 skin \nand lymph no de \nmetastases  Response  \n \n Group A vs. Group \nB: no significant \ndifferences  Randomization \nscheme not \ndescribed, 2b \nlow qual ity \nRCT  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 614 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \nschedules in \nrecurrent or \nmetastatic \nmalignant \nmelanoma   \nGroup A: 9 Gy X 3, 2 \nfractions per week  \n \nGroup B: 5 Gy X 8, 2 \nfractions per week  \n  \n \n \n \n \n  \nCR   n=11 (65%) vs. \nn=13 (72%)  \nPR    n=5 (29%) vs. \nn=5 (28%)  \nNC   n=1 (6%) vs. \nn=0 (0%)  assessment not \nblinded, lesions not \npatients were \nrandomized, very \nheterogeneous \npopul ation, small \nsample size  \n \n6.5.5.  Literatur  \nOvergaard J, von der Maase H, Overgaard M. A randomized study comparing two high -dose per fraction radiation schedules in recurrent or metastatic malignant melanoma. Int \nJ Radiat Oncol Biol Phys 1985;11:1837 -1839  \nSause WT, Cooper JS, Rush S, et al. Fraction size in external beam radiation therapy in the treatment of melanoma. Int J Radiat Oncol Biol Phys 1991;20:429 -432 \n \n \n \n \n \n \n \n \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 615 von 732 7. AG Nachsorge  \n \n7.1. Frage VII.3.  Selbstuntersu chung im Rahmen der Nachsorge - Adaptation  \nFrage VII.3.  Sollte die Selbstuntersuchung ein Bestandteil der Nachsorge sein?  \n \n7.1.1.  Synopse  (kurz)  \nThema/Fragestellung  LL Austr alien  \nNew Zealand Guidelines \nGroup 2008  LL GB  \nNICE 2006  LL Frankreich  \nFrench National Au thority for \nHealth 2005  LL Kanada  \nCancer Care O ntario 2007  \n3. Sollte die \nSelbstuntersuchung ein \nBestandteil der Nachso rge \nsein?  Notwendiger Bestandteil der \nNachsorge (C)  Bestandteil der Nachsorge f\u00fcr \njeden Patienten, leben slang; \nDurchf\u00fchrung von \nSchulung en zur \nSelbstunte rsuchung durch \n\u00c4rzte oder Pfl egekr\u00e4fte  LL Frankreich  \nFrench National Authority for \nHealth 2005  nur relevant f\u00fcr \nmedikament\u00f6se Therapien  \n \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 616 von 732 7.1.2.  Empfehlung, Hintergrunds text und Literatur australischen und franz\u00f6sischen  Quell -Leitlinie n \n LL Aust ralien  \nNew Zealand Guidelines Group 2008  LL GB  \nNICE 2006  LL Frankreich  \nFrench National Authority for Health \n2005  \nSchl\u00fcsselempfe hlungen  S. 122  \n \n1. Self -examination by patients is \nessential and they should be taught the \nprocess. Routine follow -up by the \npatient\u2019s preferred health profe ssional \nmay be appropriate to emphasise sun \nsmart behaviour and pe rform skin \nchecks  \nGrade of Recommend ation: C  \n Empfehlungen zur Selbstunters uchung \nin der NICE Guideline b eziehen sich nur \nauf SCC und BCC, daher werden hier \ndie Angaben aus dem Guideline \nEvidence R eview wiedergegeben:  \n \n S. 51  \n \nSuivi \nStade I AJCC  \nStandards  \n[\u2026] \n\u25a0 \u00e9ducation du patient \u00e0 \n\u2019autod\u00e9pistage d\u2019un nouveau \nm\u00e9lanome et \u00e0 l\u2019autod\u00e9tection d\u2019une \nr\u00e9cidive.  \nNachsorge  \nStadium I nach AJCC  \nStandards  \n[\u2026] \n\u25a0 Anleitung des Patienten zur \nSelbstuntersuchung auf ein neues \nMelanom und zur selbst\u00e4ndigen \nErkennung eines Rezidivs . \n \n \nStades IIA et IIB AJCC  \nStandards  \n[\u2026] \n\u25a0 \u00e9ducation du patient \u00e0  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 617 von 732  LL Aust ralien  \nNew Zealand Guidelines Group 2008  LL GB  \nNICE 2006  LL Frankreich  \nFrench National Authority for Health \n2005  \nl\u2019autod\u00e9pistage d\u2019un nouveau \nm\u00e9lanome et \u00e0 l\u2019autod\u00e9tection d\u2019une \nr\u00e9cidive.  \nStadien II A und IIB  \nStandards  \n[\u2026] \n\u25a0 Anleitung des Patienten zur \nSelbstuntersuchung auf ein neues \nMelanom und zur selbst\u00e4ndigen \nErkennung eines Rezidivs . \n \nStades IIC et III AJCC  \nStandards  \n[\u2026] \n\u25a0 \u00e9ducation du patient \u00e0 \nl\u2019autod\u00e9pistage d\u2019un nouveau \nm\u00e9lanome et \u00e0 l\u2019auto d\u00e9tection d\u2019une \nr\u00e9cidive.  \nStades IIC et III AJCC  \nStandards  \n[\u2026] \n\u25a0 Anleitung des Patienten zur \nSelbstuntersuchung auf ein neues \nMelanom und zur selbst\u00e4ndigen \nErkennung eines Rezidivs .  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 618 von 732  LL Aust ralien  \nNew Zealand Guidelines Group 2008  LL GB  \nNICE 2006  LL Frankreich  \nFrench National Authority for Health \n2005  \nHintergrundtexte  S. 121 \u2013 122  \n \n19.2 Undertaking follow -up \nCurrent guidel ines world -wide do not \nspecify where routine follow -up should \ntake place or who should do it. [6,7] \nHowever, it is becoming a ccepted by \nmost [8 \u201310] but not all [11 \u201313] that \npatients themselves rather than \ndoctors are likely to d etect their own \nrecurrence.  \nThose studies reporting a high p atient-\ndetection rate attribute this to patients \nreceiving thorough explan ations of the \nsigns and symptoms of recurrences \nand new primary melanomas. Despite \nsuch explanations, it is obvious that \nthe abi lity of individual pat ients to \ndetect recurrence varies. S ome can \nidentify recurrences that are not \ndiscernible to doctors, while others can \nbe unaware of a large tumour mass. \nThe existence of these latter patients \nperhaps explains the reticence of some \ncentres to forego routin e follow -up. S. 370 (Guideline Evidence R eview)  \n \nPatient self examination  \n \nThe questions  \nIn the follow -up of patients with skin \ncancer, what is the usefu lness of \neducation for self examin ation? \n \nThe nature of the e vidence  \nTwelve papers were identified \nrepresenting eleven studies (with one \nRCT reported at two stages of fo llow-\nup) as follows:  \n\u2022 One RCT of good quality  \n\u2022 One systematic review of good \nquality  \n\u2022 One case control study of good \nquality  \n\u2022 Eight observationa l studies, four of \ngood quality, one of fair quality and  \nthree of poor quality  \nOnly one study originates from the UK. \nSeven studies are from the US, one \nstudy is from Australia and two studies S. 51  \n \nJUGEMENT ARGUMENT\u00c9 DES EXPERT S \n[\u2026] \nFace \u00e0 l\u2019ensemble de ces \nconsid\u00e9r ations, il semble raisonnable \nd\u2019envisager une surveillance min imale, \n\u00e0 savoir bas\u00e9e essentiellement sur \nl\u2019examen clinique et l\u2019\u00e9ducation du \npatient \u00e0 l\u2019autod\u00e9p istage. Pour les \nm\u00e9lanomes de stade I AJCC qui \npr\u00e9sentent globalement un faible \nrisque de r\u00e9cidive, l\u2019examen clinique \nannuel ou biannuel aura pour objectif \nla d\u00e9tection d\u2019un \u00e9ventuel second \nm\u00e9lanome. Pour les patients de stades \nII et III AJCC, une \u00e9chograp hie \nganglionnaire de la zone de drainage \npeut \u00eatre envisag\u00e9e en option (accord \nd\u2019experts).  \nLes autres examens d\u2019imagerie (\u00e0 la \nrecherche de m\u00e9tastases \u00e0 distance) \nn\u2019ont pas apport\u00e9 la preuve qu\u2019ils \npouvaient influer sur la survie en partie \ndu fait de l\u2019abs ence de th \u00e9rapeutique  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 619 von 732  LL Aust ralien  \nNew Zealand Guidelines Group 2008  LL GB  \nNICE 2006  LL Frankreich  \nFrench National Authority for Health \n2005  \nIn Australia, with its heightened \nawareness of the disease, up to 75% of \npatients detect their own recu rrences. \n[14] World -wide the mean percentage \nis 62%. [1]  \nThe UK Medical Research Cou ncil has \ndesigned a \u2018framework for the design \nof an inte grated follow -up program\u2019. \n[15] One technique e mployed was to \ninterview patients to determine their \npreferred follow -up requirements. \nMost supported follow -up by general \npractitioners, and felt that the main \npurpose of follow -up was reassu rance. \nHowever, t here was concern over \ntravelling times, costs, brevity of \nconsult ations, and poor continuity.  \nNearly all queried the experience and \nskill of the general practiti oners and \nsaid training would be vital, with rapid \naccess to specialist advice if necessary. \nTotal skin examination, instruction in \nself-examination and the provision of \nmore info rmation were seen as \ndesirable at visits to general are from Italy. Generalisabi lity to the \nUK is therefore limited . \nSeven studies are of patients at risk of \nmelanoma based upon family hi story or \npresence of naevi. Three studies are of \nscreened pop ulations and two studies \nare of patients with proven melanoma.  \n \nSummary of the supporting evidence \nfor the recomme ndations  \n \nSelf examination (SE) versus ph ysician \nexamination  \nThere is consistent evidence that \nexpert physician e xamination has \ngreater reliability than SE in detecting \nmelanoma. Sy stematic review evidence \nsuggests that m elanoma lesions \ndetected by physicians are  thinner than \nthose detected by p atients. \nObservational study ev idence  \nsuggests that detection by \ndermato logist is associated with earlier \nmelanoma diagnosis and that i nput by \nphysicians is the strongest single efficace \u00e0 ce stade.  \nEn l\u2019absence d\u2019\u00e9tudes portant \nsp\u00e9cifiquement sur l\u2019int\u00e9r\u00eat de la \nsurvei llance et de son rythme, il n\u2019est \npas apparu possible de formuler des \nconclusions evidence -based \u00e0 partir de \nla litt\u00e9rature. De ce fait, les \nrecommandations qui seront \u00e9tablies  \nne pourront reposer que sur des \naccords d\u2019experts et seront le reflet \nd\u2019un consensus pour un protocole de \nsurveillance minimum bas\u00e9 sur \nl\u2019examen clinique complet et \nl\u2019\u00e9ducation du patient \u00e0  \n\u2019autod\u00e9pistage.  \n \nCONFRONTATION  \nLes nouvelles donn\u00e9es identifi\u00e9es \nconvergent globalement avec les \ndonn\u00e9es pr\u00e9sent\u00e9es dans les \ndocuments initiaux de 1995 et 1998 et \napportent de no uveaux \u00e9l\u00e9ments, \nnotamment concernant l\u2019\u00e9chographie \nganglio nnaire qui peut \u00eatre propos\u00e9e \npour le suivi des p atients op\u00e9r\u00e9s de  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 620 von 732  LL Aust ralien  \nNew Zealand Guidelines Group 2008  LL GB  \nNICE 2006  LL Frankreich  \nFrench National Authority for Health \n2005  \npractitioners. Other studies assessing \npatients\u2019 opinions of the value of \nfollow -up [6,16] found that most \nconsi dered ro utine follow -up \nworthwhile, with only a few conside ring \nthat it was not. While favouring follow -\nup, more than half the patients in these \nstudies reported anxiety before each \nvisit. \n \nEvidence summary  \n \nThere is a consensus that the major ity \nof patients detec t their own recu rrence \nif they have received a tho rough \nexplanation of the signs and symptoms \nof recu rrences and new primary \nmelanomas  \nLoE: IV  \nReferences: 14 \u201316 \n \nSelf-examination may be co mbined, if \nappropriate, with routine follow -up by \nthe patient\u2019s pre ferred health \nprofessional  determinant of SE, although there is \nlittle e vidence for i mproved survival  \narising from recurrences of melanoma \ndiagnosed by patients co mpared to \nrecurrences diagnosed by ho spital \ndoctors. The same level of  \nevidence suggests that SE based on \nnaevi count has poor concordance with \ndermatological assess ment for risk of \nmelanoma and is not reliable.  \n \nFactors affecting SE  \nStudies have identified a number of \npatient characteristics and also events \nwhich are associated with SE. \nSystematic review evidence suggests \nthat elderly men have lower rates of SE. \nThere is observatio nal study evidence \nthat factors ass ociated with greater \nlikelihood of p atients performing self \nskin examin ation are:  \n\u2022 skin awareness  \n\u2022 habitual sun protection  \n\u2022 previous benign skin b iopsy \n\u2022 family cancer history  stades II et III AJCC (option, accord \nd\u2019experts). L\u2019examen clinique co mplet \net l\u2019\u00e9ducation \u00e0 l\u2019autod\u00e9pistage du \npatient restent le standard.  \nLa fr\u00e9quence est \u00e0 adapter au stade du \npatient : une \u00e0 deux fois par an pour \nles patients atteint s d\u2019un m\u00e9l anome de \nstade I et tous les 3 mois pour les \nautres stades.  \n \nS. 51  \n \nBEGR\u00dcNDETES URTEIL DER EXPERTEN  \n[\u2026] \nIm Angesicht dieser \u00dcberlegungen \nscheint es vern\u00fcnftig, eine minimale \n\u00dcberwachung in Erw\u00e4gung zu zi ehen, \ndas hei\u00dft im Prinzip basierend auf de r \nklinischen Untersuchung und der \nAnleitung des Patienten zur \nSelbstuntersuchung.   \nBei Melanomen im Stadium I nach \nAJCC, die insgesamt ein geringes \nRezidivrisiko haben, wird die j\u00e4hrl iche \noder zweij\u00e4hrliche klinische  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 621 von 732  LL Aust ralien  \nNew Zealand Guidelines Group 2008  LL GB  \nNICE 2006  LL Frankreich  \nFrench National Authority for Health \n2005  \nLoE: IV  \nReferences: 14 \u201316 \n \u2022 personal history of skin cancer  \n\u2022 physician or nurse exam ination or \nrecommendation  \n\u2022 help from a spouse (esp ecially wives \nassisting hu sbands)  \n\u2022 presence of a wall mirror  \n\u2022 age <50 years  \nThe same level of evidence su ggests \nthat older patients may be less likely to \nperform SE.  \n \nRates of SE  \nEstimates of rates of SE v ary widely \nwithin the studies identified, according \nto factors such as populations studied \nand di fferent definitions of SE or \nquestions used by researchers to \nascertain rates of SE. Subs equently, \nestimates of rates of SE f rom \nobserv ational studies have range 9% to \n87%. A rate of 71.6% for SE performed \nwithin the preceding year, was r eported \namongst first degree relatives of \nmelanoma p atients by Manne et al., \n(2004). Systematic review ev idence Untersuchung die Erkennung eines \nevent uellen zweiten Melanoms zum \nZiel haben.  \nF\u00fcr Patienten in den Stadien II und III \nnach AJCC kann eine Lymphknoten -\nSonographie des Abflussgebi etes als \nOption ins Auge gefasst we rden \n(Expertenmeinung).  \nAndere bildgebende Verfahren (zur \nSuche nach Fernmetastas en) haben \nnoch nicht den Beweis erbracht, dass \nsie das \u00dcberleben beeinflu ssen, zum \nTeil aufgrund einer fehle nden \neffektiven Therapie in diesem Stadium.  \nDurch das Fehlen von Studien zum \nThema Nachsorge und Nachsorge -\nIntervalle scheint es nicht m\u00f6glich, aus  \nder Literatur evidenzbasierte \nSchlussfolgerungen zu ziehen.  \nDaher beruhen die gegebenen \nEmpfehlungen nur auf \nExpertenmeinung und spiegeln einen \nKonsensus f\u00fcr eine minimale \nNachsorge basierend auf vollst\u00e4ndiger \nklinischer Unters uchung und Anleitung  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 622 von 732  LL Aust ralien  \nNew Zealand Guidelines Group 2008  LL GB  \nNICE 2006  LL Frankreich  \nFrench National Authority for Health \n2005  \nsuggests that the effect of pro moting \nSE cannot be disti nguished from that of \nroutine screening in patients seeing the \nphysician for unrelated reasons. RCT \nand case control study evidence \nsuggests that rates of SE can be \nsignificantly i mproved through \neducational i nterventions.  \n \nRole of  photography in SE  \nEvidence from one RCT suggests that \nthe use of photography as an  \nadjunct to health education pr oduces \nno short term (i.e. same day as \nintervention) difference in compl iance \nabove standard education for SE  \nbut the same level of ev idence i s \nsuggestive of a four month follow -up \nadvantage in terms of rate of SE \nthrough the use of ph otographs.  \n \nBenefit of SE  \nCase control study evidence suggests \nthat SE is assoc iated with a marginally \nsignificant reduced risk of melanoma des Pa tienten zur Selbstuntersuchung \nwider.  \n \nGEGEN\u00dcBERSTELLUNG  \nDie neuen Daten deuten in die gle iche \nRichtung wie die Daten aus den ersten \nDokumenten von 1995 bis 1998 und \nbringen neue Elemente ein, vor allem \nbez\u00fcglich der Lymp hknoten -\nSonographie, die f\u00fcr die Na chsorge von \noperierten Patienten der Stadien II und \nIII empfohlen werden kann (Option, \nExpertenko nsens).  \nDie vollst\u00e4ndige klinische \nUnters uchung und die Anleitung zur \nSelbs tuntersuchung des Patienten \nbleiben Standard.  \nDie Nachsorgefrequenz ist an das \nStadium des Patienten anzupassen: \nein- bis zweimal f\u00fcr Patienten mit \nMelanom Stadium I und alle 3 Mon ate \nf\u00fcr Patienten der anderen Stadien.    \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 623 von 732  LL Aust ralien  \nNew Zealand Guidelines Group 2008  LL GB  \nNICE 2006  LL Frankreich  \nFrench National Authority for Health \n2005  \nincidence: OR 0.66  \n[95% CI 0.44 -0.99] which is repor tedly \nan inexpensive screening met hod. \nObservational study evidence su ggests \nthat female sex, high educational level \nand pe rformance of SE are associated \nwith thinner melan oma tumours.  \n\u2022 The prevalence study by Ai tken et al. \n(2004) found that 25.9% of ra ndomly \nselected adults reported whole body SE \nwithin the last 12 months and 1055 \n(33.9%) within the last 3 years and \nconcluded that input by physicians is \nthe stron gest single determinant of SE.  \n\u2022 The case control study by Be rwick et \nal. (1996) found that SE was performed \nby 15% of all subjects (p atients with \nmelanoma and population matched \ncontrols) and was associa ted with a \nmarginally significant  r educed risk of \nmelanoma in all su bjects: OR 0.66 [95% \nCI \n0.44-0.99].  \n\u2022 The qualit ative study by Be rwick et al. \n(2000) found that amongst a sample of  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 624 von 732  LL Aust ralien  \nNew Zealand Guidelines Group 2008  LL GB  \nNICE 2006  LL Frankreich  \nFrench National Authority for Health \n2005  \npatients with a hi story of melanoma \nand also lower risk patients without a \nhistory of mel anoma, the rate of \nreported SE was 32% at baseline, rising \nto 64% after an educational \ninterve ntion (p = 0.03).  \n\u2022 The survey of patients referred by \ntheir GPs to a pi gmented lesion clinic \nundertaken by Carli et al. (2002) found \npoor conco rdance between SE and \ndermatological assessment for both \ncommon and atypical naevi and \nconcluded that SE of melanoma risk is \nnot rel iable. \n\u2022 The case series study by Carli et al. \n(2003) found that 40.6% of patients \nwith melanoma sampled self detec ted \ntheir melanoma tumour. F emale sex \n(OR 0.70 [95% CI 0.50 -0.97]), high \neducational level (0.44  \n[95% CI 0.24 -0.79]) and perfo rmance \nof SE (0.65 [95% CI 0.45 -0.93]) were \nfactors associated with thinner \ntumours. 48% of patients performed SE, \nbut only 20.4% reg ularly.   \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 625 von 732  LL Aust ralien  \nNew Zealand Guidelines Group 2008  LL GB  \nNICE 2006  LL Frankreich  \nFrench National Authority for Health \n2005  \n\u2022 The systematic review by Helfan et al. \n(2001) found melanoma l esions \ndetected by physicians to be thinner \nthan th ose detected by p atients.  \nElderly men had lower rates of SE and \nthe authors reco mmended that \nphysicians perform skin examin ation in \nthese patients. The authors r eported \nthat the effect of promoting SE cannot \nbe disti nguished from  \nthat of routine screening in patients \nseeing the physician for unrelated \nreasons.  \n\u2022 The qualitative survey of first degree \nrelatives of patients with mel anoma by \nManne et al. (2004) found the rate of \nSE in the last year to be 71.6%. SE \ncorrelated closely with having received \na clin ical skin exa mination by a \nphysician.  \n\u2022 The case series study of patients with \nmetastatic mel anoma by Odili  \nand Evans (2001) found that 56% of \ncases of recurrent m elanoma were \npatient detected and no si gnificant  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 626 von 732  LL Aust ralien  \nNew Zealand Guidelines Group 2008  LL GB  \nNICE 2006  LL Frankreich  \nFrench National Authority for Health \n2005  \ndifference in survival between \nrecurrences d iagnosed by SE and those \ndiagnosed by hospital do ctor were \nfound.  \n\u2022 The qualitative study by Ol iveria et al. \n(1999) found that amongst a sample of \nCaucasian people without melanoma, \nskin aw areness was a strong factor \nassociated with SE whereas older age \nand higher education was associated \nwith a decreased likelihood of \nperfor ming \nSE. \n\u2022 The RCT by Phelan et al. (2003) \ncompared nurse educ ation for SE and \nprovision of skin photographs with \nnurse education and prov ision of \nstandard brochure in patients with 5 o r \nmore dysplastic na evi, with or without \na history of melanoma. The mean \ngroup scores for knowledge,  \nawareness and confidence increased in \nboth groups at imm ediate  \nfollow -up (p < 0.0001) but th ere were \nno significant diffe rences in scores   \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 627 von 732  LL Aust ralien  \nNew Zealand Guidelines Group 2008  LL GB  \nNICE 2006  LL Frankreich  \nFrench National Authority for Health \n2005  \nbetween the phot ography group and \nthe br ochure group.  \n\u2022 The RCT of patients at high risk for \nmelanoma based upon dy splastic naevi \nby Oliveria et al. (2004) pr ovided \nfurther follow -up to the study by \nPhelan et al. (2003) and found that a \nteaching intervention with ph oto bo ok \ndemonstrated a 51% i ncrease in 3 or \nmore reported examinations at 4 \nmonth follow -up, co mpared to a 17.6% \nincrease in the group which received \nteaching only [p = 0.001].  \n\u2022 The observational pilot study (as part \nof a subsequent trial) by Wei nstock et \nal. (2004) found the rate of SE amongst \npatients attending for routine follow -\nup visits to be between 12% and 38%. \nHelp from a partner and presence of a \nwall mirror were associated with higher \nrates of SE whereas visual impairment \nwas found to be associated wi th lower \nrates of SE.  \nBemerkungen   Diese Leitlinie bezieht sich auf MM und \nauf NMSC.  Keine Literaturangaben zu Fragen der \nSelbstuntersuchung ; Angaben sind  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 628 von 732  LL Aust ralien  \nNew Zealand Guidelines Group 2008  LL GB  \nNICE 2006  LL Frankreich  \nFrench National Authority for Health \n2005  \ndaher nur konsensbasiert.  \n \n \nLiteratur:  \n \nLL Austr alien New Zealand Guidelines Group 2008  \n7. Bain NS, Campbell NC, Ritchie LD, et al. Striking the right balance in colorectal cancer care --a qualitative study of rural and urban patients. Fam P ract 2002;19:369 -374 \n11. Basseres N, Grob JJ, Richard MA, et al. Cost-effectiveness of surveillance of stage I melanoma. A retrospective appraisal based on a 10 -year experience in a dermatology \ndepartment in France. Dermatology 1995;191:199 -203 \n6. Baughan CA, Hall VL, Leppard BJ, et al. Follow -up in stage I cutaneous malignant melanoma: an audit. Clin Oncol (R Coll Radiol) 1993;5:174 -180 \n16. Dancey A, Rayatt S, Courthold J, et al. Views of UK melanoma patients on routine follow -up care. Br J Plast Surg 2005 ;58:245 -250 \n1. Francken AB, Bastiaannet E, Hoekstra HJ. Follow -up in patients with localised primary cutaneous melanoma. Lancet Oncol 2005;6:608 -621 \n14. Francken AB, Shaw HM, Accortt NA, et al. Detection of first relapse in cutaneous melanoma patients: imp lications for the formulation of evidence -based follow -up \nguidelines. Ann Surg Oncol 2007;14:1924 -1933  \n27. Garbe C, Paul A, Kohler -Spath H, et al. Prospective evaluation of a follow -up schedule in cutaneous melanoma patients: recommendations for an effecti ve follow -up \nstrategy. J Clin Oncol 2003;21:520 -529 \n13. Hofmann U, Szedlak M, Rittgen W, et al. Primary staging and follow -up in melanoma patients --monocenter evaluation of methods, costs and patient survival. Br J Cancer \n2002;87:151 -157 \n10. Jillela A, Man i S, Nair B, et al. The role for close follow -up of melanoma patients with AJCC stage I -III: a preli minary analysis. Proc Am Soc Clin Oncol 1995; 14:413  \n8. Kersey PA, Iscoe NA, Gapski JA, et al. The value of staging and serial follow -up investigations in p atients with completely resected, primary, cutaneous malignant melanoma. \nBr J Surg 1985;72:614 -617 \n15. Murchie P, Hannaford PC, Wyke S, et al. Designing an integrated follow -up programme for people treated for cutaneous malignant melanoma: a practical appl ication of the \nMRC framework for the design and evaluation of complex interventions to improve health. Fam Pract 2007;24:283 -292 \n12. Poo -Hwu WJ, Ariyan S, Lamb L, et al. Follow -up recommendations for patients with American Joint Committee on Cancer Stages I-III malignant melanoma. Cancer \n1999;86:2252 -2258  \n9. Ruark D, Shaw H, Ingvar C, et al. Who detects the primary recurrence in stage I cutaneous melanoma: patient or doctor? Mel anoma Res 1993; 3(Supplement 1):44.  \n \nLL GB NICE 2006  \nSiehe Evidence Table 5.3, S . 375 \u2013 379 des Guideline Evidence R eview \n \n \n \n \n \n \n \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 629 von 732 7.2. Frage VII.4., VII.5. und VII.6.  Nachsorge -Dauer und -Intervalle  \u2013 De-novo-Recherche  \nFrage VII.4.  Wie lange sollte die Nachsorge von Melanompatienten erfolgen?  \nFrage VII.5.  In welchen Intervallen sollte die Nachsorge erfolgen?  \nFrage VII.6.  Welche Untersuchungen sind im Rahmen der Nachsorge bei asymptomatischen Patienten indiziert?  \n7.2.1.  PICO, Suchw\u00f6rter  \n \nSuchw\u00f6rter  \nStichwort  melanoma  Surveillance  Relapse  \nSynonyme   Follow -up, After -care, aftercare, p ost-\noperative care recurrence  \nOber -/Unterbegriffe , Mesh Term  S. Suchstrategie  (Kapitel 7.4.2. und Kapitel I.6.)  \n \n7.2.2.  Datenbanken, Suchstrategien, Trefferzahlen  \nDatenbank  Suchstrategie  Datum  Treffer \n1. Suche     \nMedline  \"melanoma\"[tiab] AND (\"relapse\"[tiab] OR \"recurrence \"[tiab] OR \"surveillance\"[tiab] OR \n\u201cfollow -up\u201d[tiab] OR aftercare[tiab] OR \u201cafter -care\u201d[tiab] OR \u201cpost -operative care\u201d)  23.01.2012  7047  \nCochrane Library  (melanoma and (surveillance or \"follow up\")).ti.  23.01.2012  278 \nEmbase  (melanoma and (surveillance or  \"follow up\")).ti.  23.01.2012  443 \n2. Suche  s. \u201cEvidenztabelle I.6, I.7, I.8, VII.6\u201d , Kapitel I.6   \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 630 von 732 3. Suche/Erg\u00e4nzungen  (\"second primary\"[title] AND melanoma) OR \"second melanoma\"[title] OR (\"multiple \nprimary\"[title] AND melanoma)  23.01.2012  186 \nBemerkung en: Datum der Erst -Recherche (1. Suche) f\u00fcr Medline und Cochrane war der 21.12.2010 bzw. f\u00fcr die Erg\u00e4nzungs -Recherche (3. Suche) der \n08.06.2011. Die erste EMBASE -Recherche erfolgte am 11.05.2011. Eine let zte Update -Recherche (initiale Suche, Erg\u00e4nzungsrech erche) erfolgte am 23.01.2012 \nf\u00fcr EMBASE, am 26.01.2012 f\u00fcr Medline bzw. am 19.01.2012 f\u00fcr Cochrane. In den Tabellen angegeben sind die Zahlen der letzten Update -Recherche. Die Daten \nf\u00fcr die zweite Suche f\u00fcr die Frage VII.6 en tnehmen Sie bitte der Tabelle \u201eI.6, I.7, I.8, VII.6\u201c  unter Kapitel I.6 . \n \n7.2.3.  Auswahlkriterien  \nAuswahl der Literatur  \nGesamttreffer  7954  \nEinschlusskriterien  Thematische \u00dcbereinstimmung  \nSprachen: e,dt  \nAusschlusskriterien  Case Reports, narrative Reviews, Bench Research  \nAnzahl nach Abstrac tscreening  163 (inkl. Dupletten)  \nAnzahl ausgew\u00e4hlter Volltexte, vorgesehen f\u00fcr Bewertung  59 \nBemerkungen  \nZum Thema \u201cmultiple melanomas\u201d liegt ein Review von Francken et al. (2005) vor, das Studien bis Februar 2004 umfasst, das in diese Tabelle ebenfalls mit \naufgenommen wurde .  \n \nDie Tabelle enth\u00e4lt alle relevanten Rechercheergebnisse f\u00fcr die Fragen VII.4., VII.5., VII.6.  \nDie Literatur wurde entsprechend der Fragestellungen zugeteilt, s. hierf\u00fcr auch die \u00dcbersicht am Ende der Tabelle. Im Rahmen der AG -Treffen wurde durch die \nExperten eine konsensbasierte Beantwortung der Frage VII.5 entschieden. Da diese Entscheidung nach erfolgter Literatursuche g etroffen wurde, sind die \nErgebnisse der Frage VII.5 in dieser Tabelle aufgef\u00fchrt. Auch die Nachsorgetabelle zu d en verschiedenen Untersuchungen und Intervallen zu den jeweiligen \nTumorstadien wurde konsensbasiert erstellt auf Basis der vorliegenden Literatur. Aufgrund der Studiendesigns und von thematis chen \u00dcberschneidungen ist eine  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 631 von 732 Auswahl der Literatur  \nstrikte Auftrennung der Literatur nach Fragestellung nicht m\u00f6glich. Aus diesem Grund wurde die Literatur, bei gleicher Suchstrategie, in dieser Tabelle \nzusammengefa\u00dft. Studien zu der Frage VII.6 zu der hier aufgef\u00fchrten Suchstrategie befinden sich in dieser Tabelle. Weitere St udien zu der Frage VII.6, die im \nRahmen der 2. Literaturrecherche/Erg\u00e4nzungen (s.o.) identifiert wurden, sind in der Tabelle \u201eI.6, I.7, I.8, VII.6_kurz\u201centhal ten. \n \n7.2.4.  Evidenztabelle  \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nLeiter et al. (2011)  To anal yze stage - \nand time -dependent \nhazard rates (HR) \nand to discuss \ncurrent surveillance \nrecommendations.  Prognostic study  \n \n 33,384 patients \nwith CM stage I -III \n \n Overall survival  \n \nRelapse -free \nsurvival  \n \nHazard ratios (HRs) \nfor recurrences and \nsecondary \nmelanom a melanoma -specific \n5- and 10 -year \nsurvival: 91.9% and \n87.2%, respectively  \n \nRecurrences \nrecorded in 4999 \npatients (15.3%; \nstage I, 7.1%; stage \nII, 32.5%; and stage \nIII, 51.0%)  \n \nmedian RFS time: 44 \nmonths  \n10-year recurrence -\nfree survival was \n78.9% (95% \nconfidence interval \n73.1-90.5); in stage Very large and \nmulti -center patient \ncohort  1b-  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 632 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \nI, 89.0%; stage II,  \n56.9%; and stage III, \n36.0%.  \n \nHR for recurrent \nCM: \n- Stage IA: \nconstantly low level \nHR </= 1:125 per \nyear \n- stage IB: higher \nHRs >/= 1:40 for \nthe first 3 years and \ngenerally in stages II \nto III  \n \nFrom 3 years of \nfollow -up onward, \nstage II and III CIs \noverlapped/ no \nsignificant \ndifferences for the \ndevelopment of \nrecurrences. After \n10 years of follow -\nup HR of all 3 \nstages did not differ  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 633 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \nsignificantly.  \n \nOf all patients 2.3% \ndeveloped \nsecondary \nmelanomas , with a \nconsistently low HR \n< 1:220 per year  \nVoit et al. (2001)  \n \n to evaluate whether \nearly detection of \nmetastases \nimproves relapse -\nfree and overall  \nsurvival  Diagnostic study  \n \n 829 consecutive \nmacroscopical ly \ndisease -free \nmelanoma patients  Sensitivity  \n \nSpecificity  \n \nPositive predictive \nvalue (PPV)  \n \nnegative  \npredictive value \n(NPV)  \n \nSurvival  \n \nrelapse -free survival  \n \noverall survival  \n2- and 4 -year \nsurvival rates  Physical \nexamination (PE): \nsensitivity 25.2%, \n(95% confidence \ninterval [CI]: 19.9 \u2013\n31.2%), PPV 57.5%, \n(95% CI: 47.5 \u2013 \n66.9%). specificity: \n98,4%, NPV 93.8%.  \n \nultrasound B -scans \n(UBS): sensitivity \n99.2%, 95% CI: \n97.3\u201399.6%, \nspecificity: 98.3%  \n(95% CI: 97.7 \u2013\n98.7%), PPV: 83.3% \n(95% CI: 78.5 \u2013 \n87.4%), NPV: 99.9 % No information \nabout the examiner \n(blinded for the \nresults of the other \nexamination?)  1b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 634 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \n(95% CI: 99.6 \u2013\n100.0%.  \n \nB-scan was highly  \nsuperior to physical \nexamination  \n(P = 0.001).  \n \nOut of 242 proven \nmelanoma \nmetastases, 24.8% \nwere detected by \nboth methods \nsimultaneously.  \n \nSurvival curbes: see \nfull-text \nFrancken et al. \n(2005)  To discuss \nfrequency and \nduration of follow -\nup, type of health \nprofessional \ninvolved, optimum \nintensity of routine \ninvestigation, and \npatients\u2019 \nsatisfaction with Systematic re view \n(without meta -\nanalysis)  \n \n 72 articles included  \n \nGiven separately for \nevery included study \n(see original article)  Various  first recurrence:  \n- 20\u201328% local or \nin-transit \nrecurrences  \n- 26\u201360% regional \nrecurrences  \n- 15\u201350% distant \nmetastases  \n \nUltimately  Systematic literature \nsearch, but no \nmeta -analysis (no \nsummary of effect \nmeasures)  \n \n 2a  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 635 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \nfollow -up. - 3\u20135% local or in -\ntransit recurrence  \n- 5\u201313% regional \nnodes  \n- 3\u201310% distant \nmetastates  \n \n62% of patients \ndetected their first \nrecurrence \nthemselves  \n \nfrequency of late \nrecurrences \n(DFS>10 years) \nbetween 1% to 25%  \n \nIncidence of \nsubsequent PM: 2% \nto 7%  \n \nOptimu m frequency \nand length of \nfollow -up services: \nno true evidence for \nfollow -up \nsurveillance in  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 636 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \nlocalised melanoma \naccording to the \narticles In no study \nany benefit in DFS \nor OS associated \nwith follow -up \nsurveillance  \nPeric et al (2011 ) determine whether \nregular \nmeasurements of \nserum S100B are a \nuseful tool for \ndiscovering patients \nwith CM metastases \nand to evaluate the \ndiagnostic value of \nPET-CT during the \nfollow -up Diagno stic study  115 CM patients \nincluded in regular \nfollow up  \n \n(82 patients with \nclinical signs of \ndisease progression, \n33 (28.7%) \nasymptomatic \npatients with two \nsubsequent elevated \nvalues of S100B)  Sensitivity  \n \nSpecificity  \n \nPPV \n \nNPV S100B: Sensitivity, \nspecifi city, PPV and \nNPV 33.8%, 90.9%, \n96.0% and 17.5% \nrespectively in \npatients with clinical \nsigns of disease \nprogression.  \n \nSensitivity and PPV \nof S100 in \nasymptomatic \npatients were \n100.0% and 69.7%.  \n \nPET-CT: \nsensitivity, \nspecificity, PPV and \nNPV of PET -CT for \nsymptomatic  2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 637 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \npatients: 98.5%, \n90.9%, 98.5% and \n90.9%  \n \nsensitivity, \nspecificity, PPV and \nNPV of PET -CT for \nasymptomatic \npatients: 100%, \n90.0%, 95.8% and \n100%  \nKruger et al. (2011 ) to demonstrate the \nhigh efficacy of \nultrasonography as \na noninvasive \ntechn ique \nfor early detection \nof lymph node \ninvolvement during  \nclinical follow -up, \nespecially in \npatients with \nsubclinical  \nmetastases.  Diagnostic study  433 melanoma \npatients with stage -\ndependent  \nfollow -up intervals \nof 3 to 12 months  \n Sensitivity  \n \nSpecificity  Sensitivity and \nspecificity of \ncombined clinical \nand sonographic \ninvestigations: \n0.9394 (95% \nconfidence interval: \n0.7977 \u20130.9926)] \nand 0.9808 (95% \nconfidence interval: \n0.9717 \u20130.9875)] \nrespectively.  \n \ncombinatorial \napproach was \nsignificantly Prospective d esign  2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 638 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \nsuperior with rega rd \nto detection of \nmetastases  \ncompared with \nclinical \ninvestigations alone \n(P<0.0001)  \n \nSignificant \ndifferences between \nclinical follow -up \nand sonographically \nassisted follow -up \nfor stages I (P = \n0.0389), III( P = \n0.0101), and IV (P \n=0.0016).  \nTurner et al. (2011)  to relate the \nestimated delay in \ndiagnosis of \nrecurrence or SPM in \npatients with stage I \nor II melanoma to \nthe number of visits \nneeded by two \ndifferent monitoring \nschedules. Prognostic study  2,998 consecutive  \npatients first \ndiagnosed with \nstage I or II \nmelanoma  Delay in diagnosis \nof recurrence  \n \npredictors of \ndeveloping new \nprimary  small difference in \nmodeled delay in \ndiagnosis (extra  \n44.9 and 9.6 \npatients per 1,000 \nfor recurrence and \nnew primary, \nrespectively, with \ndelay >2 months) \nusing a schedule Big patient cohort  2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 639 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \nSecondarily, to \nestimate the effect \nof \nprognostic f actors \non development of \nrecurrence or SPM  that requires far \nfewer visits (3,000 \nfewer visits per \n1,000  \npatients) than \nrecommended by \ncurrent guidelines.  \n \nAJCC substage= \npredictor o f \nrecurrence  \n \nage and date of \nprimary \ndiagnosis=predictor\ns of \ndeveloping new \nprimary  \nAukema TS et al. \n(2010)  \n to assess the clinical \nrelevance of \nincreased S -100B \nduring follow up of \nhigh-risk melanoma \npatients and to \ndetermine the v alue \nof subsequent \nwhole -body PET/CT Diagnostic study  \n \n 46 melanoma \npatients who were \nfound to have an \nelevated serum S -\n100B level during \nfollow -up  \n \n survival  \n \nAccuracy  \n \nSensitivity  \n \nSpecificity  \n \nnegative predictive Median of the \nelevated S -100B \nserum levels during \nfollow -up: 0.14 \n\u00b5g/L, range 0.10 \u2013\n1.33 \u00b5g/L.  \n \nPET/CT:  \nhypermetabolic  sensitivity of MRI \nnot determined \nbecause of the low \nincidence of brain \nmetastases.  \n \nSmall population  \n \n 2b \n \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 640 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \nand brain MRI.  value (NPV)  \n \npositive pr edictive \nvalue (PPV)  \n \nFalse -positives (FP)  \n \nFalse negatives (FN)  lesions in 27 of 46 \npatients (59%).  \nFN: n=0  \nFP: n=4  \nby median follow -\nup of 1 year  \nsensitivity: 100% \nspecificity: 83%  \naccuracy: 91%  \nPPV: 85%  \nNPV: 100%.  \n \nMRI: \nBrain metastases in \n1 patient (2%).  \nNPV: 100%  \nspecificity: 100%  \n \nPPV of an elevated \nserum S -100B: 50% \n(S-100B level>0.10 \n\u00b5g/L).  \n \nOf the 23 patients \nwith a true positive \nPET/CT scan, 6 \n(26%) received  \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 641 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \nsurgical treatment \nwith curative intent; \n17 (74%) received \npalliative treatment \nor supportive care.  \n \n2-year-survival: \n51.9% in patients  \nwith a positive \nPET/CT compared \nwith 100% in the  \npatients with normal \nPET/CT findings \n(P=0.002).  \nBrown RE et al. \n(2010)  \n to determine the \nclinical efficacy of \nroutine CXR for  \nrecurrence \nsurveillance in \nmelanoma.  Diagnostic study  \n \n 1,235 patients  \nwith invasive \ncutaneous \nmelanoma \u22651.0 mm \nin Breslow  \nthickness and \nwithout clinical \nevidence of regional \nor distant \nmetastases  \n Sensitivity  \n \nSpecificity  \n \nPPV \n \nNPV 210 patients (17.0%) \nhad a recurrence: \nlocal or in -transit in \n36,2%, distant \n(nonlung) \nmetastases in \n35,2%, l ung-only \nmetastases in \n13,3%.  \n \n99% (n = 4,180) of \nCXR were read as \neither \u2018\u2018normal\u2019\u2019 or post hoc analysis on \ndata from a \nprospective, \nrandomized, \nmultiinstitutional \nstudy on melanoma \n(Sunbelt Melanoma \nTrial)  \n \nno information \nabout reference \nstandard  \n 2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 642 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \nfalsely positive (FP). \n0.9%(n = 38) of all \nCXR obtained were \ntrue positives (TP).  \n \nSensitivity and \nspecificity: 7.7% and \n96.5%, respectively.  \nHohnheiser et al. \n(2010)  to identify factors \nthat influence time \nto recurrence and \nsurvival after the \nfirst recurre nce with \na special interest in \nlate recurrences.  Prognostic study  \n \n 2487 patients with \nthe first \nmanifestation of a \ncutaneous \nmalignant \nmelanoma  Overall survival  \n \nTime to first \nrecurrence  \n \nPrognostic factors  Significant \nindependent \nprognostic factcors \nfor survival (Cox \nregression analysis):  \n- patient\u2019s age  \n- sex \n- tumor \nlocalization,  \n- pT \n- pN.  \n \nmedian time to first \nrecurrence: 24 \nmonths.  \n \n5-recurrence -rate: \n81.6%  \n Retrospective review \n(prospective \ndatabase)  \n \nLarge patient cohort  \n \n 2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 643 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \nlate recurrences -\nrate (>10 -years): \n6.5% \n \nindependent factors \nfor time to \nrecurrence. (Cox \nregression analysis)  \n- age at primary  \n- treatment  \n- pT \n- pN  \n- type of recurrence \nwere found to be  \n \nindependent factor \ninfluencing survival \nafter a first \nrecurrence:  \n - type of \nrecurrence  \n \n(advanced age at \ndiagnosis of \nrecurrence male sex  \nmarginally \nsignificant)   \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 644 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \nLeiter et al. ( 2010)  To investigate \nwhether detection in \nan early phase is \nassociated with \nprolonged survival \nand whether the \nobserved longer \nsurvival times are a \nmere conseq uence \nof detection at an \nearlier time point \n(lead time bias).  Prognostic study  \n \n 1969 patients with \nmelanoma stage I \u2013 \nIII, recurrences in \n112 patients  disease -specific \nmortality  \n \nOverall survival (OS)  \n \nSurvival after \nrecurrence (SAR)  \n \nAdjusted survival \ntime by using sjourn \ntime  disease -specific \nmortality: 69.6% \n(n=78).  \n \nOverall 10 -year \nsurvival rate: 36.1%  \n10-year SAR \nsurvival rate: 25.4%  \n \n10-year OS \nprobability for \ndetection in early \nphase: 42.6% for \nearly phase vs. \n25.6% for advanced \nphase  \n (P = 0.012)  \n \nAdjustment for lead \ntime:  \n10-year OS \nprobability: 40.5% \n(95 CI: 27.4, 53.6) \nfor early phase \nrecurrences \nvs.25.6% (95% CI: \n12.5, 38.7) for Adjustment for \nimportant \nconfounding factor  \n \nEstimated sojourn \ntime (no evidence \nbase available)  \n \nMissing data in 10 \nof 112 patients for \nCox proportional \nhazard model  2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 645 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \nadvanced phase \nmetastases  \n(P=0.021)  \n \nindependent \nprognostic factors \n(multivariate \nanalysis):  \n- detection of early \nphase metastases  \n(P = 0.022)  \n- stage at primary \ndiagnosis (P \n<0.0001)  \nRueth et al. (2 010) To examine whether  \nconditional survival \n(CS) is more \naccurate in \npredicting  \nlongterm melanoma \nsurvival.  Prognostic study  8647 T2 -T4 \npatients patients \nwho underwent \nsurgical treatment \nfor melanoma  \n \n cancer -specific \nsurvival  \n \n10-year-survival \nrate At diagnosis:  \n10-year survival \nrates:  \nlow-risk: 79.6%  \nhigh-risk: 41.2% \nP<0.001  \n \ninitial predictors of \nsurvival: age, \ngender, location, \nulceration  \n \nOn CS analysis:  Very large patient \ncohort  \n \nOnly available study \nwhich gives data for \nthis outcome \n(conditional \nsurvival)  \n \nCS is a function of \nthe traditional \nsurvival estimates, \nadjusted to reflect 2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 646 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \n- survival \ndifferences  \nuntil 8 years after \ntreatment  \n- 10-year survival \nrates:  \nlow-risk :95. 4% \nhigh-risk: 91.7%  \nP = 0.51  \n \nOn Multivariate \nanalysis: age, \ngender, location, \nulceration: no \nlonger predictive \nafter 8 years  the probability  \nof survival \nconditioned on \nliving to a certain \npoint in follow -up \n \nthe low -risk \ncategory: T2 \u2013T3, N0  \n \nhigh-risk category \nT4N0 or T2 -4N1-3 \nMurchie et al. \n(2010)  to evaluate the \neffects o f GP-led \nmelanoma follow -\nup on patient \nsatisfaction, in \ncomparison to \nhospital -led follow -\nup, follow -up \nguideline \ncompliance, anxiety \nand depression, as RCT \n \n 142 melanoma \npatients free of \nrecurrent disease  Patient satisfaction \nmeasu red by \nquestionnaire  \n \nAdherence to \nguidelines  \n \nHealth status \nmeasured by SF -36  \n \nAnxiety and cluster -adjusted \nmean summary \nsatisfaction score:  \n- at baseline no \nsignificant \ndifference be tween \ngroups  \n- at follow -up \nsignificantly lower \nin the intervention \ngroup 26.4 (95% CI: Reliable \nrandomization \ndesign; blinding not \npossible  \n \nStudy took place in \nScotland; \ntransferability to \nGerman health care \nsystem?  2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 647 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \nwell as health \nstatus.  depression \nmeasured by the \nHospital Anxiety \nand Depression \nScale HADS  24.9\u2013 \n27.9) vs 33.5 (95% \nCI: 32.5 \u201334.4),  \n \nAdherence o \nguidelines:  \n- in the year before \nthe study: 84,9% in \nthe intervention \ngroup and 85.4% of \nthe control group  \n- At follow -up: \n98.1% in the \nintervention group \nand 80.9% of the \ncontrol group  \n \nSF-36 scores and \nHADS score:  \nno statistically \nsignificant \ndifferences between \ngroups at either \nbaseline or follow -\nup.  \nMorton RL et al. \n(2009)  to evaluate the \naccuracy of Diagnos tic study  \n 108 patients  AJCC  \nstage IIIA/B (N1a, sensitivity  \n CXR: sensitivity, \n48%; 95% Not all patients \nreceive verification 2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 648 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \n \n detecting \nasymptomatic \npulmonary \nmetastases by \nsurveillance chest \nX-rays (CXRs) in \nmelanoma patients \nwith a positive SNB   N2a) disease  specificity  \n \ntime to diagnosis  \n \nsurvival  confidence interval \n[95% CI], .27 \u2013.68) \nspecificity, 78%; 95% \nCI, .77 \u2013.79 \n \nAdditional \nmetastatic disease \nwas ap parent in 18% \nof CXR -detected \nversus 76% of non -\nCXR-detected \npatients (p<0.05)  \n \nmedian time to \ndiagnosis of \npulmonary \nmetastases: 24 \nmonths (95% CI, 12 \u2013\n41) vs. 16 months \n(95% CI, 10 \u201330, p = \n0.30 log rank).  \nmedian survival of \n42 months (95% CI, \n24\u201384)vs. 3 6 \nmonths (95% CI, 18 \u2013\n46, p = 0.53 log \nrank)  using a reference \nstandard (only \npatients with \npositive CXR)   \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 649 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \nTarhini AA et al. \n(2009)  To asses the effect \nof elevated serum \nS100B level at \nbaseline and during \ntherapy.  Progostic study  \n Sera from 670 \npatients with high \nrisk melanoma \n(\u2265stage IIB disease) \nbanked at baseline \nand 3 additional \ntime points were \ntested for S100B  \n \n Overall survival (OS)  \n \nRFS median OS time: 7.2 \nyears (95% CI, 6.0 \nyears to not \nreached). RFS time: \n3.1 years (95% CI, \n2.4 to 3.7 years).  \n \nMultivariate analysis \nwas performed \nadjusting for \nsignificant \nprognostic factors \n(ulceration and \nlymph node status) \nand treatment. \nBaseline S100B was \na significant \nprognostic factor \nfor survival (HR = \n1.39; 95% CI, 1. 01 \nto 1.92; P = 0.043)  \n \nS100B values \nmeasured at later \ntime points over 1 \nyear were also \ndemonstrated to be Patients w ere \nincluded in an \nintergroup trial \nE1694 was a \nrandomized \ncomparison of  \nheGM2ganglioside \nvaccine (GMK)  \nversus HDI that \naccrued 880 \npatients.  \n \nNo information \nabout staging  2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 650 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \nsignificant \nprognostic factors \nfor RFS and OS. \nLower S100B values \nat baseline and \nduring follow -up \nwere associated \nwith longer survival.  \nLeiter  et al. (2009)  To develop an \nefficient and cost -\neffective \nsurveillance \nstrategies, \ndependent on tumor \nstage  Economic study  \n \n Same cohort as \nLeiter et al. (2010) \nand Garbe et al. \n(2003)  \n \n1969 patients  Total costs  \n \nCosts per \nrecurrence detection  Total costs for \nroutine melanoma \nfollow -up during \nthis 2 -year period: \n236.30\u20acpatient.  \n \nCosts for follow -up \nexaminations in:  \n- stage I: \n307914\u20ac/887261  \n- stage II: \n62673\u20ac/252292$  \n- stage III: \n89651\u20ac/352214$)  \n \ncosts for the \ndetection of one \nrecurrence for \nphysical Retrospective \nanalysis of \nprospective study \ndata \n \nFor detailed tables \nof costs, see \noriginal publication  \n \nThe calculation of \ncosts was based on \nthe 2004 GO\u00c4 \n(Germany) and on \nthe 2004 Medicare \nfee reimbursement \nschedule (USA)  \n \n. 2b   \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 651 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \nexamination and LN \nsonography:  \n- stage \n14289\u20ac/4391$ and \n18035\u20ac/131423$  \n- stage II: \n500\u20ac/512$ and \n1333\u20ac/9712$  \n- stage III: \n168\u20ac/171$ and \n1250\u20ac /9112$, \nrespectively.  \n \nCost for CR to \ndetectof one 1 \nrecurrence:  \n- stage I: \n22886\u20ac/20 512$)  \n(stage II an d III: see \nfull-text) \n \nTotal costs \namounted to \n990.8\u20ac/2208$ per \npatient (stage I) and \nup to 1841\u20ac/  \n4009$ per patient  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 652 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \n(stage III)  \nEgberts et al. (2009 ) \n to investigate \nwhether a serial \nanalysis of protein \nS-100B in serum \nwith a luminescence \nimmunoassay \ncompared with \nroutine LDH \nassessment could \nbe of value as an \nindicator of \nmelanoma \nprogression  Diagnostic study  97 patients with \nstage II/III disease \ntreated within \nprospective \nrandomized trials  Sensitivity  \n \nSpecificity  \n \nPPV sensitivity to detect \nmetastasis:  \nS-100B: 36.5% vs.  \nLDH: 17,3%,  \n(P=0.006).  \n \nsensitivity in \npatients progressing \nto stage  \nIV: S-100B: 53.8% \nvs. LDH: 23.1% \n(P=0.008)  \n \nSpecificity 98% for \nboth S -100B and \nLDH \n \nPPV: S -100B% 73% \nvs. LDH: 64%  Treatment bias: \nPatients were \ntreated with \ndifferent adjuvant \ntherapies  \n \n 2b \nMoore  Dalal et al. \n(2008)  to determine the \neffect of the method \nof detection of \ninitial recurrences \nand \ntiming of visit on Prognostic study  198 Clinical stage \nI/II patients who \ndeveloped \nrecurre nce after \nSLNB and who were \nevaluable for Method of \nrecurrence detection  \n \nPrognistic factors of \nsurvival  \n Median follow -up \nafter first \nrecurrence: 17 \nmonths.  \n \nSelf-detection of  2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 653 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \npost-recurrence \nsurvival in patients  \nundergoing SLN \nbiopsy  longterm follow -up  recurrences in 55% \nof patients, 78% \nwere seen earlier \nthan their scheduled \nvisit. \n \nSelf-detected \nphysical  \ndiseases:  \n-24% in -transit  \n-23% nodal  \n \nPhysician detection \nin 45%, in 46% by a \nscheduled \nradiographic test \n(CXR  \n16%; CT 29%; PET \n1%). \n \nmethod of detection \nsignificantly \npredicted post -\nrecurrence survival \n(p<0.05)  \n \nMultivariate analysis  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 654 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \nadjusted for worst \nsite of recurrence, \nmethod of detection \nremained \nsignificantly \nassociated with \npost-recurrence \nsurvival (P = 0.02) \nTiming of visit did \nnot affect survival  \nHengge et al. (2007)  to analyze the \nfollow -up of  \nmelanoma patients \nunder clinical and \neconomic aspects \non an as -treated \nbasis based on \ncurrent \nrecommendations of \nthe AJCC/UICC 2002 \nand the German \nDermatologic \nSociety.  Economic analysis  \n \n 526 melanoma \npatients stage I -III Recurrence  \n \nMethod of \nexaminatio n \n \nDirect medical costs \nper metastasis  \n \nQALYs  Detection of 57 \nrecurrences in \nstages I -III (5-year \nfollow -up period), \n61% detected by \nphysician and 39 % \nby patients. \nDetection of 25 \nSPM. \n \nThe total costs for \nmelanoma follow -\nup in stages I \u2013III for \nthe 5 -year term at \nthe tertiary care \nuniversity center \naccounted for Retrospective data  \n \nPatients kept only \nabout 75% of \nfollow -up \nappointments (real \ncosts possibly even \nhigher)  \n \nCosts were \ncalculated according \nto standardized \naverage fees (GO\u00c4 \n2004)  2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 655 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \n725,095 \u20ac \n($870,114)  \n- Clinical \nexaminations \nrepresented 21,437 \n\u20ac ($145,724)  \n- technical \nexaminations \naccounted for \n286,656 \u20ac \n($343,987)  \nlaboratory costs \ntotaled 317,002 \u20ac  \n($380,402) \nrespectively  \nFerrone et al. (2005)  To determine the \nincidence of \nmultiple primary \nmelanomas (MPM) \nfrom a prospective, \nsingle -institution, \nmultidisciplinary \ndatabase, and to \ndescribe the clinical \nand pathological \ncharacteristics and \nrisk factors specific Prognostic study  \n \n 4484 patients \ndiagnosed with a \nfirst PM, 385 h ad \n>=PM  Incidence of MPM  \n \nRisk factors for MPM  For 74% of patients, \nthe initial melanoma \nwas the thickest \ntumor.  \n \nestimated \ncumulative 5 -year \nrisk of:  \n- a SPM for the \nwhole cohort: \n11.4%, with 5,5% \noccurring within the Retrospective \ndesign (prospective \ndatabase)  2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 656 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \nto these patients.  1st year  \n- a MPM for patients \nwith a positive \nfamily history or \ndysplastic nevi: \n19.1% and 23.7%, \nrespectively.  \n- a third PM  \nfrom the date of the \nSPM: 30.9%, with  \n15.6% occurring \nwithin the 1st year  \nMachet et al. (2005)  \n to study the value of \nadding ultrasound \nlymph node \nexamination (7.5 \nMHz) to the routine \nclinical examination \nrecommended by \nFrench guidelines in \nmelanoma follow -\nup. Diagnostic study  373 patients \nenrolled in a follow -\nup protocol  Sensitivity  \n \nspecificity  Sensitivity of clinical \nexamination and \nultrasound  \nExamination: 71,4% \n[95% confidence \ninterval (CI) 55.4 \u2013\n84.3] and 92.9  \n(95% CI 80.5 \u201398.5), \nrespectively. \nP=0.02). Specificity \nof clinical \nexamination and \nultrasound \nexamination: 99.6% \n(95% CI 99.2 \u201399.8) No information \nabout design \n(prospective/retrosp\nective)  2b \n \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 657 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \nand 97.8% (95% CI  \n97.0\u201398.4) , \nrespectively.  \nGoggins et Tsao \n(2003)  To examine how the \nrisk of a SPM tumor \nvaried with time \nfrom diagnosis of \nCM and examined \nthe patient -specific \nfactors that modify \na CM patient\u2019s risk \nof developing a \nsecond primary \ntumor.  Prognostic study  \n \n 61,245 melanoma \npatients, of whom \n2.32% developed \n>=1 additional \nprimary CM  Incidence of \nadditional primary \nCM \n \nRisk factors  >/= 1 additional \nCM in 2.32% of the \n61,245 patients \nduring follow -up, \nca. 22% of these \npatients had 2 \nsynchronous \nprimary CMs.  \n \nHRs correspond to \nmean rates of \n271.3, 227.8, 229.3 \nand 224.4 cases per \n100,000 per year \nfrom 1 \u20134 years, for \n5\u201310 years, 10 \u201315 \nyears, and 15 \u201320 \nyears after \ndiagnosis, \nrespectively.  \n \npresence of 1st CM \non th e face, neck, \nand trunk \uf0e0 Retrospective \ndesign  \n \nLarge patient cohort  \n \nFor cumulative risk \nand monthly hazard \ndiagrams see \noriginal article  2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 658 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \nincreased risk for \n2nd CM (in both \nunivariate and \nmultivariate \nmodels):  \n \nstage IV disease \uf0e0 \nlower risk of 2nd \nCM \nGarbe  et al. (2003)  To prospectively \nexamine and \nevaluate the results \nof follow -up \nprocedures in a \nlarge cohort of \ncutaneous \nmelanoma patients.  Prospective cohort \nstudy  \n 2,008 patients with \nstage I -IV \n Recurrence \ndetection  \n \nTime to detection of \nrecurrence  \n \nModes of detection  Detection of \nrecurrences:  \n- in 71% on \nscheduled follow -up \nexaminations  \n- in 17% by patients \nthemselves, in 13% \nof these recurrences \ndiagnosis was \nestablished during \nsubsequent regular \nfollow -up \nexaminations  \n- in 12% by \nphysicians not \nparticipating in the \nmelanoma follow -\nup schedule  Descriptive study  \n \nStandardized \nfollow -up \nprocedures  \n \nDetailed description \nof procedures and \nof follow -up of \nstudy drop -outs \n \nData about yield of \ndifferent imaging \nmethods vs. \nphysical \nexamination not \nlisted here (see \noriginal article)  2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 659 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \n \nIn 2,3% of patients, \nSPM were identified.  \n \nModes of detection: \nsee full -text \nManola et al. (2000)  To identify factors \nthat are prognostic \nfor survival in \npatients with \nmetastatic \nmelanoma treated \nin eight Eastern \nCooperati ve \nOncology Group \n(ECOG)  \ntrials conducted \nover the past 25 \nyears.  Prognostic study  See fulltext  Survival  \n \nRelative risks  Median survival: 6.4 \nmonths (95% \nconfidence interval, \n6.1 to 6.9 months.) \nF \n \nfactors conferring \nthe greatest \nincreased risk of \ndeath:  \n- number of  \nmetastatic sites (RR \n= 1.12)  \n- ECOG \nperformance status \n>= 1 (RR = 1.49)  \n- metastatic  \ndisease in the GIT \n(RR = 1.49), liver \n(RR = 1.44), pleura \n(RR = 1.35), or lung  2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 660 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \n(RR = 1.19).  \n \nPrior \nimmunotherapy (RR \n= 0.84) and female \nsex (RR = 0.87)were \nassociated with \nprolonged survival.  \n \nresponse to \nprotocol treatment \n(RR = 0.57) was a \nsignificant \nprognostic factor:  \n \nPrognostic for \npoorer survival:  \n- increased number  \nof sites of \nmetastasis (RR = \n1.30)  \n- abnormal LDH (RR \n= 1.89)  \n- abnormal alkaline \nphospha tase (RR = \n1.76)  \n- abnormal platelets  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 661 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \n(RR = 1.63)  \n- GI metastases (RR \n5 1.66)  \nSchlagenhauff et al. \n(2000)  To evaluate the \nsignificance of \nserum protein S100 \nin \nscreening for \nmetastases during \nregular follow -up \nexaminations of \npatients with \nmalignant \nmelanoma.  Diagnostic study  \n \n 411 melanoma \npatients with PM \nwith a tumour \nthickness >= 1.5 \nmm  \n \n(237 patients stage \nII, 148 patients \nstage III, 26 stage \nIV) \n \n Sensitivity  \n \nSpecificity  \n \nFalse -negatives (FN)  \nTrue-negative (TN)  \nTrue-positives (TP)  \nFalse -positi ves (FP)  \n \n \nPositive predictive \nvalue (PPV)  \n \nNegative predictive \nvalue (NPV)  \n \nefficiency of protein \nS100 as a diagnostic \ntest Serum protein S100 \ncut-off value at \n0.13 \u00b5g/l:   \nFN: n=28  \nTN: n=355  \nTP: n=13  \nFP: n=15  \nPPV: 46  \nNPV: 93  \nTest efficiency (< 2): \n1.39. The protein \nS100 values of the \nmetastasis group \nwere significantly  \nhigher (P =0.0.001).  \n \nS100:  \nsensitivity: 0.32, \nspecificity: 0.96  \n \ncut-off value of \n0.08 \u00b5g/l (outcomes \nfor this cut -off: see \nfull-text):lower Interval between \nrelapse and serum \nanalysis of S100: up \nto 2 months (clinical \nsituation may \nchange during this \ninterval)  \n 2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 662 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \nspecificity, PPV and \ntest efficiency  \nsensitivit y: 41%  \nBrobeil et al. (1997)  To determine the \nimpact of an \nintensive follow -up \nprotocol on the \nstage of disease at \ndiagnosis of \nsubsequent primary \nmelanomas.  Prevalence study  \n \n 101 patients with \nSPM (67 with \nsynchronous and 44 \nwith metachronous \nSPM) Incidence of MPM  \n \nTumor thickness in \nprimary and \nsecondary lesions  Of 2,600 patients: \n4.3% of patients \nwith SPM  \n \nmean tumor \nthickness: 1,72 mm \nfor PM vs. 0.58 mm \nfor SPM  \n \nmean thickness of \nmetachronous \nmelanoma: 2.27 \n(range 0.18 -10.2) \nmm for PM vs. 0,90 \n(range 0.11 -2.58) \nmm for SPM  \n \ninitial primary \nmelanomas tended \nto be thicker (by an \naverage of 3.8 mm, \np = 0.008).  Retrospective \ndesign  \n \nPredominantly male \npatients  2b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 663 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \nBasseres et al. \n(1995)  To assess the cost -\neffectiveness of \nsurveillance in stage \nI melanoma.  Prevalence study  528 patients with \nmelanoma stage I \nand Clark\u2019s level II \nor higher (214 \nmales, 314 females)  Time to relapse  115/52 8 patients \nhad relapses.  \n \nThe rate of relapse \nand the mean time \nbetween initial \nresection and \nrelapse: 9.6% and \n37 months for \nmelanoma < 1.5 \nmm, 34% and 24 \nmonths for \nmelanoma of 1.5 to \n3 mm, 47.7% and 17 \nmonths for \nmelanoma > 3 mm.  \n \nTime between \nrelapse  and last \nfollow -up \nexamination: \uf0a3 2 \nmonths in 9% of \ncases, \uf0a3 3 months in \n23% and \uf0a3 4 months \nin 34%.  Retrospective \ndesign  \n \nFor cost analysis see \nfull text of paper  2b \nDe Giorgi et al. \n(2010)  To identify main risk \nfactors associated Prognostic study  \n 40 patients with \nMPM  Thickness of SPM  \n Overall mean \nthickness of Retrospective \ndesign  2b-  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 664 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \nwith MPM and to \ninvesti gate the \nassociation between \nregular follow up \nand tumour \nthickness of a SPM   Odds ratio of having \nMPM \n \n melanoma: 0.517 \nmm for first \nmelanoma and 0.64 \nmm for SPM (P = \n0.12).  \n \nSignificant \ndifference in mean \ntumour thickness in \npatients not \nattending follow up \nvs. patients adhered \nto follow up (1.22 \nmm vs. 0,36 mm)  \n \nOR of having a \ndiagnosis of MPM in \ncomparison with \nSPM: \n- female 1.94 (vs. \nmale)  \n- >/= 1 atypical \nnevi 4.18  \n- positive family \nhistory 2.18   \nSmall patient \nsample with \nsecondary \nmelanoma  \nBower et al. (2010)  To determine the \noutcome and  Prognostic factors  41 melanoma \npatients with Diseas e-free-\nsurvival  Thickness of \nsubsequent vs. Posthoc analysis  \nfrom a multi -2b-  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 665 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \nincidence of \nmultiple primary \nmelanoma (MPM) \nand other cancer \ntypes among \npatients with \nmelanoma. The risk \nfor secondary \nnonmelnoma \nmalignancies was \nalso assessed.  multiple melanoma \nand no evidence of \ndistant metastasis \nand no palpable \nnodal metastasis.  \n \n(Patients with \nsynchronous lesions \nnot included)   \noverall survival  primary melanomas: \nmedian 0,32 mm \nversus 1,50mm, \np<0,0001)  \n \nMultivariant \nanalysis: age \n(p=0,028), \nlymphovascular \ninvasion (p=0,010) \nand SSM subtype of \nthe original \nmelanoma \n(p=0,024) were \nassociated with \nMPM.  \n \nPatients with MPM \nvs. patients with \nsingle primary \nmelanoma:  \n- 5-year-DFS:  \n88,7 vs. 81.3%, \np=0,380  \n- 5-years -OS \n95,3 vs. 80%, p= \n0,005  institutional \nprospective \nrandomized trial  \n \nLoss-to-follow -ups \nnot commented  \n \nPatients with \nmelanoma <1mm \nexcluded  \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 666 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \n \ndetection of \nsecondary \nmelanomas within \nthe first year in \n29,3% of patients, \ndetection of \nsubsequent  \nmelanoma within 60 \ndays in 9,8 % after \nprimary melanoma.  \n \nMedian time to \ndevelopment of \nsecond primary: 29 \nmonths. \nNonmelanoma \nmalignancies in \n6,1% of patients  \nFusi et al. (1993)  To determine \nwhether there are \nsignificant trends in \nthe prognostic \nfactors or in the \ntiming and sites of \nrecurrence.  Prognostic study  \n \n 250 patients with \nrecurrent malignant \nmelanoma  Time to recurrence  \n \nSites of recurrence  \n \nSurvival  Sites of first \nrecurrence: 52% \nregional nodes, 17% \nlocal recurrences, \n8% in -transit \nmetastases,  23% to \na distant organ.  \n Retrospective \ndesign  \n \nPopulation not \ndescribed in detail  2b-  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 667 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \nDiagnosis of \nrecurrences: 67% \nwithin 24 months, \n81% within 36 \nmonths  \n \nSurviva l after the \ndiagnosis of \nrecurrence was \nindependent of:  \n- thickness of the \nprimary tumor  \n- duration of DFI  \n(local, in -transit or \nregional nodal)  \n \ndiagnosis of distant \norgan metastasis: \nshorter survival  \n \nlocal recurrence, in -\ntransit metastasis, \nand regiona l nodal \nmetassis: \ncomparable \nsurvivals  \nRomano et al. implications for Prognostic study  340 patients AJCC Relapse -free 5-year RFS for stage Retrospective 2b-  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 668 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \n(2010)  follow -up \nguidelines   \n stage III who \nrecurred  survival  \n \nOverall survi val \n \nMode of relapse \ndetection  \n \n5-year survivals  IIIA, IIIB, and IIIIC \npatients was 63%, \n32%, and 11%, \nrespectively  \n \nSite of first relapse:  \n- local/in -transit \n28% \n- regional nodal \n21% \n- systemic 51%  \n \n1st relapses  \ndetected by patient \nor family, physician, \nor by screening \nradiologic tests in \n47%, 21%,  \nand 32% of patients, \nrespectively.  \n \nFactors associated \nfor better OS \n(multivariate \nanalysis):   \n- younger age  \n- 1st relapse being design  \n \nestimated site -\nspecific risk of first \nrelaps e for each \nsubstage  \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 669 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \nlocal/in -transit or \nnodal, \nasymptomatic, or \nresectable.  \n \nestimated 5 -year \nsurvivals for stages \nIIIA, IIIB, and IIIC \nfrom time of 1st \nrelapse: 20%, 20%, \nand, 11%, \nrespectively. \nSurvival curves \nshowed a plateau at \naround 50 months \nin all substages.  \nStucky et al. (2010)  Understanding the \nrisk factors for local \nand in -transit \nrecurrences (LR/ITR) \nmay help facilitate \nmethods of \nprevention, early \ndetection, and \ntreatment.  Prognostic study  \n 255 patients treated \nwith surgical \nresection of a single \nmelanoma and with \nat least 18 months \nof follow -up  \n \n(26 patients with \nLR/ITR)  Time to recurrence  \n \nSite of recurrence  average time to \nLR/ITR: 16.2 \nmonths (range, 4.2 \u2013 \n82.4 mo).  \n \nWithin 12 months of \nfollow -up:LR/ITR in \n53% of the patients  \n \nwithin 18 months of \nfollow up:  78% of Retrospective \ndesign  2b-  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 670 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \nrecurrences  \n \npatients with LR/ITR \n(n=26):  \n- 3% local \nrecurrences  \n- 5% in transit \nrecurrence  \n- 2% both LR/ITR  \n- 56% concurrent \nregional LN \nmetastases.  \n \nLR/ITR was \nassociated with:  \n- older age  \n- thicker original \ntumo r \n- presence of \nangiolymphatic \ninvasion in the \noriginal melanoma  \nMeyers et al. (2009)  To determine the \nimpact of routine \nimaging on the \nmethod of detection \nof first recurrence in Prognostic study  \n \n 118 patients with \nstage II or III  \n  Mode of recurrence \ndetection  \n \nTime to recurrence  \n Median time to \nrecurrence: 14 \nmonths (range, 2 \u2013\n88 months)  \n Retrospective \nanalysis of \nprospective \ndatabase  \n 2b-  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 671 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \npatients with stage \nII and sentinel \nlymph node \u2013positive \nstage III melanoma.  Overall survival  \n \nCosts  Types of recurrence: \n9% local, 40% in \ntransit, 16% regional \nlymph node basin, \n35% distant  \n \nMode of detection:  \n- self-detection in \n37% asymptomatic \npatients  \n- 30% of patients \nwith symptoms that \nled to detection of \nrecurrence  \n- in 23% by \nphysician during \nroutine follow -up \nexamination  \n- in 7% by ro utine \nfollow -up imaging  \n- in 3% by high LDH \nvalues  \n \nMedian survival \nafter recurrence: 22 \nmonths \n(locoregional Small patient cohort   \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 672 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \ndisease) vs. 7 \nmonths (distant \ndisease)  \n \nno difference in \nsurvival among \nsymptomatic vs. \nasymptomatic \npatients  \n \nno significant \ndifference in \nsurvival between a \nself-detected \nrecurrence and \nrecurrence detected \nby either a physician \nor by routine \ndiagnostic scans.  \nFrancken et al. \n(2008)  To calculate \nrecurrence rates and \nestablis h prognostic \nfactors for \nrecurrence to help \nredesign a follow -\nup schedule.  Prognostic study  \n \n. 4726 patients with a \nsingle invasive \nprimary cutaneous \nmelanoma and \nstage I or II disease  Recurrence rate  \n \nDisease -free \nsurvival  \n \nDisease -specific \nsurvival  Recurrence occurred \nin 18.9% (895 of \n4748) of patients \noverall, 5.2% (95 of \n1822)  \nof those with stage \nIA disease, 18.4% \n(264 of 1436) with Retrospective \ndesign  \n \nPart of the cohort \nvery old (sta rting \n1959)  \n \nFor Kaplan -Meier 2b-  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 673 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \nIB, 28.7% (215 of \n750) with IIA,  \n40.6% (213 of 524) \nwith IIB and 44.3% \n(86 of 194) with IIC \ndisease. Overall, the \nmedian disease -free \nsurvival time was \n2.6 years, but there \nwere marked \ndifferences between \nAJCC subgroups.  \nPrimary tumour \nthickness, \nulceration and \ntumour mitotic rate \nwere important \npredictors of \nrecurrence.  curves for time to \nfirst recurrence see \noriginal article  \n \nTime between \nrelapse and last \nfollow -up not \nmeasured  \nKhan et al. (2006)  \n To help develop \nparameters for \nfuture trials, \ntreatment history \nand  Prognostic study  212 patients with \npathologically \nproven stage IV \nmelanoma  \n \n survival  median survival of \nstage M1c: 6.0 \nmonths. Survival \nwas longer for stage \nM1a and M1b and \nshorter in older \npatients. No \nsignificant  2b-  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 674 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \ndifferences were \nfound in survival \nbased on gender.  \n \nPatien ts with a \nnormal LDH level \nsurvived almost \ntwice as long \n(median survival, \n12.0 months, [95% \nCI 8.85 \u201315.15]) \ncompared to those \nwith an elevated \nLDH level (median \nsurvival 6.0 months, \n[95% CI 3.51 \u20138.49]); \nthese were \nsignificantly \ndifferent by the log -\nrank t est (\u03c72 = \n5.88, P = .0154).  \nMartenson ED et al. \n(2001)  \n \n To evaluate whether \nS-100B protein in \nserum is an \nindependent \nprognostic marker \nin malignant  Prognostic study  \n \n \n 1,007 consecutive \npatients for \nscheduled follow -up \nvisits.  \n \n(876 stage I, 35  Disease -specific \nsurvival  \n The mean serum \nconcentration of S -\n100B protein was \nsignificantly related \nto clinical stage  \n Follow -up \ndiagnost ic \nprocedures not \nstated in article  \n \nStudy included in 2b- \n \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 675 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \nmelanoma.  stage II, 96 stage III)  \n \n significant \ndifferences in \ndisease -specific \nsurvival for patients \nwith S -100B values \n> and < 0.10 mg/L, \nboth when analyzed \nin the whole group \nof patients and in \nthe subset of \npatients with \nmetastatic disease \n(clinical stages II to \nIII) \n \nSignificantly lower \nlevels in patients in \nwhom the \nmetastases had \nbeen resected \ncompared  \nwith patients with \nsubcutaneous \nand/or LN \nmetastases \n(P=0,004)  or \ndisseminated  Mocellin et al. 2008  \n \nThe three -stage \nsystem for \nclassification of \nmalignant \nmelanoma   \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 676 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \nmetastases (P < \n0,001).  \n \nmultivariant \nanalysis: In clinical \nstages II and III, the \nS-100B protein level \nin serum was the \nstrongest \nindependent \nprognostic factor \nfor melanoma \nsurvival (P<0,001)  \nMruck  et al. (1999)  \n To investigate the \npredictive value of \nthe protein S100 as \na tumor marker in \nthe post -surgical \nfollow -up staging of \npatients with high \nrisk melanomas \n(Clark levels IV/V, \nthickness>0,75 \nmm) Diagnostic study  50 patients  \n Sensitivity  \n \nSpecificity  \n \nPredictive values  FDG-PET: \nSensitivity=100%, \nspecificity=95%  \n \nConventional \nimaging: \nSensitivity=9 2%, \nspecificity=82%  \n \nS100 :  \nCut-off-levels were \n0,1\u00b5g/l and \n0,2\u00b5g/l:  \nSensitivity=85%, Selection criteria not \ndescribed  \n \nNo information \nabout time interval \nbetween blood \nsample and imaging \nprocedures  \n \nSmall patients \ncohort  2b-  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 677 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \nspecificity=55% \nwhen measured by \nRIA, \nSensitivity=77%, \nspecificity=61% \nwhen measured by \nLIA \n \nNPV=91% (RIA) and \n88% (LIA)  \nPPV=39% (RIA), 40% \n(LIA) \n \nAt a cut -off level of \n4,0\u00b5g/l, TK showed \na sensitivity of 70% \nand a specificity of \n41%. \nPoo-Hwu et al. \n(1999)  To evaluate the \nfollow -up pr otocol \ninstituted in 1987 at \nthe Yale Melanoma \nUnit to improve \nupon the detection \nof disease \nrecurrence in \npatients with Retrospective \nprognostic study  \n \n 373 patients \nfollowed according \nto the protocol \nschedule.  \nAJCC Stage I -III \n Recurrence -free \ninterval  \n \nOverall survival  \n \nModes of detection  median time interval \nto recurrence:  \n- stage I:22.0 \n(range, 2.0 \u201360.5) \nmonths  \n- stage II 13.2 \n(range, 2.4 \u201371.0) \nmonths  \n- stage III: 10.6 Detailed follow -up \nprocedure given  \n \nRetrospective \ndesign  2b-  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 678 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \nAmerican Joint \nCommittee on \nCancer Stage I -III \ncutaneous \nmelanoma.  (range, 2.3 \u201353.8) \nmonths  \n \n51% locoregional \nrecurrences \ndetected by \npatients,  \n64% distant \nmetastases detected \nby physicians  \n \nphysician -detected \nrecurrences:  \n- 57% by history or \nphysical \nexamination  \n- 18% by abnormal \nchest X -ray \n- 23% by CT scan or \nMRI \n- 2% by elevated \nLDH \n \nmedian survivals:  \n34 months for \nlocoregional vs. 13 \nmonths for distant  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 679 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \nrecurrences  \n \nAll 19 patients with \nMPM were identified \nby physician -\nperformed physical \nexamination.  \nvon Schoultz et al.  \n(1996)  \n To asses the \npotential prognostic \nvalue of serum \nconcentrations of S -\n100\u00df  Serum levels of S -\n100\u00df protein were \nmeasured in a \nconsecutive series \nof 643 patients with \ncutaneous \nmalignant \nmelanoma during \n08/1990 -10/1992  \n \n 643 patients in total  \n553 p atients: stage I  \n(with/without \nsatelilites within 5 \ncm), 24 patients: \nstage II (in -transit \nmetastases and/or \nregional lymph node \nmetastases), 66 \npatients: stage III \n(distant metastases)  \n \n Overall survival  Significant \ncorrelateion of \nserum \nconcentrations of  S-\n100\u00df to clinical \nstages. They were \nsignificant higher in \nmen than in women \n(p<0,001).  \n \nAssociation between \nOS rate with serum \nlevels of S -100. \n \nobserved/expected \ndeath ratio was \nmarkely increased \nwith increasing \nlevels of S -100\u00df \n(P<0,001). A No information \nabout number of \nblood samples \ntaken  \n \nPoor inf ormation \nabout population  \n \nNo information \nabout study design \n(prospective/ \nretrospective?)  \n \nDisease \nclassification \ndifferent from AJCC \nwas used  \n \nstudy included in \nMocellin et al. 2008  2b-   \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 680 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \nfivefold i ncrease in \nrelative hazard was \nindicated by a value \nof S-100\u00df >0,6\u00b5g/l \n(P<0,001) and when \nits cut -off level was \nused S100\u00df had \nadditional \nprognostic value \nindependent of \nclinical stage \n(P<0,001).  \nKaufmann , Crone -\nM\u00fcnzbrock (1992)  To evaluate the \nvalue of CT and U S \nin detecting \nabdominal \nmetastases.  Diagnostic study  \n 849 patients with \nmalignant \nmelanoma  \n \n \n \n \n Sensitivity  \n \nspecificity  Interval between \ntherapy of primary \nmelanoma and \ndiagnostis of \nreccurence: 2,5 \nyears  \n \nUS: sensitivity; 53%, \nspecificity; 98%  \n \nCT sens itivity 85%, \nspecificity 94%  Selection criteria not \ndescribed  \n \nNo information \nabout time interval \nbetween ultrasound \nand CT  2b- \nKelly et al. (1985)  To develop \nguidelines for the Prognostic study  \n 295 patients with \nmetastatic disease -free interval  \n independent \nsignificant predictor Incomplete patient \nrecords (of 295 2b-  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 681 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \nfollow -up of \npatients with \nprimary cutaneous \nmelanoma   \n \n \n \n \n  malignant \nmelanoma(clinical \nStage I).  predictors of \ndisease -free interval  \n \nrecurrence rate  of DFI: tumor \nthickness (p = \n0.0015)  \n(not significant: sex, \nage, elective \nregional LN -\ndissection, tumor \nlocation)  \n \ndiminution of \nDFIfrom 3.97 years \n(< 1.0 mm) to 1.10 \nyears (> 5.0 mm) is \nevident with \nincreasing \nthickness.  \n \nAssociation between \nincreased risk of \nrecurrence and \nincreases in tumor \nthickness >1.5 mm \nin the first 4 ye ars \n(greatest increase in \nrisk is in the 1st \nyear)  patients, only 177 \nwere included in \nmultivariate \nanalysis)  \n \nFor details of \nsurvival and \nrecurrence \nstatistics, see \noriginal article  \nAlvarado  et al. to asses s the Prevalence study  146 patients with incidence rate of Recurrences in 75% Limitation of study 3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 682 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \n(2011)  \n frequency of the \npelvic metastases in \npatients with \nprimary melanoma \nin the head and \nneck to identify \nevidence supporting \nthe \nuse of pelvic CT \nscans in this group \nof patients.   \n \n primary melanoma \nwho had adequate \nfollow -up \nevaluation for at \nleast 5 years.  \n \n(109: stage I or II \ndisease, 33: \npatients stage III, 4: \nstage IV)  \n \n metastases  \n \nSurvival  \n \nTime to recurrence  \n \n of patients  \n \nmedian time to the \nfirst recurrence: 13 \nmonths.  \n \nMedian duration of \nthe OS: 3.8 years.  \n \nMedian duration of \nthe OS for the 110 \npatients with \nrecurrences: 2.3 \nyears.  \n \n48% of patients had \nremained alive >4 \nyears from the  \ntime of the first \ndiagnosis of \nmelanoma, \ndevelopement of \nmetastases in 56% \nof patients, \ndevelopement of \npelvic metastases in \n7% of patients  and bias not \ndescr ibed \n \nPatients with \nmucosal melanoma \nincluded   \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 683 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \n \nmost common sites \nof first recurrence: \nlymph nodes (n=41, \n37%), satellite soft \ntissue (n=41, 37%), \nchest (n=33, 30%), \nabdomen (n=13, \n15%), and the brain \n(n=7, 6%).  \nDeRose et al. (2011)  \n to determine the \nutility and cost \neffectiveness of \nradiological \nrestaging of \npatients with stage \nIIB\u2013IIIC melanoma at \nthe 3 -year follow -\nup time point  Economic and \nprevalence study  210 patients with \nstage IIB \u2013IIIC \nmelanoma  Recurrence rate  \n \nTime to recurrence  \n \nTP \n \nFP \n \ncosts per diagnosis  Recurrences in 55% \nof patients, in 69% \nwith disease \nsymptoms  \n \n88% recurrences \nbefore 3 years \n(median time to \nrecurrence 12 \nmonths,  \n95% confidence \ninterv al: 10 \u201316 \nmonths)  \n \n25 head CTs, 27 \nhead MRIs, 52 torso \nCTs were Reference standard \nnot described  3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 684 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \nperformed. In total: \n3 FP and 2 TP  \n \nTotal cost per \ndiagnosis:$312 990.  \nHansel et al. (2009)  To analyse the \nfrequency of late \nrecurrent MM in \nsouth -easter n \nGermany  Prevalence study  \n \n 1881 patients in \nstage I or II (AJCC) \nwith a follow -up of \n> or = 10 years  \n \n \n(1 uveal melanoma, \nexcluded)  Overall survival  \n \nRelapse -free \nsurvival  20 patients with late \nrecurrence of \nmelanoma . largest \nperiod from \ndiagnosis of PM  to \nrecurrence: 25.1 \nyears, median 13.9  \n \nLoco-regional \nmetastases in \n63.2%, distant \nmetastases in 42%, \ndeaths in 75%  \n \nAll but one of the \nsurvivors had in -\ntransit metastases \nonly (n=3).  \n \nOS: between 10.9 \nand 35.7 years \n(median 14.7).  Conclusion about \ninfrequence of late \nrecurrence can be \ndrawn, but \nstatistical \nconclusions inside \nthis small cohort are \nnot valid because of \nsmall patient \nsample  3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 685 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \n \nStatistical variate  \nanalysis failed to \nidentify possible \nfactors significantly \nassociated with late \nrecurrence  \nEinwachter -\nThompson, MacK ie \n(2008)  To review patients \nwith invasive \nmelanoma thinner \nthan 0.5 mm \nfollowed for at least \n5 years to provide \nan evidence base for \nconsidering \nmodification of \nguidelines.  cohort study  \n 430 patients with \ninvasive melanoma \n< 0.5 mm Deaths  \n \nInterval between \ntwo primaries  19% deaths from \nmelanoma in the \nwhole group.  \n \n11 patients \ndeveloped \nsimultaneous or \nsubsequent primary \nmelanoma (3 \nsimultaneously, 5 \nwithin 36 months, 1 \nbetween 3 -5 years, \n2 between 69 and \n73 months after the \nfirst diagnosis.)  Data on thin \nmelanomas only  \n \nRetrospective \ndesign  \n \nIn some cases \npathological review \nshowed melanoma \n> 0.5 mm at \ndiagnosis  or some \npatients developed \nthicker SPM  3b \nFrancken AB et al. \n(2008)  To asses the \nfrequency of patient \ndetection of both \nfirst primary Prevalance study  112 patients with \nrecently diagnosed \nSPM  \n FPM and SPM -\ndetection rate  Patients deteced \n59% of the FPMs vs. \n46% of the SPMs \nthemselves  Only patients with \nSPMs were \ninterviewed  \n 3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 686 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \nmelanomas (FPMs) \nand second primary \nmelanoms (SPMs)    \nsignificant \npredictors for a \npatient-de-tected \nFPM: \n- females gende  \n- greater Breslow \ntumour thickness  \n- younger age  \n(OR 4,9; 3,2 and 0,9 \nrespectively).  \n \npredicting factors \nfor the patient \ndetection of a SPM:  \n- greater tumour \nthickness  \n- ready visibility of \nthe lesion to the \npatient  \n(OR 1,9 and 3,6 \nrespectively)  (both in situ and \ninvasive melanomas \nwere included.)  \n \nExcluded were \npatients who had \nmultiple primary \nmelanomas or who \ndeveloped a \nrecurrence earlier \nthan the SPM \n(amongst others)  \nFrancken et al. \n(2007)  In this prospective \nstudy the frequency \nof detection of first \nmelanoma \nrecurrence (FMR) by Prevalence study  \n \n 211 patients with a \nfirst melanoma \nrecurrence (FMR) \nwere interviewed  Median time to \ndetecti on of an FMR  \n \nSites of recurrence  \n median time to \ndetection of FMR: \n28 months (range, \n2\u2013322) \n risk of bias (in \ngroup B, only \npatients  with \nunambiguous \ninformation in 3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 687 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \npatient or doctor \nwas analyzed  Modes of detection  \n \nMean survival  Symptoms present \nin 74%, in 39% FMR \ndetected as a \nconsequence of \nsymptoms.  \n \nin 56 patients FMRs \ndetection was at a \nfollow -up vis it: \n- 63% by physical \nexamination  \n- 14 % by chest x -\nray  \n- 11% by LN \nultrasound  \n \nDetection of FMR:  \n- in 154 patients by \npatient, partner, or \nrelative  \n- in 57 patients by a \ndoctor  \n \nmean survival time: \n23.8 months.  patients records \nwere included)  \nZogakis et al. (2007)  To estimate survival \nand time to first Prevalence study  \n 773 melanoma \npatients with Overal l survival  \n Recurrence in 8,9 % \nof patients with  Subgroup of \nsentinel -node-3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 688 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \nrecurrence in \npatients with \nnegative sentinel \nnodes.   tumor -negative \nSLNs  Disease -free \nsurvival  \n \nTime to first \nrecurrence  tumor -negative \nSLNs \n \n1-year, 3 -year, and \n5-year DFS rates: \n98%, 91%, and 88%, \nrespectively.  \n \n1-year, 3 -year, and \n5-year OS rates: \n99.7%, 96%, and \n92.7%, res pectively.  \n \nSignificant \ndifferences in \nsurvival between \npatients with \nlocal/in -transit and \nnodal vs. distant \nfirst recurrence  \n \nNo significant \ndifference in time to \nthe development of \nlocal/in -transit vs. \nnodal vs.distant \nrecurrence  negative patients  \n \nRetrospective \ndesign  \n \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 689 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \nBeyeler M et al. \n(2006)  \n To compare  \nthe efficacy of \nimaging techniques \nand serum S100 in  \nthe early detection \nof melanoma \nprogression  Diagnostic study  127 patients  Sensitivity  \n \nMode of detection  In 5.5% of patients, \nS100 was the  \nfirst indicator of \ndisease progression.  \n \n40.2% of relapses \nnoted by the \npatients themselves,  \n27.6% diagnosed by \na doctor. Imaging \nprocedures lead to \ndetection of \nmelanoma \nrecurrence in 26.8%. \n(US in 6 patients, \nPET scan in 12 \npatien ts, \nCT scan in 13 \npatients, PET -CT in \n3 patients, chest x -\nray in 0 patients)  \n \nS100 sensitivity:  \n37%. Population not \ndescribed.  \n \nSmall patient \nnumber in every \nstage  \n \nspecificity not given  \n \nNo information \nabout time interval \nbetween imaging \nprocedures and \nblood samples.  3b \nDiFronzo et al. \n(2001) To investigate \nwhether routine \nreassessment and cohort study  3310 patients with \nprimary melanoma \nAJCC stage I/II  Rate of patients who \ndeveloped SPM  114 patients with \nAJCC Stage I or II \nmelanoma Standard follow -up \nprocedure is defined  \n 3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 690 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \ncareful education of \npostoperative \npatients would \nfacilitate earlier \ndiagnosis of a \nsubsequent second \nprimary melanoma, \nas reflected by \nreduced thickness \nof that lesion .  \n developed a SPM  \n \nAJCC stages of SPM:  \n- lower in 48%  \n- same -stage in \n50% \n \nmean tumor \nthickness for PM: \n1.32 +- 1.02 mm, \nfor SPM: 0.63 + - \n0.52 mm  \n \nlevel of invasion of \nSPM vs. PM  \n- decreased in 60% \n- remained the \nsame in 27%  \n- increased in 13% \nof patients.  \n \nsignificant \ndifferences in stage, \ntumor thickness, \nand level of invasion \nbetween PM and \nSPM (paired t te st)   \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 691 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \nDicker et al. (1999)  To address the \nfollowing questions: \n(i) what is the \noverall risk of \nrecurrence? (ii) \nWhen do \nrecurrences occur? \n(iii) How are they \ndetected? (iv) What \nis the risk of \nrecurrence from \nmelanomas which \nappeared to be \nconfined to the \nepidermis when \nthey were excised? \n(v) How are second \nprimary melanomas \ndetected? (vi) Do \npatients alter their \nbehaviour after \nattending a \nmelanoma follow -\nup clinic?  Prevalence study  \n \n 1568 patients with \nstage I m elanoma  \n \n Risk of recurrence  \n \nFirst site and \ndetection of \nrecurrences  \n \nChanges in \nbehaviour (see full \ntext) Overall 19% \ndeveloped \nrecurrences  \n \n79% of recurrences \noccurred during the \nfirst 3 years. <8% \nafter the 10 -year \ninterval.  \n \npatients detected \ntheir r ecurrences \nmore often than  \ndoctors at follow -up \nclinics  \n \nThe first site of \nrecurrence was:  \n- local 17%  \n- in transit 6%  \n- local nodes 56%  \n- distal 22%  Large patient cohort  \n \nNo standardized \nfollow -up protocol  3b \nJohnson et al. \n(1998)  To characterize the \nsubgroup of \npatients with cohort study  \n \n 60 with with \nmultiple primary \nmelanomas, and  Time to diagnosis of \nsecond melanoma  \n In 30% MPM were \ndiagnosed \nconcurrently within Retro spective \ndesign  \n 3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 692 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \nmultiple \nmelanomas.  Tumor thickness of \nsecond melanoma  1 month, in 63% > 1 \nmonth apart,  and in \n7% concurrently and \nsubsequently (>2 \nprimaries).  \n \nmedian time interval \nbetween subsequent \ndiagnoses of 2nd \nPM: 63 months \n(range 2 -456) \n \nin patients with > 2 \nPM: median time \ninterval between \nsubsequent lesions: \n42 months (range \n2-456).  \n \nAppearance of \nsubsequent primary  \n- 42% within 3 years  \n- 17% between 3 -7 \nyears  \n- 42%> 7 years  \n- 19% > 10 years  \n- 6% > 15 years  Small patient cohort   \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 693 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \nAfter initial \ndiagnosis  \n  \nmean tumor \nthickness from the \n1st primary lesion \nto the subsequent \nlesion(s) decreased \nfrom 0.98 to 0.90 \nmm. \nSylaidis  et al. (1997)  To investigate the \nincidence of \nrecurrence in thick \n(> 4 mm) localized \nmelanoma to draw \nconclusions about \nduration and \nfrequency of follow -\nup. cohort study  \n \n 244 patients  \n(176 patients had \ntheir first recurrence \nbetween years 1 and \n10 postoperatively)  Overall survival (= \ndisease specific \nsurvival in this \nstudy)  \n \nSurvival after first \nrecurrence  5-year survival: 45% \n(95% CI 39%, 51%)  \n \n10-year survival: \n37% (95% CI: 31%, \n43%).  \n \n- 42 patients wi th \nlocal recurrences: \n5-year survival rate \nof 26% (95% CI: 13%, \n39%).  \n- 93 with regional \nrecurrences: 5 -year \nsurvival rate of 18% \n(95% CI: 10%, 26%).  \n- 41 with distant Retrospective \ndesign  \n \nPatient cohorts only \nincludes patients \nwith melanoma > 4 \nmm thickness  \n \nNo attempts to \nrecover patients lost \nto follow up  \n \nPatients who died of \nother diseases were \nexcluded  3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 694 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \nmetastases: 5 -year \nsurvival rate of 5% \n(95% CI: 0%, 11%).  \nMartini et al. (1994)  To establish a \nfollow -up guide for \ncutaneous \nmelanoma.  Prevalen ce study  \n 840 stage I \ncutaneous \nmelanoma patients  \n \n(recurrence in 202 \npatients)  Time to first \nrecurrence  \n \nPathway of first \nrecurrence  Mean time to first \nrecurrence: 22.27 \nmonths (median \n13.5 months).  \n \n45.54% of relapses \noccurred during the \n1st year, 79.21 % \nduring the first 3 \nyears, 89.6% in the \nfirst 4 years and \n94.55% in the first 5 \nyears.  \n \nRecurrences \nsignificantly earlier \n(mean 18.18 \nmonths, median \n10.5 months) in \nmales than in \nfemales (mean \n26.78 months, \nmedian 17.5 \nmonths).  Retrospective \ndesign with \nincomplete patients \nrecords (only 675 of \n840 patients \n\u201chistologically \nevaluable\u201d).  \n \nPatient cohort \ncontains melanoma \nin situ (105 lesions \nnot invasive).  3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 695 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \n \nPathway of first \nrecurrenc e: \n81.19%: lymphatic  \n17.33%:hematic  \n1,48%: unknown  \nBaughan et al. \n(1993 ) To assess the \nobjective value of \nfollow -up in \ndiagnosing and \ntreating tumour \nrelapse and its \nsubjective value as \nperceived by \npatients.  cohort study  \n \n 339 melanoma \npatients (65 patients \ndeveloped \nrecurrences)  Time to relapse  \n \n5-year-survival  \n \nQuestionnai re \nresults (subjective \nvalue of follow -up \nto patients)  82% of first relapses \noccurred within 3 \nyears and none has \nyet been seen after \n7 years.  \n \nActuarial 5 -year-\nsurvival (doctor -\ndiagnosed vs. \npatient -diagnosed \nrecurrences): 18 vs. \n20 % (P>0,8)  \n \nFor time to  first \nrelapses over year \nof follow -up, see \nfig. 1 in original \narticle.  Retrospective \ndesign  \n \nNo standard follow -\nup protocol  3b \nKang et al. (1992)  To examine the \nnatural history and cohort study  \n 41 patients with \nmultiple cutaneous Interval between \nmelanoma In 39% the MPM \nwere diagnosed Retrospective \ndesign  3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 696 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \nimpact of regular \nfollow -up \nevaluation of \nmultiple primary \ncutaneous \nmelanoma   melanoma  diagnoses  \n \nTumor thickness  \n \n concurrently (vs. \n61% subsequently).  \n \nSignificant decrease \nin Breslow\u2019s \nthickness from the \n1st PM (1.21 \uf0b1 0.28 \nmm) to the second \n(0.51 \uf0b1 0.08 mm) \n(P<0.05)  \n \nmedian time interval \nbetween sequential \nmelanomas: 36 \nmonths (range 2 -\n372)  \nSmall patient cohort  \nBrandt et al. (1990)  To investigate the  \nprognostic value of \nseveral factors on \ncancer-specific \nsurvival and \ncancerspecific \ndisease -free \nsurvival, from time \nof excision on, by \nperforming life -\ntable analysis on Prevalance study  \n \n 231 patients who \nunderwent local \nexcision  \nas the single \ntreatment of \nmelanoma with a \nthickness  \nof <= 1.5 mm.  Cancer -specific \nsurvival (CSS)  \n \ncancer -specific \ndisease -free \nsurvival  During follow -up: - \n14/206 patients \ndied. \u2013 (6 patients \nas a result of the \ndisease, 8 from \nother causes)  \n \nRecurrence in11 \npatients:  \n- 4 local \nrecurrences  Retrospective \ndesign  \n \nNo standard therapy \nand follow -up \nprotoco l  \n \nDifferent excision \nmargins have been \nused 3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 697 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \n206 evaluable \npatients.  - 4 LN me tastases  \n- 3 distant disease.  \n \n- Actuarial 5 -year \nCSS: 96.1%  \n- 10-year \nCSS:92.3%  \n- 15-year CSS: \n92.3%.  \n \ncancer -specific DFS \nafter 5 years: 95.2%, \nafter 10 years: \n86.9%, after 15 \nyears: 86.9%.  \nMcCarthy et al. \n(1988)  To re -examine \nfollow -up regimens \nand provide follow -\nup guidelines \ntailored to the risk \nof the individual \npatient.  Prevalence study  \n \n 886 melanoma \npatients with \nevidence of \nrecurrent disease  Recurrence rate  \n \nSite of first \nrecurrence  \n \nTime to first \nrecurrence  Time to first \nrecurrence \ndepended upon:  \n- thickness of the \ntumor  \n- whether ELND was \nperformed or not  \n \nTimes to recurrence \nfor 50% respectively \n95% of the recurrent \npatients in mo nths:  Retrospective \ndesign  \n \nDifferent follow -up \nschedules over time  \n \nLarge patient cohort  3b  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 698 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \n- 32 months and \n134 months for 0.1 \n\u2013 0.7 mm tumor \nthickness  \n- 25 months and \n116 months for 0.8 \n\u2013 1.5 mm tumor \nthickness without \nELND  \n- 36 months and \n145 months for 0.8 \n\u2013 1.5 mm tumor \nthickness with ELND  \n- 16 months and \n108 months for 1.6 \n\u2013 3.0 mm tum or \nthickness without \nELND,  \n- 20 months and \n112 months for 1.6 \n\u2013 3.0 mm tumor \nthickness with ELND  \n- 12 months and 60 \nmonths for > 3.0 \nmm tumor thickness \nwithout ELND  \n- 19 months and 60  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 699 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \nmonths for > 3.0 \nmm tumor thickness \nwith ELND  \nBuljan M et al. \n(2010)  To analyse the \nclinical, \nhistopathological \nand epidemiological \ncharacteristics of 36 \npatients, with \nmultiple primary \nmelanomas (MPM)  cohort study  \n \n \n 36 patients (3,6%) \nwere diagnosed with \nMPM.  \n \n28 patients: 2 \nprimary melanoma  \n6 had 3 melanoma \nand 2 had 4 \nmelanomas.  Time interval \nbetween first and \nsubsequent \nmelanoma  Diagnosis was \nestablished \nsynchronously in 11 \npatients  \n \nin the the other \npatients time \ninterval between PM \nand SPM varied from \n1 month to 16 \nyears, average time \ninterval : 41 \nmonths.  Retrospective \ndesign  \n \nSmall population  \n \nNo data concerning \nexamination \nintervals of follow -\nup 3b- \nMcMeniman et al. \n(2010)  To define the risk \nfactors for multiple \nprimary melanoma  \n(MPM).  Prognostic factors  \n \n 58 patients with \nmore than one \nprimary were \ninterviewed via \ntelephone  \n \n Rate of patients who \ndeveloped MPM  \n \nAge at diagnosis  \n \nTumor thickness  \n \nRisk factors  50% of patients had \ntheir first melanoma \nbetween 40 \u201359 \nyears of age.  \n \n68% had the same \nor a less invasive \nlevel of melanoma \non their subsequent \nlesion/s.  Data incomplete or \ninaccurate on many \npatients  \n \nRisk of recal l bias  \n \nSmall patient cohort  3b-  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 700 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \n \nWith subsequent \nmelanomas a \ngreater proportion \nwere found by the \ndermatologist.  \n \nRisk factors: see \nfull-text  \nZissimopoulos et al. \n(2009)  \n \n To evaluate 111In -\nO Scintiscan in \nmalignant \nmelanoma for the \ndetection of \nrecurrence and \nmetastatic disease, \nafter clinical and \nhistological \ndiagnosis and initial \nsurgery treatment \nand during 3 years \nof follow -up. Diagnostic study  35 patients with \nmalignant \nmelanoma  \n \n20 female, 15 male, \nmean age 46\u00b17, \nrange 32 -51 years  \n \nTreatments in some \npatients: Interferon \nalpha, IL -2 Positive - rate During 3 years of \nthe follow -up \nperiod, 26/35 of the \npatien ts \nhad clinical \nrecurrence.  \n \n(17 patients: \nregional lymph node \nmetastases, 9 distal \nmetastases)  \n \nIn 111In -O \nScintiscan  \n20/26 patients had \npositive scans with \n56 lesions, 6 had \nnegative scans. CT Selection criteria not \ngiven  \n \nSmall sample size  \n \nNo information \nabout false positives \nand false negatives.  \n \nPositive CT: only \nnumber of \nmetastases is given \nbut not number of \npatients  \n \nNo information \nabout interval \nbetween CT and 4  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 701 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \nimages showed only \n31 lesions.  111In -O Scintiscan  \n \nNo information \nabout results of \nother  staging \nmodalities  \nSolivetti FM et al.  \n(2006)  to assess the \npotential of \nultrasonography \n(US) in the detection \nof in-transit or \nsatellite metastases.  Diagnostic study  600 patients who \nhad thick melanoma  \n(>1 mm) and who \nwere clinically free \nof in-trans it or \nsatellite melanoma \nmetastases during \nfollow -up.  \n \n Number of detected \nmetastases  \n \nUS features of in -\ntransit metastases  US suspicion of in -\ntransit or satellite  \nmetastases in 63 \npatients. A total of \n95 lesions were \nidentified. Lesion \ndiameter ranged \nfrom 4 mm to \n17mm (mean \ndiameter 8 mm). \nFour of 95 lesions \nhad a diameter >1 \ncm; most (82 cases) \nhad diameters of 6 \u2013\n8 mm.  \n \nNo false positive or \nfalse negative US  \n \nUS features: see \nfull-text  4  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 702 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \nDancey et  al. (2004)  to assess patient \nopinions on follow -\nup. \n \nto ascertain whether \nGPS would be \nwilling to follow \nmelanoma patients \nup in a primary care \nsetting  cohort study  231 melanoma \npatients and 50 GPs \nwho filled out a \nquestionnaire  \n \n \n Patients` opinion on \nfollow -up \n \nGP satisfaction  98% found the \nclinics to be u seful \n \n22,5% felt it was \ndifficult to attend \nthe clinic  \n \n53% expressed  \nsome degree of \nanxiety at attending \nthe outpatient \ndepartment  \n \n12%: recurrence, \n52% of them \ndetected it \nthemselves  \n \n60% of patients \nwould be happy to \nconsider routine \nfollow -up with th eir \nGP \n \n70% of local GPs \nwould be unhappy \nto monitor their  4  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 703 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \npatients.  \nJohnson et al. \n(1999)  to determine the \nvalue of follow -up \nin two subgroups of \npatients with a thin \nmelanoma less than \n0.76 mm and 0.76 \u2013 \n1.5 mm thick.  Prevalence study  \n \n 306 patients: 178 \nwith a melanoma < \n0.76 mm (group 1) \nand 128 with a \nmelanoma of 0.76 \u2013 \n1.5 mm (group 2)  \n \n Recurrence rate  Recurrences in 4 \npatients (2.2%) in \ngroup 1 and 16 \n(12.5%) in group 2  \n \ngroup 1:  \nall patients \npresented with \nuntreatable, \nwidespread \nmetastatic dis ease, \ndetected by a \nclinician in the \nfollow -up clinic.  \n \ngroup 2: 1: local \nrecurrence, 1 in -\ntransit recurrence, 3 \nsubcutaneous \nrecurrence, 7 nodal \nmetastases and 4 \npatients distant \nmetastases. In \n13/16 patients, \nrecurrence was \ndetected by clinician Standardized \nfollow -up procedure  4  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 704 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \nin the f ollow -up \nclinic.  \nMooney et al. (1998)  To asses the impact \non survival by \ncomponents of a \nsurveillance \nprogram (physical \nexamination, blood \ntests, and chest \nradiograph) used to \ndetect recurrences \nin patients with \ncutaneou s \nmelanoma  Prognostic study  \n 1004 patients AJCC \nStage I or II  \n \n \n Method of detection  \n \nSurvival  \n \n5-, 10- and 15 -year \nsurvival  Physical \nexamination \ndetected 72% \nconstitutional \nsymptoms indicated \n17% and chest \nradiograph revealed \n11% of recurrences. \nBlood t ests did not  \npredict any \nrecurrence. 9/17 \npatients with \nrecurrences \ndetected by chest \nradiograph alone  \nunderwent curative \nsurgical resection. \nThese patients had \na statistically \nsignificant \nprolonged survival \ncompared to those \nsurgical candidates \nwho did no t \nundergo resection. Retrospective \ndesign  \n \nNo information \nabout \nverification/referenc\ne test  4  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 705 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \nNo statistically \nsignificant \ndifference in OS \nbetween patients \nwith \nasymptomatic \npulmonary \nrecurrences and \nthose with \nsymptomatic \npulmonary \nmetastases  \n \nThe 5 -year, 10 -\nyear, and 15 -year \nOSrates, with their \nassociated 95% CI, \nfor patient s who \nremained disease \nfree: 92%\u00b12%, 85% \n\u00b13%, and 77% \u00b14%, \nrespectively. The \nrates for patients \nwith recurrences are \n46% \u00b1 8%, 17% \u00b1 \n6%, and 14% \u00b1 6%, \nrespectively.   \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 706 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \nMooney et al. (1 997) To assess costs and \npotential benefits of \nan intensive chest \nX-ray (CXR) \nscreening program \nto detect \nasymptomatic \npulmonary \nmetastases in \npatients with \nintermediate -\nthickness, local, \ncutaneous \nmelanoma.  Economical study  \n \n A hypothetical \ncohort of pati ents \ndiagnosed in 1996 \nwith intermediate -\nthickness, local, \ncutaneous \nmelanoma. \nIntermediate \nthickness melanoma \nwas defined as \u2265 \n(AJCC) Stage I - \nclassification pT2  Potential savings in \nyears of life from \nsurgical resection of \nlung metastases in \nquality -adjusted \nand non -quality \nadjusted life years \n(QALY AND NQALY), \nundiscounted and \ndiscounted  \n \nCost-effectiveness \nratio (C/E) of CXR \nscreening  For the base case, \ncost of screening \nper NQALY was \n$150,000 and was \n$165,000 for QALY \nin 1996 dollars \nusing undiscounte d \nhealth benefits. \nScreening accounted \nfor approximately \n80% of program \ncosts and treatment \naccounted for 20%. \nAnnual cost -\neffectiveness ratios \nwere lowest in Years \n3\u201310 of screening. \nThe total cost of a \n20-year screening \nprogram for \npatients diagnosed \nin 1996 was \nestimated to be \nbetween $27 \u2013$32 \nmillion.  No level of evidence \nwas assigned \nbecause of unique \nstudy design and \nhypothetical cohort \nof patients   \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 707 von 732 7.2.5.  Literatur  \nLiteratur:  Zuteilung zur \nFragestellung:  \nVII.4 VII.5 VII.6 \nAlvarado et al. (2011)  x x x \nBasseres et al. (1995 ) x x x \nBaughan et al. (1993 ) x x  \nBeyeler et al. (2006 )   x \nBower et al. (2010)  x x  \nBrandt et al. (1990 ) x   \nBrobeil et al. (1997 ) x x  \nBrown et al. (2010 )   x \nBuljan et al. (2010 ) x x  \nDancey et al. (2004 ) x x  \nDe Giorgi et  al. (2010 ) x x  \nDeRose et al. (2011 ) x x x  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 708 von 732 Dicker et al. (1999 ) x x  \nDiFronzo et al. (200 1) x x  \nEgberts et al. (2009)   x \nEinwachter -Thompson, MacKie (2008 ) x x  \nFerrone et al. (2005 ) x x  \nFrancken et al. (2008)     \nFrancken et al. (2005 ) x x  \nFrancken et al. (2007 ) x x x \nFusi et al. (1993)  x x  \nGarbe et al. (2003)  x x x \nGoggins et Tsao (2003)  x x  \nHansel et al. (2009)  x x  \nHengge et al. (2007 ) x x x \nHohnheiser et al. (2010)  x x  \nJohnson et al. (1998)  x x   \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 709 von 732 Johnson et al. (1999)  x x x \nKang et al. (1992)  x x  \nKr\u00fcger et al. (2011)    x \nKaufmann, Crone -M\u00fcnzbrock (1992)   x x \nLeiter et al. (2009 )    \nLeiter  et al. (2010)  x x  \nLeiter  et al. (2011)  x x  \nMachet et al. (2005)    x \nManola et al (2000)  x  x \nMartenson et al. (2001)     \nMartini e t al. (1994)  x x  \nMcCarthy et al. (1988)  x x  \nMcMeniman et al. (2010)  x x  \nMeyers et al. (2009)  x x x \nMooney et al. (1997)      \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 710 von 732 Mooney et al. (1998)   x x x \nMoore Dalal et al. (2008 ) x x x \nMorton RL et al. (2009 )  x x \nMruck S et al. (1999 )   x \nMurchi e et al. (2010)  x x  \nPeric et al (2011 )   x \nPoo-Hwu et al. (1999 ) x x  \nRueth et al. (2010 )  x  \nSchlagenhauff  et al. (2000)    x \nSolivetti et al.  (2006)    x \nStucky et al. (2010)  x x  \nSylaidis et al. (1997)  x x  \nTarhini AA et al. (2009)   x  x \nTurner et al. (2011)  x x  \nVoit et al. (2001)    x  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 711 von 732 von Schoultz et al. (1996)    x \nZissimopoulos et al. (2009 )   x \nZogakis et al. (2007)  x x  \n \n \nAlvarado GC, Papadopoulos NE, Hwu W -, et al. Pelvic computed tomography scans for surveillance in patients with primary melanoma in the head and neck. Melanoma Res \n2011;21:127 -130 \nAukema TS, Olmos RA, Korse CM, et al. Utility of FDG PET/CT and brain MRI in melanoma patients with increased serum S -100B level during follow -up. Ann Surg Oncol \n2010;17:1657 -1661  \nBasseres  N, Grob JJ, Richard MA, et al. Cost-effectiveness of surveillance of stage I melanoma. A retrospective appraisal based on a 10 -year experience in a dermatology \ndepartment in France. Dermatology 1995;191:199 -203 \nBaughan CA, Hall VL, Leppard BJ, et al. Foll ow-up in stage I cutaneous malignant melanoma: an audit. Clin Oncol (R Coll Radiol) 1993;5:174 -180 \nBeyeler M, Waldispuhl S, Strobel K, et al. Detection of melanoma relapse: first comparative analysis on imaging techniques versus S100 protein. Dermatology 2 006;213:187 -\n191 \nBower MR, Scoggins CR, Martin RC,2nd, et al. Second primary melanomas: incidence and outcome. Am Surg 2010;76:675 -681 \nBrandt SE, Welvaart K, Hermans J. Is long -term follow -up justified after excision of a thin melanoma (less than or equal t o 1.5 mm)? A retrospective analysis of 206 patients. J \nSurg Oncol 1990;43:157 -160 \nBrobeil A, Rapaport D, Wells K, et al. Multiple primary melanomas: implications for screening and follow -up programs for melanoma. Ann Surg Oncol 1997;4:19 -23 \nBrown RE, Strom berg AJ, Hagendoorn LJ, et al. Surveillance after surgical treatment of melanoma: futility of routine chest radiography. Surgery 2010;148:711 -6; discussion \n716-7 \nBuljan M, Situm M, Bolanca Z, et al. Multiple primary melanoma: epidemiological and prognostic  implications; analysis of 36 cases. Coll Antropol 2010;34 Suppl 2:131 -134 \nDancey A, Rayatt S, Courthold J, et al. Views of UK melanoma patients on routine follow -up care. Br J Plast Surg 2005;58:245 -250 \nde Giorgi V, Rossari S, Papi F, et al. Multiple prim ary melanoma: the impact of atypical naevi and follow up. Br J Dermatol 2010;163:1319 -1322  \nDeRose ER, Pleet A, Wang W, et al. Utility of 3 -year torso computed tomography and head imaging in asymptomatic patients with high -risk melanoma. Melanoma Res \n2011;2 1:364 -369 \nDicker TJ, Kavanagh GM, Herd RM, et al. A rational approach to melanoma follow -up in patients with primary cutaneous melanoma. Scottish Melanoma Group. Br J Dermatol \n1999;140:249 -254 \nDiFronzo LA, Wanek LA, Morton DL. Earlier diagnosis of second p rimary melanoma confirms the benefits of patient education and routine postoperative follow -up. Cancer \n2001;91:1520 -1524  \nEgberts F, Hitschler WN, Weichenthal M, et al. Prospective monitoring of adjuvant treatment in high -risk melanoma patients: lactate deh ydrogenase and protein S -100B as \nindicators of relapse. Melanoma Res 2009;19:31 -35 \nEinwachter -Thompson J, MacKie RM. An evidence base for reconsidering current follow -up guidelines for patients with cutaneous melanoma less than 0.5 mm thick at \ndiagnosis. B r J Dermatol 2008;159:337 -341 \nFerrone CR, Ben Porat L, Panageas KS, et al. Clinicopathological features of and risk factors for multiple primary melanomas. JAMA 2005;294:1647 -1654  \nFrancken AB, Accortt NA, Shaw HM, et al. Follow -up schedules after treatment  for malignant melanoma. Br J Surg 2008;95:1401 -1407  \nFrancken AB, Bastiaannet E, Hoekstra HJ. Follow -up in patients with localised primary cutaneous melanoma. Lancet Oncol 2005;6:608 -621 \nFrancken AB, Shaw HM, Accortt NA, et al. Detection of first relapse i n cutaneous melanoma patients: implications for the formulation of evidence -based follow -up guidelines. \nAnn Surg Oncol 2007;14:1924 -1933  \nFrancken AB, Shaw HM, Thompson JF. Detection of second primary cutaneous melanomas. Eur J Surg Oncol 2008;34:587 -592 \nFusi S, Ariyan S, Sternlicht A. Data on first recurrence after treatment for malignant melanoma in a large patient population. Plast Reconstr Surg 1993;91:94 -98  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 712 von 732 Garbe C, Paul A, Kohler -Spath H, et al. Prospective evaluation of a follow -up schedule in cutaneo us melanoma patients: recommendations for an effective follow -up strategy. J \nClin Oncol 2003;21:520 -529 \nGoggins WB, Tsao H. A population -based analysis of risk factors for a second primary cutaneous melanoma among melanoma survivors. Cancer 2003;97:639 -643 \nHansel G, Schonlebe J, Haroske G, et al. Late recurrence (10 years or more) of malignant melanoma in south -east Germany (Saxony). A single -centre analysis of 1881 patients \nwith a follow -up of 10 years or more. J Eur Acad Dermatol Venereol 2010;24:833 -836 \nHengge UR, Wallerand A, Stutzki A, et al. Cost -effectiveness of reduced follow -up in malignant melanoma. J Dtsch Dermatol Ges 2007;5:898 -907 \nHohnheiser AM, Gefeller O, Gohl J, et al. Malignant Melanoma of the Skin: Long -term Follow -up and Time to First Rec urrence. World J Surg 2010  \nJohnson RC, Fenn NJ, Horgan K, et al. Follow -up of patients with a thin melanoma. Br J Surg 1999;86:619 -621 \nJohnson TM, Hamilton T, Lowe L. Multiple primary melanomas. J Am Acad Dermatol 1998;39:422 -427 \nKang S, Barnhill RL, Mihm MC,Jr, et al. Multiple primary cutaneous melanomas. Cancer 1992;70:1911 -1916  \nKaufmann PM, Crone -Munzebrock W. Tumor follow -up using sonography and computed tomography in the abdominal region of patients with malignant melanoma]. Aktuelle \nRadiol 1992;2:81 -85 \nKelly JW, Blois MS, Sagebiel RW. Frequency and duration of patient follow -up after treatment of a primary malignant melanoma. J Am Acad Dermatol 1985;13:756 -760 \nKhan MA, Andrews S, Ismail -Khan R, et al. Overall and progression -free survival in metastatic  melanoma: analysis of a single -institution database. Cancer Control \n2006;13:211 -217 \nKruger U, Kretschmer L, Thoms KM, et al. Lymph node ultrasound during melanoma follow -up significantly improves metastasis detection compared with clinical examination \nalone: a study on 433 patients. Melanoma Res 2011;21:457 -463 \nLeiter U, Buettner PG, Eigentler TK, et al. Is detection of melanoma metastasis during surveillance in an early phase of development associated with a survival benefit? Melanoma \nRes 2010;20:240 -246 \nLeiter U, Marghoob AA, Lasithiotakis K, et al. Costs of the detection of metastases and follow -up examinations in cutaneous melanoma. Melanoma Res 2009;19:50 -57 \nLeiter U, Buettner PG, Eigentler TK, et al. Hazard rates for recurrent and secondary cutaneous melanoma: An analysis of 33,384 patients in the German Central Malignant \nMelanoma Registry. J Am Acad Dermatol 2011  \nMachet L, Nemeth -Normand F, Giraudeau B, et al. Is ultrasound lymph node examination superior to clinical examination in melanoma follow -up? A monocentre cohort study \nof 373 patients. Br J Dermatol 2005;152:66 -70 \nManola J, Atkins M, Ibrahim J, et al. Prognostic factors in metastatic melanoma: a pooled analysis of Eastern Cooperative Oncology Group trials. J Clin Oncol 2000;18:3782 -\n3793  \nMartens on ED, Hansson LO, Nilsson B, et al. Serum S -100b protein as a prognostic marker in malignant cutaneous melanoma. J Clin Oncol 2001;19:824 -831 \nMartini L, Brandani P, Chiarugi C, et al. First recurrence analysis of 840 cutaneous melanomas: a proposal for a follow -up schedule. Tumori 1994;80:188 -197 \nMcCarthy WH, Shaw HM, Thompson JF, et al. Time and frequency of recurrence of cutaneous stage I malignant melanoma with guide lines for follow -up study. Surg Gynecol \nObstet 1988;166:497 -502 \nMcMeniman E, De'Ambrosis  K, De'Ambrosis B. Risk factors in a cohort of patients with multiple primary melanoma. Australas J Dermatol 2010;51:254 -257 \nMeyers MO, Yeh JJ, Frank J, et al. Method of detection of initial recurrence of stage II/III cutaneous melanoma: analysis of the ut ility of follow -up staging. Ann Surg Oncol \n2009;16:941 -947 \nMooney MM, Kulas M, McKinley B, et al. Impact on survival by method of recurrence detection in stage I and II cutaneous melan oma. Ann Surg Oncol 1998;5:54 -63 \nMooney MM, Mettlin C, Michalek AM, et a l. Life -long screening of patients with intermediate -thickness cutaneous melanoma for asymptomatic pulmonary recurrences: a cost -\neffectiveness analysis. Cancer 1997;80:1052 -1064  \nMoore Dalal K, Zhou Q, Panageas KS, et al. Methods of detection of first recur rence in patients with stage I/II primary cutaneous melanoma after sentinel lymph node biopsy. \nAnn Surg Oncol 2008;15:2206 -2214  \nMorton RL, Craig JC, Thompson JF. The role of surveillance chest X -rays in the follow -up of high -risk melanoma patients. Ann Sur g Oncol 2009;16:571 -577 \nMruck S, Baum RP, Rinne D, et al. Diagnostic accuracy and predictive value of the tumor -associated antigen S100 in malignant melanomas: validation by whole body FDG -PET \nand conventional diagnostics. Anticancer Res 1999;19:2685 -2690  \nMurchie P, Nicolson MC, Hannaford PC, et al. Patient satisfaction with GP -led melanoma follow -up: a randomised controlled trial. Br J Cancer 2010;102:1447 -1455  \nPeric B, Zagar I, Novakovic S, et al. Role of serum S100B and PET -CT in follow -up of patients wi th cutaneous melanoma. BMC Cancer 2011;11  \nPoo-Hwu WJ, Ariyan S, Lamb L, et al. Follow -up recommendations for patients with American Joint Committee on Cancer Stages I -III malignant melanoma. Cancer \n1999;86:2252 -2258   \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 713 von 732 Romano E, Scordo M, Dusza SW, et al. Site and timing of first relapse in stage III melanoma patients: implications for follow -up guidelines. J Clin Oncol 2010;28:3042 -3047  \nRueth NM, Groth SS, Tuttle TM, et al. Conditional survival after surgical treatment of melanoma: an analysis of the Surveill ance, Epidemiology, and End Results database. Ann \nSurg Oncol 2010;17:1662 -1668  \nSchlagenhauff B, Schittek B, Ellwanger U, et al. Significance of serum protein S100 levels in screening for melanoma metastasis: does protein S100 enable early detection of \nmelanoma recurrence? Melanoma Res 2000;10:451 -459 \nSolivetti FM, Di Luca Sidozzi A, Pirozzi G, et al. Sonographic evaluation of clinically occult in -transit and satellite metastases from cutaneous malignant melanoma. Radiol Med \n2006;111:702 -708 \nStucky CC, Gray RJ, Dueck AC, et al. Risk factors associated with local and in -transit recurrence of cutaneous melanoma. Am J Surg 2010;200:770 -775 \nSylaidis P, Gordon D, Rigby H, et al. Follow -up requirements for thick cutaneous melanoma. Br J Plast Surg 1997;50:349 -353 \nTarhini AA, Stuckert J, Lee S, et al. Prognostic significance of serum S100B protein in high -risk surgically resected melanoma patients participating in Intergroup Trial ECOG \n1694. J Clin Oncol 2009;27:38 -44 \nTurner RM, Bell KJ, Morton RL, et al. Optimizing the frequency of follow -up visits for patients treated for localized primary cutaneous melanoma. J Clin Oncol 2011;29:4641 -\n4646  \nVoit C, Mayer T, Kron M, et al. Efficacy of ultrasound B -scan compared with physical examination in follow -up of melanoma patien ts. Cancer 2001;91:2409 -2416  \nvon Schoultz E, Hansson LO, Djureen E, et al. Prognostic value of serum analyses of S -100 beta protein in malignant melanoma. Melanoma Res 1996;6:133 -137 \nZissimopoulos A, Karpouzis A, Kouskoukis C. Indium -111 pentetreotide scin tigraphy and CT scans after 3 years in the follow -up of patients with malignant melanoma. Hellenic \nJournal of Nuclear Medicine 2009;12:142 -145197  \nZogakis TG, Essner R, Wang HJ, et al. Natural history of melanoma in 773 patients with tumor -negative sentinel  lymph nodes. Ann Surg Oncol 2007;14:1604 -1611  \n \n \n \n \n \n \n \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 714 von 732 8. AG Begleittherapie  \n8.1. Frage VIII.1. Misteltherapie  \nFrage VIII.1. Beeinflusst eine Misteltherapie das Gesamt\u00fcberleben und/oder die rezidivfreie Zeit von Melanompatienten?  \n8.1.1.  PICO, Suchw\u00f6rter  \nPICO - Schema  \nPopulation  Intervention  Comparison  Outcome  \nMelanoma patients  Mistletoe  Observation  Overall survival, progression free \nsurvival  \n \nSuchw\u00f6rter  \nStichwort  melanoma  mistletoe  primary   \nSynonyme      \nOber -/Unterbegriffe  Skin cancer  Viscum album    \nMesh Term  melanoma  mistletoe    \n \n8.1.2.  Datenbanken, Suchstrategien, Trefferzahlen  \nDatenbank  Suchstrategie  Datum  Treffer \n1. Suche     \nMedline  (\u201cmelanoma\u201d OR \u201cmelanoma\u201d[MeSH Terms] OR \u201cskin cancer\u201d) AND (\u201cmistletoe\u201d OR \u201cviscum 28.09.10  41  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 715 von 732 Datenbank  Suchstrategie  Datum  Treffer \nalbum\u201d OR \u201cmistletoe\u201d[MeSH Terms])  \nCochrane Library  (melanoma and (mistletoe or viscum album)).ti,ab.  28.09.10  2 \nEmbase  (melanoma and (mistletoe or viscum album)).ti,ab.  12.10.10  47 \n    \nUpdate Suche     \nMedline  s.o. 26.01.12  42 \nCochrane Library  s.o. 26.01.12  2  \nEmbase  s.o. 23.01.12  53  \n \n8.1.3.  Auswahlkriterien  \nAuswahl der Literatur  \nGesamttreffer  97 \nEinschlusskriterien  Klinische Studien zur Misteltherapie bei Melanomapatienten, alle Stadien  \nVergleichsarm: Beobachtung oder Standardtherapie , Sprachen: e,dt  \nAusschlusskriterien  Studien oder Revie ws mit Einschluss anderer/gemischter Tumorentit\u00e4ten  \nCase Reports , Experimentelle Arbeiten  \nAnzahl nach Abstractscreening, vorges ehen f\u00fcr Bewertung  3 \nAnzahl ausgew\u00e4hlter Studien durch Handsuche (Durchsicht der Referenzlisten der ausgew\u00e4hlten Arbeiten)  3 \nAusgeschlossene Studien (mangelhafte methodische Qualit\u00e4t)  3 \nBer\u00fccksichtigte Studien  3  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 716 von 732 8.1.4.  Evidenztabelle  \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nKleeberg et al. 2003  \n \nFinal r esults of the \nEORTC 18871/DKG \n80-1 randomised \nphase III trial:rIFN - \na2b versus rIFN -g \nversus ISCADOR M1 \nversus observ ation \nafter surgery in \nmelanoma patients \nwith either high -\nrisk primary \n(thickness >3 mm) \nor regional lymph \nnode m etastasis  To clarify whether \nclaims of the \nefficacy of Iscador M  \nwere justified  Prospective, \nrandomised phase \nIII adjuvant trial  803 pts: 423 pts \nwere ra ndomized in \nthe EORTC 18871 \n3-arm trial, 407 pts \nin the DKG -80-1 4-\narm trial (102 pts in \nthe co ntrol arm, \n101 pts in the rIFN -\nalpha arm, 102 in \nthe rIFN -gamma \narm and  102 in \nIscador -M arm).  \nThus 204 pts were \nused to a ssess the \nvalue of Iscador: \n102 co ntrols vs. \n102 pts in the \nIscador group.  \n \nStage IIb: 48%/49%  \nStage III: 52%/51%  \n \nBaseline \ncharact eristics were \nwell b alanced   \n \n \nDisease free Inte rval \nrate (DFI)  \n \nOverall Survival (OS)  \n  Iscador M1 ve rsus \ncontrol  \n \nHR 1.32 (0.93, 1.87)  \n \n \nHR 1.21 (0.84, 1.75)  \n \n \nThe data su pport, \nbut do not provide \nsignificant proof of \nearlier wa rnings \nabout a p otential \nnegative effect of \nmistletoe extracts in \nmelanoma p atients, \nsince the \nobservations did not \nreach signifi cance.  The trials were \nstopped after \nreaching the \nplanned sample size \nfor the IFN -question \nand after having the \nresults of an interim \nevaluation showed \nan appro ximately \n10% lower 2 -year \nDFI rate in the \nIscador arm \ncompared wi th the \ncontrol group.  \nFunding:  \nIn part by grant \nDKG 80 -1 1b \n \nIndivi dual \nRCT  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 717 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \nAugustin et al. 2005  \n \nSafety and Efficacy \nof the Long -term \nAdjuvant Trea tment \nof Primary \nInterm ediate - to \nHigh-Risk Malignant \nMelanoma \n(UICC/AJCC Stage II \nand III) with a \nStandar dized \nFermented \nEuropean Misteltoe \n(Viscum album L.) \nExtract To evaluate the \ntherapeutic safety \nand efficacy of \nFermented \nEuropean Misteltoe \nExtract (FME)  Mulicenter, \ncomparative, \nepidemi ological \ncohort study  686 Patients, 329 \ntreated with FME vs. \n357 cont rols from \n35 centers;  \n \nUICC/AJCC tumor \nstage (II/III) %  \n91,5/8,5 vs \n95.0/5.0  \n \nTreatment group:  \n83,3% patients \nreceived FME P  \n16,7% received FME \nM, Q or others  \n \nmedian duration of \ntherapy: 30 months  Prim. endpoint  \nTumor -related \nsurvival \nSec. endpoint  \nOveral l Survival  \nDisease -free-\nsurvival  \nBrain metastasis -\nfree survival  Significant \nreduction of tumor -\nrelated mortality \nhazard in the FME \ngroup  \nTumor -related \nmortality rate 8,9% \nFME group vs. \n10,7% control group  \nAdjusted hazard \nratios (FME vs. \ncontrol): \nHR Tumor -related \nsurvival = 0,41  \nHR Overall survival \n= 0,64  \nHR Disease -free \nSurvival = 0,73  \nHR Brain \nmetast asis-free \nsurvival = 0,33  Limits:  \nNot randomized \ndesign  \nThus, baseline \ncharacteristics were \nwell ba lanced  \nPotential biases \nwere well a ddressed \nby using a \nstandardized \nparallel goups study \ndesign, independent \nauditing of data \nquality, mult ivariate \nadjusted en dpoint \ncriteria for potential \nconfounders and \nother measures.  \nFunding:  \nThe study was \nsupported by an \neducational grant of \nthe Research \nInstitute Hiscia, \nArlesheim \n(Switze rland) \n(Iscador)  2b \n \nIndividual \nCohort \nStudy   \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 718 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \nAlbarr\u00e1n Weick, M. \n1998  \n \nRetrospe ktive Fall -\nKontroll -Studie zum \nStellenwert der \nadjuvanten Ther apie \ndes malignen \nMelanoms mit \nIscador P.c.Hg.  To evaluate the \nimpact of adjuvant \nIscador on \nprogre ssion free \nsurvival and Overall \nSurvival  Matched pairs (1:3) \nretrospective c ohort \nstudy  Of 1288 \ndocumented \nmelan oma patients \nof the University \nHospita lFreiburg, \n458 patients \nreceived I scador. \n273 of this patients \nwere ev aluated in \nthe study  \n \nControl group:  \n819 of more than \n25 000 melanoma \npatients within the \nGerman Central \nMalignant \nMelanoma Registry.  Progression free \nsurvival  \nOverall Survival  No significant \ndifferences between \nthe groups \nregarding overall \nsurvival (p=0,9669) \nand progression \nfree survival \n(p=0,5746)  \n \nIscador treatment \nhad no d etrimental \neffect on overall \nsurvival  Study is well \nreported  \nInvasionlevel was \nnot well balanced \nbetween the groups \n(more Level IV and \nIII in control group)  \nLimits:  \nRetrospective \ndesign, Iscador \npreparation was not \nstanda rdized  \nFunding:  \nnot reported  \nInaugural \nDissert ation 2b \n \nIndividual \nCohort \nStudy  \n \nAusgeschlossene Studien  \nStudy  Aims  Design  Population  Outcomes  Results  Comments  LoE \nStumpf et al. 2003  \n \nRetrospective Study \nof Melanoma \nPatients Treated to analyze  \nsurvival time and \nsurvival rate of all \npatients with \nmalignant  Retrospective Study  284 melanoma \npatients of the \nTumorambulanz \nHerdecke were \nincluded,  Survival time  \nSurvival rate  \n Survival time and \nsurvival rate were \ncomparable to \ncontrols of \nliterature  Poor quality \uf0e0 \nstudy excluded  \n \nLimits:  \nretrospective 4 \n \npoor quality \ncohort study   \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 719 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \nwith Mistletoe \nExtrac ts melanoma who had \nbeen counseled at \nthe Tumoramb ulanz \nHerdecke  94 patients with \nsufficent dat a were \nanalysed, 66 of this \npatients r eceived \nmistle toe \ntreatment.  \nThis 66 patients \nwere compared with \npatient data from \nthe literature  design, \nheterogen eous \npatient collective: \npatients with and \nwithout meta stases, \nclinical stage was \nnot indicated, \nCompar ison with \nliterature data \nbased on clark level  \nDifferent trea tment \nregimens (Iscador \nM, Iscador P a nd \nothers) \nFunding:  \nThe study was \npartially initiated \nand f inanced by \nHelixor GmbH&Co  \nGrossarth -Maticek \net al. 2007  \n \nEfficacy and Safety \nof the Long -term \nTreatment of \nMelanoma with a \nMistletoe To investig ate if the \nlong-term \napplic ation of the \nmistletoe \nprepar ation Iscador \nshow any effect in \nprospe ctive \ncontrolled  Study 1: \nRand omised \nmatched -pair study \n(22 p airs) \n \nStudy 2: Non -\nrandomised \nmatched -pair study Study population \nconsisted of 1499 \nmelanoma patients \nof different german \ncentres  \n \nMelanoma patients \nwithout metasta ses, Overall survival  \nProgression free \nsurvival  \nSelf regulation  Overall survival:  \nNo difference \nbetween Iscador \nand control group  \n \nSignificant better \nprogression free \nsurvival in Iscador Poor quality \uf0e0 \nstudy excluded  \n \nRecruitment period \nwas between 1973 \nand 1988  \nTwo studies were \nanalysed seperately 4 \n \npoor quality \ncohort study   \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 720 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \nPreparation \n(Iscador) studies on survival, \ntumor progression, \nand psychosomatic \nself-regulation of \npatients with  \nmelanoma  (32 pairs)  receiving \nconventional \ntherapies were \nmatched to \nmelanoma patients \nwith sam e \nchara cteristics to \nreceive additio nally \nIscador  \n group:  \nHR, 95% CI \nStudy 1:  \nHR 0,49 (0,32, 0,75)  \nStudy 2:  \nHR 0,72 (0,54, 0,97)  \n \nSelf regulation:  \nSignificant better \nself regulation after \nIscador therapy \np=0,0048  but were reported \ntogether  \nLimits  \nSmall sample size  \nQuestionable \nmethod of \nrandomis ation (two \nslips of paper with \nthe names of two \npatients were drawn \nof a hat)  \nkaplan meier curves \navailable of overall \nsurvival (n.s.) but \nnot of progression \nfree survival \n(significant)  \nFunding:  \nNo statement \nincluded  \nAffiliation of \nCorresponding \nauthor: Institut \nHiscia, CH -\nArlesheim (I scador)  \nSchuppli R. 1990  \n To assess the \ntherapeutic  effect of Controlled study  \n High risk melanoma \npatients  Overall survival  Risk factor Survival  \nIscador group: 3,4  Poor quality \uf0e0 \nstudy excluded  4 \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 721 von 732 Study  Aims  Design  Population  Outcomes  Results  Comments  LoE \nAdjuvant treatment \nof malignant \nmelanoma with \nIscador P c Hg.]  Iscador plus Hg on \noverall survival   \n114 patients treated \nwith BCG alone  \n84 patients treated \nwith BCG and \nIscador P c Hg  Contol group: 2,3  The study was \nconducted at the \nDepartment of \nDermatology, \nUniversitiy B asel, \n1981 -1988  \nLimits:  \nStudy reporting of \nlow quality  \nNo baseline \ncharachteristics, \n(groups balanced?)  \nStatistical methods \nwere not reported  \nFunding:  \nNo sta tement \nincluded  poor quality \ncohort study  \n8.1.5.  Literatur  \nAlbarranweick M. Retrospektive Fall -Kontroll -Studie zum Stellenwert  der adjuvanten Therapie des malignen Melanoms mit Iscador P.c.Hg. 1998  \nAugustin M, Bock PR, Hanisch J, et al. Safety and efficacy o f the long -term adjuvant treatment of primary intermediate - to high -risk malignant melanoma (UICC/AJCC stage II \nand III) with a standardized fermented European mistletoe (Viscum album L.) extract. Results from a multicenter, comparative,  epidemiological co hort study in Germany and \nSwitzerland. Arzneimittelforschung 2005;55:38 -49 \nGrossarth -Maticek R, Ziegler R. Efficacy and safety of the long -term treatment of melanoma with a mistletoe preparation (Iscador). Schweizerische Zeitschrift fur \nGanzheitsMedizin 20 07 \nKleeberg UR, Suciu S, Brocker EB, et al. Final results of the EORTC 18871/DKG 80 -1 randomised phase III trial. rIFN -alpha2b versus rIFN -gamma versus ISCADOR M versus \nobservation after surgery in melanoma patients with either high -risk primary (thickness  >3 mm) or regional lymph node metastasis. Eur J Cancer 2004;40:390 -402 \nSchuppli R. Die adjuvante Behandlung des malignen Melanoms mit Iscador\u00ae c.Hg. Krebs und Alternativmedizin 1990  \nStumpf C, Rosenberger A, Rieger S, et al. Retrospective study of malignan t melanoma patients treated with mistletoe extracts. Forsch Komplementarmed Klass Naturheilkd \n2003;10:248 -255 \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 722 von 732 9. AG Versorgungsqualit\u00e4t und Qualit\u00e4tsindikatoren  \n9.1. Frage IX.1.  Klinische Studien - Adaptation  \nFrage IX.1.  Welchen Patienten sollte eine Teilnehme an  klinischen Studien empfohlen werden?  \nDie Frage wurde letztendlich Konsens -basiert beantwortet  \n9.1.1.  Synopse Quellleitlinien (kurz)  \nThema/Fragestellung  LL Austr alien  \nNew Zealand Guidelines \nGroup 2008  LL GB  \nNICE 2006  LL Frankreich  \nFrench National Authority \nfor Health 2005  LL Kanada  \nCancer Care O ntario \n2007  \n1. Sollte Patienten die \nTeilnahme an klinischen \nStudien em pfohlen werden?  Teilnahme an Studien sollte \nPatienten ab St. I nach \nResektion des Prim\u00e4rtumors \nangeboten we rden (B);  \nPatienten sollten dar\u00fcber \ninformiert we rden, dass sie \nvon der Teilna hme an einer \nStudie wahrscheinlich ke ine \nNachteile zu e rwarten haben \n(A)  Teilnahme an St udien sollte \nallen Patienten erm\u00f6glicht \nwerden, auch unter 19 -\nj\u00e4hrigen; kein Beweis f\u00fcr Vor - \noder Nachteile f\u00fcr den \nPatienten durc h \nStudienteilnahme  Keine Erw\u00e4 hnung  Nur relevant f\u00fcr \nmedikament\u00f6se Therapien  \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 723 von 732 9.1.2.  Empfehlung, Hintergrundstext und Literatur australischen und franz\u00f6sischen Quell -Leitlinien  \n LL Austr alien  \nNew Zealand Guidelines Group \n2008  LL GB  \nNICE 2006  LL Frankreich  \nFrenc h National Authority for \nHealth 2005 ) LL Kanada  \nCancer Care O ntario 2007  \nSchl\u00fcsselempfe hlungen  S. 128  \n \nPatients can be informed that \nthey are unlikely to be \ndisadvantaged by participation \nin an RCT.  \n \nGrade of Recommendation: A   Keine Erw\u00e4hnung  Systemic Ad juvant Therapy for \nPatients at High Risk for  \nRecurrent Melanoma: Upda ted \nGuideline Recommend ations \n2009  \n \nS. 2 \nRecommendations  \nPatients with high -risk \nmelanoma should be \nencouraged to participate in \nappropriate clin ical trials \nexploring novel therape utics, \ngiven that at most a small OS \nbenefit exists with currently \navailable ther apies.  \n \n \nHintergrundtexte  S. 127  \n \n20. Clinical Trials  \nThe clinical trial is an \ninstrument designed to assess Patient -centered care  \n \nC. Evidence  \n \nS. 41  Keine Erw\u00e4hnung  Keine Erw\u00e4hnung   \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 724 von 732  LL Austr alien  \nNew Zealand Guidelines Group \n2008  LL GB  \nNICE 2006  LL Frankreich  \nFrenc h National Authority for \nHealth 2005 ) LL Kanada  \nCancer Care O ntario 2007  \nthe effectiv eness of potentially \nnew or altered interventions \nthat i nvolve a wide range of \nclinical a ctivity.  \nTrials frequently involve drug \ntherapy, but may address new \ndevices, surgical procedures, \ntreatment by external \ninstrumentation (e.g. \nradiotherapy), or psychosocial \naspects of cli nical \nmanagement. [1]  \nCommonly, the s tudy question \nis whether a new treatment is \nbetter than the old one. It is \ncustomary to compare each \nnew treatment group with a \ncontrol group, the members of \nwhich must be offered \ntreatment matching the best \nstandard cu rrently available for \ntheir considera tion b efore \njoining the trial. [1]  \nThe randomised clinical trial \n(RCT), which involves random  \nClinical trials  \nOne high -quality systematic \nreview investigated patient \noutcomes r elated to mortality \nand mo rbidity among \nparticipants and \nnonpartic ipants in clinical \ntrials. RCTs of different \nspecial ities were included, but \nthe largest pr oportion was of \npatients with cancer. The \nreview found little evidence for \nbetter outcomes through \nparticipation in trials aside \nfrom those ari sing from the \neffects of the trea tments \ncompared, or differences \nbetween participants and non -\nparticipants.  \nThe same review found no \nevidence of greater risk arising \nfrom tria l participation.  \nA previous, poorer -quality \nsystematic review than the one  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 725 von 732  LL Austr alien  \nNew Zealand Guidelines Group \n2008  LL GB  \nNICE 2006  LL Frankreich  \nFrenc h National Authority for \nHealth 2005 ) LL Kanada  \nCancer Care O ntario 2007  \nallocation of patients to their \ntreatment or control group, is \nbecoming the \u2018gold sta ndard\u2019 \nfor assessment of new \nmanagement processes.  \nClinical trials involve \nsignificant funding and require \nthe informed consent from \npatients and frequently, the \ninvolvement of a number of \ncentres and health \nprofessionals to obtain an \nappropriate number of \nsubjects to ensure sound \nstatistical power.  \nThe conduct of trials by \ncooperative groups of trialists \nis the most likely way to \nadvance evidence -based \nmedicine through well -\ndesigned pr otocols and \nrigorous evaluation. [2]  \nHowever, in our community \nsome people are concerned \nabout RCTs, believing that cited above examined evidence \nfor better patient outcomes \nthrough RCT participation. The \nmajority of RCTs were of \npatients with cancer. The \nreview concluded that it is \nlikely that c linical trials have a \npositive, rather than a \nnegative, effect on survival and \nmorbidity ou tcomes, with \nbenefits arising from the use of \ntrial protocols.  \nOne literature review found \nthat children and adolescents \nwith mel anoma are not entered \ninto clin ical trials. \nRetrospective studies have \nfound that adole scents with \ncancer are not as likely to be \nentered into clinical trials as \nchildren and adults.  \nAn audit of skin cancer MDT \nactivity undertaken in the \nSouth West of England found \nthat many trusts did not h ave  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 726 von 732  LL Austr alien  \nNew Zealand Guidelines Group \n2008  LL GB  \nNICE 2006  LL Frankreich  \nFrenc h National Authority for \nHealth 2005 ) LL Kanada  \nCancer Care O ntario 2007  \npatients involved in such trials \nmay be at risk from fa ctors \nthat would not occur in \ntreatment outside a trial. On \nthe other hand, others see \nparticipation in an RCT as \nbeing of benefit to the trial \nsubject and probably an \noptimal way of receiving the \nbest contemp orary care and \nclinical o versight.  \nA recent Cochrane Review \nassessed the effect of \nparticip ation in RCTs (\u2018trial \neffects\u2019) i ndependent both of \nthe effects of the clinical \ntreatments being co mpared \n(\u2018treatment effects\u2019) and any \ndifferences between p atients \nwho participated in RCTs and \nthose who did not. [3]  \nThe outcome of this review led \nits authors to conclude that \nthere is no greater risk from \nparticipating in RCTs than sufficient infrastructure to \nensure that patients are \noffered trial entry.  \nAn audit of implementation of \nrecommendations made in the \nCalman \u2013Hine Report (1995) \nunde rtaken by the Commission \nfor Health I mprovement (CHI) \nand the Audit Commission in \n2001 f ound that only a small \nproportion of patients with \ncancer are involved in clinical \ntrials. Trial participation was \nless lik ely in settings outside of \nlarge cancer ce ntres.  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 727 von 732  LL Austr alien  \nNew Zealand Guidelines Group \n2008  LL GB  \nNICE 2006  LL Frankreich  \nFrenc h National Authority for \nHealth 2005 ) LL Kanada  \nCancer Care O ntario 2007  \nthere is from being treated \noutside an RCT. The authors \nconsidered that the belief or \nassertion that results of  RCTs \ncannot be a pplied to usual \npractice is cha llenged by the \nreview. [2] This outcome would \nappear to pr ovide a sound \nbasis for clinicians to offer \nparticipation in RCTs to their \npatients.  \nAny uncertainty about the \neffects of treatment can best \nbe resolv ed through a \nrandomised trial as long as the \neligibility crit eria for the trial \nmatch the patient popul ation \nseen in usual practice, or the \ntrial treatment is a pplied only \nto patients who match the \neligibility criteria. [4]  \n \nEvidence summary  \nOutcomes for p atients who \npartic ipate in RCTs on average  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 728 von 732  LL Austr alien  \nNew Zealand Guidelines Group \n2008  LL GB  \nNICE 2006  LL Frankreich  \nFrenc h National Authority for \nHealth 2005 ) LL Kanada  \nCancer Care O ntario 2007  \ndo not differ from those of \npatients who receive similar \ntreatments and do not \npartic ipate in a trial.  \nLoE: I  \nReference: [2]  \n    \nLiteratur:  \n \nLL Austr alien New Zealand Guideline s Group 2008  \n4. Kunz R, Vist G, Oxman AD. Randomisation to protect against selection bias in healthcare trials. Cochrane Database Syst Rev  2007;(2):MR000012   \n3. Optimising Cancer Care in Australia. 1 \u2013122. 2002. Melbourne. Available from <http:/www.cosa.org .au/documents/optim_Cancer_Care_final.pdf>. Clinical Oncology Society \nof Australia, The Cancer Cou ncil Australia and The National Cancer Control Initiative.  \n1. The Cancer Council Victoria. About Clinical Trials. Available from <http:www.cancervic.org.au/br owse.asp?ContainerID=about_clinical_trials> accessed 1 September 2007  \n2. Vist GE, Hagen KB, Devereaux PJ, et al. Outcomes of patients who participate in randomised controlled trials compared to similar patients receiving similar intervent ions who \ndo not pa rticipate. Cochrane Database Syst Rev 2007;(2):MR000009  \n \nLL GB NICE 2006  \n1. Braunholtz DA, Edwards SJ, Lilford RJ. Are randomized clinical trials good for us (in the short term)? Evidence for a \"trial effect\". J Clin Epidemiol 2001;54:217 -224 \n2. Peppercorn  JM, Weeks JC, Cook EF, et al. Comparison of outcomes in cancer patients treated within and outside clinical trials: conceptua l framework and structured review. \nLancet 2004;363:263 -270 \n3. Poirier V, Wright S, Lucke T, Verne J, Sandhu J, De Berker D, et al.  Auditing current Skin Cancer Multi -disciplinary Team (MDT) practices against the Manual of Cancer Se rvices \nStandards in the South West Region.  \n4.  Vist GE, Hagen KB, Devereaux PJ, et al.  Systematic review to determine whether participation in a trial inf luences outcome. BMJ 2005;330:1175  \n \n \n \n  \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 729 von 732 10. Abk\u00fcrzungsverzeichnis  \n \nAUC    area under curve  \nBCG    Bacille Calmette Guerin  \nBM    brain metastases  \nBT    Breslow Thickness  \nCD    conventional diagnostics  \nCI    confidence interval  \nCLND     Complete lymph node dissect ion  \nCM    cutaneous melanoma   \nCR    Complete Response  \nCR    conventional radiography  \nCS    conditional survival  \nCSP    conventional screening proc edures  \nCT    chemotherapy  \nCWS, P3     cell wall skeleton and purified trehalose dimycolate  \nCXR    Chest X -ray CXR  \nDFI    disease -free interval  \nDFS    disease - free su rvival  \nDM    distant metastases  \nDMFD     distant metastasis -free survival  \nDMFI     distant metastasis -free interval  \nDMFS     distant metastasis -free survival  \nDMM     desmoplastic malignant melanoma  \nDNCB     Dinitrochlorobenzene  \nDNM    desmoplastic neurotropic melanoma  \nDPCP     Diphencyprone  \nDSS    disease -specific survival   \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 730 von 732 DTIC    dacarbazine  \nELND     \u00b4elective lymph node di ssection`  \nFAS    full analyses set  \nFMR    first mel anoma recurrence  \nFN     false negative  \nFP    false positives  \nGIT    gastrointestinal tract  \nGKS     Gamma Knife surgery  \nGy    Gray \nHACE     Hepatic artery chemoembolization  \nHAI    Hepatic artery infusion  \nHDI    high dose interferon  \nHR    Hazard ratio  \nHRQL     health related quality of  life \nIDI    intermediate dose interferon  \nIES    Impact of Event Scale  \nIFN    Interferon  \nIHP    Isolated hepatic perfusion  \nIl-2    Interleukin 2  \nIL-BCG    intralesionally - bacillus Calmette Guerin  \nILP    isolated limb perfusion  \nincl.    including  \nITT    Intent To Treat  \nLDI    low dose interferon  \nLM    lentigo maligna  \nLMM    lentigo maligna melanoma  \nLN    lymph node(s)  \nMCS    Mental Component Summary  \nMER    methanol extraction residue of bacillus Calmette -Guerin   \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 731 von 732 Mets    metastases  \nMM    malignant melanom a \nMPM    multiple primary melanomas  \nMPV-BCG   multiple puncture vaccination - bacillus Calmette Guerin  \nMUP    melanoma with unknown primary  \nMV    Megavolt  \nn.r.    not reported  \nn.s.    not significant  \nNC    no change  \nNED    no evidence of disease  \nNMM     nodular malignant melanoma  \nNR    not reached  \nOBS    observation  \nOR    Odds ratio  \nOS    Overall survival  \nPCS    Physical Component Summary  \nPD    Progressive Disease  \nPDS    power Doppler sonography  \nPE    physical eexamination  \nPM     primary melanoma  \nPP    Per protocol  \nPR    Partial Response  \nPV-10    10% w/v Rose Bengal in saline  \nRCT    randomized controlled trial  \nRECIST     Response Evaluation Criteria in Solid Tumors  \nRFS    Relapse -free su rvival, Recurrence free survival  \nrIFN-beta   recombinant interferon beta  \nRR    Relapse Rate  \nRR    relative risk   \n \n\u00a9 Leitlinienprogramm Onkologie | S3-Leitlinie Melanom - EVIDENZ TABELLEN  | Januar 2013    Seite 732 von 732 RSCL      Rotterdam Symptom Checklist  \nRT    radiotherapy  \ns.c.    subcutaneous  \nSD    Stable Disease  \nSIRT    selektive interne Radio -Therapie  \nSLN    senitinel lymph node  \nSLNB     sentinel -lymph node biopsy  \nSM    second  melanoma  \nSPM    second primary melanoma  \nSRS    stereotactic radiosurgery  \nSSM    superficial spreading melanoma  \nST    soft tissue  \nTACE     Trans -arterial chemoembolization  \nTD    Total dose  \nTLND     therape utic lymph \u2013node -dissection  \nTMZ    temozolomide  \nTN    true negatives  \nTP    true positives  \nUICC    Union International Contre Cancer  \nUS    ultrasound  \nWBRT     whole brain radiation therapy  \nWHO     World Health Organisation  \nVs.    versus  \nWb    whole body  \n ", "language": "PDF", "image": "PDF", "pagetype": "PDF", "links": "PDF"}